#CLS_PREDICTION_ENTITY|MASK_PREDICTION_ENTITY|ACTUAL_ENTITY|CLS_PREDICTIONS|MASKED_PREDICTIONS|MASKED_WORD|SENTENCE
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|lithium valproate AND carbamazepine psychosis|lithium carbamazepine phenobarbital valproate phenytoin|lithium|is being evaluated as a monotherapy and in the iti-007-402 trial , lumateperone is being evaluated as an adjunctive therapy with entity or valproate .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|lithium valproate AND carbamazepine psychosis|lithium antipsychotics benzodiazepines antidepressants antidepressant|lithium|current drug therapy for bipolar disorder includes the use of entity and anti-depressants .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|lithium valproate AND carbamazepine psychosis|lithium benzodiazepines antipsychotics antidepressants valproate|lithium|mood-stabilizing drugs can treat bipolar symptoms when they are present , including entity and anticonvulsants , such as valproic acid and lamotrigine .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|lithium valproate AND carbamazepine psychosis|medicines generic marketed affordable expensive|lithium|retail sales of energizers entity and rechargeable products increased 22% in the quarter while our price-oriented product sales declined 12% .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1), ('DIS', 1)])|drug|lithium valproate AND carbamazepine psychosis|paclitaxel docetaxel bortezomib metformin gemcitabine|lithium|to date , the only drug that interacted with zs-9 is entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|lithium valproate AND carbamazepine psychosis|alb ma ed po lat|lithium|mr . friess and mr . schwartz sold most of their shares of pisv for $275 , 000 and pisv became china entity technologies inc . listed on the otcbb symbol ( cltt ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|lithium valproate AND carbamazepine psychosis|electrically externally powered battery specially|lithium|chairman of cardiac pacemakers , inc . , a company founded by mr . villafana to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|lithium valproate AND carbamazepine psychosis|battery electrical electric lithium electrochemical|lithium|the e-go is an all-electric vehicle powered by advanced entity batteries .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|lithium valproate AND carbamazepine psychosis|lithium heavy magnesium dual dry|lithium|inc . , a company that is engaged in the manufacture , commercialization and distribution of a wide variety of standard and customized entity ion rechargeable batteries .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|lithium valproate AND carbamazepine psychosis|olanzapine fluoxetine lithium naltrexone gabapentin|lithium|these adjunctive agents may include atypical antipsychotics , like aripiprazole and quetiapine , or other agents such as buproprion and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|lithium valproate AND carbamazepine psychosis|fluoxetine gabapentin lithium olanzapine clozapine|lithium|in the last few years several academic research initiatives were conducted to explore the efficacy of approved drugs such as entity , varenicline ( chantix ® ) , riluzol and dalfampridine .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|lithium valproate AND carbamazepine psychosis|lithium olanzapine haloperidol carbamazepine fluoxetine|lithium|for the treatment of patients with depressive episodes associated with bipolar i disorder as monotherapy and as adjunctive therapy with entity or valproate , which expires in june 2016 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|lithium valproate AND carbamazepine psychosis|electrically externally battery powered optimally|lithium|( now a division of guidant corporation ) , a company founded by mr . villafaña to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lithium valproate AND carbamazepine psychosis|lithium monotherapy carbamazepine olanzapine fluoxetine|lithium|in the iti-007-402 trial , patients receive lumateperone or placebo adjunctive to their existing mood stabilizer entity or valproate .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|lithium valproate AND carbamazepine psychosis|lithium electrochemical counter magnesium dry|lithium|and as director to aug 2015 where he led a team of scientists and entrepreneurs for the development of solid-state entity ion battery for electric vehicles and smart grid applications .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|lithium valproate AND carbamazepine psychosis|lithium heavy dry magnesium electrochemical|lithium|the car is all-electric and powered by advanced entity ion batteries .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|lithium valproate AND carbamazepine psychosis|lipids hormones vitamins ketones sugars|lithium|· with further investment , other patches can be developed which are able to measure alternative analytes , including lactates , uric acid , entity and drugs .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|lithium valproate AND carbamazepine psychosis|batteries battery electrodes cycling electronics|lithium|recently , higher power , higher priced entity and rechargeable batteries have grown in response to more demanding power needs of more advanced devices .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lithium valproate AND carbamazepine psychosis|lithium monotherapy olanzapine carbamazepine gabapentin|lithium|abilify®  in february , the fda approved abilify as an adjunct to mood stabilizers entity or valproate for the maintenance treatment of bipolar i disorder .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|lithium valproate AND carbamazepine psychosis|magnesium battery electric lithium alkali|lithium|the u . s . retail battery category is defined as alkaline , carbon zinc , entity , rechargeable and specialty batteries .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|propofol fentanyl magnesium dexmedetomidine bupivacaine|vecuronium|( sugammadex ) injection 100 mg / ml was approved by the fda for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|magnesium fentanyl atropine propofol salbutamol|vecuronium|is specifically designed to reverse the effects of certain muscle relaxants , marketed in the united states as zemuron ( r ) ( rocuronium bromide ) and entity bromide .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|polyvinyl Am lithium magnesium vinyl|vecuronium|we initiated a recall of a batch of entity bromide , a product we 43 market on behalf of a third party , in february 2001 due to concerns with filtration-testing
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|lidocaine paclitaxel vancomycin methotrexate morphine|vecuronium|the first u . s . regulatory approvals on products that are difficult to produce , such as etoposide ( with gll ) , bleomycin , pancuronium and entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|author spons proceed subm approval|vecuronium|the company is manufacturing and marketing entity bromide prior to expiration of the patent covering this product pursuant to a licensing arrangement .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|metformin calcitonin ibuprofen doxycycline magnesium|vecuronium|nevzat ilac sanayii a . s . , a subsidiary of amgen , inc . , ( mn ) to acquire the rights to three products : methylprednsilone sodium succinate , entity and pamidronate disodium .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|propofol fentanyl dexmedetomidine bupivacaine magnesium|vecuronium|in december 2015 , the fda approved bridion for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|bupivacaine propofol fentanyl lidocaine midazolam|vecuronium|of a clinical trial site for sugammadex , mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|propofol fentanyl magnesium bupivacaine dexmedetomidine|vecuronium|demand of bridion ( sugammadex ) injection 100 mg / ml , a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|gemcitabine carboplatin docetaxel paclitaxel trastuzumab|vecuronium|in addition , we have been able to help alleviate market shortages through the launches of entity and paclitaxel .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|benzyl lithium magnesium methylene bromide|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity bromide under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|magnesium diclofenac dexmedetomidine atropine salbutamol|vecuronium|for purposes of this paragraph , the term " krypton products " refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|propofol bupivacaine fentanyl lidocaine sevoflurane|vecuronium|sugammadex sodium injection is mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|salbutamol magnesium vinyl diclofenac nicotine|vecuronium|dosage product portfolio are 45 products for which the company is currently the sole generic source , one of which is entity bromide .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|bromide barium magnesium vinyl polyvinyl|vecuronium|due to deviations from the fda  s manufacturing regulations , we are conducting voluntary product recalls of entity bromide and pte-4 products .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|vaccines cigarettes medicines tablets chemicals|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|polyvinyl Am lithium magnesium vinyl|vecuronium|we initiated a recall of a batch of entity bromide , a product we market on behalf of a third party , in february 2001 due to concerns with filtration- testing
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|magnesium diclofenac metoprolol salbutamol dexmedetomidine|vecuronium|for purposes of this paragraph , the term krypton products refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|propofol bupivacaine fentanyl lidocaine morphine|vecuronium|for odanacatib for osteoporosis , suvorexant for insomnia and sugammadex sodium injection for reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sevoflurane neuromuscular bupivacaine intraoperatively Versus|vaccines cigarettes medicines cannabis chemicals|vecuronium|in march 2000 , schein resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|ceftriaxone imipenem metronidazole vancomycin ampicillin|avibactam|the ceftazidime / entity combination product forest expects will receive three years of hatch-waxman exclusivity upon approval .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|imipenem ta dor ceftriaxone am|avibactam|for cre infections , physicians have resorted to older drugs such as colistin or more recently drugs such as tigecycline and ceftazidime / entity .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|azithromycin clarithromycin ciprofloxacin AMP fluconazole|avibactam|entity is a novel , non beta-lactam , beta lactamase inhibitor , quite a mouthful , itself as a molecule does not possess intrinsic antibacterial
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|CLA MRSA ABL CDI BCG|avibactam|entity is currently being developed in combination with ceftazidime , a cephalosporin antibiotic .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|arginine glutathione glutamine EDTA nitrite|avibactam|the addition of entity to ceftazidime protects ceftazidime from breakdown by β-lactamases .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|ciprofloxacin ceftriaxone imipenem metronidazole gentamicin|avibactam|it consists of a combination of entity and ceftazidime - a third generation antipseudomonal cephalosporin with a well-established efficacy and safety profile .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|EDTA nitrite arginine lactose AMP|avibactam|the addition of entity protects ceftazidime from being broken down by beta-lactamases that are produced by resistant bacteria .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|imipenem azithromycin ciprofloxacin vancomycin ceftriaxone|avibactam|it has structural similarities to entity , a bli recently approved in combination with ceftazidime ( avycaz ) .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|imipenem vancomycin ceftriaxone monotherapy ciprofloxacin|avibactam|almirall for las100977   0 . 25 licensing payment to astrazeneca for entity and ceftazidime / entity   0 . 75 rounding  
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|imipenem ceftriaxone ciprofloxacin ampicillin am|avibactam|actavis and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|He She FDA India Success|avibactam|entity is also protected by an issued united states patent directed to combinations with an antibiotic that expires in 2026 .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|ceftriaxone TEM imipenem ciprofloxacin ADA|avibactam|entity is a first-in-class broad-spectrum β-lactamase inhibitor , which protects ceftazidime against degradation by class a , c and some d , β-lactamases .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|he she He FDA She|avibactam|in addition , entity is protected by a united states composition-of-matter patent that expires in 2022 , without pte .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|imipenem ceftriaxone ampicillin ciprofloxacin gentamicin|avibactam|based on the results of these studies , we and astrazeneca initiated phase iii studies for ceftazidime / entity in patients with ciai in december 2011 and in patients with cuti in july 2012 .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|imipenem ceftriaxone ciprofloxacin vancomycin gentamicin|avibactam|in fiscal 2013 , these costs were largely related to clinical trials for nebivolol / valsartan , aclidinium / formoterol , vilazodone , memantine , and ceftazidime / entity .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|imipenem ceftriaxone ta ampicillin am|avibactam|actavis plc and astrazeneca plc are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|else yourself next another too|avibactam|so we are very excited to introduce to you entity .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|vancomycin clarithromycin clindamycin metronidazole carbapenem|imipenem ceftriaxone ciprofloxacin gentamicin ta|avibactam|forest laboratories and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|capecitabine irinotecan docetaxel gemcitabine cetuximab|irinotecan|erbitux product labeling to include overall survival data as a single agent in egfr-expressing mcrc patients after failure of both entity- and oxaliplatin-based regimens .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|irinotecan everolimus paclitaxel capecitabine Dox|irinotecan|sn38 is the active metabolite of cpt-11 ( entity ) , which is approved for the treatment of colorectal cancer .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|formulation FDA approval name approved|irinotecan|the fda approved entity as camptosar in 1994 for use in colorectal cancer .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|bevacizumab capecitabine trastuzumab docetaxel cetuximab|irinotecan|erbitux ( r ) is approved in united states , austria , canada , germany and switzerland for metastatic colorectal in combination with entity in entity-refractory patients .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|PDT FU paclitaxel cetuximab CPT|irinotecan|we did observe statistically significant improvements in progression free survival , or pfs , and other efficacy endpoints for ha-entity compared with irinotecan alone .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|gemcitabine etoposide docetaxel paclitaxel doxorubicin|irinotecan|entity and cisplatin are two established anticancer drugs which together constitute an active combination for treating sclc .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('BIO', 1)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|vincristine carboplatin cyclophosphamide irinotecan bevacizumab|irinotecan|note : chemotherapy regimens included temozolomide and entity .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|irinotecan capecitabine bevacizumab carboplatin gemcitabine|irinotecan|is to assess the safety and pharmacokinetics of mm-121 in combination with cetuximab and mm-121 in combination with cetuximab and entity .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|bevacizumab paclitaxel rituximab bortezomib cetuximab|irinotecan|one of our clinical development strategies is to replace the use of entity with mm-398 by demonstrating that mm-398 has favorable efficacy and safety characteristics compared to entity .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|deployed marketed licensed commercially market|irinotecan|that are currently conducted by aventis , together with certain patents and other assets relating to territories where pfizer currently markets entity , including the united states .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|paclitaxel gemcitabine docetaxel trastuzumab bortezomib|irinotecan|” the study was initiated following the demonstration of synergy between nimotuzumab and entity in the laboratories of daiichi sankyo in gastric cancer cell lines .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|irinotecan capecitabine bevacizumab cetuximab oxaliplatin|irinotecan|advanced colorectal cancer in which nuc-3373 will be combined with many of the agents typically combined with 5-fu , including leucovorin , entity , oxaliplatin and monoclonal antibodies .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|vaccination ii cessation augmentation prophylaxis|irinotecan|clinical development of mm-398 we are pursuing two approaches in the ongoing clinical development of mm-398 : replace entity .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|irinotecan paclitaxel docetaxel gemcitabine capecitabine|irinotecan|two camptothecin derivatives , topotecan and entity , have been approved by the fda for the treatment of small-cell lung , ovarian , and colorectal cancers .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|irinotecan capecitabine bevacizumab cetuximab paclitaxel|irinotecan|most systemic therapies for colorectal cancer include 5-fu , either as monotherapy or in combination with another chemotherapeutic , typically oxaliplatin or entity .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|irinotecan capecitabine cetuximab fluorouracil gemcitabine|irinotecan|this study enrolled 463 patients with metastatic colorectal cancer who had failed standard entity- and oxaliplatin-containing chemotherapy .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|paclitaxel doxorubicin gemcitabine irinotecan metformin|irinotecan|these two adcs facilitate targeted delivery of sn-38 , the active metabolite of entity , an effective , yet toxic chemotherapeutic , directly to tumor cells .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|Dox Cis Tax carboplatin Drug|irinotecan|entity and cisplatin combinations were evaluated systematically for drug ratio-dependent synergy in vitro using a panel of 20 tumor cell lines .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('BIO', 1)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|thalidomide bortezomib imatinib irinotecan oxaliplatin|irinotecan|our clinical strategy is to administer birinapant with therapies ( for example , azacitidine or entity ) that induce the production of tnf or related molecules .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|irinotecan gefitinib capecitabine paclitaxel cetuximab|dal LMWH colleagues statins statin|irinotecan|since that time he has had increasing responsibility for overseeing the global research plans and teams for entity and dalteparin .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|max pyruvate paclitaxel metformin metronidazole|statement category name configuration section|minocycline|“its quite unique in that its a entity topical ; i dont like a lot of the entity oral [ products ] , but entity topical – i can certainly get excited about .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|max pyruvate paclitaxel metformin metronidazole|formulations dosing fluconazole administrations contraceptives|minocycline|reported novel imaging techniques , suggesting that bpx-01 effectively targets p . acnes in the skin without the systemic side effects of oral entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|max pyruvate paclitaxel metformin metronidazole|corticosteroid ophthalmic spray topical ointment|minocycline|in october , they received approval for their first product , amzeeq , a topical entity formulation for the treatment of acne .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|max pyruvate paclitaxel metformin metronidazole|cream lidocaine NaCl FC fluconazole|minocycline|in this study , no serious adverse events were observed and the treatment-related adverse events were related to dermal irritation in the 2% entity treatment arm .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|max pyruvate paclitaxel metformin metronidazole|clindamycin azithromycin metronidazole erythromycin fluconazole|minocycline|our lead product candidate , fmx101 for moderate-to-severe acne , is a novel topical foam formulation of the antibiotic entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|max pyruvate paclitaxel metformin metronidazole|alfa ex lambda ve 125|minocycline|in september 1999 we recognized a gain of $2 . 7 million on the sale of our vectrin ( r ) entity hcl product line .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|max pyruvate paclitaxel metformin metronidazole|formulation corticosteroid contraceptive retinoid ingredient|minocycline|solodyn , a branded oral entity , the current standard of care for moderate-to-severe acne , accounted for nearly one half of the total branded oral market for
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|max pyruvate paclitaxel metformin metronidazole|ascorbate oxalate magnesium nitrate pyrophosphate|minocycline|thus , it has been demonstrated that the amount of either entity or edetate that leaks into the serum is very low or none at all .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|max pyruvate paclitaxel metformin metronidazole|metronidazole fluconazole probiotics azithromycin vancomycin|minocycline|limitations of use : this formulation of entity has not been evaluated in the treatment of infections .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|max pyruvate paclitaxel metformin metronidazole|withdrawn eg ie another bevacizumab|minocycline|are marketed outside the u . s . during 1998 , the company filed anda  s for two products previously selected , from which one product , entity , received approval in march 1999 .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|max pyruvate paclitaxel metformin metronidazole|UVB erythema UVA cream fluconazole|minocycline|dose a resulted in 5 mg / cm2 of entity , which translates to approximately about 1 mg / g of skin .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|max pyruvate paclitaxel metformin metronidazole|steroids formulations glucocorticoids corticosteroid preparations|minocycline|limitations of current standard of care for acne : oral entity , such as solodyn , is the current standard of care for moderate-to-severe acne .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|max pyruvate paclitaxel metformin metronidazole|clarithromycin microbial multidrug metronidazole chloroquine|minocycline|mpts in blood serum and saliva in order to observe the drug release profile , and to assess the development of entity resistance .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|max pyruvate paclitaxel metformin metronidazole|curcumin prodrug DOX doxorubicin siRNA|minocycline|bpx-04 is designed to deliver the active , entity , into the skin without further irritating the skin .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|max pyruvate paclitaxel metformin metronidazole|cigarette sales dollar beer marijuana|minocycline|the prior year sales included $6 , 373 of entity sales which the company stopped selling in late 1999 because of deteriorating market conditions .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|max pyruvate paclitaxel metformin metronidazole|corticosteroid steroids retinoid contraceptives prednisone|minocycline|oral entity has been a commonly used treatment for acne for years .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|max pyruvate paclitaxel metformin metronidazole|metformin curcumin tryptophan resveratrol statins|minocycline|this approach was via structure-activity relationship chemistry-based modifications of the seven and nine positions of entity .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|max pyruvate paclitaxel metformin metronidazole|hydrophobic glycan tubulin aromatic conserved|minocycline|used its expertise in biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the entity core structure .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|max pyruvate paclitaxel metformin metronidazole|foam vaginal EV MF topical|minocycline|success in iga @ week 12 difference from vehicle fmx103 entity foam , 1 . 5% 10-week study epsolay® ( † ) sol-gel did not conduct a head-to-head comparison trial or study .
OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|max pyruvate paclitaxel metformin metronidazole|raw crude starting manufacturing packaging|minocycline|or the cipan agreement , which provides the terms and conditions under which cipan will manufacture and supply to the company entity starting material and crude omadacycline .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|rituximab bevacizumab bortezomib thalidomide paclitaxel|rasagiline|that are intended to alter the course of the disease , including the investigational drugs known as cep-1347 , gdnf , tch-346 and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Prior Alpha vulgaris tyrosinase|ten 125 tablet dried injectable|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|eg alt itraconazole metformin imatinib|rasagiline|a number of mao inhibitors are approved for pd therapy , including zelapar ( selegiline / valeant ) and azilect ( entity ; teva / lundbeck ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Prior Alpha vulgaris tyrosinase|submitted latest official updated FDA|rasagiline|teva and its strategic partner h . lundbeck a / s recently submitted the entity regulatory file to the european agency for evaluation of medicinal products .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|levodopa coated flexible floating tablet|rasagiline|about azilect® ( united states ) indication azilect® ( entity tablets ) is indicated for the treatment of the signs and symptoms of parkinsons disease ( pd ) both as initial therapy alone and
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|melatonin curcumin resveratrol quercetin metformin|rasagiline|youdim has published numerous articles describing entity  s neuroprotective and neurorescue activities in various laboratory models .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|125 levodopa tablet coated ten|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|levodopa Parkinson DBS parkinsonism dyskinesia|rasagiline|completion of the two phase iii clinical trials in march , teva submitted to the fda a new drug application for entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|whose levodopa injectable DBS capsule|rasagiline|developed by teva , entity tablets are approved in over 40 countries for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|tablet 125 levodopa coated ten|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|AND Prior Alpha vulgaris tyrosinase|midazolam morphine dopamine propranolol diclofenac|rasagiline|selectivity was tested by evaluating the interaction between tyramine and entity in healthy subjects .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|125 tablet ten levodopa flexible|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Prior Alpha vulgaris tyrosinase|tablet ten dried injectable crushed|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease and its second innovative drug , is now available in 29 countries .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Prior Alpha vulgaris tyrosinase|probiotics medicines therapeutics vaccines AgNPs|rasagiline| teva pharmaceutical industries ltd . ( israel ) : we are in collaboration with teva pharmaceutical industries ltd . to develop and commercialize entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|SC TAC RS max tablets|rasagiline|about azilect&reg azilect&reg tablets ( entity ) 1 mg / day are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Prior Alpha vulgaris tyrosinase|commercially market freely popularity soon|rasagiline|teva expects to market entity in europe with h . lundbeck a / s , and in the united states with its new strategic partner eisai inc . teva
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Prior Alpha vulgaris tyrosinase|max tablet ten ring 2nd|rasagiline|about azilect &reg azilect&reg 1 mg tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone and
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|tablet ten flexible levodopa 125|rasagiline|azilect® ( entity tablets ) is indicated as initial monotherapy and as an adjunct to levodopa for the treatment of the signs and symptoms
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|levodopa coated flexible tablet ten|rasagiline|about azilect® azilect® tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinsons disease both as initial therapy alone and
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|AND Prior Alpha vulgaris tyrosinase|tablet levodopa flexible ten crushed|rasagiline|azilect® ( entity tablets ) is indicated as an initial monotherapy and as an adjunct to levodopa for the treatment of the signs and
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|AND cholinergic Beta max propranolol|magnesium diclofenac chloride pyrid lithium|bethanechol|according to wolters kluwer , total sales of generic entity chloride 5mg , 10mg and 25mg tablets at awp were $56 million in 2007 .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|antidepressant fluoxetine depot antidepressants alfa|prednisolone glucocorticoids salbutamol prednisone methylprednisolone|nortriptyline|crx-170 is a novel synergistic combination drug candidate containing low dose budesonide and low dose entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|antidepressant fluoxetine depot antidepressants alfa|fluoxetine tramadol ketamine tricyclic haloperidol|nortriptyline|clinical trials of the antiepileptic agents gabapentin and lamotrigine and the antidepressants entity and amitriptyline have all been negative .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|antidepressant fluoxetine depot antidepressants alfa|prednisolone salbutamol ICS prednisone fluconazole|nortriptyline|on multiple measures such as psoriatic infiltrate thickness , erythema and clinical skin condition and produced greater improvements than mometasone and entity alone .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 2)])|drug|antidepressant fluoxetine depot antidepressants alfa|vaccination NSAIDs levodopa steroids diarrhea|nortriptyline|the 2 most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant fluoxetine depot antidepressants alfa|melatonin olanzapine benzodiazepines ketamine naltrexone|nortriptyline|procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant fluoxetine depot antidepressants alfa|melatonin olanzapine ketamine naltrexone benzodiazepines|nortriptyline|license from procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5mg to 10mg ) of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|antidepressant fluoxetine depot antidepressants alfa|cr doxycycline celecoxib PDT pi|nortriptyline|crx-170 did not show a modulation of the inflammatory marker cd163 from the treatment baseline , although entity clearly did decrease cd163 on its own .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|antidepressant fluoxetine depot antidepressants alfa|midazolam fluoxetine haloperidol clonidine diazepam|nortriptyline|crx-191 contains a mid- potency glucocorticosteroid , mometasone , and a low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|antidepressant fluoxetine depot antidepressants alfa|fluoxetine midazolam haloperidol olanzapine clonidine|nortriptyline|crx-191 contains a mid-potency glucocorticosteroid , mometasone , and a very low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|antidepressant fluoxetine depot antidepressants alfa|vaccination NSAIDs levodopa steroids metformin|nortriptyline|the most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant fluoxetine depot antidepressants alfa|melatonin olanzapine ketamine naltrexone benzodiazepines|nortriptyline|license from procom one , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|antidepressant fluoxetine depot antidepressants alfa|fluoxetine midazolam haloperidol lithium clonidine|nortriptyline|about crx-170 crx-170 is an oral synergistic combination drug candidate containing low doses of the steroid prednisolone and the anti-depressant entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis paclitaxel alfa formulations formulation|formulations vaccines contraceptives AEDs preparations|terbinafine|we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|psoriasis paclitaxel alfa formulations formulation|fluconazole itraconazole metronidazole colchicine azithromycin|terbinafine|mycova™ combines an existing , approved drug for nail fungus , entity , with the nexact® technology that enhances the absorption of the drug through the skin .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|psoriasis paclitaxel alfa formulations formulation|medicines vaccines opioids contraceptives cannabis|terbinafine|consistent with this strategy , during fiscal 2006 we commenced sales of generic entity in certain european markets through an out-licensing arrangement .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|psoriasis paclitaxel alfa formulations formulation|bevacizumab tacrolimus steroids fluconazole itraconazole|terbinafine|“novartis formulation”means any topical formulation of entity ( other than the nexmed formulation ) developed by or on behalf of novartis .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|psoriasis paclitaxel alfa formulations formulation|fluconazole itraconazole azithromycin ciprofloxacin amphotericin|terbinafine|nm100060 is topically applied , and incorporates entity , a currently marketed oral anti-fungal drug , with the nexact® technology , which facilitates the permeation of the drug through the nail
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|psoriasis paclitaxel alfa formulations formulation|ointment cream alfa hydrochloride antifungal|terbinafine|aerosol no protection lamisil entity ( entity hydrochloride ) fungal infection of the skin and nails caused by dermatophyte fungi tinea capitis fungal infections of the skin
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|psoriasis paclitaxel alfa formulations formulation|topical trade antifungal medicinal generic|terbinafine|worldwide sales of the branded entity product lamisil , the most prescribed systemic drug for onychomycosis , were $1 . 2 billion in 2004 and $978 million in 2006 , when
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis paclitaxel alfa formulations formulation|randomised pivotal definitive latter planned|terbinafine|umang vohra though the entity trials are ongoing , we have not got an early read kind of a methodology for that trial and we hope
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|psoriasis paclitaxel alfa formulations formulation|metformin antidiabetic olanzapine resveratrol risperidone|terbinafine|significant product launches in fiscal 2006 included glimepiride tablets and zonisamide tablets in the united states and entity tablets in the united kingdom .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|psoriasis paclitaxel alfa formulations formulation|itraconazole fluconazole cyclosporine thalidomide azithromycin|terbinafine|treatments are segmented into two approaches , either oral therapies , such as entity , or topical products , such as jublia , an azole , and kerydin , an oxaborole .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis paclitaxel alfa formulations formulation|investigational medicinal own generic topical|terbinafine|evolved for promius pharma as a whole and how do you see that going forward and some update on your entity product for which you had phase three already enrolled?
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|psoriasis paclitaxel alfa formulations formulation|metformin atorvastatin fluoxetine olanzapine sildenafil|terbinafine|new product launches in fiscal 2006 included the generic versions of glimepiride , lansoprazole , lisinopril , sertraline and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|psoriasis paclitaxel alfa formulations formulation|omeprazole clarithromycin metronidazole ciprofloxacin diclofenac|terbinafine|during fiscal 2008 , we launched carvedilol tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , entity and ciprofloxacin er tablets .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|psoriasis paclitaxel alfa formulations formulation|formulations bevacizumab rituximab trastuzumab tacrolimus|terbinafine|despite its high labeled efficacy ( 38% ) , we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis paclitaxel alfa formulations formulation|KP MF EV DF PV|terbinafine|lamisil ( entity ) , a systemic drug approved for onychomycosis , had worldwide peak sales of $1 . 2 billion in 2004 , before generic entry .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|psoriasis paclitaxel alfa formulations formulation|fluconazole itraconazole erythromycin metronidazole cyclosporin|terbinafine|preclinical studies have shown that itraconazole , the antifungal agent in hyphanox , has a broader spectrum of activity than entity , the antifungal agent in lamisil .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|psoriasis paclitaxel alfa formulations formulation|methamphetamine buprenorphine cocaine fluoxetine olanzapine|terbinafine|however , this was offset to some extent by a decrease in sales of entity and sertraline .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|psoriasis paclitaxel alfa formulations formulation|buprenorphine risperidone bevacizumab paracetamol trastuzumab|terbinafine|period ending june 30 , 2010 , 1 . 4 million new prescriptions were filled in the united states for both branded and generic versions of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|psoriasis paclitaxel alfa formulations formulation|itraconazole fluconazole MF KP DF|terbinafine|lamisil ( entity ) is a treatment for fungal nail infection ( onychomycosis ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|psoriasis paclitaxel alfa formulations formulation|gabapentin Germany ie eg Switzerland|terbinafine|a generic version of lamisil , entity , recently became available .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|Prior starting AND peg alfa|ribavirin ritonavir metformin lamivudine chloroquine|ledipasvir|harvoni combines the ns5a inhibitor entity with sofosbuvir and is indicated for an eight , 12 or 24 week treatment duration depending on prior treatment history , cirrhosis
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|Prior starting AND peg alfa|ribavirin sof statin peg ritonavir|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni , a entity / sofosbuvir combination for patients with genotype 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|Prior starting AND peg alfa|ribavirin ritonavir imatinib lamivudine sorafenib|ledipasvir|pending patent applications directed to the use of combinations for the treatment of hcv , and , specifically , to the combination of entity and sofosbuvir .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|Prior starting AND peg alfa|ribavirin lamivudine ritonavir metronidazole sof|ledipasvir|gilead sciences markets harvoni as a  cure  for hepatitis c . it combines two drugs : sovaldi ( sofosbuvir ) and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|Prior starting AND peg alfa|boron phosphorus sulfur lactose metals|ledipasvir|additionally , abbvie has obtained canadian patent no . 2 , 857 , 339 ( the 339 patent ) which purports to cover a solid composition that contains entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|Prior starting AND peg alfa|ribavirin lamivudine ritonavir metformin metronidazole|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|Prior starting AND peg alfa|ribavirin ritonavir lamivudine metformin atorvastatin|ledipasvir|in october 2014 , we also received approval of the fixed-dose combination of entity and sofosbuvir , now known commercially as harvoni .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|Prior starting AND peg alfa|ribavirin ritonavir lamivudine metformin clarithromycin|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni® , a fixed-dose combination of sofosbuvir and entity ( a ns5a inhibitor ) for patients with genotype 1 hcv .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|Prior starting AND peg alfa|clarithromycin fluconazole rifampin chloroquine rifampicin|ledipasvir|the hcv ns5a drug resistance assay assesses resistance to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|Prior starting AND peg alfa|ritonavir ribavirin metformin sorafenib lamivudine|ledipasvir|resistance to sofosbuvir , which was approved as a single daa in 2013 and as a co-formulation with the ns5a inhibitor , entity , in 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|Prior starting AND peg alfa|ritonavir ribavirin sorafenib simvastatin statin|ledipasvir|separately , results from a phase 2 study demonstrated the safety and efficacy of entity / sofosbuvir in patients with genotypes 4 or 5 infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|Prior starting AND peg alfa|ribavirin lamivudine ritonavir metformin metronidazole|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi® ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|Prior starting AND peg alfa|EGCG Zinc chloroquine Interferon AMP|ledipasvir|entity inhibits the ns5a hcv viral protein .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|cure cured R0 responders zero|fluoxetine|as cured ( with a ham-d score lower than 8 ) , we had between 37% and 39% , of a similar order to entity .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|fluoxetine risperidone ketamine morphine olanzapine|fluoxetine|vilazodone has greater in vitro potency and selectivity for serotonin reuptake than compounds such as entity .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|fluoxetine olanzapine gabapentin diazepam ketamine|fluoxetine|compete with newer generation anti-depressants used to treat hot 17 table of contents flash frequency , such as venlafaxine by wyeth , entity by eli lilly and paroxetine by glaxo smith kline .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|He MDMA FDA Placebo She|fluoxetine|entity is the generic equivalent of eli lilly  s prozac antidepressant , which is patent protected and had annual sales of $1 . 7 billion for the twelve months ended september 30 , 1997 .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|isomer isomers variant formulation enantiomers|fluoxetine|in the same preclinical studies , the ssri entity did not induce rapid onset antidepressant-like responses .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|antipsychotic risperidone olanzapine antipsychotics fluoxetine|fluoxetine|entity capsules central nervous system anti-psychotic rs .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|bevacizumab trastuzumab tamoxifen celecoxib metformin|fluoxetine|product sales , excluding entity and tamoxifen , were approximately $122 million during the third quarter .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|gabapentin fluoxetine antidepressants lithium olanzapine|fluoxetine|commonly prescribed drugs for other symptoms include ditropan or detrol for bladder dysfunction , provigil for fatigue , entity for depression , and amitriptyline for pain .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|you NSAIDs IBS nausea sedation|fluoxetine|you can see that the adverse effects are relatively traditional for entity : essentially digestive , gastrointestinal orders and nausea and disappear in function of time .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|fluoxetine gabapentin ketamine olanzapine tramadol|fluoxetine|major marketed brands include tofranil ( imipramine ) , prozac ( entity ) , paxil ( paroxetine ) , luvox ( fluoxamine ) and zoloft ( sertaline ) .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|venom ginseng capsule formulation monkey|fluoxetine|the api entity has been the subject of multiple studies in humans and has been approved for use in humans for decades .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|marketing publication granted sale approval|fluoxetine|the company filed its application for entity in january 1996 , and has been sued for patent infringement by eli lilly , initiating the patent challenge process .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|fluoxetine tricyclic AND antidepressants vulgaris|request Internet board campus ice|fluoxetine|based on a recent federal court of appeals ruling , lilly  s composition of matter patent on entity will expire in the summer of 2001 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|AND bup injectable nicotine depot|morphine caffeine lidocaine methadone fentanyl|bupropion|/ mecamylamine tablets formulation and method of making tablets containing entity and mecamylamine issued march 9 , 2010 expires july 25 , 2027 us appl .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|AND bup injectable nicotine depot|naltrexone nicotine olanzapine pharmacotherapy gabapentin|bupropion|neuropsychiatric reactions in patients taking entity for smoking cessation serious neuropsychiatric reactions have occurred in patients taking bupropion for smoking cessation .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|AND bup injectable nicotine depot|phenytoin simvastatin atorvastatin valproate erythromycin|bupropion|adverse events and laboratory findings appeared to be consistent with the individual components of empatic , entity and zonisamide .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|AND bup injectable nicotine depot|buprenorphine methadone morphine naltrexone nicotine|bupropion|however , we could be exposed to potential patent infringement liability from other third parties who hold patents on various formulations of entity and naltrexone .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|drug|AND bup injectable nicotine depot|Placebo SC metformin naltrexone CBT|bupropion|approximately 60 smokers interested in quitting will be randomized in a 1 : 1 ratio to receive either axs-05 or entity for 4 weeks .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND bup injectable nicotine depot|DMF MET Dox TMP DAP|bupropion|for all doses tested , administration of dm in combination with entity resulted in substantial increases in auc0‑12 and cmax values of dm on day 8 as compared to day 1 of dosing .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|AND bup injectable nicotine depot|metformin resveratrol curcumin bevacizumab sildenafil|bupropion|in addition , empatic contains entity , the same active ingredient that gave rise to the fdas concerns regarding the cardiovascular safety profile of nb32 , which depending
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|AND bup injectable nicotine depot|olanzapine magnesium metformin sildenafil naltrexone|bupropion|aplenzin is a once-daily formulation of entity hydrobromide and has been approved in 174mg , 348mg , and 522mg extended-release tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|AND bup injectable nicotine depot|another nonrespond responders zero superiority|bupropion|we are very encouraged by the magnitude of superiority in responders over entity , the active control .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|AND bup injectable nicotine depot|alfa eg XL rh Pro|bupropion|in 2001 , we licensed our once-daily formulation of entity hcl to gsk and have been collaborating with them to seek regulatory approval of wellbutrin xl .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND bup injectable nicotine depot|er os mic das bup|bupropion|for this period also includes a $3 . 0 million bond received from glaxo to settle all patent infringement litigation relating to entity hcl , er 100 mg and 150 mg tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('BIO', 1)])|drug|AND bup injectable nicotine depot|calcitonin ibuprofen bisphosphonates doxycycline methotrexate|bupropion|that we are pursuing ; however , generic forms of the active ingredients of our product candidates , including zoledronic acid , dm , and entity , are available and could be used off‑label .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND bup injectable nicotine depot|naltrexone ab ef pal ex|bupropion|we have entered into long-term supply agreements for the supply of naltrexone and entity api .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|AND bup injectable nicotine depot|GSK os 125 Ro ex|bupropion|biovail also acquired the right to market its once-daily formulation of entity hcl in canada under the trade name wellbutrin® xl if regulatory approval is received .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|AND bup injectable nicotine depot|excipients FDA metformin bevacizumab psoriasis|bupropion|for example , we have in-licensed from glaxosmithkline certain formulation patents related to entity that expand our formulation options as we develop our commercial formulation of contrave .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|AND bup injectable nicotine depot|naltrexone diclofenac buprenorphine naloxone tramadol|bupropion|the basis of the pet results , we added a second set of patients randomized either to 32mg naltrexone plus 400mg entity sr or a double placebo .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|AND bup injectable nicotine depot|risperidone depot olanzapine naltrexone injectable|bupropion|forfivo xl® ( entity extended-release ) is the first 450 mg bupropion hcl tablet indicated for major depressive disorder , approved by the fda .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|AND bup injectable nicotine depot|formulation potency counterpart brand substance|bupropion|cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|AND bup injectable nicotine depot|formulation potency brand enantiomer counterpart|bupropion|: cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|topical AND alfa ophthalmic preparations|GSK vaccines vaccinia influenza BCG|albuterol|for which we provide sterile manufacturing services include several influenza 2 table of contents vaccines , xopenex® , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|topical AND alfa ophthalmic preparations|smokers bronchoscopy nonsmokers sputum COPD|albuterol|in the respiratory market , we compete primarily against entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|topical AND alfa ophthalmic preparations|docetaxel bevacizumab rituximab bortezomib paclitaxel|albuterol|we also evaluated rpl554 administered as an add-on therapy to either entity or ipratropium , in each case as compared to entity or ipratropium alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|topical AND alfa ophthalmic preparations|Placebo azithromycin ICS ACT salbutamol|albuterol|symbicort demonstrated a 51% reduction in the rate of annual asthma exacerbations , compared to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|topical AND alfa ophthalmic preparations|salbutamol propranolol cannabinoid naltrexone THC|albuterol|xopenex inhalation solution and generic entity inhalation solution currently account for the majority of beta-agonist inhalation solution prescriptions in the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|topical AND alfa ophthalmic preparations|methadone morphine sy salbutamol nicotine|albuterol|the second quarter 2007 to institute a new , bundled payment amount for xopenexò brand leventity hcl inhalation solution and generic entity inhalation solution products .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|topical AND alfa ophthalmic preparations|salbutamol lidocaine propofol phenobarbital morphine|albuterol|effective january 1 , 2007 , cms established new billing codes and payment methodologies for other compounded inhalation drugs , including entity and ipratropium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|topical AND alfa ophthalmic preparations|salbutamol magnesium zinc barium morphine|albuterol| proair digihaler ( entity sulfate 117 mcg ) inhalation powder is the first and only digital inhaler with built-in sensors which connects to a companion
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|topical AND alfa ophthalmic preparations|investigational injectable approved ideal ophthalmic|albuterol|in 1998 , ivax also applied for approval to market an entity non-cfc formulation in various european countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|drug|topical AND alfa ophthalmic preparations|Placebo Asthma Exercise EPA MMF|albuterol|entity is the most widely used mdi product approved for the treatment of asthma , accounting for nearly $680 million in sales
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|topical AND alfa ophthalmic preparations|He She FDA Tobacco Food|albuterol|entity is marketed by glaxowellcome plc ( " glaxowellcome " ) , schering-plough and others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|topical AND alfa ophthalmic preparations|powder flexible salbutamol nicotine portable|albuterol|with xopenex hfa , we compete with generic chlorofluorocarbon-based entity metered-dose inhalers and brand-name hfa entity metered-dose inhalers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|topical AND alfa ophthalmic preparations|weekly triple QD monthly probiotic|albuterol|cfc-containing entity mdis are required to be phased-out before the end of 2008 , with patients increasingly transitioning to hfa 2 mdis .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|topical AND alfa ophthalmic preparations|prednisolone prednisone ICS corticosteroid salbutamol|albuterol|there was no difference in the exacerbation rate between symbicort and twice-daily maintenance budesonide plus entity , despite a 52% reduction in the mean steroid dose with symbicort .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|topical AND alfa ophthalmic preparations|salbutamol selenium ibuprofen rice mannitol|albuterol|upon commercialization , zambon will be entitled to certain royalties on payments received by us for entity , ipratropium and cromolyn sales for specified periods .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|topical AND alfa ophthalmic preparations|HES Its ACT Therapy TXA|albuterol|entity has been marketed for many years , is well established and sells at prices substantially lower than xopenex inhalation solution .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|topical AND alfa ophthalmic preparations|fluoro var chlor fum penta|albuterol|this increase was principally due to the continued transition of patients previously using chlorofluorocarbon ( cfc ) entity mdis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|topical AND alfa ophthalmic preparations|ex eryth av var alfa|albuterol|almost one-half of the market is still comprised of cfc entity mdis , representing a sizeable remaining market opportunity for the xopenex hfa product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|topical AND alfa ophthalmic preparations|federal financial Medicaid grant official|albuterol|non-refundable $65 million cash deposit and issuance of letters of credit for the remaining balance , to be held by the entity settlement trust fund as security for potential future payments .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|topical AND alfa ophthalmic preparations|IgE egg generic peanut hair|albuterol|this reflected the impact of generic entity substitutes on ventolin in the us , the impact of covid-19 pandemic related destocking in europe and allergy market contraction in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|diclofenac alfa P2Y depot ophthalmic|ointment cream alfa hydrochloride tablets|tromethamine|pursuant to the sprix purchase agreement , the company acquired specified assets and liabilities associated with sprix ( ketorolac entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|diclofenac alfa P2Y depot ophthalmic|hydrochloride ophthalmic topical HCl acetate|tromethamine|entities acting in concert with them , are enjoined from making any preparations to make , sell , or offer for sale ketorolac entity ophthalmic solution 0 . 5% in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|diclofenac alfa P2Y depot ophthalmic|cream ophthalmic topical depot ointment|tromethamine|district court for the eastern district of texas alleging patent infringement claims against the company relating to the 0 . 4% ketorolac entity formulation .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|diclofenac alfa P2Y depot ophthalmic|acetate cream alfa HCl hydrochloride|tromethamine|egalet has two approved products : oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|diclofenac alfa P2Y depot ophthalmic|alfa hydrochloride HCl XL citrate|tromethamine|the company has two vda drug candidates currently being tested in clinical trials , fosbretabulin entity , or fosbretabulin , and oxi4503 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|diclofenac alfa P2Y depot ophthalmic|registry formulation pump insert website|tromethamine|the fosbretabulin entity is being provided to ctep under a cooperative research and development agreement ( crada ) with oxigene and the bevacizumab is being
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|diclofenac alfa P2Y depot ophthalmic|HCl hydrochloride alfa cream acetate|tromethamine|for example , ketorolac entity is an injectable nsaid that had significant sales prior to the fdas imposing a black box warning limiting the combined
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|diclofenac alfa P2Y depot ophthalmic|acetate cream alfa hydrochloride HCl|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|diclofenac alfa P2Y depot ophthalmic|acetate cream alfa hydrochloride HCl|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|diclofenac alfa P2Y depot ophthalmic|hydrochloride sulfate HCl alfa sulphate|tromethamine|drug substances the api used in sprix nasal spray is ketorolac entity , in oxaydo is oxycodone hydrochloride , in arymo er is morphine sulfate , and in egalet‑002 is oxycodone hydrochloride .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|diclofenac alfa P2Y depot ophthalmic|alfa acetate hydrochloride ointment cream|tromethamine|pursuant to which the company engaged jhs to provide certain services related to the manufacture and supply of sprix® ( ketorolac entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|diclofenac alfa P2Y depot ophthalmic|alfa hydrochloride HCl acetate cream|tromethamine|use only cii , developed using egalets proprietary guardian technology , oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|diclofenac alfa P2Y depot ophthalmic|alfa hydrochloride HCl acetate cream|tromethamine|we are marketing two innovative pain products , sprix® ( ketorolac entity ) nasal spray and oxaydotm ( oxycodone hci , usp ) tablets for oral use onlycii .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|diclofenac alfa P2Y depot ophthalmic|B1 diphosphate B2 glucuronide lactone|tromethamine|our lead compound is ca4p , which is also known as combretastatin a4-phosphate , fosbretabulin entity , fosbretabulin and zybrestat® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|diclofenac alfa P2Y depot ophthalmic|alfa acetate cream hydrochloride ointment|tromethamine|pursuant to the purchase agreement , the company acquired specified assets and liabilities associated with sprix® ( ketorolac entity )
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|diclofenac alfa P2Y depot ophthalmic|alfa hydrochloride HCl acetate cream|tromethamine|the company is currently marketing sprix® ( ketorolac entity ) nasal spray ( “sprix nasal spray” ) and oxaydo® ( oxycodone hci , usp ) tablets for oral use only—cii ( “oxaydo” ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|vancomycin AND ceftriaxone azithromycin alfa|sildenafil metformin clopidogrel digoxin acetaminophen|ceftriaxone|the increase in other u . s . sales was primarily due to increased sales of new products ( entity and deferoxamine ) to alternate site healthcare customers .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|vancomycin AND ceftriaxone azithromycin alfa|clindamycin metronidazole azithromycin ciprofloxacin lidocaine|ceftriaxone|the current standard of treatment for bacterial urethritis / gonorrhea requires combination therapy including both an intramuscular injection of entity and oral azithromycin ( 1000 mg ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|vancomycin AND ceftriaxone azithromycin alfa|vancomycin ciprofloxacin metronidazole chloramphenicol ribavirin|ceftriaxone|cdi , c . difficile associated diarrhea ( cdad ) and aad in patients hospitalized for a lower respiratory tract infection and receiving iv entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|vancomycin AND ceftriaxone azithromycin alfa|contraception therapeutics PrEP formulations contraceptives|ceftriaxone|to utilize ihma  s expertise and experience in " bridge " oral drug delivery techniques to research , develop and commercialize oral forms of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|vancomycin AND ceftriaxone azithromycin alfa|raw gross fresh finished imported|ceftriaxone|included in the amount pending approval at june 30 , 2005 was $7 . 4 million of entity raw material and finished product .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|vancomycin AND ceftriaxone azithromycin alfa|USD dollars GDP Medicaid pharmacy|ceftriaxone|included in the amount pending approval at december 31 , 2005 was $7 . 4 million of entity , which was approved by the fda in february 2006 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|vancomycin AND ceftriaxone azithromycin alfa|azithromycin clarithromycin clindamycin erythromycin amoxicillin|ceftriaxone|study with a single oral dose of 1000 mg of solithromycin compared with the standard of care , 500 mg of entity administered intramuscularly and 1000 mg of oral azithromycin .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|vancomycin AND ceftriaxone azithromycin alfa|ciprofloxacin clindamycin azithromycin metronidazole tetracycline|ceftriaxone|current treatment of bacterial urethritis includes two drugs : entity administered intramuscularly and oral azithromycin , which is added to treat co-infections with chlamydia .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|vancomycin AND ceftriaxone azithromycin alfa|olanzapine docetaxel latter fluconazole itraconazole|ceftriaxone|there was one treatment-related serious adverse event in the entity group .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|vancomycin AND ceftriaxone azithromycin alfa|ciprofloxacin erythromycin gentamicin ceftriaxone metronidazole|ceftriaxone|in a recent survey , 95% and 76% of the esbl isolates of escherichia coli found in utis were resistant to entity and levofloxacin , respectively .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 2), ('DIS', 1)])|drug|vancomycin AND ceftriaxone azithromycin alfa|azithromycin clindamycin trachomatis monotherapy erythromycin|ceftriaxone|intramuscular entity now represents the last-resort treatment option for gonorrhea , although resistant strains are beginning to emerge .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|vancomycin AND ceftriaxone azithromycin alfa|doxycycline erythromycin metronidazole imipenem clindamycin|ceftriaxone|of the most common treatments for serious bacterial infections , vancomycin , daptomycin , entity and tigecycline are only available as injectable or iv formulations .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|vancomycin AND ceftriaxone azithromycin alfa|iv bid sc orally vancomycin|ceftriaxone|treatment related diarrhea was reported by one subject following sulopenem single dose iv , and by a further two subjects following entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|vancomycin AND ceftriaxone azithromycin alfa|orally SC subcutaneous intravenously bid|ceftriaxone|itt patients were similar on each regimen ( 9 / 10 , 9 / 11 and 7 / 12 , on sulopenem single iv dose , sulopenem multidose iv and entity , respectively ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|vancomycin AND ceftriaxone azithromycin alfa|azithromycin clindamycin ciprofloxacin erythromycin clarithromycin|ceftriaxone|of a single 1000 mg dose of oral solithromycin in patients with uncomplicated gonorrhea and chlamydia infections compared with intramuscular entity plus oral azithromycin .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vancomycin AND ceftriaxone azithromycin alfa|vancomycin azithromycin ceftriaxone imipenem fluconazole|ceftriaxone|treatment-emergent adverse events were reported in six subjects each in the sulopenem groups and eight subjects in the entity group .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|vancomycin AND ceftriaxone azithromycin alfa|bevacizumab formulation risperidone warfarin metformin|ceftriaxone|entity is currently only marketed in an intravenous formulation .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|vancomycin AND ceftriaxone azithromycin alfa|azithromycin metronidazole clindamycin tetracycline doxycycline|ceftriaxone|the current standard of treatment for gonorrhea is a single intramuscular injection of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|vancomycin AND ceftriaxone azithromycin alfa|metformin bevacizumab levodopa fluconazole metronidazole|ceftriaxone|there is no oral formulation of entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|drug|vancomycin AND ceftriaxone azithromycin alfa|risperidone bevacizumab CBT TM levodopa|ceftriaxone|develop existing pre-clinical and clinical candidates , including cab-175 and an oral version of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|Concurrent Beta Allergy alfa Other|vi se os iv ex|vilanterol|for the treatment of copd , the collaboration is developing combination products , relovair and the lama / laba ( gsk573719 / entity or 719 / vi ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|Concurrent Beta Allergy alfa Other|warfarin acetaminophen paracetamol ritonavir metformin|vilanterol|anoro™ ellipta® ( umeclidinium bromide / entity , umec / vi ) on april 28 , 2014 , gsk and theravance announced that anoro™ ellipta® , the first once-daily product approved in the u . s .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|Concurrent Beta Allergy alfa Other|mannitol theophylline erythromycin misoprostol ibuprofen|vilanterol|are required and in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|Concurrent Beta Allergy alfa Other|lithium imatinib tin namely inositol|vilanterol|the lead laba candidate , entity trifenatate ( or vi ) , is a gsk-discovered laba and gsk and we have jointly determined to focus the collaborations laba development
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|Concurrent Beta Allergy alfa Other|salbutamol ICS MPA propionate prednisolone|vilanterol|therefore fluticasone furoate / entity should be used with caution in patients with severe cardiovascular disease .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|Concurrent Beta Allergy alfa Other|statin infliximab bevacizumab tacrolimus metformin|vilanterol|our economic interest will not include any payments associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|Concurrent Beta Allergy alfa Other|inhaled salbutamol topical theophylline metformin|vilanterol|· fluticasone furoate ( ff ) and entity trifenatate ( vi ) are promising agents for a combined , long-acting , once-daily treatment of asthma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|Concurrent Beta Allergy alfa Other|statin olanzapine bevacizumab infliximab metformin|vilanterol|our economic interest does not include any payments by gsk associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|Concurrent Beta Allergy alfa Other|salbutamol theophylline acetaminophen amoxicillin mL|vilanterol|anoro® ellipta® ( umeclidinium / entity ) to be reimbursed in australia for chronic obstructive pulmonary disease - administered using a new dry powder inhaler called
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|Concurrent Beta Allergy alfa Other|salbutamol propionate ICS prednisolone theophylline|vilanterol|donohue october 26 , 2014 , 1 : 30 pm - 3 : 00 pm cdt efficacy and safety of once-daily umeclidinium added to fluticasone furoate / entity in chronic obstructive pulmonary disease :
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|Concurrent Beta Allergy alfa Other|vi iv ti se ex|vilanterol|lama / laba combination ( gsk573719 / entity or 719 / vi ) the phase 3a program for the once-daily lama / laba dual bronchodilator 719 / vi is progressing well .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|Concurrent Beta Allergy alfa Other|bevacizumab sham metformin paclitaxel coil|vilanterol|our economic interest will not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|Concurrent Beta Allergy alfa Other|bevacizumab coil sham sun injectable|vilanterol|our economic interest does not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|Concurrent Beta Allergy alfa Other|salbutamol prednisone metformin acetaminophen diaphragm|vilanterol|closed triple or ff / umec / vi ( fluticasone furoate / umeclidinium bromide / entity )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|Concurrent Beta Allergy alfa Other|inhaled eg salbutamol namely ICS|vilanterol|at 24h being developed for use as a monotherapy for asthma and in combination with a once-daily long-acting beta2 agonist ( laba ) , entity trifenatate ( vi , gw642444m ) , for asthma and copd .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|Concurrent Beta Allergy alfa Other|salbutamol metformin prednisolone prednisone theophylline|vilanterol|had , or were at high-risk for , cardiovascular disease ; the primary objective was to evaluate the impact of fluticasone furoate ( ff ) / entity ( vi ) on all-cause mortality .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|Concurrent Beta Allergy alfa Other|salbutamol prednisone propranolol phenylephrine theophylline|vilanterol|breo is a fixed-dose combination of the inhaled corticosteroid ( ics ) fluticasone furoate ( ff ) and the long-acting beta2-agonist ( laba ) entity ( vi ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|Concurrent Beta Allergy alfa Other|theophylline erythromycin amoxicillin mannitol ibuprofen|vilanterol|ellipta is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('BIO', 1)])|drug|Prior brachytherapy carboplatin paclitaxel cetuximab|rituximab everolimus bevacizumab bortezomib id|arcitumomab|we continue to strengthen our u . s . and european sales and marketing effort for cea-scan ( r ) ( entity ) as well as our european effort for leukoscan ( r ) ( sulesomab ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|alfa CMV prophylaxis 2a peg|azithromycin rituximab lamivudine cyclosporine probiotic|ganciclovir|cell / bone marrow and solid organ transplant patients at risk for cmv infection or with active cmv disease receive entity or valentity ( both marketed by f . hoffmann-la roche ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa CMV prophylaxis 2a peg|CMV VC CPC CMC CAT|ganciclovir|valcyte , the oral pro-drug of cytovene ( entity ) , is the most widely prescribed anti-cmv medication in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa CMV prophylaxis 2a peg|ribavirin lamivudine rifampicin rituximab monotherapy|ganciclovir|demonstrated activity in cell culture against both clinical isolates and viruses which have become resistant to current therapies , such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|alfa CMV prophylaxis 2a peg|Medicaid pharmacists prices buprenorphine medicines|ganciclovir|in 2008 , the market for cmv drugs was $600 million with entity controlling over 90% of the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|alfa CMV prophylaxis 2a peg|cream chlorhexidine honey ointment fluconazole|ganciclovir|development of products that have achieved cumulative sales of close to $2 , 000 , 000 , 000 , including monistat ; delfen cream , for herpes virus infection ; entity ; solaraze ; and maci .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|alfa CMV prophylaxis 2a peg|chloroquine lamivudine ribavirin doxycycline rituximab|ganciclovir|currently approved drugs for cmv retinitis are entity , foscarnet , cidofovir and fomivirsen , or vitravene .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|alfa CMV prophylaxis 2a peg|aspirin methotrexate warfarin statins metformin|ganciclovir|the company is aware that a number of physicians have prescribed cytogam in combination with entity for the prevention of cmv disease in certain patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|alfa CMV prophylaxis 2a peg|cream gloves lidocaine ointment acne|ganciclovir|products that have achieved cumulative sales of close to two billion dollars including , monistat , delfen cream for herpes virus infectons , entity , solaraze , and maci .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa CMV prophylaxis 2a peg|siRNA adriamycin MMC imatinib BrdU|ganciclovir|the hytk gene was used to mark the cells and allow for ablation of the cells by administration of entity if undesirable side effects resulted from the therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|alfa CMV prophylaxis 2a peg|duplicate FACS tandem succession advance|ganciclovir|cells will be stimulated with anti-ig antibodies , and selected in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa CMV prophylaxis 2a peg|ribavirin lamivudine ritonavir chloroquine clarithromycin|ganciclovir|drug therapies approved or commonly used for cmv infection include antiviral compounds such as entity , valentity , cidofovir and foscarnet .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|alfa CMV prophylaxis 2a peg|CTL proteasome investigator protease cytokine|ganciclovir|cells containing the tk reporter will be killed by the entity unless a peptide inhibitor is present which inhibits the gene  s expression ( appendix h ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa CMV prophylaxis 2a peg|bevacizumab VEGF FDA Chemotherapy Therapy|ganciclovir|entity is available in intravenous and oral doses , as well as in an intraocular implant form .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa CMV prophylaxis 2a peg|thymidine AMP uridine TK uracil|ganciclovir|in vivo activity for a bacterial strain which expresses the herpes simplex virus thymidine kinase gene for the conversion of entity to its toxic phosphorylated forms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|alfa CMV prophylaxis 2a peg|azithromycin rituximab bevacizumab probiotics BCG|ganciclovir|in spite of trials conducted with entity for cmv prevention , entity is approved for use only as a preemptive therapy or treatment for cmv in hct .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|alfa CMV prophylaxis 2a peg|prophylaxis regimens HSCT Chemotherapy BCG|ganciclovir|entity was limited in its ability to be used as a preventive therapy by the risk of significant neutropenia , which has
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alfa CMV prophylaxis 2a peg|rituximab cyclosporine tacrolimus chloroquine lamivudine|ganciclovir|dr . martin is the co-inventor of entity , a pharmaceutical now used for treatment of cytomegalovirus infection .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|alfa CMV prophylaxis 2a peg|fluconazole prednisone prednisolone steroids itraconazole|ganciclovir|the company believes that , with the exception of oral entity , none of the drugs described above are currently administered prophylactically prior to manifestation of cmv retinitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|alfa CMV prophylaxis 2a peg|antioxidants vitamins melatonin carotenoids steroids|ganciclovir|our one commercial product , vitrasert , primarily competes with treatments involving the systemic delivery of entity , a roche holdings ag product , and other drugs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa CMV prophylaxis 2a peg|ribavirin lamivudine ritonavir chloroquine rifampicin|ganciclovir|such as tumor cells , the tk gene renders these cells sensitive to the toxic effect of the fda-approved antiviral drug , entity ( " gcv " ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|bevacizumab paclitaxel Placebo trastuzumab capecitabine|talazoparib|bmn-673 means sellers proprietary compound known as bmn-673 or entity , having the chemical structure set forth in schedule 1 ( d ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|innovation profit money sustainability productivity|talazoparib|good presentation , and i agree that the offer from sanofi really substantially undervalued the business and the pipeline and especially entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|cetuximab bevacizumab infliximab rituximab capecitabine|talazoparib|we are excited about entity and pidilizumab .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|trastuzumab gefitinib imatinib erlotinib capecitabine|talazoparib|for a select group of patients with hr-d breast cancer , entity , an oral parp inhibitor , was approved by the fda in 2018 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|commit respond proceed refer conform|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc . ### 11
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|away lessons exclusively starting evolved|talazoparib|through acquisition of medivation in aug , 2016 , medivation acquired entity from biomarin in 2015 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('BIO', 1)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|bevacizumab cetuximab everolimus sorafenib bortezomib|talazoparib|trials , and our future drug development activities , including those with respect to pidilizumab ( which is referred to as mdv9300 ) and entity ( which is referred to as mdv3800 ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|GSK TM 1a RS France|talazoparib|business development at medivation , identified and led the acquisition of a compound that was subsequently developed and approved as talzenna ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|NSCLC monotherapy trastuzumab ACT HER|talazoparib|to start potential registrational trials  many of which will be the first initiated for a parp inhibitor  for entity in multiple other tumor types by the end of 2016 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|travel move withdraw trade choose|talazoparib|similarly , the company acquired the worldwide rights to entity just seven months ago from biomarin , again demonstrating an ability to move quickly and boldly by 9 table of
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|investigators therapeutics biology regimens biomarker|talazoparib|entity would complement our solid tumor pipeline with potential in a variety of cancers , both in our current pipeline such as
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|bevacizumab rituximab docetaxel bortezomib gemcitabine|talazoparib|based on these data , we initiated a phase 1 / 2 clinical trial of the combination of telaglenastat plus entity in patients with rcc and tnbc in march 2019 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|commit respond conform proceed go|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|everolimus sirolimus vancomycin bevacizumab infliximab|talazoparib|xtandi , we are well positioned for long-term sustainable growth with a promising pipeline that includes two late-stage wholly owned assets : entity and pidilizumab .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|inspiration insight insights medicines DHA|talazoparib|bofa merrill lynch - analyst can you talk a little bit about the process that you went through to acquire entity from biomarin?
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|paclitaxel sorafenib Prior P2Y gemcitabine|ritonavir metformin ribavirin lamivudine gefitinib|talazoparib|approved parp inhibitors include olaparib , entity and niraparib .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|alfa paclitaxel diclofenac AND sorafenib|herbal topical approved investigational dried|ropinirole|partner for jzp-4 , its potential treatment for epilepsy and bipolar , disorder and will no longer pursue development of jzp-7 , its entity gel product candidate for restless legs syndrome .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel diclofenac AND sorafenib|investigational medicinal approved generic FDA|ropinirole|we were previously targeting an nda submission for our entity product candidate in calendar 2008 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel diclofenac AND sorafenib|formulation recipients formulations supplementation infusions|ropinirole|staccato entity we have identified two new preclinical product candidates for development based on the single-dose staccato platform currently being manufactured in
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|alfa paclitaxel diclofenac AND sorafenib|Daily Oral dry Nasal hydrochloride|ropinirole|entity oral spray is ideal for the geriatric population who may be suffering from dysphagia ( difficulty swallowing ) ; 85% of sufferers of
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|alfa paclitaxel diclofenac AND sorafenib|levodopa fentanyl lidocaine epinephrine apomorphine|ropinirole|our formulation of entity oral spray may represent a more convenient way for the patient or healthcare provider to deliver entity to patients suffering stiffness and / or tremors .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|alfa paclitaxel diclofenac AND sorafenib|Surgery Radiotherapy Exercise Chemotherapy SCS|ropinirole|entity is indicated for the treatment of the signs and symptoms of idiopathic parkinson  s disease .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|alfa paclitaxel diclofenac AND sorafenib|levodopa therapeutics pharmacotherapy formulation generator|ropinirole|we completed a non-clinical study with long-term delivery of dopamine agonists which supports the potential to develop an implant delivering entity for treating parkinsons disease .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|alfa paclitaxel diclofenac AND sorafenib|olanzapine eg levodopa metformin risperidone|ropinirole|commonly prescribed dopamine agonists that directly activate dopamine receptors include agents such as mirapex ( pramipexole / bi ) and requip ( entity / glaxosmithkline ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|alfa paclitaxel diclofenac AND sorafenib|levodopa metformin apomorphine gabapentin thalidomide|ropinirole|japan , and in 2006 in the u . s . the competition for parkinson  s disease drugs includes l-dopa , cabergoline , bromocriptine , pergolide , lisuride and entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|alfa paclitaxel diclofenac AND sorafenib|metformin levodopa risperidone diltiazem diclofenac|ropinirole|the new prolonged release tablet of entity is taken once daily , and is indicated for the treatment of parkinson  s disease ( pd ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|alfa paclitaxel diclofenac AND sorafenib|apomorphine levodopa risperidone olanzapine haloperidol|ropinirole|we have performed the preclinical development work on a transdermal formulation of entity , a proven and fda-approved dopamine agonist for treating parkinsons disease .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|alfa paclitaxel diclofenac AND sorafenib|DBS hydrochloride levodopa apomorphine agonists|ropinirole|our proprietary pipeline also includes corplex entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|drug|alfa paclitaxel diclofenac AND sorafenib|risperidone levodopa apomorphine Placebo haloperidol|ropinirole|entity is a dopamine agonist currently available in daily or more frequently dosed oral formulations for the treatment of parkinson  s disease
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|drug|paclitaxel gemcitabine AND metformin psoriasis|IBD psoriasis AIDS osteoporosis autism|nebivolol|the decrease in research and development expenses is the result of the completion of clinical studies related to entity , for which a nda was filed on april 30 , 2004 .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|paclitaxel gemcitabine AND metformin psoriasis|lidocaine morphine ketamine bupivacaine tramadol|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan inc . ( mylan ) and expires in 2020 and we submitted a patent term extension application to
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel gemcitabine AND metformin psoriasis|diagnosing worsening preventing managing idiopathic|nebivolol|could you give us a little bit more color on the timing of the nda filing for entity congestive heart failure?
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|paclitaxel gemcitabine AND metformin psoriasis|BB propranolol SU AG metoprolol|nebivolol|bystolic® ( entity ) , a beta-blocker for the treatment of hypertension , recorded sales of $142 . 9 millionin in the fourth quarter 2014 , an increase of
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|paclitaxel gemcitabine AND metformin psoriasis|ketamine lidocaine morphine fentanyl buprenorphine|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan laboratories inc . and expires in 2020 .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|paclitaxel gemcitabine AND metformin psoriasis|metformin atorvastatin simvastatin enalapril statins|nebivolol|* trial 305 ( general population ) trial 202 ( african-american patients ) add-on therapy vs . placebo trial 321 ( entity added to current antihypertensive treatment )
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|drug|paclitaxel gemcitabine AND metformin psoriasis|NSCLC CRC AIDS psoriasis vaccination|nebivolol|brand segment r&d is primarily the result of the completion , during fiscal 2004 , of the phase iii clinical studies for entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel gemcitabine AND metformin psoriasis|sales license approval funding payments|nebivolol|today , we are announcing that the best available option is to out license entity to a major brand pharmaceutical company , which will co develop and commercialize this product .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel gemcitabine AND metformin psoriasis|disposable overhead transportation pharmacy financial|nebivolol|eps to gaap diluted eps : adjusted diluted eps $ 0 . 26 mylan bertek and entity expenses ( $0 . 05 ) restructuring charges and other non-recurring expenses ( $0 . 02 ) contingent legal liability
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel gemcitabine AND metformin psoriasis|NIH own virtual academic approved|nebivolol|we expect to experience increased research and development expenses in support of the entity clinical program , as well as milestone payments under our license agreement .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel gemcitabine AND metformin psoriasis|recruitment randomization blinding sustainability RCTs|nebivolol|the restructuring , while r&d expense increased as a result of an increase in ongoing studies , including those with respect to entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|paclitaxel gemcitabine AND metformin psoriasis|deaths immigrants income GDP admissions|nebivolol|the overall decrease is primarily the result of the outlicensing of entity , which occurred late in fiscal 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel gemcitabine AND metformin psoriasis|Germany Denmark Europe France Spain|nebivolol|the irs regarding whether the proceeds received by the company in connection with the 2008 sale of its rights in entity constituted a capital gain or ordinary income .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|drug|paclitaxel gemcitabine AND metformin psoriasis|osteoporosis T2DM psoriasis ADHD IBD|nebivolol|the increase was primarily attributable to research and development expense due to ongoing clinical studies related to entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel gemcitabine AND metformin psoriasis|money cash financial price file|nebivolol|number one , ed , can you walk me through the five-cent charge in entity and bertek expenses and point me to where i can find it on the p&l?
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel gemcitabine AND metformin psoriasis|funding registry TAVI registries ART|nebivolol|the opportunity to launch entity will significantly expand our existing cardiovascular franchise .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel gemcitabine AND metformin psoriasis|discussion you completion adoption publication|nebivolol|changes of the king business and the lack of appropriate other acquisition alternatives we have chosen a different course for entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|paclitaxel gemcitabine AND metformin psoriasis|metformin bevacizumab eg atorvastatin sildenafil|nebivolol|our flagship product , altaceò . this is a perfect fit with mylan because of its growing pipeline of proprietary products , including entity , a hypertension product .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|paclitaxel gemcitabine AND metformin psoriasis|metoprolol propranolol BB TM AG|nebivolol|bystolic ( entity ) , our beta-blocker indicated for the treatment of hypertension launched in january 2008 , achieved sales of $59 , 522 , an increase of $21 , 857
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|paclitaxel gemcitabine AND metformin psoriasis|salbutamol azithromycin diclofenac olanzapine gabapentin|nebivolol|for the same period last year , third party development costs were largely related to clinical trials for entity , aclidinium / formoterol , vilazodone and roflumilast .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|metronidazole itraconazole comparing clarithromycin phosphatase|metronidazole clarithromycin erythromycin fluconazole itraconazole|tinidazole|nitroimidazoles for use in the invention include metronidizole , ornidazole , secnidazole , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|metronidazole itraconazole comparing clarithromycin phosphatase|Besides From Taking Within Compound|tinidazole|entity vaginal effervescent tablet the key component of entity vaginal effervescent tablet is entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|metronidazole itraconazole comparing clarithromycin phosphatase|metronidazole probiotics ceftriaxone ciprofloxacin infliximab|tinidazole|six ulcerative colits patients with ipaa ( 3 refractory pouchitis , 2 crohns disease , 1 irritable pouch syndrome ) received entity plus xifaxan or ciprofloxacin for 2-4 weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|AND Primary Blood alfa GSK|vancomycin chloroquine honey genistein metronidazole|lifitegrast|( “r&d” ) was up 6% particularly due to investment in new uses for ldx ( the active ingredient in vyvanse ) , shp602 and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|drug|AND Primary Blood alfa GSK|psoriasis CAP AMD osteoporosis COPD|lifitegrast|the new drug application for entity included data from four randomized , controlled clinical trials with more than 1 , 800 patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND Primary Blood alfa GSK|topical ophthalmic diluted diclofenac bevacizumab|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|AND Primary Blood alfa GSK|RGD bevacizumab trastuzumab curcumin octreotide|lifitegrast| shire plc has a small molecule integrin antagonist , entity , which is formulated for topical , ophthalmic delivery and is currently in phase 3 clinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|AND Primary Blood alfa GSK|therapeutics CAM vaccines azithromycin pharmacotherapy|lifitegrast| if approved , shire would benefit from the launch of entity for dry eye disease in 2016 , and hopes to increase awareness , diagnosis and treatment of this condition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|AND Primary Blood alfa GSK|BW DOI KC weighing 125|lifitegrast|leukocytes [ ] selected based on its properties for further development as a candidate to treat dry eye disease [ graphic omitted ] entity ( formerly sar 1118 ) mw 610 g / mol 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|AND Primary Blood alfa GSK|topical ophthalmic eyed diluted ocular|lifitegrast|these relate to the xiidra ( entity ophthalmic solution ) product which takeda had subsequently announced a sale agreement for .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|AND Primary Blood alfa GSK|forward away beyond therapeutics innovation|lifitegrast|“our commitment to moving entity forward reflects our intent to grow in the ophthalmics therapeutic category in areas of unmet patient need .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|AND Primary Blood alfa GSK|FDA approval market Europe commercially|lifitegrast|shire plc recently received fda approval to market entity for the treatment of dry eye and will be launching the product in the u . s . restasis , and other products , have
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|AND Primary Blood alfa GSK|approved licensed FDA approval manufactured|lifitegrast|shire plc is developing its product candidate , entity , and is in pivotal phase 3 clinical trials in the u . s . shire has said it plans to resubmit an nda for entity in 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|AND Primary Blood alfa GSK|pharmacotherapy prophylaxis monotherapy indication dosing|lifitegrast|press release www . shire . com shire plans to submit a new drug application to fda for entity for dry eye disease in adults · fda submission planned for 1st quarter 2015 · shire forms business
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND Primary Blood alfa GSK|topical diclofenac ophthalmic corticosteroid diluted|lifitegrast|these relate to the xiidra® ( entity ophthalmic solution ) product which takeda has subsequently announced a sale agreement for , as included in note 33 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|AND Primary Blood alfa GSK|approval granted psoriasis FDA marketing|lifitegrast|of any of our product candidates , such as our planned submission of a new drug application to the fda for entity , may be delayed for any number of reasons and , once submitted ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|AND Primary Blood alfa GSK|Vietnam India Japan Thailand Taiwan|lifitegrast|on shp602 ( formerly known as spd602 ) for iron overload and on development programs acquired through business development in 2013 , including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|AND Primary Blood alfa GSK|ace ie ex diluted lyophil|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra&#xae ; ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|AND Primary Blood alfa GSK|occasion request going board ice|lifitegrast|maybe to refresh the topic , on entity , obviously the other key near-term event with the october 25 pdufa date .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1), ('DIS', 1)])|drug|AND Primary Blood alfa GSK|bevacizumab metformin bortezomib rituximab everolimus|lifitegrast|opus-3 , a randomized , double-masked , 12-week phase 3 study enrolled 711 patients to evaluate the efficacy and safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|AND Primary Blood alfa GSK|PDT azithromycin bevacizumab CPAP rituximab|lifitegrast|in addition , patients treated with entity showed a statistically significant improvement in ocular discomfort and eye dryness , symptoms of dry eye disease , as reported by patients
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|AND Primary Blood alfa GSK|cure sham Placebo itching tear|lifitegrast|when i look at restasis relative to entity , in terms of efficacy measures , sustaining tear production and goblet cell density , i think restasis is a great option .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|AND Primary Blood alfa GSK|tacrolimus prednisone bevacizumab diclofenac cyclosporine|lifitegrast|in the united states , yet only two drugs are approved for dry eye disease treatment , restasis® ( cyclosporine 0 . 05% ) and xiidra® ( entity 5% ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|mit AND alfa CD34 VEGF|irinotecan gemcitabine oxaliplatin carboplatin paclitaxel|floxuridine|the 1 : 1 molar ratio of irinotecan : entity was frequently synergistic and avoided antagonism whereas other ratios exhibited a loss of synergy and in some cases the appearance
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|mit AND alfa CD34 VEGF|docetaxel carboplatin MMC paclitaxel oxaliplatin|floxuridine|range of preclinical solid tumor models , cpx-1 consistently provided dramatic improvements in therapeutic efficacy over the unencapsulated free-drug cocktail of irinotecan : entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|mit AND alfa CD34 VEGF|liposomes liposome gemcitabine docetaxel doxorubicin|floxuridine| cpx-1 is a liposomal formulation of irinotecan : entity , which is a clinical stage product candidate ;  cpx-8 is a hydrophobic docetaxel prodrug nanoparticle which is a preclinical stage
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|mit AND alfa CD34 VEGF|gemcitabine docetaxel paclitaxel oxaliplatin bevacizumab|floxuridine|scientific rationale of cpx-1 the combination of irinotecan and entity was screened for drug ratio dependent synergy in vitro in a panel of tumor cell lines .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|mit AND alfa CD34 VEGF|irinotecan carboplatin capecitabine sorafenib cetuximab|floxuridine|from 7 . 8 months to 12 . 0 months ( p = 0 . 05 ) for patients with advanced , unresectable colorectal liver metastases receiving sir-spheres and entity ( fudr ) vs fudr alone .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ophthalmic topical alfa lactone antifungal|es olanzapine EM AN EA|eszopiclone|additionally , in early 2003 , sepracor filed an nda for estorra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ophthalmic topical alfa lactone antifungal|cigarettes medicines cannabis chemicals goods|eszopiclone|in exchange , sepracor permitted aventis to assign sepracors obligation to pay a royalty on sales of entity in the u . s . to a third party .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|ophthalmic topical alfa lactone antifungal|CPAP metformin olanzapine methadone dexmedetomidine|eszopiclone|in addition , patients on entity reported improved daytime alertness ( p less than 0 . 005 ) and improved daytime ability to function ( p less than 0 . 001 ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|ophthalmic topical alfa lactone antifungal|midazolam olanzapine melatonin dexmedetomidine gabapentin|eszopiclone|furthermore , patients treated with entity 2 mg reported significant improvements in daytime alertness ( p<0 . 03 ) and sense of physical well-being ( p<0 . 05 ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ophthalmic topical alfa lactone antifungal|pesticides pharmaceuticals medicines chemicals substances|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity outside of the united states , canada and mexico and with respect to several other compounds .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ophthalmic topical alfa lactone antifungal|investigational own medicinal prototype topical|eszopiclone|our entity product will be marketed by gsk in its territory primarily as lunivia® brand entity for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|ophthalmic topical alfa lactone antifungal|olanzapine metformin tacrolimus fluoxetine MMF|eszopiclone|no decline in therapeutic effect was observed on any outcome parameter over the course of the trial , and entity was well tolerated .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|ophthalmic topical alfa lactone antifungal|diclofenac ibuprofen metronidazole fluconazole curcumin|eszopiclone|upon approval of estorra , during which the fda would not approve an abbreviated new drug application for any product containing entity , the active ingredient of estorra .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|ophthalmic topical alfa lactone antifungal|risperidone olanzapine generic buprenorphine fentanyl|eszopiclone|has filed an abbreviated new drug application ( anda ) with the u . s . food and drug administration ( fda ) for generic versions of entity tablets ( 1 mg , 2 mg and 3 mg ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ophthalmic topical alfa lactone antifungal|formulation formulations generic coated market|eszopiclone|products that we launched in the united states during the year ended march 31 , 2015 : product innovatorsbrand innovator entity lunesta® seprocor fenofibrate capsules
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|ophthalmic topical alfa lactone antifungal|melatonin gabapentin CPAP salbutamol sildenafil|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , which was approved in december 2004 by the fda and launched in the first quarter of 2005 , and rozerem® ( ramelteon ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|ophthalmic topical alfa lactone antifungal|methadone ketamine buprenorphine naltrexone midazolam|eszopiclone|in clinical trials with entity , one case of overdose with up to 36 mg of entity was reported in which the subject fully recovered .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|ophthalmic topical alfa lactone antifungal|name America labeling marketing allergy|eszopiclone|the fda is currently reviewing our nda for estorra brand entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ophthalmic topical alfa lactone antifungal|market sales brand advertising marketing|eszopiclone|as a result of this policy , we capitalized $1 , 735 , 000 of lunesta brand entity inventory during the first quarter of 2005 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|ophthalmic topical alfa lactone antifungal|pesticides cannabis chemicals nicotine flavonoids|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity in japan and with respect to several other compounds .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ophthalmic topical alfa lactone antifungal|FP bro FT ef tem|eszopiclone|we cannot assure you that we adequately responded to the fdas concerns or that the entity nda will be approved .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|ophthalmic topical alfa lactone antifungal|CPAP GSK NIV metformin melatonin|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , marketed by sepracor , inc . , which was approved in december 2004 by the fda and launched in the first quarter of
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ophthalmic topical alfa lactone antifungal|publication marketing approval granted registration|eszopiclone|assuming favorable results from the ongoing studies , we anticipate submitting an nda for entity to the fda , in 2002 , which , if approved , we would market under the name estorra .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ophthalmic topical alfa lactone antifungal|contains name formulation tablet Plus|eszopiclone|other events on april 4 , 2005 , sepracor commercially launched lunesta brand entity 1 mg , 2 mg and 3 mg tablets for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|ophthalmic topical alfa lactone antifungal|methadone itraconazole midazolam buprenorphine levodopa|eszopiclone|individuals have fully recovered from racemic zopiclone overdoses up to 340 mg ( 56 times the maximum recommended dose of entity ) .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|atropine magnesium AND nitrate diclofenac|fentanyl midazolam lidocaine morphine bupivacaine|atropine|between august and october , 2010 , we reintroduced entity , morphine , dextrose , and epinephrine prefilled syringes .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|atropine magnesium AND nitrate diclofenac|zinc magnesium chondroitin ferrous morphine|atropine|in november 2000 , we received our first fda approval to manufacture and sell diphenoxylate with entity sulfate tablets .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|atropine magnesium AND nitrate diclofenac|magnesium propranolol clopidogrel metoprolol salbutamol|atropine|for propranolol er driven by price , tempered by the impact of the second quarter 2017 launch of diphenoxylate hydrochloride and entity sulfate .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|atropine magnesium AND nitrate diclofenac|cream hydrochloride ointment suspension alfa|atropine|while macrodose entity 1% is currently fda-approved for pupil dilation in the united states , its significant side effect profile has impeded clinical utility
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|atropine magnesium AND nitrate diclofenac|magnesium ceftriaxone gentamicin streptomycin atropine|atropine|trobigard is designed for intramuscular self- or buddy-administration of entity sulfate and obidoxime chloride for pre-hospital intervention .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atropine magnesium AND nitrate diclofenac|bevacizumab topical sham hydrogel ophthalmic|atropine|anticipated milestone : initiate and complete phase iii vision trials in 2020 about micropine for progressive myopia micropine ( entity ophthalmic solution )
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|atropine magnesium AND nitrate diclofenac|magnesium ferrous chondroitin zinc Calcium|atropine|“micropine product” means entity sulfate , as the sole active pharmaceutical ingredient , formulated and loaded into a cartridge for delivery using , and delivered by means
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|atropine magnesium AND nitrate diclofenac|bevacizumab riboflavin melatonin VEGF curcumin|atropine|for example , our micropine program which is a micro-formulation of entity , is intended to slow myopia progression in the pediatric population .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|atropine magnesium AND nitrate diclofenac|lidocaine midazolam ketamine morphine propofol|atropine|exposed to approximately 75% less nerve agent and then treated immediately with the current standard therapy , a three-drug cocktail of entity , 2-pam and diazepam .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|atropine magnesium AND nitrate diclofenac|lidocaine dexmedetomidine bupivacaine ketamine vancomycin|atropine|contract by dod valued at up to approximately $23 million to develop a multi-drug auto-injector for nerve agent antidote delivery ( entity and pralidoxime chloride ) , which we refer to as d4 .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atropine magnesium AND nitrate diclofenac|dosing PDT regimens bevacizumab drops|atropine|despite activity , safety concerns such as pupil dilation , photosensitivity and accommodation difficulties associated with standard entity , 1% have tempered initial clinical adoption .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|atropine magnesium AND nitrate diclofenac|bevacizumab melatonin therapeutics steroids VEGF|atropine|the first pipeline opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|atropine magnesium AND nitrate diclofenac|bevacizumab therapeutics VEGF melatonin steroids|atropine|the first pipeline 4 table of contents opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|atropine magnesium AND nitrate diclofenac|benzodiazepines analgesics diazepam phenobarbital propofol|atropine|the standard of care for post-exposure treatment involves repeated doses of a cocktail of drugs including entity , oxime reactivators ( " 2-pam " ) and anti-convulsants .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|atropine magnesium AND nitrate diclofenac|sedation benzodiazepines benzodiazepine steroids sevoflurane|atropine|the director ( nih od ) , and the ninds competition the current standard of care for nerve agent exposure is entity® and benzodiazepines .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|hydrochloride diclofenac alfa fluorouracil AND|GSK TM metformin olanzapine THC|naldemedine| acquired rights to commercialize symproic® ( entity ) tablets 0 . 2 mg in the u . s . on april 4 , with bdsis sales force fully trained and actively promoting symproic as of may
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|hydrochloride diclofenac alfa fluorouracil AND|naltrexone buprenorphine gabapentin morphine orally|naldemedine|shionogi & co . is developing entity , another mu-opioid receptor antagonist , for patients with oic .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine allergy Allergy allergen eosinophils|GSK France TM Germany ELISA|methacholine|the only fda-approved direct test is provocholine® ( entity ) , marketed by methapharm inc .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|methacholine allergy Allergy allergen eosinophils|Oxygen Air Water Alcohol CO2|methacholine|entity is inhaled as a vapour and causes bronchial constriction in asthmatic patients .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('BIO', 1)])|drug|methacholine allergy Allergy allergen eosinophils|methacholine histamine allergen eosinophils nitroglycerin|methacholine|the first category , known as direct challenge tests , use either histamine or entity to directly cause airway narrowing .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1), ('BIO', 1)])|drug|methacholine allergy Allergy allergen eosinophils|serotonin histamine acetylcholine eosinophils norepinephrine|methacholine|the response from the direct tests ( entity and histamine ) are not dependent on the presence of inflammatory cells and their mediators and have a poor sensitivity for
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|methacholine allergy Allergy allergen eosinophils|methacholine mannitol bronchial histamine allergen|methacholine|volume in 1 second ( fev1 ) > 65% ;  increase in fev1 of at least 12% with bronchodilator use over baseline fev1 ;  entity challenge test with a pc20 £ 8mg / ml .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine allergy Allergy allergen eosinophils|Nasal allergen methacholine Post Daily|methacholine|entity challenge treatment differences ( pc20 ) performed 25h post-dose and 24h following an inhaled allergen challenge table 1 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|methacholine allergy Allergy allergen eosinophils|methacholine allergen histamine mannitol bronchial|methacholine|the primary phenotypes for analysis include lifetime history of asthma , age of asthma onset , entity challenge response , smoking history , and skin prick tests for twelve common allergens .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|methacholine allergy Allergy allergen eosinophils|methacholine salbutamol histamine FEV1 spirometry|methacholine|aridol also had similar specificity to entity , ( 66% versus 70% respectively ) in subjects without exercise induced bronchoconstriction .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|methacholine allergy Allergy allergen eosinophils|methacholine allergen histamine CO2 mannitol|methacholine|efficacy will be evaluated using standard measures of respiratory function , e . g . , fev1 , entity challenge , serial spirometry .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|drug|methacholine allergy Allergy allergen eosinophils|mannitol methacholine histamine mucus atropine|methacholine|s . spector et al . , mannitol inhalational challenge : will it replace entity or histamine?
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine allergy Allergy allergen eosinophils|electrically mechanically spontaneously relaxed tracheal|methacholine|moreover , ck-2018571 relaxed entity pre-constricted tracheal rings in a concentration-dependent manner , suggesting its potential utility as a bronchodilator .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|methacholine allergy Allergy allergen eosinophils|methacholine histamine mannitol bronchial nicotine|methacholine|the 500 mg tid treatment group , including serial spirometry , morning and evening peak flow rates and pc20 values in a entity challenge test ( common measures of respiratory function ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|methacholine allergy Allergy allergen eosinophils|bronchial SPT methacholine basophil histamine|methacholine|· adding vi to ff also provided further reduction of ahr as measured by entity responsiveness 24h after the allergen provocation .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine allergy Allergy allergen eosinophils|tolerate utilizing comparing inhaled needing|methacholine|provocholine diagnosis of bronchial airway hyperactivity in subjects who do not have clinically apparent asthma entity chloride immunoglobulins ivig 5% treatment
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine allergy Allergy allergen eosinophils|purposes ii centres COPD spirometry|methacholine|in comparison entity , an approved lung function test in the u . s . , identified 54% of cases .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|methacholine allergy Allergy allergen eosinophils|histamine serotonin norepinephrine bradykinin noradrenaline|methacholine|examples include entity and histamine .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|methacholine allergy Allergy allergen eosinophils|examining evaluating investigating utilizing comparing|methacholine|to an individual or company to sell a product meta-analysis pooling and examining data from a number of studies entity inhalation test a test used in the diagnosis of asthma .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|methacholine allergy Allergy allergen eosinophils|midazolam eg lidocaine ie Placebo|methacholine|of 501 patients , and the study showed that aridol performed as well or better than the only currently approved test , entity .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|morphine bupivacaine MSCs bevacizumab methylprednisolone|cytarabine|for safety reasons , continuous intrathecal infusion of entity is not a viable option .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|docetaxel gemcitabine paclitaxel rituximab cyclophosphamide|cytarabine|these patients typically receive frontline therapy , usually chemotherapy , including entity and an anthracycline , a therapy that has not changed in over 40 years .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|Tra Ex dr San tin|cytarabine|products the products prepared for enzon by skyepharma are defined in the supply agreement including depocyt® , ( entity liposome injection , sky0101 ) formulation 1 . 5 ( us ) iii .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|rituximab methotrexate steroids cyclophosphamide glucocorticoids|cytarabine|% can be achieved , and patients with good-risk or standard-risk chromosomal changes will typically receive post-remission therapy with high dose entity .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|Chemotherapy lithium chloroquine amiodarone phenytoin|cytarabine|entity is one of several drugs most commonly used for this therapy .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|bortezomib rituximab docetaxel cyclophosphamide bevacizumab|cytarabine|in may 2007 , our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda after accrual of 268 patients .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|methotrexate cyclophosphamide cytosine doxorubicin fluorouracil|cytarabine|from the trial showed positive safety and response rate data for subjects treated with a combination of motixafortide and high-dose entity ( ara-c ) , or hidac .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1), ('DIS', 1)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|docetaxel bortezomib bevacizumab capecitabine metformin|cytarabine|an investigator-sponsored phase i / ii trial in combination with entity for elderly patients with previously untreated aml was initiated in may 2008 .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|carboplatin paclitaxel irinotecan methotrexate gemcitabine|cytarabine|a number of nucleoside drugs , such as gemcitabine and entity , also known as ara-c , both generic drugs , are in wide use as conventional chemotherapies .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('BIO', 3), ('DIS', 1)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|imatinib methotrexate etoposide bortezomib ATRA|cytarabine|is in the efficacy portion of a phase 2 clinical trial for acute myeloid leukemia ( “aml” ) in combination with low-dose entity ( “ldac” ) and in combination with decitabine .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|rituximab bevacizumab methotrexate chloroquine ribavirin|cytarabine|because the therapeutic half-life of entity in the csf is relatively short , frequent and repeated injections are necessary for effective treatment .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|aspirin clopidogrel warfarin ibuprofen celecoxib|cytarabine|certain compositions containing vosaroxin , with expiry in 2030 ; and · u . s . patent no . 7 , 968 , 565 claims a combination of vosaroxin and entity , with expiry in 2026 .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|monotherapy celecoxib azithromycin metformin warfarin|cytarabine|the rate of serious adverse events was 55 . 5% in the vosaroxin combination arm compared to 35 . 7% in the placebo and entity arm .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|formulations tablets dosing regimens vaccines|cytarabine|clinical trials have demonstrated , however , that depocyt provides certain clinical advantages versus generic entity .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|methotrexate cyclophosphamide carboplatin rituximab prednisone|cytarabine|patients who achieve a cr after induction will go on to receive consolidation therapy with high dose entity ( hidac ) with ento or placebo as per their randomization assignment .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|paclitaxel gemcitabine doxorubicin methotrexate ribavirin|cytarabine|a number of nucleoside drugs , such as gemcitabine , or gemzar® , from eli lilly , and entity , also known as ara-c , a generic drug , are in wide use as conventional chemotherapies .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 2)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|doxorubicin anthracycline etoposide paclitaxel vincristine|cytarabine|our lead product is vyxeostm , a nano-scale liposomal formulation of entity : daunorubicin , completed a phase 3 clinical trial for the treatment of acute myeloid leukemia ( aml ) .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|docetaxel cyclophosphamide gemcitabine CHOP carboplatin|cytarabine|high-intensity induction chemotherapy is typically entity plus an anthracycline ( so called 7+3 ) administered over a 28-day cycle .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|rituximab bortezomib docetaxel bevacizumab cyclophosphamide|cytarabine|our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda in may 2007 .
OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|etoposide doxorubicin methotrexate anthracycline paclitaxel|Chemotherapy Apoptosis Radiation Interferon Radiotherapy|cytarabine|entity acts by inhibiting a vital enzyme in dna synthesis , resulting in death of a dividing cell .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|formulations progesterone formulation propionate steroids|topical inhaled prophylactic rescue weekly|mometasone|three of the patients who responded received entity steroids tapered to zero by day 21 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|formulations progesterone formulation propionate steroids|tacrolimus prednisolone methylprednisolone prednisone progesterone|mometasone|we are also developing a topical water-based hydrogel formulation of entity , a medium-potency steroid , primarily for the treatment of atopic dermatitis .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|formulations progesterone formulation propionate steroids|salbutamol fentanyl paclitaxel gabapentin chlorhexidine|mometasone|to $160 million in the first six months of 2013 compared with the same periods of 2012 . global sales of dulera ( entity furoate / formoterol fumarate dihydrate )
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|formulations progesterone formulation propionate steroids|prednisolone prednisone tacrolimus azithromycin bevacizumab|mometasone|^ nasonex and entity are currently the only other intranasal steroids approved for the treatment of nasal polyps .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|formulations progesterone formulation propionate steroids|hydrogel alginate polymer PVA chitosan|mometasone|we are currently in formulation development with entity hydrogel and expect to file an investigational new drug application , or ind , in 2006 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|formulations progesterone formulation propionate steroids|PPI salbutamol ICS diuretic metformin|mometasone|indacaterol as a single agent and in combination with an ics ( entity ) , is being developed by novartis and schering-plough .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|formulations progesterone formulation propionate steroids|chlorhexidine isopropyl intranasal salbutamol mom|mometasone|respiratory global sales of nasonex ( entity furoate monohydrate ) , an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms , increased 3% in the first quarter of
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|formulations progesterone formulation propionate steroids|chlorhexidine salbutamol tacrolimus grass mom|mometasone|sc loading dose followed by q8w 150mg sc and ( iii ) placebo , in each case concomitant with 400 micrograms daily of entity furoate nasal spray .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|formulations progesterone formulation propionate steroids|prednisolone hydrocortisone prednisone progesterone methylprednisolone|mometasone|crx-191 contains a mid-potency glucocorticoid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|formulations progesterone formulation propionate steroids|ethyl phthalate isopropyl benzyl chlorhexidine|mometasone|a decision issued in june 2013 held that the merck patent covering entity furoate monohydrate was valid , but that it was not infringed by apotex corp . s proposed product .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|formulations progesterone formulation propionate steroids|prednisolone hydrocortisone prednisone methylprednisolone glucocorticoid|mometasone|crx-191 contains a mid-potency glucocorticosteroid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|formulations progesterone formulation propionate steroids|chlorhexidine mom grass cotton bud|mometasone|patients are being treated with two multi-dosing frequencies of subcutaneously-administered etokimab or placebo , each in combination with entity furoate nasal spray as background therapy .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|formulations progesterone formulation propionate steroids|salbutamol prednisone theophylline prednisolone corticosteroid|mometasone|sch 418131 , mff , is a combination of two previously approved drugs for the treatment of asthma : entity ( asmanex ) and formoterol ( foradil ) .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|formulations progesterone formulation propionate steroids|corticosteroid topical psoriasis acne cream|mometasone|ovixan® is an improved prescription entity cream for the treatment of psoriasis and eczema , and oviderm® is a moisturizer for the treatment of dry skin .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|formulations progesterone formulation propionate steroids|salbutamol mom bud flut inhaled|mometasone| qmf149 ( indacaterol acetate / entity furoate ) is a once daily fixed-dose combination being investigated in asthmatic patients who are uncontrolled on an inhaled corticosteroid .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|formulations progesterone formulation propionate steroids|salbutamol eg theophylline amoxicillin ICS|mometasone|novartiss qvm-149 ( entity / glycopyrronium / indacaterol ) is under review by the ema for asthma .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|formulations progesterone formulation propionate steroids|cannabis cigarette cigar marijuana nicotine|mometasone|during the first quarter of 2004 is primarily due to the purchase of raw materials related to the eligard , atrisone , entity and fluticasone products .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|formulations progesterone formulation propionate steroids|FFA PDT tacrolimus ICS steroids|mometasone|prior to treatment with nomacopan ( coversin ) , two out of the three patients were already on topical corticosteroids ( entity ) while a third was naïve to steroid treatment .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|formulations progesterone formulation propionate steroids|salbutamol prednisolone ICS theophylline prednisone|mometasone|new combinations of formoterol with ciclesonide , fluticasone or entity are being developed by sanofi-aventis , abbott ( with skyepharma ) , and novartis ( with schering-plough ) respectively .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|formulations progesterone formulation propionate steroids|chlorhexidine intranasal fentanyl topical tacrolimus|mometasone|nasonex , or entity furoate nasal spray , is currently the only other branded ins approved by the fda for the treatment of nasal polyps .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|peel lidocaine transdermal depot hydrochloride|lidocaine epinephrine bupivacaine diclofenac midazolam|prilocaine|phn to receive the qutenza patch application after a 60-minute pretreatment with an fda-approved topical anesthetic ( 2 . 5% lidocaine / 2 . 5% entity ) .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|peel lidocaine transdermal depot hydrochloride|bupivacaine fentanyl ketamine morphine lidocaine|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two , well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|peel lidocaine transdermal depot hydrochloride|epinephrine bupivacaine lidocaine fentanyl morphine|prilocaine|emla ( lidocaine + entity ) is a local anaesthetic for topical application .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|peel lidocaine transdermal depot hydrochloride|bupivacaine fentanyl morphine ketamine lidocaine|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|peel lidocaine transdermal depot hydrochloride|epinephrine lidocaine bupivacaine morphine fentanyl|prilocaine|> emla ( lidocaine and entity ) is used as a local anaesthetic for topical application to prevent pain associated with injections and superficial surgical procedures .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|peel lidocaine transdermal depot hydrochloride|lidocaine ethanol diclofenac epinephrine verapamil|prilocaine|the skin permeation data compares a 2 . 5% lidocaine gel and the emla cream , which contains 2 . 5% lidocaine and 2 . 5% entity .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|peel lidocaine transdermal depot hydrochloride|lidocaine topical capsaicin TAP epinephrine|prilocaine|this product in the third quarter of 2018 . on july 2 , 2018 , we announced approval of an anda for lidocaine and entity cream usp , 2 . 5% / 2 . 5% .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|peel lidocaine transdermal depot hydrochloride|HCl remifentanil PCA vaginal propofol|prilocaine|local intracervical anesthetic block is achieved using 8 . 8 ml citanest ( entity ) with octapressin .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|peel lidocaine transdermal depot hydrochloride|lidocaine tacrolimus epinephrine corticosteroid diclofenac|prilocaine|in particular , the dojs subpoena to impax focused on four generic medications : digoxin tablets , terbutaline sulfate tablets , entity / lidocaine cream , and calcipotriene topical solution .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|peel lidocaine transdermal depot hydrochloride|hydrochloride HCl sulfate sulphate topical|prilocaine|number of products marketed under lidocaine entity topical cream 1 number of product
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|peel lidocaine transdermal depot hydrochloride|epinephrine lidocaine bupivacaine fentanyl morphine|prilocaine|> emla ( lidocaine + entity ) is used as a local anaesthetic for topical application .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|peel lidocaine transdermal depot hydrochloride|tetrac lign rop proc EM|prilocaine|for example , one non-injectable , subsurface local anesthetic commercially available today is oraqix® ( lidocaine and entity periodontal gel ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|ex m2 max rh delta|dexrazoxane|totect&#xa0 ; &#xae ; &#xa0 ; ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|alfa paclitaxel P2Y Bis quercetin|methotrexate cyclophosphamide prednisolone cyclosporine doxorubicin|dexrazoxane|bulk drug substances the muscle relaxants atracurium besylate , pancuronium bromide and vecuronium bromide , the immunosuppressant drug cyclosporine and the prodrug entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa paclitaxel P2Y Bis quercetin|ex trastuzumab Dox depot Lu|dexrazoxane|totect® ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|Reactive Its Their Iron Intracellular|dexrazoxane|entity metabolites trap the iron ions involved in the process which leads to myocardial damage caused by anthracycline oncolytic agents such as doxorubicin .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa paclitaxel P2Y Bis quercetin|cigarettes rice MSCs medicines cannabis|dexrazoxane|we launched totect during a national shortage of entity in late 2017 , resulting in strong initial demand for the product .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|Vaccine FDA Technology He Tobacco|dexrazoxane|entity is manufactured using a proprietary process covered by patents filed in several countries .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alfa paclitaxel P2Y Bis quercetin|cannabis MDMA amiodarone marijuana cocaine|dexrazoxane|( f ) " cardioxane-trademark- " means the substance known by the chemical name of entity , and any analogues or derivatives thereof .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|tablets vaccines capsules preparations medicines|dexrazoxane|sicor s . p . a . manufactures entity according to a proprietary process covered by process patents filed in many countries .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('BIO', 1)])|drug|alfa paclitaxel P2Y Bis quercetin|lidocaine vincristine ketamine doxorubicin morphine|dexrazoxane|the companys entry into the oncology specialty includes two initial supportive care medications : ethyol® ( amifostine ) injection and totect® ( entity hydrochloride ) injection .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|name approved prepared jelly powder|dexrazoxane|zinecard ( r ) ( entity for injection ) sold in the u . s . and canada , is a preparation for reducing cardiac side effects in women with metastatic
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|chemicals money funds customers companies|dexrazoxane|he oversaw the distribution of our new totect brand during a national shortage of entity resulting in many new customer relationships for the company .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|ex GSK Ara formerly alfa|dexrazoxane|apricus bio currently markets totect® ( entity hcl ) , the only drug approved in the us for the treatment of anthracycline extravasation .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|collaboration partnerships partnership concurrently projects|dexrazoxane|sicor s . p . a . developed entity with chiron bv , including performing clinical trials , developing dosage form manufacturing , marketing and sales .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|market own scientific marketing patent|dexrazoxane|totect was acquired by clinigen in march 2016 to expand its entity portfolio and enter the u . s . market .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|alfa paclitaxel P2Y Bis quercetin|Dox everolimus GSK DHA FDA|dexrazoxane|” about totect® ( entity ) totect is an anthracycline extravasation agent approved by the united states food and drug administration .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa paclitaxel P2Y Bis quercetin|ex Ro Dox GSK den|dexrazoxane|totect® ( entity hcl ) was approved by the fda in 2007 for the treatment of anthracycline extravasation , which is the leaking of chemotherapy
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|drug|alfa paclitaxel P2Y Bis quercetin|hearts hamsters cardiomyocytes myocardium MSCs|dexrazoxane|administration of entity with such oncolytic agents protects tissues of the heart and allows for higher dosages of the oncolytic agent .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|alfa paclitaxel P2Y Bis quercetin|trastuzumab Dox doxorubicin bevacizumab TM|dexrazoxane|about totect® ( entity ) injectiontotect is an anthracycline extravasation agent approved by the fda .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa paclitaxel P2Y Bis quercetin|market patent pharmaceutical marketing pharmacy|dexrazoxane|totect was acquired by clinigens specialty pharmaceuticals ( sp ) division in march 2016 to expand its entity portfolio for the u . s . market .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|alfa paclitaxel P2Y Bis quercetin|metoprolol propranolol lidocaine nicotine sildenafil|dexrazoxane|totect® cumberland announced fda approval of new labeling of totect® ( entity hydrochloride ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND phenylephrine P2Y estradiol alfa|alkaloids alkaloid morphine flavonoids derivative|phenylephrine|each 5ml dose contains the api entity hci , pyrilamine maleate and dextromethorphan hbr .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2)])|drug|AND phenylephrine P2Y estradiol alfa|diclofenac lidocaine paracetamol gabapentin topical|phenylephrine|european medicines agencys committee for medicinal products for human use had adopted a positive opinion for omeros drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|AND phenylephrine P2Y estradiol alfa|mannitol salbutamol ibuprofen diclofenac theophylline|phenylephrine|pse also competes against entity , an alternate nasal decongestant available in non-prescription products .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND phenylephrine P2Y estradiol alfa|ex 2nd 125 mini intrad|phenylephrine|biorphen ( entity hcl injection ) is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|AND phenylephrine P2Y estradiol alfa|diclofenac lidocaine bevacizumab topical steroids|phenylephrine|the companys drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% is marketed for use during cataract surgery or intraocular lens ( iol ) replacement to maintain
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND phenylephrine P2Y estradiol alfa|pharmaceutical market funding capital financial|phenylephrine|ongoing entity supply disruptions from 503b compounding facilities , including the announced shutdown of compounding industry leader pharmedium in january , have highlighted the
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|AND phenylephrine P2Y estradiol alfa|melatonin gabapentin ginger resveratrol caffeine|phenylephrine|otc products contain any one of several active ingredients including glycerin , entity , pramoxine , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|AND phenylephrine P2Y estradiol alfa|diclofenac lidocaine bevacizumab topical steroids|phenylephrine|our marketed drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% was broadly launched in the u . s . in april 2015 for use during cataract surgery or intraocular
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND phenylephrine P2Y estradiol alfa|FDA pharmacists biotechnology HIT therapeutics|phenylephrine|ventrus is also required to reimburse s . l . a . for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|AND phenylephrine P2Y estradiol alfa|paclitaxel docetaxel diltiazem FDA gemcitabine|phenylephrine|is also required to reimburse s . l . a . pharma for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|AND phenylephrine P2Y estradiol alfa|morphine ketamine tramadol clonidine fentanyl|phenylephrine|these products generally contain active ingredients such as acetaminophen , dextromethorphan , diphenhydramine , guaifenesin , loratadine , entity , and pseudoephedrine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|AND phenylephrine P2Y estradiol alfa|capsaicin diclofenac rectal nitroglycerin vaginal|phenylephrine|: 267  270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|AND phenylephrine P2Y estradiol alfa|midazolam fentanyl histamine morphine ketamine|phenylephrine|aldex ct is an antihistamine / decongestant combination administered orally in a chewable tablet form containing the api diphenhydramine hcl and entity hcl .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|AND phenylephrine P2Y estradiol alfa|diclofenac lidocaine topical bevacizumab steroids|phenylephrine|our marketed drug product omidria™ ( entity and ketorolac injection ) 1% / 0 . 3% is approved in the u . s . for use during cataract surgery or intraocular lens , or iol , replacement
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|AND phenylephrine P2Y estradiol alfa|pe diclofenac ciprofloxacin erythromycin gentamicin|phenylephrine|microdose delivery of entity 10% ( pe - µd ) was associated with significantly less systemic exposure than traditional eye drops ( pe 10% ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|AND phenylephrine P2Y estradiol alfa|diclofenac lidocaine ibuprofen paracetamol tacrolimus|phenylephrine|application seeking approval from the u . s . food and drug administration to market a generic version of the companys drug omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|AND phenylephrine P2Y estradiol alfa|bevacizumab lidocaine ketamine sildenafil propranolol|phenylephrine|on june 28 , 2013 , the group filed an nda for vazculep ( entity hydrochloride injection ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|AND phenylephrine P2Y estradiol alfa|vaginal Lactobacillus hyaluronan sildenafil barrier|phenylephrine|entity gel ( ven 308 ) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis , an fda orphan indication .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|AND phenylephrine P2Y estradiol alfa|bevacizumab fluconazole paclitaxel bortezomib docetaxel|phenylephrine|because of the extensive patient exposure to entity , we intend to develop ven 308 as a topical formulation through a section 505 ( b ) nda .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|AND phenylephrine P2Y estradiol alfa|capsaicin diclofenac nitroglycerin lidocaine vaginal|phenylephrine|: 267 - 270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|paclitaxel platinum AND carboplatin gemcitabine|docetaxel cyclophosphamide capecitabine carboplatin bevacizumab|pemetrexed|in the th-302 plus entity arm , th-302 is administered intravenously on days 1 and 8 of a 21 day cycle .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|paclitaxel platinum AND carboplatin gemcitabine|atorvastatin everolimus metformin rituximab simvastatin|pemetrexed|obtain approval for talotrexin , we will compete with existing antifolate therapies currently being sold by pfizer ( trimetrexate ) , eli lilly & co . ( entity ) and novartis ( edatrexate ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel platinum AND carboplatin gemcitabine|od st na sem da|pemetrexed|pth-305 : nsclc ( w / entity ) 2 / 2006 to 6 / 2007 400 , 600 136 138 os was lower in talabostat vs placebo .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|paclitaxel bevacizumab fluconazole tacrolimus metformin|pemetrexed|eagle  s solution : ep-5101 ( pemfexy™ ) ep-5101 is an rtd liquid formulation of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|paclitaxel etoposide cyclophosphamide gemcitabine bevacizumab|pemetrexed|interim data conducted on a small number of patients showed encouraging response rates with the combination of carboplatin , entity and bavituximab .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|paclitaxel platinum AND carboplatin gemcitabine|docetaxel gefitinib capecitabine paclitaxel irinotecan|pemetrexed|administered as monotherapies , these include entity ( alimta® ) , docetaxel ( taxotere® ) , or erlotinib ( tarceva® ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|paclitaxel etoposide docetaxel gemcitabine irinotecan|pemetrexed|the addition of apatorsen to carboplatin and entity therapy did not demonstrate an overall survival benefit in the study ( hr= 1 . 067 ; 80% ci : 0 . 838-1 . 359 ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel platinum AND carboplatin gemcitabine|First Then Open Besides Firstly|pemetrexed|entity , supply agreement term sheet in december 2016 , we entered into a binding term sheet with nang-kuang pharmaceutical co . , ltd and
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|irinotecan paclitaxel cyclophosphamide carboplatin etoposide|pemetrexed|of the thirty-two patients with relapsed or refractory nsclc treated with th-302 in combination with either docetaxel or entity , eight patients achieved prs and fourteen patients achieved sd .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|paclitaxel etoposide prednisone bevacizumab gemcitabine|pemetrexed|·a phase ib ist evaluating bavituximab in combination with carboplatin and entity in up to 25 patients with previously untreated stage iv nsclc .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|gemcitabine etoposide docetaxel paclitaxel irinotecan|pemetrexed|with docetaxel in metastatic squamous nsclc that has progressed after previous therapy ( arm b ) ; or · in combination with entity and cisplatin in mesothelioma ( arm c ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|Vaccine formulation alfa MTD tablet|pemetrexed|entity is dosed according to its package insert .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|packaging marketing cannabis contraception biotechnology|pemetrexed|which we allege infringement against apotex inc . ( apotex ) in response to its application to market products using alternative forms of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|paclitaxel etoposide gemcitabine irinotecan docetaxel|pemetrexed|the aim of the trial is to determine if adding apatorsen to carboplatin and entity therapy could extend pfs outcome .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|metformin gemcitabine bevacizumab rituximab docetaxel|pemetrexed|the second 400-patient trial , evaluating the combination of talabostat with entity versus placebo and entity opened to enrollment in february 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|paclitaxel platinum AND carboplatin gemcitabine|gefitinib docetaxel capecitabine gemcitabine bevacizumab|pemetrexed|each study will combine pf-3512676 with either avastin® ( bevacizumab ) , erbitux® ( erlotinib ) or alimta® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|bortezomib trastuzumab bevacizumab rituximab paclitaxel|pemetrexed|patients continued entity with weekly apatorsen or placebo infusions as maintenance treatment until disease progression if they completed a minimum of 3 cycles of chemotherapy treatment .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel platinum AND carboplatin gemcitabine|se he org nd st|pemetrexed|some of our competitors include pfizer ( trimetrexate ) , eli lilly & co . ( entity ) , novartis ( edatrexate ) , and allos ( pdx ) , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|paclitaxel platinum AND carboplatin gemcitabine|monotherapy regimens prophylaxis immunosuppression TMZ|pemetrexed|strata 1 and 3 also had maintenance entity or continued egfr-tki therapy , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|paclitaxel platinum AND carboplatin gemcitabine|paclitaxel gemcitabine docetaxel irinotecan bevacizumab|pemetrexed|the denali trial is testing demcizumab with entity and carboplatin versus entity and carboplatin alone in first-line advanced non-small cell lung cancer patients .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa AND allergy infliximab psoriasis|called whose alongside generic topical|moxidectin|both products  entity formulations offer numerous advantages over traditional deworming agents .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|alfa AND allergy infliximab psoriasis|medicinal topical licensed cosmetic herbal|moxidectin|cydectin , a entity product to control parasites in animals , will have patent protection until at least 2011 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa AND allergy infliximab psoriasis|topical approved injectable marketed pharmaceutical|moxidectin|the first entity formulation for horses , equest gel , was launched in new zealand .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|former investigational interventional superiority 2nd|oxaliplatin|this data represents a five-fold improvement to results seen from the entity arm of the study .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|PFS biomarker chemotherapeutic oncological personalized|oxaliplatin|also performed a gene identification study which analyzed over 700 new genes , and identified 16 genes as being predictive of entity benefit for use in patients with stage iii disease .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|medicines vaccines opioids paracetamol prescriptions|oxaliplatin|in 2010 ) , following a court ruling barring manufacturers of generics in the u . s . from selling their unapproved generic versions of entity from june 30 , 2010 .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|docetaxel bevacizumab irinotecan gemcitabine paclitaxel|oxaliplatin|currently in clinical trials , including trials for hormone refractory prostate cancer , inoperable liver cancer , and in combination with capecitabine or entity .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|capecitabine platinum irinotecan oxaliplatin cetuximab|oxaliplatin|the company began offering the oncotype dx colon cancer test for use in patients with stage iii disease treated with entity containing adjuvant therapy .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|irinotecan oxaliplatin gemcitabine capecitabine carboplatin|oxaliplatin|other chemotherapies include capecitabine ( xeloda® ) , entity ( eloxatin® ) , fluorouracil or leucovorin .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|medicines vaccines trastuzumab bevacizumab AEDs|oxaliplatin|in the first half of 2010 ) after a court ruling barred generics manufacturers from selling their unauthorized generic versions of entity in the united states from june 30 , 2010 .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|neoadjuvant irinotecan palliative platinum cytotoxic|oxaliplatin|two weeks in patients with advanced non-small cell lung cancer ; and ø a u . s . phase iii trial in patients undergoing treatment with entity regimens for advanced colorectal cancer .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|docetaxel bevacizumab gemcitabine paclitaxel carboplatin|oxaliplatin|marketed products in oncology include padexol injection ( paclitaxel ) , didox capsule ( doxifluridine ) , oxp injection ( entity ) and crabcan injection ( irrinotecan ) .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|carboplatin platinum docetaxel paclitaxel Chemotherapy|oxaliplatin|entity , a formulation of dach platinum , is a chemotherapeutic which was initially approved in france and in europe in 1999 for
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|medicinal nut cosmetic topical brand|oxaliplatin|on june 30 , 2010 , the company ceased selling sun pharmas entity product in the united states market , pending the appeal .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|paclitaxel carboplatin Dox verapamil doxorubicin|oxaliplatin|the originator of the drug , and several generic manufacturers ; ▪ carboplatin , marketed by bristol-myers squibb in the us ; and ▪ entity , marketed exclusively by sanofi-aventis .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|subcutaneous capsule Oral Topical injectable|oxaliplatin|entity injection 50mg / 10ml and 100mg / 20ml are the ab-rated generic versions of eloxatin® , which had annual sales of approximately $1 . 4 billion for
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|irinotecan paclitaxel carboplatin capecitabine gemcitabine|oxaliplatin|other combinations of gemcitabine with cisplatin , entity , irinotecan or docetaxel tested in phase 3 trials have not been of superior benefit to gemcitabine alone .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|irinotecan methotrexate oxaliplatin uracil fluorouracil|oxaliplatin|for most patients , initial chemotherapy is based on folfox ( 5-fu , leucovorin and entity ) , or similar agents .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|innovations pharmaceuticals formulations medicines innovation|oxaliplatin|the growth was driven by an increase in specialty injectable pharmaceuticals , primarily a result of the third-quarter launch of entity in solution form in the united states .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|carboplatin gemcitabine paclitaxel docetaxel doxorubicin|oxaliplatin|demonstrated preliminary evidence of efficacy but grade 2 innate immune adverse effects were seen with standard doses of gemcitabine and entity and 10 µg / kg doses of mt-3724 .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|irinotecan capecitabine gemcitabine oxaliplatin docetaxel|oxaliplatin|aroplatin aroplatin is a novel liposomal formulation of a third-generation platinum chemotherapeutic structurally similar to entity , a recently approved treatment for colorectal cancer .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|subcutaneous depot intramuscular injectable syringe|oxaliplatin|on august 11 , 2009 , teva commenced sales of its 50mg / 10ml and 100mg / 20ml entity injection products .
OrderedDict([('DRUG', 5), ('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin cetuximab platinum|platinum carboplatin docetaxel paclitaxel Chemotherapy|oxaliplatin|entity , a compound of dach platinum , is a chemotherapeutic which was initially approved in europe in 1999 for the treatment of
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|steroids analogues hormones depot analogs|hormonal glucocorticoid GH oestrogen corticosteroid|levothyroxine|skin reactions , hypothyroidism in patients taking entity replacement , gi perforation , in some cases fatal and tumor lysis syndrome , which can be life threatening , have also been reported
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|steroids analogues hormones depot analogs|diclofenac elemental extra atorvastatin quaternary|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales decreased to $26 million during the second quarter ended june 30 , 2007 from $29 million during the second
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|steroids analogues hormones depot analogs|diclofenac lithium warfarin balanced hypertonic|levothyroxine|if the fda were to determine that another entity sodium product is bioequivalent to levoxyl® , generic substitution for levoxyl® may become possible which could result in a decrease in
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids analogues hormones depot analogs|investigational topical brand approved inhaled|levothyroxine|could be affected by future actions of the fda and by uncertainty in the entity sodium product market .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids analogues hormones depot analogs|FDA colleagues Medicare ourselves providers|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement with entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|steroids analogues hormones depot analogs|diclofenac elemental quaternary atorvastatin extra|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales totaled $32 million during the fourth quarter and $100 million for the year ended december 31 , 2007 , compared
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|drug|steroids analogues hormones depot analogs|diclofenac levodopa lithium atorvastatin warfarin|levothyroxine|in december 2004 , the entity sodium tablet product received the ab rating to synthroid® .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|steroids analogues hormones depot analogs|quaternary diclofenac lithium concentrated warfarin|levothyroxine|on august 14 , 1997 , the fda announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|steroids analogues hormones depot analogs|diclofenac salbutamol max balanced diluted|levothyroxine|net sales of levoxyl ( r ) ( entity sodium tablets , usp ) equaled $28 . 7 million during the first quarter ended march 31 , 2004 , a decrease of 14% from $33 . 2
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|steroids analogues hormones depot analogs|medicines cigarettes cannabis tablets acetaminophen|levothyroxine|volumes were favorably impacted due to increased sales of entity as customer demand increased in anticipation of the transition of the product .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids analogues hormones depot analogs|plans buildings clients labour trust|levothyroxine|complementing our second quarter performance was a well-executed plan associated with the transition of entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|steroids analogues hormones depot analogs|prophylactic fentanyl dosing administering Met|levothyroxine|nitrofurantoin during our 180-day exclusivity period ; the delay in the launch of our fentanyl product and the regulatory actions surrounding entity sodium .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|steroids analogues hormones depot analogs|diclofenac atorvastatin metformin salbutamol sildenafil|levothyroxine|worldwide agreement with jerome stevens pharmaceuticals , inc . to market and distribute jerome stevens  nda ( new drug application ) approved form of entity sodium , usp tablets .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids analogues hormones depot analogs|diclofenac quaternary prescription table topical|levothyroxine|of $2 , 220 , 931 due to an improvement in timely collections , and the launch of the company  s new product sales campaign for entity sodium tablets in april 2003 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids analogues hormones depot analogs|diclofenac quaternary van lithium hydrophilic|levothyroxine|drug administration , which we refer to as the fda ,  announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|steroids analogues hormones depot analogs|diclofenac generic plain warfarin tablet|levothyroxine|this dual approval will now allow pharmacists to substitute entity sodium tablets for both dominant brands .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|steroids analogues hormones depot analogs|diclofenac iodine valproate iod iodide|levothyroxine|thyromed chewable tablets contain the active ingredient entity sodium , which is a clinically proven replacement for the naturally occurring hormone secreted by the thyroid gland .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids analogues hormones depot analogs|diclofenac supplemental balanced salmon excess|levothyroxine|these chewable tablets , which are administered daily for the life of the dog , provide entity sodium , a replacement therapy for the hormone normally produced by the dog .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids analogues hormones depot analogs|Medicare Medicaid providers reimbursement payment|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement for entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids analogues hormones depot analogs|diclofenac generic balanced topical quaternary|levothyroxine|application for an equivalent product after august 14 , 2001 must submit an anda seeking approval of a generic substitute for a entity sodium product with an approved nda .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|lidocaine topical capsaicin corticosteroid diclofenac|neomycin|triamcinolone acetonide and entity paste used for neurodermatitis circumscripta and chronic eczema .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|gentamicin vancomycin ciprofloxacin imipenem azithromycin|neomycin|existing drugs , such as tobramycin , entity , zithromax® and zyvox® , demonstrate that successful medicines can modulate rna function .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|clindamycin tetracycline vancomycin gentamicin chloramphenicol|neomycin|our products that contain virginiamycin , oxytetracycline or entity are classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|vancomycin tetracycline clindamycin erythromycin gentamicin|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antibacterials .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|gentamicin zinc silver magnesium chondroitin|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|clindamycin penicillin erythromycin gentamicin azithromycin|neomycin|the company believes that current antibiotic therapies , including entity and metronidazole , are inadequate treatments , however , due to their limited antibacterial spectrum and side effects .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|NC T2DM CON PBS volunteers|neomycin|the abnormal plasma amino acid pattern characterized by decreased levels of bcaas and elevated levels of aaas , as compared to entity , which was used as an active control .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|itraconazole fluconazole contraceptives metformin ritonavir|neomycin|nexavar exposure decreases when coadministered with oral entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|vancomycin clindamycin tetracycline gentamicin erythromycin|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|AND cytotoxic fluorouracil alfa paclitaxel|chondroitin silver zinc gentamicin magnesium|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate ( neosporin-registered trademark- ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa analogues analogue lamivudine boost|lamivudine CMV delta prophylactic ga|tenofovir|the later stages of the phase iii clinical trials for adefovir dipivoxil will not arise in the clinical trials for entity df or that we will achieve adequate treatment benefits .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa analogues analogue lamivudine boost|EPO bevacizumab Flu Dox rituximab|tenofovir|initiate in 2017 the phase 2b clinical trial to evaluate sb 9200 as a monotherapy and in combination with viread ( entity ) targeting approximately 200 patients with chronic hbv .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa analogues analogue lamivudine boost|lamivudine Interferon ribavirin 1b regimens|tenofovir|entity has potent activity against chronic hepatitis b . it is particularly useful in patients who have developed drug resistance to other
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|alfa analogues analogue lamivudine boost|ten lamivudine methotrexate doxycycline zinc|tenofovir|unenforceable and / or will not be infringed by teva  s manufacture , use or sale of a generic fixed-dose combination of emtricitabine and entity disoproxil fumarate .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa analogues analogue lamivudine boost|lamivudine clarithromycin rifampicin ritonavir ribavirin|tenofovir|the most commonly used therapy for chronic hbv is life-long suppressive therapy with nrtis , like entity or entecavir .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa analogues analogue lamivudine boost|ten gem inhaled bud meg|tenofovir| viread sales of viread® ( entity disoproxil fumarate ) were $189 . 4 million in the third quarter of 2005 , a two percent decrease from $193 . 9 million in the
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alfa analogues analogue lamivudine boost|vancomycin fluconazole rifampicin clarithromycin clindamycin|tenofovir|use of viread should be considered for treating adult patients with hiv-1 strains that are expected to be susceptible to entity as assessed by laboratory testing or treatment history .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa analogues analogue lamivudine boost|ip dd vi sc es|tenofovir|nrtis , such as epivir ( 3tc ) , emtriva ( ftc ) , viread ( entity ) , retrovir ( azt ) and zerit ( d4t ) , have become the predominant class of drugs in hiv therapy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|alfa analogues analogue lamivudine boost|lamivudine nucleoside ribavirin coenzyme antiviral|tenofovir|txl is a highly potent analog of the antiviral drug entity df ( viread® ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa analogues analogue lamivudine boost|excluding formerly liposomal bis IN|tenofovir|which gilead is funding and conducting a phase 2 clinical trial examining the co-administration of inarigivir and vemlidy® 25 mg ( entity alafenamide ) in patients infected with chronic hbv .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa analogues analogue lamivudine boost|ten polyethylene inhaled reconstituted simvastatin|tenofovir|addendum to entity disoproxil fumarate manufacturing supply agreement the parties hereby acknowledge and agree to the following :
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa analogues analogue lamivudine boost|ribavirin lamivudine ritonavir chloroquine AZT|tenofovir|nucleotide compound , uses the same proprietary lipid technology as cmx001 to deliver high intracellular concentrations of another potent antiviral drug , entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|alfa analogues analogue lamivudine boost|ten polyethylene inhaled polyvinyl coenzyme|tenofovir|and in april 2013 , gilead and teva reached an agreement in principle to settle the lawsuit on the patents covering entity disoproxil fumarate contained in the atripla*
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa analogues analogue lamivudine boost|own FDA automated intended file|tenofovir|we cannot predict the outcome of these proceedings on our entity df patent application .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa analogues analogue lamivudine boost|vaccines medicines PrEP vaccination formulations|tenofovir|in addition , in late 2011 , generic entity also became available in turkey , which resulted in an increase in the rebate for viread in turkey .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa analogues analogue lamivudine boost|Whether Background lamivudine Only Oral|tenofovir|entity df is in the same class of drugs as adefovir dipivoxil .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|alfa analogues analogue lamivudine boost|Placebo sham probiotic metformin Max|tenofovir|of cmx157 in healthy volunteers and are on track to complete the ongoing phase 2a head-to-head study of cmx157 vs . entity df ( tdf , gileads viread® ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa analogues analogue lamivudine boost|lamivudine ritonavir regimens monotherapy HAART|tenofovir|entity and entecavir have emerged as the standard of care in this disease with very low rates of resistance over five
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa analogues analogue lamivudine boost|ribavirin lamivudine bevacizumab monotherapy methotrexate|tenofovir|the replicor 401 study , a study of naps in combination with entity and pegylated interferon , reported a 39% functional cure rate .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa analogues analogue lamivudine boost|ten inhaled lamivudine gem weekly|tenofovir|in the notice related to teva  s anda for a generic version of truvada , teva challenged four patents related to entity disoproxil fumarate and two additional patents related to emtricitabine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alfa Prior topical Concurrent methotrexate|chloroquine melatonin methotrexate cyclosporine thalidomide|amifostine|we are also aware of research relating to the use of high doses of entity ( a drug used to control some of the side effects of chemotherapy and radiation therapy ) for the protection of hearing
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa Prior topical Concurrent methotrexate|bevacizumab paclitaxel trastuzumab docetaxel capecitabine|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 and irofulven .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa Prior topical Concurrent methotrexate|app eg ie FDA TV|amifostine|we anticipate that ethyolregistered trademark ( entity ) will be a meaningful product for medimmune following our merger .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|drug|alfa Prior topical Concurrent methotrexate|app ECs SMS FDA Belgium|amifostine|sales of ethyol-registered trademark- ( entity ) increased 48% and 23% for the quarter and six months ended june 30 , 1999 , respectively , compared to the same periods
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa Prior topical Concurrent methotrexate|Germany PET France Canada radio|amifostine|medical applications the arsenal of medical radiation-protectors is limited to ethyol™ ( entity ) , sold by medimmune , and acquired by astrazeneca international .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|alfa Prior topical Concurrent methotrexate|metformin fluconazole itraconazole tacrolimus olanzapine|amifostine|mycelex-registered trademark- ( clotrimazole ) troche , which alza began marketing in the second half of 1997 , and increased sales of ethyol-registered trademark- ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alfa Prior topical Concurrent methotrexate|capecitabine gemcitabine docetaxel hydrochloride bevacizumab|amifostine|entity ( ethyolâ ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|alfa Prior topical Concurrent methotrexate|steroids aspirin carboplatin lidocaine methotrexate|amifostine|we are also aware of research relating to the use of high dose entity for the protection of hearing in connection with platinum-based chemotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa Prior topical Concurrent methotrexate|intranasal topical diclofenac intramuscular inhaled|amifostine|we market synagis ( palivizumab ) , flumist ( influenza virus vaccine live , intranasal ) , ethyol ( entity ) and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa Prior topical Concurrent methotrexate|TM MDMA France FDA THC|amifostine|sun pharmaceutical industries limited has submitted an abbreviated new drug application to the fda for a generic version of ethyol ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alfa Prior topical Concurrent methotrexate|capecitabine gemcitabine docetaxel hydrochloride bevacizumab|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|alfa Prior topical Concurrent methotrexate|diclofenac bevacizumab prednisolone methotrexate infliximab|amifostine|the company markets synagis ( palivizumab ) , ethyol ( entity ) , and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alfa Prior topical Concurrent methotrexate|doxycycline methotrexate chloroquine cyclophosphamide rifampicin|amifostine|neupogen ( r ) currently faces market competition from a competing csf product , granulocyte macrophage colony stimulating factor ( " gm-csf " ) and from the chemoprotectant , entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa Prior topical Concurrent methotrexate|brachytherapy alfa iodine radiosurgery doxorubicin|amifostine|entity ( ethyol® ) is approved by the fda as a radioprotector .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa Prior topical Concurrent methotrexate|ii France EU app Italy|amifostine|in december 1995 , alza entered into a marketing and distribution agreement with u . s . bioscience , inc . ( " u . s . bioscience " ) for ethyol-registered trademark- ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|alfa Prior topical Concurrent methotrexate|alfa cream hydrochloride capecitabine docetaxel|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity and radiation-induced xerostomia ( damage to the
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|alfa Prior topical Concurrent methotrexate|gemcitabine hydrochloride curcumin cyclophosphamide docetaxel|amifostine|entity ( ethyol ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|alfa Prior topical Concurrent methotrexate|thalidomide bevacizumab bortezomib rituximab methotrexate|amifostine|there is one drug , entity , approved for use in reducing side effects from radiation therapy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa Prior topical Concurrent methotrexate|bevacizumab paclitaxel trastuzumab docetaxel capecitabine|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 , and irofulven .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|alfa Prior topical Concurrent methotrexate|GSK Germany France metformin FDA|amifostine|product sales of $66 million , including $33 million in worldwide sales of synagis and $25 million in sales of ethyol® ( entity ) .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|steroids alfa cyclophosphamide acetate prednisone|lidocaine acetaminophen morphine epinephrine tacrolimus|hydrocortisone|· igi will formulate four combination products of entity and lidocaine at different strengths : 1 .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|steroids alfa cyclophosphamide acetate prednisone|PDT LPS AgNPs CQ TSA|hydrocortisone|at 4 µm , 42% at 8 µm and 52% at 16 µm . therefore , the ic50 was 16 µm . by comparison , entity at 10 µm caused a 54% reduction in il-8 expression .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|steroids alfa cyclophosphamide acetate prednisone|NaCl cream lidocaine chlorhexidine diclofenac|hydrocortisone|in canada , 0 . 5% entity , a common anti-inflammatory product , described in the monograph , hydrocortisone topical published by health canada on january 22 , 2007 , can be
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|steroids alfa cyclophosphamide acetate prednisone|ie injectable tablet depot eg|hydrocortisone|on november 15 , 2011 , we acquired rights to plenadren® ( entity , modified release tablet ) for treatment of ai .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|steroids alfa cyclophosphamide acetate prednisone|Topical Az Tac Ac Its|hydrocortisone|entity rectal cream is used for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|steroids alfa cyclophosphamide acetate prednisone|antifungal metronidazole fluconazole itraconazole metformin|hydrocortisone|discuss how fda views our package of the us experience with ketoconazole and entity combination and discuss how much value in the historical experience will be accepted .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|steroids alfa cyclophosphamide acetate prednisone|EM topical lot Derm tim|hydrocortisone|this was partially offset by the product launch of entity butyrate lotion .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|steroids alfa cyclophosphamide acetate prednisone|azithromycin amoxicillin penicillin omeprazole acetaminophen|hydrocortisone|the launch of entity with acetic acid along with strong sales of sulfamethoxazole with trimethoprim and fluticasone propionate nasal spray also contributed to the
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|steroids alfa cyclophosphamide acetate prednisone|topical Topical Prop ophthalmic am|hydrocortisone|-jun-11 t36® 0 . 5% entity ointment 80026139 30-jun-11 pedia-safe polyvitamin drops1 80001571 05-apr-06 ferroheme2 1 licensed to the company by canagen in an agreement dated
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|steroids alfa cyclophosphamide acetate prednisone|curcumin quercetin indomethacin LPS EPO|hydrocortisone|cbn was similar to entity with respect to anti-inflammatory activity in this model .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|steroids alfa cyclophosphamide acetate prednisone|corticosteroid analgesic cream sedative ointment|hydrocortisone|anamantlehc , launched in january 2003 , is a prescription cream containing a topical anesthetic and entity , which treats hemorrhoids and anal fissures .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|steroids alfa cyclophosphamide acetate prednisone|chloroquine UVB cream capsaicin honey|hydrocortisone|the combination of aloe vera and entity offers therapeutic benefits for skin irritations such as minor burns , allergic itch , insect bite itch , sun burn itch , eczema in
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|drug|steroids alfa cyclophosphamide acetate prednisone|Gastrointestinal Systemic Other vomiting Local|hydrocortisone|entity injection toxic symptom caused by various infections , hypocorticoidism caused by various infections , anaphylactic shock .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|steroids alfa cyclophosphamide acetate prednisone|paracetamol nitroglycerin tramadol metformin morphine|hydrocortisone|cma issued a statement of objections to a third party and the company in relation to the supply of 10mg entity tablets in the u . k . between 2013 and 2016 .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|steroids alfa cyclophosphamide acetate prednisone|lidocaine curcumin ingredient retinol ingredients|hydrocortisone|both products are formulated with aloe vera and cortiveraä contains 0 . 5% entity and cortivera plusä contains 1% entity .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|steroids alfa cyclophosphamide acetate prednisone|cream transdermal topical dry triple|hydrocortisone|formulation design up to 8 78 , 600 · igi will formulate a entity cream product .
OrderedDict([('DRUG', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|steroids alfa cyclophosphamide acetate prednisone|polyphenols antioxidants exosomes lipids DHA|hydrocortisone|lidamantle®hc also contains entity , which helps to reduce inflammation .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin simvastatin statins atorvastatin aspirin|rosiglitazone|commonly prescribed drugs include diabetic medicines such as metformin , entity and sulfonylurea .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|metformin AND triglycerides Insulin antidiabetic|FDA ii France app VI|rosiglitazone|for the district of colorado into the group  s us sales and promotional practices and for product liability cases regarding avandia ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|metformin AND triglycerides Insulin antidiabetic|bevacizumab paclitaxel gemcitabine capecitabine metformin|rosiglitazone|a fixed combination product of starlix and entity was approved by fda in 2003 .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin everolimus ex olanzapine resveratrol|rosiglitazone|will compete with cs-917 include the insulin sensitizers actos , or pioglitazone , co-marketed by takeda and eli lilly , and avandia , or entity , marketed by glaxosmithkline .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin simvastatin probiotics atorvastatin statin|rosiglitazone|cvr number : 24256790 the three lead® studies showed that liraglutide in combination with either glimepiride or metformin or metformin and entity is well tolerated .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin simvastatin atorvastatin statins statin|rosiglitazone|the study investigated the effect of different doses of liraglutide in combination with metformin and entity , and included 533 patients with type 2 diabetes .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|metformin AND triglycerides Insulin antidiabetic|sildenafil MDMA progesterone resveratrol cocaine|rosiglitazone|june 2007 the group voluntarily dismissed its infringement claims in respect of the patent covering the maleate salt form of entity ( the active ingredient in avandia ) .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin atorvastatin sildenafil nicotinamide resveratrol|rosiglitazone|starlix ( diabetes ) was also filed in the us in december for use in combination with entity , a commonly used oral antidiabetic .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin olanzapine sildenafil metoprolol atorvastatin|rosiglitazone|with respect to avandamet ( entity maleate / metformin hydrochloride ) tablets , the company anticipates resupplying the distribution channels within two weeks .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 3)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin Placebo olanzapine T2DM simvastatin|rosiglitazone|this weight loss was achieved with blood sugar-lowering efficacy comparable to entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|metformin AND triglycerides Insulin antidiabetic|cannabis paracetamol fluoxetine ketamine gabapentin|rosiglitazone|site at cidra , puerto rico ; product liability and anti-trust litigation relating to paxil ( paroxetine ) , and product liability cases regarding avandia ( entity ) and other products .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|metformin AND triglycerides Insulin antidiabetic|ethyl bis diethyl dimethyl metoprolol|rosiglitazone|for example , recent studies have suggested an increased cardiovascular risk in patients using avandia® ( entity maleate ) .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin bevacizumab caution aging amiodarone|rosiglitazone|there also have been concerns of other cardiovascular issues with entity and also concerns raised regarding bladder cancer associated with treatment with tzds .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1), ('BIO', 1)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin glucagon rapamycin resveratrol everolimus|rosiglitazone|insulin sensitizing agents approved to treat t2d are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('BIO', 1), ('DIS', 1)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin carbohydrates sugar glucagon meals|rosiglitazone|of starlix® ( nateglinide ) improves glycemic control and is well-tolerated in patients whose type 2 diabetes is inadequately controlled by taking entity alone .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin meals aspirin simvastatin lipids|rosiglitazone|after a run-in period of metformin and entity , patients in the study were randomised to add-on treatment with either liraglutide or placebo .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin resveratrol polyphenols palmitate atorvastatin|rosiglitazone|entity ( avandia® ) and pioglitazone ( actos® ) fall into this category of anti-diabetic agent .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin atorvastatin resveratrol simvastatin olanzapine|rosiglitazone|tzds include pioglitazone , marketed by eli lilly & company and takeda pharmaceutical company limited as actos , and entity , marketed by glaxosmithkline plc as avandia .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|metformin AND triglycerides Insulin antidiabetic|fluconazole paclitaxel metformin bevacizumab azithromycin|rosiglitazone|a comparator with entity , which has been shown to have some efficacy in humans , indicates the mgl-3196 performs better than entity in this study .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1), ('BIO', 1)])|drug|metformin AND triglycerides Insulin antidiabetic|metformin glucagon rapamycin resveratrol everolimus|rosiglitazone|insulin sensitizing agents approved to treat type 2 diabetes are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|lidocaine morphine epinephrine acetaminophen diclofenac|tetracaine|we entered into a license agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch ( zars agreement ) .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|lidocaine acetaminophen epinephrine diclofenac morphine|tetracaine|license agreement with zars pharma that will give it the exclusive north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|morphine ibuprofen lidocaine acetaminophen bupivacaine|tetracaine|the drug formulation is a eutectic mixture of lidocaine 70 mg and entity 70 mg .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|epinephrine lidocaine morphine remifentanil midazolam|tetracaine|this product combines our peel technology with a proprietary formulation of lidocaine and entity to safely and efficiently anesthetize contoured areas of the body .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|lidocaine diclofenac acetaminophen epinephrine ibuprofen|tetracaine|we entered into a license agreement with zars pharma for the north american rights to synera® ( lidocaine 70 mg and entity 70 mg ) topical patch , referred to as the zars agreement .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|lidocaine HCl epinephrine acetaminophen hydrochloride|tetracaine|allergy u . s . rx lidocaine ointment xylocaine™ dermatologics and topicals u . s . rx lidocaine / entity gel pliaglis® dermatologics and topicals u . s . rx loratadine solution claritin® allergy
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|epinephrine remifentanil lidocaine ketamine bupivacaine|tetracaine|it uses our chadd technology and a proprietary formulation of lidocaine and entity to provide more convenient and faster anesthetic effect compared to the most commonly used product .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|HPLC blank quantification EIA colorimetric|tetracaine|the fda has specified a limit of 1 . 5% tetra acid relative to entity assay .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|please throughout entering pend see|tetracaine|must demonstrate an acceptable level of tetra acid , which is a compound that is formed as the active product ingredients , entity assay , degrade over time .
OrderedDict([('DRUG', 3), ('OTHER', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|lidocaine bupivacaine anesthetic diclofenac hydrochloride|lidocaine epinephrine diclofenac acetaminophen morphine|tetracaine|we entered into an agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|AND Other depot antidepressants metformin|morphine capsaicin tramadol lidocaine gabapentin|pramoxine|current phn treatments are symptomatic , affecting the pain signaling circuit ( such as novocaine , entity , capsaicin , etc . ) , and do not produce lasting control .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|AND Other depot antidepressants metformin|acetate hydrochloride sulfate chloride sulphate|pramoxine|manufacture had to be obtained by copley before it shipped in interstate commerce and distributed for human use , brompheril , hydrocortisone entity , potassium chloride or procainamide .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|AND Other depot antidepressants metformin|ibuprofen lidocaine diclofenac phenylephrine paracetamol|pramoxine|preparation h® or similar products for symptomatic relief ( active ingredients can vary by country but generally include glycerin , phenylephrine hcl , entity hcl , and white petrolatum ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|AND Other depot antidepressants metformin|lidocaine capsaicin phenylephrine mannitol epinephrine|pramoxine|otc products contain any one of several active ingredients including glycerin , phenylephrine , entity , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|Insulin alfa GH thyroxine steroids|Note Form MEDLINE Medline FDA|liothyronine|entity , a concordia product , was included in the initial draft .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|Insulin alfa GH thyroxine steroids|MDMA metformin paclitaxel buprenorphine DHA|liothyronine|we believe that due to the fact that the market for entity is small , the manufacture and sale of generic forms of this compound are not economically attractive to potential competitors .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|Insulin alfa GH thyroxine steroids|Sodium diclofenac Calcium Vitamin Zinc|liothyronine|entity sodium , one of the company  s products , was included in the initial draft .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|Insulin alfa GH thyroxine steroids|diclofenac dextran amphotericin ferrous ferric|liothyronine|the company recorded a total impairment charge of $301 , 538 , primarily related to entity sodium - $128 , 191 , fusidic acid -
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|Insulin alfa GH thyroxine steroids|diclofenac replace elemental bind concentrate|liothyronine|during the second quarter of 2017 , the company also became aware of the anticipated launch of a competitive product to entity sodium .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|Insulin alfa GH thyroxine steroids|warfarin ciprofloxacin tetracycline ibuprofen aspirin|liothyronine|amcos product portfolio in the united kingdom is its largest and is predominantly comprised of products such as levothyroxine , entity and nitrofurantoin .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|Insulin alfa GH thyroxine steroids|diclofenac generic warfarin quaternary digoxin|liothyronine|generic entity sodium tablets are also available from coastal pharmaceuticals , mylan , and sigma pharmaceuticals .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|Insulin alfa GH thyroxine steroids|diclofenac prednisolone dextran cyclosporine prednisone|liothyronine|the remaining decrease of 13% is due to volume declines on key products including entity sodium , prednisolone and nefopam .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|Insulin alfa GH thyroxine steroids|buprenorphine generic nicotine stimulant tablet|liothyronine|the cma pricing investigation , which commenced in october 2016 , relates to three products , including entity tablets .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|Insulin alfa GH thyroxine steroids|warfarin ciprofloxacin phenytoin tetracycline theophylline|liothyronine|concordia international sells products such as entity , nitrofurantoin and levothyroxine within this category of the pharmaceutical market .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa PSA AND allergy analogues|Blood Plasma supplements Participants PTH|urofollitropin|entity - this is fsh derived from the urine of postmenopausal women .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa PSA AND allergy analogues|Technology Ultrasound NMR FSH Immunohistochemistry|urofollitropin|entity is used in research to develop fertility drugs and in basic endocrinology research .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|drug|alfa PSA AND allergy analogues|LDL lipids biomolecules platelets polysaccharides|urofollitropin|sicor currently expects to file a process patent covering purification of entity in early 1997 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa PSA AND allergy analogues|LDL pharmaceuticals polysaccharides biomolecules lipids|urofollitropin|sicor currently expects to file a process patent covering purification of entity in 1997 and is in discussions with potential partners about marketing the product in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa PSA AND allergy analogues|feasible approved desired applicable efficacious|urofollitropin|in order to commercialize therapeutics , initially entity , the company must outsource the manufacturing to a fda-regulated facility .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa PSA AND allergy analogues|FSH spermatozoa progesterone GnRH hCG|urofollitropin|the company  s present product candidates targeted to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa PSA AND allergy analogues|eg ie mucin CD44 glycoprotein|urofollitropin|in addition , at its facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa PSA AND allergy analogues|estrogens androgens hormones spermatozoa progesterone|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post- menopausal women .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|alfa PSA AND allergy analogues|FSH GnRH progesterone LHRH Insulin|urofollitropin|entity is involved in the stimulation of ovulation and is used in the treatment of certain types of infertility .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa PSA AND allergy analogues|estrogens androgens hormones spermatozoa progesterone|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post-menopausal women .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa PSA AND allergy analogues|ie eg namely too meanwhile|urofollitropin|in addition , at its santhia facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa PSA AND allergy analogues|FSH spermatozoa GnRH progesterone microspheres|urofollitropin|the company  s present products envisioned to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|vaccination allergy Prior vaccines AND|bevacizumab PrEP metformin another infliximab|eravacycline|we may be unable to develop and commercialize entity or any other product candidate and , even if we do , may never achieve profitability .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|vaccination allergy Prior vaccines AND|vaccines probiotics generic medicines chemicals|eravacycline|our operations to date have been limited to financing and staffing our company , developing our technology and developing entity and other product candidates .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|vaccination allergy Prior vaccines AND|GSK TM MRSA FDA BV|eravacycline|the companys commercial product , xerava ( entity ) , a fully synthetic fluorocycline , is an intravenous ( iv ) antibiotic that is approved for use as a first-line empiric monotherapy for
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|vaccination allergy Prior vaccines AND|funding vaccines medicines PrEP initiatives|eravacycline|our current plan is to commercialize entity outside the united states with collaborators .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|vaccination allergy Prior vaccines AND|metronidazole imipenem vancomycin clindamycin azithromycin|eravacycline|xerava was investigated for the treatment of ciai as part of the companys ignite ( investigating gram-negative infections treated with entity )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|vaccination allergy Prior vaccines AND|doxycycline tetracycline azithromycin erythromycin metronidazole|eravacycline|the companys lead product candidate , entity , is a fully synthetic tetracycline derivative that the company is developing as a broad-spectrum intravenous and oral antibiotic for use
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|vaccination allergy Prior vaccines AND|worldwide globally therapeutics increasingly progressively|eravacycline|tetraphase pharmaceuticals is developing entity for complicated urinary and intra-abdominal infections , as well as pneumonia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1)])|drug|vaccination allergy Prior vaccines AND|she gefitinib rituximab bortezomib he|eravacycline|for example , although entity achieved favorable results in the lead-in part of our phase 3 clinical trial in cuti , the pivotal portion of the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|vaccination allergy Prior vaccines AND|pharmacists you FDA consumers manufacturers|eravacycline|this may make it difficult for entity to compete with these products .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|vaccination allergy Prior vaccines AND|prophylaxis vaccination fluconazole monotherapy vaccines|eravacycline|its phase 3 clinical trials ( ignite1 and ignite4 ) would be sufficient to support submission of a new drug application for entity for the treatment of ciai .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|vaccination allergy Prior vaccines AND|vancomycin imipenem metronidazole antimicrobials probiotics|eravacycline|approval of xerava was based on our ignite ( investigating gram-negative infections treated with entity ) phase 3 program .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|vaccination allergy Prior vaccines AND|clindamycin vancomycin penicillin prophylaxis azithromycin|eravacycline|moreover , the company does not believe that the statement indicates in any respect that entity covers any or all of these infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|vaccination allergy Prior vaccines AND|bevacizumab paclitaxel bortezomib rituximab thalidomide|eravacycline|if clinical trials of entity or of any other product candidate that we advance to clinical trials fail to demonstrate safety and efficacy to the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|vaccination allergy Prior vaccines AND|PrEP buprenorphine naltrexone metformin FDA|eravacycline|if entity is approved , it may be priced at a significant premium over other competitive products .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|vaccination allergy Prior vaccines AND|cigarettes medicines marijuana funds nicotine|eravacycline|prior written notice if any governmental agency takes any action that prevents the company from importing , exporting , purchasing or selling entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|drug|vaccination allergy Prior vaccines AND|gum xer incontinence mouth OM|eravacycline|tetraphase is currently selling xeravatm ( entity ) in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vaccination allergy Prior vaccines AND|vancomycin imipenem clindamycin metronidazole gentamicin|eravacycline|however , we do not believe these limitations would apply to entity or any of our other investigational antibiotics .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|vaccination allergy Prior vaccines AND|companies investigators FDA platforms biology|eravacycline|entity , along with the companys proprietary drug discovery platform technology , make tetraphase an exceptional opportunity that i look forward to being
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|vaccination allergy Prior vaccines AND|bevacizumab fluconazole tacrolimus itraconazole levodopa|eravacycline|case based on our achievement of company goals with respect to the development of the intravenous and oral formulations of entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|alfa hydrochloride paclitaxel formulations P2Y|lidocaine morphine ketamine bupivacaine fentanyl|dyclonine|a bema ( tm ) product containing entity as a local anesthetic prior to dental procedures and for the treatment of canker sores has been consumer tested .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|alfa hydrochloride paclitaxel formulations P2Y|polymer formulation hydrogel barrier FDA|dyclonine|mucosal surfaces single claim  layered bioerodable pharmaceutical ( entity only ) carrier device .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND cervix phosphatase psoriasis vulgaris|subcutaneous epidural bolus intramuscular throughout|atosiban|the safety and pharmacokinetics of obe022 administered to pregnant women , who are receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|AND cervix phosphatase psoriasis vulgaris|naloxone naltrexone propranolol atropine dexmedetomidine|atosiban|these effects were blocked by the oxytocin receptor antagonist , entity , indicating the effects of intranasal oxytocin were mediated by oxytocin receptors .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|AND cervix phosphatase psoriasis vulgaris|misoprostol metformin oxytocin aspirin paracetamol|atosiban|in singleton pregnancies , 12 . 5% of women receiving ebopiprant plus entity delivered within 48 hours compared to 26 . 8% receiving entity only ( or 90% ci : 0 . 39 ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|AND cervix phosphatase psoriasis vulgaris|oxytocin hydrochloride misoprostol sulfate acetate|atosiban|ferring pharmaceuticals entity , an oxytocin receptor antagonist , has been used in investigator initiated trials in connection with ivf outside the united states .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|AND cervix phosphatase psoriasis vulgaris|FDA ART IPV BV IVIG|atosiban|with respect to obe022 , tractocile ( entity ) is approved to delay preterm birth outside of the united states , and we anticipate potential competition as a single agent ,
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|AND cervix phosphatase psoriasis vulgaris|misoprostol oxytocin buprenorphine Placebo remifentanil|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the united states .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|AND cervix phosphatase psoriasis vulgaris|oxytocin dexmedetomidine naloxone naltrexone misoprostol|atosiban|to exacerbate behavioral changes , entity , an oxytocin antagonist , was administered to the pups by slow intravenous push .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|AND cervix phosphatase psoriasis vulgaris|midazolam metformin propofol diazepam ketamine|atosiban|two groups were given placebo in place of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND cervix phosphatase psoriasis vulgaris|throughout subcutaneous once intramuscular bolus|atosiban|the safety and pharmacokinetics of obe022 in pregnant women , who were already receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|AND cervix phosphatase psoriasis vulgaris|misoprostol clonidine oxytocin dexmedetomidine naltrexone|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the u . s . the usefulness of these ß2-adrenergic
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|AND topical comparing vulgaris Allergy|iv rag VI rush vi|suvorexant|franchises grew · fda approved grastek and ragwitek sublingual allergen extract immunotherapy tablets and accepted filings for v503 and entity
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|AND topical comparing vulgaris Allergy|melatonin olanzapine naltrexone gabapentin fluoxetine|suvorexant|these may include the following :  entity , an orexin receptor antagonist , is being developed by merck & co . , inc . for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|AND topical comparing vulgaris Allergy|gabapentin benzodiazepines ketamine paracetamol fluoxetine|suvorexant|three of these medicines were filed in the u . s . ( entity for insomnia ; sugammadex for neuromuscular blockade and a combination of ezetimibe and atorvastatin for atherosclerosis ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|AND topical comparing vulgaris Allergy|marketing adoption employment publication deployment|suvorexant|the company is continuing with plans to seek approval for entity in other countries around the world .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|drug|AND topical comparing vulgaris Allergy|insomnia melatonin OSA RLS migraine|suvorexant|· received a complete response letter from the fda regarding the new drug application for entity , mercks investigational medicine for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|AND topical comparing vulgaris Allergy|metformin melatonin olanzapine bevacizumab fluoxetine|suvorexant|if approved , entity would be the first in a new class of medicines , called orexin receptor antagonists , for use in patients with insomnia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|AND topical comparing vulgaris Allergy|metformin olanzapine leptin octreotide eg|suvorexant|in august 2014 , merck & co . s dual orexin receptor antagonist , entity , was approved by the fda and is currently marketed under the name belsomra® .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|AND topical comparing vulgaris Allergy|benzodiazepines gabapentin nifedipine melatonin lidocaine|suvorexant|the effects produced by doras on rem sleep explain the motor effects and other side effects seen with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|drug|AND topical comparing vulgaris Allergy|Safety Subjects compliance Participants Efficacy|suvorexant|entity will be evaluated by the controlled substance staff of the fda during nda review .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND topical comparing vulgaris Allergy|GSK bevacizumab BV BR TM|suvorexant|for the treatment of advanced melanoma and metastatic nsclc in patients whose disease has progressed after other therapies , and belsomra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|AND topical comparing vulgaris Allergy|FDA pharmacists marketing vaccines publication|suvorexant|merck has announced that it plans to file regulatory applications for entity in 2012 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND topical comparing vulgaris Allergy|OX NPY BAT DEX CCK|suvorexant|merck is marketing belsomra® ( entity ) , which is a dual orexin receptor anatomist indicated for insomnia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|AND topical comparing vulgaris Allergy|GSK BR BB LY BT|suvorexant|in august 2014 , merck announced that the fda approved belsomra ( entity ) for the treatment of adults with insomnia who have difficulty falling asleep and / or staying asleep .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|AND topical comparing vulgaris Allergy|gabapentin metformin fluoxetine olanzapine celecoxib|suvorexant|seeing significant progress in the pipeline this year , and we expect six major filings over the next 18 months , including entity for insomnia and odanacatib for osteoporosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|AND topical comparing vulgaris Allergy|OX MET VPA DEX MDMA|suvorexant|neurosciencebelsomra ( entity ) , an orexin receptor antagonist indicated for the treatment of insomnia , characterized by difficulties with sleep onset and / or sleep maintenance .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|AND topical comparing vulgaris Allergy|approval outbreaks restrictions regulations overdose|suvorexant|both fda approval and a separate scheduling determination by the u . s . drug enforcement administration are required before merck can introduce entity in the united states .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|AND topical comparing vulgaris Allergy|risperidone olanzapine trastuzumab buprenorphine ketamine|suvorexant|on may 22 , 2013 , the fdas peripheral and central nervous system drugs advisory committee will meet to discuss the nda for entity ( mk-4305 ) tablets .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|AND topical comparing vulgaris Allergy|sildenafil eg melatonin olanzapine ie|suvorexant|mk-4305 , entity , is an investigational insomnia medicine in a new class of medicines called orexin receptor antagonists for use in patients with
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|psoriasis alfa allergy Prior trastuzumab|PDT cream psoriasis Therapy Surgery|guselkumab|entity is currently being investigated in clinical studies in several indications , including plaque psoriasis , pediatric psoriasis , psoriatic arthritis , crohns disease , hidradenitis
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|psoriasis alfa allergy Prior trastuzumab|rituximab bevacizumab infliximab Antibody trastuzumab|guselkumab|entity ( tremfya® ) is the first approved antibody binding the p19 subunit of il-23 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis alfa allergy Prior trastuzumab|FDA GSK France Germany USA|guselkumab|in july , subsequent to the quarter , the fda approved tremfya™ ( entity ) for the treatment of adults living with moderate to severe plaque psoriasis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|psoriasis alfa allergy Prior trastuzumab|rituximab bevacizumab trastuzumab bortezomib cetuximab|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand and are specific to the il-23 pathway , which is believed to be
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|psoriasis alfa allergy Prior trastuzumab|infliximab probiotics IBD thalidomide celecoxib|guselkumab|of morphosys ag , said : we are very pleased that our licensee janssen has further expanded the clinical development program of entity by initiating a clinical study in ulcerative colitis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|psoriasis alfa allergy Prior trastuzumab|rituximab IgG1 bevacizumab scFv trastuzumab|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosyss proprietary technology to receive marketing approval for the treatment
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|psoriasis alfa allergy Prior trastuzumab|infliximab rituximab bevacizumab everolimus methotrexate|guselkumab|to the same period a year ago driven by strong uptake of stelara® ( ustekinumab ) and the u . s . launch of tremfya® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis alfa allergy Prior trastuzumab|newer randomised planned conducting continuing|guselkumab|more information about entity clinical studies is available on clinicaltrials . gov .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|psoriasis alfa allergy Prior trastuzumab|rituximab MMF infliximab sirolimus celecoxib|guselkumab|moreover , entity is currently being investigated in two phase 3 trials in psoriatic arthritis and also in a phase 2 / 3 clinical study program in crohns disease .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|psoriasis alfa allergy Prior trastuzumab|bevacizumab infliximab cetuximab trastuzumab alfa|guselkumab|entity ( tremfya ® ) overview guselkumab ( tremfya ® ) is a human hucal antibody targeting the p 19 subunit of il - 23 that is being
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|psoriasis alfa allergy Prior trastuzumab|GSK TM VI everolimus scFv|guselkumab|in july 2018 , morphosys announced that its licensee , janssen , initiated a clinical development program with tremfya® ( entity ) in crohns disease .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|psoriasis alfa allergy Prior trastuzumab|rituximab bevacizumab trastuzumab bortezomib cetuximab|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il‑23 ligand and are specific to the il‑23 pathway , which is believed to be
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|psoriasis alfa allergy Prior trastuzumab|GSK infliximab TM France SC|guselkumab|the european commission approved tremfya® ( entity ) for the treatment of adults with moderate to severe plaque psoriasis and granted approval to broaden the existing marketing authorization
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|psoriasis alfa allergy Prior trastuzumab|cream ointment formulation psoriasis vulgaris|guselkumab|entity is currently approved in the eu for the treatment of moderate to severe plaque psoriasis in adults who are candidates
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|psoriasis alfa allergy Prior trastuzumab|infliximab itraconazole tacrolimus fluconazole methotrexate|guselkumab|in november 2017 , the eu commission granted european approval of entity ( tremfya® ) for the treatment of patients with moderate-to-severe plaque psoriasis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|psoriasis alfa allergy Prior trastuzumab|rituximab bevacizumab IgG1 scFv TM|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosys  s proprietary technology to receive marketing approval for the treatment
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|psoriasis alfa allergy Prior trastuzumab|psoriasis PDT cream formulation ointment|guselkumab|entity is currently being investigated in clinical studies in several indications , including additional studies in plaque psoriasis , pediatric psoriasis , psoriatic arthritis ,
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|psoriasis alfa allergy Prior trastuzumab|rituximab bevacizumab bortezomib trastuzumab cetuximab|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand to confer specificity for the il-23 pathway that is believed to be
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa trastuzumab paclitaxel analogue bisphosphonates|registry Trial Protocol registration collection|triptorelin|entity is in pre-registration in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|alfa trastuzumab paclitaxel analogue bisphosphonates|paclitaxel progesterone calcitonin rapamycin subcutaneously|triptorelin|two additional agents are also currently marketed , trelstar by watson , delivers entity , and zoladex marketed by astrazeneca , a biodegradable rod , that contains goserelin .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|alfa trastuzumab paclitaxel analogue bisphosphonates|gabapentin ibuprofen thalidomide metformin resveratrol|triptorelin|in addition , in europe or certain other parts of the world , entity ( debiopharm s . a . ) and buserelin ( hoechst marion roussel , inc . ) are also approved and being marketed .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alfa trastuzumab paclitaxel analogue bisphosphonates|metformin sildenafil misoprostol diltiazem midazolam|triptorelin|women were randomized to one of four mvt-602 dose groups ( 0 . 1 µg , 0 . 3 µg , 1 µg or 3 µg ) , to entity , 0 . 2 mg , or to placebo .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|alfa trastuzumab paclitaxel analogue bisphosphonates|Compound formulation And Insulin originally|triptorelin|entity marketed as trelstar® ( watson pharmaceuticals ) and marketed as decapeptyl® ( ipsen ) is also a lhrh agonist .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa metformin Prior psoriasis GSK|capecitabine bevacizumab irinotecan gemcitabine paclitaxel|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa metformin Prior psoriasis GSK|irinotecan gemcitabine paclitaxel capecitabine bevacizumab|rasburicase|dr . bizzari was the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of oxaliplatin , docetaxel and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa metformin Prior psoriasis GSK|France Germany Spain GSK Italy|rasburicase|a specific r&d effort has already culminated in the launch of fasturtec® ( entity ) in 2001 , for prevention of the increase in blood uric acid levels during chemotherapy of acute leukemia .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa metformin Prior psoriasis GSK|gemcitabine capecitabine paclitaxel bevacizumab trastuzumab|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa metformin Prior psoriasis GSK|France Germany GSK Brazil Spain|rasburicase|for sanofi-aventis ( formerly rhône-poulenc , rhône-poulenc rorer and aventis ) where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa metformin Prior psoriasis GSK|capecitabine irinotecan gemcitabine bevacizumab paclitaxel|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa metformin Prior psoriasis GSK|capecitabine bevacizumab irinotecan gemcitabine paclitaxel|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|clopidogrel P2Y AND aspirin metformin|lithium ethyl clopidogrel silver warfarin|clopidogrel|to $5 . 3 billion in 2007 compared to 2006 due to loss of exclusivity of pravachol and the impact of generic entity bisulfate , partially offset by growth in other key products .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|clopidogrel P2Y AND aspirin metformin|lithium ethyl sulfur diethyl cobalt|clopidogrel|filed a revocation action before the scottish court of session seeking to invalidate the sanofi-aventis patent in the uk claiming entity bisulfate .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|clopidogrel P2Y AND aspirin metformin|lithium ethyl methylene fluoride silver|clopidogrel|apotex filed a notice of appeal appealing the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel P2Y AND aspirin metformin|another nearly Day HES roughly|clopidogrel|growth in total prescriptions ( trx ) of entity 82 table of contents bisulfate remained strong , at 11 . 8% ( ims npa 3 channels  q4 2006 ) in the fourth
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|clopidogrel P2Y AND aspirin metformin|antiretroviral gefitinib antiviral TKI antifungal|clopidogrel|however , the presence of less common cyp2c10 non-functional alleles or variation in other genes may negatively impact the efficacy of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel P2Y AND aspirin metformin|entitled name title pill Act|clopidogrel|drug interactions medco health solutions inc . robert epstein , said it is an example of the " law of unintended consequences " entity ( plavix ( r ) )
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|clopidogrel P2Y AND aspirin metformin|statin endpoint visit centre stand|clopidogrel|medco outcomes study entity alone 0 . 18 entity+ppi 0 . 25 relative risk 1 . 50 ( 1 . 39-1 . 62 ) podium-presented at american heart association 11 / 11 / 08 *
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|clopidogrel P2Y AND aspirin metformin|omeprazole caution metformin acetaminophen PPI|clopidogrel|however , this is confounded by the fda warning against the use of certain ppis , such as omeprazole , with entity ( plavix ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|clopidogrel P2Y AND aspirin metformin|VPA DHA AZT metformin lamivudine|clopidogrel|o comment : entity is expected to be converted efficiently to its active metabolite in patients with this genotype .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|clopidogrel P2Y AND aspirin metformin|lithium ethyl ammonium polyvinyl vinyl|clopidogrel|on august 12 , 2008 , the federal court of australia held that claims of patent no . 597784 covering entity bisulfate , hydrochloride , hydrobromide , and taurocholate salts were valid .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel P2Y AND aspirin metformin|pump formulation bolus suspension emulsion|clopidogrel|captisol-enabled intravenous entity is an intravenous formulation of the anti-platelet medication designed for situations where the administration of oral platelet inhibitors is not
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|clopidogrel P2Y AND aspirin metformin|clopidogrel PPA RES TRAP sildenafil|clopidogrel|plavix® / iscover® plavix® ( entity ) , a platelet adenosine diphosphate ( adp ) receptor antagonist with a rapid onset of action that selectively inhibits platelet aggregation induced by
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|clopidogrel P2Y AND aspirin metformin|lithium ethyl arsenic choline barium|clopidogrel|genrx-apotex appealed the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|clopidogrel P2Y AND aspirin metformin|warfarin gefitinib antiretroviral VPA antidepressant|clopidogrel|the presence of less common cyp2c19 alleles or variations in other genes may additionally enhance or reduce the efficacy of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|clopidogrel P2Y AND aspirin metformin|clopidogrel aspirin warfarin BMS celecoxib|clopidogrel|stent thrombosis at 48 hours had been met , as cangrelor demonstrated statistically significant improvement for this endpoint as compared to entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|clopidogrel P2Y AND aspirin metformin|ibuprofen buprenorphine metformin methadone paracetamol|clopidogrel|the federal court also held that the process claims , pharmaceutical composition claims , and claim directed to entity and its pharmaceutically acceptable salts were invalid .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|clopidogrel P2Y AND aspirin metformin|metformin paclitaxel ritonavir docetaxel bevacizumab|clopidogrel|when pa32540 and entity were dosed 10 hours apart , data from the study indicate no ex-vivo drug-drug interaction based on the study  s pre-specified primary analysis .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|clopidogrel P2Y AND aspirin metformin|ethyl lithium diethyl cobalt dimethyl|clopidogrel|and the minister of health in response to a notice of allegation from apotex directed against canadian patent 1 , 336 , 777 covering entity bisulfate .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|clopidogrel P2Y AND aspirin metformin|omeprazole clarithromycin olanzapine metformin clopidogrel|clopidogrel|us launch of tacrolimus ( prograf® ) ; and the launches in various european countries of pantoprazole ( marketed in the us as protonix® ) , entity ( plavix® ) , and esomeprazole ( nexium® ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|clopidogrel P2Y AND aspirin metformin|clopidogrel warfarin anticoagulants ibuprofen NSAIDs|clopidogrel|according to present plans , all patients will receive background treatment including heparin , aspirin and entity ( plavix® ) , if not contraindicated .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|cephalosporins penicillin chloramphenicol clindamycin gentamicin|cefadroxil|crude bulk drugs of the cephalosporin division and cefalexin and entity of the penicillin division were new products the company introduced during the six-month period of 2008 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|ceftriaxone gentamicin erythromycin clindamycin azithromycin|cefadroxil|cefalexin and entity are penicillin g downstream products that are widely used to treat urinary tract infections , respiratory tract , skin and soft tissue
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|tamoxifen misoprostol diclofenac progesterone aspirin|cefadroxil|the increase was lead by increases in market share for medroxyprogesterone , naltrexone , danazol and sales of entity , which the company launched in june 1999 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|metformin thalidomide aspirin methotrexate tamoxifen|cefadroxil|the increase was led by higher sales of warfarin sodium , naltrexone , medroxyprogesterone , danazol , entity and hydroxyurea .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|lactose levodopa diclofenac fluoride riboflavin|cefadroxil|for sake of clarity and avoidance of doubt , " product " does not include any non-oral suspension forms or formulations of duricef ( r ) ( entity monohydrate ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|ceftriaxone ciprofloxacin gentamicin amoxicillin ampicillin|cefadroxil|cefzil* cefprozil , an oral cephalosporin used in the treatment of respiratory infections and sinusitis duricef* entity , an oral cephalosporin .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|cef ceft am tro ga|cefadroxil|offset by the decrease in gross margins in cephalosporin crude bulk drugs , cephalosporin formulation drugs as well as cefalexin and entity divisional revenues and gross margin analysis
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|azithromycin Antimicrobial Antibiotic Lactobacillus clindamycin|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|tob am ox ceft cef|cefadroxil|% 9 . 94 % cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|azithromycin Antimicrobial Antibiotic Lactobacillus clindamycin|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|bevacizumab verapamil paclitaxel trastuzumab tramadol|cefadroxil|although ivax remains the only fda approved generic manufacturer of entity , the company marketing the brand name version of this drug is marketing its own generic form of this product .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|vaccines cigarettes medicines marijuana cannabis|cefadroxil|net revenues attributable to sales of entity , approved in march 1996 , were $17 . 1 million in the 1996 second quarter .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|tob am ox ceft cef|cefadroxil|% 9 . 94% cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|ceftriaxone amoxicillin diclofenac azithromycin vancomycin|cefadroxil|sales for the cefalexin and entity for the first quarter of 2010 were approximately 3% lower than the same period in 2009 , because of a 4%
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|erythromycin clindamycin cephalosporins vancomycin ceftriaxone|cefadroxil|the penicillin division currently operates the production and sales of clavulanic acid , cefalexin and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|diclofenac alfa vancomycin clarithromycin Concurrent|vancomycin gentamicin azithromycin clindamycin ribavirin|cefadroxil|cefalexin and entity were launched and included in the companys product portfolio only at the beginning of 2008 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|AND Prior gemcitabine psoriasis Versus|trastuzumab metformin docetaxel capecitabine tamoxifen|alpelisib|qd : once daily 111 table of contents we also assessed the anti-tumor activity of zn-c5 , alongside fulvestrant and entity , in each case as monotherapy , in preclinical models .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|AND Prior gemcitabine psoriasis Versus|eg ie trastuzumab bevacizumab everolimus|alpelisib|• byl719 ( entity , approved in the us as piqray ) is an orally bioavailable , alpha-specific pi3k inhibitor approved in combination with fulvestrant for the
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Prior gemcitabine psoriasis Versus|FDA GSK India neoadjuvant 1b|alpelisib|· byl719 ( entity ) phase iii solar-1 trial data presented at esmo showed byl719 plus fulvestrant nearly doubles median progression free survival in patients with
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|AND Prior gemcitabine psoriasis Versus|GSK FDA Arm Efficacy 1b|alpelisib|· byl719 ( entity ) solar-1 trial of the investigational alpha-specific inhibitor byl719 in combination with fulvestrant met its primary endpoint showing an improvement in
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|AND Prior gemcitabine psoriasis Versus|GSK everolimus metformin TM atorvastatin|alpelisib| byl719 ( entity ) is an orally bioavailable , alpha isoform-specific pi3k inhibitor .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Prior gemcitabine psoriasis Versus|gov FDA org Trial GenBank|alpelisib|·entity ( byl719 ) is on track for a us submission in pik3ca-related overgrowth spectrum ( pros ) in 2021 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|AND Prior gemcitabine psoriasis Versus|trastuzumab imatinib erlotinib gefitinib docetaxel|alpelisib|% of pi3k mutated late stage breast cancer patients achieved an objective response in a phase iii clinical trial with entity , a recently approved pi3k inhibitor .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|AND Prior gemcitabine psoriasis Versus|bortezomib rituximab paclitaxel gemcitabine bevacizumab|alpelisib|therapy in this population , including ibrance , kisqali , afinitor , verzenio , and other therapies currently in phase 3 clinical development such as entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|AND Prior gemcitabine psoriasis Versus|trastuzumab paclitaxel bevacizumab metformin gemcitabine|alpelisib|biomedical research , inc . , or novartis , to evaluate the combination of op-1250 and novartis ribociclib , a cdk4 / 6 inhibitor , as well as entity , their pi3kα inhibitor .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|AND Prior gemcitabine psoriasis Versus|metformin gemcitabine docetaxel paclitaxel TAM|alpelisib|we also observed that the combination of zn-c5 and entity had more potent anti-tumor activity than the combination therapy using 3 mg / dose of fulvestrant and 50 mg / kg of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|AND Prior gemcitabine psoriasis Versus|metformin bevacizumab docetaxel trastuzumab paclitaxel|alpelisib|zn-c5 and fulvestrant were also assessed in combination with entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1), ('BIO', 1)])|drug|AND Prior gemcitabine psoriasis Versus|everolimus metformin bortezomib rapamycin TKI|alpelisib|more recently piqray® ( entity ) , an inhibitor of the alpha isoform phosphatidylinositol-3-kinase , became the first agent approved for use in a specific subpopulation of hr+
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Prior gemcitabine psoriasis Versus|GSK TM ir Lu PI3K|alpelisib|about piqray® ( entity ) piqray is a kinase inhibitor approved in combination with fulvestrant for the treatment of postmenopausal women , and men , with hr+ / her2- ,
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|AND Prior gemcitabine psoriasis Versus|curcumin CDDP docetaxel paclitaxel EGCG|alpelisib|even greater anti-tumor activity was observed with the combination of 1 mg / kg of zn-c5 and 50 mg / kg of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|AND Prior gemcitabine psoriasis Versus|metformin bevacizumab everolimus docetaxel capecitabine|alpelisib|fulvestrant used in combination with entity , an oral pi3k inhibitor marketed as piqray® by novartis approved by the fda in may 2019 , has demonstrated improved clinical
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|AND Prior gemcitabine psoriasis Versus|FDA bevacizumab paclitaxel everolimus GSK|alpelisib|approved may 2019 ( breast cancer ) [ accelerated approval ] limited toxicities to date does not cross blood-brain barrier ü û ü piqray ( entity )
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|AND Prior gemcitabine psoriasis Versus|imatinib TKI sorafenib gefitinib BRAF|alpelisib|entity , marketed as piqray® by novartis , is the only fda-approved inhibitor for cancers with mutated pi3kα .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|drug|AND Prior gemcitabine psoriasis Versus|sorafenib gefitinib imatinib bortezomib bevacizumab|alpelisib|the study showed that entity added toxicity with only marginal additional activity , therefore the beacon crc trial will replace it with binimetinib in the triplet
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|AND Prior gemcitabine psoriasis Versus|genistein curcumin TSA chloroquine omeprazole|alpelisib|in contrast , entity and gdc-0077 ( an orthosteric pi3kα inhibitor currently in development ) biochemically inhibited the mutant and wild-type proteins with approximately equivalent potency .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|AND Prior gemcitabine psoriasis Versus|PET trastuzumab therapeutics statins genotyping|alpelisib|while these factors limit the clinical utility of entity , these data nonetheless establish mutant pi3kα as a clinically validated target in breast cancer .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('BIO', 1), ('DIS', 1)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|bortezomib bevacizumab PDT metformin thalidomide|omadacycline|to depend on independent clinical investigators and cros to conduct our clinical trials , including our planned phase 3 trials of entity in absssi .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|Research FDA Trial dosing Therapy|omadacycline|entity is ready to advance into phase 3 , the final stage of clinical development .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|vancomycin doxycycline bevacizumab amoxicillin gentamicin|omadacycline|entity ( paratek pharmaceuticals ) and lefamulin ( nabriva therapeutics ) , and dalafloxcacin ( melinta ) all are expected to be pursued as a possible treatment for
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|psoriasis COPD ADHD IBD migraine|omadacycline|in hong kong and three pending patent applications in taiwan , respectively that relate to different methods of treatment related to entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|companies pharmacists innovation scientists employees|omadacycline|under the novartis agreement , novartis was to have led development activities for entity , and the company was to have co-developed and contributed a share of the development expense .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|azithromycin vancomycin imipenem he ciprofloxacin|omadacycline|if approved by the fda , entity will also compete with other antibiotics in the community-acquired pneumonia market .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|ALS NSCLC CLL CML CRC|omadacycline|payment of $50 , 000 to tufts for achieving the first milestone following commencement of the phase 3 non-registration clinical trial for entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|FDA publication funding grant investigators|omadacycline|this prsu was awarded under the 2015 plan and vests upon fda approval of entity , and shall , upon achievement of the milestone , be eligible to vest as to 100% of the prsus subject to the
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|vancomycin doxycycline erythromycin clindamycin azithromycin|omadacycline|our success is currently dependent on the successful development and commercialization of our most advanced product candidates , entity and sarecycline .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|latest anticipated intended approved pertinent|omadacycline|to working with the fda as it considers the comments from the committee members and completes its review of the entity new drug applications .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 3)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|olanzapine metformin azithromycin CBT atorvastatin|omadacycline|in all three studies , entity met all primary and secondary efficacy outcomes designated by the fda and was generally safe and well-tolerated .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|vancomycin bevacizumab imipenem paclitaxel doxycycline|omadacycline|in addition , achaogen , inc . developed and gained approval for plazomicin and paratek pharmaceuticals , inc . developed and gained approval for entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|FDA infliximab bevacizumab paclitaxel Medicare|omadacycline|to obtain a return on the investments we have made in our or any of our partners product candidates , including entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|name thinking reality text opinion|omadacycline|“crude entity” has the meaning set forth in the recitals hereto .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|TXA telemedicine tPA ACT misoprostol|omadacycline|we believe entity , if approved , will be used in the emergency room , hospital and community care settings .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|doxycycline clindamycin vancomycin erythromycin azithromycin|omadacycline|if entity and sarecycline are not successfully developed and commercialized , we will not have any product candidates under development from which we
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|bevacizumab rituximab PDT olanzapine everolimus|omadacycline|under our spa agreement , we plan to commence a pivotal registration program including two phase 3 registration trials of entity for the treatment of absssi in the second half of 2012 .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|etc eg ie Inc Canada|omadacycline|substantial additional funding in connection with the companys continuing operations to support commercial activities associated with its lead product candidate , entity .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|doxycycline vancomycin clindamycin erythromycin imipenem|omadacycline|our two lead antibacterial product candidates are entity and sarecycline .
OrderedDict([('OTHER', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|steroids NSAIDs alkaloids paclitaxel diclofenac|cetuximab docetaxel paclitaxel fluconazole capecitabine|omadacycline|for oral therapy , patients randomized to entity received 200 mg of entity ( dosed as two 100 mg capsules ) every 24 hours .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|cannabis cocaine marijuana fluoxetine heroin|tamoxifen|increased product sales were due mainly to the introduction of fluoxetine in august 2001 , as well as , increased sales of entity and other products .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|tamoxifen trastuzumab sildenafil magnesium citrate|tamoxifen|soltamox ( entity citrate ) oral solution , our first proprietary , fda approved product , is a drug primarily used to treat breast cancer .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|brachytherapy hysterectomy radiosurgery tamoxifen lasers|tamoxifen|external beam radiation and entity are both used to treat gynecomastia .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|sildenafil magnesium citrate zinc lithium|tamoxifen|the company acquired exclusive u . s . marketing rights to its &#160 ; first commercial , fda-approved proprietary product license &#160 ; soltamox&#174 ; ( entity citrate ) oral solution .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|docetaxel diclofenac celecoxib metformin Placebo|tamoxifen|femara is generally well tolerated and adverse reactions rates in the first-line study in which femara was compared to entity were similar with those seen in second-line studies .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|magnesium zinc chlorhexidine citrate silver|tamoxifen|the alamo sales team , in addition to promoting our products soltamox ( entity citrate ) and gelclair , also promotes two mission products : ferralet® 90 , and aquoral® .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|Radiation Adjuvant Systemic Targeted Vaccine|tamoxifen|entity therapy is currently indicated by the fda for breast cancer patients for five years .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|curcumin paclitaxel honey MDMA acetaminophen|tamoxifen|nevertheless , we believe that soltamox being the first and only liquid form of entity to successfully make some in roads in to that market .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|tamoxifen progesterone HRT metformin estrogens|tamoxifen|during 2001 , we announced the issuance of an u . s . patent on the use of our anti-estrogen compound in combination with entity .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|brachytherapy lymphadenectomy hysterectomy NAC mastectomy|tamoxifen|a dcis score result , to help guide treatment decision-making in women with dcis treated by local excision , with or without entity .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|federal private own legal insurance|tamoxifen|we maintain $20 million of product liability insurance and have an indemnification provision in our entity agreement .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|generic brand respective imported market|tamoxifen|us revenues for nolvadex fell 27% to $337 million , as sales of our entity products fell as a result of the expiry of our distribution agreement with barr laboratories .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|thalidomide cyclosporine methotrexate metformin tacrolimus|tamoxifen|however , a number of medical therapies have been used to treat peyronies including vitamin e , colchicine , potassium aminobenzoate ( potaba ) , entity , interferon a2a and corticosteroids .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|tamoxifen trastuzumab hormonal antiretroviral conservation|tamoxifen|women were assessed for risk of developing breast cancer using the brevagen test to determine eligibility for five years of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|Average Total Drug Medicare Annual|tamoxifen|entity sales increased 56% from $145 , 161 to $226 , 749 .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|BMS graphene MTA ketamine lidocaine|tamoxifen|due to its proven superiority over entity , it has won category leadership in france , spain , belgium , mexico , switzerland and australia .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|capecitabine docetaxel paclitaxel bevacizumab metformin|tamoxifen|treatment was stopped due to toxicities in three patients in the everolimus plus entity arm and in four patients in the entity-only arm .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|PSA oncological oncologic personal chemotherapeutic|tamoxifen|oncotype dx predicts likelihood of recurrence because it predicts both prognosis and entity benefit .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|plans claims funds employees insurance|tamoxifen|the plaintiff in this action , however , asserts that the companys alleged misclassification of entity improperly denied plan benefits and breached an alleged fiduciary duty under erisa .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tamoxifen trastuzumab paclitaxel capecitabine gefitinib|tamoxifen TAM progesterone estradiol genistein|tamoxifen|entity , the most commonly used serm treatment for breast cancer , also inhibits this action by estradiol , but with less affinity for
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|cultivar vulgaris Des du van|losartan metformin sildenafil MMF captopril|lesinurad|entity is a selective inhibitor of urat1 , a transporter in the proximal tubule cells of the kidney that regulates uric acid
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|cultivar vulgaris Des du van|SQ TMP LL sildenafil SN|lesinurad|about zurampic ( entity ) 200mg tablets zurampic ( entity ) works in combination with xanthine oxidase inhibitors ( xois ) to treat hyperuricemia associated with uncontrolled gout .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|cultivar vulgaris Des du van|planned permanent legal scheduled next|lesinurad|closing of the entity transaction is subject to the expiration or termination of the waiting period under the hart-scott-rodino antitrust improvements act of 1976 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|cultivar vulgaris Des du van|raw domestic private official finished|lesinurad|the write-down was recorded as write-down of entity commercial supply to net realizable value in the companys condensed consolidated statement of operations .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|cultivar vulgaris Des du van|FDA grant federal marketing financial|lesinurad|to $140 million ) , and · amortization of intangible assets to be $8 million ( not applicable prior to the u . s . entity license ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|cultivar vulgaris Des du van|atorvastatin ciprofloxacin metformin aspirin ibuprofen|lesinurad|astrazeneca entered into a licensing agreement with ironwood pharmaceuticals for the exclusive us rights to zurampic and the fixed-dose combination of entity and allopurinol .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|cultivar vulgaris Des du van|rituximab infliximab methotrexate thalidomide MTX|lesinurad|however , entity , like all other ults , has been shown to increase flares upon initiation of treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|cultivar vulgaris Des du van|atorvastatin FDA FA MMF DMF|lesinurad|entity is an oral inhibitor of urat1 , which is the transporter that mediates reuptake of uric acid from the proximal tubules of the kidney and drives renal elimination of uric acid .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|cultivar vulgaris Des du van|Placebo Chemotherapy FDA metformin Vaccine|lesinurad|entity is a drug in phase 3 development by astrazeneca plc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|cultivar vulgaris Des du van|rituximab antioxidants PDT metformin celecoxib|lesinurad|we are developing entity to be used as both monotherapy and in combination with drugs like allopurinol and febuxostat to treat the large number
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|cultivar vulgaris Des du van|eg atorvastatin metformin mannitol diclofenac|lesinurad|for patients who require more control or who are contraindicated , the uricosuric agent , entity , may be prescribed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|cultivar vulgaris Des du van|Ultim More Simultaneous Now Per|lesinurad|entity entity , our most advanced product candidate , previously called rdea594 , is an inhibitor of urat1 , a transporter in the kidney that regulates uric acid excretion from the body .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|cultivar vulgaris Des du van|printed approved investigational respective stored|lesinurad|we calculated gross product revenue based on the wholesale acquisition cost that we charged our distributors for the entity products .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|cultivar vulgaris Des du van|Exercise Surgery Diet Therapy Zinc|lesinurad|entity has been shown to normalize the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|cultivar vulgaris Des du van|sirolimus eg infliximab everolimus bevacizumab|lesinurad|these drugs are entity , sifalimumab , anifrolumab , mavrilimumab and brodalumab .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|cultivar vulgaris Des du van|MMF HES NAC IVIG Chemotherapy|lesinurad|entity carries a black box warning associated with renal toxicity and is contraindicated in patients with renal impairment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|cultivar vulgaris Des du van|federal civil NIH Medicare CMS|lesinurad|january 2007 , as amended , for our cambridge , massachusetts corporate headquarters and a reduction in reimbursement obligations to astrazeneca under the entity license .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|cultivar vulgaris Des du van|Exercise PAS Diet Placebo PTH|lesinurad|entity normalizes the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|cultivar vulgaris Des du van|celecoxib monotherapy simvastatin metformin supplementation|lesinurad|entity is being studied as an add-on treatment to allopurinol patients not reaching target sua levels , as an add-on to febuxostat
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|cultivar vulgaris Des du van|metformin celecoxib atorvastatin ciprofloxacin methotrexate|lesinurad|the combination of entity and allopurinol has been generally well tolerated in the ongoing extension portion of study 203 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|metformin depot AND formulations alfa|omeprazole cimetidine metronidazole indomethacin diclofenac|prucalopride|compared to the group receiving entity ( an fda approved drug for the treatment of chronic idiopathic constipation ) , the pcs12852 dose groups showed higher stool frequency for
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|Lactobacillus ASA EA CAM BV|prucalopride|entity has been approved for commercialization in certain european countries for the treatment of chronic constipation in women but has not yet been launched .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|publication retrieval reviews approval publications|prucalopride|shire has discussed with the fda the requirements for filing an nda for entity and is currently working towards fulfilling those requirements in anticipation of an nda submission .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|Trial PrEP FDA Research Technology|prucalopride|entity was launched in several european markets .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|ii iii USA Asia M2|prucalopride|phase 3 globally global ( excluding italy and latin america ) resolor ( entity ) chronic constipation ( males ) phase 3 in eu europe spd 556 ( m0002 )
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|policies catalysts standards innovations therapeutics|prucalopride|shire intends to develop entity in the united states for cc .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|metformin depot AND formulations alfa|probiotics infliximab misoprostol Lactobacillus tablets|prucalopride|alan has played a major role in development of gastroenterology products such as motilium® and entity and has considerable experience and knowledge of the gastrointestinal ( gi ) space .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|invest market compete enroll travel|prucalopride|johnson & johnson has rights to entity in north american and certain european countries and we expect entity to provide competition in markets around the world .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|GSK France Germany FDA TM|prucalopride|shire plc obtained approval of motegrity™ ( entity ) in the u . s . for the treatment of cic in adults in december 2018 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2), ('DIS', 1)])|drug|metformin depot AND formulations alfa|gabapentin tramadol SCS buprenorphine ketamine|prucalopride|sloots ej , et al . efficacy and safety of entity in patients with chronic non-cancer pain suffering from oic .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|consensus expertise trust approval insight|prucalopride|movetis was acquired by shire in september 2010 , which intends to develop entity in the u . s . for cc .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|coming excluded missing going called|prucalopride|another prokinetic compound in development in europe , with the potential for commercialization in the united states and asia , is entity from movetis .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('BIO', 1)])|drug|metformin depot AND formulations alfa|trastuzumab bevacizumab cannabis bisphosphonates CAM|prucalopride|shire has recently announced it acquired rights to develop and commercialize entity in the u . s . for the cc indication .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|metformin depot AND formulations alfa|Research He She Technology Trial|prucalopride|entity was launched in germany in january 2010 , in the u . k . in march 2010 and in belgium in september 2010 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|metformin depot AND formulations alfa|omeprazole metronidazole indomethacin cimetidine PPI|prucalopride|pcs12852 increased stool frequency with faster onset when compared to entity , an fda approved drug for the treatment of chronic idiopathic constipation .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|metformin depot AND formulations alfa|probiotics Lactobacillus colleagues Google infliximab|prucalopride|a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|metformin depot AND formulations alfa|probiotics colleagues Google Lactobacillus infliximab|prucalopride|held a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|metformin depot AND formulations alfa|probiotics naltrexone EA ginger acetaminophen|prucalopride|janssen belgium exclusive license agreement to develop and market entity as a treatment for chronic constipation in the u . s . motegrity , approved in december 2018 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|metformin depot AND formulations alfa|sildenafil probiotics fluoxetine melatonin naltrexone|prucalopride|trials are on-going in europe testing entity in the treatment of chronic constipation in men .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|metformin depot AND formulations alfa|FDA Germany paclitaxel France Canada|prucalopride|the most recent entrant to the cc marketplace , solely in europe , is resolor ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|Beta vulgaris Alpha alfa Lactobacillus|works Web decision WW CON|polidocanol|additional manufacturing information and documentation is also being prepared by kreussler for submission to the fda to support the entity nda .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|Beta vulgaris Alpha alfa Lactobacillus|lidocaine propofol isoflurane ketamine sevoflurane|polidocanol|in contrast , aethoxysklerol contains entity , a chemical with anesthetic properties , which we believe may be one of the key advantages of aethoxysklerol .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|Beta vulgaris Alpha alfa Lactobacillus|Ori um First Be Ins|polidocanol|entity nda submission and review  in july 2009 , bioform medicals partner , chemische fabrik kreussler & co . gmbh ( kreussler ) , submitted
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|Beta vulgaris Alpha alfa Lactobacillus|Canada India Medicaid Medicare Germany|polidocanol|the $0 . 7 million milestone payment pursuant to our agreement with kreussler for exclusive united states licensing and distribution rights of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|Beta vulgaris Alpha alfa Lactobacillus|investigational generic approved medicinal marketed|polidocanol|the definition of product ( s ) may be amended from time to time to include additional entity product ( s ) in accordance with article ii ( b ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|drug|Beta vulgaris Alpha alfa Lactobacillus|bevacizumab VEGF TCM angiogenesis sirolimus|polidocanol|our partner , kreussler , is also making good progress in the nda review of entity , our future sclerotherapy product .  31 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND alfa hydrochloride ophthalmic tablets|Oral Sodium High Nasal Total|nedocromil|brannan jd , anderson sd , freed r , leuppi jd , koskela h , chan h-k . entity sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|drug|AND alfa hydrochloride ophthalmic tablets|diclofenac quaternary barium penicillin topical|nedocromil|the basic chemical patents for sodium cromoglycate have already expired , and such patents for entity sodium expire principally between 1998 and 2006 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|AND alfa hydrochloride ophthalmic tablets|diclofenac mannitol salbutamol cro ibuprofen|nedocromil|“bulk form” means cromolyn sodium micronized stage 9 ( the “intal bulk form” ) and entity sodium dried stage 11 ( the “tilade bulk form” ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|Plus Versus P2Y HCl alfa|app int IN IS IT|etravirine|during 2008 , the company received regulatory approval in the u . s . , canada and european union for intelencetm ( entity ) for hiv combination therapy .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|Plus Versus P2Y HCl alfa|infliximab bevacizumab rituximab everolimus metformin|etravirine|while at johnson & johnson , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|Plus Versus P2Y HCl alfa|metformin bevacizumab atorvastatin eg simvastatin|etravirine|tibotecs drug , entity , received fda marketing approval in early 2008 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|Plus Versus P2Y HCl alfa|IN int ex IT EV|etravirine|in january 2008 , the company received accelerated approval from the u . s . food and drug administration ( fda ) for intelence ( entity ) tablets , an anti-hiv medication .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|Plus Versus P2Y HCl alfa|infliximab bevacizumab rituximab everolimus metformin|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|Plus Versus P2Y HCl alfa|infliximab bevacizumab rituximab everolimus ritonavir|etravirine|while at j&j , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|Plus Versus P2Y HCl alfa|ritonavir lamivudine ribavirin chloroquine metformin|etravirine|two new drugs , intelence ( entity ) and prezista ( darunavir ) from tibotec therapeutics , a division of ortho biotech products , l . p . , are included in the revised drug resistance
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|Plus Versus P2Y HCl alfa|infliximab bevacizumab rituximab everolimus metformin|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|Plus Versus P2Y HCl alfa|infliximab bevacizumab rituximab everolimus sirolimus|etravirine|the development and launches of several products , including page 1 of 3 remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|Plus Versus P2Y HCl alfa|ritonavir lamivudine ribavirin bevacizumab rituximab|etravirine|company group chairman for johnson & johnsons worldwide virology business unit , where she oversaw the launches of prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|dimer analogue alfa hCG 99m|herbal arsenic iodine edible topical|dimercaprol|bal in oil is a therapeutic entity injection used to treat arsenic , gold and mercury poisoning .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|constituents substances ingredients polysaccharides antioxidants|galantamine|reminyl was launched using natural entity extracted from daffodil bulbs .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|gabapentin phenytoin lithium atorvastatin magnesium|galantamine|related to ad , patients with ad are prescribed drugs for enhancing their cognition , and include acetylcholinesterase inhibitors such as , donepezil , entity , rivastigmine and memantine .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|Mer Ste Ment Mon Tra|galantamine|entity ir tablets are the ab-rated generic versions of ortho-mcneil and janssen&#8217 ; s razadyne &#174 ; , which had annual sales of approximately
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|brand propri advertis author unus|galantamine|successful in their allegations of patent infringement , barr could be required to pay damages relating to the sale of its entity ir tablets .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|finally eventually ultimately perhaps additionally|galantamine|he contributed to the clinical development of currently marketed drugs in epilepsy ( topiramate and levetiracetam ) and entity in alzheimers .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|methotrexate rituximab colchicine infliximab immunoglobulins|galantamine|seeking a declaration to nullify the supplementary protection certificate ( " spc " ) for ep 236684 ( the patent that claims the use of entity for the treatment of alzheimer  s disease ) .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|itraconazole fluconazole chloroquine rapamycin metronidazole|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimers drug entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|condoms CPAP vaccines medicines cannabis|galantamine|deemed to include all parents licensed to shire or its affiliates in the territory in respect of the use of entity for cfs ) .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|generic tablet metformin flexible risperidone|galantamine|in october 2008 , barr commenced sales of its 8 mg , 16 mg and 24 mg entity extended release ( er ) capsules .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|gabapentin phenytoin lithium haloperidol diclofenac|galantamine|other drugs commonly used to treat ad , such as donepezil and entity , inhibit acetylcholinesterase but not butyrylcholinesterase .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|gabapentin lithium phenytoin magnesium atorvastatin|galantamine|treatments for ad patients are only indicated for enhancing cognition in ad patients , and include acetylcholinesterase inhibitors such as donepezil , entity , rivastigmine and memantine .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|paracetamol cannabis thalidomide acetaminophen bevacizumab|galantamine|the first european application for marketing of entity was submitted in march 1999 ; subsequently , various other applications have been made .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|itraconazole chloroquine fluconazole metronidazole rapamycin|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimer  s drug entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|sildenafil metoprolol magnesium clonidine salbutamol|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|Ben Mer Hal Ba Bac|galantamine|entity er capsules are the ab-rated generic versions of ortho-mcneil and janssens razadyne er® , which had annual sales of approximately $110
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|haloperidol ketamine diazepam lithium atropine|galantamine|in a pre-clinical animal model of cognition , prx-03140 demonstrated synergistic activity when combined with the acetylcholinesterase inhibitor entity ( razadyne ) .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|gabapentin chloroquine lithium atorvastatin levodopa|galantamine|namzaricin the market for alzheimers disease treatments , namzaric competes or will compete with branded and generic products such as entity , rivastigmine , memantine , and donepezil .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|sildenafil metoprolol magnesium clonidine salbutamol|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|alfa Alpha 1a P2Y acetylcholinesterase|generic risperidone morphine metformin fentanyl|galantamine|in august 2008 , barr commenced sales of its 4 mg , 8 mg and 12 mg entity immediate release ( ir ) tablets .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|alfa warfarin P2Y hydrochloride platelets|LMWH warfarin citrate aspirin sulfate|protamine|entity , a drug that reverses the anticoagulant effect of heparin , is rarely used in pci due to its unpredictable effect and
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|alfa warfarin P2Y hydrochloride platelets|metformin olanzapine cannabis aspirin insomnia|protamine|in medical studies , entity has been associated with adverse side effects , such as abnormal changes in blood pressure , depression of heart function and acute
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|alfa warfarin P2Y hydrochloride platelets|warfarin aspirin LMWH anticoagulant clopidogrel|protamine|phase ii clinical trials indicate that neutralase can reverse heparin anticoagulation without the adverse changes in blood pressure associated with entity usage .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa warfarin P2Y hydrochloride platelets|newly originally locally liposomal individually|protamine|our preclinical data demonstrated improved antigen expression at the site of injection if the entity formulated vaccine was injected via a needle free jet device .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|alfa warfarin P2Y hydrochloride platelets|penicillin clindamycin vancomycin metronidazole protease|protamine|one patient that died was found to have used entity and not neutralase .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|alfa warfarin P2Y hydrochloride platelets|aspirin clopidogrel warfarin citrate ASA|protamine|although entity is available as an antidote for heparin , it does not work with lmwh and there currently are no antidotes for
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|alfa warfarin P2Y hydrochloride platelets|LMWH aspirin warfarin bevacizumab paclitaxel|protamine|arc183 has shown potential in preclinical studies to be equally effective , with fewer side effects than heparin and entity in combination .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa warfarin P2Y hydrochloride platelets|newly originally presently commercially locally|protamine|bi1361849 was administered via conventional needle based intradermal injection , later shown to be a suboptimal mode of injection for the entity formulated rabies vaccine .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|alfa warfarin P2Y hydrochloride platelets|naltrexone ketamine erythromycin diclofenac sildenafil|protamine|in the ufh antagonist market , entity is the only available antidote for and antagonist to ufh and , as such , entity currently dominates this market .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa warfarin P2Y hydrochloride platelets|flaw unsu insufficient vast spur|protamine|because of entitys virtual monopoly of the ufh antidote / antagonist market , we believe that it may be
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|drug|alfa warfarin P2Y hydrochloride platelets|warfarin LMWH anticoagulation fibrinolysis fibrinolytic|protamine|be safely used in the general cardiac surgery patient population by demonstrating similar results to a regimen of heparin plus entity reversal .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|alfa warfarin P2Y hydrochloride platelets|cosmetic alarm unpleasant discomfort migraine|protamine|because of entitys potentially problematic side effect profile , we believe that our heptagonist products may penetrate into
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|drug|alfa warfarin P2Y hydrochloride platelets|aspirin anticoagulation warfarin anticoagulants LMWH|protamine|in addition , the effects of heparin are routinely reversed with entity , the use of which has been associated with an allergic reaction and a subsequent increase in the risk of death
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa warfarin P2Y hydrochloride platelets|hence thereby consequently otherwise clopidogrel|protamine|reversed at the end of the procedure and which does not have the significant side effects associated with heparin and entity would result in improved outcomes for patients undergoing ohs .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 3)])|drug|alfa warfarin P2Y hydrochloride platelets|concentrates fibrinogen FVIII platelets antithrombin|protamine|that directly or indirectly support clotting , such as vitamin k ; fresh frozen plasma , or ffp ; prothrombin complex concentrates , or pccs ; entity ; and recombinant factor viia , or rfviia .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|alfa warfarin P2Y hydrochloride platelets|LMWH aspirin bevacizumab warfarin clopidogrel|protamine|currently , entity is the only product commercially available for the reversal of heparin anticoagulation .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|alfa warfarin P2Y hydrochloride platelets|LMWH warfarin clopidogrel aspirin UF|protamine|the efficacy of rpf4 for the reversal of the anticoagulant effects of heparin in cardiac catheterization patients in comparison to entity .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa warfarin P2Y hydrochloride platelets|prophylaxis alfa today powder dosing|protamine|market opportunity unfractionated heparin ( ufh ) entity is the only available reversing agent for ufh .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa warfarin P2Y hydrochloride platelets|IgG microtubules fibronectin SV40 adenovirus|protamine|an antigenic protein that is expressible in human cells as well as the same mrna formed as a complex with entity .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa warfarin P2Y hydrochloride platelets|cf pa inh cr kr|protamine|k , ffp and , more recently , pccs , while low molecular weight heparin patients needing reversal are often managed with ffp or entity .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|vulgaris AND fluoxetine antidepressants depot|naltrexone metformin olanzapine fluconazole rituximab|escitalopram|( n=301 ) for the first eight weeks , followed by a two-week period in which patients discontinued study drug but continued receiving entity and placebo .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|vulgaris AND fluoxetine antidepressants depot|fluoxetine olanzapine gabapentin risperidone naltrexone|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) , effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|vulgaris AND fluoxetine antidepressants depot|fluoxetine antidepressant antidepressants haloperidol olanzapine|escitalopram|these results showed an increase of serotonin and dopamine after a single dose of min-117 , unlike the reference antidepressant entity which only induced a modest and transient increase .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|vulgaris AND fluoxetine antidepressants depot|bup ti tem cit pi|escitalopram|to approximately 195 legal actions asserting product liability claims relating to the use of celexa® ( citalopram hbr ) ( celexa ) or lexapro® ( entity oxalate ) ( lexapro ) .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|vulgaris AND fluoxetine antidepressants depot|dul SSR esc TR EM|escitalopram|sales of lexapro® ( entity oxalate ) , an ssri indicated for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder in adults ,
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|vulgaris AND fluoxetine antidepressants depot|fluoxetine lithium olanzapine haloperidol ECT|escitalopram|is a significant predictor of patient response and remission from depression when utilized one week following initiation of treatment with entity , an anti-depressant drug .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|vulgaris AND fluoxetine antidepressants depot|own fabricated investigational prepared resultant|escitalopram|our entity thin film is currently in pre-clinical development .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|vulgaris AND fluoxetine antidepressants depot|documents databases concepts guideline documentation|escitalopram|cns clinical research division ; and forest laboratories , as director , cns clinical development , where he was involved in the development of entity ( lexapro ) .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|vulgaris AND fluoxetine antidepressants depot|ran am bis ra mes|escitalopram|ranitidine 170 152 gemcitabine 153 143 entity oxalate 128 227 others 2 , 246 3 , 105
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|vulgaris AND fluoxetine antidepressants depot|fabricated PET prepared own investigational|escitalopram|our entity thin film is currently in pre-clinical development and we expect to conduct pilot bioavailability / bioequivalence clinical trials during the first half
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|vulgaris AND fluoxetine antidepressants depot|fluoxetine agonists dex midazolam amphetamine|escitalopram|that affect the serotonin system , as 176 table of contents shown recently in generalized anxiety disorder trials with the ssris entity and paroxetine .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|vulgaris AND fluoxetine antidepressants depot|fluoxetine olanzapine ketamine risperidone gabapentin|escitalopram|major brands include prozac ( fluoxetine ) , lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) and effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|vulgaris AND fluoxetine antidepressants depot|author insert specification name lic|escitalopram|patent infringement based on tevas filing of an abbreviated new drug application for a generic equivalent to our lexapro brand entity oxalate .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|vulgaris AND fluoxetine antidepressants depot|PrEP marketing advertising sales PEP|escitalopram|this reduction was principally due to the launch of entity in the first quarter of 2012 , our most significant product launch with shared exclusivity in the prior year .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|vulgaris AND fluoxetine antidepressants depot|deprivation poverty recession aging retirement|escitalopram|excluding the impact of entity in both periods , third party net revenues in north america were essentially flat on a year-over-year basis .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|vulgaris AND fluoxetine antidepressants depot|dul SSR Ac MAO Ax|escitalopram|· lexapro® ( entity oxalate ) , an ssri for the initial and maintenance treatment of mdd in adults and adolescents and generalized anxiety disorder in
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|vulgaris AND fluoxetine antidepressants depot|Tobacco MDMA CAS BPA EPA|escitalopram|entity is marketed by forest laboratories , inc . under the brand name lexapro® and generated sales of $2 . 0 billion in 2006 .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|vulgaris AND fluoxetine antidepressants depot|Each Another Its Their Prop|escitalopram|entity oxalate entity is in a class of drugs called selective serotonin reuptake inhibitors .
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|vulgaris AND fluoxetine antidepressants depot|mC dul TO Tra bup|escitalopram|lexapro® : lexapro ( entity oxalate ) , our single isomer version of citalopram hbr , for the treatment of mdd in adults and adolescents and generalized anxiety
OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|vulgaris AND fluoxetine antidepressants depot|fluoxetine olanzapine gabapentin sildenafil risperidone|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertaline ) and effexor xr ( venlafaxine ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|alfa AND Concurrent paclitaxel lithium|metformin risperidone olanzapine propranolol naltrexone|tiotropium|boehringer-ingelheim is developing a combination product with entity and the long-acting beta agonist bi-1744 for the treatment of copd .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|drug|alfa AND Concurrent paclitaxel lithium|Placebo bid metformin capsules ibuprofen|tiotropium|explore efficacy and safety at doses of 15 . 6 to 125mcg od and 15 . 6mcg and 31 . 25mcg twice daily ( bid ) compared with entity od or placebo in subjects with copd .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|alfa AND Concurrent paclitaxel lithium|salbutamol prednisone Placebo ICS diclofenac|tiotropium|significantly greater than placebo and similar in magnitude to a combination therapy active control of salmeterol dosed twice daily plus entity dosed once daily .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|alfa AND Concurrent paclitaxel lithium|furosemide azithromycin salbutamol ICS prednisone|tiotropium|separately , a phase iii study showed that once-daily nva237 is superior to placebo and similar to entity in improving lung function in patients with moderate-to-severe copd .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|alfa AND Concurrent paclitaxel lithium|vancomycin Placebo monotherapy ciprofloxacin enalapril|tiotropium|% of the patients in the study , yupelri demonstrated nominally statistically significant and clinically relevant improvements in trough fev1 versus entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa AND Concurrent paclitaxel lithium|ICS salbutamol spirometry CPAP furosemide|tiotropium|the studies showed that when used in conjunction with entity , indacaterol produces a significantly greater improvement in lung function than entity alone .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa AND Concurrent paclitaxel lithium|salbutamol theophylline ICS spirometry methacholine|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity , a commonly used long-acting bronchodilator , in approximately 30 patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|alfa AND Concurrent paclitaxel lithium|bortezomib docetaxel bevacizumab rituximab capecitabine|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity in approximately 30 patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa AND Concurrent paclitaxel lithium|salbutamol ICS methacholine spirometry theophylline|tiotropium|phase 2a clinical trial in the united kingdom evaluating rpl554 in approximately 30 patients with copd as an add-on therapy to entity , a commonly used bronchodilator .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|alfa AND Concurrent paclitaxel lithium|enrollment Placebo SRP starting docetaxel|tiotropium|no : p27 ( a6797 ) umec / vi as step-up therapy from entity in moderate symptomatic copd : a randomized , 12-week study exhibit 99 . 4 press release issued : wednesday 18th may 2016
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|alfa AND Concurrent paclitaxel lithium|anticipated midazolam Cmax FEV1 pharmacodynamics|tiotropium|early post-dose spirometry data suggested a more rapid onset of action than entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa AND Concurrent paclitaxel lithium|salbutamol theophylline furosemide spirometry ICS|tiotropium|mg and 6 mg , or placebo , dosed twice-daily for three days , in addition to a dual bronchodilator therapy comprising entity and olodaterol , a commonly used lama / laba , dosed once daily .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|alfa AND Concurrent paclitaxel lithium|metformin paclitaxel docetaxel diclofenac bevacizumab|tiotropium|the primary analysis was to determine non-inferiority ( based on a margin of -50ml ) or superiority of umeclidinium to entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa AND Concurrent paclitaxel lithium|formulation formulations bevacizumab paclitaxel risperidone|tiotropium|showed that nva237 was well-tolerated with a similar incidence of adverse events for patients treated with nva237 , placebo and open-label entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|alfa AND Concurrent paclitaxel lithium|ibuprofen od enalapril metformin juice|tiotropium|· in both studies , placebo and open-label od entity 18mcg were comparators .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa AND Concurrent paclitaxel lithium|usual conservative ICS triple rescue|tiotropium|•verona pharma announced positive data in a 4-week phase 2b copd trial with nebulized ensifentrine on top of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alfa AND Concurrent paclitaxel lithium|salbutamol magnesium bromide dexmedetomidine nicotine|tiotropium|table of contents  braltus® ( entity bromide ) , a long-acting muscarinic antagonist , indicated for adult patients with copd , delivered via the zonda® inhaler , was launched in europe
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|alfa AND Concurrent paclitaxel lithium|diclofenac ibuprofen vancomycin itraconazole naltrexone|tiotropium|when compared to placebo , glycopyrronium 50 mcg was also numerically higher than ol entity 18 mcg versus placebo at all-time points for trough fev1 ( day 1 and weeks 12 , 26 and 52 ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|alfa AND Concurrent paclitaxel lithium|salbutamol inhaled bromide anticholinergic benzodiazepine|tiotropium|been playing a central role in the management of copd , and are currently the most common therapy in copd ( e . g . , entity bromide ; a long-acting bronchodilator ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|alfa AND Concurrent paclitaxel lithium|salbutamol Placebo amoxicillin ibuprofen acetaminophen|tiotropium|patients were randomised 1 : 1 to umeclidinium 62 . 5mcg inhalation powder or entity 18mcg .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel docetaxel tacrolimus prednisone Prior|FDA app approval supplement kit|flutemetamol|in october 2013 , the fda approved entity , under the name vizamyltm , for adults being evaluated for ad and dementia with pet brain imaging .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|paclitaxel docetaxel tacrolimus prednisone Prior|PET gadolinium tau tracers 18F|flutemetamol|in addition to fluorbetapir , there are two other beta-amyloid imaging agents available : florbetaben from piramal enterprises , imaging division , and entity from ge healthcare .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|paclitaxel docetaxel tacrolimus prednisone Prior|photograph PET pict radio digit|flutemetamol|the filing also includes data from a recently completed [ 18f ] entity pet image reader training validation study , results of which will be presented at a scientific forum in coming months .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|paclitaxel docetaxel tacrolimus prednisone Prior|fluconazole itraconazole olanzapine rituximab fluoxetine|flutemetamol|as an aid to the evaluation of patients with signs of alzheimers disease : amyvid® ( florbetapir ) , marketed by lilly , and vizamyl® ( entity ) , marketed by ge healthcare .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|paclitaxel docetaxel tacrolimus prednisone Prior|PET gadolinium tau 18F fluorescein|flutemetamol|in addition to fluorbetipir , there are two other beta-amyloid imaging agents in late stage development : florbetaben from bayer schering and entity from general electric .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|GnRH octreotide LHRH melatonin oxytocin|goserelin|among the different classes of peptides , gnrh / lhrh agonists ( leuprorelin , entity ) account for almost 50 percent of the market .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|calcitonin progesterone paclitaxel estradiol GnRH|goserelin|formulations such as lupron and eligard , which deliver leuprolide , trelstar , which delivers triptorelin , and zoladex , a biodegradable rod , which delivers entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|rituximab imatinib anthracycline gemcitabine trastuzumab|goserelin|patients in the second arm will receive bnt112 combined with entity acetate and cemiplimab , and patients in the third arm will receive bnt112 combined with entity acetate alone .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|rituximab docetaxel imatinib gemcitabine trastuzumab|goserelin|primary objective of this study will be to establish the safety and tolerability of bnt112 alone , or in combination with entity acetate with or without cemiplimab .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|estradiol GnRH androgen LHRH oestradiol|goserelin|zoladex ( entity acetate implant ) is a lhrh agonist for treating prostate and breast cancer .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|estradiol phorbol ethyl oestradiol prostaglandin|goserelin|for all classes , the only astrazeneca drug at issue is zoladex™ ( entity acetate implant ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 3), ('DRUG', 3), ('DIS', 1)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|hyaluronic prostaglandin prednisolone retinoic glucocorticoid|goserelin|astrazeneca announced that it had entered into an agreement with tersera therapeutics llc ( tersera ) for the commercial rights to zoladex ( entity acetate implant ) in the u . s . and canada .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('BIO', 1)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|bevacizumab bisphosphonates paclitaxel ibuprofen ketamine|goserelin|launches of generic entity ( the active ingredient in zoladex ) are expected in europe during 2012 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|octreotide depot prostaglandin GnRH glucocorticoid|goserelin|zoladex ( entity acetate implant ) , available in one month and three month depots , is the worlds second largest lhrh agonist by value .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|glucocorticoid hyaluronic prednisolone retinoic silicone|goserelin|in the us , the us department of justice has been conducting an investigation into the sales and marketing of zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('BIO', 1)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|ketamine gabapentin bevacizumab naltrexone bisphosphonates|goserelin|competition in the lhrh agonist market is expected to increase in europe during 2011 , with further launches of generic entity ( the active ingredient in zoladex ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|tamoxifen estradiol diclofenac octreotide propranolol|goserelin|examples of commercially marketed lhrh agonists are lupron® ( leuprolide acetate ) , zoladex® ( entity acetate ) , viadur® ( leuprolide acetate ) and eligard® ( leuprolide acetate ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|tamoxifen metformin trastuzumab yes TAM|goserelin|lee011 + tamoxifen + entity or nsai + entity hr+ / her2- premenopausal abc 1st line 2018 iii - fully enrolled lee011 + fulvestrant hr+ / her2- postmenopausal abc 1st / 2nd line 2018 iii
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|alfa trastuzumab paclitaxel docetaxel formulation|estradiol ethyl prednisolone retinoic calcitonin|goserelin|for all classes , the only astrazeneca drug at issue is zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|Primary Hip BMD echocardiography Surgery|lidocaine ketamine tramadol morphine caffeine|biperiden|increases over the same quarter in the prior year in certain molecules including cyclizine hydrochloride , codeine phosphate + paracetomol and entity hydrochloride .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|octreotide alfa analogs analogues GH|inactive market investigational tracer approved|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|octreotide alfa analogs analogues GH|analogue amide hydrochloride octreotide acetate|lanreotide|somatuline entity ( " somatuline " ) is another long- acting somatostatin analog .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|somatostatin octreotide injectable depot metformin|lanreotide|we look forward to advancing mycapssa as a preferred treatment option for patients with acromegaly treated with octreotide and entity injectables ,  mr . kannan concluded .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|metformin octreotide somatostatin docetaxel GH|lanreotide|on june 26 , 2020 , chiasma received fda approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|octreotide alfa analogs analogues GH|investigational market inactive approved tracer|lanreotide|we do not have composition of matter patent coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|drug|octreotide alfa analogs analogues GH|octreotide somatostatin ghrelin depot metformin|lanreotide|receptor type 2 ( sst2 ) biased agonist , in patients with acromegaly whose disease is not biochemically controlled by octreotide lar or entity depot alone .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|octreotide alfa analogs analogues GH|investigational inactive title market approved|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® autogel® ) alone .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|octreotide alfa analogs analogues GH|lan octreotide cab depot ra|lanreotide|hormone levels used to measure disease at 24 weeks versus continued treatment with the long acting release form of octreotide , or entity autogel , meeting the primary endpoint .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|octreotide metformin somatostatin docetaxel propranolol|lanreotide|week 13 in acromegaly patients who were switched from an injected somatostatin receptor ligand ( srl ) depot of either octreotide or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|fluconazole steroids progesterone paclitaxel levodopa|lanreotide|the somatuline® autogel® formulation requires no excipient other than water and releases entity over a period of at least 28 days and up to 56 days .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|metformin octreotide docetaxel somatostatin GH|lanreotide|approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|octreotide alfa analogs analogues GH|gemcitabine trastuzumab paclitaxel irinotecan bevacizumab|lanreotide|a pilot trial involving six children with neuroblastoma cancer and seven adults with neuroendocrine cancer has been completed using entity as the targeting agent .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|octreotide alfa analogs analogues GH|octreotide somatostatin depot amyl hydrocortisone|lanreotide|these products include sandostatin lar depot ( octreotide / im injection ) by novartis a . g . , and somatuline depot ( entity acetate ) by tercica inc .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 2)])|drug|octreotide alfa analogs analogues GH|ghrelin calcitonin octreotide leptin somatostatin|lanreotide|active substance the active substance in somatuline® depot is entity , which inhibits the growth and secretion of several endocrine , exocrine and paracrine functions .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|octreotide alfa analogs analogues GH|octreotide somatostatin metformin ghrelin bevacizumab|lanreotide|somatuline® depot is an injectable sustained-release formulation containing entity , a somatostatin analogue .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|octreotide bevacizumab somatostatin docetaxel metformin|lanreotide|surgical removal of the pituitary tumor consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|octreotide metformin bevacizumab somatostatin docetaxel|lanreotide|care for patients diagnosed with acromegaly consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|octreotide bevacizumab somatostatin metformin analogs|lanreotide|long-acting analogues of the hormone somatostatin , such as octreotide and entity have established themselves as a primary treatment of neuroendocrine tumors , although with limited efficacy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|octreotide somatostatin bevacizumab metformin docetaxel|lanreotide|somatostatin analogs octreotide ( marketed as sandostatin ) and entity ( marketed as somatuline ) are selective for sst2 receptors and are the preferred first-line pharmacologic treatments .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|octreotide alfa analogs analogues GH|depot metformin NET octreotide GH|lanreotide|acromegaly in the united states : sandostatin lar ( octreotide ) marketed by novartis ; signifor lar ( pasireotide ) marketed by novartis ; and somatuline depot ( entity ) marketed by ipsen .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|alfa vancomycin AND diclofenac comparing|vancomycin ciprofloxacin amoxicillin Sodium chlorhexidine|cefotetan|entity disodium injectable ( vial ) 1gr , 2gr , 10gr vials entity ® nda / anda indicated for the treatment of various bacterial infections .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|alfa vancomycin AND diclofenac comparing|ceftriaxone AMP azithromycin imipenem ABL|cefotetan|entity is a second-generation cephalosporin with a broad range of anti-microbial activity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|alfa vancomycin AND diclofenac comparing|vancomycin imipenem ferric ciprofloxacin amoxicillin|cefotetan|entity disodium 20mg / ml injectable ( bag ) 50ml bags entity ® nda indicated for the treatment of various bacterial infections .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa vancomycin AND diclofenac comparing|approved licensed intended marketed FDA|cefotetan|we received fda approval for and launched our first injectable product , cefotan® ( entity for injection ) , in the first quarter of 2016 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa vancomycin AND diclofenac comparing|FDA themselves legislation approval market|cefotetan|we launched entity in september 2007 and are currently the only company to market entity in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|alfa vancomycin AND diclofenac comparing|paclitaxel docetaxel fluconazole carboplatin curcumin|cefotetan|march 31 , 2007 were $23 . 6 million of paclitaxel ( whole plant ) , $3 . 9 million in other abraxane® related materials and $3 . 0 million of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa vancomycin AND diclofenac comparing|licensed intended approved market FDA|cefotetan|and ·in december 2015 , the company received approval of its supplemental new drug application from the fda for cefotan® ( entity for injection ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa vancomycin AND diclofenac comparing|intended licensed pen approved market|cefotetan|received approval of the company  s supplemental new drug application ( snda ) from the u . s . food and drug administration ( fda ) for cefotan® ( entity for injection ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa vancomycin AND diclofenac comparing|FDA themselves advertising approval again|cefotetan|we launched entity in september 2007 and are currently the only company to market entity vials in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa vancomycin AND diclofenac comparing|approved licensed FDA marketed market|cefotetan|we have received fda approval for our first product in this portfolio , cefotan® ( entity for injection ) , which we launched in the first quarter of 2016 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|alfa vancomycin AND diclofenac comparing|methylprednisolone prednisolone doxycycline tacrolimus topical|cefotetan|·the company launched cefotan® ( entity disodium for injection ) and lidocaine 5% ointment in march of 2016 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|alfa vancomycin AND diclofenac comparing|ceftriaxone ASA MPA IVIG TXA|cefotetan|entity is often used for surgical prophylaxis and offers the longest half-life of any cephalopsorin .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|alfa vancomycin AND diclofenac comparing|gadolinium prednisolone methylprednisolone magnesium arsenic|cefotetan|in the third quarter , app launched entity disodium for injection .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|vulgaris AND allergy carbamazepine valproate|diazepam midazolam fluoxetine MDMA ketamine|topiramate|an overactive thyroid ; by patients taking a type of anti-depressant called maoi ; or by patients who are allergic to phentermine , entity , or any of the ingredients in qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|vulgaris AND allergy carbamazepine valproate|metformin olanzapine octreotide acetaminophen levodopa|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus :
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|vulgaris AND allergy carbamazepine valproate|FDA EMA labeling approved generic|topiramate|we anticipate that the label for qnexa , if approved , will contain the similar suicidality warnings to those contained in the entity label .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|vulgaris AND allergy carbamazepine valproate|caffeine nicotine cocaine ethanol paracetamol|topiramate|the exercise primarily includes identifying these mother-infant pairs exposed to entity at the doses that the fda has recommended .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|drug|vulgaris AND allergy carbamazepine valproate|ibuprofen warfarin paracetamol metformin acetaminophen|topiramate|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , phentermine / entity , under the trade name qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|vulgaris AND allergy carbamazepine valproate|benzodiazepine carbamazepine valproate benzodiazepines olanzapine|topiramate|immediate release formulations of entity and oxcarbazepine are available in generic form and are marketed under the brand names of topamax and trileptal , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vulgaris AND allergy carbamazepine valproate|gabapentin carbamazepine valproate tacrolimus simvastatin|topiramate|et-104 is one of etons three neurology-focused liquid product candidates , along with et-105 ( lamotrigine oral suspension ) and et-101 ( entity oral solution ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|vulgaris AND allergy carbamazepine valproate|valproate carbamazepine benzodiazepine benzodiazepines risperidone|topiramate|the company has two marketed products for epilepsy , oxtellar xr ( extended-release oxcarbazepine ) and trokendi xr ( extended-release entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|vulgaris AND allergy carbamazepine valproate|metformin probiotics caffeine cyclophosphamide Placebo|topiramate|in the qnexa studies , which included 15 offspring from women exposed to qnexa or entity , there were no reports of congenital malformations .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 3)])|drug|vulgaris AND allergy carbamazepine valproate|metformin olanzapine octreotide levodopa atorvastatin|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus : authors : w . timothy garvey , md ( a ) ; craig a .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|vulgaris AND allergy carbamazepine valproate|GABA Zinc Calcium Inflammation Nrf2|topiramate|entity is believed to work in epilepsy through various mechanisms .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|vulgaris AND allergy carbamazepine valproate|gabapentin buprenorphine methadone fluoxetine tramadol|topiramate|in addition , we currently do not have manufacturing agreements in place for entity or phentermine .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|vulgaris AND allergy carbamazepine valproate|acetaminophen naltrexone paracetamol ibuprofen verapamil|topiramate|in july 2012 , vivus , inc . obtained fda approval for its combination product , phentermine / entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vulgaris AND allergy carbamazepine valproate|valproate carbamazepine benzodiazepine benzodiazepines gabapentin|topiramate|the company has two marketed products for epilepsy , oxtellar xr® ( extended-release oxcarbazepine ) and trokendi xr® ( extended-release entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|vulgaris AND allergy carbamazepine valproate|naltrexone acetaminophen olanzapine naloxone ibuprofen|topiramate|and patient market research to assess potential growth of the obesity therapeutics market as well as preference shares between nb32 , phentermine / entity and lorcaserin .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|vulgaris AND allergy carbamazepine valproate|metformin naltrexone risperidone olanzapine buprenorphine|topiramate|the pharmaceutical company performing research of entity alone announced they had discontinued development of a time-release formulation due to side effects at high doses .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|vulgaris AND allergy carbamazepine valproate|metronidazole clarithromycin fluconazole ibuprofen prednisone|topiramate|<a  leland wilson> : we typically characterize our product as the low-dose combination of phentermine and entity , so thats what thats referring to , yes .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|vulgaris AND allergy carbamazepine valproate|MDMA paracetamol buprenorphine THC olanzapine|topiramate|u . s . attorneys office in boston , massachusetts seeking documents relating to the marketing , including alleged off-label marketing , of the drug topamax® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|vulgaris AND allergy carbamazepine valproate|naltrexone olanzapine metformin risperidone gabapentin|topiramate|qsymia® ( phentermine and entity extended release ) is approved by fda for chronic weight management .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|vulgaris AND allergy carbamazepine valproate|gabapentin valproate phenytoin metformin olanzapine|topiramate|or aeds , available in the united states and worldwide , including the generic products levetiracetam , lamotrigine , carbamazepine , oxcarbazepine , valproic acid and entity .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|docetaxel gemcitabine paclitaxel carboplatin bortezomib|theophylline|fully funds a 36 patient phase 1 / 2 investigator-sponsored phase 1 / 2 study for use of hs-110 as a combination therapy with entity and oxygen .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|fluoxetine phenytoin haloperidol verapamil valproate|theophylline|therapeutic monitoring of cyp1a2 substrates with a narrow therapeutic index ( e . g . entity and tizanidine ) is recommended when coadministered with ocaliva .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|trough tacrolimus theophylline paclitaxel levodopa|theophylline|monitor entity levels if concurrent administration cannot be avoided .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|PAF ACh CGRP VIP Exercise|theophylline|entity relaxes the smooth muscle of the bronchial airways and thus acts mainly as a bronchodilator .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|warfarin clopidogrel statin ASA aspirin|theophylline|when taking zyflo , entity dose should be reduced by 50% and appropriately monitored ; patients taking propranolol or warfarin should be monitored and doses adjusted
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|stimulant substance analgesic antidepressant antipsychotic|theophylline|respiratory sales growth was moderated in 1995 by lower sales of theo-dur , a sustained-action entity , due to increased generic competition .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|spray sting topical repe injectable|theophylline|the company noted that it discontinued marketing its u . s . entity products in june 2001 and that proventil repetabs have not been available since july 2001 .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|salbutamol theophylline furosemide erythromycin azithromycin|theophylline|the most commonly used oral bronchodilator is entity , a drug with good efficacy but which is capable of producing certain undesirable side effects such as disturbances in heart
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|salbutamol theophylline furosemide spirometry steroids|theophylline|the bronchodilator agents most often used are ß2 agonists , anticholinergics , and entity .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|histamine salbutamol theophylline aspirin capsaicin|theophylline|euphyllin , a drug based on a substance called entity , is used for the treatment of asthma and copd .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|vaccines formulation vaccination labeling approval|theophylline|[ * * * ] entity ( including product sold under the theochron ( r ) trademark )
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|salbutamol ICS Oxygen CPAP Exercise|theophylline|entity and albuterol are frequently prescribed to produce dilation of bronchioles for both emphysema and chronic bronchitis .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|ribavirin metformin clopidogrel paclitaxel bevacizumab|theophylline|patients taking zyflo cr and entity should reduce the entity dose by 50% .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|salbutamol tablets formulations insecticides gloves|theophylline|decree also includes a recall , initiated in early may 2002 and directed to u . s . trade accounts , of all lots of entity , usp tablets and proventil ( albuterol sulfate , usp ) repetabs .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|salbutamol mannitol erythromycin cimetidine theophylline|theophylline|antihistamines , antiemetics , histamine h-2 receptor antagonists , barbiturates , prostoglandins , and bronchial dilators selected from the group consisting of terbutaline , and entity .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|choline phosphatidylcholine caffeine ethanol acetylcholine|theophylline|other products choledyl ( r ) choledyl ( r ) ( oxtriphylline ) is the choline salt of entity .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|formulated stored sold marketed trastuzumab|theophylline|[ * * * ] entity in elixir form sold under the elixophyllin ( r ) trademark [
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|theophylline carbamazepine salbutamol valproate phenobarbital|theophylline|offices and central labs to measure patient blood drug levels for the most commonly prescribed therapeutic drugs to control asthma ( entity ) and epilepsy ( carbamazepine , and phenytoin ) .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|theophylline mannitol sildenafil caffeine furosemide|theophylline|bronchodilators dilate the airways and include beta agonists ( such as albuterol and bitolterol ) , xanthines ( such as entity ) and anticholinergics ( such as ipratropium ) .
OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|gefitinib metformin theophylline paclitaxel clarithromycin|metronidazole azithromycin clindamycin gentamicin erythromycin|theophylline|serious and fatal reactions have been reported in patients receiving concur-rent administration of ciprofloxacin and entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|generic France insecticide probiotics tacrolimus|inotersen|the company holds the rights for the commercialization of tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) for the treatment of rare diseases in countries in latin america and the caribbean .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|sevoflurane sold ketamine electricity divers|inotersen|slower rate than revenue with the increase primarily due to higher sg&a expenses as ionis prepares to commercialize volanesorsen and entity this year .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|financial market stock specimen insurance|inotersen|commercial entity inventory acquired from ionis commercial inventory acquired clinical material acquired from ionis clinical material acquired liability for costs incurred and
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|tax he court law Act|inotersen|that the defendants breached their fiduciary duties in connection with the licensing transaction that we and ionis entered into regarding entity and akcea-ttr-lrx .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|originally namely bevacizumab metformin rituximab|inotersen|akcea has received marketing approval for an antisense drug , entity that was developed by ionis , in the u . s . , the eu and canada , for the treatment of hattr amyloidosis .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|documentation mail computers email letters|inotersen|the parties agree to maintain books and records for entity and ionis-ttr-lrx that will allow each party to provide the other party with net revenues , expenses ( including each cost category
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|metformin atorvastatin omeprazole simvastatin ibuprofen|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  potentially best-in-class oral small molecule ttr stabilizer
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|gabapentin atorvastatin vancomycin fluoxetine metformin|inotersen|today announced a collaboration under which ptc will commercialize two of akceas rare disease drugs in latin america ( latam ) : tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|consumers respondents likes president tax|inotersen|both entity and volanesorsen are progressing toward regulatory filings for marketing authorization .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|ketamine tramadol gabapentin morphine diclofenac|inotersen|icon clinical research limited , inc research toronto , inc . and medpace for the clinical studies for our drugs , including volanesorsen and entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|azithromycin doxycycline gabapentin metformin chloroquine|inotersen|ag10 also will not be the first treatment on the market for attr-pn as tafamidis , patisiran , and entity are approved for the treatment of attr-pn in a variety of countries globally .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|TM GSK France FDA Germany|inotersen|we created tegsedi™ ( entity ) the worlds first rna-targeted therapeutic approved for the treatment of polyneuropathy of hereditary transthyretin ( ttr ) amyloidosis ( attr ) in adult patients
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|metformin atorvastatin omeprazole simvastatin ibuprofen|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  oral small molecule ttr stabilizer
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|paclitaxel excipients trastuzumab docetaxel alfa|manufacturing iterative own business optimization|inotersen|for ionis , this transaction achieves all the goals we laid out at the outset of our entity process .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|diclofenac ophthalmic hydrochloride alfa formulation|diclofenac topical bevacizumab prostaglandin methylprednisolone|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%fda approval received for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|diclofenac ophthalmic hydrochloride alfa formulation|topical bevacizumab diluted diclofenac crude|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%launched in the us , received ema approval and launched in europe , and received health canada approval for the
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|diclofenac ophthalmic hydrochloride alfa formulation|Recently Currently First Specifically Previously|nepafenac|entity , new formulation anti-inflammatory us 2011 eu 2012 approved approved - ilevro approved in q4 2012 - ilevro approved q2 2013
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|diclofenac ophthalmic hydrochloride alfa formulation|bevacizumab tacrolimus diclofenac gentamicin azithromycin|nepafenac|· alcon received approval to market ilevro , a new formulation of entity ophthalmic suspension ( 0 . 3% ) , in the us .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|diclofenac ophthalmic hydrochloride alfa formulation|diclofenac corticosteroid topical lidocaine bevacizumab|nepafenac|in august 2005 , the fda approved nevanac ( entity ophthalmic suspension ) 0 . 1% for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|criminal court legal official murder|phentermine|sus has been named as a defendant in a total of 4 , 196 such entity lawsuits , in respect of which sus has been dismissed as a defendant in 3 , 936 cases .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|alfa steroids preparations transdermal AND|valproate gabapentin statin simvastatin phenytoin|phentermine|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , entity / topiramate , under the trade name qsymia .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|alfa steroids preparations transdermal AND|valproate carbamazepine gabapentin phenytoin lithium|phentermine|qnexa is our investigational drug candidate involving low doses of entity and topiramate .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|metformin fluoxetine melatonin caffeine olanzapine|phentermine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including entity , phendimetrazine , mazindol , benzphetamine and diethylpropion .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|alfa steroids preparations transdermal AND|Per 125 From 20th First|phentermine|entity hcl , usp sales in the year ended december 31 , 2001 reflected an increase in unit volume from the refilling of distribution
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|valproate metformin gabapentin lithium phenytoin|phentermine|in particular , it is possible that patients will seek to acquire entity and topiramate , the generic components of qsymia .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|alfa steroids preparations transdermal AND|fluoxetine olanzapine methamphetamine MDMA naltrexone|phentermine|a defendant in more than two thousand five hundred multi-defendant lawsuits involving the manufacture and sale of dexfenfluramine , fenfluramine , and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|cannabis metformin paracetamol acetaminophen MDMA|phentermine|the lawsuits allege that the manufacturers of entity knew that its use could cause serious side effects , but failed to warn against those dangers .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa steroids preparations transdermal AND|prescription list acetaminophen market ladder|phentermine|to fisons ) and 585 ( as to rugby ) personal injury lawsuits in the u . s . ( including class actions ) concerning the weight-loss drug entity ( fisons brand name ionamin ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|alfa steroids preparations transdermal AND|simvastatin metformin olanzapine atorvastatin fluconazole|phentermine|the equate study also contained a mid-dose of qnexa containing 46 mg of topiramate cr and 7 . 5 mg of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|metformin valproate simvastatin gabapentin olanzapine|phentermine|drug candidate for the treatment of obesity , incorporating low doses of active ingredients from two previously approved products , topiramate and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|themselves metformin olanzapine acetaminophen antipsychotics|phentermine|contrary to the approved labelling of these products , physicians in the us co-prescribed entity with fenfluramine or dexfenfluramine for management of obesity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|metformin naltrexone olanzapine gabapentin valproate|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( &#x201c ; fda&#x201d ; ) for chronic weight management .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|drug|alfa steroids preparations transdermal AND|Insulin metformin Alcohol Obesity BAT|phentermine|entity is the largest selling antiobesity therapeutic and is available in several generic forms .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|nicotine propranolol sildenafil clonidine salbutamol|phentermine|&#160 ; the company had one approved and marketed product , suprenza ( entity hydrochloride ) , which it had out licensed for promotion in the united states , canada and mexico .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa steroids preparations transdermal AND|flu diclofenac ten naltrexone methylp|phentermine|to a decline in both unit volume and selling prices of fluvoxamine maleate and a decline in unit volume of entity hcl , usp .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|alfa steroids preparations transdermal AND|metformin simvastatin gabapentin atorvastatin statin|phentermine|as expected , the chmp recommended against approval of the marketing authorization application ( maa ) for qsiva ( entity / topiramate er ) for the treatment of obesity in the european union .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|alfa steroids preparations transdermal AND|He Zinc Vaccine BV India|phentermine|entity is sold at much lower prices than we charge for qsymia .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|metformin olanzapine paracetamol acetaminophen benzodiazepines|phentermine|there are a number of generic pharmaceutical drugs that are prescribed for obesity , predominantly entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|alfa steroids preparations transdermal AND|metformin olanzapine naltrexone gabapentin valproate|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( “fda” ) for chronic weight management .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|atorvastatin AND metoprolol statins reductase|metformin curcumin melatonin bevacizumab paclitaxel|carvedilol|which is available as both an oral and an iv formulation , and querto® , a therapeutic based on a substance called entity .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|atorvastatin AND metoprolol statins reductase|metoprolol metformin diltiazem atorvastatin clopidogrel|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|atorvastatin AND metoprolol statins reductase|metoprolol propranolol diltiazem amiodarone nifedipine|carvedilol|coreg ( entity ) is a beta-blocker indicated for the treatment of congestive heart failure and flomax ( tamsulosin ) is indicated for the treatment of
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|atorvastatin AND metoprolol statins reductase|Portug Gran Cam Ber Aust|carvedilol|flamel technologies has collaborations with a number of leading pharmaceutical and biotechnology companies , including glaxosmithkline ( coreg cr® , entity phosphate ) .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atorvastatin AND metoprolol statins reductase|Calcium Sodium Dietary Vitamin Oral|carvedilol|entity phosphate is indicated for the treatment of hypertension and heart failure .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|atorvastatin AND metoprolol statins reductase|own generic respective market injectable|carvedilol|teva and numerous other generic producers began selling their entity tablets ( the generic version of coreg® ) in september of 2007 .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|atorvastatin AND metoprolol statins reductase|formulation depot FDA statin pump|carvedilol|european marketing application submitted in october 2014 ; and ( ix ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atorvastatin AND metoprolol statins reductase|own generic respective cannabis market|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|atorvastatin AND metoprolol statins reductase|diclofenac magnesium ferric zinc aluminum|carvedilol|this technology has successfully transitioned to commercial stage with coreg cr® , a micropump-based controlled-release formulation of entity phosphate , sold in the us since 2007 by gsk .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|atorvastatin AND metoprolol statins reductase|metformin tacrolimus diclofenac fluconazole curcumin|carvedilol|first part of the market includes generic drugs based on the immediate release of the generic active ingredient known as entity ( such as coreg® produced by glaxosmithkline ) .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|atorvastatin AND metoprolol statins reductase|diclofenac paclitaxel magnesium sildenafil ferrous|carvedilol|when we entered into a license agreement for use of our micropump platform for an extended release formulation of entity phosphate .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|atorvastatin AND metoprolol statins reductase|formulation depot mixture analogue pump|carvedilol|planned for the third quarter of 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|atorvastatin AND metoprolol statins reductase|formulation statin FDA depot metformin|carvedilol|european marketing application submitted in october 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|atorvastatin AND metoprolol statins reductase|omeprazole clarithromycin metformin celecoxib metronidazole|carvedilol|during fiscal 2008 , we launched entity tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , terbinafine and ciprofloxacin er tablets .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|atorvastatin AND metoprolol statins reductase|own medicinal investigational respective herbal|carvedilol|teva would be permitted to continue selling its entity products , given that gsk  s patent has expired .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|atorvastatin AND metoprolol statins reductase|losartan sildenafil metformin captopril atorvastatin|carvedilol|since 1991 , entity has been approved as a treatment for hypertension in several european countries , and in september 1995 , it was approved by
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|atorvastatin AND metoprolol statins reductase|diuretic vasodilator mixture metoprolol statin|carvedilol|bucindolol in sort of all comers , what you see is a data set that compares favorably to metoprolol or a entity , at least on the data that are available .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|atorvastatin AND metoprolol statins reductase|medicinal finished pharmaceutical generic own|carvedilol|successful in its allegations of patent infringement , teva could be required to pay damages relating to past sales of its entity products .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atorvastatin AND metoprolol statins reductase|own generic respective cannabis market|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|atorvastatin AND metoprolol statins reductase|metoprolol metformin diltiazem atorvastatin clopidogrel|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|AND vulgaris Allergy mosquitoes GSK|gabapentin melatonin fluoxetine olanzapine metformin|lemborexant|merck is marketing belsomra® ( suvorexant ) and eisai is marketing dayvigo® ( entity ) which are dual orexin receptor antagonists indicated for insomnia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|AND vulgaris Allergy mosquitoes GSK|DEX olanzapine es app OX|lemborexant|in december 2019 , eisai announced u . s . fda approval of dayvigo™ ( entity ) , a dual orexin receptor antagonist for the treatment of insomnia in adult patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|AND vulgaris Allergy mosquitoes GSK|antagonists orally substances analogs analogues|lemborexant|purdue and eisai are developing entity and glaxosmithkline is developing sb-649868 which are also dual orexin receptor antagonists .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|aspirin LMWH clopidogrel paclitaxel bevacizumab|lansoprazole|volume was flat as a result of competition on us sales of enoxaparin , lost us authorized generics of gemcitabine and entity in the prior year , and lower sales in germany .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|PPI TCA omeprazole ASA TA|lansoprazole|the principal indications for prevacid ( entity ) , a proton pump inhibitor , are for short-term treatment of duodenal ulcers , gastric ulcers and erosive esophagitis .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|herbal pharmaceutical injectable tablet silicone|lansoprazole|in september 2008 , abbott and takeda settled that patent infringement lawsuit against apotex and apotex was allowed to begin selling generic entity capsules in canada on may 1 , 2009 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|Germany FDA Europe AIDS BMS|lansoprazole|the original united states compound patent covering entity is licensed by tap from takeda and will expire in 2009 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|name brand raw own ag|lansoprazole|with tap pharmaceutical products inc . , or tap , granting tap the right to develop one or more products based on its entity ppi product and derivatives of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|omeprazole PPI cimetidine amoxicillin clarithromycin|lansoprazole|in the treatment of reflux oesophagitis , it provides healing and symptom relief in more patients than losec / prilosec , entity or pantoprazole .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|monomers polymers parts chemicals precursors|lansoprazole|to tap the north american rights to develop , manufacture and sell products resulting from the use of our technology with entity and derivatives of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|antioxidants formulations curcumin nanomaterials nicotine|lansoprazole|our ongoing work with tap pharmaceuticals on an improved formulation of entity continues to progress smoothly .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|newly commercially formerly publicly newer|lansoprazole|million ) , which caused pricing to decline , as well as nearly usd 100 million of prior-year sales of sandozs gemcitabine and entity authorized generics .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|acetaminophen ibuprofen indomethacin diclofenac celecoxib|lansoprazole|dosage forms of acetaminophen , and an improved method of manufacturing for drugs requiring protection from stomach acid , such omeprazole and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|omeprazole clarithromycin metronidazole metformin celecoxib|lansoprazole|with respect to omeprazole and entity , we believe that we have created an improved method of manufacture , requiring less time and producing higher purity amid better
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|monomers analogues analogs esters polymers|lansoprazole|the north american rights to develop , manufacture and sell products resulting from the use of our immediate-release ppi technology with entity and derivatives of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|omeprazole clarithromycin PPI cimetidine clopidogrel|lansoprazole|nexium ( esomeprazole ) is the first proton pump inhibitor ( ppi ) to offer significant clinical improvements over losec / prilosec and its main competitors , entity and pantoprazole .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|PPI CIP GSK PEP FDA|lansoprazole|tap also markets prevacid-registered trademark- ( entity ) , a proton pump inhibitor , and has a co-promotion arrangement with the company for prevacid-registered trademark- .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|celecoxib curcumin metformin omeprazole diclofenac|lansoprazole|prevonco™ for the treatment of solid tumors , contains a currently third-party marketed anti-ulcer compound , entity , for the treatment of solid tumors .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|buprenorphine paracetamol metformin acetaminophen medicines|lansoprazole|sales of entity , which was launched in december 2004 , accounted for 8% of our branded pharmaceutical revenues during the six months ended june 30 , 2005
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|tablets omeprazole metformin tablet HCl|lansoprazole|pantoprazole faces competition from various other branded ppis , including takedas entity and astrazenecas esomeprazole .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|curcumin celecoxib metformin metronidazole omeprazole|lansoprazole|prevonco™ for the treatment of solid tumors , contains a marketed anti-ulcer compound , entity , that could be used alone or in combination with other chemotherapeutic agents .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|omeprazole PPI metformin clarithromycin cimetidine|lansoprazole|tap also markets prevacid® ( entity ) , a proton pump inhibitor .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|clarithromycin metformin omeprazole psoriasis NSAIDs|omeprazole approval hope diarrhea promise|lansoprazole|preceding these notable launches , takeda pioneered gastroenterological breakthroughs in proton pump inhibitors beginning in the 1990s with entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|itraconazole antifungal psoriasis clarithromycin vulgaris|fluconazole itraconazole ciprofloxacin clarithromycin metronidazole|terconazole|prescription drugs in the antifungal field include nizoral ( ketoconazole ) , sporanox ( itraconazole ) , terazol ( entity ) and daktarin ( miconazole nitrate ) antifungal products .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|itraconazole antifungal psoriasis clarithromycin vulgaris|fluconazole itraconazole erythromycin clarithromycin metronidazole|terconazole|product in this category which does not contain a fungicide such as 95 table of contents clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|itraconazole antifungal psoriasis clarithromycin vulgaris|itraconazole tacrolimus fluconazole metronidazole bevacizumab|terconazole|the approved prescription therapies for vvc are diflucan ( fluconazole ) and terazol ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|itraconazole antifungal psoriasis clarithromycin vulgaris|fluconazole itraconazole erythromycin metronidazole clarithromycin|terconazole|a probiotic , purfem is the only product in this category which does not contain a fungicide such as clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|psoriasis allergy methotrexate paclitaxel topical|TM GSK Max Nasal alfa|azelastine|the astelin ( entity ) tablet nda for asthma will be withdrawn as soon as it is no longer needed to support the other two
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|psoriasis allergy methotrexate paclitaxel topical|TM Nasal GSK Ex Max|azelastine|the astelin ( entity ) tablet nda for rhinitis is pending at the fda .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|psoriasis allergy methotrexate paclitaxel topical|HCl 2a TM 2b GSK|azelastine|division the division had a successful year highlighted by the first full year of marketing a new antihistamine , 2 astelin ( entity ) nasal spray .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|psoriasis allergy methotrexate paclitaxel topical|ex Der BU eg max|azelastine|in august 2002 , we entered into an agreement with medpointe inc . to co-promote medpointe  s nasal-spray antihistamine , astelin® ( entity hcl ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|psoriasis allergy methotrexate paclitaxel topical|ex Der 125 GSK Ro|azelastine|in august 2002 , we signed an agreement with medpointe , inc . for the co-promotion of astelin® ( entity hcl ) , a nasal-spray antihistamine .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|psoriasis allergy methotrexate paclitaxel topical|ex San 1a com Der|azelastine|on october 1 , 2004 , we terminated our co-promotion agreement with medpointe , inc . , or medpointe , for the co-promotion of astelin brand entity hcl for the treatment of allergic rhinitis .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|pacemaker AND warfarin alfa P2Y|tablets tablet metformin bevacizumab gabapentin|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of april 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|pacemaker AND warfarin alfa P2Y|GSK metformin es HCl TM|patiromer|on october 21 , 2015 , the u . s . food and drug administration , or fda , approved our first drug , veltassa® ( entity ) for oral suspension , or veltassa , for the treatment of hyperkalemia .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|pacemaker AND warfarin alfa P2Y|bevacizumab eg metformin MTA PET|patiromer|relypsas lead product candidate is entity , which is also known as rly5016 , is a non-absorbed potassium binder that is currently being evaluated for the treatment of
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|namely ie eg named id|patiromer|also aware of two products for which regulatory approval in the united states has been sought for treatment of hyperkalemia , entity from relypsa and zs-9 from zs pharma .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|specialists PC society another colleagues|patiromer|veitinger , a member of our board of directors , under which dr . veitinger provides certain consulting services to us in connection with entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|drug|pacemaker AND warfarin alfa P2Y|Placebo amoxicillin bevacizumab metformin docetaxel|patiromer|to hospitals / other institutions for the full month of march and the three month period ended march 31 , 2016 for veltassa ® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|sale granted marketing instance purchase|patiromer|the agreement , dsm fine chemicals has agreed to manufacture and supply for commercial sale the active pharmaceutical ingredient ( api ) for entity , the companys lead product candidate .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|another approved taxa investigational tem|patiromer|drug discovery technology or by selectively pursuing the in-licensing or acquisition of additional compounds that would be commercially synergistic with entity fos .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|pacemaker AND warfarin alfa P2Y|psoriasis COPD glaucoma ADHD BPH|patiromer|if the companys new drug application for entity is not accepted by the fda on or before december 31 , 2013 , 25% of the shares subject to the option shall
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|pacemaker AND warfarin alfa P2Y|TM GSK metformin bevacizumab HCl|patiromer|we are substantially dependent on the success of our first and only drug , veltassa® ( entity ) for oral suspension , or veltassa .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|market pay manufacturers advocate opt|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the u . s . until at least 2030 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|your Tra taxa dd ORF|patiromer|we are not permitted to market entity fos in the u . s . until we receive approval of our nda from the fda .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|vi cosmetic medicinal patent lic|patiromer|in this offer to purchase ) with vifor fresenius medical care renal pharma ltd . ( vfmcrp ) , an affiliate of galenica , to commercialize entity fos outside of the united states and japan .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|pacemaker AND warfarin alfa P2Y|tablets bevacizumab Germany metformin GSK|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of february 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|market pay advocate manufacturers substitute|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the united states until at least 2030 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|pacemaker AND warfarin alfa P2Y|DT bup lic polyp dul|patiromer|relypsa intends to commercialize entity fos , if approved , with its own dedicated u . s . -based commercial team and specialty sales force of approximately 120 sales representatives .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|pacemaker AND warfarin alfa P2Y|bicarbonate magnesium mannitol diltiazem verapamil|patiromer|the challenge all potassium binders ( e . g . entity ) have limited efficacy on per gram basis therapeutic dose for kayexelate , entity or zs-9 substantially the same ( 15-30 g / day )
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|another your NIH NCI FDA|patiromer|business entity clinical development program—pivotal phase 3 trial , page 101 please expand your discussion of your results to identify the serious adverse
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|pacemaker AND warfarin alfa P2Y|Calcium Zinc diltiazem Iron diclofenac|patiromer|entity is a non-absorbed , potassium binding polymer .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|pacemaker AND warfarin alfa P2Y|EV BV TF FV VD|patiromer|veltassa ( entity fos ) , an oral , polymer-based potassium binder , was approved for marketing by the fda in october 2015 and was commercially launched
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ethyl another mitomycin alfa chloroquine|methamphetamine amphetamine haloperidol MDMA ketamine|benzphetamine|several older agents , indicated for short-term administration , are amphetamine-like compounds including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|ethyl another mitomycin alfa chloroquine|olanzapine metformin fluoxetine valproate haloperidol|benzphetamine|in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|ethyl another mitomycin alfa chloroquine|fluoxetine carbamazepine olanzapine ibuprofen metformin|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ethyl another mitomycin alfa chloroquine|haloperidol phenytoin carbamazepine fluoxetine valproate|benzphetamine|several older drugs , indicated for short-term administration , include phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|ethyl another mitomycin alfa chloroquine|glycol valproate acetate isomers carbonate|benzphetamine|the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , 33 table of contents entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|ethyl another mitomycin alfa chloroquine|fluoxetine olanzapine metformin haloperidol melatonin|benzphetamine|products in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ethyl another mitomycin alfa chloroquine|methamphetamine amphetamine haloperidol MDMA ketamine|benzphetamine|several older drugs , indicated for short-term administration , have an amphetamine-like profile , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|drug|ethyl another mitomycin alfa chloroquine|metformin atorvastatin simvastatin omeprazole ritonavir|benzphetamine|mg tab mysoline® promethazine 12 . 5 , 25 , 50mg tab ( 2 separate andas ) phenergan® fenofibrate 54 , 160mg tab lofibra® entity 50mg tab didrex® not currently marketed .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|ethyl another mitomycin alfa chloroquine|fluoxetine olanzapine ibuprofen paracetamol metformin|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , mazindol , entity and diethylpropion .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|vancomycin gentamicin ceftriaxone ciprofloxacin imipenem|ciprofloxacin|infecton® is the proprietary combination of the widely used antibiotic , entity , with technetium ( 99mtc ) , the most commonly used radioisotope in nuclear medical imaging .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|antipsychotics benzodiazepines analgesics acetaminophen diuretics|ciprofloxacin|should inform their physician if they are taking , or planning to take , any prescription or over-the-counter drugs , especially antidepressants and entity .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|topical silicone gentamicin dry diluted|ciprofloxacin|about otiprio® otiprio ( entity otic suspension ) is a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|antimicrobial antibacterial injectable metronidazole ciprofloxacin|ciprofloxacin|bayer corporation has developed a once-daily entity product for the treatment of urinary tract infections , which is currently marketed by schering-plough corporation .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|fentanyl ketamine morphine bupivacaine lidocaine|ciprofloxacin|and we agreed to settle the then pending litigation regarding bayer  s patent protecting entity hydrochloride .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|seminal scientific own patent landmark|ciprofloxacin|carlsbad has withdrawn all other defenses it had originally raised challenging the validity and enforceability of bayer ag  s entity patent .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|metformin bevacizumab fluconazole tacrolimus levodopa|ciprofloxacin|we intend to begin marketing and selling the tablet dosage form of entity through our alliance with lannett if and when anda approval is given by the fda and following the expiration of
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|topical ex called diluted dry|ciprofloxacin|otiprio ( entity otic suspension ) is the first drug approved in the united states for use during tympanostomy tube placement ( ttp ) surgery and
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|Lactobacillus azithromycin MMF clarithromycin Flu|ciprofloxacin|entity is approved as therapy for infectious diarrhea with a dosing regimen of twice daily administrations for five to seven days .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|granted publication money decades adoption|ciprofloxacin|if we lost our patent protection for entity , or if the expiration of the patent were accelerated to october 2002 , we believe that we would forego significant revenue .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|another your investigational medicinal foreign|ciprofloxacin|if we are not already distributing the product , we , along with our partner , will have the right to begin distributing entity product manufactured by bayer .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|own medicinal finished investigational draft|ciprofloxacin|the decrease in the quarter reflects the launch of the company  s entity product on june 9 , 2003 .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|clarithromycin azithromycin metronidazole ceftriaxone ciprofloxacin|ciprofloxacin|limitations of entity , rifaximin and tmp / smx , three of the most commonly prescribed treatments for infectious diarrhea , include one or more of the following :
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|pesticides cannabis medicines asbestos cigarettes|ciprofloxacin|based on the plaintiffs expert testimony in the california case , estimated sales of entity in california were approximately $500 million during the alleged damages period .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|funding publications publication messages comments|ciprofloxacin|pursuant to the terms of the agreement , we began distributing entity on june 9 , 2003 .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|December El Am NCT0 du|ciprofloxacin|year ended march 31 , 2002 2003 entity hcl rs .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|ciprofloxacin ceftriaxone erythromycin vancomycin azithromycin|ciprofloxacin|gyra and parc are the targets of the fluoroquinolone class of antibacterial agents , such as entity .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|Placebo GSK TA FDA NET|ciprofloxacin|the fda placed the valortim® / entity study on partial clinical hold pending the outcome of the investigation .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|ciprofloxacin metronidazole ceftriaxone doxycycline amoxicillin|ciprofloxacin|proquin® xr ( entity hydrochloride ) is a once-daily treatment for uncomplicated urinary tract infections that the company no longer manufactures or markets .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin vancomycin itraconazole clarithromycin methicillin|own patent federal informed personal|ciprofloxacin|we intend to continue taking vigorous action to maintain our entity patent rights in the united states through their normal expiry in december 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|P2Y derivative intermediates scaffold benzo|nitrate acetate silver chloride salt|sulfadiazine|the most common topical antimicrobial agent used is silver entity cream .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|P2Y derivative intermediates scaffold benzo|nitrate acetate chloride sulfate silver|sulfadiazine|wound epithelialization was 11 days for patients treated with transcyte as compared to 18 days for patients treated with silver entity cream .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|P2Y derivative intermediates scaffold benzo|nitrate dioxide sulfate cream chloride|sulfadiazine|as compared to silver entity , dermagraft-tc may reduce the pain , time and cost associated with once or twice daily dressing changes and excision .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|P2Y derivative intermediates scaffold benzo|paste spray cream powder ointment|sulfadiazine|a number of studies have been conducted which compared the efficacy of collagenase santyl ( r ) to standard treatment ( silver entity ) for deep second degree burns .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|P2Y derivative intermediates scaffold benzo|ointment dressing cream burns spray|sulfadiazine|intended for delivery through the skin ) for the treatment of burns that is expected to not only reduce infection ( silver entity ) , but also enhance tissue growth .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|P2Y derivative intermediates scaffold benzo|log selectin Akt pi glycoprotein|sulfadiazine|in this same model , d2a21 demonstrated significant improvement in percent survival ( 85% versus 0% in the control group , p entity ( ssd ) and sulfamylon .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|P2Y derivative intermediates scaffold benzo|nitrate chloride dioxide sulfate cream|sulfadiazine|in a clinical trial under a physician  s ide , transcyte was evaluated as an alternative to silver entity in the treatment of patients with limited to moderate partial-thickness burns .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|P2Y derivative intermediates scaffold benzo|dressing cream nitrate ointment sulfate|sulfadiazine|transcyte was compared to silver entity which had twice daily dressing changes and wound debridement as per the burn center  s standard practice .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|P2Y derivative intermediates scaffold benzo|silver nitrate mL iodine grams|sulfadiazine|sildaflo is a dressing that incorporates silver 6 entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|P2Y derivative intermediates scaffold benzo|nitrate cream sulfate chloride dioxide|sulfadiazine|in partial-thickness burns , dermagraft-tc , as compared to silver entity , has been shown to significantly reduce pain and to heal burns faster and with less scarring .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|P2Y derivative intermediates scaffold benzo|topical Topical investigational Novel Oral|sulfadiazine|entity silver ointment health product designed to assist in the prevention of infections related to burns .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|P2Y derivative intermediates scaffold benzo|nitrate dioxide cream ointment peroxide|sulfadiazine|transcyte , as compared to silver entity in treating second degree burns , has been shown to heal burns faster .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|P2Y derivative intermediates scaffold benzo|nitrate dioxide sulfate chloride ions|sulfadiazine|sildaflo is a dressing that incorporates silver entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|P2Y derivative intermediates scaffold benzo|topical Topical prophylactic antifungal investigational|sulfadiazine|entity silver ointment designed to the treatment or the prevention of infections related to burns .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|P2Y derivative intermediates scaffold benzo|topical sterile silver black diclofenac|sulfadiazine|banlangen tablets , dansheng tablets and entity silver ointment remain listed in the updated state insurance catalogue .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|P2Y derivative intermediates scaffold benzo|topical silver ophthalmic sterile herbal|sulfadiazine|at present , xuesaitong soft capsules and entity silver ointment have already been listed in the insurance catalogue .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|alfa Prior paclitaxel Alpha P2Y|furosemide ceftriaxone metformin melatonin olanzapine|conivaptan|the study evaluated both 20 and 40 mg / day doses of entity in hyponatremic patients and was conducted at 26 u . s . and 2 international centers .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|alfa Prior paclitaxel Alpha P2Y|SC EV DEX VI BT|conivaptan|of an open label multicenter study adding to the growing body of literature supporting the efficacy and use of vaprisol ( entity ) injection .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|alfa Prior paclitaxel Alpha P2Y|dexmedetomidine ketamine mannitol lidocaine dextrose|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|alfa Prior paclitaxel Alpha P2Y|mannitol dexmedetomidine ketamine dextrose lidocaine|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol is an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|AND Concurrent paclitaxel psoriasis topical|dal Mer France LMWH metformin|roflumilast|two of our newest products , daliresp ( entity ) and viibryd ( vilazodone hcl ) became available to patients during the june 2011 quarter and were formally launched in late august
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5)])|drug|AND Concurrent paclitaxel psoriasis topical|erythromycin ciprofloxacin ibuprofen azithromycin fluoxetine|roflumilast|and these products were nebivolol , milnacipran , ceftaroline , entity , aclidinium , linaclotide , levomilnacipran and cariprazine .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|drug|AND Concurrent paclitaxel psoriasis topical|ice sun lidocaine EM topical|roflumilast|pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing entity cream , entity foam , arq-252 or arq-255 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|AND Concurrent paclitaxel psoriasis topical|celecoxib NSAID simvastatin ibuprofen statin|roflumilast|one such treatment is an oral formulation of a pde4 inhibitor ( entity ) with anti-inflammatory properties , although frequency of adverse events has limited its use in copd patients .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|AND Concurrent paclitaxel psoriasis topical|TM BV GSK Dox everolimus|roflumilast|this year in addition to teflaro . in addition , we are hopeful to obtain fda approval later this quarter for daxas ( entity ) , for the treatment of copd .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|AND Concurrent paclitaxel psoriasis topical|com everolimus paclitaxel se org|roflumilast|q31 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Concurrent paclitaxel psoriasis topical|billion million mL capsules tablets|roflumilast|* forced expiratory volume in 1 second , primary endpoint of the ratio trial table of contents pharmaceuticals 9 entity , administered at a daily dose of 500 µg , is an effective product .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|AND Concurrent paclitaxel psoriasis topical|MMF ICS theophylline PTX SQ|roflumilast|daliresp ( entity ) , our selective phosphodiesterase 4 ( pde4 ) enzyme inhibitor indicated for the treatment to reduce risk of exacerbations in patients with severe
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|AND Concurrent paclitaxel psoriasis topical|iv paclitaxel approved tolerability Germany|roflumilast|as oral administration ariflo® ( cilomilast ) of glaxosmithkline pharmaceuticals , recently found approvable for maintenance of lung function in certain patients , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Concurrent paclitaxel psoriasis topical|ii iii FDA th USA|roflumilast|daliresp ( entity ) us patent proceedings in 2015 and subsequently , in response to paragraph iv notices from multiple anda filers , astrazeneca filed patent
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|AND Concurrent paclitaxel psoriasis topical|steroids glucocorticoids fluconazole corticosteroid anesthetics|roflumilast|each of these areas present a variety of treatment challenges which may be well suited to treatment with topical entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|AND Concurrent paclitaxel psoriasis topical|imatinib metformin sorafenib everolimus chloroquine|roflumilast|in addition , we did not observe the gastrointestinal or other side effects associated with entity , the only pde4 inhibitor currently on the market approved for the treatment of copd .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND Concurrent paclitaxel psoriasis topical|EA PDT VPA Chemotherapy Therapy|roflumilast|entity was generally well tolerated in the treatment of patients with copd .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Concurrent paclitaxel psoriasis topical|GSK FDA GLP TM ex|roflumilast|daliresp ( entity ) patent proceedings in the us in april 2015 , astrazeneca received several paragraph iv notices challenging certain patents listed in the
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|AND Concurrent paclitaxel psoriasis topical|com everolimus paclitaxel org se|roflumilast|q34 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|AND Concurrent paclitaxel psoriasis topical|imatinib metformin sorafenib capecitabine everolimus|roflumilast|our clinical trials , and has not been observed to result in the gastrointestinal or other side effects commonly associated with entity , the only pde4 inhibitor currently on the market .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('BIO', 1)])|drug|AND Concurrent paclitaxel psoriasis topical|everolimus paclitaxel com org bortezomib|roflumilast|q33 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|AND Concurrent paclitaxel psoriasis topical|org se R0 th app|roflumilast|daliresp / daxas ( entity ) copd $215m , up 14% ( 15% at cer ) growth driven by favourable affordability-programme changes and inventory movements in the us .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|AND Concurrent paclitaxel psoriasis topical|bupivacaine NaCl lidocaine vancomycin ethanol|roflumilast|we therefore elected to reduce the maximum concentration from 0 . 5% entity to 0 . 3% entity for subsequent development .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|AND Concurrent paclitaxel psoriasis topical|marine industrial pharmaceutical plastic aromatic|roflumilast|page 4 investment projects 2003 altana pharma will establish an ultra-modern entity tablet-producing factory in cork , ireland .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|topical Versus AND diclofenac alfa|discontinuation lowering simvastatin metformin reposition|levamlodipine|simceres strategic cardiovascular portfolio also continues to grow with our recently launched cholesterol lowering drug rosuvastatin and hypertension drug entity both performing well .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|AND psoriasis Primary vulgaris VI|vaginal silver zinc magnesium estradiol|butoconazole|the caption immediately below the picture of gynazole-1 ( r ) reads : " gynazole-1 ( r ) ( entity nitrate ) vaginal cream 2% only one dose .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|AND psoriasis Primary vulgaris VI|silver nitrate magnesium aluminum nicotine|butoconazole|the product combines roche  s proprietary entity nitrate with kv  s proprietary site release ( r ) drug delivery technology .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|AND psoriasis Primary vulgaris VI|vaginal diclofenac topical silver lactose|butoconazole|its licensing partner , ferring , inc . of canada has received approval from the canadian regulatory agency , hpb to market kv  s gynazole-1 ( r ) ( entity nitrate 2% vaginal cream ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|AND psoriasis Primary vulgaris VI|silver diclofenac chlorhexidine topical vaginal|butoconazole|important safety information for gynazole-1 ( entity nitrate vaginal cream usp , 2% ) 5 . 7% of patients enrolled in the gynazole●1 clinical trials reported complaints such as vulvar / vaginal
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|AND psoriasis Primary vulgaris VI|formulation cream Tw topical diluted|butoconazole|gynazole-1 ( r ) ( entity nitrate 2% ) is a rapidly growing branded prescription vaginal antifungal product indicated for the local treatment of vulvovaginal candidiasis in butoconazole 
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|dysplasia defects AND neuropathy dystrophy|IBD T1D SCD T2DM T1DM|achondroplasia|january 2014 , we announced the initiation of a phase 2 clinical trial for vosoritide for the treatment of children with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|dysplasia defects AND neuropathy dystrophy|T1D CKD T1DM SCD T2DM|achondroplasia|the phase 3 study is a randomized , placebo-controlled study of vosoritide in approximately 110 children with entity ages 5-14 for 52 weeks .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|dysplasia defects AND neuropathy dystrophy|psoriasis NAFLD NSCLC BPH COPD|achondroplasia|currently , there are no medical therapies for entity approved by the fda .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|dysplasia defects AND neuropathy dystrophy|osteoporosis OI osteosarcoma CKD T2D|achondroplasia|in animal models of entity , administration of synthetic cnp and cnp analogues rescued the impaired bone growth phenotype without significant adverse effects .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|disease|dysplasia defects AND neuropathy dystrophy|ALL ADHD autism neuroblastoma IBD|achondroplasia|we announced the initiation of a phase 2 clinical trial for bmn 111 for the treatment of children with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|dysplasia defects AND neuropathy dystrophy|dementia autism T2DM psoriasis disabilities|achondroplasia|this is approximately 25 percent of people with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|dysplasia defects AND neuropathy dystrophy|dementia autism T2DM psoriasis IBD|achondroplasia|this is approximately 25% of people with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|dysplasia defects AND neuropathy dystrophy|Europe NSCLC BMS Safety T2DM|achondroplasia| bmn-111 for entity : the company expects to initiate a phase 2 trial in patients in mid 2013 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|dysplasia defects AND neuropathy dystrophy|psoriasis IBD SSc burns vasculitis|achondroplasia|on july 23 , 2020 , the company announced that it had submitted the maa for vosoritide for the treatment of children with entity to the ema .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|dysplasia defects AND neuropathy dystrophy|T2D T2DM OSA insomnia IBS|achondroplasia|the goal is to provide a safer and more efficacious therapy for entity , than daily administration of short-acting cnp analogues .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|dysplasia defects AND neuropathy dystrophy|IBD JIA KD ITP ALL|achondroplasia|global phase 2 multiple dose , randomized study to assess the safety , tolerability , pharmacokinetics and efficacy of recifercept in children with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|dysplasia defects AND neuropathy dystrophy|T1D T2DM T1DM T2D SCD|achondroplasia|continuing studies include our phase 3 study of vosoritide in approximately 110 children with entity for 52 weeks and a long-term open-label phase 2 study of approximately 23 children .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dysplasia defects AND neuropathy dystrophy|scoliosis myopia DMD dwarf SMA|achondroplasia|transcon cnp is being developed for the treatment of entity , the most common form of dwarfism .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|dysplasia defects AND neuropathy dystrophy|CHF CKD OSA COPD PAH|achondroplasia|genetically-defined cancers , and bmn-111 , a modified c-natriuretic peptide , which is currently in phase i clinical development for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|dysplasia defects AND neuropathy dystrophy|osteoporosis deformities hypercalcemia myopia tumorigenesis|achondroplasia|natriuretic peptide , or cnp , is a regulator of bone growth and can rescue defects in fibroblast growth factor 3 that cause entity resulting in dwarfism .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|dysplasia defects AND neuropathy dystrophy|psoriasis T2DM COPD migraine T2D|achondroplasia|rapid clinical development and ( iv ) the possible approval and commercialization of biomarins product candidates , including vosoritide for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|dysplasia defects AND neuropathy dystrophy|T1D T2DM CKD T1DM T2D|achondroplasia|the phase 2 study is a randomized , placebo-controlled study of vosoritide in approximately 70 infants and young children with entity ages zero to less than 60 months for 52 weeks .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neuropathy myopathy AND dysplasia psoriasis|Europe Japan France Sweden cardiology|adrenoleukodystrophy|we will also regain control of the preclinical programs in entity ( ald ) and two ophthalmic programs .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuropathy myopathy AND dysplasia psoriasis|palsy vasospasm aneurysms glioma migraine|adrenoleukodystrophy|european medicines agency ( ema ) granted an accelerated assessment to elivaldogene autotemcel ( eli-cel , lenti-d gene therapy ) for the treatment of cerebral entity ( cald ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|neuropathy myopathy AND dysplasia psoriasis|format linkage randomization linker backbone|adrenoleukodystrophy|trb : x-linked entity , plans current status evaluation of vk0214 ongoing , encouraging in vitro results in vivo model in progress poc results expected 2016
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neuropathy myopathy AND dysplasia psoriasis|reality First Then construction Europe|adrenoleukodystrophy|cerebral entity ( cald ) the cald platform includes three patent portfolios , described below .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|neuropathy myopathy AND dysplasia psoriasis|psoriasis AIDS T2DM CML CLL|adrenoleukodystrophy|our lenti-d product candidate has been granted orphan drug status by the fda and the ema for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuropathy myopathy AND dysplasia psoriasis|amyloidosis immunodeficiency arthritis vasculitis thrombocytopenia|adrenoleukodystrophy|our second trß agonist is vk0214 , which we are evaluating in the orphan disease known as x-linked entity , or x-ald .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|neuropathy myopathy AND dysplasia psoriasis|palsy vasospasm AVM aneurysms migraine|adrenoleukodystrophy|our lenti-d product candidate to treat cerebral entity ( cald ) •
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neuropathy myopathy AND dysplasia psoriasis|databases library FDA server collection|adrenoleukodystrophy|on our two most advanced programs in tdt and cerebral entity , these data will dictate the timing and path for future regulatory submissions in the us and europe .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|neuropathy myopathy AND dysplasia psoriasis|hypercholesterolemia hyperlipidemia myopathy cataract cholestasis|adrenoleukodystrophy|vk0214 is being evaluated as a potential treatment for x-linked entity ( x-ald ) , a devastating disease caused by a defect in a peroxisomal transporter called abcd1 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|disease|neuropathy myopathy AND dysplasia psoriasis|cannabis bevacizumab MDMA marijuana thalidomide|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|neuropathy myopathy AND dysplasia psoriasis|myeloma malignancies palsy oncology clinic|adrenoleukodystrophy|clinical study of our bb2121 product candidate in relapsed / refractory multiple myeloma and updates on our lenti-d program in cerebral entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|disease|neuropathy myopathy AND dysplasia psoriasis|thalassemia psoriasis cardiomyopathy osteoporosis amyloidosis|adrenoleukodystrophy|diseases treatable with hematopoietic stem cell transplants include inherited metabolic diseases , such as krabbe syndrome , metachromatic leukodystrophy , hurler syndrome and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|disease|neuropathy myopathy AND dysplasia psoriasis|cannabis bevacizumab MDMA marijuana thalidomide|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuropathy myopathy AND dysplasia psoriasis|palsy aneurysms infarct glioma astrocytoma|adrenoleukodystrophy|bio intends to use the net proceeds of this offering primarily to advance its clinical studies in ccald ( childhood cerebral entity ) , beta-thalassemia major and sickle cell disease .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neuropathy myopathy AND dysplasia psoriasis|ROP CDH stillbirth AIS autism|adrenoleukodystrophy|the worldwide incidence rate for entity , or ald , the superset of ccald , is approximately one in 20 , 000 newborn males .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|neuropathy myopathy AND dysplasia psoriasis|Disease autism migraine ataxia ADHD|adrenoleukodystrophy|entity , or ald , is a genetically determined neurological disorder that affects 1 in every 17 , 900 boys worldwide or 1 in 50 , 000
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|disease|neuropathy myopathy AND dysplasia psoriasis|cannabis medicines flavonoids bevacizumab MDMA|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the discovery programs .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|neuropathy myopathy AND dysplasia psoriasis|NEC GBS Pregnancy Stroke ROP|adrenoleukodystrophy|entity is a rare , often fatal condition believed to occur with an incidence of approximately one in 17 , 000 births .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|neuropathy myopathy AND dysplasia psoriasis|glomerulonephritis glycosylation thrombocytopenia amyloidosis cytotoxicity|adrenoleukodystrophy|▪ evaluation of vk0214 in an in vivo model of x-linked entity ( x-ald ) recently completed .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neuropathy myopathy AND dysplasia psoriasis|format formats crystallography arrays plates|adrenoleukodystrophy|▪ advancing ind-enabling work for vk0214 in x-linked entity ( x-ald ) ; ind filing planned in 2h19 .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|malformation fetus palate ears Developmental|hydrocephalus scoliosis strabismus nystagmus anomalies|anencephaly|ntds include often devastating abnormalities such as spina bifida and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|acidosis Insulin metformin intolerance Secondary|spasticity SMA ALS ataxia scoliosis|argininemia|own decreased spasticity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|acidosis Insulin metformin intolerance Secondary|T2DM SMA thalassemia CML hemophilia|argininemia|enzyme activity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|uncontrolled COPD Asthma allergy AND|psoriasis periodontitis scleroderma fibromyalgia gout|asthma|acute inflammatory disease , as well as an oral anti-cytokine therapy that could be directed at chronic inflammatory diseases such as entity , rheumatoid arthritis and crohns disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|uncontrolled COPD Asthma allergy AND|allergy vasculitis hypersensitivity autoimmunity atopy|asthma|we currently have programs in entity / allergy , autoimmunity , transplant rejection , rheumatoid arthritis / inflammatory bowel disease , and tumor growth .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|uncontrolled COPD Asthma allergy AND|ALL NSCLC enrollment recruitment CRC|asthma|we remain on track to initiate a phase 1a single ascending dose clinical trial for entity in the second quarter with preliminary data anticipated by the end of 2014 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|uncontrolled COPD Asthma allergy AND|approved investigational EMA CAM topical|asthma|•we reported positive , pivotal , phase 2b data for dupilumab in the entity indication and completed enrollment of three phase 3 studies of dupilumab in atopic dermatitis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|uncontrolled COPD Asthma allergy AND|hematology dermatology cardiology dentistry psychology|asthma|acuspheres three initial product candidates are designed to address large unmet clinical needs within cardiology , oncology and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uncontrolled COPD Asthma allergy AND|neurodegeneration migraine colitis addiction IBD|asthma|vla-4 antagonists represent a new class of compounds that has shown promise in multiple preclinical animal models of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uncontrolled COPD Asthma allergy AND|migraine IBS T2D ADHD T2DM|asthma|the primary focus of the collaboration will be to discover orally available vla-4 antagonists as treatments for entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|uncontrolled COPD Asthma allergy AND|asthmatics rhinitis cough urticaria AE|asthma|cromolyn is considered first line therapy in mild persistent entity and is frequently prescribed for children .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|uncontrolled COPD Asthma allergy AND|rhinitis dermatitis encephalomyelitis pruritus vasculitis|asthma|is designed to mediate the suppression of ige and ige-producing cells and originally was developed for the treatment of allergic entity and other ige-mediated diseases .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|uncontrolled COPD Asthma allergy AND|psoriasis COPD CKD T2DM JIA|asthma|development program to date for prv-300 included studies in healthy adult volunteers and adult patients with stable ( mild to moderate ) entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|uncontrolled COPD Asthma allergy AND|allergies allergy eczema rhinitis autoimmunity|asthma|are engaged in the discovery , development and commercialization of novel therapeutics based on synthetic dna for the treatment of cancer , entity / allergies and infectious diseases .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uncontrolled COPD Asthma allergy AND|esophagitis pneumonia exacerbations gastroenteritis vasculitis|asthma|glaxosmithklines , or gsk  s , mepolizumab ( nucala ) which targets il-5 was approved for severe eosinophilic entity in adults and children older than 12 in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|uncontrolled COPD Asthma allergy AND|psoriasis rhinitis COPD eczema acne|asthma|beclomethasone is a steroid used to treat the inflammatory component of entity and certain symptoms of copd .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|uncontrolled COPD Asthma allergy AND|obese migraine allergic Asian immunocompetent|asthma|receptor subtypes , it can cause unwanted side effects including flushing , dyspnea and headache , and it should not be used in entity patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uncontrolled COPD Asthma allergy AND|psoriasis SLE SSc AAV AMD|asthma|the first human proof-of-concept data being obtained in a phase 2 study of genentechs anti-il-13 antibody lebrikizumab for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uncontrolled COPD Asthma allergy AND|migraine asthmatic burn febrile painful|asthma|however , in certain instances , the process may be overly active , such as during an acute entity attack where an immediate inflammatory reaction occurs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|uncontrolled COPD Asthma allergy AND|allergic allergy psoriasis influenza eczema|asthma|xmab7195 were developing for entity and allergic disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|uncontrolled COPD Asthma allergy AND|hypersensitivity constriction narrowing patency obstructive|asthma|it is a prophylactic agent indicated for the management of bronchial entity and exercise-induced bronchospasm .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|uncontrolled COPD Asthma allergy AND|CKD T2DM SSc PAH SLE|asthma|clinical development program for zyflo consisted of 21 safety and efficacy trials in an aggregate of approximately 3 , 000 patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|uncontrolled COPD Asthma allergy AND|migraine psoriasis osteoporosis insomnia acne|asthma|and sales infrastructure to promote zyflo and the controlled-release formulation of zileuton that we are developing for the treatment of entity upon regulatory approval from the fda .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|GCT neuroblastoma glioma pelvis meningioma|neuroblastoma glioblastoma osteosarcoma meningioma cholangiocarcinoma|chordoma|we are conducting a multi-cohort , global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|GCT neuroblastoma glioma pelvis meningioma|evaluable surviving participating fewer excluded|chordoma|the other three entity subjects in the study have been diagnosed with progressive disease .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|GCT neuroblastoma glioma pelvis meningioma|NSCLC SCLC myeloma glioma CRC|chordoma|the trial was an open-label , phase 1 trial and enrolled 38 patients with metastatic cancer or entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|GCT neuroblastoma glioma pelvis meningioma|Japan Europe Canada Brazil France|chordoma| a phase 2 study in entity is being prepared for initiation at the nci .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|GCT neuroblastoma glioma pelvis meningioma|NSCLC HNSCC GBM PC NPC|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|GCT neuroblastoma glioma pelvis meningioma|evaluable million surviving hundred randomised|chordoma|the company believes that the summary results from the 11 entity patients enrolled in this trial compare favorably with historically published data .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|GCT neuroblastoma glioma pelvis meningioma|lymphomas mesothelioma NSCLC SCLC sarcomas|chordoma|additional phase ib / ii clinical trials in various indications are newly opened , including for colorectal and hepatocellular cancers and entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|GCT neuroblastoma glioma pelvis meningioma|neuroblastoma lymphomas mesothelioma myeloma NSCLC|chordoma|trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|GCT neuroblastoma glioma pelvis meningioma|NSCLC CRC T2DM COPD T2D|chordoma|we are excited about the recent initiation of the phase 2 trial of gi-6301 at the nci for patients with entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|GCT neuroblastoma glioma pelvis meningioma|named approved finally called termed|chordoma|mva-bn brachyury for the treatment of metastatic cancer and entity mva-bn brachyury is a cancer immunotherapy developed using our proprietary validated mva-bn platform .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|GCT neuroblastoma glioma pelvis meningioma|glioblastoma neuroblastoma meningioma osteosarcoma lymphomas|chordoma|we have obtained orphan drug designations for tazemetostat for the treatment of patients with fl , entity , malignant rhabdoid tumors , or mrt , soft tissue sarcoma , or sts , and mesothelioma .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|GCT neuroblastoma glioma pelvis meningioma|NSCLC HNSCC GBM SCLC osteosarcoma|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity is still enrolling patients .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|GCT neuroblastoma glioma pelvis meningioma|latter former historical neoadjuvant exploratory|chordoma|we added the entity cohort due to the high rate of enrollment of these patients in the other ini1-negative cohort and the observed clinical
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|GCT neuroblastoma glioma pelvis meningioma|cirrhosis AIDS cholangiocarcinoma schistosomiasis HBV|chordoma|the clinical and commercial landscape for pancreas cancer , non-small cell lung cancer , colorectal cancer , mtc , entity and chronic hepatitis b infection is rapidly changing .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|GCT neuroblastoma glioma pelvis meningioma|neuroblastoma melanomas lymphomas mesothelioma glioblastoma|chordoma|which we collectively refer to as ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|GCT neuroblastoma glioma pelvis meningioma|Columbia Washington Technology Skin Medicine|chordoma|dr . mahony also serves on the board of entity foundation , a nonprofit organization dedicated to improving the lives of those affected by chordoma .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|disease|GCT neuroblastoma glioma pelvis meningioma|NSCLC mesothelioma adenocarcinoma osteosarcoma GIST|chordoma|are conducting a multi-cohort global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or metastatic entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|disease|GCT neuroblastoma glioma pelvis meningioma|CRC NSCLC osteosarcoma glioma GBM|chordoma|it is believed that radiation therapy can reduce the risk of recurrence after surgery and prolong survival for entity patients .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|GCT neuroblastoma glioma pelvis meningioma|glioblastoma NSCLC CLL IBD CML|chordoma|the company believes that the gi-6301 tarmogen® , exclusively licensed to celgene corporation , has demonstrated promising initial results in entity patients evaluated in a recent phase 1 study .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|GCT neuroblastoma glioma pelvis meningioma|Pediatric paediatric adolescent neuroblastoma IBD|chordoma|the cohort of patients in the phase 2 study of entity patients is ongoing , and we are evaluating tazemetostat in the dose-expansion portion of a phase 1 study in pediatric patients
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis NSCLC CRC migraine COPD|choroideremia|the company&#8217 ; s lead product candidate , nsr-rep1 , for the treatment of entity is in phase 3 clinical development .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis scleroderma allergy AIDS eczema|choroideremia|products for the treatment of the indications for which we have product candidates , including fabry disease , cystic fibrosis , xlrp and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|CRC psoriasis NSCLC CML IBD|choroideremia|we are aware that biogen inc . , or biogen , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|paclitaxel bevacizumab docetaxel trastuzumab rituximab|choroideremia|the designation of the first [ *** ] such roche product classes under section 2 . 2 ( including entity ) is included in the initiation payment set forth in section 12 . 1 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|NSCLC CRC psoriasis gemcitabine CLL|choroideremia|the pipeline also includes spk-7001 in an ongoing phase 1 / 2 clinical trial for entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|RD AMD ROP TBI blinding|choroideremia|spk-rpe65 to address a broad spectrum of blinding conditions , starting with the development of spk-chm for the potential treatment of entity , currently in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|cataract cataracts myopia retinopathy glaucoma|choroideremia|these diseases include entity , diabetic retinopathy , glaucoma , lebers congenital amaurosis ( lca ) , macular telangiectasia , retinitis pigmentosa , wet amd and xlrs , among others .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1), ('DRUG', 1)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis hypercholesterolemia osteoporosis migraine T2DM|choroideremia|spk-7001 has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis NSCLC T2DM CRC CML|choroideremia|has been granted orphan product designation by the european commission and fda for its product candidate for the treatment of entity that is in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|FVIII VWF hemophilia vWF Epo|choroideremia|our pipeline includes : a product candidate targeting entity , or chm , currently in a phase 1 / 2 clinical trial ; a product candidate for hemophilia a , currently in a phase 1 / 2
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|retinoblastoma glaucoma cataract retinopathy neovascularization|choroideremia|some irds , such as retinitis pigmentosa ( rp ) , usher syndrome , or entity ( chm ) are associated with a gradual loss of vision , eventually leading to complete blindness .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|advance France Japan Germany Europe|choroideremia|in addition , roche currently holds a license to 4d-110 in entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis CRC IBD ALS T2DM|choroideremia|we are aware that nightstarx is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1), ('DRUG', 1)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis hypercholesterolemia T2DM osteoporosis migraine|choroideremia|spk-chm has also been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|Note Methods Design Purpose Background|choroideremia|entity : spark therapeutics is enrolling patients in its first phase 1 / 2 clinical trial of spk-chm , an aav-based gene therapy for the
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis migraine acne CRC IBS|choroideremia|our first such follow-on product candidate is spk-chm for the treatment of entity , or chm .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|CRC NSCLC glioblastoma psoriasis CLL|choroideremia|our lead product candidate , nsr-rep1 , for the treatment of entity , or chm , is entering phase 3 clinical development in the first half of 2018 and represents the most clinically advanced
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1), ('DRUG', 1)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis hypercholesterolemia T2DM osteoporosis migraine|choroideremia|spk-chm has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis migraine GVHD osteoporosis IBD|choroideremia|as a result , we have not sought , and may be unable to seek , patent protection for spk-chm to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|neovascularization Peripheral proliferative Cerebral Retinal|psoriasis CRC NSCLC IBD osteoporosis|choroideremia|we are aware that nightstar therapeutics plc , or nightstar , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND Metabolic Mixed deficient pyruvate|SMA OI CMT T2DM CKD|citrullinemia|current therapy for entity type 1 is considered difficult for patients and generally ineffective , including diet restriction and nitrogen scavengers , and the only curative
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND Metabolic Mixed deficient pyruvate|SMA neuropathy OI CMT encephalopathy|citrullinemia|individuals with entity type i can build-up excessive levels of ammonia and citrulline in their blood , potentially resulting in neurological deficits and other toxicities .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND Metabolic Mixed deficient pyruvate|GSK your you del Baseline|citrullinemia|*** revision to work plans for pku and entity
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|AND Metabolic Mixed deficient pyruvate|Alzheimer Crohn Parkinson SMA GBS|citrullinemia|to evaluate the therapeutic response to dtx601 , we plan to measure ammonia levels , which is a well-established measure of entity type i disease status .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND Metabolic Mixed deficient pyruvate|she know he yes yourself|citrullinemia|you know , wilson , or pku or entity?
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND Metabolic Mixed deficient pyruvate|SMA Diabetes OI dengue GBS|citrullinemia|the incidence of entity type 1 is estimated at approximately 1 per 250 , 000 live births , affecting more than 2 , 000 individuals worldwide .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|Known myopathy Hemoglobin Protein psoriasis|hemophilia insufficiency Disease thalassemia SLE|afibrinogenemia|entity , the condition where the factor i is completely absent , is estimated to afflict one in one million , or 300 patients
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|Known Hemoglobin AND Hb neuropathy|T2DM dementia CKD psoriasis T2D|homocystinuria|the company is orphan medical  s exclusive direct-to-patient distributor for cystadane ( tm ) , indicated for patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|Known Hemoglobin AND Hb neuropathy|Europe India Japan France Taiwan|homocystinuria|acn00177 in entity in the second quarter of 2020 , we announced the approval of our clinical trial application , or cta , by the united
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Known Hemoglobin AND Hb neuropathy|IBD psoriasis CRC SCD ACS|homocystinuria|there are approximately 1 , 000 patients with entity in the united states .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|Known Hemoglobin AND Hb neuropathy|alcoholism ADHD methamphetamine migraine autism|homocystinuria|humans and an antidote for methanol or suspected methanol ingestion in humans ; and cystadane® ( betaine anhydrous for oral solution ) , for entity , a genetic disease .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|Known Hemoglobin AND Hb neuropathy|psoriasis osteoporosis migraine BPH glaucoma|homocystinuria|cystadane is a known compound which has already been used to treat entity and is , therefore , not patentable for this indication .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|Known Hemoglobin AND Hb neuropathy|insomnia BPH migraine T2DM OAB|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|Known Hemoglobin AND Hb neuropathy|etiology amyloidosis ataxia gout fever|homocystinuria|elevated blood levels of this amino acid arise in the rare genetic disease of classical entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|Known Hemoglobin AND Hb neuropathy|CRC CKD ICH CVD CML|homocystinuria|for aeb4104 demonstrating decreases in plasma homocysteine levels that improved important disease-related abnormalities and survival in a preclinical model of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|Known Hemoglobin AND Hb neuropathy|malignancies leishmaniasis sclerosis hypercholesterolemia psoriasis|homocystinuria|( “orphan” ) , a privately held , clinical-stage biopharmaceutical company focused on the development of product candidate ot-58 for the treatment of classical entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Known Hemoglobin AND Hb neuropathy|stillbirth preeclampsia CDH GDM NEC|homocystinuria|it has been estimated that entity occurs about once in every 200 , 000 live births worldwide .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|Known Hemoglobin AND Hb neuropathy|HH Mediterranean homocysteine folate MMA|homocystinuria|understanding entity entity is an inherited disorder of methionine metabolism that results in elevated homocysteine and homocystine , or thcy , in plasma and urine .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|Known Hemoglobin AND Hb neuropathy|insomnia migraine BPH T2DM OAB|homocystinuria|the company obtained orphan drug status for cystadane for the treatment of entity , which provided marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|Known Hemoglobin AND Hb neuropathy|Part Pers lie Disc Technical|homocystinuria|acn00177 in entity overview : our product candidate , acn00177 , is a novel pegylated , or polyethylene glycol modified , human enzyme engineered to degrade free homocysteine and
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Known Hemoglobin AND Hb neuropathy|HSCT BAT ART DBS SCS|homocystinuria|we believe classical entity represents a viable market opportunity with significant unmet medical need , which we plan to address by continuing our preclinical development
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|Known Hemoglobin AND Hb neuropathy|NAFLD T2DM T2D hypercholesterolemia SCD|homocystinuria|it is the first agent approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|Known Hemoglobin AND Hb neuropathy|worldwide globally entities subtype variant|homocystinuria|the board of hcu network america , a non-profit which provides advocacy and support for patients affected by the rare disease entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Known Hemoglobin AND Hb neuropathy|insomnia migraine BPH T2DM psoriasis|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 24 , 2003 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|Known Hemoglobin AND Hb neuropathy|T2DM NAFLD T1DM T2D hypercholesterolemia|homocystinuria|cystadane is approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|Known Hemoglobin AND Hb neuropathy|ALS CML SMA CMT DMD|homocystinuria|the majority of entity patients suffer mutations of a gene that regulates the production of the enzyme known as cystathionine beta-synthase , or cbs , which
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|Known Hemoglobin AND Hb neuropathy|Europe market clinic clinics manufacturing|homocystinuria|trial in patients with arginase 1 deficiency and closing cancer trials ; offset by a ramp-up in manufacturing for acn00177 in entity and higher personnel-related expenses .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|Known nephropathy Pregnancy Protein Disease|hypercholesterolemia CKD gout stones hyperparathyroidism|cystinuria|tablets ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|Known nephropathy Pregnancy Protein Disease|publication optimization innovation granted exploitation|cystinuria|aeglea has an active discovery platform , with the most advanced program for entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Known nephropathy Pregnancy Protein Disease|Disease Hypertension stone stones Kidney|cystinuria|entity is an inherited disease that causes stones made of the amino acid cystine to form in the kidneys , bladder and / or
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|Known nephropathy Pregnancy Protein Disease|COPD CKD hospitalized obese T2DM|cystinuria|our patent-pending customizable delayed-release tiopronin medications that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|Known nephropathy Pregnancy Protein Disease|pipeline grant plug company cons|cystinuria|aeglea has two programs in ind-enabling studies for homoentity and cystinuria and an active discovery pipeline .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|Known nephropathy Pregnancy Protein Disease|ADHD insomnia T2DM CRC osteoporosis|cystinuria|additionally , we have commenced ind-enabling studies for our aeb5100 program for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|Known nephropathy Pregnancy Protein Disease|CKD hypercholesterolemia stones hyperparathyroidism gout|cystinuria|( tiopronin ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Known nephropathy Pregnancy Protein Disease|CKD nephropathy proteinuria AKI T2D|cystinuria|evaluating sparsentan for fsgs and iga nephropathy , and the recent approval and launch of thiola ec for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|Known nephropathy Pregnancy Protein Disease|CHF hypercholesterolemia RAS OSA CAD|cystinuria|captopril is not fda approved for the treatment of entity but has been prescribed for patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|Known nephropathy Pregnancy Protein Disease|nephropathy proteinuria glomerulonephritis amyloidosis ESRD|cystinuria|evaluating the suitability of our ersg library for development in additional renal disorders , including autosomal dominant polycystic kidney disease , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|Known nephropathy Pregnancy Protein Disease|CKD AKI PC BPH glomerulonephritis|cystinuria|and cysteine , decreased the amount of cystine in the urine and reduced kidney stone formation in a preclinical model of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|disease|Known nephropathy Pregnancy Protein Disease|hemophilia CKD T2DM cirrhosis anemia|cystinuria|aeb5100 in patients with entity aeb5100 is a novel recombinant human enzyme that degrades plasma cystine and cysteine .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Known nephropathy Pregnancy Protein Disease|COPD CKD Asian T2DM hospitalized|cystinuria|our patent-pending tiopronin delayed-release compounded formulations that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Known nephropathy Pregnancy Protein Disease|MMA Hypertension Disease CKD AKI|cystinuria|entity occurs due to genetic mutations in amino acid transporters that lead to increased amounts of cystine in the urine .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|Known nephropathy Pregnancy Protein Disease|psoriasis COPD acne osteoporosis insomnia|cystinuria|thiola•in 2018 , the company expects an nda to be filed for its new formulation of thiola for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Known nephropathy Pregnancy Protein Disease|Disease Hypertension CKD Kidney Diabetes|cystinuria|entity is a chronic genetic disease that causes stones made of the amino acid cystine to form in the kidneys , bladder
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|Known nephropathy Pregnancy Protein Disease|hypercholesterolemia CKD stones gout hyperparathyroidism|cystinuria|( tiopronin ) is approved in the united states for the prevention of cysteine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Known nephropathy Pregnancy Protein Disease|ESRD CKD KD nephropathy albuminuria|cystinuria|clinical development programs and evaluating the suitability of our ersg library for development in additional renal disorders , including adpkd and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Known nephropathy Pregnancy Protein Disease|T2DM psoriasis COPD Asian IBD|cystinuria|citrate delayed release compounded formulations that may be prescribed by physicians as a lower-cost therapeutic alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|Known nephropathy Pregnancy Protein Disease|IBD dementia psoriasis CKD ACS|cystinuria|the company believes there are 10 , 000-12 , 000 patients with entity in the united states , of which 4 , 000-5 , 000 patients may be appropriate candidates for treatment .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|Eligible evaluable Ten Consecutive Twenty|galactosemia|entity patients will be eligible for treatment up to 28 days total ( single dose followed by 27 consecutive days of dosing ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|T2D T2DM NAFLD T1D CKD|galactosemia|therapeutics plans to leverage recent fda guidance permitting biomarker-based development in low prevalence , slowly progressing rare metabolic diseases , such as entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|Diabetes galactose AND Known neuropathy|cerebrovascular osteoporosis neurodegenerative arrhythmia aging|galactosemia|in particular , the company is currently targeting treatments for cardiovascular disease , entity and diabetic complications .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|expert ten interested invited scientific|galactosemia|we also hosted an educational symposium featuring a panel of entity experts .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Diabetes galactose AND Known neuropathy|IBD AIS TBI oncology CKD|galactosemia|we will continue to characterize at-007 long-term safety in adult entity patients and intend to initiate a pediatric study .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Diabetes galactose AND Known neuropathy|hemodialysis T2D CKD T2DM CRC|galactosemia|the key biomarker outcome of the study was reduction in galactitol , an aberrant toxic metabolite of galactose , formed by ar in entity patients .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|Diabetes galactose AND Known neuropathy|IBD migraine CKD ADHD T2D|galactosemia|at-007 treatment resulted in a statistically significant and robust reduction in plasma galactitol versus placebo in adult entity patients .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|Diabetes galactose AND Known neuropathy|NAFLD psoriasis CRC NSCLC T2DM|galactosemia|” recent highlights ·presented data on at-007 for treatment of entity at the entity foundation 2020 virtual conference .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|untreated evaluable ten randomised responding|galactosemia|at-007 was well tolerated , with no drug-related adverse events noted to date in entity patients or in the 72 healthy volunteers treated in part 1 of the trial .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|India Europe Japan advance Germany|galactosemia|· received fda orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|psoriasis NAFLD OSA migraine T2DM|galactosemia|· presented data highlighting at-007 for the treatment of entity at the ashg annual meeting .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|pharmacokinetic dosing monotherapy multicenter pharmacokinetics|galactosemia|·announced start of at-007 pediatric entity study ; released additional 40mg / kg data from adult entity study .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|neonates monotherapy dosing piglets recipients|galactosemia|june 2020 , we announced additional supportive biomarker efficacy and safety data for at-007 in entity at 40 mg / kg .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|Japan Taiwan Europe Korea India|galactosemia|in may 2019 , we received orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Diabetes galactose AND Known neuropathy|CKD T2DM T1D ADHD T2D|galactosemia|in june 2019 we initiated a pivotal phase 1 / 2 study in healthy volunteers and adults with entity to evaluate safety , pharmacokinetics , and biomarker endpoints in adults with entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Diabetes galactose AND Known neuropathy|Japan Taiwan Korea Europe Ethiopia|galactosemia|we initiated a phase 1 / 2 study of at-007 in entity in june 2019 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|disease|psoriasis vulgaris dermatitis glucosidase acne|turn fact erythrocytes mammals summary|galactosialidosis|in entity , the missing protease , cathepsin a , is a lysosomal stabilizing agent for the two other enzymes : sialidase and beta-galactosidase .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|psoriasis vulgaris dermatitis glucosidase acne|FAP ALS LCA LSD FA|galactosialidosis|rhppca is in preclinical development as an enzyme replacement therapy for entity , a rare lysosomal storage disease for which there are no currently approved drug therapies .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|psoriasis vulgaris dermatitis glucosidase acne|QD tolerated visit participant What|galactosialidosis|emil : well entity is another small enzyme therapy program like our mps7 program .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|psoriasis vulgaris dermatitis glucosidase acne|pipeline Google publication web videos|galactosialidosis|how the opportunities at dimension compared to those in your own pipeline at a similar stage such as arcturus and entity?
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 2)])|disease|psoriasis vulgaris dermatitis glucosidase acne|osteoporosis anemia T2DM T2D psoriasis|galactosialidosis|currently no issued patents that cover the rhppca composition of matter or the use of rhppca for the treatment of entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|psoriasis T2DM migraine COPD NSCLC|glioma|in january 2013 , the ema also granted orphan drug protection to val-083 for the treatment of entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|BCC dysplasia fever gliomas mucositis|glioma|in february 2018 , an investigator-sponsored trial was initiated evaluating day101 in pediatric low-grade entity ( plgg ) , for which sunesis believes the scientific rationale is compelling .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|psoriasis CRC COPD NSCLC migraine|glioma|california , san francisco , which is conducting phase 2 clinical trials of prophage series g-100 and g-200 for the treatment of entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|NSCLC mesothelioma osteosarcoma cholangiocarcinoma lymphomas|glioma|research our primary business focus is the clinical development of litx for the treatment of hepatoma , metastatic colorectal cancer , entity and one or more possible follow-on indications .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|Japan NSCLC Europe Taiwan Canada|glioma|rcc tumors received and approximately 85% of the tumors received from patients in our ongoing phase 2 clinical trials in entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|hypercalcemia hyperthermia glioma gliomas arrhythmias|glioma|by nih , a third party might be able to develop a cintredekin besudotox based drug for the treatment of malignant entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|glioma mesothelioma gliomas lymphomas aspergillosis|glioma|the company has completed a phase ii clinical trial for use of su101 as a treatment for refractory malignant entity and has recently initiated a phase iii clinical trial in first relapse entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|mesothelioma NSCLC osteosarcoma glioma AIDS|glioma|investigator sponsored trials include a phase 2 clinical trial in colorectal cancer and a phase 1 clinical trial in entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|mesothelioma glioma gliomas meningioma GCT|glioma|the median survival time was over 609 days ( approximately 21 months ) , which compares favorably to the survival historically recorded for malignant entity patients ( approximately 12 months ) .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|GBM glioblastoma glioma gliomas astrocytoma|glioma|in vivo studies that cannabinoids have a synergistic effect with temozolomide , the standard chemotherapeutic agent used in the treatment of entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|psoriasis migraine NSCLC NAFLD T2DM|glioma|sl-701 was awarded orphan drug designation from the fda for the treatment of entity in january 2015 .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|neoplastic tumoral GBM angiogenic cancerous|glioma|hypericin compounds to inactivate viruses and retroviruses , as a therapeutic or preventative for viral or retroviral diseases , and for anti- entity ( brain tumor ) indications .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1), ('BIO', 1)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|malignancies anemia migraine psoriasis hypercholesterolemia|glioma|ca4p has been granted orphan drug designation for the treatment of entity in the united states .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|gliomas glioma mesothelioma neoplasms melanomas|glioma|orphan drug act , gliadel® wafer became entitled to seven years of market exclusivity for the treatment of patients with malignant entity undergoing primary surgical resection .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|GBM glioblastoma glioma gliomas astrocytoma|glioma|phase 2 clinical trials in a range of indications and is currently in a phase 2 clinical trial in recurrent entity , a type of brain cancer .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|glioma mesothelioma gliomas astrocytoma neoplasms|glioma|the first of these trials was a phase i / ii recurrent malignant entity clinical trial .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|glioblastoma glioma colorectal neuroblastoma neuroendocrine|glioma|is overexpressed in numerous difficult to treat tumors including lung , breast , bladder , gastric , ovarian , endometrial , cervical , melanoma , esophageal , pancreatic , and entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|psoriasis fibromyalgia migraine arthritis IBD|glioma|our product pipeline also includes compounds in phase 1 and 2 clinical development for entity , ulcerative colitis type 2 diabetes and schizophrenia .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|CRC NSCLC EOC BC PDAC|glioma|the crada also covers research to determine whether expression of a component of this pathway correlates with prognosis in entity patients .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|glioma neuroblastoma NOS glioblastoma adenocarcinoma|diarrhea addiction T2DM allergies T2D|glioma|granted protection under the orphan drug act by the united states food and drug administration ( “fda” ) for the treatment of entity , including gbm .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|Platelet AND Diabetes psoriasis Disease|hereditary syndromic atrophic sporadic ataxia|progeria|we are also developing lonafarnib monotherapy for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|Platelet AND Diabetes psoriasis Disease|vo symp ed cons publ|progeria|( a ) the parties acknowledge that a priority review voucher may be available and awarded to eiger as the sponsor of the entity nda ( “entity prv” ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Platelet AND Diabetes psoriasis Disease|spot ovary uremic box periodic|progeria|eiger has initiated a rolling new drug application ( nda ) submission process for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|Platelet AND Diabetes psoriasis Disease|spot ovary uremic anemia malformation|progeria|licensed field of use under the merck agreement to include all uses of lonafarnib related to the treatment of hutchinson-gilford entity syndrome ( entity ) in humans .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|Platelet AND Diabetes psoriasis Disease|name participant Investigator Note registry|progeria|eiger agrees not to retain the entity prv for itself or any of its affiliates .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|Platelet AND Diabetes psoriasis Disease|hereditary ataxia familial syndromic classic|progeria|with prf any proceeds from the monetization of any prv that we may receive for lonafarnib for the treatment of entity and progeroid laminopathies to support future entity research .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|disease|Platelet AND Diabetes psoriasis Disease|spot dwarf malformation ovary anemia|progeria|eiger is preparing an nda and maa for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies with plans to file in q4 2019 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|Platelet AND Diabetes psoriasis Disease|hereditary granulomatous axonal spastic atrophic|progeria|the u . s . food and drug administration ( fda ) accepted the new drug application ( nda ) for accelerated review of zokinvytm ( lonafarnib ) for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Platelet AND Diabetes psoriasis Disease|hereditary acne cutaneous hemorrhagic migraine|progeria|and data controlled by prf to prepare and file any new drug application ( “nda” ) for a product containing lonafarnib for entity and progeroid laminopathies .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|disease|Platelet AND Diabetes psoriasis Disease|mammals man adulthood primates vertebrates|progeria|that progerin may make the nucleus unstable , and that cellular instability may lead to the process of premature aging in entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|Platelet AND Diabetes psoriasis Disease|anemia box uremic spot adrenal|progeria|hutchinson-gilford entity syndrome ( entity ) overview ultra-rare , fatal , premature aging pediatric disease point mutation in the lamin a gene results in a farnesylated aberrant protein ,
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Platelet AND Diabetes psoriasis Disease|SCD autism T1D DMD AIDS|progeria|children with entity die of the same heart disease that affects millions of normally aging adults ( arteriosclerosis ) , but at an average age of
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|Platelet AND Diabetes psoriasis Disease|NSCLC psoriasis CML CLL CRC|progeria|as a result we may not successfully obtain approval by the fda of an nda for lonafarnib for entity in the near term , or at all .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|dizziness nausea vomiting diarrhea hypotension|hydrocephalus|two events occurred in one patient , these were headache and entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|hydrocephalus idiopathic intractable ICP neurogenic|hydrocephalus|prevents obstruction in the cerebrospinal fluid ( csf ) catheters implanted in the ventricle of the brain of patients who suffer from entity or normal pressure hydrocephalus ( nph ) .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|advancement tendon shunt conjunctival arteriovenous|hydrocephalus|we believe that our cerebral spinal fluid ( csf ) pressure management product line , including the advanced orbis sigma ii entity shunt , is unsurpassed in the industry .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|Conventional Existing Surgical Modern Aortic|hydrocephalus|entity shunt designs have changed little since their introduction in the 1950s .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|ataxia headache hydrocephalus headaches nystagmus|hydrocephalus|bone sclerosis impinges cranial nerve and spinal foramina with resulting neurologic abnormalities , including entity , progressive blindness and auditory impairment .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|coagulopathy thrombocytopenia Mortality Stroke DIC|hydrocephalus|entity has also been reported in children with severe hypoplasminogenemia , apparently related to the deposition of fibrin in the cerebral ventricular
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|ulcers hydrocephalus ulcer gait headache|hydrocephalus|the same condition , known as normal pressure entity ( nph ) , presented mostly in the elderly population , causing thinking and reasoning problems , difficulty walking , etc .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|COVID ICD supra Long infra|hydrocephalus|implantable drainage valve for treatment of entity - french patent application no . 9306356 filed june 27 , 1993 ( docket 91087 ) .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|ascites aneurysms tumours burns cysts|hydrocephalus|this slow accumulation means that the fluid pressure may not be as high as in other types of entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|hydrocephalus PDA AIS AVM AAA|hydrocephalus|wayne state university , which supports the scstms potential as a viable technology for preventing occlusion in shunts used to treat entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|anemia hypoglycemia gliomas TBI spasticity|hydrocephalus|shunts in the brain to help drain excess csf either externally or into the body for reabsorption to help treat entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|Birth Obesity Diabetes India Disease|hydrocephalus|entity occurs in about 1 in every 500 births in the u . s . alone1 , 2 over 1 , 000 , 000 people in the united states currently
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|CRC IBD FO colitis diarrhea|hydrocephalus|microbot is developing scs as a device for the treatment of entity and nph and is developing tipcat as an endoscopic tool , with colonoscopy as the most immediate application of the tipcat
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|hydrocephalus ICP obstructive idiopathic OSA|hydrocephalus|virob platform , microbot is currently developing its first product candidate : the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|hydrocephalus meningitis swelling spasticity eg|hydrocephalus|tuberous sclerosis complex is also associated with a variety of resulting disorders including seizures , swelling in the brain ( entity ) , developmental delays and skin lesions , , .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|hydrocephalus Hypertension HH AVM Surgery|hydrocephalus|entity is most often treated by the surgical insertion of a shunt system .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|allergy glaucoma neuropathy headache intolerance|hydrocephalus|mannitol injection entity , glaucoma , edema caused by deep burning or scald , acute renal failure and ascites .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|migraine osteoporosis spasticity prolapse scoliosis|hydrocephalus|silicone products , state of the art implanted application systems for spinal opiates and market leading valve systems for treatment of entity .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|hydrocephalus obstructive ICP idiopathic shunt|hydrocephalus|using the virob platform , microbot is currently developing the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('DIS', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|hydrocephalus glioma malformation meningitis encephalopathy|hydrocephalus ascites anemia aneurysms DIC|hydrocephalus|the proposed indication for use of the scs device would be for the treatment of entity as a component of a shunt system when draining or shunting of csf is indicated .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|metformin AND uncontrolled mellitus hypothyroidism|ovulation alopecia menopause infertility puberty|hyperprolactinemia|both sgas and fgas can cause entity , a hormonal imbalance resulting from d2 receptor blockade , which can lead to enlargement of breast tissue in males and infertility .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2), ('DRUG', 1)])|disease|metformin AND uncontrolled mellitus hypothyroidism|hypercalcemia osteoporosis hyperparathyroidism prolactin anemia|hyperprolactinemia|x213 could be developed to treat entity in prolactinomas , a condition of benign tumors on the pituitary gland that leads to sexual dysfunction , infertility , and osteoporosis .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|metformin AND uncontrolled mellitus hypothyroidism|Cohort Part Day Cycle stratum|hyperprolactinemia|treated for potential oncology indications for up to 48 weeks ; doses up to 20x higher than expected clinical dose for entity 1 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|disease|metformin AND uncontrolled mellitus hypothyroidism|osteoporosis psoriasis migraine hypothyroidism scleroderma|hyperprolactinemia|by fda for use in humans for more than 15 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|metformin AND uncontrolled mellitus hypothyroidism|aging tomorrow prematurity ageing infancy|hyperprolactinemia|corporation ) , and we exercised our right to bring the product back into our portfolio to develop it for diseases of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|metformin AND uncontrolled mellitus hypothyroidism|pheochromocytoma hypothyroidism migraine neuroblastoma hyperthyroidism|hyperprolactinemia|respect to the other approved indications , and bromocriptine remains on the market for the treatment of parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|metformin AND uncontrolled mellitus hypothyroidism|NSCLC IBD psoriasis CRC COPD|hyperprolactinemia|finalized the design of a proof-of-concept study for xoma 213 , which may offer a new therapeutic option for patients with entity , and anticipate initiating the study midyear .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|disease|metformin AND uncontrolled mellitus hypothyroidism|migraine osteoporosis glioblastoma psoriasis mesothelioma|hyperprolactinemia|upjohn announced nda submissions to the fda for pramipexole for parkinson  s disease , remisar ( r ) for bladder cancer and dostinex ( r ) ( cabergoline ) for entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|metformin AND uncontrolled mellitus hypothyroidism|dyskinesia tremor parkinsonism ataxia delirium|hyperprolactinemia|this mechanism likely contributes to the favorable safety profile of iti-007 , with reduced risk for entity , akathisia , extrapyramidal symptoms , and other motoric side effects .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|metformin AND uncontrolled mellitus hypothyroidism|tolerability dyskinesia neuroprotection neurotoxicity Safety|hyperprolactinemia|the favorable safety profile of iti-007 with reduced risk for akathisia , extrapyramidal side effects and other motoric side effects , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|metformin AND uncontrolled mellitus hypothyroidism|insomnia migraine ADHD psoriasis alcoholism|hyperprolactinemia|cabergoline was recently launched in certain european countries for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|metformin AND uncontrolled mellitus hypothyroidism|supplementation sedation olanzapine restriction dosing|hyperprolactinemia|iti- 2 007 likely contributes to its favorable clinical profile with motoric tolerability similar to placebo and without entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|disease|metformin AND uncontrolled mellitus hypothyroidism|osteoporosis psoriasis fibromyalgia migraine hypothyroidism|hyperprolactinemia|approved by fda for use in humans for approximately 20 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|disease|metformin AND uncontrolled mellitus hypothyroidism|trastuzumab everolimus capecitabine tamoxifen docetaxel|hyperprolactinemia|our endocrine portfolio also includes a phase 2-ready product candidate , xoma 213 , targeting the prolactin receptor , and entity , and multiple research-stage programs .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|metformin AND uncontrolled mellitus hypothyroidism|insomnia TS migraine GH hyperthyroidism|hyperprolactinemia|inhibit prolactin secretion with no reported effect on other pituitary hormones and are therefore generally the drugs of choice for entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|metformin AND uncontrolled mellitus hypothyroidism|Conclusion Conclusions Note CONCLUSIONS Objective|hyperprolactinemia|entity : as with other drugs that antagonize dopamine d2 receptors , fanapttm elevates prolactin levels .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|mellitus AND uncontrolled nervosa neuropathy|SCD ALL autism IBD CKD|hypophosphatasia|asfotase alfa has shown very compelling phase ii clinical data in infants and juveniles with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 2)])|disease|mellitus AND uncontrolled nervosa neuropathy|osteoporosis periodontitis osteoclasts arthritis neoplasia|hypophosphatasia|we note that other examples of animal models of bone disease such as osteoporosis and entity have previously translated in vivo findings into the clinic .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|mellitus AND uncontrolled nervosa neuropathy|hemophilia osteoporosis preeclampsia anemia fibromyalgia|hypophosphatasia|time investing in preparations for the anticipated 2015 launch of our second commercial product , asfotase alfa for the treatment of entity ( hpp ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|na ex Hb log van|You Med Be Do Sa|kuru|and related stockholder matters market information our common stock is traded on the nasd  s over-the-counter bulletin board under the symbol " entity ob " since november 6 , 2008 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis AND psychosis neuropathy vulgaris|Other whose Severe mellitus AND|leprechaunism| type a and type b syndrome  rabson-mendenhall syndrome  entity type a syndrome patients have high circulating concentrations of insulin with impaired glucose tolerance or diabetes .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|psoriasis AND psychosis neuropathy vulgaris|autism hypoglycemia PCOS NIDDM hypothyroidism|leprechaunism|defects in the insulin receptor or insulin signaling pathways and include type a and type b syndromes , rabson-mendenhall syndrome and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis AND psychosis neuropathy vulgaris|scleroderma migraine autism hypothyroidism psoriasis|leprechaunism|these conditions include :  type a and type b syndrome ,  rabson-mendenhall syndrome , and  entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Malignant extremity dysplasia hemangioma Known|inv translocation trisomy pheochromocytoma glioblastoma|lymphangioleiomyomatosis|the exist-2 study will evaluate everolimus in patients with angiomyolipoma associated with either ts or sporadic entity ( lam ) 9 .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|neuroblastoma GCT glioma osteosarcoma medull|astrocytoma glioblastoma meningioma glioma meningiomas|medulloblastoma|the following tumor types were treated thus far : high-grade glioma , entity , neuroblastoma , and ependymoma .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|neuroblastoma GCT glioma osteosarcoma medull|retinoblastoma neuroblastoma mesothelioma glioblastoma glioma|medulloblastoma|of five childhood cancers typically treated with intensive cisplatin therapy , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuroblastoma GCT glioma osteosarcoma medull|glioblastoma neuroblastoma retinoblastoma astrocytoma gliomas|medulloblastoma|the work at nih has now extended to the most common brain tumor of children , entity , and to the most common cancer of children , neuroblastoma .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuroblastoma GCT glioma osteosarcoma medull|glioblastoma astrocytoma retinoblastoma gliomas neuroblastoma|medulloblastoma|the work at nih was then extended to the most common brain tumor of children , entity , and to the most common extracranial solid tumor of children , neuroblastoma .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|disease|neuroblastoma GCT glioma osteosarcoma medull|glioblastoma glioma mesothelioma osteosarcoma neuroblastoma|medulloblastoma|in addition , compounds from both series have anti-cancer activity in animal models of glioblastoma multiforme , neuroblastoma , and entity , all cancers of neural tissue .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuroblastoma GCT glioma osteosarcoma medull|meningioma glioblastoma astrocytoma glioma neuroblastoma|medulloblastoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , entity , and malignant meningioma .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|neuroblastoma GCT glioma osteosarcoma medull|glioblastoma astrocytoma glioma meningioma meningiomas|medulloblastoma|joint patent applications with nih have been filed for the treatment of glioblastoma multiforme , entity , and neuroblastoma .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|neuroblastoma GCT glioma osteosarcoma medull|retinoblastoma neuroblastoma mesothelioma glioblastoma glioma|medulloblastoma|of one of five childhood cancers typically treated with intensive cisplatin therapy , including hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|neuroblastoma GCT glioma osteosarcoma medull|colorectal uterine NSCLC mammary endometrium|medulloblastoma|in 2016 , the fda also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|neuroblastoma GCT glioma osteosarcoma medull|ct NSCLC R0 AND id|medulloblastoma|ii - paragon-hf to start aug . 2014 29 lde225 solid tumors ≥ 2018 i entity ≥ 2018 iii lee011 breast cancer 2016 iii - phase iii registration study enrolling solid tumors ≥
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|neuroblastoma GCT glioma osteosarcoma medull|glioblastoma neuroblastoma astrocytoma osteosarcoma meningioma|medulloblastoma|sl-301 has demonstrated activity against brain and pancreatic cscs and tumor bulk in vitro , and against glioblastoma and entity cscs in in vivo animal models .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|neuroblastoma GCT glioma osteosarcoma medull|gliomas neuroblastoma glioma GBM glioblastoma|medulloblastoma|have presented data indicating that val-083 offers potential therapeutic alternatives for the treatment of pediatric brain tumors including shh-p53 mutated entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|neuroblastoma GCT glioma osteosarcoma medull|NSCLC IBD SCD ALL CRC|medulloblastoma|phase i clinical trials that are designed to evaluate dose and safety of gdc-0449 in pediatric and adult patients with entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|disease|neuroblastoma GCT glioma osteosarcoma medull|zebrafish CSCs astrocytes microglia MSCs|medulloblastoma|emory studies so far have indicated that entity may be particularly vulnerable to the ability of wp1066 to block the activated form of stat3 , a key signaling protein
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|neuroblastoma GCT glioma osteosarcoma medull|mesothelioma glioblastoma NSCLC lymphomas glioma|medulloblastoma|treated with intensive cisplatin therapy for localized and disseminated disease , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuroblastoma GCT glioma osteosarcoma medull|glioblastoma meningioma glioma astrocytoma neuroblastoma|medulloblastoma|no conventional therapy exists , or a relapsed brain tumor with a predilection for lm dissemination ( primitive neuroectodermal tumor , rhabdoid tumor , entity ) .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|neuroblastoma GCT glioma osteosarcoma medull|colorectal uterine NSCLC mammary endometrium|medulloblastoma|the fda has also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuroblastoma GCT glioma osteosarcoma medull|glioblastoma glioma astrocytoma neuroblastoma gliomas|medulloblastoma|pre-clinical studies of lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , entity and malignant meningioma .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|neuroblastoma GCT glioma osteosarcoma medull|NSCLC mesothelioma glioblastoma GIST CRC|medulloblastoma|we have been granted orphan drug designation in the united states for gbm , ovarian cancer , and entity , and in europe for gbm .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|meningioma glioma meningiomas NOS GCT|glioma meningioma gliomas astrocytoma mesothelioma|meningioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , medulloblastoma , and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|disease|meningioma glioma meningiomas NOS GCT|glioblastoma glioma gliomas neuroblastoma meningiomas|meningioma|in february 2012 , the fda granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|meningioma glioma meningiomas NOS GCT|glioblastoma glioma gliomas neuroblastoma migraine|meningioma|the fda has granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|meningioma glioma meningiomas NOS GCT|glioblastoma meningioma glioma meningiomas astrocytoma|meningioma|in addition , preclinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness , neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|meningioma glioma meningiomas NOS GCT|meningioma glioblastoma glioma meningiomas astrocytoma|meningioma|in addition , pre-clinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|meningioma glioma meningiomas NOS GCT|meningioma meningiomas glioma astrocytoma hemangioma|meningioma|entity and schwannoma are rare , benign tumors that can present in different locations within the brain and the spinal cord and
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|meningioma glioma meningiomas NOS GCT|glioma meningioma astrocytoma gliomas glioblastoma|meningioma|intend to collaborate with ohio state to conduct a phase 0 investigator-initiated study of ar-42 in patients with schwannoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|disease|meningioma glioma meningiomas NOS GCT|NSCLC PCa meningioma glioma osteosarcoma|meningioma|this patient was a 61-year-old female that was subsequently diagnosed with a non-treatment related entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|meningioma glioma meningiomas NOS GCT|glioma gliomas astrocytoma glioblastoma meningioma|meningioma|lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , medulloblastoma and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|disease|meningioma glioma meningiomas NOS GCT|glioblastoma glioma gliomas neuroblastoma osteosarcoma|meningioma|in preclinical studies , ar-42 has demonstrated anti-tumor activity in both entity and schwannoma .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|comorbidities illnesses PCa infertility pathologies|obesity|in the majority of these men , often with co-morbid entity , t replacement is not optimal and indeed may be counterproductive .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|tax credit financial cash educational|obesity|eps growth  restating 2012 to exclude the 2012 entity impact of $0 . 10 and including the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|approved investigational allergy intended oncologic|obesity|development of the pyy compound and has recently announced that it expects to file an ind on pyy for an entity indication in 2003 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|randomised multicenter pivotal pragmatic Randomized|obesity|exhibit 99 . 01 regeneron initiate phase ii entity clinical trial tarrytown , new york ( march 28 , 2000 ) - regeneron pharmaceuticals , inc . ( nasdaq : regn ) announced that it has initiated a
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|anemia worldwide anaemia SCD MDS|obesity|with open-label one year extensions , and was planned to include approximately four to six patients with genetically confirmed pomc deficiency entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|reproductive fertility contraception erectile gynecologic|obesity|-k . about vivus vivus , inc . is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing entity and sexual health .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|osteoporosis acne infertility insomnia migraine|obesity|the company also has drug candidates or development programs for entity , erectile dysfunction , cardiovascular diseases , pulmonary diseases , inflammatory diseases and dermatologic diseases .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|another competitive government financial zero|obesity|strong business momentum continues to accelerate sales & eps growth * sales growth in local currency retrospectively adjusted to exclude entity intervention business .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|Lead launched track hit company|obesity|in addition , outsourced clinical expenses in the companys entity program increased by $0 . 3 million in 2007 for phase 1 clinical trials on the companys lead compound , ngd-4715 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|ADHD AUD T2DM migraine NAFLD|obesity|tolerability of topiramate , which was the scientific rationale for combining these two agents at low doses for the treatment of entity and related co-morbidities .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|chair assistant nurse leader king|obesity|dr . amatruda was the senior vice president and franchise head , diabetes and entity at merck research laboratories .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|tax credit financial cash educational|obesity|* 2012 eps growth includes the 2012 entity impact of $0 . 10 and the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|hyperglycemia comorbidities osteoporosis anemia aging|obesity|axokine is being developed for the treatment of entity and complications of entity such as type ii diabetes .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|aging nutrition hormones menopause toxins|obesity|incontinence may be caused by a wide range of factors , including childbirth , menopause , surgery , entity , drugs and neurological damage .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|hyperglycemia stressors periodontitis environmentally metabolically|obesity|academic researchers have increasingly linked chronic entity induced inflammation with type 2 diabetes and the potential role of inflammation in promoting insulin resistance in type 2 diabetes
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|curves curvature graph slopes rings|obesity|● increased waist circumference ( central or apple-shaped entity ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|OSA insomnia AN T2DM NAFLD|obesity|about orexigen therapeutics orexigen therapeutics , inc . is a biopharmaceutical company focused on the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|SLE autoimmunity CRC preeclampsia IBD|obesity|we believe that this discovery indicates that overactivity of this gpcr may be associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|NSCLC psoriasis CRC T2DM angiogenesis|obesity|the companys lead combination product candidates targeted for entity are contrave , which is in phase 3 clinical trials , and empatic , which is in the later stages of phase 2
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|AND uncontrolled hyperlipidemia mellitus dyslipidemia|NAFLD MetS T2D adiposity CVD|obesity|conversely , transgenic mice that overexpress dgat-1 in adipose tissue are predisposed to entity when fed a high-fat diet and have elevated levels of circulating free fatty acids .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|disease|osteoporosis AND BMD mellitus vertebral|CRC AIDS osteoporosis cholera CVD|osteoporosis|the revenue decline in the second quarter largely reflects lower sales of fosamax for the treatment and prevention of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis AND BMD mellitus vertebral|hospitalized burn geriatric COPD hypertensive|osteoporosis|ystps trademarks xiangbala jidan and zangyu in particular are well recognized in china among physicians and hospital administrators , pharmacists and entity patients .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis AND BMD mellitus vertebral|newer approved adjunctive innovative hormonal|osteoporosis|other entity therapies include estrogen replacement therapy , selective estrogen receptor modulators , bisphosphonates and several new biologics that are under development .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|osteoporosis AND BMD mellitus vertebral|angina dementia osteoporosis cardiomyopathy COPD|osteoporosis|and outcomes management programs targeted at major categories of disease commonly found in the elderly , such as congestive heart failure , entity and atrial fibrillation .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|osteoporosis AND BMD mellitus vertebral|BMD osteoporosis PTH hypercalcemia remission|osteoporosis|a key set of parameters in the monitoring of entity , both before and after therapy , are biochemical markers of bone metabolism .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|osteoporosis AND BMD mellitus vertebral|rhinitis asthmatics COPD allergy convenience|osteoporosis|under the asset purchase agreement , par acquired certain assets pertaining to calcitonin nasal spray for entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|osteoporosis AND BMD mellitus vertebral|osteoporosis acne infertility complaints insomnia|osteoporosis|and estraderm mx ( estradiol ) transdermal patches are treatments for symptoms of estrogen deficiency in post-menopausal women , and prevention of post-menopausal entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|osteoporosis AND BMD mellitus vertebral|osteoporosis hyperparathyroidism arthritis CKD hypercalcemia|osteoporosis|▪ approved for treatment of adult entity ▪ synthetic analogues of pyrophosphate ▪ inhibit bone resorption ▪ can be given orally or intravenously , depending on compound ▪
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|osteoporosis AND BMD mellitus vertebral|hypercholesterolemia obese hypoglycemia preeclampsia hyperlipidemia|osteoporosis|portfolio will include two drug candidates in advanced clinical trials for the treatment of types 1 and 2 diabetes , severe entity and polycystic ovary syndrome .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|osteoporosis AND BMD mellitus vertebral|sarcopenia osteoporosis frailty aging malnutrition|osteoporosis|currently in preclinical development as a potential treatment for age-related muscle loss , frailty , weight loss associated with cancer cachexia and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis AND BMD mellitus vertebral|nutrition reproduction aging allergy physiology|osteoporosis|since 1990 , he has been the organizer and chairman of the international symposia on nutrition and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis AND BMD mellitus vertebral|psychology ethics psychiatry pharmacology genetics|osteoporosis|he is treasurer of the international foundation of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis AND BMD mellitus vertebral|providers clients stakeholders equipment initiatives|osteoporosis|also organize free community healthcare activities , such as arranging for bone density tests and organizing seminars on our products and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis AND BMD mellitus vertebral|TBI burn COPD burns OSA|osteoporosis|we believe this study population contains a patient population reflective of the type of severe entity patients that specialists will treat in their practices .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|disease|osteoporosis AND BMD mellitus vertebral|dyslipidemia insomnia hypercholesterolemia hyperlipidemia dementia|osteoporosis|we also anticipate using our sales force to promote pharmaceutical products that address other midlife conditions such as hypertension , entity , depression and incontinence .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|osteoporosis AND BMD mellitus vertebral|malignancies arrhythmias strokes allergies neoplasms|osteoporosis|is also associated with a wide range of adverse events , including high blood pressure , weight gain , diabetes , serious infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|osteoporosis AND BMD mellitus vertebral|osteoporosis CHF AN HCM migraine|osteoporosis|company and sb will continue to work together to develop one or more novel therapeutic approaches to the treatment of entity utilizing the company  s calcium receptor technology .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteoporosis AND BMD mellitus vertebral|allergy alopecia kel ROP psoriasis|osteoporosis|we have licensed worldwide rights to our manufacturing and delivery technologies for pth for the treatment of entity to gsk .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|osteoporosis AND BMD mellitus vertebral|insomnia psoriasis osteoporosis COPD OSA|osteoporosis|pursuant to a tenth amendment , we have been granted the exclusive right to negotiate an expansion of the field of use to include treatment of entity ( the &#8220 ; option&#8221 ; ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis AND BMD mellitus vertebral|syphilis AIDS influenza varicella oncology|osteoporosis|hepatitis c , and multiple sclerosis business categories , as well as other lower margin business categories , including human immunodeficiency virus and entity , versus the prior year .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma pheochromocytoma meningioma glioma glioblastoma|paraganglioma|we will make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma lymphomas pheochromocytoma NSCLC glioma|paraganglioma|administration ( fda ) has designated azedra as a breakthrough therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|neuroblastoma GCT arising NOS originating|another entered planned undergo randomised|paraganglioma|agent for prostate cancer phase 2 testing completed azedra™ treatment of pheochromocytoma and entity phase 2b registrational trial under special protocol assessment ( spa ) relistor®
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma glioblastoma NSCLC lymphomas GIST|paraganglioma|study of azedra demonstrating a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers , pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma meningioma NSCLC pheochromocytoma glioma|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma glioblastoma pheochromocytoma cholangiocarcinoma NSCLC|paraganglioma|a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|neuroblastoma GCT arising NOS originating|ET NET PTC pheochromocytoma ACC|paraganglioma|to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with pheochromocytoma / entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|neuroblastoma GCT arising NOS originating|colorectal neuroendocrine testicular urothelial uterine|paraganglioma|twenty-four subjects were enrolled ( 11 female , 13 male ) , and seven subjects experienced stable disease in breast , neuroendocrine , entity , head / neck or colorectal cancer .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|neuroblastoma GCT arising NOS originating|adrenal sporadic classic true retroperitoneal|paraganglioma|about pheochromocytoma and entity pheochromocytomas and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|neuroblastoma GCT arising NOS originating|pheochromocytoma meningioma neuroblastoma GIST NSCLC|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity , an ultra-orphan indication .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|neuroblastoma GCT arising NOS originating|pheochromocytoma neuroblastoma GIST NSCLC cholangiocarcinoma|paraganglioma|under compassionate use and named patient programs in 10 european countries in almost 1 , 300 patients , including those with pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|neuroblastoma GCT arising NOS originating|colorectal testicular glioma mesothelioma neuroblastoma|paraganglioma|or disease stabilization was observed in several cancer types , including parotid gland adenocarcinoma , colon , kaposi  s sarcoma , melanoma , ovarian , pancreatic and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|neuroblastoma GCT arising NOS originating|glioma neuroblastoma meningioma glioblastoma GIST|paraganglioma|dysregulation of hif-2α under pseudohypoxia is thought to contribute to pah and entity , a neuroendocrine tumor .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma lymphomas pheochromocytoma glioblastoma GIST|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine tumors .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma lymphomas pheochromocytoma glioblastoma GIST|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma meningioma pheochromocytoma NSCLC glioma|paraganglioma|candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma pheochromocytoma carcinoid carcinomas glioblastoma|paraganglioma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable pheochromocytoma and entity , which are rare neuroendocrine tumors .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|neuroblastoma GCT arising NOS originating|neuroblastoma lymphomas adenocarcinoma GIST ACC|paraganglioma|other than azedra , there are currently no approved anticancer treatments in the u . s . for malignant , recurrent , and / or unresectable pheochromocytoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|neuroblastoma GCT arising NOS originating|testicular hepatocellular mesothelioma retinoblastoma neuroblastoma|paraganglioma|stable disease was observed in several cancer types , including melanoma , ovarian , kaposi  s sarcoma , angiosarcoma , parotid gland adenocarcinoma , colorectal , pancreatic and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|AND neuropathy Known vulgaris mellitus|Systematic Critical Annual Open Ongoing|phenylketonuria|camp km , et al . entity scientific review conference : state of the science and future research needs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|AND neuropathy Known vulgaris mellitus|STEMI ICH CNV rt ISR|phenylketonuria|table of contents until march 2020 , we had been developing rtx-134 for the treatment of entity , or pku .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|AND neuropathy Known vulgaris mellitus|Gene Genes du del PTEN|phenylketonuria|page 2 of 3 about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 1)])|disease|AND neuropathy Known vulgaris mellitus|hemophilia thalassemia homozygous G6PD heterozygous|phenylketonuria|kuvan is a commercialized product for the treatment of patients with entity ( pku ) and / or for primary bh4 deficiency in certain countries .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|disease|AND neuropathy Known vulgaris mellitus|T2DM NAFLD osteoporosis hypercholesterolemia dyslipidemia|phenylketonuria|privately held biotechnology company focused on developing therapies for orphan metabolic diseases , to evaluate sepiapterin ( " cnsa-001 " ) for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|AND neuropathy Known vulgaris mellitus|glioblastoma AIDS hemophilia CKD CML|phenylketonuria|company will use intrexons technology relating to the development and commercialization of novel biotherapeutics for the treatment of patients with entity ( pku ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|AND neuropathy Known vulgaris mellitus|NSCLC CRC STEMI GBM glioblastoma|phenylketonuria|or in-license are currently pending patent applications except that we own one issued u . s . patent directed to methods of treating entity with rtx-134 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|AND neuropathy Known vulgaris mellitus|T2DM NAFLD dyslipidemia hyperlipidemia T2D|phenylketonuria|privately held biotechnology company focused on developing therapies for the orphan metabolic diseases , is developing cnsa-001 for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|AND neuropathy Known vulgaris mellitus|pay anyone yourself private trade|phenylketonuria|· october 1 , 2015 , biomarin to acquire rights to entity ( pku ) franchise from merck serono : the company announced that it has entered into a definitive agreement to acquire all
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|AND neuropathy Known vulgaris mellitus|psoriasis glioblastoma CLL Diabetes glioma|phenylketonuria|• pegvaliase for entity ( pku ) : pivotal results for the phase 3 prism-2 study ( formerly referred to as 165-302 ) that pegvaliase met the primary endpoint
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|AND neuropathy Known vulgaris mellitus|hemophilia AIDS psoriasis glioblastoma retinoblastoma|phenylketonuria|investigational product candidates include phenoptin ( sapropterin hydrochloride ) , a phase 3 product candidate for the treatment of entity ( pku ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|AND neuropathy Known vulgaris mellitus|publication Europe Germany Canada Medicare|phenylketonuria|and in the third quarter of 2017 , both france and germany had their first commercial sales . • kuvan® for entity :
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND neuropathy Known vulgaris mellitus|variant falciparum homozygous glycoprotein Mutations|phenylketonuria|about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|AND neuropathy Known vulgaris mellitus|1a IIa iii vi 2b|phenylketonuria|mucopolysaccharidosis iv type a , or mps iva mucopolysaccharidosis vi , or mps vi entity , or pku 6 kuvan has been granted orphan drug status in the eu , which together with pediatric
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|AND neuropathy Known vulgaris mellitus|hypercholesterolemia adiposity CVD NAFLD MetS|phenylketonuria|substantial progress has been made over the past six decades , beginning with the first report of dietary control of entity in the early 1950s .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|AND neuropathy Known vulgaris mellitus|thalassemia SCD encephalopathy autism neuropathy|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad ) and entity ( mead johnson phenyl-free ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|AND neuropathy Known vulgaris mellitus|encephalopathy thalassemia SCD neuropathy constipation|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad® ) and entity ( mead johnson phenyl-free® ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|AND neuropathy Known vulgaris mellitus|homozygous variant Phe heterozygous delta|phenylketonuria|about entity ( pku ) pku is caused by a defect in the gene encoding phenylalanine hydroxylase ( pah ) , a liver enzyme that metabolizes phe .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|pheochromocytoma meningioma carcinoid adenoma neuroblastoma|pheochromocytoma|we will make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|gliomas glioma mesothelioma lymphomas melanomas|pheochromocytoma|azedra program " means the company  s therapeutic program for the treatment of malignant entity , pediatric neuroblastoma and carcinoid cancers with ultratrace iobenguane i 131 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|pheochromocytoma GIST neuroblastoma NET ACC|pheochromocytoma|trial to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with entity / paraganglioma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|adenomas pheochromocytoma GIST carcinomas adenocarcinomas|pheochromocytoma|although the majority of entity and paragangliomas are benign , approximately 10-25% of these tumors present with metastasis , and up to 35% of these cases are
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|ALL neuroblastoma MDS CML glioblastoma|pheochromocytoma|we are currently pursuing adult clinical trials for entity and pediatric clinical trials for neuroblastoma , which are detailed below .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|neuroblastoma ALL glioblastoma glioma malignancies|pheochromocytoma|the company is conducting azedra pivotal trials for both adult entity and pediatric neuroblastoma neuroendocrine tumor indications .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|glioblastoma glioma neuroblastoma NSCLC colorectal|pheochromocytoma|azedra clinical development plan azedra is under development for the systemic treatment of the metastatic neuroendocrine cancers entity and neuroblastoma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|pheochromocytoma carcinoid meningioma GIST adenoma|pheochromocytoma|to become a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|pheochromocytoma glioma meningioma GIST gliomas|pheochromocytoma|that the first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant entity and paraganglioma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|pheochromocytoma glioma meningioma mesothelioma gliomas|pheochromocytoma|two product candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant entity and paraganglioma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|carcinoid neuroendocrine colorectal NET GI|pheochromocytoma|azedra is currently in a phase 1 trial for entity or carcinoid tumors , and has received orphan drug status and a fast track designation by the united states food and
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|pheochromocytoma GIST carcinoid neuroblastoma NET|pheochromocytoma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable entity and paraganglioma , which are rare neuroendocrine tumors .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|pheochromocytoma carcinoid adenomas neoplasms tumours|pheochromocytoma|about entity and paragangliomas entitys and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|pheochromocytoma GIST neuroblastoma glioma NET|pheochromocytoma|perelman school of medicine presented preliminary dosimetry data from the phase 2 study in patients with iobenguane-avid metastatic and / or recurrent entity / paraganglioma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|neuroblastoma hippocampal hepatoma glioma striatal|pheochromocytoma|pharmacology 2005 ; 74 : 65-78 . " local anesthetic procaine protects rat entity pc12 cells against beta-amyloid-induced neurotoxicity " .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|pheochromocytoma GIST neuroblastoma carcinoid lymphomas|pheochromocytoma|in addition to potentially treating entity and paraganglioma , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|pheochromocytoma neuroblastoma carcinoid AND adenocarcinoma|RCC pheochromocytoma adenocarcinoma meningioma GIST|pheochromocytoma|patients harboring a rare head and neck cancer , known as paraganglioma , and a rare adrenal or extra-adrenal cancer , known as entity , and rare subset clear cell rcc .
OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|glioma neuroblastoma GCT prolactin pheochromocytoma|Diabetes Obesity PSP Carcinoma Pregnancy|prolactinoma|entity is a condition in which a non-cancerous tumor of the pituitary gland overproduces prolactin .
OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|glioma neuroblastoma GCT prolactin pheochromocytoma|psychosis mania risperidone monotherapy olanzapine|prolactinoma|study for xoma 213 , which , if successful , will allow us to advance the compound into a phase 2 study for entity and potentially into anti-psychotic medication-induced hyperprolactinemia .
OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glioma neuroblastoma GCT prolactin pheochromocytoma|evaluable psoriasis hospitalized obese registered|prolactinoma|for ten percent of the 140 , 000 entity patients in the united states , existing therapies are poorly tolerated or not effective .
OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|glioma neuroblastoma GCT prolactin pheochromocytoma|PSP ACC TS HH PAC|prolactinoma|entity is a condition of benign tumors on the pituitary gland .
OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|glioma neuroblastoma GCT prolactin pheochromocytoma|cure discontinuation remission hypoglycaemia dosing|prolactinoma|we intend to move xoma 213 into clinical development , initially for symptomatic entity potentially followed by medication-induced hyperprolactinemia .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|Cholesterol Hepatic triglycerides hyperlipidemia hypercholesterolemia|sham forehead spray swallow capsule|sitosterolemia|treatment experience with zetia in the pediatric population is limited to 4 patients ( 9 to 17 years ) in the entity study and 5 patients ( 11 to 17 years ) in the hofh study .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Cholesterol Hepatic triglycerides hyperlipidemia hypercholesterolemia|AIDS SCD vasculitis KD PAD|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain blood test results .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Cholesterol Hepatic triglycerides hyperlipidemia hypercholesterolemia|autism ADHD survived hypothyroidism diarrhea|sitosterolemia|this finding indicated that the infant definitely has entity , despite the prior contradictory test results .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Cholesterol Hepatic triglycerides hyperlipidemia hypercholesterolemia|scleroderma COPD AIDS SLE fibromyalgia|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain test results .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|Cholesterol Hepatic triglycerides hyperlipidemia hypercholesterolemia|hypercholesterolemia FH KD WT variant|sitosterolemia|treatment experience with ezetimibe in the pediatric population is limited to 4 patients ( 9 to 17 years ) with homozygous entity and 5 patients ( 11 to 17 years ) with hofh .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|disease|vulgaris psoriasis AND acne Severe|buprenorphine morphine methadone benzodiazepines opioids|trichotillomania|patent claims the use of opioid antagonists , including nalmefene , for the treatment of impulse control disorders with the exception of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vulgaris psoriasis AND acne Severe|migraine addiction autism psoriasis acne|trichotillomania|dr . blochs research interests focus on studying tourette syndrome , ocd , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|vulgaris psoriasis AND acne Severe|tic del ph aph ros|trichotillomania|yale school of medicine - n oted researcher on the study of tourette syndrome , obsessive - compulsive disorder and entity prof . daniele piomelli
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|vulgaris psoriasis AND acne Severe|tar honey ey fire ticks|trichotillomania|dr . blochs research interests focus on studying ts , ocd , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|psoriasis urticaria acne eczema rhinitis|vitiligo|has registered a variety of domain names and established an initial website to include in depth information regarding psoriasis , eczema , entity , and the psoria-light device .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|autoantibodies autoimmunity MSI PML Treg|vitiligo|two prior clinical trials of immunotherapies conducted by others suggest that the development of entity was correlated with a favorable response to therapy in melanoma patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|psoriasis BCC AK acne eczema|vitiligo|the enrollment and / or results for a number of phase 2 studies with ati-502 for the topical treatment of aa and entity , including results from its auatb-201 study .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|acne psoriasis dermatitis urticaria eczema|vitiligo|specified dermatological conditions , including alopecia areata , or aa , androgenetic alopecia , or aga , also known as male or female pattern baldness , entity and atopic dermatitis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|acne psoriasis alopecia eczema scleroderma|vitiligo|raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts , alopecia areata , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|acne psoriasis urticaria scleroderma eczema|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the patient significant psychosocial stress .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|acne psoriasis urticaria scleroderma eczema|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the client significant psychosocial stress .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|uveitis headache glaucoma keratitis cataract|vitiligo|to date , some patients have experienced entity and uveitis , but there has been no other evidence of off-target effects associated with til therapy .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|urticaria acne vitiligo psoriasis eczema|vitiligo|pharos 2 excimer laser system is fda-cleared and is used as a tool in the treatment of psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|psoriasis SSc scleroderma vitiligo AIDS|vitiligo|we have demonstrated that plasma from individuals with entity contains anti-melanoma activities , and we are attempting to develop vitigam for the treatment of stage iii and stage iv melanoma .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|urticaria psoriasis eczema vitiligo acne|vitiligo|pharos was granted ce mark clearance in september of 2016 for use in the treatment of psoriasis , entity , atopic dermatitis and leukoderma by the application of uvb ultraviolet light .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|hemophilia SCD AIDS psoriasis scleroderma|vitiligo|vitigam is an igg-based product manufactured from the plasma of donors with entity , a benign skin condition affecting up to 2% of the general population .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|psoriasis dermatitis acne alopecia urticaria|vitiligo|the continued development of arq-151 for atopic dermatitis , arq-154 for seborrheic dermatitis and scalp psoriasis , arq-252 for hand eczema and entity , and arq-255 for alopecia areata .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|NSCLC CRC psoriasis CLL glioblastoma|vitiligo|we plan to commence a phase 2 clinical trial for ati-50002 , for the treatment of entity , in the second half of 2017 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|psoriasis acne eczema urticaria scleroderma|vitiligo|the fda has granted 510 ( k ) clearance to market pharos in the u . s . for psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|restenosis hypoglycemia AKI CIN pCR|vitiligo|as of september 8 , 2011 , entity was observed in four out of 25 ( 16% ) patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|psoriasis scleroderma acne SSc vitiligo|vitiligo|we also plan to develop ati-50001 and ati-50002 as potential treatments for entity , a disorder in which white patches of skin appear on different parts of the body .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|urticaria eczema psoriasis acne dermatitis|vitiligo|otc aoxing ointment walnut meat and camphor used to treat psoriasis , entity and various dermatitis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|Melan SSc Skin scleroderma psoriasis|vitiligo|entity is an autoimmune condition in which the patient  s immune system attacks melanoctyes , the cells responsible for skin pigmentation and potential melanoma cancer cells .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis vulgaris AND pigmentation hypothyroidism|psoriasis acne plaque urticaria vitiligo|vitiligo|developing the xtrac laser system to be the standard of care for psoriasis , and expanded its utilization to include dermatitis , entity and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1), ('DRUG', 1)])|disease|neovascularization GCT DCIS hemangioma Malignant|GIST glioblastoma osteosarcoma retinoblastoma TNBC|angiosarcoma|first quarter highlights , we recently announced the fda has granted us orphan drug designation for oraxol for the treatment of entity , a rare form of malignant blood vessel cancer .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|neovascularization GCT DCIS hemangioma Malignant|NSCLC MM Japan myeloma osteosarcoma|angiosarcoma|a phase 3 study in entity is planned , and stratification of pfs in the phase 2 trial by tumor endoglin expression may identify other sarcoma histologies
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|neovascularization GCT DCIS hemangioma Malignant|psoriasis SSc MBC AE NSCLC|angiosarcoma|¡ in addition , one patient with entity who had a dramatic initial response on skin lesions was not evaluable for response due to death from sepsis ( not
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|neovascularization GCT DCIS hemangioma Malignant|NSCLC SCLC TNBC MBC MM|angiosarcoma|we are also evaluating oral paclitaxel in the treatment of entity and in combination with other therapies , including anti-vegf and anti-pd-1 therapies .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neovascularization GCT DCIS hemangioma Malignant|shorter 24h initiating maintaining stopping|angiosarcoma|cr cr trc105 + votrient is active in entity pfs in 13 vegf inhibitor-naïve patients of 7 . 8 months vs . 3 month pfs expected with votrient most vegf inhibitor patients
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|neovascularization GCT DCIS hemangioma Malignant|SCC melanomas adenocarcinoma MM malignancies|angiosarcoma|in may 2019 , we announced early and complete response data from a clinical study of oral paclitaxel in cutaneous entity , and the study is continuing to enroll .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neovascularization GCT DCIS hemangioma Malignant|India Europe Japan Germany France|angiosarcoma|• announcement of the results of the interim analysis from the phase 3 pivotal tappas trial of trc105 in entity is expected in the second half of 2018 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|neovascularization GCT DCIS hemangioma Malignant|glioblastoma NSCLC glioma GBM GIST|angiosarcoma|we are initially focused on entity which is a tumor that highly expresses endoglin , the target of trc105 , and therefore may be more responsive to treatment
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|neovascularization GCT DCIS hemangioma Malignant|Europe glioblastoma myeloma Japan tandem|angiosarcoma|trc105 is currently being studied in a pivotal phase 3 trial in entity and multiple phase 2 clinical trials , in combination with vegf inhibitors .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|neovascularization GCT DCIS hemangioma Malignant|NSCLC CRC PC RCC GBM|angiosarcoma|efficacy in the phase 3 tappas trial evaluating trc105 in combination with votrient® ( pazopanib ) in patients with advanced or metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|neovascularization GCT DCIS hemangioma Malignant|psoriasis leishmaniasis ulcers vasculitis melanomas|angiosarcoma|xiangxue life sciences ( xlifesc )  reported promising clinical results from a clinical study of oraxol in cutaneous entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1), ('DRUG', 1)])|disease|neovascularization GCT DCIS hemangioma Malignant|osteosarcoma STS MCL glioblastoma GIST|angiosarcoma|a total of five patients with entity , a sarcoma subtype known to express high levels of endoglin , have been evaluated for response in the phase 1b / 2 study .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|disease|neovascularization GCT DCIS hemangioma Malignant|rituximab bevacizumab docetaxel exception imatinib|angiosarcoma|one of these patients , with entity , has an ongoing complete response at month 4 of treatment .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|neovascularization GCT DCIS hemangioma Malignant|osteosarcoma STS MM glioblastoma sarcomas|angiosarcoma|received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue sarcoma , including entity , in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neovascularization GCT DCIS hemangioma Malignant|Japan Europe Korea India France|angiosarcoma|we have leveraged this platform in all of our ongoing clinical trials including our international phase 3 tappas trial in entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|neovascularization GCT DCIS hemangioma Malignant|glioblastoma GBM NSCLC SCLC GIST|angiosarcoma|we are particularly excited by the ongoing complete responses seen in entity , a tumor type known to express high levels of endoglin , and expect to initiate a phase 3 trial in this
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neovascularization GCT DCIS hemangioma Malignant|CRC NSCLC PCa PC malignancies|angiosarcoma| presented preclinical data on oraxol in the treatment of entity at the american association for cancer research ( aacr ) annual meeting on april 3 , 2019  announced acceptance of
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neovascularization GCT DCIS hemangioma Malignant|Japan Europe Taiwan Spain Ethiopia|angiosarcoma|we plan to initiate a phase 3 study in entity in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|neovascularization GCT DCIS hemangioma Malignant|Europe Japan Canada France Germany|angiosarcoma|we have seen complete ongoing responses in these tumor types and plan to initiate initial phase 3 development in entity and an international multicenter phase 2 trial in gtn in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|neovascularization GCT DCIS hemangioma Malignant|NSCLC CRC GBM RCC PC|angiosarcoma|phase 3 tappas trial ( a randomized phase 3 trial of trc105 and pazopanib versus pazopanib alone in patients with advanced entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fever AND chi Paulo para|influenza vaccinia rabies H5N1 investigational|chikungunya|the interim analysis has shown that with a single dose administered , up to 98% of study participants produced a neutralizing antibody response against the entity virus by day 7 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fever AND chi Paulo para|dengue WNV BV CMV rubella|chikungunya|is vector test systems , inc . , vector test systems , inc . markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fever AND chi Paulo para|varicella meningitis allergy etc AIDS|chikungunya|to manufacture virus-like particle based vaccines for third parties for indications other than respiratory viruses , certain allergies , hiv , malaria and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|fever AND chi Paulo para|dengue measles cholera influenza varicella|chikungunya|hds is also in the process of developing the platform for the qualitative testing for other infectious diseases including typhoid , entity , zika and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fever AND chi Paulo para|dengue Salmonella syphilis plague Leishmania|chikungunya|there are also a number of emerging markets for lateral flow tests for infectious diseases such as burkholderia , entity , lassa , leptospirosis , marburg , rickettsia and zika .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fever AND chi Paulo para|JC vaccinia influenza BK dengue|chikungunya|•antibody against entity virus ( mrna-1944 ) : we announced positive interim data in the first analysis of safety and activity in a phase 1 clinical
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|fever AND chi Paulo para|rabies influenza dengue measles cholera|chikungunya|vaxart may consider developing vaccines targeting other infectious diseases including entity , ebola , hepatitis b , herpes simplex virus 2 , or hsv-2 , and venezuelan equine encephalitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|fever AND chi Paulo para|dengue rubella varicella influenza fever|chikungunya|chembio to fund the 12-month development of a dpp® fever panel assay to simultaneously detect malaria , dengue , ebola , lassa , marburg , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|fever AND chi Paulo para|influenza GSK vaccinia dengue measles|chikungunya|solicited aes after each study vaccination for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo % ( no . with
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|fever AND chi Paulo para|dengue WNV CMV BV DENV|chikungunya|is vector test systems inc . vector test systems inc markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests . .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|fever AND chi Paulo para|monoclonal neutralizing adaptive engineered tailored|chikungunya|specifically , the positive phase 1 results from our cmv vaccine and entity antibody programs provide important validation for our approach as we move ahead .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|fever AND chi Paulo para|dengue rubella measles WNV varicella|chikungunya|today announced the signing of a long-term agreement with bio-manguinhos to commercialize chembios poc diagnostic tests for dengue , zika and entity in brazil .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|fever AND chi Paulo para|dengue syphilis rubella varicella measles|chikungunya|expanding beyond sexually transmitted disease , to include future poc tests for fever and tropical diseases such as malaria , dengue , zika , entity , ebola , lassa and marburg .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|fever AND chi Paulo para|vaccinia influenza measles dengue herpes|chikungunya|all subjects reported full resolution by day 4 post vaccination , and thereby distinct from the persistent type observed in post entity virus infection arthralgias .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fever AND chi Paulo para|influenza vaccinia GSK rotavirus BCG|chikungunya|unsolicited aes reported for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo no . , % of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|fever AND chi Paulo para|AIDS dengue rabies schistosomiasis plague|chikungunya|zydus cadilaindiapartnership agreement to address the global threat of entity and develop a entity vaccine an emerging infectious disease in africa , asia and the indian subcontinent .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fever AND chi Paulo para|JC influenza BK rabies herpes|chikungunya|the antibody against entity virus is our first systemic secreted therapeutic for which we have filed an ind .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|fever AND chi Paulo para|dengue influenza rabies yellow plague|chikungunya|cepis priority diseases include ebola virus , lassa virus , middle east respiratory syndrome coronavirus , nipah virus , rift valley fever and entity virus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|fever AND chi Paulo para|influenza DENV SIV RSV H1N1|chikungunya|vaccine pre-clinical phase i hiv-1 x rsv on hold hsv on hold malaria x influenza x entity x 5 hiv-1 and aids hiv-1 ( human immunodeficiency virus type 1 ) is a retrovirus
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|fever AND chi Paulo para|ELISA WB Rapid influenza cytotoxicity|chikungunya|of vaccines , diagnostics and biopharmaceuticals , primarily to meet the demands of brazil  s national public health system , related to the dpp® entity assay .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|bot botulinum vulgaris allergy Allergy|rotavirus hepatitis dengue GBS fever|botulism|in addition , our botvax® b vaccine has successfully protected hundreds of thousands of horses and foals against type b entity ( commonly known as shaker foal syndrome ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|bot botulinum vulgaris allergy Allergy|methanol PQ cocaine dengue intentional|botulism|of the national institutes of health ( contract no . hhsn272200800028c ) , to support ongoing development of drug candidates for the treatment of entity poisoning .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|bot botulinum vulgaris allergy Allergy|plague dengue rabies influenza varicella|botulism|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , tularemia , and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bot botulinum vulgaris allergy Allergy|Clostridium GBS Burn SMA CDI|botulism|entity is a frequently fatal disease caused by botulinum toxins produced by the bacterium clostridium botulinum .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|bot botulinum vulgaris allergy Allergy|shell mushroom lethal pathogen fire|botulism|zebra mussels are also believed to be the source of deadly avian entity poisoning that has killed tens of thousands of birds in the great lakes since the late 1990s .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|bot botulinum vulgaris allergy Allergy|methanol PQ cocaine herbicide LSD|botulism|an additional contract with niaid to support our on-going development of drug candidates toward clinical trials in the treatment of entity poisoning .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|bot botulinum vulgaris allergy Allergy|leishmaniasis tetanus influenza rabies cholera|botulism|we evaluated the use of mrna for passive immunization in two indications , rabies and entity , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|bot botulinum vulgaris allergy Allergy|vaccines medicines pharmaceuticals vaccination pathogens|botulism|sales of neogens vaccine for equine entity and amvet veterinary pharmaceuticals experienced strong increases as they continued to gain market acceptance .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|bot botulinum vulgaris allergy Allergy|botulinum fever rotavirus diarrhea streptococci|botulism|in addition , the companys botvax b vaccine has successfully protected thousands of high-value horses and foals against type b entity , commonly known as shaker foal syndrome .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|bot botulinum vulgaris allergy Allergy|rotavirus inactivated polysaccharide vaccinia botulinum|botulism|the companys boxvax b vaccine is also produced in the tampa , facility , utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|disease|bot botulinum vulgaris allergy Allergy|diarrhea anaphylaxis fever neurotoxicity anemia|botulism|supply of 200 , 000 doses of bat that are intended for treating individuals who have been exposed to the toxins that cause entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|bot botulinum vulgaris allergy Allergy|hepatitis rotavirus dengue allergy cholera|botulism|our botvax® b product is the only usda-approved vaccine for the prevention of type b entity in horses .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|bot botulinum vulgaris allergy Allergy|him rabies AIDS plague varicella|botulism|david scarlett a complaint was filed on july 16 , 2008 by counsel representing mr . scarlett in ohio who alleges to have contracted entity from a castleberrys product .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bot botulinum vulgaris allergy Allergy|Infants Infection Cases Diagnosis CDI|botulism|entity can also be contracted if botulinum bacteria contaminate wounds or colonize in the intestine of infants , which is referred to as infant botulism .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|bot botulinum vulgaris allergy Allergy|influenza plague rabies fungi Salmonella|botulism|expands our capabilities in biological warfare defense research and allows for the development of vaccines for smallpox , anthrax and plague , entity and other biological pathogens .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|disease|bot botulinum vulgaris allergy Allergy|cocaine arsenic methanol sun mushroom|botulism|other companies are developing other products targeting entity poisoning , and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bot botulinum vulgaris allergy Allergy|botulinum grass streptococcal corn bean|botulism|the companys botvax ®b vaccine is also produced in the lansing facility utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|disease|bot botulinum vulgaris allergy Allergy|cocaine sun methanol arsenic PQ|botulism|other companies are developing other products targeting entity poisoning and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|bot botulinum vulgaris allergy Allergy|spasticity TN neuropathy episodes spasm|botulism|bat is indicated for the treatment of symptomatic entity following documented or suspected exposure to botulinum neurotoxin serotypes a , b , c , d , e , f , or g in adults and
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|bot botulinum vulgaris allergy Allergy|botulinum adenovirus influenza HSV poli|botulism|in the veterinary market , neogen markets botvax b , the only usda approved vaccine for the prevention of entity type b in horses .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|vulgaris Skin Disease syphilis fever|Mouse IBD MAC CMV Lyme|bartonellosis|entity ( cat scratch fever ) vaccine bartonella henselae is the causative agent of cat scratch fever .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|dermatitis arthritis acne allergies psoriasis|supine midline pelvis eg axillary|torticollis|the patient  s head may turn to the right or left ( entity ) , may tilt to one side ( laterocollis ) , or may tilt upwards ( retrocollis ) or downwards ( anterocollis ) .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|dermatitis arthritis acne allergies psoriasis|dystonia dyskinesia rigidity ataxia tic|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( “twstrs” ) total score .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|dermatitis arthritis acne allergies psoriasis|dystonia spasm migraine dyskinesia syndromes|torticollis|also known as spasmodic entity , cervical dystonia is a painful and debilitating neurological movement disorder .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|dermatitis arthritis acne allergies psoriasis|dystonia spasm dyskinesia migraine ataxia|torticollis|cervical dystonia ( also referred to as spasmodic entity ) may be primary ( meaning that it is the only apparent neurological disorder , with or without a family history ) or may
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|dermatitis arthritis acne allergies psoriasis|dyskinesia tic dystonia voice ataxia|torticollis|units or 250 units showed a statistically significant greater change from baseline as measured on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|dermatitis arthritis acne allergies psoriasis|dystonia migraine dyskinesia ataxia tic|torticollis|cervical dystonia affects approximately three in every 10 , 000 people , or about 90 , 000 people in the united states , according to the national spasmodic entity association .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|dermatitis arthritis acne allergies psoriasis|dystonia dyskinesia rigidity tic ataxia|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) -total score .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|dermatitis arthritis acne allergies psoriasis|dystonia dyskinesia rigidity tic ataxia|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|dermatitis arthritis acne allergies psoriasis|dyskinesia dystonia ataxia headache tic|torticollis|treatment until the return of signs and symptoms that warrant retreatment , based on subjects reaching their target toronto western spasmodic entity rating scale ( twstrs ) score .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|NHL neuroblastoma CLL DLBCL CD20|clones CTCs melanomas CSCs tumours|lymphoma|first , the cd19 antigen is used in the clinic to distinguish entity derived from b cells from those derived from t cells .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|disease|NHL neuroblastoma CLL DLBCL CD20|lymphomas CLL myeloma leukaemia NHL|lymphoma|plan to file an ind and initiate our own clinical trial for mb-106 for the treatment of patients with non-hodgkin entity and chronic lymphocytic leukemia .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|NHL neuroblastoma CLL DLBCL CD20|lymphomas GVHD ulcers syndromes ulcer|lymphoma|for which a u . s . marketing application is currently being reviewed by the fda for the treatment of relapsed aggressive non-hodgkin  s entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|NHL neuroblastoma CLL DLBCL CD20|lymphomas NHL carcinomas malignancies NSCLC|lymphoma|inc . yeah , so invariably we want to look for drugs which are active in diffuse large b-cell entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|NHL neuroblastoma CLL DLBCL CD20|diarrhea diarrhoea BPH leishmaniasis schistosomiasis|lymphoma|we currently have two products ( at-004 and at-005 ) for treatment of entity in dogs which have received a conditional license from the u . s . department of agriculture , or the usda .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|NHL neuroblastoma CLL DLBCL CD20|immunogenicity toxicities cytotoxicity potency specificities|lymphoma|the treatment of generalized lipodystrophy , and carries a boxed warning for the risks of anti-metreleptin antibodies with neutralizing activities and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|NHL neuroblastoma CLL DLBCL CD20|AIDS oncology civil palliative rehabilitation|lymphoma|type : debit period type : duration x - definitionrepresents the maximum amount of grants to be received from the leukemia and entity society ( lls ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|NHL neuroblastoma CLL DLBCL CD20|malignancies tumours NHL myeloma Disease|lymphoma|approximately 50% to 60% of dlbcl patients are cured with first-line therapy and do not have recurrence of their entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|NHL neuroblastoma CLL DLBCL CD20|colitis IBD IBS GVHD malignancies|lymphoma|to finance the analysis of unblinded data on biovaxidtm , an active immunotherapeutic in a pivotal phase 3 study of non-hodgkins entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|NHL neuroblastoma CLL DLBCL CD20|lymphomas carcinomas NHL ATL neoplasms|lymphoma|phase ii clinical trials to assess the oms electroimmunotherapy technology in patients with melanoma , merkel cell carcinoma and cutaneous t-cell entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|NHL neuroblastoma CLL DLBCL CD20|presently soon becoming just actively|lymphoma|we are also aware of other potentially competitive biologic therapies for non-hodgkin  s entity in development .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 2)])|disease|NHL neuroblastoma CLL DLBCL CD20|CLL myeloma lymphomas leukaemia lymphocytic|lymphoma|this trial will seek to treat both non-hodgkins entity and chronic lymphocytic leukemia patients that have failed venetoclax .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|NHL neuroblastoma CLL DLBCL CD20|horses monkeys SJ cats breeds|lymphoma|morphosys will continue to be responsible for its ongoing clinical studies with tafasitamab in non-hodgkins entity ( nhl ) , cll , r / r dlbcl and first-line dlbcl .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|NHL neuroblastoma CLL DLBCL CD20|lymphomas NSCLC malignancies myeloma mesothelioma|lymphoma|an open-labeled , uncontrolled , dose-escalation , phase i clinical trial of cudc-427 ( nct01226277 ; iam4914g ) began in patients with refractory solid tumors or entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|NHL neuroblastoma CLL DLBCL CD20|lymphomas NHL carcinomas malignancies DLBCL|lymphoma|one of the issues is even in the novel space there are a limited number of agents which have significant activity in diffuse large b-cell entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1), ('DRUG', 1)])|disease|NHL neuroblastoma CLL DLBCL CD20|lymphomas CML ALL myeloma NHL|lymphoma|cancers because the therapy can deplete all b cells or t cells including normal and cancer cells in leukemia and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|NHL neuroblastoma CLL DLBCL CD20|dermatitis ulcers mucositis constipation malignancies|lymphoma|designed to assess the safety and tolerability of vegf trap in patients with solid tumor malignancies and subjects with non-hodgkins entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|NHL neuroblastoma CLL DLBCL CD20|ALL ATL NHL CLL DLBCL|lymphoma|a large proportion of t-cell entity patients are refractory to or relapse following treatment with standard therapies and there remains a need to develop an effective
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|NHL neuroblastoma CLL DLBCL CD20|lymphomas NHL neoplasms carcinomas DLBCL|lymphoma|in february 2013 , we received clia approval for matba®-dlbcl , our proprietary microarray for diagnosis , prognosis and patient monitoring in diffuse large b cell entity ( dlbcl ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|NHL neuroblastoma CLL DLBCL CD20|colitis IBS diarrhea ulcers dermatitis|lymphoma|process for review of inds , initiate a clinical trial of adi-001 targeting cd20 for the treatment of patients with non-hodgkins entity and treat the first patient in the first half of 2021 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|neurogenic Malignant AND Known proliferative|LS TOF CDH TS anomalies|myelomeningocele|dr . moise is also actively involved in the open fetal surgical repair program for entity ( spina bifida ) at the fetal center .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|proliferative subcortical lupus dementia multifocal|encephalomyelitis glomerulonephritis encephalitis vasculitis neuropathy|leukoencephalopathy|this decision was based on reports of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|proliferative subcortical lupus dementia multifocal|glomerulonephritis neuropathy neutropenia encephalitis infiltrates|leukoencephalopathy|these include : fatal infusion reactions , tumor lysis syndrome ( tls ) with associated acute renal failure , severe mucocutaneous reactions and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|proliferative subcortical lupus dementia multifocal|encephalitis encephalomyelitis myelopathy meningitis PML|leukoencephalopathy|in immunosuppressed individuals , jc virus is responsible for a life-threatening infection of the brain and spinal cord called progressive multifocal entity , or pml .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|proliferative subcortical lupus dementia multifocal|encephalitis glomerulonephritis vasculitis encephalopathy encephalomyelitis|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain which usually leads to death or severe disability .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|proliferative subcortical lupus dementia multifocal|infiltrates sclerosis pneumonitis neuropathy pneumonia|leukoencephalopathy|dyspnea and bronchospasm have been reported , and due to the mechanism of action , increased risk for infections and progressive multifocal entity must be advised and monitored .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|proliferative subcortical lupus dementia multifocal|encephalitis encephalopathy encephalomyelitis glomerulonephritis meningitis|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|proliferative subcortical lupus dementia multifocal|encephalitis encephalomyelitis retinitis meningitis encephalopathy|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|proliferative subcortical lupus dementia multifocal|multifocal JC cytomegalovirus encephalitis PML|leukoencephalopathy| progressive multifocal entity ( pml ) : jc virus infection resulting in pml and death has been reported in adcetris-treated patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|proliferative subcortical lupus dementia multifocal|glomerulonephritis encephalomyelitis encephalitis vasculitis uveitis|leukoencephalopathy|these events involved two cases of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|proliferative subcortical lupus dementia multifocal|glomerulonephritis encephalitis PML nephritis uveitis|leukoencephalopathy|shown a reduction in arr of 67% , but it may cause serious side effects including increased risk of progressive multifocal entity ( pml ) , a rare and potentially fatal viral disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|proliferative subcortical lupus dementia multifocal|encephalitis glomerulonephritis encephalopathy vasculitis encephalomyelitis|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain that usually leads to death or severe disability .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|proliferative subcortical lupus dementia multifocal|glomerulonephritis uveitis encephalopathy encephalitis astrocytoma|leukoencephalopathy|the new label identifies anti-jc virus ( jcv ) antibody status as a risk factor for progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|proliferative subcortical lupus dementia multifocal|degeneration sclerosis retinitis neovascularization blindness|leukoencephalopathy|however , tysabri  s association with progressive multifocal 69 table of contents entity , " pml , " has limited its usage to patients for whom other treatment has failed .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|proliferative subcortical lupus dementia multifocal|gliomas glioma astrocytoma neovascularization neuropathy|leukoencephalopathy|several initiatives under way that may lead to defi ning patients who are at greater risk of developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|proliferative subcortical lupus dementia multifocal|glomerulonephritis GN uveitis glioma astrocytoma|leukoencephalopathy|inclusion of anti-jcv antibody status as an additional factor to aid in stratifying patients at risk for developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|proliferative subcortical lupus dementia multifocal|encephalopathy glomerulonephritis neuropathy encephalitis neurodegeneration|leukoencephalopathy|we have also begun animal studies related to two orphan diseases , multiple system atrophy ( msa ) and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|proliferative subcortical lupus dementia multifocal|glomerulonephritis GN glioma encephalopathy gliomas|leukoencephalopathy|collaboration will focus on the discovery and development of therapeutics based on rnai for the potential treatment of progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|proliferative subcortical lupus dementia multifocal|encephalomyelitis demyelinating glomerulonephritis neuropathy vasculitis|leukoencephalopathy|progressive multifocal entity ( pml )  a rare and potentially fatal demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|proliferative subcortical lupus dementia multifocal|neuropathy sclerosis PML retinitis glomerulonephritis|leukoencephalopathy|biologics used for multiple sclerosis increased the risk of infections and progressive multifocal entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|proliferative subcortical lupus dementia multifocal|glomerulonephritis glioma gliomas astrocytoma uveitis|leukoencephalopathy|to inform physicians and patients of the benefits and risks of tysabri treatment and minimize potential risk of progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|glaucoma corneal neovascularization psoriasis AND|CMV MMC cytomegalovirus AK myopia|keratoconus|in 2000 , this patient underwent corneal transplantation caused by entity , simultaneously with extraction of a cataract and implantation of an artificial lens .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|glaucoma corneal neovascularization psoriasis AND|haze myopia neovascularization keratitis ulcers|keratoconus|are the only fda-approved riboflavin ophthalmic formulations used with our kxl system to treat progressive 122 table of contents entity and corneal ectasia following refractive surgery .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|glaucoma corneal neovascularization psoriasis AND|burn KT ESRD refractive corneal|keratoconus|literature estimates that as many as 20% of entity patients ultimately require a corneal transplant , a costly and invasive procedure with high failure rates .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|glaucoma corneal neovascularization psoriasis AND|myopia astigmatism glaucoma refractive blindness|keratoconus|trial underway ; us clinical trial planned • 38 globally issued patents with 59 pending patent applications vision correction pipeline $3b entity $15b presbyopia $8b low myopia
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|glaucoma corneal neovascularization psoriasis AND|AMD myopia glaucoma CMT psoriasis|keratoconus|typically diagnosed in a patients teenage years , entity is characterized by progressive thinning and weakening of the cornea , resulting in vision loss .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|glaucoma corneal neovascularization psoriasis AND|glaucoma cataracts cataract neovascularization uveitis|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|glaucoma corneal neovascularization psoriasis AND|myopia glaucoma keratocon cataract scleroderma|keratoconus|ten patients with advanced entity , or severe corneal scarring , were implanted with the recombinant collagen implants and have been followed for more than five years .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|glaucoma corneal neovascularization psoriasis AND|Disease KC AMD CNV PAC|keratoconus|entity is a degenerative corneal disease that impairs vision and is characterized by progressive thinning of the cornea and the development
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|glaucoma corneal neovascularization psoriasis AND|myopia glaucoma scleroderma cataract AMD|keratoconus|one significant cause of night myopia is entity , an orphan disease that starts at a young age with progressive thinning of the cornea usually due to genetic and
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glaucoma corneal neovascularization psoriasis AND|glaucoma AMD cataract cataracts progressed|keratoconus|i  d say there  s  if you look at the prevalence now , there  s 1 . 1 million eyes that are available that have entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glaucoma corneal neovascularization psoriasis AND|psoriasis topical cytotoxic antiviral immunomodulatory|keratoconus|unlike conventional entity treatments , studies have found that avedros photrexa® actually slows or halts disease progression .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|glaucoma corneal neovascularization psoriasis AND|glaucoma cataract cataracts neovascularization uveitis|keratoconus|of the enzyme hyaluronidase 7 8 to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|glaucoma corneal neovascularization psoriasis AND|disabilities T1D SCI dementia T2D|keratoconus|we believe that there are approximately 400 , 000 people in the united states , western europe and japan who currently have entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|glaucoma corneal neovascularization psoriasis AND|antiviral eradication adjunctive antiretroviral triple|keratoconus|avedro estimates the total u . s . opportunity for its entity therapy to be approximately $3 billion .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|glaucoma corneal neovascularization psoriasis AND|glaucoma cataract cataracts neovascularization uveitis|keratoconus|to digest proteoglycans to treat a variety of eye diseases and conditions , including vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|glaucoma corneal neovascularization psoriasis AND|another bad true aging something|keratoconus|know were going to probably get bogged down in migs shortly but just when you think a little bit about entity , arguably an undiagnosed or under diagnosed , i should say , disease state .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glaucoma corneal neovascularization psoriasis AND|glaucoma cataracts cataract uveitis scarring|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification , and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|glaucoma corneal neovascularization psoriasis AND|psoriasis scleroderma ALS arthritis neutropenia|keratoconus|for our latest-generation kxl system , its associated investigational drug formulations and our investigational boost goggles for the treatment of progressive entity in an epi-on procedure .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|glaucoma corneal neovascularization psoriasis AND|psoriasis BCC lymphedema acne burns|keratoconus|keraform we are developing keraform , our proprietary system for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|osteoporosis fibromyalgia periodontitis cataracts gout|osteonecrosis|thus , we expect that new clinical indications may include orthopedics , secondary osteoporosis ( including glucocorticoid induced osteoporosis ) , entity , and osteoarthritis .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|osteomyelitis GCT tumours osteosarcoma aneurysms|osteonecrosis|in march 2006 , our proprietary trcs received an orphan drug designation from the fda for use in the treatment of entity of the femoral head .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|blow damages discomfort harm deformities|osteonecrosis|plaintiffs allege aredia causes entity to the jaw .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|Apoptosis Injury osteoporosis Bone Disease|osteonecrosis|“entity” means the death of bone cells due to decreased blood flow .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|osteomyelitis destruction section parts shielding|osteonecrosis|entity of the femoral head involves the death of cells in the bone and marrow within the femur head and in
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|neurotoxicity EM DIC PML cytotoxicity|osteonecrosis|in our original ind submission , we described a finding of entity ( microscopic evidence of bone and bone marrow death ) in a toxicity study of gen-003 conducted in mice .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|dislocation osteomyelitis instability osteosarcoma shortening|osteonecrosis|there have been no cases of entity of the jaw or atypical femoral fracture in the entire tymlos development program .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|osteosarcoma tumours GCT malignancies bones|osteonecrosis|describing changes to the label for zometa and aredia , another intravenous bisphosphonate used to treat metastatic bone disease , relating to entity of the jaw .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|osteoporosis hypercalcemia hyperparathyroidism hyperthyroidism anemia|osteonecrosis|additional patent applications are for specific methods of manufacturing strontium salts and for other clinical indications , such as treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|hypoglycemia hypoglycaemia AEs MACE dizziness|osteonecrosis|there were no events of entity observed in the trial .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|wounds amputation ischaemia severely thereby|osteonecrosis|more severe complications can occur , such as deep tissue infections and entity threatening life of the limb .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|osteosarcoma resorption osteomyelitis eruption swelling|osteonecrosis|plaintiffs claim to have experienced entity of the jaw after having been treated with zometa or aredia , which are used to treat patients whose cancer has
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|osteomyelitis GCT osteosarcoma dislocation tumours|osteonecrosis|the orthopaedic institute , könig-ludwig-haus , university of würzburg , germany , involving the first use of our brcs to treat patients suffering from entity of the femoral head .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|osteosarcoma Carcinoma Impact eruption Union|osteonecrosis|entity of the jaw ( onj ) : onj has been reported in patients with cancer receiving treatment including bisphosphonates , chemotherapy and / or corticosteroids .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|aneurysms dysplasia osteomyelitis tumours malformations|osteonecrosis|aastrom product candidates to treat entity of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the fda .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|osteomyelitis osteosarcoma swelling tumours deformities|osteonecrosis|the most frequent serious adverse reactions were entity of the jaw , bone giant cell tumor , anemia , pneumonia , and back pain .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|dislocations surgeries osteoporosis osteomyelitis deformities|osteonecrosis|other potential orthopedic applications include wrist fractures , poor-healing fractures , and entity , or conditions of bone degeneration .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis neovascularization neuropathy osteomyelitis AND|swelling irritation weakness eruption erythema|osteonecrosis|the most frequent adverse reaction resulting in discontinuation of xgeva® was entity of the jaw .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|meningitis osteomyelitis pneumonia bacteremia endocarditis|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing , such as bacteremia and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|IBD COPD AIDS burn IBS|osteomyelitis|most entity patients currently use chemical drugs such as antibiotics for treatment which may develop drug resistance if the chemical drugs are
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|pharmaceutical dairy labour retail cigarette|osteomyelitis|increase in marketing expenses , which increased from $43 , 000 to $95 , 000 as a result of a commissioned research study on the entity market .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|bacteremia IBD periodontitis leishmaniasis vasculitis|osteomyelitis|lefamulin has shown substantial tissue penetration and activity against the most common causative organism in all forms of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|meningitis bacteremia osteomyelitis encephalitis pneumonia|osteomyelitis|invasive pneumococcal disease includes bacteremic pneumonia , bacteremia , sepsis , meningitis and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|osteomyelitis candidiasis meningitis aspergillosis abscesses|osteomyelitis|up to 90% of cases of hematogenous entity , most frequently in children , are caused by s . aureus .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|bacteremia osteomyelitis meningitis pneumonia aspergillosis|osteomyelitis|these data indicate that s . aureus bloodstream infections including infective endocarditis and entity may be a potentially promising area of clinical development with ceftobiprole .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|meningitis endocarditis osteomyelitis bacteremia otitis|osteomyelitis|is exebacase , a lysin which targets staph aureus , including methicillin-resistant strains , which causes serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|meningitis osteomyelitis endocarditis bacteremia otitis|osteomyelitis|organisms , such as methicillin-resistant staph aureus ( mrsa ) and p . aeruginosa , which can cause serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2), ('DRUG', 1)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|osteoporosis osteomyelitis periodontitis osteosarcoma mucositis|osteomyelitis|are currently one of the few resorbable bone void fillers available in international markets for the prevention and treatment of entity , an acute or chronic infection of the bone .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|osteomyelitis periodontitis bacteremia endocarditis sinusitis|osteomyelitis|could fulfill the need for a safe , long-term oral therapy to treat chronic infections such as prosthetic joint infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|herbal ten dry topical triple|osteomyelitis|sui yan pian kang gu sui yan pian ( entity treatment tablets ) is used to treat bone and bone marrow inflammations .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|pneumonia meningitis bacteremia diarrhea influenza|osteomyelitis|gram-positive bacteria can also cause other serious illnesses , including pediatric and adult entity , community- and habp , including vabp , bacteremia and diabetic foot infection .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2), ('DRUG', 1)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|osteoporosis osteomyelitis periodontitis osteoporotic OI|osteomyelitis|medicated pellets are currently the only synthetic resorbable bone void filler available on the international market for the treatment of entity , an acute or chronic inflammation of bone .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1), ('DRUG', 1)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|psoriasis osteoporosis scleroderma osteomyelitis vasculitis|osteomyelitis|for example , applications of mdp-25 include metastatic bone disease , pagets disease , arthritic disease and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|malignancies osteomyelitis osteosarcoma THA AIDS|osteomyelitis|mtf-101 , a diaminopyrimidine that may be suitable for testing in clinical trials to demonstrate safety and efficacy in patients with entity and patients with prosthetic joint infections .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|meningitis osteomyelitis pneumonia bacteremia endocarditis|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing such as bacteremia and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|osteomyelitis bacteremia periodontitis malignancies sinusitis|osteomyelitis|the need for a safe , long-term oral therapy to treat chronic infections such as refractory bone and joint infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|migraine ADHD psoriasis CDI NSCLC|osteomyelitis|our goal is to develop an effective therapy for entity that permits infrequent dosing .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteomyelitis abscess vertebral psoriasis meningitis|IBD NSCLC psoriasis CRC T2DM|osteomyelitis|we believe that lefamulin has the potential to be an effective treatment option for entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|Another Its Ongoing Her My|dermatomyositis|entity clinical program update corbus is currently evaluating anabasum in an on-going phase 2 study for the treatment of skin-predominant dermatomyositis .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|psoriasis vasculitis urticaria dermatitis ulcer|dermatomyositis|change in the cutaneous entity activity and severity index ( “cdasi” ) activity score is a secondary efficacy outcome .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|urticaria SLE PBC psoriasis scleroderma|dermatomyositis|above disease programs , we performed phase i pilot clinical trials with eculizumab in patients afflicted with the chronic autoimmune disorders entity , psoriasis , and bullous pemphigoid .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|myocarditis scleroderma vasculitis colitis cardiomyopathy|dermatomyositis|servier also began testing gevokizumab in a variety of small clinical studies , including polymyositis / entity and schnitzler syndrome .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma sarcoidosis psoriasis vasculitis lupus|dermatomyositis|in patients with any one of the following six different autoimmune diseases : cle , sle , sjögrens syndrome , systemic sclerosis , polymyositis and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|psoriasis scleroderma amyloidosis SSc patches|dermatomyositis|resunab is currently in phase 2 studies for the treatment of diffuse cutaneous systemic sclerosis and skin-predominant entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma sarcoidosis vasculitis psoriasis arthritis|dermatomyositis|two rare autoimmune connective tissue conditions , polymyositis and entity , have been alleged to occur with increased frequency in patients who have received cosmetic collagen treatments .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|DMD fibromyalgia scleroderma MG IBM|dermatomyositis|new drug application with the fda to commence a phase ib pilot clinical study trial with 5g1 . 1 in patients with entity , a severe inflammatory muscle disorder .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma DMD SSc SMA SLE|dermatomyositis|based on these ongoing efforts , we have focused our development strategy on entity , a form of the disease in which there is muscle and skin involvement .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|cutaneous lupus psoriasis arthritis SLE|dermatomyositis|lenabasum is currently being evaluated in entity and systemic lupus erythematosus .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma sarcoidosis psoriasis lupus myocarditis|dermatomyositis|age , and the treatment of certain rheumatology related conditions , including the treatment of the rare and closely related neuromuscular disorders entity and polymyositis .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma psoriasis bronchiectasis sarcoidosis migraine|dermatomyositis|continue to increase as we advance to clinical trials for indications for the treatment of cystic fibrosis , systemic sclerosis and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma sarcoidosis psoriasis myocarditis vasculitis|dermatomyositis|forms of b-cell lymphoma , including waldenströms macroglobulinemia and diffuse large b-cell lymphoma , and in orphan autoimmune diseases , including polymyositis and entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma psoriasis CLL glioblastoma ALS|dermatomyositis|we are developing imo-8400 for the treatment of a rare disease called entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma bronchiectasis psoriasis sarcoidosis eczema|dermatomyositis|lenabasum is currently being evaluated in systemic sclerosis , cystic fibrosis , entity , and systemic lupus erythematosus .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma psoriasis sarcoidosis vasculitis bronchiectasis|dermatomyositis|lenabasum is not approved for the treatment of systemic sclerosis , entity , cystic fibrosis or systemic lupus erythematosus .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|myocarditis scleroderma vasculitis sarcoidosis colitis|dermatomyositis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / entity , schnitzler syndrome , and giant cell arteritis .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|scleroderma psoriasis bronchiectasis sarcoidosis NSCLC|dermatomyositis|dose in the phase 2 clinical trials currently underway and recently completed with jbt-101 in cystic fibrosis , systemic sclerosis and entity , respectively .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|SLE scleroderma MG IBD urticaria|dermatomyositis|entity is an autoimmune disorder in which the immune system attacks the patients muscles and skin , which may cause extensive rash
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis scleroderma neuropathy AND amyloidosis|polym meningitis MM idiopathic KD|dermatomyositis|by therapeutic area paid prescriptions multiple sclerosis ( ms ) nephrotic syndrome ( ns ) infantile spasms ( is ) entity / polymyositis ( dm / pm ) ** jan-10 67 6 26 feb-10 72
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|psoriasis vulgaris AND psychosis ulcer|periodontitis meningitis sinusitis AIDS bacteremia|leprosy|enl , a complication of entity , is a chronic bacterial disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis vulgaris AND psychosis ulcer|periodontitis AIDS IBD meningitis arthritis|leprosy|enl , an inflammatory complication of entity , is a chronic bacterial disease associated with excess tumor necrosis factor alpha , or tnf ( alpha ) production .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis vulgaris AND psychosis ulcer|AIDS leishmaniasis addiction schistosomiasis poverty|leprosy|novartis as the pharmaceutical partner in the global alliance set up by the who for the elimination of entity takes great pride in having been able to contribute to this achievement .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis vulgaris AND psychosis ulcer|AIDS leishmaniasis schistosomiasis influenza pneumonia|leprosy|we expanded our programs designed to facilitate the supply of drugs to indigent patients suffering from entity , malaria , tuberculosis and chronic myeloid leukemia ( cml ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis vulgaris AND psychosis ulcer|IBD psoriasis SLE scleroderma endometriosis|leprosy|from the fda which allowed us to market thalomid® for the treatment and suppression of enl , an inflammatory complication of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|psoriasis vulgaris AND psychosis ulcer|hospitalized IBD burn AIDS SLE|leprosy|enl occurs in about 30% of entity patients , and is characterized by cutaneous lesions , acute inflammation , fever , and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis vulgaris AND psychosis ulcer|periodontitis psoriasis SLE cirrhosis aging|leprosy|enl is an inflammatory complication of entity associated with excess tnf ( alpha ) production .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis vulgaris AND psychosis ulcer|Asian Caucasian immunocompromised psoriatic burn|leprosy|approval from the fda to market thalidomide for the treatment of erythema nodosum leprosum , an inflammatory skin condition of some entity patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|psoriasis vulgaris AND psychosis ulcer|antimalarial generic prescription crude antiviral|leprosy|the group provided further support for patients in developing countries by supplying entity drugs free of charge and by selling coartem , our new antimalarial treatment , to the who at cost .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|psoriasis vulgaris AND psychosis ulcer|aging psoriasis ageing pruritus scleroderma|leprosy|market and sell thalomid ( thalidomide ) for the treatment of erythema nodosum leprosum ( enl ) , a severe and debilitating condition associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|disease|psoriasis vulgaris AND psychosis ulcer|prescription antidepressant antipsychotic rescue antihypertensive|leprosy|we have given entity medication free of charge since the year 2000  again to 3 million patients and on an ongoing basis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|psoriasis vulgaris AND psychosis ulcer|schistosomiasis leishmaniasis dengue AIDS hepatitis|leprosy|this approval reinforces the company  s commitment to reduce the burden of neglected tropical diseases including fascioliasis , entity and malaria .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|psoriasis vulgaris AND psychosis ulcer|urticaria leishmaniasis psoriasis eczema leprosy|leprosy|when given orally , dapsone is used for the treatment of such diseases as entity , malaria and dermatitis herpetiformis , an autoimmune skin disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|psoriasis vulgaris AND psychosis ulcer|Asthma Obesity Tuberculosis Diabetes NAFLD|leprosy|entity afflicts millions worldwide , although the disease is relatively rare in the united states .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|psoriasis vulgaris AND psychosis ulcer|IBD hospitalized burn AIDS SLE|leprosy|enl occurs in about 30% of entity patients and is characterized by skin lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis vulgaris AND psychosis ulcer|psoriasis scleroderma AIDS acne vasculitis|leprosy|infection caused by a protozoal parasite that affects the skin and abdominal organs , causing ulcers or skin disorders that resemble entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|psoriasis vulgaris AND psychosis ulcer|IBD hospitalized AIDS burn SLE|leprosy|enl occurs in about 30% of entity patients and is characterized by cutaneous lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis vulgaris AND psychosis ulcer|psoriasis malignancies myeloma hematological hematologic|leprosy|approved for sale in the u . s . , thalidomide has been used as an investigational agent to treat thousands of patients for entity and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis vulgaris AND psychosis ulcer|aspergillosis IBD leishmaniasis GBS BCC|leprosy|although entity is relatively rare in the united states , the disease afflicts millions worldwide .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis vulgaris AND psychosis ulcer|dementia aging arrhythmias frailty cardiomyopathy|leprosy|the fda an approvable letter for its nda for thalomid for the treatment of enl , a disease state associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|fever Plasmodium Mycobacterium cruzi bovis|Do Can Mer Prop Register|ehrlichiosis|entity diseases quilvax-l ( tm ) 10 million licensing schering- product to prevent dogs at risk efficacy and plough .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|fever Plasmodium Mycobacterium cruzi bovis|encephalitis leishmaniasis endocarditis meningitis syphilis|ehrlichiosis|the most prevalent and well known tick-borne disease is lyme disease , but there are others such as anaplasmosis , entity , and babesiosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 2)])|disease|fever Plasmodium Mycobacterium cruzi bovis|leukaemia neoplasia neoplasms leukemias malignancies|ehrlichiosis|aquila also has several issued and pending patents in the field of lyme disease and human granulocytic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|fever Plasmodium Mycobacterium cruzi bovis|AND del phen pi ale|ehrlichiosis|x2 ehrlichia equi igg & igm ( hge ) abs each [ *** ] * 7846 86609x2 ; 86618x2 entity ( granulocytic ) & lyme disease evaluation each
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|serology vaccinia vaccines AND hepatitis|varicella dengue rubella pertussis adenovirus|mumps|other diseases such as rubella , polio , measles , entity , chickenpox , and typhoid are nowhere near as common as they were a hundred years ago .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|serology vaccinia vaccines AND hepatitis|varicella rubella adenovirus dengue pertussis|mumps|polio , measles , entity and many other viral illnesses are now controllable and smallpox has been eradicated from nature .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|serology vaccinia vaccines AND hepatitis|varicella rubella measles influenza mum|mumps|the company recently applied for regulatory clearance in canada to market episcreen for the detection of measles , entity and rubella .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|serology vaccinia vaccines AND hepatitis|equine bovine canine avian swine|mumps|product portfolio includes vaccines against hepatitis a and b , seasonal influenza , h5n1 pandemic influenza ( avian flu ) , h1n1 influenza ( swine flu ) , entity and canine rabies .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|serology vaccinia vaccines AND hepatitis|inactivated rabies own influenza licensed|mumps|in december 2011 , sinovac dalian , an operating subsidiary of the company obtained the production license from the sfda for its entity vaccine .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|serology vaccinia vaccines AND hepatitis|rubella varicella measles dengue CMV|mumps|legionella and influenza ,  epstein barr virus , and  other viral pathogens , including measles , entity , rubella and varicella .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|serology vaccinia vaccines AND hepatitis|rubella varicella pneumonia dengue mum|mumps|mercks sales of m‑m‑r ii , a vaccine to help protect against measles , entity and rubella , were $103 million for the third quarter of 2015 compared with $86 million for the third quarter of
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|serology vaccinia vaccines AND hepatitis|rubella varicella measles CMV cytomegalovirus|mumps|these viruses include measles , entity , rubella , varicella , and epstein-barr and may be involved in the pathogenesis of ms in several ways : transient or persistent
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|serology vaccinia vaccines AND hepatitis|pertussis rubella syphilis diphtheria hepatitis|mumps|( e ) annual medical report indicating satisfactory health status , including immunization for communicable disease such as hepatitis b , entity , measles , rubeola and tuberculosis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|serology vaccinia vaccines AND hepatitis|varicella measles influenza dengue herpes|mumps|conjugate , enterovirus 71 ( ev71 ) ( against hand , foot & mouth disease ) , japanese encephalitis , animal and human rabies , hib and epidemic meningitis , chickenpox , entity and rubella .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|serology vaccinia vaccines AND hepatitis|SCD KD aspergillosis NEC CVD|mumps|while death from entity is rare , it can be associated with a number of serious complications , such as meningitis and encephalitis , especially in older
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|serology vaccinia vaccines AND hepatitis|varicella rubella dengue adenovirus pertussis|mumps|live virus vaccines , including those for smallpox , polio , measles , entity , rubella and chicken pox , have had a long record of preventing disease .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|serology vaccinia vaccines AND hepatitis|rubella varicella diphtheria measles dengue|mumps|examples include the measles , entity , rubella ( mmr ) , yellow fever ( a flavivirus ) , varicella , influenza , smallpox and the oral vaccine against polio , which has been widely deployed
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|serology vaccinia vaccines AND hepatitis|influenza rabies tetanus hepatitis varicella|mumps|company overview china bio-immunity corporation ( the “company” or “we” ) , a nevada corporation , is a leading provider of rabies and entity vaccines in the peoples republic of china ( “prc” ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|serology vaccinia vaccines AND hepatitis|generic investigational licensed influenza pharmaceutical|mumps|things , that the company defrauded the u . s . government by falsifying data in connection with a clinical study conducted on the entity component of the companys m-m-r ii vaccine .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|serology vaccinia vaccines AND hepatitis|herpes influenza rabies measles hepatitis|mumps|dth skin tests have been commonly used to detect t cell responses to tuberculosis , fungal pathogens , and entity virus .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|serology vaccinia vaccines AND hepatitis|varicella measles diphtheria flu mum|mumps|claim to suffer from autism or autism spectrum disorder as a result of receiving thimerosal-containing childhood vaccines and / or the measles , entity and rubella ( mmr ) vaccine .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|serology vaccinia vaccines AND hepatitis|equine insect microbial canine poultry|mumps|&nbsp ; revenue for animal and entity vaccines without a right of return provided to customers is recognized when delivery has occurred .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|serology vaccinia vaccines AND hepatitis|measles varicella influenza diphtheria rubella|mumps|priorix tetra , which builds on gsks existing entity , measles and rubella vaccine with the addition of varicella protection , will be filed in european and international markets .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|serology vaccinia vaccines AND hepatitis|rubella influenza varicella CMV BCG|mumps|these cell lines have been successfully used to produce a number of human vaccines ( rubella , entity , measles , rabies and hepatitis a ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|asbestos mesothelioma AND scleroderma pleural|mesothelioma asbestos emphysema works COPD|asbestosis|that entity , lung cancer , and other rare types of cancer have been associated with exposure primarily in asbestos-related industries where
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asbestos mesothelioma AND scleroderma pleural|mesothelioma emphysema pneumonia bronchitis cirrhosis|asbestosis|when inhaled , asbestos fibers can cause certain diseases , including entity , mesothelioma and lung cancer ( and risks for smokers are dramatically compounded ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asbestos mesothelioma AND scleroderma pleural|emphysema mesothelioma pneumonia pneumonitis COPD|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity and cancer ) increases .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asbestos mesothelioma AND scleroderma pleural|mesothelioma emphysema pneumonia pneumonitis COPD|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity or cancer ) increases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Infection Skin psoriasis Deep Known|pneumonia cough PCP CAP COPD|legionellosis|of contents serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Infection Skin psoriasis Deep Known|pneumonia PCP CAP cough influenza|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 73 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Infection Skin psoriasis Deep Known|pneumonia PCP cough CAP COPD|legionellosis|against several serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Infection Skin psoriasis Deep Known|pneumonia PCP CAP cough influenza|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 75 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Known AND BMD fragility Calcium|Response Improvement Disease Progression Outcome|osteomalacia|entity was characterized by the pathologist as improving from severe to mild disease .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1), ('BIO', 1)])|disease|Known AND BMD fragility Calcium|nephropathy nephrotoxicity neurotoxicity anemia toxicities|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dementia .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|Known AND BMD fragility Calcium|nephropathy nephrotoxicity diarrhea hypercalcemia wasting|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dialysis dementia .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND BMD fragility Calcium|immunity radiosens remission ICI immunosuppression|osteomalacia|with respect to the tumor-induced entity indication , this goal measured completion of enrollment for our phase 2 study , generation of data to support proof of concept
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|Known AND BMD fragility Calcium|osteoporosis deformities hypercalcemia deformity anemia|osteomalacia|tio results from typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , bone fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|disease|Known AND BMD fragility Calcium|angiogenesis neovascularization hypercalcemia thrombocytopenia anemia|osteomalacia| krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 2)])|disease|Known AND BMD fragility Calcium|osteoporosis hypercalcemia osteosarcoma calcification hyperparathyroidism|osteomalacia|crysvita is being studied for the treatment of tumor induced entity ( tio ) , a rare disease that impairs bone mineralization .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|Known AND BMD fragility Calcium|BMD staging grading mineralization synovitis|osteomalacia|the bone biopsy data demonstrated substantial improvement in entity from severe to mild disease .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|Known AND BMD fragility Calcium|osteoporosis Pain Fatigue Aging Osteoarthritis|osteomalacia|entity leads to severe bone pain , fatigue , muscle weakness and risk of recurring bone fractures .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|Known AND BMD fragility Calcium|osteoporosis hyperparathyroidism OI adolescence puberty|osteomalacia|bone growth plates at the end of adolescence , in addition to continuing vascular and organ calcification , enpp1 deficiency manifests as entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Known AND BMD fragility Calcium|cognition QoL mood QOL HRQOL|osteomalacia|in our past discussions with fda , they emphasized that improvement in entity could also be considered an important outcome for adults with xlh .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|Known AND BMD fragility Calcium|osteoporosis hyperparathyroidism hypercalcemia periodontitis gout|osteomalacia|of pth lead to excessive release of calcium and phosphorus from bones , causing debilitating metabolic bone diseases , such as osteoporosis , entity , rickets and renal osteodystrophy .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|disease|Known AND BMD fragility Calcium|angiogenesis hypercalcemia neovascularization anemia thrombocytopenia|osteomalacia|krn23 ( ux023 ) for the treatment of tio krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|Known AND BMD fragility Calcium|osteoporosis deformities deformity scoliosis hypercalcemia|osteomalacia|for tio , a disease characterized by typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|Known AND BMD fragility Calcium|anemia overgrowth osteoporosis angiogenesis hypercalcemia|osteomalacia|crysvita is being developed to treat xlh and tumor-induced entity ( tio ) , diseases characterized by excess levels of fgf23 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 2)])|disease|Known AND BMD fragility Calcium|angiogenesis hypercalcemia neovascularization anemia osteoporosis|osteomalacia|krn23 ( ux023 ) for the treatment of tio we are also developing krn23 for the treatment of tumor-induced entity , or tio .
OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|psoriasis neuropathy CML thrombocytopenia anemia|ataxia encephalitis neuropathy encephalopathy syndromes|leukodystrophy|trauma has a neurosteroid compound intended to treat rare brain disorders , such as als , niemann picks disease , krabbes disease , metachromatic entity and other leukodystrophies .
OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|psoriasis neuropathy CML thrombocytopenia anemia|neurodegenerative neurodegeneration dementia degenerative degeneration|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain , which prevents proper synaptic communication of neurons .
OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|psoriasis neuropathy CML thrombocytopenia anemia|neurodegenerative neurodegeneration dementia demyelination degeneration|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain .
OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|psoriasis neuropathy CML thrombocytopenia anemia|intelligence psychopathology thinking ideation empathy|leukodystrophy|with regard to our biomarker for metachromatic entity , we own two separate patent families .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND allergy vaccination Allergy esophagitis|CMV pathogens HBV influenza HCMV|pertussis|and one of the ways of blocking the transmission of entity to newborns is to create an immunized cocoon around them so that all of the adults that are in contact
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|AND allergy vaccination Allergy esophagitis|tetanus diphtheria crude pertussis rabies|pertussis|accordingly , the company has been selling its acellular entity toxoid to ssi for formulation into dtap and dtap-ipv for sale in sweden and 12 denmark , respectively .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|AND allergy vaccination Allergy esophagitis|MRSA Candida Pseudomonas Acinetobacter acne|pertussis|to date , we have initiated development of a mab therapy for the treatment of entity and acinetobacter infections .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|AND allergy vaccination Allergy esophagitis|influenza measles pertussis diarrhea NEC|pertussis|the incidence of entity is increasing in association with exposure of unvaccinated and under-vaccinated individuals including infants who are not yet fully vaccinated , exposure
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND allergy vaccination Allergy esophagitis|pertussis meningococcal pneumococcal Lyme diphtheria|pertussis|certiva [ trademark ] is the company  s investigational vaccine against diphtheria , tetanus and entity disease .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|AND allergy vaccination Allergy esophagitis|Influenza Tuberculosis HAV dengue Leishmania|pertussis|entity is an endemic disease , but epidemics occur every 3 - 5 years .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|AND allergy vaccination Allergy esophagitis|pertussis diphtheria tetanus tox adsorbed|pertussis|quadracel® , a quadrivalent booster vaccine ( fifth dose ) including diphtheria , tetanus , accelular entity and ipv is being developed for the u . s . market .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND allergy vaccination Allergy esophagitis|botulinum lethal bovine snake hereditary|pertussis|the validity of the italian counterpart of connaught  s european patent 0 322 115 ( the "  115 patent " ) which allegedly relates to entity toxin mutants .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND allergy vaccination Allergy esophagitis|flu influenza poli Hi MMR|pertussis|full-year polio / entity / hib vaccines sales were down 0 . 7% to 1 , 749 million .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|AND allergy vaccination Allergy esophagitis|BPD bronchiolitis NEC CLD CAP|pertussis|infants with entity often require hospitalization in pediatric intensive care units , frequently requiring mechanical ventilation .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|AND allergy vaccination Allergy esophagitis|poli influenza pertussis ace rotavirus|pertussis|reported 2013 reported change on a reported basis change at constantexchange rates polio / entity / hib vaccines ( including pentacel® and pentaxim® ) 1 , 154 1 , 148 +0 . 5% +1 . 9%
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|AND allergy vaccination Allergy esophagitis|pertussis polysaccharide tetanus diphtheria influenza|pertussis|the company  s manufacturing operations for neisvac-c ( tm ) , certiva ( r ) and its acellular entity vaccine are located principally in one facility .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|AND allergy vaccination Allergy esophagitis|CRC AIDS ALS CLL leishmaniasis|pertussis|worldwide , nearly 50 million cases of entity are diagnosed annually and about 350 , 000 people die of the disease .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND allergy vaccination Allergy esophagitis|Vaccine vaccines vaccination alfa allergy|pertussis|illumigene® bordetella entity ( whooping cough )  commercialized in march 2014 6 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND allergy vaccination Allergy esophagitis|poli diphtheria MMR BV influenza|pertussis|+33 . 3 % total vaccines 1 , 800 1 , 422 +26 . 6 % +24 . 5 % polio / entity / hib vaccines posted 2017 first-half net sales of 901 million , up 41 . 3% cer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|feet ankle plantar craniofacial Achilles|scarring pigmentation acne itching ulceration|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin atrophy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|feet ankle plantar craniofacial Achilles|scarring atrophic itching ulceration diffuse|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin 82 table of contents atrophy .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|glaucoma DMD scleroderma myopia BCC|hypoparathyroidism|we believe transcon pth may provide patients suffering from entity with a pth replacement therapy that is designed to fully address all aspects of the disease more than standard of
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|osteoporosis malignancies BPH CKD periodontitis|hypoparathyroidism|we now have the financial resources to fund the continued u . s . development of preos in a variety of indications , including entity and osteoporosis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|psoriasis mucositis toxicities GVHD neutropenia|hypoparathyroidism|treatment , even with the less frequent regimens , may be an effective treatment option for those patients suffering from less severe entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|T2DM psoriasis insomnia RLS migraine|hypoparathyroidism|eb612 for the treatment of entity we believe eb612 may offer several advantages over natpara for the following reasons : • eb612 is designed to be dosed
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|NSCLC psoriasis CRC COPD CLL|hypoparathyroidism|would enable us to seek u . s . marketing approval of npsp558 as a new standard of care for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|DMD psoriasis ALS hyperthyroidism SCD|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|DBS cr tau id ss|hypoparathyroidism|we believe positive results from steps and replace will enable us to seek u . s . marketing approval of gattex for sbs and npsp558 for entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|osteoporosis BPH menopause endometriosis PCOS|hypoparathyroidism|origin ] injection ) is being evaluated in a phase 3 registration study known as replace as a hormone replacement therapy for entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|DMD psoriasis ALS hyperthyroidism SCD|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|CKD DMD hyperparathyroidism osteoporosis hypercalcemia|hypoparathyroidism|showed the predicted pharmacokinetic and pharmacodynamic response , suggesting the ability to normalize serum and urinary calcium levels in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1), ('BIO', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|osteoporosis osteomyelitis periodontitis gout spondylitis|hypoparathyroidism|candidate we chose to pursue was pth , which has the potential for therapeutic use in a number of indications including entity , osteoporosis and non-union fractures .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|CKD volunteers recipients osteoporosis Subjects|hypoparathyroidism|( sbs ) and a phase 3 registration study has been completed for natpara ( recombinant human parathyroid hormone ( rhpth [ 1-84 ] ) in adult entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|BD SCC psoriasis BV CPP|hypoparathyroidism|while sbs and entity are relatively rare disorders , we believe they represent a substantial commercial opportunity to us due to the significant unmet need
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|CKD hemodialysis ESRD osteoporosis oncology|hypoparathyroidism|replace , a phase 3 registration study of npsp558 , the companys bioengineered replica of human parathyroid hormone ( rhpth 1-84 ) , in adult entity patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|osteoporosis hypercalcemia hyperparathyroidism CKD AN|hypoparathyroidism|the symptoms of entity are typically managed with large doses of oral calcium supplementation and active vitamin d therapy to reduce the severity of
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 3)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|hyperparathyroidism hypercalcemia anemia osteoporosis anaemia|hypoparathyroidism|short bowel syndrome ) and our study of npsp558 is known as replace ( recombinant parathyroid hormone to normalize calcium and treat entity ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|psoriasis T2DM osteoporosis acne insomnia|hypoparathyroidism|criteria for 20 , 250 of these options was satisfied when the fda accepted the bla for natpara for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|Europe oncology Africa Brazil dentistry|hypoparathyroidism|we are committed to advancing the development of preos in entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|IBD hemophilia ITP migraine CKD|hypoparathyroidism|we are also developing natpara® ( rhpth [ 1-84 ] ) for the treatment of adult entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|AND hyperparathyroidism hypothyroidism hyperthyroidism hypercalcemia|CKD T2DM SCD osteoporosis DMD|hypoparathyroidism|reported the fdas approval of natpara as an adjunct to calcium and vitamin d to control hypocalcemia in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|Salmonella Allergy fever serology fungus|adenovirus cytomegalovirus dengue varicella influenza|typhus|doxycycline is an antibiotic used to treat anthrax , rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Salmonella Allergy fever serology fungus|herpes varicella syphilis zoster rubella|typhus|diseases that can be acquired from such accidents include hiv / aids , hbv , hcv , diphtheria , gonorrhea , entity , herpes simplex virus , malaria , syphilis and tuberculosis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Salmonella Allergy fever serology fungus|dengue adenovirus cytomegalovirus influenza syphilis|typhus|doxycycline is an antibiotic used to treat rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|serology Disease AND Allergy vaccination|influenza adenovirus dengue measles rotavirus|rabies|these efforts , we will continue the development of these drugs , as well as our other drug development endeavors that include entity , dengue viruses , and ebola / marburg viruses .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|serology Disease AND Allergy vaccination|diphtheria pertussis influenza tetanus varicella|rabies|talecris also has a line of hyperimmune therapies that provide treatment for tetanus , entity , hepatitis b , hepatitis a and rh factor control during pregnancy and at birth .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|serology Disease AND Allergy vaccination|influenza vaccinia helper progeny rabies|rabies|the candidate ligands for this nanoviricide were designed by the company using publicly available information regarding the interaction of the entity virus with cells .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|serology Disease AND Allergy vaccination|vaccinia zoster BCG polysaccharide licensed|rabies| an additional phase ii study in healthy adults evaluating crucells monoclonal antibody in combination with a entity vaccine is scheduled to start in india in the second quarter of 2009 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|serology Disease AND Allergy vaccination|CMV varicella cytomegalovirus syphilis rubella|rabies|seasonal influenza , hiv , oral and genital herpes ( hsv ) , viral diseases of the eye including ekc and herpes keratitis , hepatitis c , entity , dengue fever , and ebola virus , among others .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|serology Disease AND Allergy vaccination|rabies vaccinia tomato herpes influenza|rabies|cv7202 is an mrna that encodes the entity virus glycoprotein , rabv-g , formulated with lnps .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|disease|serology Disease AND Allergy vaccination|IgG leukocyte monoclonal polyclonal bovine|rabies|sales volume for human albumin and human immunoglobulin for intravenous decreased by 19 . 4% and 24 . 3% , respectively , while human entity immunoglobulin recorded an increase of 94 . 9% .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|serology Disease AND Allergy vaccination|psoriasis CLL themselves him IBS|rabies|nihe thereafter requested that we develop a drug for entity , a request to which we agreed .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|serology Disease AND Allergy vaccination|H5N1 dengue adenovirus H7 WNV|rabies|types i , ii , iii , & iv ; · hepatitis b virus ( hbv ) ; · hepatitis c virus ( hcv ) ; · entity ; · ebola and marburg viruses ; · japanese encephalitis ; and · west nile virus .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|serology Disease AND Allergy vaccination|influenza diphtheria cholera measles HBV|rabies|our lead vaccine program , cv7202 , is being developed for prophylactic vaccination against entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|serology Disease AND Allergy vaccination|rabies influenza HSV CMV dengue|rabies|rabicide , a nanoviricide against entity finished its first set of animal studies in the first quarter of 2007 in vietnam .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|serology Disease AND Allergy vaccination|influenza pathogens vaccines pneumonia vaccination|rabies|[ **** ] against rsv , para influenza , cmv pneumo ( including s . pneumoniae , branhamalla , non-typable haemophilus influenza and otitis media ) and entity in the field in the territory .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|serology Disease AND Allergy vaccination|anaphylaxis tetanus cholera leishmaniasis allergy|rabies|we evaluated the use of mrna for passive immunization in two indications , entity and botulism , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|serology Disease AND Allergy vaccination|CMV CD3 CD19 GBM CD20|rabies|anti-entity immune globulin therapy is prescribed for individuals suspected of recent exposure to the entity virus .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|serology Disease AND Allergy vaccination|Disease Tuberculosis Infection BV Transmission|rabies|entity is commonly transmitted by infectious saliva from the bite of a rabid animal .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|serology Disease AND Allergy vaccination|rabies canine feline inactivated FMD|rabies|since 2010 , isconova and vetbiochem have collaborated on the development of entity vaccines for dogs and cats .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|serology Disease AND Allergy vaccination|NSCLC CLL CRC MBC glioblastoma|rabies|in january 2020 , we reported preliminary data from our phase 1 trial of cv7202 in entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|serology Disease AND Allergy vaccination|vaccinia dengue influenza rabies hepatitis|rabies|have entered into work orders for the preclinical development of a lassa virus vaccine , a yellow fever vaccine and our entity virus vaccine .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|serology Disease AND Allergy vaccination|influenza rabies varicella adenovirus dengue|rabies|licenses in perpetuity for technologies developed by theracour for the virus types : hiv , hcv , herpes , asian ( bird ) flu , influenza and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|serology Disease AND Allergy vaccination|HBV influenza CMV adenovirus rabies|rabies|further , the company has identified highly active nanoviricide drug candidates against ebola / marburg , and against entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|AND psoriasis allergic fever vulgaris|rabies dengue varicella leishmaniasis herpes|psittacosis|dr . moore has conducted clinical research on infectious diseases such as venezuelan equine encephalitis , tuberculosis , listeriosis , entity , human orf , malaria , and hiv / aids .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|glaucoma psoriasis eczema acne probing|conjunctiv trachomatis chlamyd orch hom|trachoma|chlamydia entitytis also causes the ocular disease entity , which is a form of vesicular conjunctivitis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glaucoma psoriasis eczema acne probing|blindness retinitis AMD pathogens meningitis|trachoma|through the iti , we donate the antibiotic zithromax to combat blinding entity in developing countries .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glaucoma psoriasis eczema acne probing|globally deaths epidemic disparities blindness|trachoma|we intend to help the world health organization achieve its goal of eliminating blinding entity by the year 2020 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glaucoma psoriasis eczema acne probing|CMV influenza uveitis AMD dengue|trachoma|increase in annual dividends to $1 . 36 from $0 . 80•since 2010 , donated more than 580 million doses of zithromax ( azithromycin ) to treat entity , the leading cause of infectious blindness .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|glaucoma psoriasis eczema acne probing|collaboration partnership collaborative partnerships outreach|trachoma|internationally , we have two innovative access programs : the international entity initiative ( iti ) and the diflucan partnership program ( dpp ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|glaucoma psoriasis eczema acne probing|collaborative cooperative collaboration scientific consensus|trachoma|dr . feczko is a member of the technical expert committee for the international entity initiative of the task force for global health .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|glaucoma psoriasis eczema acne probing|trachomatis chlamyd Chlamydia genital hom|trachoma|because c . entitytis also causes entity , the world  s most common form of preventable blindness , the who estimates chlamydia is responsible for at least 15 percent of
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|glaucoma psoriasis eczema acne probing|night preventable sudden irreversible threatening|trachoma|in response , the number of people at risk of entity blindness worldwide has been reduced to 158 million from more than 300 million in 2010 . shantanu narayen , lead independent director of
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|disease|glaucoma psoriasis eczema acne probing|infra neuron arteri rodent opac|trachoma|because c . entitytis also causes entity , the worlds most common form of preventable blindness , the who estimates c . entitytis is responsible for at least 15 percent of the
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|glaucoma psoriasis eczema acne probing|AMD Stroke Diabetes Hypertension ROP|trachoma|entity is the leading cause of preventable blindness worldwide .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|glaucoma psoriasis eczema acne probing|meningitis sinusitis osteomyelitis herpes burns|trachoma|medicine for human diseases to treat a host of bacterial infections , including acute otitis media infection , pharyngitis , pneumonia , skin infection , entity , and etc .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|glaucoma psoriasis eczema acne probing|immunization grant vaccination outreach funding|trachoma|the iti , in which pfizer is a partner , has initiated entity programs in nine developing countries to date and plans to launch programs in an additional 10 countries .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|glaucoma psoriasis eczema acne probing|trachomatis chlamyd genital hom Chlamydia|trachoma|because c . entitytis also causes entity , the worlds most common form of 4 preventable blindness , the who estimates chlamydia is responsible for at least 15 percent
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|psoriasis uncontrolled staphylococcal vulgaris AND|abscess osteomyelitis abscesses pneumonia sinusitis|erysipelas|in this trial , patients with wound infections , major abscesses , and entity / cellulitis were enrolled in equal numbers .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|psoriasis uncontrolled staphylococcal vulgaris AND|abscess osteomyelitis abscesses ulcers ulcer|erysipelas|a lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|psoriasis uncontrolled staphylococcal vulgaris AND|abscess abscesses osteomyelitis ulcers ulcer|erysipelas|is defined as a bacterial infection of the skin with a lesion size area of at least 75 cm and includes cellulitis / entity , wound infections , and major cutanenous abscesses .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|psoriasis uncontrolled staphylococcal vulgaris AND|osteomyelitis meningitis pneumonia abscess bacteremia|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection and major cutaneous abscess .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|psoriasis uncontrolled staphylococcal vulgaris AND|abscess osteomyelitis abscesses ulcers ulcer|erysipelas|lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|psoriasis uncontrolled staphylococcal vulgaris AND|neuropathy nausea proteinuria vomiting pruritus|erysipelas|reported for at least 0 . 1% of subjects and for which p<0 . 01 included concussion ( denosumab <0 . 1% , n=1 ; placebo 0 . 3% , n=11 ) and entity ( denosumab 0 . 2% , n=7 ; placebo 0% , n=0 ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|psoriasis uncontrolled staphylococcal vulgaris AND|abscess osteomyelitis abscesses ulcer ulcers|erysipelas|examples of absssi are cellulitis / entity , wound infection , major cutaneous abscess and burn infections .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|disease|psoriasis uncontrolled staphylococcal vulgaris AND|dengue anemia meningitis hemophilia fever|erysipelas|in pairs or chains , many species of which destroy red blood cells and cause various diseases in human beings , including entity , scarlet fever , and septic sore throat .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|psoriasis uncontrolled staphylococcal vulgaris AND|osteomyelitis meningitis pneumonia abscess bacteremia|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection , and major cutaneous abscess .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|psoriasis sarcoidosis KD SLE AE|sarcoidosis|the primary treatment for entity is corticosteroids ; however , the outcome of this treatment on the ph is unclear .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|dementia psychosis psychopathology autism T2DM|sarcoidosis|there are a number of different mechanisms linking ph with entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|embolism thromboembolism endarterectomy aspergillosis embolization|sarcoidosis|we selected pulmonary entity as our first ild indication and we are currently enrolling a proof-of-concept phase 1b / 2a clinical trial .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|scleroderma psoriasis COPD fibromyalgia sarcoidosis|sarcoidosis|in 2018 , we also initiated development of inopulse for the treatment of ph associated with entity ( ph-sarc ) .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|Any Only largest another Another|sarcoidosis|entity initial phase ii trial completed .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|MRSA osteomyelitis bacteremia meningitis migraine|sarcoidosis|that we are exploring in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah , and entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|aspergillosis embolism emphysema adenocarcinoma prophylaxis|sarcoidosis|phase 1b / 2a clinical trial and , if that trial is successful , we believe we can expedite development of atyr1923 for pulmonary entity towards regulatory approval .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|embolism thromboembolism aspergillosis endarterectomy embolization|sarcoidosis|we selected pulmonary entity as our first ild indication and initiated a phase 1b / 2a proof-of-concept clinical trial in december 2018 .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|Tuberculosis sarcoidosis SLE IBD Asthma|sarcoidosis|entity is a multi-system disease which is characterized by the growth of granulomas ( inflammatory cells ) in one or more organs .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|pneumonia COPD ARDS fever cough|sarcoidosis|by mondobiotech and the ema has designated aviptadil an orphan medicinal product for the treatment of acute lung injury and entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|COPD bronchiectasis sarcoidosis exacerbations ILD|sarcoidosis|for example , we are just now beginning to explore the potential for acthar in symptomatic entity with a small pilot selling effort to pulmonologists .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|MRSA sh osteomyelitis etc mad|sarcoidosis|that we are evaluating in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah and entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|NSCLC DLBCL CRC OSCC cirrhosis|sarcoidosis|the presence of ph in entity is associated with a poor prognosis .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|COPD dyspnea psoriasis scleroderma emphysema|sarcoidosis|inopulse for ph-sarc we are also developing inopulse for the treatment of ph associated with entity , or ph-sarc .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|psoriasis IBD scleroderma metformin NSCLC|sarcoidosis|there is no approved therapy for ph associated with entity .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|vasculitis cardiomyopathy dementia cirrhosis migraine|sarcoidosis|who group v consists of ph with multifactorial mechanisms , of which we are focusing on a subset of patients with entity that has caused ild .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sarcoidosis amyloidosis uncontrolled psoriasis cirrhosis|COPD psoriasis sarcoidosis scleroderma fibromyalgia|sarcoidosis|in 2018 , we initiated development of inopulse for the treatment of ph associated with entity ( “ph-sarc” ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|vaccination tetanus serology immunization allergy|tetanus diphtheria pertussis botulinum Toxoplasma|tetanus|the same participants when stimulated with 85 table of contents cytomegalovirus ( cmv ) , epstein barr virus ( ebv ) , influenza virus and entity toxoid-derived immuno- dominant peptide panels .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|vaccination tetanus serology immunization allergy|tetanus pertussis diphtheria booster conjugate|tetanus|and is manufacturing and marketing , a line of vaccines including whole virus and split virus influenza vaccines , a combined diphtheria entity vaccine and a vaccine to prevent tuberculosis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|vaccination tetanus serology immunization allergy|tetanus botulinum diphtheria pertussis cholera|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|vaccination tetanus serology immunization allergy|tetanus pertussis rubella pneumonia zoster|tetanus|response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , diphtheria and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vaccination tetanus serology immunization allergy|cytomegalovirus CMV rubella adenovirus pertussis|tetanus|hyperimmune products currently available include hepatitis b , entity , rabies cytomegalovirus and rhod immune globulins .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|vaccination tetanus serology immunization allergy|cholera influenza rabies rotavirus polysaccharide|tetanus|during 2000 , we anticipate that innovaccines will begin to scale up an oral entity vaccine to take into human clinical trials .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|disease|vaccination tetanus serology immunization allergy|monoclonal leukocyte IgG IgG1 leucocyte|tetanus|human entity immunoglobulin – 250iu mainly used for the prevention and therapy of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vaccination tetanus serology immunization allergy|tetanus pertussis botulinum diphtheria rubella|tetanus|if ssi fails to continue to supply the company with these components , the company has a royalty-bearing license to produce diphtheria and entity toxoids for this purpose .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|vaccination tetanus serology immunization allergy|tetanus diphtheria Toxoplasma Bacillus botulinum|tetanus|then the antigenic proteins , entity toxoid and candida albicans were applied topically to the treated skin sites .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|vaccination tetanus serology immunization allergy|tetanus botulinum diphtheria pertussis cholera|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|vaccination tetanus serology immunization allergy|canine namely monoclonal equine bovine|tetanus|for our plasma products , entity immunoglobulin , factor viii and pcc are included on the life-saving essential drug list in most chinese provinces , for which drug
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|vaccination tetanus serology immunization allergy|rabies monoclonal canine bovine tetanus|tetanus|three of our approved products , human albumin , human rabies immunoglobulin and human entity immunoglobulin are affected by the 2013 adjustments .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|vaccination tetanus serology immunization allergy|tetanus pertussis pneumonia cholera zoster|tetanus|vaccines against two life-threatening bacterial diseases , diphtheria and entity , came into use early in this century .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|vaccination tetanus serology immunization allergy|CD3 OVA CD40 EBV GBM|tetanus|xmab5871 inhibited anti-entity antibody responses in mice engrafted with human b cells and immunized with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|disease|vaccination tetanus serology immunization allergy|monoclonal leukocyte polyclonal leucocyte IgG1|tetanus|human entity immunoglobulin  250iu mainly used for the prevention and therapy of tetanus .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|vaccination tetanus serology immunization allergy|rubella adenovirus varicella pertussis influenza|tetanus|ivig product enriched with naturally occurring polyclonal anti-pathogen antibodies , such as streptococcus pneumonia , h . influenza type b , cytomegalovirus , measles and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|vaccination tetanus serology immunization allergy|tetanus diphtheria pertussis vaccines flu|tetanus|sales of adacel ( adult entity / diphtheria / whooping cough booster ) , launched in the united states in july 2005 , reached 154 million in 2006 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vaccination tetanus serology immunization allergy|tetanus pertussis diphtheria botulinum rubella|tetanus|sp0173 : the current adacel® ( tdap booster vaccine containing entity toxoid , diphtheria toxoid , and 5-component acellular pertussis ) is not indicated in the us for persons aged over 64 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|vaccination tetanus serology immunization allergy|rubella adenovirus CMV RSV cytomegalovirus|tetanus|streptococcus pneumoniae , h . influenza type b , cmv , measles , entity etc . ) as well as high levels of antibodies targeted to respiratory syncytial virus , or rsv .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|vaccination tetanus serology immunization allergy|tetanus pertussis rubella MMR vomiting|tetanus|food and drug administration ( " fda " ) to market its dtap vaccine ( certiva ( registered ) ) in the united states for the prevention of diphtheria , entity , and pertussis ( whooping cough ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|diphtheria vulgaris autoantibodies serology immunization|booster diphtheria tox tetanus polysaccharide|diphtheria|vaccines business segment :  march 27 , 2007 : akorn announced the signing of a three-year exclusive distribution agreement for tetanus entity vaccine .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|diphtheria vulgaris autoantibodies serology immunization|influenza varicella dengue pertussis rubella|diphtheria|they have eradicated smallpox and dramatically reduced the mortality and morbidity associated with many other infectious diseases , such as entity , measles , polio and tetanus .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria pertussis influenza varicella tetanus|diphtheria|adaptive immune response is the basis for preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity and tetanus .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|diphtheria vulgaris autoantibodies serology immunization|pertussis diphtheria influenza varicella rubella|diphtheria|adaptive immune response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity , and tetanus .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria pertussis influenza cholera pneumonia|diphtheria|vaccines against two life-threatening bacterial diseases , entity and tetanus , came into use early in this century .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria pertussis influenza tetanus cholera|diphtheria|under supply agreements , the company manufactures the acellular pertussis component , and ssi manufactures the entity , tetanus and ipv components for the dtap and dtap-ipv vaccines .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria influenza diarrhea pneumonia cholera|diphtheria|total sales of rotarix , for rotavirus , boostrix , for prevention of entity , tetanus and whooping cough , and influenza vaccines , fluarix / flulaval , reached £274 million , up 91% .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|botulinum cholera diphtheria pertussis tetanus|diphtheria|according to the world health organization , the majority of the western world  s population is immunized to entity toxin .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria pertussis tetanus cholera measles|diphtheria|the company produces the monocomponent acellular pertussis toxoid and formulates the final product with entity and tetanus toxoids manufactured and supplied by ssi .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|tetanus diphtheria pertussis cholera called|diphtheria|the peptide is joined to a carrier , entity toxoid , to enhance the immune response .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria influenza measles flu MMR|diphtheria|vaccination against entity , tetanus and pertussis is mandated by most states for all children with a total of five doses administered at two ,
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|cholera diphtheria tetanus botulinum pertussis|diphtheria|using a plasmid with an expression cassette of the entity toxin , no immune response will be encountered as happens when using a virus ; moreover , people born in western countries are routinely
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|cholera diphtheria Pseudomonas botulinum CTX|diphtheria| crm197  we have several development and commercial partnerships in place for crm197 , which is a non-toxic mutant of entity toxin .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria pertussis tetanus botulinum cholera|diphtheria|we obtain some of the key components , including entity toxoid ( dt ) and tetanus toxoid ( tt ) , through a supply contract with aventis pasteur , one of our strategic collaborators .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|diphtheria vulgaris autoantibodies serology immunization|anticancer cytotoxic beyond foreign alter|diphtheria|gtb-1550 binds to cancer cells , the cancer cells internalize gtb-1550 , and are killed due to the action of drugs cytotoxic entity toxin payload .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|diphtheria vulgaris autoantibodies serology immunization|CMV syphilis AIDS BV HSV|diphtheria|expanded its internal research and development efforts with emphasis on a mucosal vaccine against chlamydia and a mucosal vaccine against entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|cholera diphtheria tetanus lethal pertussis|diphtheria|biocancell  s leading drug , bc-819 , is a double stranded dna plasmid construct that incorporates the gene for entity toxin ( dta ) under the regulation of the promoter sequence for h19 gene .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria pertussis influenza tetanus varicella|diphtheria|daptacel® , a trivalent vaccine against pertussis , entity and tetanus , was launched in the united states in 2002 and has become a strong sales contributor due to its
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria tetanus botulinum pertussis cholera|diphtheria|the supply commitment of materials suitable for human use consists of entity toxoid and / or tetanus toxoid .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|diphtheria vulgaris autoantibodies serology immunization|diphtheria influenza pertussis tetanus measles|diphtheria|also launched in 1995 was infanrix , the combined acellular vaccine for entity , tetanus and pertussis ( whooping cough ) in switzerland .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|neovascularization CNV choroid peel glaucoma|blindness him see go learn|choroiditis|as a student during the 1950s he had lost much of the sight in his right eye to entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|neovascularization CNV choroid peel glaucoma|uveitis neuropathy glaucoma retinopathy vasculitis|choroiditis|no vasculitis , retinitis , or entity were observed .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|disease|neovascularization CNV choroid peel glaucoma|uveitis CNV idiopathic scleroderma AMD|choroiditis|this type of uveitis is called entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|disease|feet craniofacial Achilles thumb toe|alopecia retinopathy headache anemia blindness|polydactyly|early onset obesity and hyperphagia often associated with bbs , a rare genetic disorder that is also characterized by vision loss , entity , kidney abnormalities , and other symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|feet craniofacial Achilles thumb toe|alopecia retinopathy headache osteoporosis proteinuria|polydactyly|it is a rare monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|feet craniofacial Achilles thumb toe|retinopathy alopecia headache proteinuria headaches|polydactyly|bardet-biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|feet craniofacial Achilles thumb toe|From Within comprising represents Following|polydactyly|acrania / turner syndrome / prader willi syndrom / left ventricular hypoplasia entity 112 table of contents in the trial , ongoing pregnancies were followed up to 28 days post-delivery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|feet craniofacial Achilles thumb toe|retinopathy alopecia headache proteinuria anemia|polydactyly|bardet‑biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Infection Infections Plasmodium Acinetobacter Positive|Toxicity Pain neuropathy neurotoxicity mucositis|listeriosis|entity has also been reported as a grade 3 ae .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|Infection Infections Plasmodium Acinetobacter Positive|hypotension dyspnea syncope dizziness headache|listeriosis|examples of the aes experienced include , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity among others .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|Infection Infections Plasmodium Acinetobacter Positive|hypotension dizziness headache tachycardia bradycardia|listeriosis|examples of the aes experienced include among others , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|Infection Infections Plasmodium Acinetobacter Positive|AE anaphylaxis ICH TIA hypoglycemia|listeriosis|the event was diagnosed by the treating investigator as being a case of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|Infection Infections Plasmodium Acinetobacter Positive|diarrhoea diarrhea colitis gastroenteritis fever|listeriosis|when ingested , some strains of listeria can cause entity , which affects primarily the elderly , pregnant women , newborns and adults with weakened immune systems .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|Infection Infections Plasmodium Acinetobacter Positive|neuropathy nausea hypoglycemia hypoglycaemia AE|listeriosis|one grade 3 serious ae of entity was reported .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|Infection Infections Plasmodium Acinetobacter Positive|tetanus rotavirus dog cholera canine|listeriosis|the overhalla facility was purchased by the aahd in november 1994 and presently manufactures ringworm vaccines for cattle and entity vaccines for sheep and goats .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Infection Infections Plasmodium Acinetobacter Positive|psychiatry beings nutrition society immunity|listeriosis|dr . lorbers major interest in infectious diseases is in human entity , an area in which he is regarded as an international authority .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Infection Infections Plasmodium Acinetobacter Positive|escape emergence profit interference harm|listeriosis|the attenuation of the listeria strains used in advaxis immunotherapies , these listeria are nonpathogenic and therefore limit the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|Infection Infections Plasmodium Acinetobacter Positive|escape improvements emergence profit cure|listeriosis|advaxis immunotherapies , the listeria do not replicate and spread from cell to cell at this point , limiting the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|psoriasis amyloidosis vulgaris AND Known|mosquito leprosy tick anaemia parasite|onchocerciasis|apply outside the disease endemic countries , or in relation to sales of the product for purposes other than filariasis or entity control .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|walking ankle feet club dysplasia|scoliosis pelvis extremities legs toes|clubfoot|hips at birth , prominent chin and forehead , flat feet , soft skin , floppy heart valve ( mitral valve prolapse ) , curved spine and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|meal manipulation polymorphism maneuver stimulus|gastroparesis|dr . aurora reported that this entity can result in up to an 80% slower rate of digestion , or gastric motility , in migraineurs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|colitis ulcer ulcers neuropathy ulceration|gastroparesis|this protein may have utility in the treatment of post-operative ileus and gastrointestinal motility disorders , such as diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|esophagitis cardiomyopathy neuropathy ulcer esophagus|gastroparesis|agonist of the motilin receptor that enhances esophageal motility in gerd patients and accelerates gastric emptying in patients with diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|psoriasis scleroderma migraine fibromyalgia arthritis|gastroparesis| the results of the recent atopic dermatitis ( epione ) , entity ( vly686-2301 ) and motion sickness ( motion sifnos ) studies have all been submitted to peer-review publications .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|dyspepsia discomfort ulcer dysphagia ulcers|gastroparesis|post-surgical entity is often associated with peptic ulcer surgery , bariatric procedures or esophageal procedures and is thought to result from damage / desensitization of
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|neuropathy nephropathy retinopathy episodes ulcers|gastroparesis|results from a phase 3 clinical trial of gimoti in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|migraine OSA OAB ADHD autism|gastroparesis|we believe our novel intranasal delivery formulation will address a significant unmet market need for patients with the symptoms of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|constipation IBS GERD dyspepsia IBD|gastroparesis|in march 2015 , we initiated a phase 2b study of velusetrag for the treatment of patients with entity and other gastrointestinal motility disorders .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|neuropathy episodes ulcers nephropathy ulcer|gastroparesis|are the only products currently approved in the united states to treat the symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|migraine constipation dyspepsia IBS diarrhea|gastroparesis|ati-7505 has potential use in five indications : chronic constipation , functional dyspepsia , gerd , entity and ibs with constipation .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|rhinitis exacerbations ulcers sinusitis ulcer|gastroparesis|spray , the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|urticaria psoriasis eczema pruritus migraine|gastroparesis|neurokinin-1 receptor ( nk-1r ) antagonist , which is presently in clinical development for the treatment of chronic pruritus in atopic dermatitis and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|nephropathy neuropathy retinopathy cardiomyopathy ulcers|gastroparesis|the results of these clinical trials support our belief that relamorelin has the potential to be a safe and effective treatment for diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|neuropathy nephropathy episodes retinopathy ulcers|gastroparesis|in april 2014 , we commenced a phase 3 clinical trial of evk-001 in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|diarrhea gastritis constipation dyspepsia vomiting|gastroparesis|subjects with no history of migraine , migraineurs experienced , to varying degrees , paralysis of the muscles of the stomach , or entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|neuropathy cardiomyopathy nephropathy pancreatitis ulcers|gastroparesis|motus has the worldwide rights to rm-131 ( relamorelin ) , a peptide ghrelin agonist being developed for the treatment of diabetic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|neuropathy retinopathy pruritus nausea esophagitis|gastroparesis|the company believes that emitasol ( r ) , when given intranasally , may be effective in treating diabetic entity and in preventing delayed onset emesis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|nausea constipation IBS insomnia RLS|gastroparesis|metoclopramide is the only product currently approved in the united states to treat entity , and is currently available only in oral and intravenous forms .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|IBS fibromyalgia ADHD COPD OSAS|gastroparesis|the primary endpoint will be the effect of velusetrag on symptoms in subjects with entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|neuropathy Surgery ulcer gastritis uncontrolled|neuropathy hyperglycemia mellitus retinopathy ulcers|gastroparesis|emitasol ( r ) is proposed as a method to control diabetic entity and to prevent delayed emesis associated with cancer chemotherapy .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|Aspergillus Candida psoriasis meningitis vulgaris|psoriasis CRC T2DM NSCLC migraine|cryptococcosis|in addition , the fda has granted orphan drug designation to mat2203 for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|Aspergillus Candida psoriasis meningitis vulgaris|official descriptive CDC vital epidemiological|cryptococcosis|according to entity statistics maintained on the centers for disease control and preventions website from february 2014 , the greatest burden of this disease
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|Aspergillus Candida psoriasis meningitis vulgaris|AIDS meningitis syphilis he PML|cryptococcosis|cryptococcal meningitis has become the most common cause of adult meningitis in many parts of africa , where entity now rivals tuberculosis in all-case mortality .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Aspergillus Candida psoriasis meningitis vulgaris|T2DM psoriasis ADHD migraine insomnia|cryptococcosis|●as previously reported , during the fourth quarter of 2019 , fda granted mat2203 orphan drug designation for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Aspergillus Candida psoriasis meningitis vulgaris|aspergillosis cytomegalovirus CMV Aspergillus Tuberculosis|cryptococcosis|the three major types of these infections are candidiasis , aspergillosis and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Aspergillus Candida psoriasis meningitis vulgaris|Tuberculosis aspergillosis Aspergillus fumigatus pneumonia|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|Aspergillus Candida psoriasis meningitis vulgaris|aspergillosis Fusarium osteomyelitis Aspergillus fungus|cryptococcosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , coccidioidomycosis , entity and zycomycosis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|Aspergillus Candida psoriasis meningitis vulgaris|Tuberculosis Aspergillus aspergillosis fumigatus IPF|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common life-threatening fungal
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|Aspergillus Candida psoriasis meningitis vulgaris|leishmaniasis meningitis Leishmania fever cholera|cryptococcosis|in april 2015 , the ema granted two orphan drug designations for ar-12 for the treatment of entity and tularaemia .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|abscess Disease meningitis Inflammatory Symptomatic|burns poisoning assault addiction hepatotoxicity|arachnoiditis|if left untreated , chemical entity may be fatal .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|abscess Disease meningitis Inflammatory Symptomatic|AEs hypersensitivity rash toxicities allergy|arachnoiditis|the incidence and severity of chemical entity can be reduced by coadministration of dexamethasone .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|abscess Disease meningitis Inflammatory Symptomatic|hypersensitivity allergy rash alopecia burns|arachnoiditis|patients receiving depocyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|abscess Disease meningitis Inflammatory Symptomatic|rash hypersensitivity allergy headache intolerance|arachnoiditis|in all clinical studies , chemical entity , a syndrome manifested primarily by nausea , vomiting , headache and fever , was a common adverse event .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|psoriasis AND vulgaris acne topical|Other Novel Alternative Additional Numerous|aniridia|entity therapeutic interventions , such as artificial iris implantation , are being developed by humanoptics ag . •emflaza for dmd .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|psoriasis AND vulgaris acne topical|familial ALS SMA FAP sporadic|aniridia|we estimate that approximately one-third of all entity cases are due to a nonsense mutation .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis AND vulgaris acne topical|CMT PCD LCA Asthma Schizophrenia|aniridia|entity is a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|psoriasis AND vulgaris acne topical|Europe advance rodents man macaques|aniridia|· translarna pipeline will expand with a proof of concept study in entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis AND vulgaris acne topical|Autism DMD Schizophrenia NF1 FAS|aniridia|entity is a rare genetic disorder that results in disruption in the development of the eye .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis AND vulgaris acne topical|ALS myopia migraine autism glaucoma|aniridia|for example , investigators studying entity , a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms in which
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis AND vulgaris acne topical|carriers NSCLC gliomas cohorts drivers|aniridia|ptc plans to initiate a phase 2 proof of concept study in nonsense mutation entity by year end 2015 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|psoriasis AND vulgaris acne topical|ii iii max pc vi|aniridia|in addition to its advanced dmd and cf programs , ptc is now pursuing two additional indications , mps i and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|falciparum vivax Plasmodium serology psoriasis|immunodeficiency leishmaniasis CMV immunity colitis|malaria|other pox virus vectors are being evaluated in experimental models of human entity and , in a hybrid regimen combining doses of a modified live virus , with a subunit hiv vaccine to protect high
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|falciparum vivax Plasmodium serology psoriasis|influenza GSK vaccinia rabies MV|malaria|ema regulatory decision on glaxosmithklines entity vaccine candidate rts , s , which contains agenuss qs-21 stimulon® adjuvant .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|falciparum vivax Plasmodium serology psoriasis|influenza conjugate pneumococcal allergy rabies|malaria| entity vaccine based on advac® / per . c6® technologies : crucell and its collaborator , the us national institute of allergy and infectious diseases ( niaid ) , part
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|falciparum vivax Plasmodium serology psoriasis|mosquito insect Aedes Anopheles dengue|malaria|the global plan for insecticide resistance management in entity vectors , released in 2012 , contains a five-pillar strategy on managing the threat of insecticide resistance .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|falciparum vivax Plasmodium serology psoriasis|World French scientific political legal|malaria|as per the entity foundation international , malaria now kills more people than it did 3 decades ago .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|falciparum vivax Plasmodium serology psoriasis|leishmaniasis schistosomiasis leprosy migraine alcoholism|malaria|quinine , a natural product from the bark of the cinchona tree , was one of the first treatments for entity and appeared in the 17 ( th ) century .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|falciparum vivax Plasmodium serology psoriasis|breeding gambling residency federal running|malaria|in 2004 , the entity program revenue was limited to breeding activities to create a new founder line .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|falciparum vivax Plasmodium serology psoriasis|leishmaniasis VL dengue schistosomiasis diphtheria|malaria|currently pursuing our negotiation with several countries in africa to introduce our larvicide product , greenex™ as a prevention agent for entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|falciparum vivax Plasmodium serology psoriasis|scientific political business vent academic|malaria|dr . rosenberg also serves on the boards of directors of lovelace respiratory research institute , karo bio ab , and medicines for entity venture .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|falciparum vivax Plasmodium serology psoriasis|CMV HSV VZV HCMV Chlamydia|malaria|we expect similarly to advance our novel non-clinical prophylactic vaccine and immunotherapy programs against chlamydia , hsv-2 and entity through human 3 table of contents proof of concept .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|falciparum vivax Plasmodium serology psoriasis|mosquito pest tick dengue snail|malaria|mosquito resistance to at least one insecticide used for entity control has been identified in 64 countries around the world .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|falciparum vivax Plasmodium serology psoriasis|insert code kit bank name|malaria|currently , both our cassette entity pf and entity pf / pv have been listed under the who procurement process .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|falciparum vivax Plasmodium serology psoriasis|influenza rotavirus adolescent AIDS pneumococcal|malaria|we are collaborating with the bill & melinda gates foundation on entity vaccine research .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|falciparum vivax Plasmodium serology psoriasis|ART France Canada medicines Medicare|malaria|the who has made the roll back of entity , by 50% during the decade ending 2011 , one of its 4 major objectives of the current decade .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|falciparum vivax Plasmodium serology psoriasis|investigational approved medicinal generic dual|malaria|in the case of our entity product candidate , we may encounter difficulties in finding potential patients because our initial regimen requires patients to first fail other
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|falciparum vivax Plasmodium serology psoriasis|candidiasis periodontitis leishmaniasis mastitis bacteremia|malaria|as well as an extended spectrum of activity against ca-mrsa , streptococci , haemophilus , enterococci , mycobacterium avium and in animal models of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 2)])|disease|falciparum vivax Plasmodium serology psoriasis|fever falciparum vivax anaemia anemia|malaria|who currently recommends chloroquine for the treatment of p . vivax entity where the drug remains effective .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|falciparum vivax Plasmodium serology psoriasis|microbiology toxicology hematology chemistry epidemiological|malaria|the kemri / cdc research and public health collaboration has well-developed entity , hiv , microbiology , and tuberculosis laboratories that perform a range of standard diagnostic procedures .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|falciparum vivax Plasmodium serology psoriasis|parasites falciparum vivax fever anaemia|malaria|who recommends acts for the treatment of chloroquine-resistant p . vivax entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|falciparum vivax Plasmodium serology psoriasis|dengue influenza DENV measles adenovirus|malaria|u . s . naval medical research center ( nmrc ) allowing them to use our proprietary adenovector technology for the development of vaccines against entity and dengue virus .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|disease|fungus Aspergillus aspergillosis psoriasis nail|fungi parasites yeasts mycobacteria pathogens|blastomycosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|fungus Aspergillus aspergillosis psoriasis nail|aspergillosis candidiasis osteomyelitis fungi syphilis|blastomycosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fungus Aspergillus aspergillosis psoriasis nail|aspergillosis syphilis candidiasis Tuberculosis herpes|blastomycosis|examples of such infections include aspergillosis , entity , candidiasis , coccidioidomycosis , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|fungus Aspergillus aspergillosis psoriasis nail|aspergillosis candidiasis osteomyelitis syphilis fungi|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|fungus Aspergillus aspergillosis psoriasis nail|aspergillosis candidiasis osteomyelitis fungi syphilis|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 3), ('BIO', 1)])|disease|neuropathy mellitus excluding dysplasia AND|glycoprotein hemophilia glycogen phosphorylase phosphodiesterase|mucopolysaccharidosis|if approved , this would be the first human enzyme replacement therapy for the treatment of hunter syndrome , also known as entity ii ( mps ii ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|neuropathy mellitus excluding dysplasia AND|pt es my ble tic|mucopolysaccharidosis|entity i , or mps i lambert eaton myasthenic syndrome , or lems firdapse has not received
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|neuropathy mellitus excluding dysplasia AND|tic pt migraine alopecia metformin|mucopolysaccharidosis|the u . s . patent and trademark office issued to us the u . s . patent no . 6 , 426 , 208 covering aldurazyme for the treatment of entity i ( or mps i ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|disease|neuropathy mellitus excluding dysplasia AND|thalassemia Diabetes glycoprotein hemophilia haemoglobin|mucopolysaccharidosis|alpha-n-acetylglucosaminidase ( naglu ) with a peptide derived from insulin-like growth factor 2 ( igf2 ) for the treatment of sanfilippo b syndrome or entity iiib ( mps iiib ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|neuropathy mellitus excluding dysplasia AND|see MPS BV VI BS|mucopolysaccharidosis|hgt- 1410 for sanfilippo a syndrome ( entity iiia ) hgt- 1410 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome ,
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|neuropathy mellitus excluding dysplasia AND|see MPS BV CIN VI|mucopolysaccharidosis|shp610 for sanfilippo a syndrome ( entity iiia ) shp610 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome , a lysosomal
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|neuropathy mellitus excluding dysplasia AND|homozygous hyperlipidemia heterozygous Mediterranean hypercholesterolemia|mucopolysaccharidosis|our most advanced programs are for the treatment of two severe genetic diseases , homozygous familial hypercholesterolemia ( hofh ) and entity type i ( mps i ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|disease|neuropathy mellitus excluding dysplasia AND|Hemoglobin CMT MPS Diabetes PCD|mucopolysaccharidosis|entity i , or mps i , is a rare genetic disorder that affects many body systems and that leads to organ damage .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|neuropathy mellitus excluding dysplasia AND|seizure hypersensitivity SMA tic migraine|mucopolysaccharidosis|elaprase elaprase is a treatment for hunter syndrome ( also known as entity type ii or mps ii ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|neuropathy mellitus excluding dysplasia AND|WT mC JAK2 pc del|mucopolysaccharidosis|alexion decided to reduce its investment in sbc-103 , a recombinant form of the naglu enzyme being evaluated in patients with entity iiib , or mps iiib .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|disease|neuropathy mellitus excluding dysplasia AND|acquired migraine inherited myelodysplastic galactose|mucopolysaccharidosis|naglazyme is a recombinant form of n-acetylgalactosamine 4-sulfatase ( arylsulfatase b ) indicated for patients with entity vi ( mps vi ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|neuropathy mellitus excluding dysplasia AND|migraine glioblastoma acne Leishmania macular|mucopolysaccharidosis|agreement with genzyme to establish a joint venture ( biomarin / genzyme llc ) for the worldwide development and commercialization of aldurazyme to treat entity i ( mps i ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|neuropathy mellitus excluding dysplasia AND|Anopheles Su lambda Aedes genera|mucopolysaccharidosis|our initial programs are focused on lsds such as entity ( mps ) iiia and iiib .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|neuropathy mellitus excluding dysplasia AND|bean mating plaque phage spot|mucopolysaccharidosis|this model , initially focused on gaucher disease , has extended to fabry disease , entity type i , and pompe disease .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('BIO', 1)])|disease|neuropathy mellitus excluding dysplasia AND|hemophilia Hb G6PD MPS thalassemia|mucopolysaccharidosis|decreased levels of the alpha-l-iduronidase enzyme result in -------------- individuals having entity i ( " mps i " ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|uveitis glaucoma psoriasis neovascularization AMD|uveitis periodontitis arthritis spondylitis ulcers|uveitis|we believe that reproxalap and certain of our other product candidates may qualify as an orphan drug for noninfectious anterior entity , and possibly other diseases that we may test .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uveitis glaucoma psoriasis neovascularization AMD|uveitis chamber teeth periodontitis headache|uveitis|patients with noninfectious anterior entity generally experience severe pain , sensitivity to light , and vision loss .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uveitis glaucoma psoriasis neovascularization AMD|uveitis periodontitis teeth meniscus cataract|uveitis| clinical trials in 2015 , pending successful ind submissions , we intend to initiate clinical trials in sls and noninfectious anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|uveitis glaucoma psoriasis neovascularization AMD|PCV AMD CNV CSC psoriasis|uveitis|in december 2018 for xipere , and , if approved , xipere will be the first therapy indicated for macular edema associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|uveitis glaucoma psoriasis neovascularization AMD|colitis arthritis glomerulonephritis vasculitis cystitis|uveitis|we have conducted with our mc1r peptide drug candidates have shown positive results in experimental models of inflammatory bowel disease , entity and nephritis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|uveitis glaucoma psoriasis neovascularization AMD|glaucoma AMD neovascularization cataract retinopathy|uveitis|the company is planning phase ii studies for age-related macular degeneration ( later diabetic macular edema , proliferative vitreoretinopathy and entity ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|disease|uveitis glaucoma psoriasis neovascularization AMD|bevacizumab retina ii finally neovascularization|uveitis|value . ”about ebi-031 eleven biotherapeutics  most advanced preclinical product candidate is ebi-031 for treatment of diabetic macular edema , or dme , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uveitis glaucoma psoriasis neovascularization AMD|clinic mellitus registry vasculitis Registry|uveitis|and drug administration ( fda ) to review the phase 3 eyeguard-b data together with the data from the two behçets disease entity phase 2 studies conducted independently by xoma and servier .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|disease|uveitis glaucoma psoriasis neovascularization AMD|PCV AMD CNV CSC uveitis|uveitis|also demonstrate comparability of the proposed drug , which we believe may require a clinical trial in macular edema associated with entity , against our product , unless a biowaiver is obtained .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis glaucoma psoriasis neovascularization AMD|uveitis periodontitis spondyl instability spondylitis|uveitis|both the sjögren-larsson syndrome ( sls ) trial and noninfectious anterior entity trial have begun enrollment and we expect to begin to provide preliminary data for these indications by the end of
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uveitis glaucoma psoriasis neovascularization AMD|uveitis vitreous pole vitrectomy retinitis|uveitis|lombs ) product retisert ( a surgically implanted intravitreal drug delivery device containing fa approved for the treatment of chronic non-infectious posterior entity ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|uveitis glaucoma psoriasis neovascularization AMD|hepatitis colitis arthritis dermatitis encephalomyelitis|uveitis|due to its th17 activity , we believe vtp-43742 will be most effective in psoriasis , ms , behcet  s disease and autoimmune entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis glaucoma psoriasis neovascularization AMD|glaucoma psoriasis uveitis wounds allergies|uveitis|develop and sell psividas proprietary delivery device for indications for diseases outside of the eye or for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|uveitis glaucoma psoriasis neovascularization AMD|NSCLC CRC psoriasis CIN glioblastoma|uveitis|the second quarter of 2016 ; and ( ii ) planning on initiating a phase ii study of cf101 for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|disease|uveitis glaucoma psoriasis neovascularization AMD|uveitis AMD CNV retinitis RD|uveitis|bausch + lomb markets retisert , an intravitreal implant of the corticosteroid fluocinolone acetonide , for the treatment of non-infectious entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|uveitis glaucoma psoriasis neovascularization AMD|glaucoma blindness itching uveitis cataract|uveitis|diseases , including inflammatory bowel disease , nephritis , which is inflammation of the kidneys , and rheumatoid arthritis , and ocular indications such as entity and dry eye .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|uveitis glaucoma psoriasis neovascularization AMD|uveitis chamber glaucoma capsule vitrectomy|uveitis|trial of the ns2 eye drop formulation in a serious and , we believe , poorly treated ocular disease called noninfectious anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uveitis glaucoma psoriasis neovascularization AMD|uveitis teeth chamber periodontitis chambers|uveitis|in noninfectious anterior entity , aldehydes may mediate , at least in part , inflammation , pain , fibrotic changes , and lipid destruction leading to dryness and surface irritation .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|uveitis glaucoma psoriasis neovascularization AMD|uveitis periodontitis teeth myopia cataract|uveitis|novartis ( esba105 ) and eyegate pharmaceuticals , inc . ( egp-437 ) have conducted or are conducting clinical trials in anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|uveitis glaucoma psoriasis neovascularization AMD|eg PCV AMD es myopia|uveitis|in addition to entity , rvo and wet amd , there are a number of ophthalmic conditions affecting the retina and choroid with unmet medical need
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Allergy serology fever allergic fungus|hay yellow scarlet dengue enteric|typhoid|these vaccines , which currently include vaccines to prevent urinary tract infections and entity fever , are all in basic research or preclinical stage of development .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|Allergy serology fever allergic fungus|influenza prophylactic hepatitis rabies investigational|typhoid|company also anticipates continued investment in its advanced product development pipeline , including an anthrax ig therapeutic , hepatitis b therapeutic and entity vaccine , among others .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Allergy serology fever allergic fungus|hemorrhagic enteric scarlet haemorrhagic hay|typhoid|innovative vector vaccine delivery , manufacturing and preservation technologiesthe technology behind our single dose , oral , rapidly protecting vaccines for cholera and entity fever .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|Allergy serology fever allergic fungus|influenza rabies cholera travel rotavirus|typhoid|establishing a travel vaccines franchise through its us-based subsidiary berna products corporation , which markets vivotif® , the worlds only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Allergy serology fever allergic fungus|licensed FMD rabies dengue meningococcal|typhoid|a two-year extension of the development program with brookwood pharmaceuticals and a commercial evaluation license with nih for developing a entity vaccine with gelsiteò polymer .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Allergy serology fever allergic fungus|yellow hemorrhagic swine Mediterranean haemorrhagic|typhoid|avant is also developing an oral entity fever vaccine , ty800 , for global health needs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|Allergy serology fever allergic fungus|polysaccharide cholera influenza conjugate IPV|typhoid|one oral entity vaccine and one injectable entity vaccine are currently approved and administered in the united states and europe .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|Allergy serology fever allergic fungus|yellow hemorrhagic dengue swine cold|typhoid|of health ( nih ) initiated a phase 1 / 2 in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|Allergy serology fever allergic fungus|influenza cholera rotavirus rabies meningococcal|typhoid|acambis  us-based subsidiary berna products corporation markets vivotif ( r ) , the world  s only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Allergy serology fever allergic fungus|hay hemorrhagic iv enteric tropical|typhoid|status bacterial vaccines global health choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 travelers  etec enterotoxigenic e coli infection  pre-clinical
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|Allergy serology fever allergic fungus|tetanus influenza pneumococcal pertussis flu|typhoid|patents for the technology used in the cholera and entity vaccines expire between 2013 and 2016 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|Allergy serology fever allergic fungus|Randomized Oral randomised Only Comparing|typhoid|entity phase 2 medeva tolerising peptide ( rye grass ) . . . . .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|Allergy serology fever allergic fungus|syphilis varicella dengue diphtheria leishmaniasis|typhoid|emergent biosolutions program pipeline currently includes programs focused on anthrax , tuberculosis , entity , influenza and chlamydia .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Allergy serology fever allergic fungus|hemorrhagic hay yellow scarlet dengue|typhoid|a broad portfolio of vaccines against viral and bacterial diseases , including single-dose oral vaccines aimed at protecting travelers from cholera , entity fever and other illnesses .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Allergy serology fever allergic fungus|hay hemorrhagic enteric septic periodic|typhoid|pre-clinical infectious disease choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 etec enterotoxigenic e coli infection nih pre-clinical
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|Allergy serology fever allergic fungus|tetanus varicella diphtheria dengue pertussis|typhoid|emergents clinical pipeline includes programs focused on anthrax , botulism , entity , tuberculosis , hepatitis b and chlamydia .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|Allergy serology fever allergic fungus|yellow dengue hemorrhagic swine cold|typhoid|to conduct a phase i in-patient dose ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|Allergy serology fever allergic fungus|yellow dengue hemorrhagic swine cold|typhoid|niaid to conduct a phase i in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Allergy serology fever allergic fungus|hay yellow enteric dengue hemorrhagic|typhoid|thus immunity to an intestinal disease such as entity fever , is best induced by giving the vaccine orally , so that the antigens are presented directly to the lining of
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|Allergy serology fever allergic fungus|varicella syphilis hepatitis CMV AIDS|typhoid|including rheumatoid arthritis , or ra , and systemic lupus erythematosus , or sle ; and other infectious diseases such as tuberculosis , influenza and entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis vulgaris cirrhosis mellitus AND|autism ADHD aphasia dementia migraine|porphyria|people with entity should not be treated with visudyne .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis vulgaris cirrhosis mellitus AND|claudication migraine fever catheterization exacerbations|porphyria|the most advanced of these programs are the following : amt-021 for acute intermittent entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis vulgaris cirrhosis mellitus AND|dementia autism ADHD psychosis psoriasis|porphyria|people with entity should not be treated .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis vulgaris cirrhosis mellitus AND|migraine pathogen microbial neutrophil hemorrhagic|porphyria|doses of aln-as1 resulted in lowering of aminolevulinic acid ( ala ) and porphobilinogen ( pbg ) , the toxic heme synthesis intermediates that mediate entity attacks .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|psoriasis vulgaris cirrhosis mellitus AND|fever porphy migraine urticaria claudication|porphyria|or pnh ;  filed a cta to initiate a phase 1 trial with aln-as1 in acute intermittent entity , or aip patients ;  initiated a phase 1 trial with aln-pcssc in normal human volunteers with elevated
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|psoriasis vulgaris cirrhosis mellitus AND|claudication migraine porphy headache urticaria|porphyria|this trial are encouraging , the data are preliminary in nature , based on a limited number of patients with acute intermittent entity , or aip .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|disease|psoriasis vulgaris cirrhosis mellitus AND|porphy fever sickness hepatitis pancreatitis|porphyria|we and our collaborator digna biotech are developing amt-021 as a gene therapy for acute intermittent entity , or aip , a severe liver disorder .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|psoriasis vulgaris cirrhosis mellitus AND|migraine hypoglycemic panic febrile hemorrhagic|porphyria|excluding entity attacks , three patients had four saes , including one previously reported fatal episode of hemorrhagic pancreatitis ; none of these saes were
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis vulgaris cirrhosis mellitus AND|migraine panic headache asthmatic attack|porphyria| present data from the ongoing phase 1 study  including initial data in patients that experience recurring entity attacks  in late 2016 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis vulgaris cirrhosis mellitus AND|cholestasis fever hepatitis colitis biliary|porphyria|acute intermittent entity aip disease and market background aip is a rare metabolic liver disorder resulting from mutations in the pbgd gene .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|disease|psoriasis vulgaris cirrhosis mellitus AND|encephalopathy insufficiency coma porphy acidosis|porphyria|advanced investigational rnai therapeutic , givosiran , targets aminolevulinic acid synthase 1 , or alas1 , for the treatment of patients with acute hepatic entity , or ahp .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1), ('BIO', 1)])|disease|psoriasis vulgaris cirrhosis mellitus AND|encephalopathy insufficiency haemorrhage coma porphy|porphyria|food and drug administration ( fda ) approved givlaari ( givosiran ) injection for subcutaneous use for the treatment of adults with acute hepatic entity ( ahp ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis vulgaris cirrhosis mellitus AND|migraine febrile panic fever angina|porphyria|defined mutation in the pbgd gene and elevated urinary levels of ala and pbg , but no current entity attacks .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|psoriasis vulgaris cirrhosis mellitus AND|porphy pruritus urticaria pancreatitis colitis|porphyria|amt-021 for acute intermittent entity we are developing amt-021 as a gene therapy for acute intermittent porphyria , or aip , a severe liver disorder .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|fungus Plasmodium Candida Aspergillus excluding|fever dengue influenza meningitis cholera|coccidioidomycosis|status in the united states for vt-1129 for the treatment of cryptococcal meningitis and for vt-1598 for the treatment of entity , also known as valley fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fungus Plasmodium Candida Aspergillus excluding|dengue aspergillosis Aspergillus Fusarium RSV|coccidioidomycosis|our third program , vt-1598 for the treatment of entity , a fungal infection in the southwestern united states also known as valley fever , is in ind-enabling studies targeting an ind
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|fungus Plasmodium Candida Aspergillus excluding|dengue fever vasculitis migraine influenza|coccidioidomycosis|these diseases include entity , commonly known as valley fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|fungus Plasmodium Candida Aspergillus excluding|aspergillosis osteomyelitis Fusarium candidiasis Aspergillus|coccidioidomycosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , entity , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fungus Plasmodium Candida Aspergillus excluding|Fusarium fever prophylaxis dengue Aspergillus|coccidioidomycosis|vt-1598 for entity ( valley fever ) vt-1598 is an orally available inhibitor of fungal cyp51 that has shown high potency and selectivity in in vitro studies .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|AND osteoporosis radiologically BMD radiographically|osteosarcoma osteoporosis hypercalcemia kyphosis overgrowth|osteopetrosis|infantile malignant entity ( imo ) : imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND osteoporosis radiologically BMD radiographically|vasculitis GBS VL KD AIDS|osteopetrosis|imo is a severe form of entity that typically presents in the first year of life and is associated with severe manifestations leading to death within the
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|AND osteoporosis radiologically BMD radiographically|aspergillosis mesothelioma hyperthermia neutropenia neoplasm|osteopetrosis|hcv collaboration with roche and sales of actimmune® , which is approved for two indications , chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|AND osteoporosis radiologically BMD radiographically|lymphomas aspergillosis neoplasms mesothelioma neoplasm|osteopetrosis|actimmune is currently approved in the united states for the treatment of chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|AND osteoporosis radiologically BMD radiographically|osteoporosis osteosarcoma hypercalcemia kyphosis scoliosis|osteopetrosis|infantile malignant entity ( “imo” ) imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|AND osteoporosis radiologically BMD radiographically|lymphomas mesothelioma neoplasms aspergillosis neoplasm|osteopetrosis|is approved in the united states and numerous other countries for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|AND osteoporosis radiologically BMD radiographically|lymphomas mesothelioma aspergillosis neoplasms neoplasm|osteopetrosis|actimmune has been approved by the fda f16 for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|AND osteoporosis radiologically BMD radiographically|aspergillosis candidiasis lymphomas neoplasms neoplasm|osteopetrosis|frequency and severity of serious infections associated with chronic granulomatous disease ( cgd ) and to slow the worsening of severe malignant entity ( smo ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|AND osteoporosis radiologically BMD radiographically|gliomas glioma mesothelioma aspergillosis MM|osteopetrosis|the fda approved actimmune as a treatment to delay the time to disease progression in patients with severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|AND osteoporosis radiologically BMD radiographically|mesothelioma gliomas glioma hyperthermia ascites|osteopetrosis|in the united states , the company estimates that there are approximately 1 , 200 patients with cgd and less than 500 patients with severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|AND osteoporosis radiologically BMD radiographically|hyperthermia glioma encephalopathy gliomas encephalomyelitis|osteopetrosis|is also targeting research in other diseases such as pyruvate kinase deficiency ( pkd ) , leukocyte adhesion deficiency-i ( lad-i ) , and infantile malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|AND osteoporosis radiologically BMD radiographically|mesothelioma aspergillosis lymphomas neoplasms hyperthermia|osteopetrosis|actimmune we currently market our lead product , actimmune , for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|AND osteoporosis radiologically BMD radiographically|aspergillosis lymphadenopathy candidiasis mesothelioma neoplasm|osteopetrosis|actimmune is approved by the fda for use in children and adults with chronic granulomatous disease ( cgd ) and severe , malignant entity ( smo ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|AND osteoporosis radiologically BMD radiographically|fact turn principle consequence contrary|osteopetrosis|in entity , the cells that break down bone ( osteoclasts ) do not work properly , which leads to the bones becoming thicker and not as healthy .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|AND osteoporosis radiologically BMD radiographically|psoriasis migraine COPD NSCLC ADHD|osteopetrosis|for example , we have ongoing phase 4 post-marketing commitments to the fda relating to actimmune for the treatment of entity , including a registry and drug interaction study .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|AND osteoporosis radiologically BMD radiographically|mesothelioma lymphomas neoplasms aspergillosis neoplasm|osteopetrosis|we currently market actimmune in the united states for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|AND osteoporosis radiologically BMD radiographically|Obesity osteoporosis Osteoarthritis OI Diabetes|osteopetrosis|entity is a disorder of bone development in which the bones become thickened .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|AND osteoporosis radiologically BMD radiographically|osteoporosis CKD T2DM OI periodontitis|osteopetrosis|in people with entity , this balance is not maintained and the resorption of old bone material decreases while the formation of new bone continues .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|disease|AND osteoporosis radiologically BMD radiographically|aspergillosis hyperthermia neoplasm anemia glioma|osteopetrosis|severe , malignant entity is a life-threatening , congenital disorder that primarily affects children .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|AND osteoporosis radiologically BMD radiographically|lymphomas mesothelioma neoplasms aspergillosis neoplasia|osteopetrosis|actimmune has been approved by the fda for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|Aspergillus fumigatus aspergillosis sinusitis Tuberculosis|aspergillosis|entity , a fungal infection caused by aspergillus , begins as an upper airway infection and can become a systemic fungal infection in
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis pneumonia superficial Aspergillus|aspergillosis|astellas commercially launched isavuconazole in the united states in april 2015 for the treatment of invasive entity and invasive mucormycosis in adults .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis Candida fungi pneumonia|aspergillosis|overview until recently , we were focused on developing our novel antifungal vl-2397 , for the treatment of patients with invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis pathogens pneumonia mastitis|aspergillosis|the fda has also granted vical qualified infectious disease product ( qidp ) , orphan drug and fast track designations for vl‑2397 for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|Europe NSCLC Japan Korea Africa|aspergillosis|compound , cancidastm ( caspofungintm ) or mk-0991 , in the same class as our v-echinocandin , recently received fda approval for salvage therapy in entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|meningitis aspergillosis encephalitis pneumonia migraine|aspergillosis|indications currently being explored for mat2203 include resistant candidiasis , cryptococcal meningoencephalitis , entity and leishmaniasis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis pneumonia keratitis wounds|aspergillosis|it is indicated for primary treatment of acute invasive entity and salvage therapy for rare but serious fungal infections caused by the pathogens scedosporium apiospermum and fusarium spp .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis pneumonia NSCLC adenocarcinoma|aspergillosis|fda has advised that vl‑2397 would be eligible for a limited use indication ( lui ) approval for the treatment of invasive entity for patients with limited treatment options .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis NSCLC pneumonia Aspergillus|aspergillosis|with soc vs . aspergillus spp . , we plan to initiate a phase 2 study of oral scy-078 in patients with invasive entity in the third quarter of 2018 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis Candida Aspergillus leishmaniasis|aspergillosis|we market amphotec® worldwide for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis purposes pathogens reasons wounds|aspergillosis|although we market amphotec for invasive entity , we do not believe that it will provide sufficient revenue to us in the near future , if ever , and , consequently ,
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis keratitis Aspergillus pneumonia arthritis|aspergillosis|development history of mat2203 mat2203 was extensively studied in animal model studies of various fungal infections including invasive candidiasis , entity , and visceral leichmaniasis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis Candida Aspergillus fungi|aspergillosis|amphotec is an fda-approved lipid-complexed form of amphotericin b indicated for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis adenocarcinoma SCC CCA|aspergillosis|an estimated 200 , 000 cases of invasive entity are diagnosed annually worldwide .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|Candida Aspergillus bloodstream aspergillosis CMV|aspergillosis|sequus is conducting a phase iii double-blind , randomized study comparing amphotec with amphotericin b in treating patients with first-line entity infections .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|Aspergillus Candida Pseudomonas fumigatus aspergillosis|aspergillosis|the amphotericin b cochleate demonstrated reasonable activity against at least one strain of entity fumigatus and one strain of candida albicans in vitro .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis dysplasia allergic asthmatic pathogen|aspergillosis| received a second qidp status for pulmazole to treat fungal infections in the airways of allergic bronchopulmonary entity patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|candidiasis aspergillosis NEC CMV adenocarcinoma|aspergillosis|cancidas  has not been studied as an initial therapy for invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|candidiasis aspergillosis Candida CMV pathogens|aspergillosis|hepatitis c virus ( hcv ) , infections , and amphotec® ( amphotericin b cholesteryl sulfate complex for injection ) , approved for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillosis uncontrolled AND psoriasis Aspergillus|aspergillosis candidiasis CMV schistosomiasis pathogens|aspergillosis|we have world-wide marketing rights to amphotec for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms snails millions cysts|schistosomiasis|three months ended march 31 , 2012 , approximately 60% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis leishmaniasis AIDS parasitic hydatid|schistosomiasis|deuterated praziquantel in collaboration with the therapeutics for rare and neglected diseases division of the nih for the treatment of entity and other parasitic diseases .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms anemia anaemia snails|schistosomiasis|three months ended june 30 , 2009 , approximately $943 , 137 or 15 . 52% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis leishmaniasis AIDS psoriasis nematodes|schistosomiasis|lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms anemia anaemia snails|schistosomiasis|three months ended june 30 , 2011 , approximately 22% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms anemia anaemia snails|schistosomiasis|the three months march 31 , 2010 , approximately $830 , 600 , or 17% of total revenues , resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms anemia anaemia snails|schistosomiasis|ended december 31 , 2010 , approximately $12 , 198 , 522 or 25 . 7% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms anemia anaemia cysts|schistosomiasis|three months ended september 30 , 2009 , approximately $3 , 330 , 000 or 26% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|nematodes leishmaniasis schistosomiasis parasites Fusarium|schistosomiasis|it is an anthelmintic effective against entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|Tuberculosis Leishmania Cryptosporidium Hepatitis Infection|schistosomiasis|entity is a parasitic disease that affects both animals and humans .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms anemia anaemia snails|schistosomiasis|during the three months ended june 30 , 2010 , approximately $1 , 864 , 203 or 33 . 7% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|Water Lake Obesity Disease Cryptosporidium|schistosomiasis|entity is prevalent in southern china where there are a lot of fresh water lakes and rivers .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms snails anemia cysts|schistosomiasis|nine months ended september 30 , 2012 , approximately 44% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms anemia anaemia snails|schistosomiasis|during the three months ended september 30 , 2010 , approximately $5 , 104 , 961 or 41% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis leishmaniasis AIDS nematodes fever|schistosomiasis|table of contents lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms snails mosquitoes cattle|schistosomiasis|during year ended december 31 , 2011 , approximately 36% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms anemia anaemia diarrhoea|schistosomiasis|during the three months ended march 31 , 2011 , approximately 1 , 058 , 132 or 15% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis leishmaniasis nematodes diarrhoea parasites|schistosomiasis|praziquantel is a compound of pyrazine and isoquinolin designed to treat and prevent entity in livestock .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|schistosomiasis worms snails anemia cysts|schistosomiasis|three months ended september 30 , 2011 , approximately 26% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|pylori uncontrolled DON esophagitis schistosomiasis|parasites Cryptosporidium Candida candidiasis schistosomiasis|schistosomiasis|examples of analytes in this field are : aspergillus , candida , markers or antibodies associated with entity , giardia lamblia , leishmaniasis , lyme disease , chagas , toxoplasmosis .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|Malignant hemangioma glioma neovascularization AVM|hemangioma meningioma adenocarcinoma neoplasm adenoma|lymphangioma|aortic body and other paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|Malignant hemangioma glioma neovascularization AVM|hemangioma meningioma neoplasm adenocarcinoma adenoma|lymphangioma|paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND vaccination Allergy immunity Disease|influenza RSV epidemic 2nd next|cholera|during the entity outbreak we responded to a further specific request for antibiotics and donated £250 , 000 to the british red cross to support
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|AND vaccination Allergy immunity Disease|pathogens Salmonella influenza mycobacteria parasites|cholera|quarter of 2000 , will test the safety , immunogenecity and protective capacity of the vaccine against a challenge with live virulent entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|AND vaccination Allergy immunity Disease|fever meningitis pneumonia endocarditis vaccination|cholera|qilian shan® oxytetracycline api used for treating following diseases : rickettsia , mycoplasma infection , chlamydia infection , regression fever , brucellosis entity , rabbit fever and plague .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|AND vaccination Allergy immunity Disease|diarrhea diarrhoea cholera fever gastroenteritis|cholera|( the causative agent of entity ) are often confused with travelers diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|AND vaccination Allergy immunity Disease|cholera gastroenteritis rotavirus influenza dengue|cholera|in human patients with various types of watery diarrhea , including traveler  s diarrhea , hiv-related diarrhea and other acute infectious diarrheas , including entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|AND vaccination Allergy immunity Disease|IBS diarrhea cholera constipation rotavirus|cholera|in addition , an early stage cftr inhibitor program is planned for the treatment of secretory diarrhea disorders , including entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|AND vaccination Allergy immunity Disease|Shigella Influenza rotavirus Cryptosporidium cholera|cholera|entity is an acute diarrheal illness that kills thousands of people worldwide each year due to rapid dehydration in the first 2 -18 hours after infection .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|AND vaccination Allergy immunity Disease|dengue cholera DENV BV measles|cholera|and supported the start of phase ii trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|AND vaccination Allergy immunity Disease|dengue rabies cholera WNV schistosomiasis|cholera|investigation , peru-15 may be an excellent candidate as a potential single dose , oral vaccine for travelers going to areas where entity is endemic .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|AND vaccination Allergy immunity Disease|cholera cholerae diarrhea dehydration diarrhoea|cholera|entity / general watery diarrhea we are investigating lechlemer for the indication of cholera / general watery diarrhea in adults and children .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND vaccination Allergy immunity Disease|pneumococcal influenza mucosal meningococcal rotavirus|cholera|development of a safe , effective entity vaccine is the first step in establishing avants single-dose , oral bacterial vaccine franchise .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|AND vaccination Allergy immunity Disease|cholera polysaccharide influenza rotavirus flu|cholera|ctb has already been administered to hundreds of thousands of patients worldwide and is a major component of an existing oral entity vaccine and traveler  s diarrhea vaccine .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND vaccination Allergy immunity Disease|influenza rotavirus causative pneumococcal infecting|cholera|published results have shown the vaccine to be well tolerated and immunogenic against the entity organism in the adult portion of this trial .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|AND vaccination Allergy immunity Disease|cholera botulinum tetanus diphtheria pertussis|cholera|maxvax mucosal vaccine carrier / adjuvant platform maxvax is a mucosal vaccine carrier / adjuvant platform based on the entity toxin b subunit ( ctb ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|AND vaccination Allergy immunity Disease|cholera tetanus influenza pertussis rabies|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminium-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|AND vaccination Allergy immunity Disease|cholera influenza tetanus pertussis rabies|cholera|crucell also markets travel vaccines , such as an oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|AND vaccination Allergy immunity Disease|dengue cholera measles DENV BV|cholera|this vaccine and supported the start of phase 2 trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND vaccination Allergy immunity Disease|influenza MV investigational GSK MMR|cholera|we will then determine our commercialization strategy with respect to the entity vaccine based on clinical data from the trial .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|AND vaccination Allergy immunity Disease|cholera tetanus influenza pertussis rabies|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND vaccination Allergy immunity Disease|psoriasis decades approval acne Europe|cholera|in addition , a second-generation proprietary anti-secretory agent is in development for entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|alopecia scleroderma urticaria eczema dystrophy|ichthyosis|the loss of tgm-1-activity results in the severe genetic skin disease autosomal recessive congenital entity ( arci ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|glaucoma scoliosis anomalies malformations hypothyroidism|ichthyosis|there is no prescription drug currently approved in the united states that is indicated for the treatment of congenital entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|malformations anomalies defects hypoglycemia hypothyroidism|ichthyosis|announced that the united states food and drug administration ( fda ) granted adx-102 orphan drug designation for the treatment of congenital entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|Beta Diabetes Thyroid Skin psoriasis|ichthyosis|entity vulgaris is the most common form of ichthyosis affecting around one in 250 people worldwide .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|urticaria acne dermatitis psoriasis scleroderma|ichthyosis|moisturizers that are used for the treatment of dry skin or certain inflammatory skin conditions , such as psoriasis , eczema or entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|cataract alopecia scleroderma acne psoriasis|ichthyosis| liarozolean oral therapeutic for the treatment of congenital entity , a rare genetic disease characterized by dryness and scaling of the skin .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|scoliosis cataract cataracts anomalies deafness|ichthyosis|kb105 , delivers functional human transglutaminase-1 , or tgm1 genes using our gene therapy platform to patients with tgm1-deficient autosomal recessive congenital entity , or arci .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|pruritus psoriasis alopecia acne dermatitis|ichthyosis|a dermatologic form of adx-102 is in late-stage clinical development for the treatment of entity due to sjögren-larsson syndrome , an inborn error of aldehyde metabolism .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|pruritus itching acne psoriasis cutaneous|ichthyosis|thus , ns2 may be partially or wholly effective in preventing and treating entity or other dermal symptoms , signs , or pathologies in sls .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|immunodeficiency anemia hypoxemia symptomatology encephalopathy|ichthyosis|sls patients are generally diagnosed as neonates given the severe entity that presents at birth .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|cataract neutropenia nystagmus cataracts deafness|ichthyosis|- dosing of the 4th patient in the phase 1 / 2 study of kb105 in patients with tgm1 deficient autosomal recessive congenital entity ( arci ) has completed .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|myeloma pectoris fibrillation sclerosis vulgaris|ichthyosis|compared to the same periods 2006 due to the completion of our phase 2 / 3 trial for the treatment of lamellar entity in april 2007 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|malformations anomalies scoliosis cataract glaucoma|ichthyosis|in june , barrier therapeutics announced that liarozole was granted orphan drug status from the fda for the treatment of congenital entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|psoriasis acne lupus dermatitis urticaria|ichthyosis|frequently results in lethargy and reduced libido in men above the age of 40 , and glylorin ( tm ) , a novel treatment for entity vulgaris , a debilitating skin disease .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|erythema alopecia acne dermatitis psoriasis|ichthyosis|“primary indication” means the netherton syndrome , also known as comel-netherton syndrome , ns , bamboo hair syndrome , and entity linearis cirumflexa .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|keratitis ulcer ulcers periodontitis dermatitis|ichthyosis|barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis , lamellar entity , acne , psoriasis and fungal infections .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|myopathy cutaneous ocular cardiomyopathy cataracts|ichthyosis|of fatty aldehydes in sjögren-larsson syndrome , an orphan disease caused by mutations in fatty acid aldehyde dehydrogenase , lead to severe entity , retinal disease and neurological disorders .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|acne psoriasis dermatitis lichen pruritus|ichthyosis|table of contents was licensed to ohr cosmetics for dermatological uses was evaluated in a moisturizer formulation in subjects with entity vulgaris at a non-us testing site .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|leishmaniasis neutropenia cataract syphilis hypothyroidism|ichthyosis|in april 2017 , we announced that the fda granted reproxalap orphan drug designation for the treatment of congenital entity , a severe skin disease characteristic of sls .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|amyloidosis psoriasis pigmentation Skin vulgaris|anomalies neutropenia herpes malformations syphilis|ichthyosis|in or entering phase 3 clinical trials for the treatment of seborrheic dermatitis , fungal infections , including vaginal candidiasis , and congenital entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|aspergillosis Aspergillus cytomegalovirus Fusarium candidiasis|histoplasmosis|among the most common systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|neovascularization vasculitis hypertensive penetrating CMV|histoplasmosis|visudyne is also used for the treatment of subfoveal cnv due to pathologic myopia , or severe near-sightedness , and presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|aspergillosis candidiasis osteomyelitis pneumonia schistosomiasis|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|psoriasis candidiasis CMV AIDS pneumonia|histoplasmosis|in conjunction with fujisawa , is conducting two phase iii clinical trials of ambisome in the u . s . for the treatment of entity and for the treatment of cryptococcus .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|neovascularization CNV retinoblastoma vasculitis tamponade|histoplasmosis|other macular neovascular conditions such as minimally classic and occult with no classic amd lesions , pathologic myopia and presumed ocular entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|vasculitis CMV neovascularization retinoblastoma sarcoidosis|histoplasmosis|in some countries , including the u . s . and canada , visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|aspergillosis Aspergillus cytomegalovirus Fusarium candidiasis|histoplasmosis|among the most common 5 8 systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|fungi aspergillosis fungus yeasts Aspergillus|histoplasmosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|publication approval psoriasis AIDS enrollment|histoplasmosis|the trial for entity is being monitored and analyzed by the mycology study group of the national institutes of health .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|hepatitis cytomegalovirus CMV herpes influenza|histoplasmosis|many antibody drugs are immunosuppressive , which may lead to increased risk of serious or opportunistic infection , such as tuberculosis , entity and hepatitis b , or malignancy .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|aspergillosis candidiasis pneumonia osteomyelitis bacteremia|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|hypertensive vasoconstriction retraction compartment blink|histoplasmosis|visudyne has recently been launched for two new indications , pathologic myopia ( in the united states and europe ) and ocular entity syndrome ( in the united states ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|vasculitis CMV neovascularization sarcoidosis tox|histoplasmosis|in some countries ( including the u . s . and canada ) visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|aspergillosis candidiasis osteomyelitis pneumonia Aspergillus|histoplasmosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|cavity myc aspergillosis ring irritation|histoplasmosis|presumed ocular entity syndrome ( ohs ) is a condition caused by a fungal infection endemic to certain areas in the central and eastern u . s .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|CMV vasculitis sarcoidosis neovascularization tox|histoplasmosis|in some countries visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|Pediatric Only Severe Any Chronic|histoplasmosis|entity phase iii cryptococcal meningitis phase iii daunoxome advanced kaposi  s sarcoma approved for marketing in the u . s . , canada and 12 western
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|irritation intolerance toxicities allergy reasons|histoplasmosis|in the us , visudyne has received an additional approval for cnv due to presumed ocular entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|Aspergillus aspergillosis Candida fungus hepatitis|irritation hypertensive vasoconstriction retraction hypotensive|histoplasmosis|due to pathologic myopia in the united states , canada and the european union and for cnv due to presumed ocular entity syndrome ( " ohs " ) in the united states .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|seizure uncontrolled arrhythmia psychosis glioma|AEDs prophylaxis seizure aura AED|epilepsy|mothers exposed to other antiepileptic drugs , or aeds , and a purported prevalence of 0 . 07% in infants born to mothers without entity or treatment with other aeds .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|seizure uncontrolled arrhythmia psychosis glioma|COPD rhinitis allergy eczema allergies|epilepsy|the company has clinical stage programs in entity and asthma .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|seizure uncontrolled arrhythmia psychosis glioma|neurodegeneration aging cognition autoimmunity allergy|epilepsy|the company is conducting research and development activities in a number of disease areas , including entity , pain and inflammation .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|seizure uncontrolled arrhythmia psychosis glioma|autism migraine dementia SCD ADHD|epilepsy|we are also preparing for the potential commercial launch of diazepam nasal spray , a treatment for people with entity who experience cluster seizures .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|disease|seizure uncontrolled arrhythmia psychosis glioma|osteoporosis hyperlipidemia migraine fibromyalgia insomnia|epilepsy|the products are intended to treat a variety of disorders including the following : hypertension , arthritis , seizures , entity , diabetes and pain management .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|seizure uncontrolled arrhythmia psychosis glioma|federal strict financial voluntary gaining|epilepsy|continue making payments to parteq of c$108 , 000 each quarter as a result of the renewal of the alzheimers agreement and entity agreement with parteq .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|disease|seizure uncontrolled arrhythmia psychosis glioma|antipsychotic psychotropic prescription antineoplastic antidepressant|epilepsy|in 2005 , the fda requested that all makers of entity drugs analyze their clinical trial data to determine whether these drugs increase the risk of suicide in patients .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|seizure uncontrolled arrhythmia psychosis glioma|seizure jerk episodes convulsions fits|epilepsy|myoclonic entity 0 1 ( 3 . 4% ) 2 ( 6 . 9% ) serious aes , or saes , of seizure were reported
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|seizure uncontrolled arrhythmia psychosis glioma|neuroscience neuroprotection psychiatry clinic DBS|epilepsy|to evaluate cbd and cbdvhs ( and possibly additional cbd-derivatives ) in a human in vitro neural model with an application to entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|seizure uncontrolled arrhythmia psychosis glioma|baby mother allergy register registry|epilepsy|the uk entity and pregnancy register reported a similarly increased prevalence of oral clefts ( 3 . 2% ) among infants born to mothers exposed to topiramate
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|seizure uncontrolled arrhythmia psychosis glioma|gait parkinsonism mood cognition Parkinson|epilepsy|amarins cns development pipeline includes two programs in parkinsons disease , one in entity and one in memory and cognition .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|seizure uncontrolled arrhythmia psychosis glioma|antisense biosynthetic env mutated knockout|epilepsy|a patent application relating to the epm1 entity gene is pending in the uspto .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|seizure uncontrolled arrhythmia psychosis glioma|migraine insomnia RLS GAD AN|epilepsy|patients with refractory focal seizures , which we refer to as the star 1 ( synthetic transdermal cannabidiol for the treatment of entity ) trial .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|seizure uncontrolled arrhythmia psychosis glioma|migraine spasticity ALS dystonia fibromyalgia|epilepsy|in chronic use for the treatment of entity , vigabatrin has been generally well tolerated with lower than average neurological side effects compared to other approved entity therapies .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|seizure uncontrolled arrhythmia psychosis glioma|osteoporosis insomnia AUD BPH alcoholism|epilepsy|sales of drugs for the treatment of entity decreased by approximately $967 , 000 in the second quarter of fiscal 2008 compared to the second quarter of fiscal 2007 because
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|seizure uncontrolled arrhythmia psychosis glioma|migraine dystonia tremor aphasia tinnitus|epilepsy|electrical neurostimulation technology has seen growing use in recent years for numerous applications– such as chronic pain , parkinsons , essential tremor , entity , and others .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|seizure uncontrolled arrhythmia psychosis glioma|scientific university NIH academic grant|epilepsy|this study was sponsored by the entity foundation , and conducted in 2013 in the laboratory of dr . annamaria vezzani at the mario negri institute for pharmacological research
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|seizure uncontrolled arrhythmia psychosis glioma|psoriasis NSCLC insomnia glioblastoma OCD|epilepsy|we are developing sage-217 so that it will have what we believe is an optimal profile as a monotherapy for entity in many forms .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|seizure uncontrolled arrhythmia psychosis glioma|NSCLC CRC CML CLL glioblastoma|epilepsy|with janssen pharmaceuticals , inc . , is scheduled to enter a phase 2a proof of concept clinical study for the treatment of entity in h1 2021 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|seizure uncontrolled arrhythmia psychosis glioma|approved investigational topical preferred generic|epilepsy|our two entity product candidates are spn-538 ( extended release topiramate ) , for which we submitted a new drug application , or nda , that was accepted
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|cholecystitis dyspepsia gallbladder pruritus NAFLD|cholecystitis|these include entity ( gallbladder inflammation ) , seizure , palpitations , paresthesia and vertigo .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|AEs DLT hepatotoxicity toxicities deaths|cholecystitis|there was one report of entity in a phase 1 clinical trial of lum001 and one report of elevated levels of alanine aminotransferase and aspartate aminotransferase ,
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|pneumonia osteomyelitis abscess bacteremia perforation|cholecystitis|ciai diagnoses include intra-abdominal abscess , stomach or intestinal perforation , peritonitis , appendicitis , entity , or diverticulitis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|cholecystitis cholangitis pancreatitis appendicitis peritonitis|cholecystitis|a single patient during the extension study developed acute entity and cholelithiasis later treated with cholecystectomy .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|pancreatitis nausea GVHD exacerbation AE|cholecystitis|one subject had a baseline pro-c3 of 9 . 9 ng / ml , experienced a serious ae of acute entity , stopped taking axa1125 at the end of week 1 and then discontinued from the study on week 5 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|vomiting diarrhea headache pruritus dizziness|cholecystitis|serious adverse events reported in the trial included disease progression , pyrexia , mastitis , pneumonia , nausea , entity and pain in extremity , each of which was reported only once .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|GVHD pancreatitis toxicities neuropathy neurotoxicity|cholecystitis|a single patient during the extension study experienced acute entity classified as a serious adverse event but deemed unlikely related to sbc-102 by the investigator .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|nausea AEs hepatotoxicity diarrhea CIN|cholecystitis|the one subject who received akr-001 70mg iv had a serious adverse event of entity initially reported as abdominal pain beginning on day 11 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|sinusitis bronchitis mucositis diarrhea pancreatitis|cholecystitis|two study group subjects experienced saes , severe acute entity and moderate cellulitis , with the latter subject discontinuing treatment prior to end of treatment .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|another zero ten gallbladder G3|cholecystitis|serious adverse events included skin infection ( cellulitis , two cases ) , abdominal pain and inflammation of the gall bladder ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|cholecystitis pancreatitis cholangitis cholestasis hepatitis|cholecystitis|findings from a subsequent cholecystectomy were consistent with chronic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|cholangitis pancreatitis cholecystitis ascites stones|cholecystitis|with respect to hepatobiliary events , more patients ( 3% ) on oca 25 mg experienced gallstones or entity compared to <1% on placebo and 1% on oca 10 mg .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|cholestasis hepatotoxicity autoimmunity cirrhosis nephrotoxicity|cholecystitis|the biliary system is a significant target for many conditions , including drug toxicities , entity , and liver-related abnormal function associated with the cystic fibrosis mutation .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|cholecystitis cirrhosis cholangitis cholestasis cholangiocarcinoma|cholecystitis|this potentially represents a previously unrecognized factor in the development of entity and cholelithiasis disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|periodontitis pancreatitis hepatitis peritonitis cholecystitis|cholecystitis|the project seeks to determine if human cell derived nanoparticles are pathogenic and induce inflammatory ( entity ) and calcific pathologic ( cholelithiasis ) disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|sinusitis headache osteomyelitis urticaria pruritus|cholecystitis|there were two serious aes reported , acute entity and right toe infection , which were deemed not reasonably associated with the study product , and more likely due to subject  s
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|exacerbation pancreatitis sinusitis hyperalgesia periodontitis|cholecystitis|the subject  s end-of-study pro-c3 level was 31 . 9 ng / ml , reflecting both the acute inflammatory state ( i . e . , acute entity ) and also likely a washout effect of axa1125 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|pneumonia AE fever COPD dehydration|cholecystitis|one patient was hospitalized for entity , a serious ae , two days after receiving seven days of treatment with torezolid phosphate , which the clinical investigator determined to
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|diarrhea steatosis cholecystitis stones dyspepsia|cholecystitis|both consisted of entity , or gall bladder inflammation , which is common in people who experience rapid or significant weight loss .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cirrhosis cholecystectomy cholecystitis cholangitis esophagitis|etc diarrhea peritonitis pancreatitis fever|cholecystitis|lidan paishi pian clear heat and promote diuresis , cholagogue and remove calculi , biliary tract infection , entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fever keratitis Plasmodium meningitis CMV|dengue adenovirus streptococcal varicella parasitic|tularemia|category is category a . the six agents that the cdc has classified as category a are anthrax , botulism , plague , smallpox , entity and viral hemorrhagic fevers .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|fever keratitis Plasmodium meningitis CMV|influenza pertussis cholera diphtheria Campylobacter|tularemia|barda is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fever keratitis Plasmodium meningitis CMV|influenza rabies dengue pneumonia adenovirus|tularemia|equally compelling , restanza has shown effectiveness against several lethal pathogens , including anthrax , plague , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|fever keratitis Plasmodium meningitis CMV|rabies mastitis pneumonia tetanus meningitis|tularemia|cethromycin is also being developed as a biodefense agent for use in the treatment of anthrax , plague and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|fever keratitis Plasmodium meningitis CMV|mastitis cholera meningitis pneumonia bacteremia|tularemia|these two bacteria species are considered potential bioweapons and are the causative agents for plague and entity , respectively .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fever keratitis Plasmodium meningitis CMV|vaccinia CMV influenza adenovirus BCG|tularemia|the company has been in contractual negotiations for the first two products , entity and vaccinia .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|fever keratitis Plasmodium meningitis CMV|tetanus pneumonia diphtheria meningitis encephalitis|tularemia|preliminary data from our preclinical experiments indicates that our product candidates have potent activity against biowarfare agents that cause anthrax , entity and plague .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|fever keratitis Plasmodium meningitis CMV|pneumonia meningitis tetanus bronchitis colitis|tularemia|these tests have been completed in non-human primates and have shown that solithromycin is effective in treating anthrax and entity when the infection was initiated by the pulmonary route .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|fever keratitis Plasmodium meningitis CMV|rabies plague dengue tetanus influenza|tularemia|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , entity , and botulism .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fever keratitis Plasmodium meningitis CMV|influenza pneumonia meningitis adenovirus diphtheria|tularemia|the bicyclolides are to be used as medical countermeasures against multiple biodefense bacteria found in anthrax , plague and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|fever keratitis Plasmodium meningitis CMV|rabies pneumonia influenza plague tetanus|tularemia|the fda has granted cethromycin an orphan drug designation for the prophylactic treatment of inhalation anthrax , plague and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|fever keratitis Plasmodium meningitis CMV|encephalitis dengue leishmaniasis rabies varicella|tularemia|other tick-borne diseases include rocky mountain spotted fever , babesiosis , erlichiosis , anaplasmosis , powassan disease , tick-borne relapsing fever and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fever keratitis Plasmodium meningitis CMV|Brazil India plague dengue Africa|tularemia|· received fda orphan drug designation for restanza in plague and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|fever keratitis Plasmodium meningitis CMV|dengue influenza hemorrhagic allergic SARS|tularemia|a non-exclusive , royalty-bearing license to use certain of our patents and related know how for the prevention or treatment of entity and viral hemorrhagic fever indications .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|fever keratitis Plasmodium meningitis CMV|pertussis influenza cholera diphtheria tetanus|tularemia|barda funded studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|fever keratitis Plasmodium meningitis CMV|influenza plague adenovirus cholera rabies|tularemia|for the treatment of serious hospital infections as well as the treatment of bioterror pathogens , such as anthrax , plague and entity after signs and symptoms are present .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|fever keratitis Plasmodium meningitis CMV|diphtheria tetanus pneumonia cholera meningitis|tularemia|is focused on the development of antibiotic compounds to treat biowarfare agents , including the highly infectious bacteria that cause anthrax , entity and plague .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|fever keratitis Plasmodium meningitis CMV|pertussis adenovirus Aspergillus tetanus Pseudomonas|tularemia|solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens , specifically anthrax and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|fever keratitis Plasmodium meningitis CMV|pertussis influenza cholera diphtheria tetanus|tularemia|barda also is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|fever keratitis Plasmodium meningitis CMV|plague sheep rodents swine hamsters|tularemia|after symptoms developed ; · pivotal primate study showing protective efficacy in plague ; · pivotal animal study showing 100% survival in entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|CMV hemophilia CIP SMA meningococcal|hemophilia|used in the trial consistently led to long-term expression of the hfix transgene at therapeutic levels in patients with severe entity b , without acute or long-lasting toxicity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|CIN hepatitis BRCA SMA ros|hemophilia|we further note that you cite uniqure and spark therapeutics as competitors with treatments for entity b in phase 3 clinical trials .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|hemophilia CIN thrombocytopenia ICH coagulopathy|hemophilia|human coagulation factor ix prevention and control of bleeding in patients who suffer from entity b . completed the clinical trial and preparing documentation for the registration purpose .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|anemia thalassemia hemophilia preeclampsia fever|hemophilia|kedrion markets therapies globally for entity , hemolytic disease of the newborn , immune and neurological disorders .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|honor employment retirement construction him|hemophilia|he has served as baxters global franchise head for entity since june 2012 and is expected to continue in that role until the separation is completed .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|travel construction walking recruitment centuries|hemophilia|he served as baxters global franchise head for entity from 2012 until the separation .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|anemia GVHD ITP schistosomiasis colitis|hemophilia|for example : · porcine spleen tissue was successfully implanted into a mouse , effectively treating entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|NAFLD CRC NASH malignancies HBV|hemophilia| continue to build a liver-directed gene therapy platform , with an initial focus on the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|building funding publication creation writing|hemophilia|spark hereby grants pfizer the exclusive right to negotiate an agreement with spark with respect to the entity a program subject to the terms of this section 2 . 9 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|anticoagulation warfarin hemophilia hemodialysis thrombolysis|hemophilia|the treatment concept is similar to entity , in which a patient is treated regularly with the particular clotting factor in which he is deficient .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|IBD varices GIST ITP SCD|hemophilia|vwd may experience mild symptoms , but some patients can experience severe bleeding events similar to bleeding experienced by patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|hemophilia TBI hepatitis thalassemia coagulopathy|hemophilia|an improved next-generation coagulation factor viia variant , cb 813d , that has successfully completed a phase 1 clinical trial in severe entity a and b patients .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|hemophilia sickle thalassemia prion herpesvirus|hemophilia|therapeutic proteins are increasingly used to treat diseases , including interferon beta for multiple sclerosis , factor viii for entity a , and monoclonal antibodies for various disorders .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2), ('BIO', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|hemophilia hepatitis cytochrome coagulopathy haem|hemophilia|of our collaboration agreement for the development of coagulin-b , our product candidate that we were developing for the treatment of entity b , involving administration to the liver .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|Hepatitis Hb Severe hemophilia Type|hemophilia| entity b . entity b patients typically are treated by a variety of plasma-derived , recombinant or long-acting products that are produced by a number of companies , including pfizer .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|immunoglobulins immunoglobulin cyclosporine rituximab cyclophosphamide|hemophilia|in june 2014 , we acquired medpro , a specialty pharmacy focused on specialty infusion including entity and immune globulin .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|kel CMT CRP hemophilia ros|hemophilia|many other companies are developing gene therapies to treat entity b , including baxter , uniqure and dimension .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|hemophilia BALB Bal FV Hb|hemophilia|preliminary data in entity b mice indicate that treatment with amt-060 induces normalization of fix levels as well as clotting time .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|hemophilia VTE ITP thrombocytopenia haemorrhage|hemophilia|in december 2013 , we acquired ahf , which provides specialty drugs and infusion services for bleeding disorders , principally entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|AND coagulopathy psoriasis Hepatic Pregnancy|ASC ment FDA APP om|hemophilia|outlook 2017 in 2017 we plan to : · drive our entity b program towards late stage clinical development ; · continue non-clinical and preclinical studies that are expected to support an ind
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|investigational registry approved assigned intended|leptospirosis|we are completing the manufacture of the entity product so that we can provide evaluation lots and documentation to fiocruz for their regulatory approval submission of this product
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|scFv CMV CEA PSA neu|leptospirosis|similar increases in both clinical and analytical sensitivity were observed for our human tb and entity assays .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|EIA ELISA confirmatory STR kit|leptospirosis|agreements are for the following rapid test products : i ) dpp® hiv 1 / 2 screen , ii ) dpp® hiv 1 / 2 confirmatory , iii ) dpp® entity and iv ) dpp® leishmaniasis .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|Known AND excluding hepatitis Active|dengue leishmaniasis CMV syphilis hepatitis|leptospirosis|we also have licensed the antigens used in other tests including our syphilis , tuberculosis , entity , leishmaniasis and chagas tests , and we may enter other license agreements .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|First Paulo Specifically State Canada|leptospirosis|dpp® entity – in june 2009 , as we previously reported , we were awarded a three-year $3 million small business innovative research ( sbir )
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|Evidence Document Note Percentage Practice|leptospirosis|entity [ member ] refers to agreements relates to research and development arrangements .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|Known AND excluding hepatitis Active|influenza meningitis MRSA bacteremia pneumonia|leptospirosis|in addition to viral vaccines , diamond also manufactures vaccines against bacterial infections , such as entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|Known AND excluding hepatitis Active|hepatitis influenza varicella leishmaniasis allergy|leptospirosis|the five products under agreement with fiocruz are for dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|syphilis confirmatory STR IgM ELISA|leptospirosis|believe fiocruz will receive during 2011 the required approvals from anvisa for the second dpp® syphilis test and the dpp® entity test , although there can be no assurance of this .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Known AND excluding hepatitis Active|colorimetric breath prick usability exact|leptospirosis|with respect to chembio  s dpp® entity test , bio-manguinhos had not qualified to request the technology transfer .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|Trial Note Project Plan gov|leptospirosis|dpp® entity – we have approximately nine months left of the three-year $3 million small business innovative research ( sbir ) phase ii grant
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|Known AND excluding hepatitis Active|influenza hepatitis syphilis varicella herpes|leptospirosis|separate right to request a technology transfer for that product only are : dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|Known AND excluding hepatitis Active|diarrhoea dengue cholera meningitis diarrhea|leptospirosis|bacterial vaccines are bacterial products that are used on a routine basis to prevent diseases such as black leg , entity , red water and shipping fever .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|Known AND excluding hepatitis Active|AUD syphilis CAP NAFLD CRC|leptospirosis|from the united states national institutes of health ( nih ) to fully develop , validate , and commercialize a rapid diagnostic test for entity for general use worldwide .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Known AND excluding hepatitis Active|Research Trial Pilot FDA Per|leptospirosis|· dpp® entity phase ii grant – in 2009 we were awarded a three year , $1 . 9 million small business innovative research ( sbir ) phase
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|Known AND excluding hepatitis Active|latter Pap dengue confirmatory PPD|leptospirosis|three of these products ( leishmaniasis and the hiv screening and confirmation tests ) , and we have substantially completed development of the entity test .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|PSA CEA ct Ct TF|leptospirosis|this new patent-pending platform , including the testing of our current hiv test strip ( as well as our human tb and entity assays ) that was recently approved in this new platform .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|AIDS eligibility COPD PPD CMV|leptospirosis|to be completed three-year grant from the united states national institutes of health to complete development of a test for entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|papillomavirus beings error relevance volunteers|leptospirosis|a press release entitled “chembio awarded three year $3mm nih sbir phase ii grant to complete dpp® test for human entity ” .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND excluding hepatitis Active|publication grant Research funding Europe|leptospirosis|three year , $3mm phase ii nih grant for entity awarded june 2009 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|craniofacial dysplasia syndromes malformation hypertrophic|myelodysplastic craniofacial fragility overgrowth medullary|craniosynostosis|of limb and lungs and unregulated fgf signaling leads to a variety of human bone morphogenic disorders , including dwarfism and entity syndromes .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|disease|craniofacial dysplasia syndromes malformation hypertrophic|osteogenesis ossification mineralization osteoporosis union|craniosynostosis|his research interests include the molecular mechanism of entity , which is the premature fusion of calvarial suture line in infants and tissue engineering of bone .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 2)])|disease|Known AND Congenital IIa Hemoglobin|anemia thalassemia anaemia sickle cirrhosis|hemochromatosis|u . s . safety information for auryxia® ( ferric citrate ) contraindication auryxia® ( ferric citrate ) is contraindicated in patients with iron overload syndromes , e . g . , entity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|Known AND Congenital IIa Hemoglobin|prothrombin IX protease thromboplastin anticoagulant|hemochromatosis|prontotm prothrombin ( factor ii ) approved f9923 prontotm thromborisktm approved f9949 prontotm entity approved f9904 prontotm fmf basic approved f9946 prontotm cf euro i
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|disease|Known AND Congenital IIa Hemoglobin|thalassemia anemia anaemia Hb syndromes|hemochromatosis|beta thalassemia patients suffering from iron overload and the initiation of a phase 2 study for ljpc-401in patients with hereditary entity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|Known AND Congenital IIa Hemoglobin|malignancies polyposis amyloidosis malformations migraine|hemochromatosis|it is also estimated that one million americans are afflicted with hereditary entity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 2)])|disease|Known AND Congenital IIa Hemoglobin|anemia thalassemia anaemia hypothyroidism AL|hemochromatosis|we are developing ljpc-401 for the treatment of conditions characterized by iron overload , such as entity and beta thalassemia .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND Congenital IIa Hemoglobin|acquired Auto recessive idiopathic Mixed|hemochromatosis|hereditary entity hereditary hemochromatosis is an iron overload disease that can lead to life-threatening conditions such as cirrhosis , liver cancer , diabetes , heart failure and
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|Known AND Congenital IIa Hemoglobin|syndromes malignancies anaemia anemia thrombocytopenia|hemochromatosis|treatment of patients with polycythemia vera , myelodysplastic syndromes and hereditary entity may represent additional opportunities for future development of ptg-300 .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|Known AND Congenital IIa Hemoglobin|hepatitis vasculitis meningitis allergies pancreatitis|hemochromatosis|in addition , savyon  s products are used in clinical laboratories performing pre-disposition testing ( thrombosis , entity , certain cancers and several other diseases and conditions ) .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|Known AND Congenital IIa Hemoglobin|India rice Japan Ethiopia Brazil|hemochromatosis|and chief executive officer of bond biosciences , inc . , a private start-up biotechnology company focused on addressing the iron overload in entity , from july 2016 to may 2018 .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 2)])|disease|Known AND Congenital IIa Hemoglobin|anemia anaemia thalassemia RLS hemophilia|hemochromatosis|ferisk ( tm ) is intended to become a standard in the screening , diagnosis and follow-up of hereditary entity patients , as well as others who suffer from iron overload .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 2)])|disease|Known AND Congenital IIa Hemoglobin|anemia cirrhosis thalassemia anaemia hypothyroidism|hemochromatosis|important safety information contraindication : patients with iron overload syndrome , e . g . entity , should not take auryxia ( ferric citrate ) .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|disease|Known AND Congenital IIa Hemoglobin|anemia cirrhosis anaemia HH hemophilia|hemochromatosis|in addition , hereditary entity and the more severe form , juvenile hemochromatosis , are both inherited disorders of reduced hepcidin production and consequently iron overload .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|disease|Known AND Congenital IIa Hemoglobin|thalassemia hypothyroidism cirrhosis hemophilia anemia|hemochromatosis|iron levels can be found in disorders such as cooley  s anemia , sickle cell anemia and entity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 2)])|disease|Known AND Congenital IIa Hemoglobin|anemia anaemia syndromes thalassemia amyloidosis|hemochromatosis|iron overload is also associated with hereditary entity where a genetic defect in a protein involved in iron absorption leads to excess absorption of iron and iron overload
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 2), ('DRUG', 1)])|disease|Known AND Congenital IIa Hemoglobin|anemia hypercholesterolemia cirrhosis anaemia coagulopathy|hemochromatosis|evaluate the safety and efficacy of ljpc-401 , la jollas proprietary formulation of synthetic human hepcidin , as a treatment for hereditary entity ( hh ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|jaundice encephalopathy BPD TTP hemolysis|kernicterus|in june 2001 , the center for disease control  s morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|QA readmission abortion VTE burnout|kernicterus|the national quality forum has in the past described entity as a “never event , ” one which physicians should ensure never occurs in their practice .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|hepatotoxicity autoimmunity GVHD cirrhosis neoplasia|kernicterus|however , phototherapy rapidly becomes less effective following puberty , increasing the risk for entity , resulting in the need for liver transplantation to control the disease .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|hepatotoxicity nephrotoxicity hypoglycemia neurotoxicity hypoglycaemia|kernicterus|use : atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|worldwide admissions ages persons deaths|kernicterus|the center for disease controls morbidity and mortality weekly report published four case studies of 7 table of contents entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|Stroke TBI Dementia Injury Disease|kernicterus|entity is a completely preventable condition that often results in permanent neurological damage brought on by the known toxic effects of
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|bilirubin cirrhosis jaundice diarrhea prematurity|kernicterus|the center for disease controls report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|jaundice encephalopathy BPD diarrhea hemolysis|kernicterus|in june 2001 , the center for disease controls morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|cirrhosis hepatotoxicity encephalopathy cholestasis bronchiectasis|kernicterus|bilirubin toxicity can ultimately result in a chronic , severe , and disabling condition called entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|ND meningitis PND neurotoxicity sequelae|kernicterus|the total loss of ugt1a1 activity and the resulting severe jaundice and risk of neurological sequelae ( entity ) are associated with cn type 1 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|thrombocytopenia eclampsia preeclampsia stillbirth prematurity|kernicterus|its effects on the fetus or newborn include hemolytic anemia , hyperbilrubinemia , entity , or intrauterine deaths due to hydrous fetalis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|bilirubin jaundice cirrhosis diarrhea hemolysis|kernicterus|the center for disease control  s report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|coma coagulopathy uncontrolled Severe hemorrhagic|SMA Stroke PSP MSA SCI|kernicterus|entity is a cerebral palsy-like condition in which the patient lacks muscle tone and motor control , cannot operate self-sufficiently , and typically requires long-term care .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|blasts proliferative cervix maturation endometrium|platelets monocytes erythrocytes eosinophils granulocytes|cytotrophoblasts|high complexity probes according to claim 28 wherein said fetal cells are leukocytes and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|demyelination oligodendrocytes axons astrocytes myelin|oligodendrocytes|the pathology of spinal cord injury involves extensive loss of the myelin sheath produced by entity at the site of injury .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|microglia oligodendrocytes astrocytes fibroblasts glia|oligodendrocytes|was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , astrocytes , microglial cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|afferents glia interneurons anesthetics astrocytes|oligodendrocytes|occurs in a diffuse fashion throughout the adult brain and appears to reflect a loss of axonal support by local entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|oligodendrocytes astrocytes myelin microglia fibroblasts|oligodendrocytes|in our preclinical research , we have shown that hucns-sc cells differentiate into entity , the myelin producing cells , and produce myelin .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|oligodendrocytes MSCs DCs astrocytes BMSCs|oligodendrocytes|mechanism of action underlying the enhanced remyelination in vivo and shown that multistem cells and secreted factors increase differentiation of entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|myelin axons oligodendrocytes aggregates synapses|oligodendrocytes|remyelination remyelination is the process propagating oligodendrocyte precursor cells to form entity to create new myelin sheaths on demyelinated axons in the cns .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|What interneurons Cells PCs Other|oligodendrocytes|entity are natures neuronal insulating cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|oligodendrocytes myelin axons astrocytes adulthood|oligodendrocytes|deficient in myelin production , transplantation of hcns-sc into the brain resulted in widespread engraftment of human cells that matured into entity , the myelin producing cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|oligodendrocytes microglia glia myelin neurones|oligodendrocytes|q-cells produce astrocytes and entity , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|What Cells interneurons Other PCs|oligodendrocytes|entity are natures neural insulating cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|exosomes MSCs nanofibers scaffolds Cells|oligodendrocytes|japan patent 2011-047716 – entity derived from human embryonic stem cells for remyelination and treatment of spinal cord injury are described .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|myelin axons glia nerves axon|oligodendrocytes|myelin sheath that insulates nerve fibres , or axons , in the central nervous system and the cells that make myelin , the entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|electrodes nerves thereby lasers batteries|oligodendrocytes|like the insulation covering an electrical wire , entity enable the conduction of electrical impulses along nerve fibers throughout the central and peripheral nervous system .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|astrocytes microglia oligodendrocytes neuron neurones|oligodendrocytes|$ 4 , 000 tissue culture - culture of primary entity derived from mixed glial cultures .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|oligodendrocytes astrocytes glia neurones axons|oligodendrocytes|financial statements gpc program our gpc program aims to deliver healthy allogeneic gpcs , the precursors to both astroglia and myelin-producing entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|cardiomyocytes cDNA EVs exosomes embryos|oligodendrocytes|the patent relates to methods of making entity from human embryonic stem cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|oligodendrocytes CD34 lineage maturation astrocytes|microglia oligodendrocytes neurones astrocytes fibroblasts|oligodendrocytes|the resulting differentiated cells ( astrocytes and entity , shown in figure 2 ) then can perform the support functions of these glial cells in vivo as described above .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|EPCs CD133 CD34 osteoblasts astrocytes|osteoblasts osteoclasts fibroblasts BMSCs adipocytes|osteocytes|sclerostin is produced in entity , which are mature bone cells that are thought to be the mechanoreceptor cells that regulate the activity of bone-building osteoblasts
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|EPCs CD133 CD34 osteoblasts astrocytes|osteoblasts chondrocytes fibroblasts cardiomyocytes adipocytes|osteocytes|the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least adipocytes , entity , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|EPCs CD133 CD34 osteoblasts astrocytes|osteoclasts chondrocytes fibroblasts osteoblasts proteoglycans|osteocytes|merits bone formation involves the migration of undifferentiated mesenchymal cells , differentiation into cartilage , and subsequent bone replacement by osteoblasts and entity .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts osteoclast fibroblasts osteoblast|osteoclasts|in addition , unlike currently marketed ra 1 table of contents drugs , fpa008 directly inhibits bone-destroying cells called entity .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 1)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts resorption osteoblasts mineralization osteoclast|osteoclasts|gallium acts upon bone by enhancing the formation of osteoblasts and inhibiting entity , thereby increasing bone deposition and reducing bone turnover .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DRUG', 2), ('DIS', 1)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts neurotransmitters hormones PTH|osteoclasts|up to now , bisphosphonates have been most effective in tumors where bone destruction is caused primarily by overstimulation of entity , which abnormally accelerate the breakdown of bone .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts fibroblasts chondrocytes adipocytes|osteoclasts|two main types of cells are responsible for this process : entity , which break down bone tissue , and osteoblasts , which secrete new bone tissue .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts osteoblast osteoclast BMSCs|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone‑resorbing cells called entity .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|osteoclast osteoclasts phosphatase blasts CD3|Cells MSCs BMSCs osteoclasts Tumors|osteoclasts|entity resorb bone by secreting protons and generating an acidic extracellular microenvironment .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoblasts osteoclasts osteoblast fibroblasts BMSCs|osteoclasts|sct is a hormone that inhibits the bone-tissue resorbing activity of specialized bone cells called entity , enabling the bone to retain more of its mass and functionality .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts fibroblasts MSCs BMSCs|osteoclasts|bone health is maintained through regulation of the competing activities of bone forming cells ( osteoblasts ) and bone resorbing cells ( entity ) .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|osteoclast osteoclasts phosphatase blasts CD3|neutrophils fibroblasts monocytes keratinocytes eosinophils|osteoclasts|treatment of ra in which it reversibly blocks signaling in multiple cell types involved in inflammation and tissue degradation ( e . g . macrophages , entity , mast cells and b cells ) .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoblastic osteoblasts myeloid integrin osteoclasts|osteoclasts|( osteopenia ) • ( a ) when bone marrow derived macrophages ( bmdm ) from nomid mice are stimulated with rankl ( rank ligand ) , they differentiate into entity • : 1315-1325 .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|osteoclast osteoclasts phosphatase blasts CD3|From distinguish fed representing designated|osteoclasts|rankl stimulation macrophages entity nomid bmdm nomid bmdm plus ati-450 ( a ) ( b ) bone marrow derived macrophages ( bmdm ) from nomid mice 19© copyright 2020 aclaris
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts chondrocytes fibroblasts osteoclast|osteoclasts|zoledronic acid is the most potent bisphosphonate , a class of drugs known to inhibit entity , which are key cells involved in the maintenance , repair and remodeling of bone .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts fibroblasts chondrocytes adipocytes|osteoclasts|cells called osteoblasts cause new bone formation while other cells called entity remove old bone through a process called resorption .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts BMSCs osteoblast osteoclast|osteoclasts|axs‑02 is a potent inhibitor of entity , which are bone remodeling cells that break down bone tissue .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts chondrocytes fibroblasts osteoblast|osteoclasts|bisphosphonate drugs slow down the rate at which entity , which are cells which resorb or take away bone , reduce the bones mass .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|osteoclast osteoclasts phosphatase blasts CD3|bones joints feet ankles knees|osteoclasts|in people with osteopetrosis , this balance is not maintained because their entity do not function properly .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoclasts osteoblasts osteoblast osteoclast BMSCs|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone-resorbing cells called entity .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 1), ('DRUG', 1)])|cell|osteoclast osteoclasts phosphatase blasts CD3|osteoblasts osteoclasts calcitonin osteoblast adipocytes|osteoclasts|calcitonin , a peptide , inhibits bone resorption by acting on specific receptors on entity .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|osteoclast osteoclasts phosphatase blasts CD3|immunoassays simply immunoassay ELISA radioimmunoassay|osteoclasts|ntx serum became the first and only commercially available test in the united states that measures specific bone breakdown by entity using a blood sample .
OrderedDict([('BIO', 3), ('OTHER', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|osteoclast osteoclasts phosphatase blasts CD3|HSCs monocytes blasts leukocytes neutrophils|osteoclasts|the drug appears to be selectively toxic for activated entity , displaying a negligible effect on bone marrow stromal cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|DCs monocytes neutrophils eosinophils Treg|monocytes|csf-1r is expressed on the surface of specific immune cells known as macrophages and their precursor cells known as entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|progenitors exosomes platelets leukocytes fibroblasts|monocytes|this is an exclusive license to a stem cell technology in which adult pluripotent stem cells are derived from entity obtained from the patient  s own blood .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD14 EPCs CD11b CD34 monocytes|volunteer bank cornea graft participant|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes neutrophils granulocytes DCs platelets|monocytes|targets the colony stimulating factor-1 receptor , or csf-1r , a cell surface protein thought to control the survival and function of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|CD14 EPCs CD11b CD34 monocytes|islets fibroblasts hepatocytes precursors myoblasts|monocytes|researchers have been able to turn these dedifferentiated entity into several different types of cells including islet cells , nerve cells , liver cells , blood vessel cells and skin cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|CD14 EPCs CD11b CD34 monocytes|astrocytes microglia axons neutrophils fibroblasts|monocytes|in january 2017 , we reported that targeting of mospd2 inhibits chemotaxis of entity and neuropils , and that unpublished vbl data also show mospd2 expression on certain tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes neutrophils microglia DCs granulocytes|monocytes|fpa008 ( cabiralizumab ) : an investigational antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes neutrophils DCs eosinophils microglia|monocytes|cells ; and  these proteins secondarily activate other innate immune cells such as natural killer cells and entity , which become able to recognize and kill some tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes neutrophils eosinophils microglia granulocytes|monocytes|eascs exhibit broad immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , entity or macrophages and neutrophils .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes DCs PBMCs neutrophils PBMC|monocytes|when applied to human immune cells such as entity , selective immunoproteasome inhibitors , like kzr-616 and onx 0914 , blocked the release of inflammatory cytokines following cell stimulation .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes leukocytes vessels progenitors mononuclear|monocytes|the companys stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes eosinophils microglia DCs neutrophils|monocytes|patients with various diseases , as well as established cell lines from immune and non-immune cell lineages , including t cell subsets , entity , macrophage subpopulations and cancer cell lines .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes neutrophils eosinophils microglia granulocytes|monocytes|fcgri is expressed in certain human immune cells including entity , macrophages and dendritic cells and may function to activate these immune cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes leukocytes progenitors vessels granulocytes|monocytes|our stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes monocyte microglia neutrophils eosinophils|monocytes|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and entity / macrophages .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD14 EPCs CD11b CD34 monocytes|volunteer bank cornea graft participant|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes neutrophils eosinophils granulocytes microglia|monocytes|cells with the cd4 receptor are critical components of the immune system and include t lymphocytes , entity , macrophages and dendritic cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes neutrophils microglia DCs granulocytes|monocytes|developments clinical pipeline : cabiralizumab ( fpa008 ) : an antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|monocytes leukocytes leucocytes granulocytes platelets|monocytes|our novel multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD34 monocytes|leukocytes monocytes leucocytes granulocytes platelets|monocytes|our multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|slides platelets embryos latter oocytes|fibroblasts|the entity are then harvested , tested by quality control and released by quality assurance prior to shipment .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts explants embryos homogenates slices|fibroblasts|of disease causing ability , was accomplished by making over 500 passages of the virus in chicken embryos or chick embryo entity which resulted in large genomic deletions .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts fibroblast explants epithelium epithelia|fibroblasts|products and reagents like avian cell substrates have rt activity that does not represent adventitious infectious retroviruses ( e . g . chicken embryo entity , dermal cells and eggs ) .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|fibroblasts fibroblast AND blasts neovascularization|angiogenesis fibroblasts fibroblast keratinocyte neovascularization|fibroblasts|method of enhancing wound healing by stimulating entity and keratinocyte growth in vivo , utilizing amphipathic peptides .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts keratinocytes platelets hepatocytes monocytes|fibroblasts|the company has produced clonal populations of human entity which have been transfected to express factor viii in vitro , demonstrated that the protein is properly processed and achieved protein
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts keratinocytes melanocytes dermis eosinophils|fibroblasts|hses are composed of both a dermal layer containing entity and an epidermal layer containing keratinocytes .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|keratinocytes fibroblasts hepatocytes glioblastoma osteoblasts|fibroblasts|cold selectively inhibits akt activation in human cancer cells compared to normal proliferating cells ( e . g . , human entity ) .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|fibroblasts fibroblast AND blasts neovascularization|autologous stromal transplanted regenerative progenitor|fibroblasts|used are fat injections and cell injections , which are mainly based on enriching the damaged tissue with external source of entity cells .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts keratinocytes epithelia melanocytes epithelium|fibroblasts|furthermore , ccl24 is constitutively expressed by skin and dermal entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts phagocytes monocytes leukocytes leucocytes|fibroblasts|pierer m , brentano f , rethage j , et al . the tnf superfamily member light contributes to survival and activation of synovial entity in rheumatoid arthritis .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts cardiomyocytes fibroblast hepatocytes neutrophils|fibroblasts|● increase in apoptosis of inflammatory cells , including neutrophil and pro-fibrotic cells , including entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|cornea participant keratinocyte keratinocytes forearm|fibroblasts|product consisting of a cream vehicle blended with the conditioned media extract from the cell culture of a customers own entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts PBMCs MSCs PBMC CTCs|fibroblasts|we isolated and cultured entity from lhon-nd4 patients .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts explants fibroblast keratinocytes matrices|fibroblasts|the rheumatic diseases 72 adenosine a2a receptor activation stimulates collagen production in sclerodermic dermal entity either directly and through a cross-talk with the cannabinoid system .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblasts fibroblast AND blasts neovascularization|mutants hearts fibroblasts mitochondria investigations|fibroblasts|in these entity , we demonstrated that gs010 restores mitochondrial function , including complex i activity and atp production , to the level of normal entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts neutrophils monocytes keratinocytes platelets|fibroblasts|in ssc patients , increased production of no is suggested by increased expression of inos in endothelial cells , entity , mononuclear cells infiltrating ssc skin and alveolar macrophages .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|keratinocytes fibroblasts melanocytes keratinocyte DCs|fibroblasts|much of tkt  s work has focused on gene therapy using entity , a cell type present in the skin ( and throughout the body ) that is readily obtained from patients and propagated in
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts fibres proteoglycans Cells keratinocytes|fibroblasts|entity are also found in the dermis and are responsible for creating collagen and elastin that provide strength and flexibility to
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts keratinocytes epithelium fibroblast stroma|fibroblasts|dermagraft dermagraft is a dermal substitute grown from human dermal entity and has received pma approval for the treatment of dfus .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|fibroblasts fibroblast AND blasts neovascularization|fibroblasts cardiomyocytes keratinocytes MSCs chondrocytes|fibroblasts|von zglinicki t , saretzki g , docke w , lotze c . mild hyperoxia shortens telomeres and inhibits proliferation of entity : a model for senescence? .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|Ki67 AND blasts Thy proliferative|immunoglobulins cytomegalovirus IgG thymocytes immunoglobulin|thymocytes|description thymoglobulin* [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|Ki67 AND blasts Thy proliferative|thymocytes DCs monocytes leukocytes hepatocytes|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells , known as t cells , created in the thymus to fend off infection .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|Ki67 AND blasts Thy proliferative|thymocytes Tregs DCs monocytes Treg|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells created in the thymus to fend off infection .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|Ki67 AND blasts Thy proliferative|colonies ones blasts progenitors clones|thymocytes|implants in the haart and nanoviricide treatment groups exhibited 80-85% cd4+ , cd8+ dp cells while the vehicle control groups had only approximately 30% cd4+cd8+ entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|Ki67 AND blasts Thy proliferative|immunoglobulins IgG cytomegalovirus immunoglobulin thymocytes|thymocytes|description thymoglobulin® [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|Ki67 AND blasts Thy proliferative|monocytes fibroblasts neutrophils eosinophils platelets|thymocytes|its cognate receptor , pd-1 , is a co-inhibitory transmembrane protein expressed on t cells , b cells , natural killer cells and entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|Ki67 AND blasts Thy proliferative|embryos mutants parasites clones worms|thymocytes|senescos technology allowed for approximately 90% greater survival of these entity in the presence of lps .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|neutrophils CD11b granulocytes neutrophil basophil|consciousness platelets continence appetite neutrophils|neutrophils|the effect of the drug on the recovery of entity is slow .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|neutrophils CD11b granulocytes neutrophil basophil|neutrophils granulocytes erythrocytes monocytes platelets|neutrophils|in preclinical studies , plinabulin increased the survival of entity , a type of white blood cell important in the prevention of bacterial infections .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|pathogens proteases endotoxin toxins H2O2|neutrophils|factor in promoting bacterial invasion as well as rendering the bacteria resistant to attack from reactive oxygen species ( ros ) and entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|neutrophils leukocytes platelets leucocytes Tregs|neutrophils|neulasta selectively stimulates the production of entity that are depleted by cytotoxic chemotherapy , a condition called neutropenia that makes it more difficult for the body to fight
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|immunity biology pathophysiology monocytes physiology|neutrophils|role of c5a and c5ar in hs entity are believed to play an important disease-promoting role , as well as certain cytokines and mediators commonly found in autoimmune diseases ,
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|leukocytes ANC platelets neutrophils leucocytes|neutrophils|patients treated with omidubicel recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|neutrophils leukocytes EPCs microglia osteoclasts|neutrophils|in addition , 10150 decreased sm-induced increase in the numbers of bal entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|neutrophils eosinophils granulocytes platelets monocytes|neutrophils|immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , monocytes or macrophages and entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|neutrophils CD11b granulocytes neutrophil basophil|neutrophils eosinophils monocytes microglia keratinocytes|neutrophils|addition to its expression on b cells , cd32b is also expressed on other immune cells such as dendritic cells , macrophages , entity , and mast cells .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|neutrophils CD11b granulocytes neutrophil basophil|erythrocytes platelets neutrophils monocytes granulocytes|neutrophils|these cells are programmed to end up as blood cells of a specific type , such as entity , red blood cells and platelets .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|NK monocytes CD3 platelets CD19|neutrophils|blood versus the lymphoid tissues , you have a preferential depletion of cd4 , cd8 and b cells , much greater than nk , entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 3)])|cell|neutrophils CD11b granulocytes neutrophil basophil|appetite haemoglobin platelets fever neutrophils|neutrophils|in addition , the treatment is associated with considerable adverse events like neutropenia ( low entity ) and neuropathy ( damage to the peripheral nervous system ) .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|neutrophils leukocytes neutrophil leucocytes platelets|neutrophils|although these conditions have multiple causes , each involves neutrophil adhesion to the blood vessel wall and the subsequent migration of entity into the tissue .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|neutrophils eosinophils leukocytes eosinophilia leakage|neutrophils|also treated with viprovex , did not develop the clinical symptoms of viral infection , which included increases in alveolar macrophages and entity in broncho-alveolar lavage fluid .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|neutrophils neutrophil ANC hematopoiesis neutropenia|neutrophils|the studys primary endpoint was time to neutrophil engraftment , and was met based on recovery of entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|leukocytes ANC platelets neutrophils lymphocyte|neutrophils|patients treated with nicord recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|mediators cytokine substances mediator biomarker|neutrophils|animal studies to allow manipulation and control of oxidative biomarkers of protein and dna , nitric oxide , antioxidant enzymes and inflammatory entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|neutrophils CD11b granulocytes neutrophil basophil|neutrophils leukocytes monocytes neutrophil granulocytes|neutrophils|second , pep005 activates the bodys immune system , causing entity , a type of white blood cell , to infiltrate the treated site .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|immunity BMD hematopoiesis appetite angiogenesis|neutrophils|companies such as amgen inc . have developed or are developing products to boost entity after chemotherapy .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|neutrophils CD11b granulocytes neutrophil basophil|platelets helps pathogens leukocytes quickly|neutrophils|once in the tissue , entity release toxins which attack normal cells as well as the antigen .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|cell|CD3 CD20 blasts Ki67 lymphocyte|blasts ALL hematopoiesis arising lymphomas|lymphocytes|approximately 80% of all all cases involve lineage entity in the bone marrow .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|chains clones progenitors subsets grafts|lymphocytes|were generated in the t cell transfer model which utilizes immunodeficient mice which are deficient in functional b and t entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('BIO', 2), ('DIS', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|CTCs entities blasts myeloma abnormality|lymphocytes|there are two main categories of entity : b-entity , or b-cells , and t-entity , or t-cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|CD3 CD20 blasts Ki67 lymphocyte|category entities compartment effector lineage|lymphocytes|the immune system is composed of a network of immune cells that include t entity ( t cells ) and b entity ( b cells ) .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|CD3 CD20 blasts Ki67 lymphocyte|monocytes DCs platelets neutrophils eosinophils|lymphocytes|the most crucial types of cells are antigen-presenting cells , or apcs , and entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DRUG', 1), ('DIS', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|leukocytes eosinophils bilirubin neutrophils transaminase|lymphocytes|to the occurrence and severity of these adverse events due to its role in inducing lymphopenia , or low levels of entity in the blood , and enhanced car t cell activity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|CD3 CD20 blasts Ki67 lymphocyte|immunity cytokine DCs leukocytes PBMC|lymphocytes|or more diagnostic antigens for detection of tuberculosis infection by measuring g-ifn ( gamma-interferon ) ( or , in field b , other cytokine- ) secreting entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|microbes pathogens parasites fungi chemicals|lymphocytes|allogeneic bone marrow transplant in which tissues of the host , most frequently the gut , liver , and skin , are attacked by entity in the donor ( graft ) marrow .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|progenitors granulocytes leukocytes precursors platelets|lymphocytes|abnormally large numbers of immature , abnormal entity called lymphoblasts are produced and released into the bloodstream .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|CD3 CD20 blasts Ki67 lymphocyte|CTL prime simultaneously efficiently clones|lymphocytes|as shown below , following gp2 immunotherapy , cd8+ cytotoxic t entity recognize and destroy her2 / neu-expressing cancer cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|CD3 CD20 blasts Ki67 lymphocyte|phi PBMC lymphocyte donors monocytes|lymphocytes|lymphokine any of a number of soluble physiologically active factors produced by t entity in response to specific antigens .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|platelets leukocytes monocytes neutrophils clones|lymphocytes|ceplene is designed to protect entity responsible for immune-mediated destruction of residual leukemic cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|bands clones waves blasts RBC|lymphocytes|white blood cells that have differentiated to produce a specific antibody are called b entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|monocytes DCs phagocytes eosinophils neutrophils|lymphocytes|the type of immune response is characterized by the way the response was initiated through specialized cells known as entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|CD3 CD20 blasts Ki67 lymphocyte|lymphocyte neutrophils leukocytes immunity monocytes|lymphocytes|as predefined in the clinical protocol , patient subgroups were evaluated for levels of tumor infiltrating entity ( til ) and for pd-l1 checkpoint protein expression on tumor cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|DCs CTL persons monocytes mAb|lymphocytes|consequently , in each persons bloodstream , only a relatively few entity will recognize the same antigen .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|leukocytes monocytes neutrophils leucocytes DCs|lymphocytes|til means tumor infiltrating entity that are collected from a tumor cell , including naturally-occurring t cells with specificity against such tumor .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD3 CD20 blasts Ki67 lymphocyte|leukocytes monocytes DCs precursors progenitors|lymphocytes|itk , an enzyme that functions in t‑cell signaling and differentiation , is expressed predominantly in t‑cells , which are entity that play a vital role in immune responses .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|CD3 CD20 blasts Ki67 lymphocyte|lymphocyte leukocyte NK microRNAs CD14|lymphocytes|) – lion biotechnologies , inc . ( otcqb : lbio ) , a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating entity ( til )
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|CD3 CD20 blasts Ki67 lymphocyte|chains transcripts subsets clones bands|lymphocytes|although the exact mechanism of action for alemtuzumab is unknown , it is presumed to deplete circulating t and b entity after each treatment course .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|cell|platelets basophil blasts cytometry Platelet|VWF vWF APC FVIII fibrinogen|platelets|genetically linked by an amino acid linker , targeting the a1 domain of vwf and inhibiting the interaction between ulvwf and entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|platelets basophil blasts cytometry Platelet|platelets erythrocytes neutrophils leukocytes RBC|platelets|the ellipse in the upper left- hand corner contains the phrase " virally inactivated red blood cells and entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|cell|platelets basophil blasts cytometry Platelet|fibrinogen platelets thrombin gelatin fibrin|platelets|against acutect® because fibrimage® binds to fibrin , which comprises 75-80% of an actively forming blood clot , whereas acutect® binds to entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|platelets basophil blasts cytometry Platelet|platelets coagulation neutrophils nutrients immunoglobulins|platelets|blood and immune systems , including : t cells and b cells to fight infections ; red blood cells to carry oxygen and entity to control bleeding .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 2)])|cell|platelets basophil blasts cytometry Platelet|platelets FVIII fibrinogen coagulation hemostasis|platelets|immune thrombocytopenia ( itp ) - itp is an uncommon autoimmune bleeding disorder characterized by insufficient entity in the blood .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|platelets basophil blasts cytometry Platelet|platelets monocytes fibroblasts neutrophils leukocytes|platelets|these agents work by preventing the ability of entity to aggregate together .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|platelets basophil blasts cytometry Platelet|sugar sugars pressures lipids viscosity|platelets|we have contributed novel research and technologies for approved medicines that treat cancer , osteoporosis , fungal infections and low blood entity , among others .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|platelets basophil blasts cytometry Platelet|platelets monocytes neutrophils granulocytes erythrocytes|platelets|are overproduced in the bone marrow affecting the synthesis of normal blood cells , causing a decrease in red blood cells , entity and normal white blood cells .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2), ('DRUG', 1)])|cell|platelets basophil blasts cytometry Platelet|platelets neurotransmitters biomolecules leukocytes precursors|platelets|glutamate release by a platelet acts to stimulate release of glutamate from other entity , potentially leading to aggregation and the formation of the thrombus .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|platelets basophil blasts cytometry Platelet|platelets debris concentrates parasites progenitors|platelets|banks or transfusion centers because the main objective of these banks and centers is to obtain the blood cells and entity .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|platelets basophil blasts cytometry Platelet|astrocytes neurones glia microglia oligodendrocytes|platelets|released glutamate acts by binding cell surface glutamate receptors expressed on entity themselves .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|platelets basophil blasts cytometry Platelet|platelets pathogens APC allergen parasites|platelets|the affected individuals make antibodies against their own entity leading to the entity  destruction , which in turn leads to the abnormal bleeding .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cell|platelets basophil blasts cytometry Platelet|aging OSA CKD migraine CHF|platelets|the effects of integrilin are specific to entity , avoiding interference with other normal cardiovascular processes .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|platelets basophil blasts cytometry Platelet|platelets monocytes eosinophils erythrocytes granulocytes|platelets|in many hematological disorders , there is abnormal proliferation and differentiation of the progenitor cells for red blood cells , entity and neutrophils .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|platelets basophil blasts cytometry Platelet|platelets volumes eosinophils viscosity lipids|platelets|in addition to anemia , fatigue , hair-loss , reduction in blood entity and white and red blood cells , and bone pain , one of the most common side effects of chemotherapy is nausea
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|platelets basophil blasts cytometry Platelet|neutrophils erythrocytes monocytes PMN PMNs|platelets|our laboratory personnel had previously developed a pre-clinical itp model with data showing that prtx-100 inhibits the phagocytosis ( ingestion ) of entity in vitro .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|platelets basophil blasts cytometry Platelet|platelets erythrocytes fibrinogen leukocytes neutrophils|platelets|integrilin is a small synthetic peptide administered by injection that prevents the aggregation of entity by blocking the platelet receptor glycoprotein , or gp , iib-iiia .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|cell|platelets basophil blasts cytometry Platelet|platelets astrocytes neutrophils PLC eNOS|platelets|a2 ( blocked by aspirin ) and adenosine diphosphate ( blocked by plavix® ) , researchers have recently demonstrated the release of glutamate by entity during platelet activation .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 4)])|cell|platelets basophil blasts cytometry Platelet|platelets RBCs erythrocytes leukocytes RBC|platelets|plasma donation means that donors give only plasma but not the other blood components such as entity , red cells and infection-fighting white cells .
OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|cell|platelets basophil blasts cytometry Platelet|angiogenesis VEGF coagulation telomerase osteoclasts|platelets|training he performed basic research at the royal prince of wales hospital to develop a new monoclonal antibody to inhibit entity .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|neutrophils leukocytes CD3 blasts granulocytes|fibronectin fibrinogen MHC ligands integrins|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd‑peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|neutrophils leukocytes CD3 blasts granulocytes|medicines ART cigarettes contraception vaccines|leukocytes|the costs and availability of entity are subject to fluctuation depending on a variety of factors beyond our control , including competitive factors , changes in technology , and
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|neutrophils leukocytes CD3 blasts granulocytes|beings immunoglobulins IgG embryos placenta|leukocytes|human entity produce millions of different types of antibodies , all with varying shapes that allow them to attach to and , as a
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|neutrophils leukocytes CD3 blasts granulocytes|fibronectin fibrinogen MHC ligands integrins|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd-peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|neutrophils leukocytes CD3 blasts granulocytes|granulocytes monocytes neutrophils platelets leukocytes|leukocytes|manufacture of interferon human white blood cells , also known as entity , and a stimulating agent are needed to produce human leukocyte derived interferon .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|neutrophils leukocytes CD3 blasts granulocytes|details funding equipment quantities volumes|leukocytes|if we are unable to obtain the necessary entity , we may be required to scale back our operations or stop manufacturing multiferon® .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|neutrophils leukocytes CD3 blasts granulocytes|RBCs PMNs PMN RBC neutrophils|leukocytes|in inflammation , white blood cells ( entity ) move out of the bloodstream into the inflamed tissue , for example , the cns in ms , and the lung airways in
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|neutrophils leukocytes CD3 blasts granulocytes|residue sugar moiety atom bond|leukocytes|comprising phosphosugar residues , that play a central role in the entry of is , sugar residues bearing at least one entity into inflammatory sites .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neutrophils leukocytes CD3 blasts granulocytes|platelets monocytes neutrophils leukocytes CSCs|leukocytes|the next stage of development of integrins as drug targets has focused on integrin receptors on entity .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|neutrophils leukocytes CD3 blasts granulocytes|placenta beings waste hair bodies|leukocytes|edinburgh , scotland , and has the physical and , with the company  s proprietary technology , the technical capacity to manufacture omniferon ( tm ) from human entity .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|neutrophils leukocytes CD3 blasts granulocytes|leukocytes neutrophils eosinophils monocytes leucocytes|leukocytes|in addition , the bronchoalveolar lavage of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neutrophils leukocytes CD3 blasts granulocytes|pathogens leukocytes contaminants substances microbes|leukocytes|revenue was derived from the commercial sales of its leukonet system , a medical device designed for the removal of contaminating entity from donated blood .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|neutrophils leukocytes CD3 blasts granulocytes|leukocytes neutrophils eosinophils monocytes leucocytes|leukocytes|in addition , the bronchoalveolar lavage ( bal ) of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|neutrophils leukocytes CD3 blasts granulocytes|leukocytes neutrophils monocytes leucocytes granulocytes|leukocytes|chemokines are cytokines which regulate the trafficking patterns of entity , the effector cells of the human immune system .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|neutrophils leukocytes CD3 blasts granulocytes|monocytes granulocytes neutrophils RBCs RBC|leukocytes|antibodies are made in the immune system by human white blood cells , called entity .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|neutrophils leukocytes CD3 blasts granulocytes|bags banks bank spots drawn|leukocytes|by the first quarter 2007 , we anticipate preparing new alferon n injection ( r ) lots from blood entity at our new jersey facility .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|neutrophils leukocytes CD3 blasts granulocytes|stains constituents sugars contaminants vessels|leukocytes|typically by extraction with vegetable oil and hydrophobic chromatography , and sterile filtering to remove bacteria , parasites and all undesirable blood entity .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neutrophils leukocytes CD3 blasts granulocytes|monocytes phagocytes neutrophils vessels leukocytes|leukocytes|monocytes phagocytic blood entity , originating from the bone marrow .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|neutrophils leukocytes CD3 blasts granulocytes|leukocytes leucocytes monocytes neutrophils platelets|leukocytes|addition of sialyl lewis x ( " slex " ) carbohydrate side chains yielding scr1sle x . slex is a carbohydrate which mediates binding of entity including neutrophils to selectin proteins .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3)])|cell|neutrophils leukocytes CD3 blasts granulocytes|haemoglobin CRP hematocrit bilirubin urea|leukocytes|risk of poorer clinical outcomes as measured by atlas score , a tool for evaluating cdi in patients by age , temperature , entity and albumin levels , and use of systemic antibiotics .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|monocytes DCs eosinophils Tregs precursors|macrophages|abx-cbl the cbl antigen is selectively over-expressed on activated immune cells including t-cells , b-cells and certain entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|neutrophils microglia monocytes leukocytes platelets|macrophages|activated entity release a variety of mediators of inflammation that contribute to a broad range of diseases , such as rheumatoid arthritis , osteoarthritis ,
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD14 EPCs CD11b CD16 M1|EBV HMGB1 TRAIL endotoxin FasL|macrophages|the targeting of cd47 to make cancer cells susceptible to entity , a component of the innate immune system , is analogous to the approach that has been applied with checkpoint inhibitors and
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|neutrophils monocytes granulocytes platelets microglia|macrophages|beyond cancer , we have discovered that activated entity , a type of white blood cell found at sites of acute and chronic inflammation , also over-express the folate receptor .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|neutrophils granulocytes eosinophils platelets fibroblasts|macrophages|this is carried out primarily by some specialized cells in the blood ( e . g . , monocytes and entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|CD14 EPCs CD11b CD16 M1|DCs CTL platelets neutrophils angiogenesis|macrophages|these compounds , intended for use as immuno- pharmaceutical agents , activate entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|eosinophils DCs granulocytes neutrophils monocytes|macrophages|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and monocytes / entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|CD14 EPCs CD11b CD16 M1|helper NK suppressor cytokine myeloid|macrophages|in patients with cancer , immuno-evasion occurs as a result of suppressor entity ( m2 ) and inhibitory myeloid suppressive cells and treg cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|CD14 EPCs CD11b CD16 M1|DCs EPCs NK CTCs platelets|macrophages|entity are cells found in the blood which recognize and destroy malignant cells and invading microbes .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|cell|CD14 EPCs CD11b CD16 M1|kinases microglia HSCs signalling monocytes|macrophages|the mt-2000 series is designed to modulate activated entity from a classically activated phenotype to the alternatively activated phenotype .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|CD14 EPCs CD11b CD16 M1|fibroblasts keratinocytes melanocytes capillaries nerves|macrophages|recent experiments have shown that complex polynucleotides administered topically are absorbed by cells such as keratinocytes and entity within the superficial skin .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|CD14 EPCs CD11b CD16 M1|HSCs microglia neutrophils platelets Tregs|macrophages|the mt-1000 series is designed to deplete activated entity via apoptosis and / or alter the phenotype of entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|DCs CTL monocytes Treg NK|macrophages|expressed by tumor cells and have been modified to more efficiently attract immune effector cells , such as nk cells and entity , to effectively kill tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|eosinophils granulocytes monocytes neutrophils platelets|macrophages|phagocytes are a class of white blood cells , which include monocytes , entity and neutrophils , found in abundant quantities in and around tumors and areas of infection .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|neutrophils DCs eosinophils granulocytes monocytes|macrophages|we believe that by inhibiting csf-1r activation on monocytes and entity , that axatilimab has the potential to be used to treat cgvhd .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|Cells Areas Tumors Tissue Those|macrophages|entity affected by the disease become highly enlarged due to the accumulation of glccer and are referred to as “gaucher cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|CD14 EPCs CD11b CD16 M1|monocytes microglia endothelium fibroblasts hepatocytes|macrophages|our anti-mirs promotes reverse cholesterol transport , or rct , which is the efflux of cholesterol from specific cholesterol-laden inflammatory cells called entity in atherosclerotic plaques .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|CD14 EPCs CD11b CD16 M1|granulocytes erythrocytes neutrophils monocytes platelets|macrophages|absence of an active gcd enzyme leads to the accumulation of glccer in lysosomes of certain white blood cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|monocytes thymocytes NK neutrophils myeloid|macrophages|the surface of almost all nucleated cells , and mhc class ii , expressed constitutively on professional antigen presenting cells ( apc ) , including entity and dendritic cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|CD14 EPCs CD11b CD16 M1|monocytes neutrophils NK DCs CTL|macrophages|growth factor receptors known as her2 and her3 , as well as recruit immune killer cells , such as nk cells and entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|blasts CD20 immature CD34 GCT|immature proliferating monocytes progenitors granulocytes|plasmablasts|promising approach for the treatment of rrmm patients due to the restriction of bcmas expression solely on the surface of entity and differentiated plasma cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|blasts CD20 immature CD34 GCT|DCs Cells PBMCs PBMC Samples|plasmablasts|entity are highly enriched for vaccine-specific b cells and , therefore , negligible in pre-vaccination , day 0 samples .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|blasts CD20 immature CD34 GCT|platelets NK mesangial monocytes eosinophils|plasmablasts|disease , and other conditions such as kidney transplant , are associated with autoantibodies secreted by a subset of b cells known as entity and plasma cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|cell|blasts CD20 immature CD34 GCT|dendritic leukocytes adenomas NK thymocytes|plasmablasts|cd19 is a cell surface molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|blasts CD20 immature CD34 GCT|repertoire recruitment ligands trafficking frequencies|plasmablasts|we presented data from the study demonstrating that our vaccine elicited a significant expansion of mucosal homing receptor entity to approximately 60% of all activated b cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|blasts CD20 immature CD34 GCT|analytes ratios MICs transcripts thresholds|plasmablasts|if entity are elevated in a particular sample , we then employ a multi-step process to generate a potential product candidate .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|blasts CD20 immature CD34 GCT|platelets mesangial NK monocytes leukocytes|plasmablasts|other conditions such as kidney transplant desensitization , are associated with autoantibodies secreted by a subset of immune b cells known as entity and plasma cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|blasts CD20 immature CD34 GCT|platelets monocytes leukocytes mesangial basophil|plasmablasts|in the autoantibody pathway , autoantibodies are secreted by a subset of immune system b cells known as entity and plasma cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|blasts CD20 immature CD34 GCT|DCs pathogens parasites modifications epitopes|plasmablasts|we believe these mucosal entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|blasts CD20 immature CD34 GCT|clones DCs monocytes progenitors subsets|plasmablasts|in in vitro studies using human immune cells , cpi-006 led to activation of b cells and differentiation into antibody producing entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 2)])|cell|blasts CD20 immature CD34 GCT|dendritic leukocytes adenomas NK thymocytes|plasmablasts|cd19 is a molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|blasts CD20 immature CD34 GCT|keratinocytes hepatocytes platelets leukocytes monocytes|plasmablasts|mechanism of action a number of autoimmune diseases , including nmosd , are associated with autoantibodies secreted by entity and some plasma cells .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|blasts CD20 immature CD34 GCT|DCs Tregs exosomes TLRs eosinophils|plasmablasts|we believe entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|blasts CD20 immature CD34 GCT|IgG neutrophils parasites monocytes CD34|plasmablasts|pbmcs were collected at day 0 and day 7 , enriched for entity and analyzed in elisas against either the prefusion or the postfusion version of the f protein antigen .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|blasts CD20 immature CD34 GCT|Abs ASC CD20 KIR DCs|plasmablasts|for those patients , we then examine their samples for rare antibody-producing b cells called entity that are elevated during an active immune response .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|blasts CD20 immature CD34 GCT|clones epitopes mAbs genomes cDNAs|plasmablasts|we start by isolating single entity and determining the sequences of the co-expressed antibody genes using our proprietary immune repertoire capture® technology .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|adipocytes cardiomyocytes osteoblasts fibroblasts osteoclasts|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|fibroblasts platelets adipocytes microglia neutrophils|pericytes|in wet amd abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cell|EPCs CD133 astrocytes CD34 eNOS|vessels arteries Will nerves platelets|pericytes|entity then intimately cover the outside of these blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|EPCs CD133 astrocytes CD34 eNOS|fibroblasts nerves endothelium cardiomyocytes capillaries|pericytes|these normal , blood vessel endothelial cells have matured , and have much greater supporting structures such as entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|EPCs CD133 astrocytes CD34 eNOS|EVs EPCs MSCs ECs Macroph|pericytes|entity locally supply the endothelial cells with growth and survival factors , including vegf , and play a major role in endothelial cell survival .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|EPCs CD133 astrocytes CD34 eNOS|Tumors DCs EVs CSCs MSCs|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for anti-endoglin antibodies
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|vessels grafts platelets implants capillaries|pericytes|after the entity are stripped from the new blood vessels , endothelial cells located inside the newly formed blood vessels are left unprotected and
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|EPCs CD133 astrocytes CD34 eNOS|mitochondria hepatocytes keratinocytes MSCs cardiomyocytes|pericytes|the binding of pdgf provides an important cell survival signal to entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|EPCs CD133 astrocytes CD34 eNOS|photoreceptors glia RPE retina ECs|pericytes|function of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal cells ( entity ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cell|EPCs CD133 astrocytes CD34 eNOS|helps vessels arteries thereby platelets|pericytes|entity also physically support and stabilize the abnormal new blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|EPCs photoreceptors RPE glia EPC|pericytes|of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal -21- cells ( entity ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|angiogenesis CTCs VEGF EPCs CSCs|pericytes|this increased resistance to vegf inhibitors is thought to be related to the presence of entity as a result of cancers up-regulating other angiogenesis pathways including those involving pdgfrβ .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|fibroblasts platelets adipocytes neutrophils monocytes|pericytes|( va ) from baseline over time abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|platelets EPCs fibroblasts monocytes SMCs|pericytes|pdgfrβ signaling is responsible for recruiting cells called entity which play a key role in the development and stabilization of blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|EPCs monocytes platelets neutrophils ECs|pericytes|pdgf also recruits entity to the abnormal new blood vessel , where they mature and cover the endothelial cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|Tumors CSCs MSCs DCs EPCs|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for endoglin 13
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cell|EPCs CD133 astrocytes CD34 eNOS|vessels platelets grafts arteries implants|pericytes|after the entity are stripped from the new blood vessels , endothelial cells lining the inside of the newly formed blood vessels are left
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|adipocytes cardiomyocytes osteoblasts osteoclasts fibroblasts|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|EPCs CD133 astrocytes CD34 eNOS|EPCs platelets ECs fibroblasts monocytes|pericytes|in addition , the impact of vegf inhibitors may be limited by the activity of entity , which are the cells that cover the outside of blood vessels and support and stabilize newly formed vessels .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|granulocytes neutrophils blasts granulocyte basophil|platelets neutrophils granulocytes erythrocytes monocytes|granulocytes|the enzyme tyrosine kinase in the bone marrow , which causes too many stem cells to develop into white blood cells ( entity or blasts ) .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|granulocytes neutrophils blasts granulocyte basophil|granulocytes neutrophils oligodendrocytes monocytes cardiomyocytes|granulocytes| enables aml blast cells to differentiate into entity and may be applicable in a broad range of aml patients .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|granulocytes neutrophils blasts granulocyte basophil|neutrophils platelets RBCs RBC monocytes|granulocytes|oncology biosimilar udenyca™ stimulates production of entity ( a type of white blood cell ) in order to promote the bodys ability to fight infections .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|granulocytes neutrophils blasts granulocyte basophil|saliva breath semen hair dialysate|granulocytes|for up to two years after treatment , as well as preliminary efficacy as measured by changes in cystine levels in entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|granulocytes neutrophils blasts granulocyte basophil|neutrophils eosinophils monocytes granulocytes platelets|granulocytes|of naive and activated immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , entity , mast cells and monocytes / macrophages .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|granulocytes neutrophils blasts granulocyte basophil|Th1 monocytes DCs neutrophils Treg|granulocytes|responses detected in treated pts  klh carrier as immune stimulant  gm-csf stimulates entity and macrophages antigen binding site = idiotype ( id ) biovaxld : id-klh + gm-csf  first in a
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|granulocytes neutrophils blasts granulocyte basophil|granulocytes precursors progenitors oligodendrocytes phagocytes|granulocytes|in apl , there is an abnormal accumulation of immature entity called promyelocytes .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|granulocytes neutrophils blasts granulocyte basophil|erythrocytes fibrin platelets RBCs neutrophils|granulocytes|soluble fibrin and formed elements in the blood , maintains the deformability of red blood cells , non-adhesiveness of unactiviated platelets and entity and the normal viscosity of blood .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|granulocytes neutrophils blasts granulocyte basophil|monocytes neutrophils DCs eosinophils Treg|granulocytes|immune cells recruited by the antibody to kill the cancer include entity , macrophages and nk cells .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|granulocytes neutrophils blasts granulocyte basophil|eosinophils leukocytes neutrophils granulocytes leucocytes|granulocytes|cml is a clonal bone marrow stem cell disorder in which proliferation of mature entity ( neutrophils , eosinophils , and basophils ) and their precursors is the main finding .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|cell|granulocytes neutrophils blasts granulocyte basophil|endotoxin LPS antimicrobials rifampicin rifampin|granulocytes|in an animal model of infection , the antibacterial activity of sivextro was reduced in the absence of entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|granulocytes neutrophils blasts granulocyte basophil|neutrophils granulocytes eosinophils platelets monocytes|granulocytes|mg / kg alx377 in mouse models and measured red blood cell , or rbc , platelet and white blood cell ( lymphocyte , monocytes and entity ) counts .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|granulocytes neutrophils blasts granulocyte basophil|monocytes fibroblasts osteoblasts neutrophils keratinocytes|granulocytes|gm-csf stimulates the growth and differentiation of entity and macrophages .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|granulocytes neutrophils blasts granulocyte basophil|granulocytes neutrophils HSCs platelets fibroblasts|granulocytes|however , cll-1 is also expressed on normal hematopoietic cells such as entity and monocytes .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|granulocytes neutrophils blasts granulocyte basophil|granulocytes oligodendrocytes cardiomyocytes erythrocytes neutrophils|granulocytes|aslan003 has demonstrated the ability to differentiate aml blast cells into entity in a variety of aml cell lines that do not respond to atra .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|granulocytes neutrophils blasts granulocyte basophil|granulocytes oligodendrocytes osteoclasts fibroblasts monocytes|granulocytes|evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , metamyelocytes and entity ) .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|granulocytes neutrophils blasts granulocyte basophil|aggregates granulocytes colonies leukocytes granules|granulocytes|in aml , blast cells are unable to differentiate and form entity , such as neutrophils and eosinophils , causing depletion of white blood cells .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|granulocytes neutrophils blasts granulocyte basophil|monocytes neutrophils platelets basophil granulocytes|granulocytes|lymphocytes : the white blood cells ( leukocytes ) that include the b cells and t cells , but not the others ( such as entity and eosinophils ) .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 2)])|cell|granulocytes neutrophils blasts granulocyte basophil|osteoblasts osteoclasts adipocytes cardiomyocytes osteoblast|granulocytes|the lead compound , lg7455 , activates the gcsf-gcsfr signaling pathway and induces the differentiation of human bone marrow cells into entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|cell|granulocytes neutrophils blasts granulocyte basophil|lymphoid erythroid myeloid lymphoblastic leukemias|granulocytes|clone 818-18 produces a murine igg1 monoclonal antibody which recognizes a nuclear antigen expressed in human entity and myeloid precursors and acute and chronic myeloid leukemia .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils monocytes Th17 neutrophils Th2|eosinophils|it has also been shown to impact some diseases , such as asthma , that are driven by entity , another important class of immune cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils neutrophils platelets monocytes keratinocytes|eosinophils|despite the knowledge that entity and mast cells drive many pathological conditions , there are no approved therapies that selectively target both entity and mast cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils mast platelets IgE basophil|eosinophils|believes that it is helpful to provide investors with an overview of the types of diseases that are affected by entity and / or mast cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils neutrophils monocytes NK keratinocytes|eosinophils|ak002 binds to siglec-8 , an inhibitory receptor found on entity and mast cells , which represents a novel way to selectively deplete or inhibit these important immune cells and thereby resolve
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils neutrophils leukocytes mucin monocytes|eosinophils|eg is a rare disease that is characterized by chronic inflammation due to patchy or diffuse infiltration of entity into layers of the stomach .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|monocytes eosinophils granulocytes platelets neutrophils|eosinophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , entity , and basophils ) and their precursors is the main finding .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|monocytes neutrophils microglia eosinophils Tregs|eosinophils|in ad , entity are important effector cells that promote inflammation and tissue damage .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils monocytes participates implicated accumulates|eosinophils|eotaxin-1 is expressed on type 2 t helper ( “th2” ) cells and entity in bp lesions and an increasing body of data documents the role of these cells in both the innate and
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|mononuclear polymorphonuclear NK lymphocyte splenic|eosinophils|** ** prs-060 48-hr 1 1006 ** * 0 total macrophages entity lymphocytes 48hr timepoint anticaln control *p 34 . 5 µm 60?
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|platelets erythrocytes granulocytes neutrophils monocytes|eosinophils|entity are a type of white blood cell .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils neutrophils eosinophil monocytes PMNs|eosinophils|bertilimumab may prevent eotaxin-1-induced chemotaxis of entity and neutralize eotaxin-1 in the circulation , preventing eosinophil migration .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|troponin BNP CK LVEF cTn|eosinophils|cardiac screening should be considered in patients with hes / cel , and patients with mds / mpd with high level of entity ( echocardiogram , serum troponin level ) .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils neutrophils monocytes leukocytes Tregs|eosinophils|background on eoe and current treatments eoe results from a dysregulation of th2-mediated immunity that drives recruitment of entity to the esophagus .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|NK Th1 APC Th helper|eosinophils|provided data on the mechanism of anticancer activity for il-17e , showing that il-17e activated the immune system , specifically acting on entity and b cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|monocytes eosinophils platelets granulocytes erythrocytes|eosinophils|in aml , blast cells are unable to differentiate and form granulocytes , such as neutrophils and entity , causing depletion of white blood cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|monocytes eosinophils neutrophils platelets DCs|eosinophils|importantly , and in contrast to other agents , hgen005 appears to have an effect solely on entity , without impacting other populations , such as mast cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|draws collection draw eosinophils chemistry|eosinophils|outcomes associated with asthma symptoms , as measured using the asthma control questionnaire 5 and biomarker levels as measured using blood entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils neutrophils leukocytes monocytes leucocytes|eosinophils|eotaxin  a protein that attracts entity into tissues , where they degranulate and cause tissue damage .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils neutrophils monocytes granulocytes DCs|eosinophils|in addition to the effects on neutrophils and cytokines , a trend towards reduction in other immune cells in sputum , namely entity and macrophages , was also observed .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|eosinophils basophil neutrophils eosinophil eosinophilic|eosinophils leukocytes neutrophils allergens monocytes|eosinophils|wo 97 / 00960 also discloses methods of use of the eotaxin proteins in the recruitment of entity to a particular site or in the treatment of allergic conditions .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|Hemoglobin basophil neutrophils blasts platelets|polypeptides glycoproteins EVs pathogens cyanobacteria|erythrocytes|we are aware of an issued patent outside the united states that is directed to entity that comprise exogeneous polypeptides .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|Hemoglobin basophil neutrophils blasts platelets|platelets erythrocytes granulocytes fibroblasts osteoblasts|erythrocytes|shown that our imids ( r ) can interact with stem cells and modulate them in such a way that they differentiate into entity , or red blood cells .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|Hemoglobin basophil neutrophils blasts platelets|spermatozoa oligodendrocytes erythrocytes embryos granulocytes|erythrocytes|dna , genes , and transcription factors dna is present in all cells , except mature entity , and encodes the inherited characteristics of all living organisms .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|Hemoglobin basophil neutrophils blasts platelets|lowest Per Minimum Low Higher|erythrocytes|ra101495 protects against complement-mediated hemolysis of type dose response iii pnh entity drug concentration no drug ra101495
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|Hemoglobin basophil neutrophils blasts platelets|concentrates concentrate parasites transfusions RBCs|erythrocytes|bilirubin entity ( red blood cells ) circulating in the blood stream have a life expectancy of 120 days .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|Hemoglobin basophil neutrophils blasts platelets|platelets granulocytes monocytes neutrophils leukocytes|erythrocytes|these cells have a limited life span ; neutrophils live a few hours and entity or red blood cells survive for a few weeks .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|Hemoglobin basophil neutrophils blasts platelets|monocytes granulocytes erythrocytes platelets neutrophils|erythrocytes|with an increased likelihood of sle . test method description results were obtained using flow cytometry for complement c4d fragment bound to entity ( ec4d ) and b-lymphocytes ( bc4d ) .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|Hemoglobin basophil neutrophils blasts platelets|neutrophils erythrocytes platelets granulocytes monocytes|erythrocytes|and inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ; red cells that carry oxygen through our bodies ( entity ) ; and platelets that help blood to clot .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|Hemoglobin basophil neutrophils blasts platelets|erythrocytes platelets latter RBCs lipids|erythrocytes|the entity are then separated from the other blood compounds and opened by osmotic hemolysis , thus releasing the hemoglobin molecules .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|Hemoglobin basophil neutrophils blasts platelets|hepatocytes platelets leukocytes fibroblasts nerves|erythrocytes|drugs like ribavirin to infected liver cells while reducing the amount of drug going to other cells and tissues , including entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|Hemoglobin basophil neutrophils blasts platelets|RBCs platelets erythrocytes neutrophils endothelium|erythrocytes|up to 20 percent of the eculizumab-treated population , is most commonly attributable to extravascular hemolysis driven by intense c3 deposition on entity .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|Hemoglobin basophil neutrophils blasts platelets|neutrophils erythrocytes platelets monocytes granulocytes|erythrocytes|inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|Hemoglobin basophil neutrophils blasts platelets|correctly zero adequately quantitatively delta|erythrocytes|the nine month post-infusion data point , with total hemoglobin levels of 11 . 9 g / dl , 10 . 1 g / dl fetal hemoglobin and 99 . 8 percent f-cells ( entity expressing fetal hemoglobin ) .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|Hemoglobin basophil neutrophils blasts platelets|fibroblasts monocytes platelets eosinophils neutrophils|erythrocytes|( hsa ) , a glycoprotein expressed on the surface of many human cell types , including immature human hematopoietic cells , peripheral blood lymphocytes , entity , and many human carcinomas .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|Hemoglobin basophil neutrophils blasts platelets|PBMCs PBMC erythrocytes monocytes splenocytes|erythrocytes|strong cell mediated immunity ( e . g . th1 biased cd4+ ad cd8+ ) to reduce parasitemia by clearing infected cells ( liver cells or entity ) .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('BIO', 2), ('DIS', 2)])|cell|Hemoglobin basophil neutrophils blasts platelets|myoglobin peroxidase bilirubin NADH oxidase|erythrocytes|blood : this test is based on the pseudo peroxidase action of hemoglobin and entity which catalyzes the reaction of 3 , 3 , 5 , 5-tetramethyl-benzidine and buffered organic peroxide .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|Hemoglobin basophil neutrophils blasts platelets|he you whom she whichever|erythrocytes|it provides vital oxygen supplies to places in the human body entity cannot reach for instance due to arterial sclerosis .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|Hemoglobin basophil neutrophils blasts platelets|neutrophils erythrocytes platelets monocytes granulocytes|erythrocytes|( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|Hemoglobin basophil neutrophils blasts platelets|bloodstream precursor shorter immature insoluble|erythrocytes|for example , the deposition of the c4d fragment to entity forms erythrocyte c4d , or ec4d .
OrderedDict([('BIO', 4), ('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|Hemoglobin basophil neutrophils blasts platelets|erythrocytes RBC RBCs IgG neutrophils|erythrocytes|unlike cd47-blocking antibodies , tti-622 bound minimally to human entity and did not induce hemagglutination in vitro .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|compartment hepatocytes tubules effluent vesicles|hepatocytes|target of 10% enzyme replacement at all doses in otc-deficient mouse model lunar-otc treatment increases otc expression in mouse periportal entity ( main site of ureagenesis )
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|hepatocytes keratinocytes fibroblasts MSCs chondrocytes|hepatocytes|in the companys preclinical studies , transduction of primary human entity with aavs3 pseudotyped vectors was significantly higher as compared with the other vectors listed above .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|utero germline fact excess another|hepatocytes|our initial focus is on monogenic diseases with clear biology linking the missing activity of a gene in entity to a disease outcome .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|mitochondria slices microsomes hepatocytes fibroblasts|hepatocytes|the polymer is targeted to the asialoglycoprotein receptor on liver entity by the inclusion of a galnac moiety to one end of the polymer .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|DCs fibroblasts EPCs MSCs clones|hepatocytes|improvements in the function of our immortalized entity will open more markets and expand the usage in the current markets for our cells .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|mammals piglets mosquitoes rodents newborns|hepatocytes|mrt5201 , is designed to address the underlying cause of otc deficiency by delivering mrna encoding fully functional otc enzyme to entity through intravenous administration .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|epithelia epithelium keratinocytes hepatocytes livers|hepatocytes|have shown that the rap receptor , lrp1 , is well expressed on human hcc and under-expressed on non-cancerous , but otherwise diseased , entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|DCs explants allografts fibroblasts ECs|hepatocytes|we recently demonstrated that liver entity show a rapid , primary nf-kb activation response following in vivo administration of cblb502 in mice and nhps .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|transporters pharmacokinetics circumstances toxicities hepatocytes|hepatocytes|however , combining multiple interventions , particularly multiple small molecules , places an additional burden of drug metabolism and clearance upon already stressed entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|hepatocytes hepatocyte fibroblasts HSCs livers|hepatocytes|these cells have been shown to retain many key synthetic and metabolic processes of normal human entity , the primary functional cell of the liver .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|microsomes homogenates cytosol homogenate slices|hepatocytes|pmx-30063 has been tested for stability in the presence of mouse and human liver entity to investigate the extent to which liver metabolism could be a factor upon compound administration .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|microsomes cirrhosis homogenates cytosol homogenate|hepatocytes|pmx-30063 demonstrated high stability in the presence of liver entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|hepatocytes livers lobes steatosis specimen|hepatocytes|percentage of entity showing steatosis , or fatty change , mean ± sd ( n ) 54 . 8 ± 21 . 2 49 . 9 ± 24 . 3
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|spermatogenesis cognition microcirculation mitochondria neurogenesis|hepatocytes|it has been previously demonstrated that impairment of entity by ethanol is associated with the production of free radical and oxidative stress .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|bank islets vaccines spheroids CSCs|hepatocytes|these efforts have been towards improving the functionality of our immortalized entity , introducing products utilizing these cells and expanding our intellectual property base .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|exosomes cardiomyocytes hepatocytes fibroblasts MSCs|hepatocytes|our liversafe 3d™bioassay system uses our stem cell-derived entity , or liver cells .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|astrocytes hepatocytes oocytes testis adipocytes|hepatocytes|for example , the asg receptor exists primarily in entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|hepatocytes lysosomes mitochondria exosomes cytosol|hepatocytes|patient has a mutation in both copies of the serpina1 gene , which causes aat to aggregate inside liver cells , or entity , rather than being secreted from the liver .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|hepatocytes adipocytes fibroblasts Cells platelets|hepatocytes|entity are the most biochemically complex cells in the human body and play an important role in the synthesis and metabolism
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|hepatocytes Ki67 steatosis cirrhosis maturity|hepatocytes hepatocyte mitochondria fibroblasts HSCs|hepatocytes|apoptosis of entity manifests as ballooning of the cells , a characteristic microscopic feature of nash liver tissue .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|blasts platelets basophil neutrophils CD34|platelets PCs microparticles neutrophils monocytes|megakaryocytes|lx-5431 has been demonstrated in ex vivo bone marrow culture to stimulate production of platelet forming cells called entity .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|platelets erythrocytes fibroblasts neutrophils hepatocytes|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hescs or ipscs as the starting materials .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|EPCs MSCs progenitors exosomes HSCs|megakaryocytes|in addition , bet proteins promote the generation of entity from hematopoietic stem cells .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|blasts platelets basophil neutrophils CD34|platelets fibroblasts erythrocytes RBCs hepatocytes|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hes or ips cells as the starting materials .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|platelets HSCs neutrophils leukocytes monocytes|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelet counts .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|progenitors platelets monocytes neutrophils EPCs|megakaryocytes|we believe that the blood cells most responsible for bone marrow scarring in mf are dysfunctional entity , which produce inflammatory molecules in part through elevated nf-kb signaling .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|blasts platelets basophil neutrophils CD34|platelets progenitors EPCs monocytes HSCs|megakaryocytes|the angiopoietins are in preclinical studies for their abilities to promote growth and mobilization of hemopoietic stem cells and entity .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cell|blasts platelets basophil neutrophils CD34|MDS genomics senescence hematopoiesis tumorigenesis|megakaryocytes|an editorial entitled , myelodysplasia , entity , and methylation was also published in the same issue of leukemia research ( steensma , leuk .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|platelets granulocytes neutrophils erythrocytes monocytes|megakaryocytes|precursors of the red blood cells or of the granulocytes and macrophages , which are also of the immune system , and entity , which produces platelets .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|platelets HSCs SMCs monocytes neutrophils|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelets .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|Cells Bacteria HSCs platelets Mice|megakaryocytes|entity normally function to produce platelets , which are small blood cells involved in blood clotting .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 3)])|cell|blasts platelets basophil neutrophils CD34|EPCs platelets osteoclasts Cells Platelet|megakaryocytes|entity , which are large cells found in the bone marrow , are the source of platelets that are released into the bloodstream .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|platelets EPCs osteoclasts monocytes CD34|megakaryocytes|these cells , known as entity , are found in the bone marrow and are the precursor cells to platelets .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|blasts platelets basophil neutrophils CD34|platelets PCs progenitors precursors microparticles|megakaryocytes|specifically , jak2 activation leads to proliferation of red blood cell progenitors and platelet progenitors , or entity , that fail to mature to platelets .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|blasts platelets basophil neutrophils CD34|MSCs HSCs CSCs fibroblasts MSC|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow ,
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|platelets EPCs progenitors CD34 concentrates|megakaryocytes|entity are the bone marrow cells that give rise to blood platelets . 13 about eltrombopag eltrombopag was given accelerated approval by the
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|blasts platelets basophil neutrophils CD34|platelets endothelium erythrocytes mitochondria microcirculation|megakaryocytes|itp can also result in damage to entity , leading to impaired platelet production .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|blasts platelets basophil neutrophils CD34|fungi mites microbes parasites larvae|megakaryocytes|we could not readily identify entity in our conditions on morphological grounds despite some effort with mgdf and therefore do not know which of our sampled
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|blasts platelets basophil neutrophils CD34|MSCs HSCs BMSCs MSC CSCs|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow , which further exacerbates the
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|counting autophagy fibroblasts Aging degeneration|tubule pod cytoplasm nephron proteasome|podocytes|inhibition of calcineurin within the entity can prevent the dephosphorylation of synaptopodin which in turn inhibits the degradation of the actin cytoskeletion within the podocyte .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|counting autophagy fibroblasts Aging degeneration|ICD CAS epitope IS CPP|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity : 931-8 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|counting autophagy fibroblasts Aging degeneration|microenvironment vasculature microcirculation hemodynamics endothelium|podocytes|additionally , recent evidence suggests that inhibition of calcineurin has direct physical impacts on the entity within the kidney .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|counting autophagy fibroblasts Aging degeneration|immunity immunoglobulins mediators MMPs microenvironment|podocytes|voclosporin also potentially stabilizes disease modifying entity , which protects against proteinuria .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|counting autophagy fibroblasts Aging degeneration|proteinuria albuminuria GFR eGFR FA|podocytes|( a and b ) gl-3 reduction in entity was closely paralleled by a reduction in podocyte volume .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|counting autophagy fibroblasts Aging degeneration|ICD CAS ICR OM CPP|podocytes|immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity 8 of the entity : 931-8 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|counting autophagy fibroblasts Aging degeneration|OPN MMPs proteinuria albuminuria RAGE|podocytes|voclosporin also potentially stabilizes entity , which can protect against proteinuria .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|counting autophagy fibroblasts Aging degeneration|VEGF t1 ceramide beta1 PTH|podocytes|voclosporin also potentially stabilizes entity , s-12 table of contents which can protect against proteinuria .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|counting autophagy fibroblasts Aging degeneration|expressing murine int ir ss|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 29 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|counting autophagy fibroblasts Aging degeneration|expressing murine proliferative int ss|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 30 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|counting autophagy fibroblasts Aging degeneration|carbohydrates casein meat vegetables sugars|podocytes|there were statistical trends towards associations between 24-hr urine protein and % change in gl-3 inclusion content of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|counting autophagy fibroblasts Aging degeneration|filtration tubules glomeruli capillaries tubule|podocytes|entity form part of the barrier that enable the glomerulus to filter the blood in a manner that retains large molecules
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|counting autophagy fibroblasts Aging degeneration|turn glomeruli hepatocytes VSMCs CKD|podocytes|curr pharm des 21 overactive cannabinoid 1 receptor in entity drives type 2 diabetic nephropathy .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|counting autophagy fibroblasts Aging degeneration|mesangial fibroblasts VSMCs HSCs glomeruli|podocytes|gas6 is upregulated in either endothelial / mesangial cells or entity in igan dual involvement of growth arrest-specific
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|counting autophagy fibroblasts Aging degeneration|tubules fibroblasts vessels glomeruli vasculature|podocytes|combined with reduction of local hypoxia , plxdc2 can improve the health and homeostasis of renal epithelial cells and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|counting autophagy fibroblasts Aging degeneration|expressing murine int ir predominant|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 32 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|counting autophagy fibroblasts Aging degeneration|erythrocytes lungs cerebellum hepatocytes PBMCs|podocytes|( c ) volume fraction of gl-3 inclusions in entity did not change during the 6 months migalastat treatment .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DIS', 1), ('BIO', 1)])|cell|counting autophagy fibroblasts Aging degeneration|NK etc tons dendritic Langerhans|podocytes|endothelial cells , tubular epithelial cells , cns mc5r cns , exocrine glands , lymphocytes , entity adapted from gong 2011 , catania 2004 , schioth 1997
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|counting autophagy fibroblasts Aging degeneration|endothelium microbiome cytoskeleton BBB epithelium|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|counting autophagy fibroblasts Aging degeneration|glomeruli capillaries endothelium hepatocytes fibroblasts|podocytes|fsgs is understood to start with damage to entity , cells that wrap around capillaries of the glomerulus .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|monocytes platelets neutrophils eosinophils basophil|basophils|neutrophils , eosinophils and entity , which are types of mature leukocytes , are normally formed only in the bone marrow and are stored there until they
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|basophil eosinophils blasts neutrophils Blood|murine express bind recognize designated|basophils|high affinity anti-human ige- 12 / 31 / 87 s / n 140 , 036 u . s . monoclonal antibody which bind to igge-bearing b cells and not entity tnx87-12a change et al .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|monocytes platelets neutrophils eosinophils granulocytes|basophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , eosinophils , and entity ) and their precursors is the main finding .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|eosinophils DCs monocytes neutrophils Tregs|basophils|vista is an immunoregulatory receptor and is highly expressed on various immune system cells including neutrophils , monocytes , macrophages , entity and dcs .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|monocytes fibroblasts PMNs neutrophils platelets|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic 50 of approximately 1 . 5 nm , which is approximately 15-fold greater
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|basophil eosinophils blasts neutrophils Blood|murine designated recognizes pathogenic neutralizing|basophils|high affinity anti-human ige- 7 / 29 / 88 s / n 226 , 421 u . s . monoclonal antibody which binds to ige-bearing b cells and not entity tnx87-12aa chang et al .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|eosinophils IgE keratinocytes basophil degranulation|basophils|e25 blocks ige from binding to mast cells and entity , thereby inhibiting the allergic response .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|monocytes fibroblasts PMNs neutrophils platelets|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic50 of approximately 1 . 5 nm , which is approximately 15-fold greater than
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|basophil eosinophils blasts neutrophils Blood|eosinophils keratinocytes neutrophils monocytes fibroblasts|basophils|mast cells , entity , goblet cells and other cells also play a role .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|platelets monocytes eosinophils basophil endothelium|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity through specific ige receptors on the cell surface .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|basophil eosinophils blasts neutrophils Blood|eosinophils monocytes neutrophils basophil keratinocytes|basophils|pci-32765 is a potent inhibitor of histamine release ( also known as degranulation ) from mast cells and entity , which are specific immune cells .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|basophil eosinophils blasts neutrophils Blood|eosinophils monocytes neutrophils basophil keratinocytes|basophils|to the antigen , or allergen in this case , by producing ige . ige binds to the surface of mast cells and entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|eosinophils platelets monocytes keratinocytes neutrophils|basophils|these ige molecules attach to the surfaces of mast cells or entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|eosinophils monocytes platelets neutrophils nerves|basophils|and masking the binding site for the ige receptor which prevents ige from binding to and arming mast cells and entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|basophil eosinophils blasts neutrophils Blood|mediators neutrophils eosinophils leukocytes leucocytes|basophils|similarly , calcium ions also play a central role in the activation and degranulation of tissue mast cells and circulating counterpart entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|platelets eosinophils monocytes keratinocytes endothelium|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity , thereby arming these cells .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|neutrophils granulocytes eosinophils DCs monocytes|basophils|in animal models that ccr2 is important for host defense , inflammation and immunity mediated through hematopoietic cells including monocytes and entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|monocytes neutrophils eosinophils platelets keratinocytes|basophils|siglec-8 is an inhibitory receptor located selectively on eosinophils , mast cells and , to a lesser extent , on entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|basophil eosinophils blasts neutrophils Blood|monocytes neutrophils eosinophils granulocytes platelets|basophils|omalizumab works by binding to the immune mediator immunoglobulin e , or ige , and inhibiting ige-mediated activation of mast cells and entity , types of white blood cells .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|basophil eosinophils blasts neutrophils Blood|monocytes fibroblasts granulocytes neutrophils microglia|basophils|cd123 is also expressed by plasmacytoid dendritic cells , or pdcs , entity , endothelial cells and , to a lesser extent , monocytes and eosinophils .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|glial glia astrocytes NOS immunohistochemistry|neurones fibres ganglia endings axons|neurons|in parallel , electrophysiology recordings of single ganglion entity that innervate the craniofacial muscles were performed ( 33 masticatory muscle mechanoreceptors ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|glial glia astrocytes NOS immunohistochemistry|nerves partners neurones axons electrodes|neurons|amyloid fibrils are believed to be neurotoxic and interfere with the normal communication between entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|glial glia astrocytes NOS immunohistochemistry|circuits afferents neurones interneurons axons|neurons|these entity are responsible for producing dopamine , an essential brain signaling chemical , or neurotransmitter , that enables smooth , coordinated movements of both voluntary
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|glial glia astrocytes NOS immunohistochemistry|photoreceptors photoreceptor epithelium outer pigment|neurons|these results suggest that the photoreceptor entity and pigmented retinal epithelial cells  cell types that are both lost in ga  are sandwiched between deposits of
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|glial glia astrocytes NOS immunohistochemistry|you Subjects volunteers she Participants|neurons|as a result , entity are unable to respond to normal stimuli and can become over-stimulated by a neurotransmitter or be unable to respond to
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|glial glia astrocytes NOS immunohistochemistry|brains plaques astrocytes axons synapses|neurons|in ad , tau protein is misfolded , becomes hyperphosphorylated and aggregates into neurotoxic oligomers that ultimately form neurofibrillary tangles within entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|glial glia astrocytes NOS immunohistochemistry|neurones terminals axons fibres interneurons|neurons|these symptoms are caused by the degeneration of dopaminergic entity in the substantia nigra and depletion of dopamine in the striatum .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|glial glia astrocytes NOS immunohistochemistry|axons myelin synapses glia oligodendrocytes|neurons|can transition into mild , moderate and , finally , severe stages of alzheimers disease that are characterized by greater systemic loss of entity and synapses in the brain tissue .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cell|glial glia astrocytes NOS immunohistochemistry|efflux transporters depletion neurotoxicity neurotransmission|neurons|parkinsons disease ( the “mptp model” ) showed that when administered orally , aeol 11207 crosses the blood brain barrier and protected dopamine entity in a dose-dependent manner .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|glial glia astrocytes NOS immunohistochemistry|neuron retina axons axon neurones|neurons|the dendrites and axons , or nerve endings , of the entity contain an elaborate series of thin tubes , or microtubules , which serve to support them and transport nutrients down to the
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|glial glia astrocytes NOS immunohistochemistry|axons motoneurons neuron neurones microtubules|neurons|sma is caused by a genetic defect in the smn1 gene that codes smn , a protein necessary for survival of motor entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|glial glia astrocytes NOS immunohistochemistry|oligodendrocytes neurones axons myelin synapses|neurons|accumulation of mhtt protein causes progressive loss of entity in the brain .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|glial glia astrocytes NOS immunohistochemistry|neurones neuron astrocytes oligodendrocytes fibroblasts|neurons|cord in commercial quantities , and the ability to control the differentiation of these cells constitutively into mature , physiologically relevant human entity and glia .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|glial glia astrocytes NOS immunohistochemistry|nerves neurones astrocytes axons oligodendrocytes|neurons|neurotoxic peptiderefers to a small protein ( called a peptide ) that can be toxic to entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|glial glia astrocytes NOS immunohistochemistry|listeners dB thresholds him tone|neurons|· ep1937352 sub-threshold stimulation to precondition entity for supra-threshold stimulation – opposition hearing is scheduled for january 21 , 2015 in munich , germany .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|glial glia astrocytes NOS immunohistochemistry|axons circuitry circuits skills coordination|neurons|limitations of current therapies als is a neurodegenerative disorder that involves gradual breakdown of motor entity leading to muscle weakness , disability , and ultimately death .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|glial glia astrocytes NOS immunohistochemistry|axons neurones astrocytes oligodendrocytes tau|neurons|which leads to production of a mutant huntingtin protein that is thought to be neurotoxic and promote the degeneration of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|glial glia astrocytes NOS immunohistochemistry|DRG paw amygdala NTS PVN|neurons|to further demonstrate this , we utilized in vivo electrophysiology where cbn blocked the pain signals in the entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|glial glia astrocytes NOS immunohistochemistry|glia axons neurones astrocytes terminals|neurons|loss of dopamine causes critical nerve cells , or entity , in the brain , to fire out of control , leaving patients unable to direct or control their movement in a normal
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|glial glia astrocytes NOS immunohistochemistry|axons nerves neurones motoneurons fibres|neurons|about sma sma is a severe neuromuscular disease characterized by the loss of motor entity leading to progressive muscle weakness and paralysis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|MSCs MSC cardiomyocytes exosomes fibroblasts|cardiomyocytes|we have derived human entity ( grncm1 ) from hescs for the potential treatment of heart disease .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|congestive Chronic idiopathic Severe Advanced|cardiomyocytes|cm1 – entity heart failure 6 million total patients in u . s . cells derived and characterization studies performed ( parameters analyzed showed normal cell functions
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|brand outlet company market companies|cardiomyocytes|product sales for both 2012 and 2013 is primarily attributable to an increase in unit volume sales of our icell entity and , in 2012 , to our icell neurons .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|Chronic congestive Severe idiopathic familial|cardiomyocytes|cm1 - entity heart failure 6 million total patients in u . s . cells derived and fully characterized ( all normal cell functions verified in vitro ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|medicines therapeutics exosomes ingredients probiotics|cardiomyocytes|gerons grncm1 program is developing hesc-derived entity for the treatment of heart failure .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|cardiomyocytes myocytes fibroblasts hearts myocardium|cardiomyocytes|in human entity isolated from the left ventricle of patients with end-stage heart failure , serca2a levels were correlated with improved diastolic function .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|cardiomyocytes myocytes hearts mitochondria rings|cardiomyocytes|isolated entity from aav-s100a1 treated pig heart showed superior systolic and diastolic performance .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|cardiomyocytes fibroblasts hearts myocardium thymus|cardiomyocytes|moreover , old g5terc-null mice exhibited shorter telomeres in entity than did younger counterparts , and this led to ventricular dilation , page .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|therapeutics substances vectors oligonucleotides infusions|cardiomyocytes|the targeted entity are expected to produce sustained therapeutic protein levels in the myocardium where it is needed .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|myocardium nerves diaphragm detrusor vessels|cardiomyocytes|such cells include entity or heart muscle cells , neural cells , hepatic cells and pancreatic ( logo ) islet cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|IgG saliva tears placenta islets|cardiomyocytes|the first product developed under the alliance , human entity derived from hescs , was launched in october 2010 by gehc .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|chondrocytes MSCs EPCs hepatocytes fibroblasts|cardiomyocytes|specific precursor cells which , together with a specific combination of growth factors , develop full culture wells of functional , beating human entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|myocytes cardiomyocytes myocardium electrodes valves|cardiomyocytes|the product is predominantly composed of ventricular entity which have been shown to electrically and mechanically couple to the animal myocardium in which they are injected and contract
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|smoke get medicines cannabis marijuana|cardiomyocytes|u . s . patent no . 7 , 425 , 448 was issued to geron with broad claims to entity derived from hescs .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|vaccines therapeutics DCs exosomes vectors|cardiomyocytes|that asterias will reach an agreement for support in the manufacture of vac2 or the development of hes cell derived entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|cardiomyocytes myoblasts HCM SMC myotubes|cardiomyocytes|heart muscle cells ( entity ) do not regenerate during adult life .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|hepatocytes mitochondria cardiomyocytes adipocytes fibroblasts|cardiomyocytes|dbcm is caused by metabolic derangements in entity that result in cell death and fibrosis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|fibroblasts MSCs exosomes cardiomyocytes MSC|cardiomyocytes|cm1 , hes cell-derived entity , have been extensively characterized in vitro and in vivo .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|cardiomyocytes fibroblasts ESC supernatant hepatocytes|cardiomyocytes|we used our hpsc-derived entity ( human heart cells ) in cardiosafe 3d™ , our novel , customized in vitro bioassay system for predicting potential cardiotoxicity of drug rescue
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cardiomyocytes cardiomyopathy neovascularization echocardiography mitochondria|chosen discovered grown gliomas learn|cardiomyocytes|today we have entity , two types of neural cells -- dopaminergic neurons and oligodendrocytes -- and hematopoietic cells in animal models , and we hope
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|chondrocytes cardiomyocytes osteoblasts SMCs fibroblasts|keratinocytes|these supported isolation , expansion and long-term culture of entity , fibroblasts , smooth muscle cells and mesenchymal stem cells .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes eosinophils neutrophils monocytes fibroblasts|keratinocytes|il-17 binding to il-17ra on entity stimulates and perpetuates the inflammation cascade of psoriasis .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes fibroblasts neutrophils progenitors melanocytes|keratinocytes|believes that the therapeutic utility of 2-cdap in psoriasis would result from its ability to gain direct access to hyperproliferating entity in a form that would be rapidly effective .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes melanocytes fibroblasts epidermal epithelium|keratinocytes|apligraf contains living human skin cells , entity and fibroblasts , organized in an epidermal and dermal layer .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes melanocytes fibroblasts keratinocyte epidermis|keratinocytes|hyperproliferation of entity contributes to psoriasis , and work by sugen and others has demonstrated that egf tk signalling is required for the growth of entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes fibroblasts melanocytes osteoblasts epidermis|keratinocytes|hemidesmosome formation also occurs during normal differentiation of entity as they mature from the basal layer , not only in a wound-healing situation .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|Is Currently get Persons Being|keratinocytes|etiology – entity infected by human papillomavirus ( hpv ) ; manifests as common warts , plantar warts or genital warts virus spreads via direct contact or
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes fibroblasts progenitors precursors melanocytes|keratinocytes|revitix provides a more complete array of growth factors than those produced by dermal fibroblasts or epidermal entity alone , which helps to speed the healing process of skin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|dermis epidermis bloodstream cornea retina|keratinocytes|tanning is mediated by melanocytes producing melanin , which is subsequently transferred to the entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes keratinocyte fibroblasts epidermis melanocytes|keratinocytes|in in vitro skin models , p529 was shown to inhibit keratinocyte proliferation ( growth of entity ) and induce apoptosis ( cause death of hyperproliferating entity ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|microenvironment keratinocytes epithelium microcirculation dermis|keratinocytes|in preclinical studies , xcur17 inhibited il-17ra in the entity of the skin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes fibroblasts Cells melanocytes Langerhans|keratinocytes|entity are the most abundant cells in the epidermis and account for 80 to 90% of the total epidermal cellular population .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes NSCLC CRC fibroblasts ESCC|keratinocytes|kx-01 inhibits the proliferation of entity and up-regulates p53 so its utility in clinically treating ak was of interest .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes melanocytes fibroblasts nerves Langerhans|keratinocytes|the epidermis is comprised mainly of cells known as entity that are continually regenerated and move toward the skin surface where they flatten , lose their nucleus , and become the outermost
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|fibroblasts clones nuclei keratinocytes hepatocytes|keratinocytes|this exposure can lead to oncogenic changes , such as inactivation of p53 , and consequential hyper-proliferation of mutated entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes fibroblasts melanocytes Langerhans Cells|keratinocytes|entity are the predominant cell type in the epidermis , the outermost layer of the skin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes fibroblasts keratinocyte Langerhans fibroblast|keratinocytes|first , il-8 is produced by a type of skin cell called entity , and is a potent growth factor for these skin cells .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|angiogenesis keratinocytes psoriasis neutrophils melanocytes|keratinocytes|as p529 has been shown to inhibit neovascularization , together with its effect on entity , p529 is expected to show activity in psoriasis and atopic dermatitis .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes eosinophils Langerhans fibroblasts melanocytes|keratinocytes|barrier function and inflammation in atopic dermatitis the most abundant cells in the epidermis are entity , shown in figure 16 below .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|cell|squamous keratinocytes psoriasis keratinocyte adenocarcinoma|keratinocytes melanocytes fibroblasts nerves Langerhans|keratinocytes|the epidermis is comprised mainly of cells known as entity which are continually regenerated and move toward the skin surface where they flatten , loose their nucleus and become the outermost
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes microglia oligodendrocytes glia astrocyte|astrocytes|the chronic activation of microglia and entity has been implicated as an important disease mechanism in huntingtons disease , progressive ms , and other neurodegenerative disorders .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|CD133 astrocytes Ki67 EPCs CD34|microglia STAT3 inflammasome astrocytes NLRP3|astrocytes|when innate immune dysfunction causes chronic inflammation , activated microglial cells produce soluble tnf that activates entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|CD133 astrocytes Ki67 EPCs CD34|glia interneurons motoneurons astrocytes axons|astrocytes|in addition , the target cells , motor neurons and entity , or cells supporting the neurons , reside within and surrounding the spinal cord and brain stem , which we believe can be
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes microglia oligodendrocytes neurones dendrites|astrocytes|when ipsc-derived hgpcs were transplanted into these mice , the cells spread widely throughout the brain , developing as entity and oligodendrocytes .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes microglia astrocyte oligodendrocytes glia|astrocytes|cells that repair damage to myelin and neurons and prevent chronic activation of inflammatory cells of the brain , microglia and entity , which is implicated in neurodegenerative diseases .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|CD133 astrocytes Ki67 EPCs CD34|microglia brains astrocytes TBI monocytes|astrocytes|jun ; 71 : 1500-4 ; modulation of interleukin-1beta mediated inflammatory response in human entity by flavonoids : implications in neuroprotection . brain res bull .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes oligodendrocytes microglia neurones myelin|astrocytes|entity and oligodendrocytes , the other two principle types of central nervous system cells , are also generated from the human neural stem
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1), ('DIS', 1)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes microglia TRPV1 PKC nAChR|astrocytes|av-101s ability to activate entity for focal delivery of an anti-epileptic principle , and its dual action as a nmdar glyb antagonist and quinolinic acid synthesis
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes microglia glia cardiomyocytes adipocytes|astrocytes|together , these activities lead to a cascade of enhanced disease responses in neurons , oligodendrocytes , and entity , cell types that are most vulnerable to energetic deficiencies .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes microglia nerves fibroblasts neutrophils|astrocytes|spinal cord are damaged , guanosine , which is present normally in every cell , can be released in high concentrations to stimulate entity to produce these protective factors .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|CD133 astrocytes Ki67 EPCs CD34|synapses spines dendrites mitochondria vesicles|astrocytes|conditions anavex®3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes microglia neurones fibroblasts keratinocytes|astrocytes|pre-clinical data suggest that ccr2 , and mcp-1 , are upregulated in cells , such as macrophages , microglial cells and entity which play a central role in the origination of pain signals .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD133 astrocytes Ki67 EPCs CD34|scientists investigators themselves pharmacists trainees|astrocytes|customers frequently request entity to build a more complete human neurological model .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|CD133 astrocytes Ki67 EPCs CD34|synapses spines dendrites vesicles mitochondria|astrocytes|anavex 3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes glia microglia neurones oligodendrocytes|astrocytes|the effect of iw-6463 was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , entity , microglial cells and oligodendrocytes .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 3)])|cell|CD133 astrocytes Ki67 EPCs CD34|RBCs neutrophils PMNs platelets RBC|astrocytes|clr1501 uptake was visualized with confocal microscopy and compared to matched sergbm , normal human entity , and human nscs .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes glia glioblastoma gliomas oligodendrocytes|astrocytes|glioblastoma are tumors that arise from entity , which are star-shaped cells making up the supportive tissue of the brain .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 3)])|cell|CD133 astrocytes Ki67 EPCs CD34|astrocytes myelin oligodendrocytes microglia dendrites|astrocytes|q-cells produce entity and oligodendrocytes , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|CD133 astrocytes Ki67 EPCs CD34|Unlike Like Other Besides Neural|astrocytes|entity cells found in the brain that support neuronal function these cells are synergistic with icell neurons .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|CD133 astrocytes Ki67 EPCs CD34|glia astrocytes microglia oligodendrocytes terminals|astrocytes|aß peptides are derived from the amyloid precursor protein , or app , an integral membrane protein , in neurons and entity in the brain .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|adipocytes CD14 CD34 EPCs fibroblasts|fibroblasts adipocytes cardiomyocytes hepatocytes osteoblasts|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|adipocytes CD14 CD34 EPCs fibroblasts|adipocytes fibroblasts cardiomyocytes hepatocytes osteoblasts|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|adipocytes CD14 CD34 EPCs fibroblasts|myoblasts fibroblasts osteoblasts MSCs adipocytes|preadipocytes|a paper entitled “chromium picolinate depressed proliferation and differentiation of 3t3-l1 entity” was published in nutrition research .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoblasts osteoclasts fibroblasts MSCs BMSCs|osteoblasts|only a portion of the bone remodeling process : they either block bone breakdown by osteoclasts or stimulate bone formation by entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoblasts osteoclasts fibroblasts chondrocytes adipocytes|osteoblasts|small areas of bone are constantly being broken down by special cells called osteoclasts , then made again by cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|Screening Especially Therapy Treatments Except|osteoblasts|entity for osteoporosis and non-union bone fractures we have made osteoblasts from hescs and are now conducting preclinical tests in animals .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoblasts osteoclasts fibroblasts monocytes neutrophils|osteoblasts|n / a ( generic ) ​ in osteoporosis patients , who have normal basal levels of pth , therapeutic administration of pth activates osteoclasts and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoclasts osteoblasts vesicles precursors plates|osteoblasts|it has a potent anabolic effect on bone tissues , stimulating the formation and maturation of bone-forming entity which in turn causes significant increases in new bone formation .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 1)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoblasts osteoclasts fibroblasts adipocytes MSCs|osteoblasts|k , arris and its partner believe that a new drug may be able to re-balance the activity of osteoclasts and entity and arrest the bone-destroying effects of osteoporosis .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|RANKL TRAP osteocalcin OPG PTH|osteoblasts|intravenously administered antibody that is designed to inhibit sclerostin , a protein that inhibits the activity of bone-forming cells , known as entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoclasts osteoblasts chondrocytes fibroblasts monocytes|osteoblasts|while both types of cells are activated when pth is administered , entity are activated to a greater extent , increasing net bone formation and bone mass .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|MSCs probiotics CSCs scaffolds donors|osteoblasts|current work focuses on confirming their characteristics as entity , improving cell yields , testing function in vitro and then testing the cells in animals .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|MSCs medicines nutrients exosomes substances|osteoblasts|we intend to infuse entity derived from hescs to treat osteoporosis .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoclasts osteoclast osteoblasts osteoblastic osteoblast|osteoblasts|bone loss ( mediated by osteoclasts  cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity  cells which form new bone ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|adolescence puberty adulthood adipocytes infancy|osteoblasts|because osteosarcoma usually develops from entity , it most commonly affects children and young adults experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|nearly another just altogether roughly|osteoblasts|while both types of cells are activated when pth is administered , entity 92 table of contents are activated for a longer period , increasing bone formation and bone mass .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoblasts osteoclasts MSCs fibroblasts osteoblast|osteoblasts|cells called entity cause new bone formation while other cells called osteoclasts remove old bone through a process called resorption .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoblasts osteoclasts fibroblasts stroma MSCs|osteoblasts|the condition is the stimulation of a population of normal bone cells ( osteoclasts ) relative to another population of bone cells ( entity ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|adolescence puberty adulthood infancy menarche|osteoblasts|because osteosarcoma usually develops from entity , it most commonly develops in teenagers who are experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 3), ('DIS', 1)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoclasts osteoblasts osteoclast osteoblast RANKL|osteoblasts|forteo ( marketed as forsteo in europe ) builds bone primarily by increasing the activity of entity ( cells that deposit bone ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 2)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoblasts osteoclasts OPG adipocytes fibroblasts|osteoblasts|osteoclasts mediate destruction of bone and entity are responsible for bone growth and mineral production .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoblasts osteoclasts fibroblasts BMSCs osteoblast|osteoblasts|bone loss ( mediated by osteoclasts -- cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity -- cells which form new bone ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|OrderedDict([('BIO', 4), ('OTHER', 4)])|cell|osteoblastic osteoblasts EPCs AND neovascularization|osteoblasts osteoclasts fibroblasts MSCs monocytes|osteoblasts|normal functioning of bone depends on osteoclasts and entity acting in concert .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|blasts fibroblasts progenitors Formation precursors|ones follicles immature embryos morphologically|erythroblasts|b , which are more immature entity .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|blasts fibroblasts progenitors Formation precursors|monocytes fibroblasts eosinophils neutrophils granulocytes|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|blasts fibroblasts progenitors Formation precursors|oligodendrocytes platelets spermatozoa granulocytes monocytes|erythroblasts|c , which is the population of mature entity , in comparison to ery .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|blasts fibroblasts progenitors Formation precursors|platelets monocytes erythrocytes granulocytes neutrophils|erythroblasts|reactivation of hbf occurs in immature rbcs , known as entity and reticulocytes .
OrderedDict([('OTHER', 4), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|blasts fibroblasts progenitors Formation precursors|monocytes fibroblasts platelets neutrophils eosinophils|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes , and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|detrimental deleterious booster harmful curative|transitional|the initial application of ifrs 9 at january 1 , 2018 has resulted in no significant entity effects for immunic .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|washout dosing collection waiting dosage|transitional|after the expiry of any applicable entity period , only ivds that have been ce marked under the ivd regulation may be placed on the market in the
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|retail pharmaceutical private purchase consumer|transitional|as per the benefit arrangement contemplated by the entity services agreement , the existing stock shall be delivered to purchaser exw - incoterms 2010 , delivery in monheim or other sellers
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|neurobe neuropsychological neuropsych repeat neurocognitive|transitional|the provisions of sfas 142 require that a entity impairment test be performed as of the beginning of the year the statement is adopted .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|transitional squamous Small Basal Renal|transitional|entity cell carcinoma of the bladder frequently occurs in adolescents with costello syndrome , a presentation that is rare in the general
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|Total Drug Direct Healthcare Net|transitional|“entity costs” shall mean all costs incurred by seller that are identified in exhibit “j” .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|Following Screening Modified Standard Note|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|financial pharmacy monthly user personal|transitional|will also pay bms for any required product supply at a price approximating the product cost as well as negotiated entity service fees .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|name opposite next assigned labeling|transitional|( ii ) and section 2 . 2 , in no event shall aetna use or permit any affiliate to use any mark or the entity mark
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|name strict UM latter scr|transitional|we elected to use the entity practical expedient allowing the standard to be applied only to contracts that were previously identified as leases under ias 17
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|ethical methodological funding marketing legal|transitional|retrospectively from january 1 , 2019 , but has not restated comparatives for the 2018 reporting period , as permitted under the specific entity provisions in the standard .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|retail client business consumer private|transitional|and the buyer are expected to enter into related transaction agreements at the closing of the proposed transaction , including a entity services agreement .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|stopping decision grant disclosure exclusion|transitional|respect to any grant ( including the grant made on the effective date ) a-3 to secure the benefit of any applicable entity rule promulgated under section 409a of the code .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|Medicare private insurance Medicaid federal|transitional|internal costs and out-of-pocket expenses shall not exceed the corresponding agreed to budget for such services set forth in the entity service plan .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|financial grant tax funding federal|transitional|the entity requirements of sfas 148 are effective for all financial statements for fiscal years ending after december 15 , 2002 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|procedural business legal ethical operational|transitional|we elected the optional entity guidance under asc 842 that allowed the initial recognition of the operating right-of-use assets and the corresponding lease liabilities as
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|financial greatest largest budget tax|transitional|the entity impact was finalized during the fiscal year ended june 30 , 2019 , with no significant impact on income tax expense .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|scientific ethical biomedical legal forensic|transitional|acquisition by cytyc corporation , a diagnostic and medical device company , he served as a consultant to cytyc to assist with entity matters from 2001 to 2002 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|Following Screening Modified Standard Note|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|adenocarcinoma fertilization AND neuroblastoma VI|web Delphi code Web specification|transitional|we adopted these changes using the prospective application entity alternative in accordance with the entity provisions of cica handbook section 3870 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|fertilization oocytes oocyte follicle FISH|platelets RBCs embryos RBC erythrocytes|oocytes|we anticipate that in the unites states cryopreservation of entity will be regulated similarly to viacords family umbilical cord blood cryopreservation product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|follicles oocytes eggs embryos spermatozoa|oocytes|if successful , the ovature treatment could reduce , or possibly eliminate , the need for hormonal hyperstimulation for the maturation of multiple entity prior to egg retrieval in the ivf process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|oocytes semen embryos spermatozoa eggs|oocytes|with a number of in vitro fertility clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|fertilization oocytes oocyte follicle FISH|spermatozoa platelets oocytes embryos semen|oocytes|media supplier will be required to obtain 510 ( k ) clearance for the technology we have licensed for use in the cryopreservation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|leaves seeds bark fruit leaf|oocytes|“raw material” means conforming rana pipiens entity to be supplied to spl by alfacell .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|fertilization oocytes oocyte follicle FISH|embryos oocytes eggs fetuses fibroblasts|oocytes|cancer research technology limited rnai uses in mammalian entity , preimplantation embryos and somatic cells ( ep only : wherein the rnai compound is at least 25 base pairs ) 11 / 19 / 1999
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fertilization oocytes oocyte follicle FISH|embryos fibroblasts oocytes chondrocytes myoblasts|oocytes|which includes the production of human differentiated cells from stem cells and involves the use of nuclear transfer technology , human entity , and embryonic material .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|oocytes semen embryos spermatozoa eggs|oocytes|a number of in vitro fertility ( “ivf” ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|oocytes eggs embryos spermatozoa oocyte|oocytes|the first patent covers the use of fertilized human entity for the creation of human embryonic stem cell lines , and was issued in great britain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|oocytes eggs spermatozoa embryos follicles|oocytes|another opportunity in the use of cells for therapy relates to entity , which are female egg cells essential to reproduction .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|fertilization oocytes oocyte follicle FISH|saliva feces placenta hair platelets|oocytes|of health information we obtain from research collaborators or from providers who enroll patients and collect cord blood or human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|oocytes semen embryos spermatozoa eggs|oocytes|a number of in vitro fertility ( ivf ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|oocytes eggs embryos follicles ovaries|oocytes|iscos core technology , parthenogenesis , results in the creation of pluripotent human stem cells from unfertilized entity ( eggs ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fertilization oocytes oocyte follicle FISH|fibroblasts hepatocytes chondrocytes embryos monocytes|oocytes|is focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|oocytes eggs embryos spermatozoa oocyte|oocytes|viacyte , a product expected to offer women the ability to preserve or extend their fertility through the cryopreservation of their entity ( eggs ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fertilization oocytes oocyte follicle FISH|fibroblasts hepatocytes embryos chondrocytes monocytes|oocytes|are focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|embryos oocytes spermatozoa chromosomes reproduction|oocytes|the second and third patents , both covering parthenogenetic activation of human entity , were 47 table of contents issued in japan and korea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|oocytes embryos follicles spermatozoa oocyte|oocytes|for ovature , ovascience was exploring different subculture systems that allow for even further maturation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|embryos oocytes eggs blastocysts ovaries|oocytes|although our focus is on stem cells derived from unfertilized entity , certain aspects of that work may involve the use of nuclear transfer technology or material deemed to be embryonic material .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization oocytes oocyte follicle FISH|oocytes embryos eggs ovaries follicles|oocytes|although our focus is on parthenogenetic stem cells derived from unfertilized entity , certain aspects of that work may involve the use of embryonic stem cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|fibroblasts keratinocytes platelets MSCs graft|chondrocytes|autologous cultured entity ( " carticel ( tm ) aucc " ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|Therapy Collagen Especially ideal favorable|chondrocytes|chnd1 : entity for cartilage disorders and degenerative disc disease articular cartilage is the shock absorber for joints .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|keratinocytes fibroblasts seeded chondrocytes grown|chondrocytes|maci® ( autologous cultured entity on porcine collagen membrane ) is an autologous cellularized scaffold product indicated for the repair of symptomatic , single or multiple full-thickness
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|chondrocytes MSCs fibroblasts ASC osteoclasts|chondrocytes|use of hystem® hydrogels with purestem™ progenitors resulting in a combined product that produces cartilage- producing cell masses known as entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|claims payments advertising insurance cigarettes|chondrocytes|some third party payers , however , do not cover carticel entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|labels makers outs boards owners|chondrocytes|the commercial success of carticel-registered trademark- entity will depend on many factors , including the following : - positive results from post-marketing studies .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|grafts allografts graft transplants patches|chondrocytes|compared to the same period a year ago due primarily to decreased shipments of both epicel skin grafts and carticel entity during the three months ended march 31 , 2002 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|pages outs labels sharing offs|chondrocytes|some third-party payers , however , do not cover carticel-registered trademark- entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|chondrocytes scaffolds MSCs hydrogels proteoglycans|chondrocytes|preclinical studies have shown that entity embedded in bst-gel ( tm ) produce a matrix having the characteristics of normal cartilage tissue .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|boards marks board tags objects|chondrocytes|genzyme biosurgery has developed a device to improve the procedure for implanting carticel-registered trademark- entity and has filed for marketing approval with the fda .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|chondrocytes fibroblasts tendon chondrocyte MSCs|chondrocytes|as reported in this article , 19 of 23 patients had restored or improved joint function after treatment with cultured autologous entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|market license approval fund legislation|chondrocytes|since the fda approved carticel entity , genzyme has seen a substantial increase in the number of third party payers who cover it .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|chondrocytes MSCs BMSCs tendons fibroblasts|chondrocytes|gtr is aware of at least one other company that is culturing autologous entity for cartilage repair in europe .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|graft implants osteotomy plating plates|chondrocytes|there are two type of entity , “articular” and “growth plate” .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 3)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|chondrocytes ligaments proteoglycans bones joints|chondrocytes|articular entity are responsible for cartilage that lines our joints , whereas growth plate entity are involved with new bone formation .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|outs pages boards ups marks|chondrocytes|the increase in sales of carticel-registered trademark- entity was a result of continued increases in the numbers of patients treated and surgeons trained as well as an increase
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|platelets keratinocytes islets fibroblasts chondrocytes|chondrocytes|the process used by gtr to grow autologous entity is not patentable , and gtr does not yet have significant patent protection covering the other methodologies used in providing carticel ( tm )
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|list market press board style|chondrocytes|since the fda approved carticel-registered trademark- entity , genzyme has seen a substantial increase in the number of third-party payers who cover it .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|chondrocytes biomaterials scaffolds proteoglycans fibroblasts|chondrocytes|solid tissue cell therapies one of the newest areas of cell therapy involves the production of entity for the restoration of cartilage .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|EPCs CD34 immunohistochemistry neovascularization angiogenesis|substance collagenase graft allograft fibroblasts|chondrocytes|chondrocyte therapy involves the surgical removal of a small amount of tissue from the patient  s knee and a therapeutic quantity of entity is produced from this surgical biopsy .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|fibroblasts fibroblast proliferative Cells proliferating|fibroblasts cardiomyocytes HSCs SMCs adipocytes|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic tissues .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|fibroblasts fibroblast proliferative Cells proliferating|stroma vessels fibroblasts stromal endothelium|myofibroblasts|in a sampling of approximately 200 tumors , epha2 was found to be expressed in tumor cells , entity and / or tumor-associated blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|fibroblasts fibroblast proliferative Cells proliferating|fibroblasts keratinocytes monocytes myotubes osteoblasts|myofibroblasts|fezagepras has been observed to regulate several cell types involved in the fibrotic pathway : macrophages , fibroblasts / entity and epithelial cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblasts fibroblast proliferative Cells proliferating|capillaries neutrophils mitochondria leukocytes fibroblasts|myofibroblasts|the number of entity and hydroxyproline ( i . e . , collagen ) content was also significantly reduced in both organs .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|fibroblasts fibroblast proliferative Cells proliferating|fibroblasts HSCs hepatocytes MSCs cardiomyocytes|myofibroblasts|moreover , ehp-101 has been shown to inhibit the tgfβ-associated differentiation of cells ( called entity ) that are responsible for fibrosis .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|fibroblasts fibroblast proliferative Cells proliferating|neutrophils fibroblasts eosinophils platelets hepatocytes|myofibroblasts|vla-1 is found on a variety of cells associated with tissue inflammation and fibrosis , including activated t-cells , macrophages and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|fibroblasts fibroblast proliferative Cells proliferating|fibroblasts keratinocytes neutrophils monocytes chondrocytes|myofibroblasts|ctgf increases the abundance of entity , a cell type that drives wound healing , and stimulates them to deposit ecm proteins such as collagen at the site of tissue injury .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|fibroblasts fibroblast proliferative Cells proliferating|fibroblasts eosinophils leukocytes neutrophils keratinocytes|myofibroblasts|in the skin , it has been shown to reduce scar formation by reduction of infiltration of entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|fibroblasts fibroblast proliferative Cells proliferating|HGF VEGF osteoblasts EPCs fibroblasts|myofibroblasts| anti-fibrosiscysteamine blocks tgf-ß signaling and thereby inhibits the production and proliferation of entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|cell|fibroblasts fibroblast proliferative Cells proliferating|Akt microglia AMPK calpain caspases|myofibroblasts|constant myofiber breakdown results in persistent activation of entity and altered production of ecm resulting in extensive fibrosis in skeletal muscles of dmd patients .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|fibroblasts fibroblast proliferative Cells proliferating|HSCs neutrophils STAT3 microglia fibroblasts|myofibroblasts|in fibrotic conditions , excess ctgf results in chronic activation of entity , which leads to chronic ecm deposition and fibrosis ( see figure above ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|fibroblasts fibroblast proliferative Cells proliferating|fibroblasts proliferating mesenchymal quiescent perivascular|myofibroblasts|anti-tshr antibodies also increase the proliferation of adipose or fat cells as well as entity , smooth muscle-like cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|fibroblasts fibroblast proliferative Cells proliferating|cardiomyocytes fibroblasts HSCs SMCs adipocytes|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic connecting tissues .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|fibroblasts fibroblast proliferative Cells proliferating|cardiomyocytes myocardium fibroblasts myocytes leukocytes|myofibroblasts|research programs involving cell-based approaches to restoring cardiac function and a research program involving a gene therapy approach to converting entity into cardiac muscle .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|fibroblasts fibroblast proliferative Cells proliferating|fibroblasts cardiomyocytes HSCs chondrocytes MSCs|myofibroblasts|in the case of normal healing of a limited tissue injury , entity eventually die by programmed cell death , or apoptosis , and the fibrous scarring process recedes .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblasts fibroblast proliferative Cells proliferating|elastin fibroblasts proteoglycans fibronectin ECM|myofibroblasts|fibrosis is the formation of excess connective tissue ( collagen and other proteins plus cellular elements such as entity ) in response to damage , inflammation or repair .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|fibroblasts fibroblast proliferative Cells proliferating|HSCs hepatocytes neutrophils fibroblasts MSCs|myofibroblasts|additionally supported by the anti-inflammatory effects , including downregulation of tnf and il-6 , that can reduce the proliferation and activation of entity in the liver .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|FFA adipocytes PCs FC FA|adipocytes|the ultrashape system targets and selectively destroys fat cells ( entity ) , leaving critical surrounding structures such as blood vessels , nerves and connective tissue unharmed .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|vessels capillaries endothelium myocardium nerves|adipocytes|in addition , the fraction also contains blood cells from the capillaries supplying the entity and the extracellular matrix .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|fibroblasts adipocytes hepatocytes keratinocytes stromal|adipocytes|in non-cancerous tissues , it is predominantly found at low levels on entity , or fat cells , and briefly on precursors to b-cells , or pre-b-cells , during normal b-cell maturation .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|nerves leukocytes adipocytes neurones fibroblasts|adipocytes|vitro studies have shown that activation of the beta-3 adrenergic receptor in the colon causes the release of somatostatin from entity , or fat cells , which causes pain relief .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|adipocytes steatosis adip lipolysis adipocyte|keratinocytes melanocytes osteoblasts thymocytes hepatocytes|adipocytes|antibodies form against the thyroid-stimulating hormone receptor , or tshr , which is present in the thyroid and other cells such as entity and fibroblasts .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|lysosomes hepatocytes mitochondria liposomes myelin|adipocytes|this attenuation by protein-rich tissue results in the preferential destruction of entity by atx-101 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|adipocytes hepatocytes fibroblasts islets visceral|adipocytes|mechanism of action atx-101 is designed to be a locally-injected drug that causes proximal , preferential destruction of entity , or fat cells , with minimal effect on surrounding tissue .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|adipocytes steatosis adip lipolysis adipocyte|NSCLC gliomas MSCs CRC CSCs|adipocytes|believe that rnai could potentially be a reliable method to selectively inhibit certain genes and their corresponding protein expression in entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|adipocytes steatosis adip lipolysis adipocyte|adipocytes fibroblasts hepatocytes adipocyte myotubes|adipocytes|the research is focused on using cultured entity ( fat cells ) as a model system for studying the regulation of gene expression involved in adipocyte differentiation and function .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|mammals tumours fibroblasts xenografts hepatocytes|adipocytes|rnai delivery for therapeutic gene silencing in cells and animals ; and  inhibition of gene expression in entity using rnai .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|adipocytes steatosis adip lipolysis adipocyte|adipocytes progenitors astrocytes fibroblasts glia|adipocytes|initial product development plans include : pluripotent stem cell-derived brown entity ( agex-bat1 ) ; vascular progenitors ( agex-vasc1 ) ; and induced tissue regeneration ( itr ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1), ('DRUG', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|adipocytes lipolysis lipids hepatocytes islets|adipocytes|the destruction of entity , or adipocytolysis , elicits a natural response in which macrophages are attracted to remove cellular debris and fat particles through the
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|adipocytes VAT steatosis waist BAT|adipocytes|in addition , msi-1436 was shown to reduce the size of entity , reduce body fat with no reduction of lean mass , and improve glucose tolerance via inhibition of a unique combination of
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|fibroblasts adipocytes leukocytes FFA ECs|adipocytes|cells obtained from the blood vessels in the lipoaspirate from the small volume of fat harvested , minus the fat cells ( entity ) and non-cellular material .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|osteoblasts osteoclasts adipocytes osteoblast fibroblasts|adipocytes|by the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least entity , osteocytes , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|adipocytes steatosis adip lipolysis adipocyte|keratinocytes melanocytes astrocytes fibroblasts epithelium|adipocytes|these antibodies activate certain cell types , such as fibroblasts and entity , present in the extraocular space , which are known to highly express tshr .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|adipocytes steatosis adip lipolysis adipocyte|adipocytes fibroblasts myoblasts MSCs osteoblasts|adipocytes|namodenoson was also shown to inhibit the proliferation of entity , further hampering the expansion of fat producing cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 2)])|cell|adipocytes steatosis adip lipolysis adipocyte|adipocytes cardiomyocytes myotubes hepatocytes islets|adipocytes|metabolic benefits of the lancl2 signaling axis are observed in hepatocytes , entity and myocytes through uptake and oxidation of glucose to improve the systemic glucose homeostasis .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|adipocytes steatosis adip lipolysis adipocyte|clinic Japan Europe clinics India|adipocytes|pending delivery of sirna into entity for treatment of diabetes and obesity michael p . czech qiong l . zhou zhen y . jiang 12 / 11 / 2002 exclusive
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|adipocytes steatosis adip lipolysis adipocyte|fibroblasts adipocytes another stroma epithelium|adipocytes|liposarcomas arise by malignant transformation of entity , not necessarily entity from within a lipoma .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|CD34 proliferative hemangi blasts neovascularization|EPCs MSCs HSCs Cells BMSCs|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell-forming , and angiogenic , meaning blood vessel endothelium-forming ,
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|CD34 proliferative hemangi blasts neovascularization|EPCs MSCs HSCs BMSCs Cells|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic ( blood cell forming ) and angiogenic ( blood vessel endothelium forming )
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD34 proliferative hemangi blasts neovascularization|progenitors endothelium lineages leukocytes erythrocytes|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 5 / 19 / 2015 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|CD34 proliferative hemangi blasts neovascularization|EPCs MSCs Cells HSCs BMSCs|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell forming , and angiogenic , meaning blood vessel
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD34 proliferative hemangi blasts neovascularization|progenitors endothelium lineages leukocytes erythrocytes|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 10 / 7 / 2014 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|CD34 proliferative hemangi blasts neovascularization|corneal RPE retina epidermal ocular|hemangioblasts|development of its rpe cells for conditions involving retinal degeneration · act is evaluating research and development programs for esc-derived entity and dermal regeneration .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|CD34 proliferative hemangi blasts neovascularization|embryos hepatocytes MSCs oocytes placenta|hemangioblasts|this patent broadly covers the derivation and growth of human entity from a non-fetal source .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 2)])|cell|blasts MDS CML blast CD3|erythrocytes neutrophils platelets granulocytes blasts|myeloblasts|acute myeloid leukemia aml is a type of cancer in which the bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells or platelets .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|cell|blasts MDS CML blast CD3|platelets blasts neutrophils thrombocytopenia granulocytes|myeloblasts|comprises normalizing peripheral blood counts , resolution of bone marrow dysplasia and reduction in the percentage of immature blood cells , or entity , to less than 5% .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|blasts MDS CML blast CD3|progenitors erythrocytes fibroblasts platelets precursors|myeloblasts|leukemia aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|blasts MDS CML blast CD3|CSCs progenitors EPCs MSCs stroma|myeloblasts|which both failure to differentiate and excessive proliferation in the stem cell compartment result in accumulation of non-functional cells termed entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|blasts MDS CML blast CD3|platelets neutrophils granulocytes monocytes progenitors|myeloblasts|the myeloid cells are predominantly immature platelet cells called entity , or blasts , which are the leukemia cells .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|blasts MDS CML blast CD3|CSCs EPCs CTCs platelets CSC|myeloblasts|this suggests that differentiation of entity  made possible by inhibition of mutated idh2  may drive the clinical efficacy of enasidenib .  targeting idh mutations is
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|blasts MDS CML blast CD3|monocytes platelets granulocytes neutrophils fibroblasts|myeloblasts|the gm-csf receptor is expressed on entity and other progenitor cells , and binding results in differentiation and maturation into monocytes .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|blasts MDS CML blast CD3|progenitors platelets erythrocytes fibroblasts precursors|myeloblasts|aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|blasts MDS CML blast CD3|platelets neutrophils blasts monocytes progenitors|myeloblasts|immature white blood cells known as entity , or blasts proliferate in the bone marrow rather than mature into normal blood cells .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|blasts MDS CML blast CD3|erythrocytes neutrophils platelets RBCs granulocytes|myeloblasts|acute myeloid leukemia market • bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells , or platelets • if left untreated , aml progresses rapidly to death
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|cell|blasts MDS CML blast CD3|blasts platelets neutrophils erythropoietin exosomes|myeloblasts|acute leukemia or blood cancer that results from the improper maturation of myeloid stem cells leading to the production of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|blasts MDS CML blast CD3|blasts progenitors erythrocytes precursors clones|myeloblasts|blast ( % ) refers to the percentage of leukemic entity , or blood cells affected by disease , compared to all blood cells in the sample .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4)])|cell|blasts MDS CML blast CD3|neutrophils blasts blast neutrophil eosinophils|myeloblasts|from this trial show that patients with relapsed , refractory acute myeloid leukemia , or aml , experienced a decrease in peripheral blood entity , a measure of clinical activity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|blasts MDS CML blast CD3|erythrocytes vessels platelets hematopoiesis neutrophils|myeloblasts|aml is a type of cancer in which the bone marrow makes abnormal entity , a type of white blood cell , red blood cells or platelets .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|neutrophils platelets blasts granulocytes Platelet|adenocarcinoma lysosomes fibroblasts mitochondria dysplasia|proerythroblasts|on stained slides the cells had the features of entity .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|neutrophils platelets blasts granulocytes Platelet|CFU erythrocytes neutrophils progenitors HSCs|proerythroblasts|increase in overall numbers of entity in mice the rapid expansion of the pro-e population also coincided with decreased numbers of erythroid burst-forming units and erythroid
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|interneurons NOS connectivity seizure GABAergic|interneurons neurones axons synapses afferents|interneurons|specifically , inhibitory gabaergic entity are susceptible to excessive excitatory amino acid release .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|interneurons NOS connectivity seizure GABAergic|interneurons neurones motoneurons ganglion nerves|interneurons|this loss of nav1 . 1 channels in inhibitory entity and other nerve cells results in dravet syndrome .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|myotubes myoblasts fibroblasts cardiomyocytes keratinocytes|myotubes|in non-clinical studies with human entity grown from 35 different nmdmd patients , ataluren also exhibited a bell-shaped dose-response curve with maximal dystrophin staining observed at 10
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|transcripts fibroblasts homozygotes alleles cDNA|myotubes|force increased exon skipping in human dmd entity with exon 51 mutation *** p < 0 . 001 in studies in the mdx mouse dmd model , a validated and
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|fibroblasts PBMCs cDNA transcriptome EVs|myotubes|we used rna-sequence ( rna-seq ) analysis of the entity from dm1 patients to create a splice score for control human subjects cells treated with sidmpk . 19 or the inactive sirna , sidmpk . 29 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|teeth diamond specimen roots discs|myotubes|mock treated dm1 entity ( open black diamonds ) show the full splice derangement .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|charts files subgroups demographics cohorts|myotubes|when patient entity were analyzed , there was a marked improvement in the splice score of the entity treated with the sidmpk . 19 compared to the inactive sidmpk . 29 ( see figure 11 below ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|embryos fibroblasts oocytes mutants hearts|myotubes|as shown in the figure on the right below , we also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|myotubes myoblasts fibroblasts cardiomyocytes mitochondria|myotubes|effect of ataluren on dystrophin staining scores in entity isolated from nmdmd mice myotubes from nmdmd patients .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|donors myotubes myoblasts volunteers beings|myotubes|able to sustain utrophin protein expression based on in vitro data generated in myoblast cells from dmd patients and human entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|myoblasts myotubes fibroblasts vessels adipocytes|myotubes|the proprietary compounds bio101 and bio103 on muscle cells in particular regarding protein syntheses and growth in the diameter of entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 2)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|osteoclasts adipocytes mitochondria neutrophils EPCs|myotubes|as depicted below , results from an in vitro study demonstrate that human entity are larger in muscle cells treated with sarconeos ( bio101 ) as compared to untreated control cells .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|mRNAs alleles transcripts miRNA PBMC|myotubes|the splice signature approached that of control entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|fibroblasts PBMCs keratinocytes MSCs leukocytes|myotubes|the studies used gymnotic uptake , or no transfection reagents , in patient-derived entity ( in vitro ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|fibroblasts embryos oocytes erythrocytes keratinocytes|myotubes|as shown in the figure on the right below , also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|myotubes osteoblasts chondrocytes fibroblasts cardiomyocytes|myotubes|fgfs can also induce or inhibit differentiation in a variety of cell types ( e . g . of myoblasts into entity ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|Arabidopsis NSCLC zebrafish PCa CRC|myotubes|in the study , we demonstrated that mbd3l2 was representative of broader dux4-driven gene expression changes in entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|PBMCs fibroblasts cohorts brains monocytes|myotubes|administration of our proprietary aso conjugated to a fab targeting tfr1 reduced expression of key dux4 biomarkers in fshd patient entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|fibroblasts myotubes keratinocytes myoblasts monocytes|myotubes|and 50% , respectively , based on our in vitro studies that were undertaken in myoblast cells from patients with dmd and entity from healthy individuals .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|mammals keratinocytes hepatocytes NSCLC cardiomyocytes|myotubes|we used active caspase-3 to quantify cell death because it is a protein that has been shown to be an important regulator of the apoptosis pathway in entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|cornea retina MSCs volunteers embryos|myotubes|human entity when dosed with smt c1100 for 7 days demonstrated and increase of utrophin protein of around 50% when compared to
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|cell|CD34 proliferative cardiomyopathy neuroblastoma neovascularization|cardiomyocytes myocardium myocytes vessels infarct|myotubes|the four hearts and in one heart diacrin noticed an increase in small vessel formation at the site of surviving entity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|creatine MSCs bupivacaine mtDNA lidocaine|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|MSCs myoblasts HSCs Cells EPCs|myoblasts|entity are precursors to muscle cells that have the capacity to fuse with other myoblasts or with damaged muscle fibers to regenerate skeletal muscle .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|myoblasts progenitors fibroblasts myotubes myosin|myoblasts|genvec , genzyme , and bioheart are all developing products consisting of skeletal entity isolated from muscle , expanded in culture , and injected into a patients heart to repair dead tissue .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|platelets leukocytes chondrocytes fibroblasts myoblasts|myoblasts|bv , was previously awarded a manufacturing permit from the netherlands ministry of health for the in vitro culture of autologous entity for use as human medications .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|saliva swabs fibroblasts photographs hair|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|hearts cardiomyocytes fibroblasts myoblasts MSCs|myoblasts|in the capacity that we have at diacrin without stressing the facilities and continuing to also be able to produce entity for cardiac repair .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|creatine MSCs bupivacaine mtDNA lidocaine|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|MSCs myoblasts fibroblasts mitochondria leukocytes|myoblasts|at the cell culturing site , our proprietary techniques are used to isolate and remove entity from the muscle tissue .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|adenovirus MSCs transfection shRNA cardiomyocytes|myoblasts|histopathology confirmed that entity expressing sdf-1a resulted in increased muscle and blood vessel formation in the damaged areas of the hearts , which was not
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|MSCs BMSCs myoblasts MSC cardiomyocytes|myoblasts|when injected into scar tissue within the heart wall , entity have been shown to be capable of engrafting in the damaged tissue and differentiating into mature skeletal muscle cells .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|scaffolds stents implants electrodes patches|myoblasts|after expansion , the entity are packaged and delivered to the clinical site for implantation into the injured heart tissue by a surgeon or interventional
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|myoblasts allografts progenitors grafts allograft|myoblasts|intellectual property in connection with products , processes or services developed or provided by genvec other than autologous and allogenic skeletal entity for cardiac therapy .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|myoblasts mitochondria dystrophin cardiomyocytes myotubes|myoblasts|similarly , the fusion of entity with other entity is essential for the formation , growth , and regeneration of skeletal muscle .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|myoblasts fibroblasts keratinocytes fibrin cardiomyocytes|myoblasts|for example , some of our competitors are exploring whether the use of cells , other than entity , is safer or more effective than myocell .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 2)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|epinephrine patches sirolimus nitroglycerin ADM|myoblasts|implantation during coronary artery bypass graft ( cabg ) surgery may lead to similar effects , as do recent studies using percutaneous delivery of entity as a stand-alone procedure .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|myoblasts myotubes cardiomyocytes MSCs fibroblasts|myoblasts|ctgf treatment of entity induced their de-differentiation , or failure to become mature muscle cells .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|saliva swabs fibroblasts photographs hair|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|myotubes fibroblasts myoblasts cardiomyocytes astrocytes|myoblasts| wve-n531 induced a dose-dependent increase in dystrophin production ( up to 71% ) in vitro in dmd patient-derived entity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|myoblasts progenitors biomaterials allografts myocytes|myoblasts|cellular based therapies such as skeletal entity and embryonic stem cells are being pursued by companies such as bioheart , mg biotherapeutics , a joint venture created by medtronic
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|neuroblastoma CD34 CD20 anaplastic Ki67|fibroblasts MSCs myoblasts scar myocytes|myoblasts|clinical therapy designed to improve cardiac function by populating regions of scar tissue within a 8 patients heart with entity derived from a biopsy of a patients thigh muscle .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid myelogenous lymphoblastic lymphocytic monocytic|lymphoblastic|we are developing marqibo for the treatment of acute entity leukemia and other blood cancers including lymphoma .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid myelogenous lymphocytic lymphoid lymphatic|lymphoblastic|exclusive license agreement pursuant to which we licensed the patent rights to a specific gene mutation with respect to chronic entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic lymphoid|lymphoblastic|achieve the primary endpoint of efficacy in the phase 2 clinical trial of blinatumomab in patients with acute entity leukemia 10 % 12 . 5 % 6 .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic monocytic|lymphoblastic|in the second quarter , we initiated a pharmacokinetic study in phase 2 for erwinaze for the treatment of acute entity leukemia in the young adult population .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic monocytic|lymphoblastic|all patients receiving autologous sb-modified t cells had non-hodgkin lymphoma , and most patients receiving allogeneic car+ t cells had acute entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic monocytic|lymphoblastic|of the most important potential uses of annamycin is in the treatment of children with either aml or all ( acute entity leukemia , which is more common in children ) .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|lymphoblastic myeloid lymphocytic myelogenous lymphoid|lymphoblastic|nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute entity leukemia after at least two prior regimens .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic monocytic|lymphoblastic|candidate blinatumomab ( mt103 ) is currently the subject of a european pivotal trial in patients with minimal residual disease positive acute entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid myelogenous lymphoblastic lymphocytic monocytic|lymphoblastic|erwinaze , a biologic product , is used in conjunction with chemotherapy to treat patients with acute entity leukemia , or all , with hypersensitivity to e . coli-derived asparaginase .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic monocytic|lymphoblastic|pbcar0191 , is an allogeneic car t cell therapy targeting the well-validated tumor target cd19 and is being developed for acute entity leukemia , or all , and non-hodgkin lymphoma , or nhl .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic monocytic|lymphoblastic|oncaspar is a first-line biologic used as part of a chemotherapy regimen to treat patients with acute entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous monocytic lymphocytic|lymphoblastic|for iclusig is bcr-abl , an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia ( cml ) and philadelphia-chromosome positive acute entity leukemia ( ph+ all ) .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|lymphoblastic myeloid monocytic myelogenous lymphocytic|lymphoblastic|sar3419 targets cd19 and is a potential new treatment for cd19-expressing b-cell malignancies including nhl and b-cell acute entity leukemia , or b-all .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic monocytic|lymphoblastic|the fda approved kymriah ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute entity leukemia ( all ) .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic lymphocytic myelogenous monocytic|lymphoblastic|it is in a phase 2 clinical trial for the treatment of patients with acute entity leukemia and a phase 1 clinical trial for the treatment of patients with non-hodgkin  s lymphoma .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|lymphoblastic myeloid myelogenous lymphocytic monocytic|lymphoblastic|patients , in august 2011 , we initiated a phase 1 clinical trial of quizartinib in pediatric patients with either relapsed acute entity leukemia , or all , or relapsed aml .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1), ('DRUG', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid myelogenous lymphocytic lymphoblastic CML|lymphoblastic|may 2005 , we commenced an open-label , multicenter phase i and ii study of talotrexin in the treatment of refractory adult entity leukemia or “all .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic monocytic|lymphoblastic|the company also acquired the u . s . and canadian marketing rights to oncaspar ( tm ) for use in the treatment of acute entity leukemia .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|lymphoblastic myeloid myelogenous lymphocytic monocytic|lymphoblastic|u . s . for advanced non-hodgkins lymphoma , and vincristine sulfate liposome injection ( marqibo® ) approved in the u . s . for advanced adult ph- acute entity leukemia ( all ) .
OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cell|lymphoblastic ALL neuroblastoma blast myeloid|myeloid lymphoblastic myelogenous lymphocytic monocytic|lymphoblastic|two other sar3419 phase ii trials are ongoing in relapsed / refractory dlbcl and in acute entity leukemia .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|neutrophils eosinophils counting basophil maturation|epithelium islets fibroblasts metaplasia epithelia|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum low-density lipoprotein ,
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|neutrophils eosinophils counting basophil maturation|intestine epithelium gut duodenum jejunum|enterocytes|by inhibiting nhe3 on the apical surface of the entity , tenapanor reduces absorption of sodium from the small intestine and colon , resulting in an increase in water secretion into the
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|neutrophils eosinophils counting basophil maturation|bloodstream circulation intestine cytosol gut|enterocytes|we believe that kp201 is then completely hydrolyzed down to hydrocodone and the ligand in the entity , which then release the hydrocodone directly into the blood stream .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|neutrophils eosinophils counting basophil maturation|epithelium transporters tubules mucin epithelia|enterocytes|it can thus inhibit iron absorption from the gi tract by interacting with duodenal entity and limit the release of iron in the bone marrow by interacting with macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neutrophils eosinophils counting basophil maturation|epithelium epithelia fibroblasts metaplasia explants|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum ldl cholesterol
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neutrophils eosinophils counting basophil maturation|epithelium epithelia crypt glands lumen|enterocytes|believe that due to kp201s low binding affinity to the µ-opioid receptors it is absorbed largely intact into the intestinal entity , which are the cells lining the small intestine .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neutrophils eosinophils counting basophil maturation|epithelium tubules epithelia glands juice|enterocytes|the cellular trans-membrane protein ferroportin , which functions as an export channel for intracellular iron in macrophages , liver hepatocytes , and duodenal entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|neutrophils eosinophils counting basophil maturation|adipocytes BAT lungs VAT pancreas|enterocytes|this was observed in a preclinical study in mice in which kd026 caused fat accumulation in entity and prevented fat accumulation in the liver tissues .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|neutrophils eosinophils counting basophil maturation|epithelium DCs adipocytes APC ECs|enterocytes|lomitapide also blocks mtp in entity ( cells lining the gastrointestinal tract ) , leading to an accumulation of fat in the intestinal mucosa .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|Sperm spermatozoa maturation Red oocyte|progesterone FSH estradiol androgen prolactin|spermatids|hormone ) drives synthesis of testosterone in the leydig cells of the testes and fsh ( follicle stimulating hormone ) drives production of entity in the sertoli cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|Sperm spermatozoa maturation Red oocyte|mitochondria spermatogenesis tubules spermatozoa nuclei|spermatids|clinical dose on a mg / m2 basis ) in a 6-month iv study had bilateral degeneration of the seminiferous epithelium with retained entity and atrophy of interstitial cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|Sperm spermatozoa maturation Red oocyte|spermat spermatozoa Leydig spermatogenesis testicular|spermatids|entity mature over a 72 day cycle in the seminiferous tubules in the testes under the influence of endogenous testosterone produced
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|Sperm spermatozoa maturation Red oocyte|erythrocytes fibroblasts hepatocytes splenocytes fibroblast|spermatids|to be mutagenic in the in vivo mouse micronucleus assay and positive for the induction of chromosomal aberrations in mouse entity and murine lymphocytes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|oocyte egg embryo spermatozoa semen|sperm|taken from the womans ovarian follicles and fertilized in vitro with either standard insemination , or icsi , in which a single entity is injected by needle into the egg .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|fertilization cytometry motile spermatozoa collection|oocyte hair cataract ocular embryo|sperm|the decrease is due to a smaller demand for the entity bank services .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|uterus embryo oocyte placenta mother|sperm|each parent , including recombination , or the exchange of dna within the parent chromosomes that occurs during the formation of the entity and the egg that become the fetus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|fertilization cytometry motile spermatozoa collection|cornea embryo corneal hair bank|sperm|the company operates in two distinct reporting segments , one for the entity bank division and one for its stem-cell and skin care divisions as of december 31 , 2009 and 2008 and for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|follicle PSA semen pill abstinence|sperm|this trial showed that androxal® was able to maintain entity counts in men being treated for their low testosterone levels , whereas testim® resulted in suppressed entity levels .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|oocyte embryo spermatozoa semen egg|sperm|the latter include , among other technologies , in vitro fertilization , or ivf , and intracytoplasmic entity injection , or icsi .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|spermatozoa mitochondria nuclei chromosomes heads|sperm|lastly , semen samples that had fewer normal entity had slightly , but not significantly , higher sorp values .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|exception exclusion subpopulation collection donation|sperm|of the protocol or for other unanticipated reasons , and we may be unable to achieve the same results with the entity of infertile donors that have been achieved with entity of fertile donors .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|fertilization cytometry motile spermatozoa collection|PSA Hb haemoglobin HBsAg bilirubin|sperm|those with an abnormally low entity concentration or overall total number , have significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|spermatozoa semen partners oocytes follicles|sperm|o application as an enhancement in human intercourse - for couples prone to male factor infertility from immotile or poorly motile entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fertilization cytometry motile spermatozoa collection|volunteers embryos beings primates hair|sperm|the university of pennsylvania safety and efficacy laboratory studies with atp ( the active ingredient in atpotent ) using human and animal entity as well as animal eggs and animal embryos .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|employ preserve retain supplies cover|sperm|the contractor must provide full service cryobiology program to include storage of embryos and entity all laboratory equipment and staffing as work load requires .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fertilization cytometry motile spermatozoa collection|spermatozoa pathogens embryos oocytes parasites|sperm|conducted in 20 women and published in the journal of reproductive medicine® in 2009 , ovaprene demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fertilization cytometry motile spermatozoa collection|spermatozoa nuclei clones motile leukocytes|sperm|abnormally few motile entity or few entity with a progressive motility were also associated with significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|testis placenta egg oocyte uterus|sperm|transgenic animal  shall mean a non-human animal , or an egg , entity or embryo of such animal , which bears in its germline a foreign gene derived from another animal species .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fertilization cytometry motile spermatozoa collection|funding fruit own bank market|sperm|continued to develop its pre-clinical-stage therapeutic agents and various treatments utilizing stem cell treatments while generating revenues and operating its entity bank division .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|fertilization cytometry motile spermatozoa collection|puberty FSH androgens eggs hair|sperm|that plays a key role in masculine growth and development during puberty — or has an impaired ability to produce entity or both .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|fertilization cytometry motile spermatozoa collection|embryos oocytes eggs fetuses spermatozoa|sperm|not viable , the work prompted calls for a moratorium or other types of restrictions on gene editing of human eggs , entity , and embryos .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|fertilization cytometry motile spermatozoa collection|erectile testicular gonadal PSA androgen|sperm|program with androxal as a treatment for men being treated for low testosterone that want to maintain or improve their entity function during treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|fertilization cytometry motile spermatozoa collection|spermatozoa pathogens parasites embryos themselves|sperm|conducted in 21 women and published in the journal of reproductive medicine in 2009 , ovaprene® demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|oocytes oocyte maturation embryo follicle|embryos oocytes fibroblasts eggs spermatozoa|gametes|( b ) donors of entity , embryos , somatic cells or human tissue did not receive valuable consideration .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|oocytes oocyte maturation embryo follicle|spermatozoa embryos oocytes hormones semen|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or " art " , services .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|oocytes oocyte maturation embryo follicle|oocytes embryos eggs spermatozoa platelets|gametes|( e ) individuals who consented to donate stored entity , embryos , somatic cells , or human tissue were not reimbursed for the cost of storage prior to the decision to donate .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|oocytes oocyte maturation embryo follicle|eggs embryos oocytes fetuses spermatozoa|gametes|( c ) a person may not knowingly , for valuable consideration , purchase or sell entity , embryos , somatic cells , or human tissue for research purposes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|oocytes oocyte maturation embryo follicle|spermatozoa embryos oocytes semen hormones|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or art , services .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|oocytes oocyte maturation embryo follicle|oocytes embryos spermatozoa eggs follicles|gametes|ivf treatment while the procurement , processing and distribution of entity and embryos for use in ivf and other assisted reproduction treatments falls within the scope of the eu rules governing
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|oocytes oocyte maturation embryo follicle|oocytes embryos fibroblasts blastocysts eggs|gametes|national stem cell oversight committee , or · been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells , or human tissue gave voluntary and informed consent .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|oocytes oocyte maturation embryo follicle|somatic haploid diploid oocytes metaphase|gametes|enactment of this act , that is derived by fertilization , parthenogenesis , cloning , or any other means from one or more human entity or human diploid cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|oocytes oocyte maturation embryo follicle|spermatozoa embryos hormones oocytes chemicals|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as art services .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|oocytes oocyte maturation embryo follicle|embryos oocytes fibroblasts eggs blastocysts|gametes|( b ) donors of entity , embryos , somatic cells , or human tissue did not receive valuable consideration .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|oocytes oocyte maturation embryo follicle|spermatozoa embryos oocytes semen hormones|gametes|procedures that require entity ( sperm and eggs ) to be handled in 3 vitro ( outside the body ) are classified as assisted reproductive technology , or " art " ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|oocytes oocyte maturation embryo follicle|oocytes embryos fibroblasts blastocysts eggs|gametes|national stem cell oversight committee , or ● been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells or human tissue gave voluntary and informed consent .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|oocytes oocyte maturation embryo follicle|embryos eggs oocytes fetuses blastocysts|gametes|of a duly authorized institutional review board ( irb ) ; and prohibits the knowing purchase , sale or transfer of human embryos or entity for valuable consideration for research purposes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|oocytes oocyte maturation embryo follicle|spermatozoa embryos oocytes hormones semen|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology ( " art " ) services .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|oocytes oocyte maturation embryo follicle|embryos oocytes eggs fibroblasts platelets|gametes|( d ) donation of entity , embryos , somatic cells , or human tissue was overseen by an irb ( or , in the case of foreign sources , an irb-equivalent ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|cell|GH secreting hormones prolactin FSH|glands secretions explants slices precursors|somatotrophs|gh is an anabolic hormone synthesized , stored in , and secreted from entity of the anterior pituitary gland in response to chemical modulators from the hypothalamus and stomach .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hormones GH reserve steroids prolactin|fibroblasts hepatocytes PBMCs LNCaP thymocytes|corticotrophs|similarly , dipyridamole did not amplify prednisolone effects in entity , cells that mediate the hpa axis suppression of high-dose glucocorticoid treatment .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|counting vulgaris Ki67 melanocytes pigmentation|keratinocytes fibroblasts melanocytes DCs eosinophils|sebocytes|because there are no preclinical models of acne , human entity , which are the cells that make up the sebaceous glands and secrete sebum , are a useful research tool for a
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|counting vulgaris Ki67 melanocytes pigmentation|epidermis dermis follicle keratinocytes cornea|sebocytes|it has also been shown in a laboratory study that a chemical that blocks acetylcholine from reaching the entity reduces sebum production .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1), ('DRUG', 1)])|cell|counting vulgaris Ki67 melanocytes pigmentation|keratinocytes melanocytes fibroblasts Langerhans SCC|sebocytes|acetylcholine has been shown in laboratory studies to increase activity in the sebum-producing skin cells called entity , which form sebaceous glands .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|blasts neutrophils fibroblasts CD34 CD3|monocytes fibroblasts leukocytes neutrophils chondrocytes|synoviocytes|synoviocyte inhibitory moa : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|cell|blasts neutrophils fibroblasts CD34 CD3|osteoclasts chondrocytes joints proteoglycans monocytes|synoviocytes|rheumatoid arthritis results from interactions between immune cells and entity that leads to joint swelling , pannus formation and bone loss .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|blasts neutrophils fibroblasts CD34 CD3|fibroblasts vessels ligaments tendons chondrocytes|synoviocytes|the synovium is lined by cells , or entity , which produce a small amount of liquid called synovial fluid that nourishes and lubricates the joint .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|blasts neutrophils fibroblasts CD34 CD3|endothelium vessels latter lungs placenta|synoviocytes|the entity , in turn , secrete a variety of chemicals that contribute to inflammation , tissue degradation and harmful new blood vessel formation .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('BIO', 5), ('OTHER', 4)])|cell|blasts neutrophils fibroblasts CD34 CD3|fibroblasts chondrocytes osteoclasts keratinocytes osteoblasts|synoviocytes|of articular joints and joint surfaces , characterized by the rapid , uncontrolled growth of the cells that line the joints , called entity .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|blasts neutrophils fibroblasts CD34 CD3|progenitors fibroblasts precursors aggregates colonies|synoviocytes|of most individuals with rheumatoid arthritis , which drive the production of tnf and the recruitment of neutrophils and fibroblast like entity .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|blasts neutrophils fibroblasts CD34 CD3|monocytes fibroblasts leukocytes neutrophils chondrocytes|synoviocytes|synoviocyte inhibition : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|blasts neutrophils fibroblasts CD34 CD3|fibroblasts progenitors clones keratinocytes precursors|synoviocytes|data published today demonstrate that ppi-2458 potently inhibits the growth of both human fibroblast-like entity derived from rheumatoid arthritis patients and human endothelial cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|fibres nerves neuromuscular Peripheral Functional|preparations fibres electrodes pairs motoneurons|mechanoreceptors|in parallel , electrophysiology recordings of single ganglion neurons that innervate the craniofacial muscles were performed ( 33 masticatory muscle entity ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|anaplastic neuroblastoma GCT primitive proliferative|donors volunteers EPCs person ones|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to assess the safety and efficacy of the cells in
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|anaplastic neuroblastoma GCT primitive proliferative|vessels ECs progenitors endothelium adipocytes|angioblasts|recyte will also develop ips cells into primitive entity , which are cells believed to be capable of reconstituting and repairing age-related changes in the vascular system .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|anaplastic neuroblastoma GCT primitive proliferative|donors volunteers EPCs ones person|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to test the safety and efficacy of the cells in
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|neutrophils monocytes leukocytes PMNs IgG|phagocytes|binding of ar-101 to p . aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|pathogens phagocytes leukocytes compartments ones|phagocytes|important entity include macrophages , that rid the body of dead cells and other debris , and granulocytes , including neutrophils , that contain granules filled
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|LPS endotoxin lipopolysaccharide H2O2 ethanol|phagocytes|t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|LPS endotoxin PMA lipopolysaccharide H2O2|phagocytes|nk / t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|neutrophils PMNs phagocytes mitochondria mutants|phagocytes|these defective entity cannot generate superoxide , leading to an inability to kill harmful microorganisms such as bacteria and fungi .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|neutrophils monocytes RBCs phagocytes granulocytes|phagocytes|one part of the innate immune system involves large white blood cells called entity ( literally , " cell-eaters " ) that can engulf and digest foreign microorganisms and other antigens .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|neutrophils monocytes phagocytes erythrocytes leukocytes|phagocytes|have been shown to induce antibodies that are protective in animal models and that facilitate killing of bacteria by human entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|mitochondria NADPH superoxide NADH phospholipids|phagocytes|laboratory research has demonstrated that ceplene reduces formation of oxygen radicals from entity , inhibiting nadph oxidase and protecting il-2-activated nk-cells and t-cells .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|Cells EPCs BMC HSCs BMSCs|phagocytes|entity were depleted using clodronate loaded liposomes through day 21 .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|monocytes DCs phagocytes neutrophils microglia|phagocytes|and increasing anti-inflammatory mediators , the production of antimicrobial effectors and increased absorption of pathogens by specially adapted cells known as entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|neutrophils Tregs HSCs DCs monocytes|phagocytes|we observed that depletion of entity , including myeloid apcs , significantly reduced our bdc-1001 surrogate-mediated anti-tumor activity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|p21 Ki67 TP53 p16 survivin|phagocytes|furthermore , significant increases in entity and cd8 t cells were measured in tumors following bdc-1001 surrogate treatment , further supporting a mechanism that bridges the innate
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|rh pa pc ab ph|phagocytes|figure 4 : bdc-1001 surrogate activity dependent on presence of entity scid / beige were dosed systemically with 5 mg / kg on day 0 , 5 and 10 .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|endothelium platelets neutrophils mitochondria cytosol|phagocytes|or other molecules in the class known as histamine type-2 ( h ) receptor agonists bind to the h receptor on the entity , the production and release of free radicals is temporarily prevented .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|mitochondria neutrophils PMNs PMN phagocytes|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|mitochondria PMNs neutrophils PMN phagocytes|phagocytes|the release of free radicals by entity results in apoptosis ( programmed cell death ) of nk cells and t cells , thereby destroying their cytotoxic capability and rendering the
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|mitochondria neutrophils PMNs PMN phagocytes|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and rendering
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|EPCs RBCs Neutroph RBC neutrophils|phagocytes|entity are a class of white blood cells found in abundant quantities at the site of tumors and viral infections .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|endotoxin EBV LPS PHA histamine|phagocytes|maxim  s researchers have shown , however , that nk cells and t cells are suppressed by entity , another component of the body  s immune system .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|neutrophils eosinophils phagocytosis CD11b CD14|leukocytes neutrophils monocytes leucocytes fibroblasts|phagocytes|table of contents results in a dramatic increase in the production of cytokines that orchestrate the proliferation and recruitment of entity to the site of damage , resulting in inflammation .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|DCs Cells PBMCs PBMC Tregs|splenocytes|entity were analyzed by flow cytometry to confirm effector / memory phenotype , and cultured with anti-human cd3 antibodies at 2 . 5 mg / ml and anti-human
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|CD25 AND cytotoxicity DCs cytometry|Cells HUVECs EVs HUVEC SMCs|splenocytes|entity were lysed and assayed for phospho- nuclear factor kappa b ( nfb ) p65 using an enzyme-linked immunosorbent assay .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|CD25 AND cytotoxicity DCs cytometry|PBMCs Plasma Sera BALF LPS|splenocytes|figure 11 : entity from eae mice treated with edp1815 produced an anti-inflammatory cytokine profile .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|corrected RBC WT graft CMV|splenocytes|svp 1 3 week week naïve recipient lmb-100 transfer entity lmb-100 + / -lmb-100 + / -
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|CD25 AND cytotoxicity DCs cytometry|PBMC PBMCs monocytes CTL cytometry|splenocytes|cell responses will be assessed by in vivo cd4 and cd8 cell depletion and measure cytotoxicity and gamma-ifn release by entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|leukocytes leucocytes neutrophils platelets lymphocyte|splenocytes|administration for 14 days ( 10 mg / kg , sid , ip ) : no effect on blood count , blood chemistry and cytokine secretion by isolated entity no herg inhibition observed ( in vitro )
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|CD25 AND cytotoxicity DCs cytometry|priming collection prime starting onto|splenocytes|svp prime challenge donor transfer entity day 0 14 aav8-hfix day 0 19 20 21 32 recipient anti-cd25 treg depletion day 0 1 28 anti-aav8 igg
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|hepatocytes neutrophils cardiomyocytes monocytes PMNs|splenocytes|in vitro studies demonstrated that treatment of isolated entity with virulizin ( r ) result in increased il-17e mrna expression .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|Cells DCs PMNs PMN MSCs|splenocytes|entity from either young or older atherosclerotic apoe ko mice were isolated from the spleen .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|brains splenocytes cords leukocytes DRG|splenocytes|to explore further the mechanisms of cns remyelination , we made a panel of monoclonal antibodies ( mabs ) derived from entity of sjl / j mice injected with homogenized spinal cord .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|PBMC PBMCs DCs CTL PBL|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in elispot ( depicted in
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|DCs PBMC PBMCs splenocytes CTL|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in enzyme-linked immune absorbent
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|PBMC PBMCs DCs CTL PCs|splenocytes|t cell responses were measured on day 15 by re-stimulating entity with either control ( medium ) or peptides corresponding to each antigen ( 1 , 2 , 6 , 9 , and 12 ) in the mrna vaccine
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|DCs recipients rabbits eggs clones|splenocytes|before transfer , immunized entity were separated or fractionated .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|PBMC PBMCs DCs recipients responders|splenocytes|robust and specific antigen specific cd8+ifng+ t cell responses were detected in entity after re-stimulation with kras mutation 1 peptide and kras mutation 2 peptide .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|neutrophils PMNs monocytes DCs fibroblasts|splenocytes|cgen-25007 exhibited anti-inflammatory activity in both human pbmcs and murine entity challenged with various inflammatory stimuli as well as in an animal model of endotoxemia .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|DCs beads BCG CAR NPs|splenocytes|enumeral platform used for antibody discovery • mice were immunized with pd - 1 - his • entity activated with lps for 3 days •
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|CD25 AND cytotoxicity DCs cytometry|livers embryos brains lungs hepatocytes|splenocytes|these methods were applied to analyze gene expression data from mouse entity exposed to either copaxone® or the purported generic ga .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|splenocytes PBL DCs PBMCs PBMC|splenocytes|cd4+ and cd8+ t cells from entity isolated from bnt162b2-immunized mice were strongly positive for ifn-ɣ and il-2 , producing high levels of the th1 cytokines but minute
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|CD25 AND cytotoxicity DCs cytometry|endothelium monocytes HUVEC leukocytes platelets|splenocytes|preincubation of the endothelial cells with blocking antibodies to eotaxin-2 was found to attenuate the adhesion of the entity to these cells ( fig . 15a ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|basophil neutrophils psoriasis eosinophils fibroblasts|scaffolds composites polymers ligaments constructs|corneocytes|in addition , to providing most of the mechanical strength of the tissue , these entity provide a stabilizing scaffold for the mortar .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|basophil neutrophils psoriasis eosinophils fibroblasts|brick shoes wood cloth concrete|corneocytes|the bricks ,  or entity , provide a durable defense against the ordinary frictional wear and tear of life .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|basophil neutrophils psoriasis eosinophils fibroblasts|keratinocytes layers epithelia lipids epidermis|corneocytes|the stratum corneum , consisting of flattened and hardened non-living entity held together by a lipid matrix , acts as the main barrier to drug delivery .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|basophil neutrophils psoriasis eosinophils fibroblasts|walls layers sheets teeth columns|corneocytes|the mortar is primarily made up of fats or lipids that are organized into broad sheets or membranes .  stacks of these membranes fill the spaces between the entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|basophil neutrophils psoriasis eosinophils fibroblasts|lipids fibrils vesicles proteoglycans melanin|corneocytes|keratinocytes , the most common cell type in the outer layer of skin , has been shown to increase the formation of entity and the production of lamellar lipids .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|clones hybridization progeny parasites blasts|pairs hybrids genomes hybridization comparisons|heterokaryons|elegans to isolate innate immunity mutations , and implementing species specific primers to distinguish rat transcipts from mouse transcripts in rat-mouse entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|hepatocytes counting Ki67 mitochondria fibroblasts|hepatocytes HSCs fibroblasts progenitors adipocytes|cholangiocytes|the licensed technology describes advanced methods for the production of mature hepatocytes and entity , the primary cell types of the liver .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hepatocytes counting Ki67 mitochondria fibroblasts|hepatocytes epithelium ducts fibroblasts epithelia|cholangiocytes|specific and robust ccl24 staining was also shown in entity , the epithelial cells of the bile ducts .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neutrophils counting blasts eosinophils CD11b|fibroblasts progenitors epithelium predominantly CMV|pneumocytes|sars - cov - 2 infects type ii entity in lung alveoli 1 these cells also serve as progenitor cells for repairing damaged alveoli .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neutrophils counting blasts eosinophils CD11b|fibroblasts adipocytes hepatocytes MSCs keratinocytes|pneumocytes|type it entity , known to be primary targets / reservoirs for flu , are plated in a transwell system , which essentially suspends the polarized cell monolayer
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|neutrophils counting blasts eosinophils CD11b|streptococci adenovirus pathogens Streptococcus pathogen|pneumocytes|in covid - 19 , infection of type ii entity results in impaired gas exchange and fluid leakage into alveoli .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|he she Medicare India funding|oncocyte|as of december 31 , 2017 , entity had $2 . 1 million outstanding and payable to biotime and affiliates in connection with the costs incurred under the shared facilities
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|She He Participants he Women|oncocyte|entity incurred no royalty expenses to date as of december 31 , 2014 .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|CD3 cytometry CD34 maturation lymphocyte|microfluidic FP cosmetic multiplex POC|oncocyte|importantly , entitys methods appear to be compliant with commercial manufacturing processes .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|your my personal another own|oncocyte|the fact that certain of our executive officers and directors own shares of entity common stock should not be considered to mean that they constitute or are acting in concert as a “group” with
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|scientific pharmaceutical biotechnology academic manufacturing|oncocyte|the patent is useful for biotimes subsidiary entity corporation for its cancer diagnostic product development .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|automatically unless dates continuously codes|oncocyte|on july 2 , 2018 , entity entered into a lease schedule under the lease agreement no . 2 for certain equipment costing approximately $209 , 000 , requiring payments of
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|CD3 cytometry CD34 maturation lymphocyte|Stem Therapeutic Neuro ex ethical|oncocyte|another subsidiary , entity corporation , focuses on the therapeutic applications of stem cell technology in cancer , including using vascular progenitor cells engineered to destroy
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1)])|cell|CD3 cytometry CD34 maturation lymphocyte|biotechnology biology microbiome physiology algae|oncocyte|additional information about biotime , recyte therapeutics , cell cure , orthocyte , entity , biotime asia , lifemap sciences , and esi can be found on the web at www . biotimeinc . com .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|FDA EMA NGS NIH bioinformatics|oncocyte|in concert with the protocol development , entity has established a broad range of support assays to monitor and measure vascular progenitor cell differentiation processes .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|abstracts he dates file funding|oncocyte|on may 11 , 2017 , entity entered into another master lease line agreement ( “lease agreement no . 2” ) with the same finance company on terms similar to lease agreement no . 1 .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|British marine Canadian Italian African|oncocyte|to beneficially own the shares owned by broadwood , in the aggregate beneficially own approximately 18 . 9% of the outstanding shares of entity common stock as of april 22 , 2019 .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|funds funding legislation incentives authority|oncocyte|under the provisions of the contracts , entity may be required to incur severance obligations for matters relating to changes in control , as defined , and involuntary terminations .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|Public Open see your General|oncocyte|you should direct any requests to : entity corporation 15 cushing irvine , california 92618 409-7600 s-11 3 , 523 , 776 shares common stock january
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|FDA Participants States You Researchers|oncocyte|entity will reimburse sbmri for 25% of the costs incurred in filing , prosecuting , and maintaining patent protection , subject to entity&#8217 ; s approval of the costs .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|She He he Alcohol she|oncocyte|entity has entered into employment contracts with certain executive officers .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|you go let say try|oncocyte|references to “entity , ” “we , ” “us , ” and “our” are references to entity corporation .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|participant Medicare society user Canada|oncocyte|of royalty bearing products commence , the annual fee will be credited towards entity  s royalty payment obligations for the applicable year .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|stock bird stocks lion generic|oncocyte|in note 3 , the asterias shares of common stock lineage held generated similar deferred tax liabilities to lineage as the entity shares discussed above .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|FDA She Technology Research He|oncocyte|entity has expanded and banked large numbers of vascular progenitor cells derived from multiple hes cell lines , including clinical-grade stem cells provided by us and our subsidiary esi .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|CD3 cytometry CD34 maturation lymphocyte|she he FDA guardian investigator|oncocyte|except as required by law , entity disclaims any intent or obligation to update these forward-looking statements .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|CD34 MSCs EPCs CD133 Cells|fungi mycobacteria biofilms MRSA leaves|amniocytes|fluorescence images demonstrating hybridization of the cep x / y and lsi 21 probes on uncultured entity .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|cell|neutrophils blasts granulocytes CD3 leukocytes|neutrophils granulocytes eosinophils monocytes PMNs|promonocytes|two leukine treated patients had progressive increase in circulating monocytes and entity and blasts in the marrow which reversed when leukine was discontinued .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('DIS', 5), ('OTHER', 4)])|cell|blasts basophil maturation Red MN|hematocrit bilirubin fibrinogen platelets haemoglobin|reticulocytes|to six months have shown a profound and durable reduction in hemolysis ( red blood cell destruction ) as assessed by hemoglobin , entity and / or bilirubin .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('BIO', 2), ('DIS', 1)])|cell|blasts basophil maturation Red MN|rituximab platelets steroids immunoglobulins bortezomib|reticulocytes|the streck patents relate to the addition of entity to hematology controls .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2), ('DRUG', 1)])|cell|blasts basophil maturation Red MN|RBCs reagents rituximab blasts platelets|reticulocytes|is successful , after cancellation of the streck patents , the company may be issued a patent covering integrated hematology controls containing entity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|blasts basophil maturation Red MN|tau erythrocytes RBC bilirubin RBCs|reticulocytes|ldh and bilirubin are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|blasts basophil maturation Red MN|erythrocytes RBCs circulation PBS fingers|reticulocytes|mg / kg , *** ) , elevated hemoglobin concentrations in entity ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|blasts basophil maturation Red MN|AEs nausea MACE pruritus proteinuria|reticulocytes|we observed an 18% reduction in entity in the 10 mg treatment arm relative to the placebo arm .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|blasts basophil maturation Red MN|oocytes melanocytes fibroblasts keratinocytes chondrocytes|reticulocytes|then exposed to a defined media formulation to promote further expansion and differentiation until they differentiate and mature into enucleated entity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|blasts basophil maturation Red MN|platelets Hb proteinuria hemolysis immunogenicity|reticulocytes|improvement in the hemolytic anemia would be expected to result in a decrease in entity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|blasts basophil maturation Red MN|RBCs erythrocytes RBC platelets PCs|reticulocytes|products provide a means of assessing the linearity of hematology analyzers for white blood cells , red blood cells , platelets and entity ( immature red blood cells ) .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 4), ('DRUG', 1)])|cell|blasts basophil maturation Red MN|RBCs erythrocytes RBC platelets CML|reticulocytes|bilirubin and ldh are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 4)])|cell|blasts basophil maturation Red MN|RBCs RBC erythrocytes platelets PCs|reticulocytes|these controls are designed for manual and automated counting of entity ( immature red blood cells ) .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 4), ('DRUG', 1)])|cell|blasts basophil maturation Red MN|hematocrit erythropoietin platelets ferritin leukocytes|reticulocytes|the increase in hemoglobin levels was preceded by an increase in entity showing that an increase in hemoglobin levels is a result of a physiologic increase in rbc production .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|blasts basophil maturation Red MN|endpoint visit formulation dosing Visit|reticulocytes|dose ( mg / kg / day ) average bodyweight at end ofstudy hematology results at end of study entity ( x 103 / µl ) neutrophils ( x 103 / µl ) control - 603 m / 324 f
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|blasts basophil maturation Red MN|oocytes spermatozoa embryos mitochondria photoreceptors|reticulocytes|at this stage , the enucleated entity are rcts that express one or more biotherapeutic proteins in the cytosol or on the cell surface .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3), ('DRUG', 1)])|cell|blasts basophil maturation Red MN|hematocrit haemoglobin Hb ferritin HCT|reticulocytes|while gbt4 showed improvement in hemoglobin , entity and ldh levels in the first 15 days , these values worsened after day 15 .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|cell|blasts basophil maturation Red MN|platelets hematocrit neutrophils leukocytes bilirubin|reticulocytes|levels and improved clinical measures of hemolysis at 16 weeks , as evaluated by changes from baseline in hemoglobin , percent of entity , and percent of unconjugated bilirubin .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 4)])|cell|blasts basophil maturation Red MN|platelets hematocrit haemoglobin fibrinogen neutrophils|reticulocytes|robust and sustained increase in red blood cells , hemoglobin and entity , supporting monthly or less frequent dosing .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 4), ('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cell|blasts basophil maturation Red MN|hematocrit lipids haemoglobin ferritin platelets|reticulocytes|receiving the 300 mg dose , measuring changes in parameters over the 14-day treatment and 7-day follow-up period including hemoglobin and entity , as well as tolerability and safety .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|blasts basophil maturation Red MN|erythrocytes hepatocytes foci endpoints progeny|reticulocytes|standard in vivo genotoxicity studies in rodents , including a 2-day comet assay and a 28-day evaluation of micronucleated entity , revealed no test-article effects on genotoxicity .
OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 3), ('DRUG', 1)])|cell|blasts basophil maturation Red MN|hematocrit haemoglobin Hb neutrophil ferritin|reticulocytes|( 700 mg ) 8 ( 900 mg ) 9 ( 3 per cohort ) akb-6548 was well tolerated , and dose responsive increases in entity and hemoglobin levels were demonstrated .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|blasts neutrophils oligodendrocytes basophil CD20|granulocytes monocytes neutrophils thrombocytopenia eosinophils|promyelocytes|in apl , there is an abnormal accumulation of immature granulocytes called entity .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|blasts neutrophils oligodendrocytes basophil CD20|granulocytes platelets neutrophils monocytes erythrocytes|promyelocytes|in apl , immature white blood cells called entity accumulate in the bone marrow .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|blasts neutrophils oligodendrocytes basophil CD20|lymphocyte PBMC Th1 PBMCs immunological|promyelocytes|in addition , the data showed that plinabulin has a superior immune profile compared to neulasta based on entity and immature neutrophil data from the clinical study .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|blasts neutrophils oligodendrocytes basophil CD20|platelets microbes MSCs granulocytes neutrophils|promyelocytes|the overgrowth of entity leads to a shortage of normal white and red blood cells and platelets in the body , which causes many of
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|blasts neutrophils oligodendrocytes basophil CD20|blasts progenitors clones clone precursors|promyelocytes|differentiation therapy causes leukemic entity to mature and undergo cell death .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 4), ('DIS', 1)])|cell|blasts neutrophils oligodendrocytes basophil CD20|platelets blasts neutrophils parasites granulocytes|promyelocytes|the accumulation of entity in the bone marrow results in a reduction in the production of normal red blood cells and platelets resulting in
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 2)])|cell|blasts neutrophils oligodendrocytes basophil CD20|granulocytes neutrophils platelets monocytes erythrocytes|promyelocytes|this fusion gene leads to the overproduction of immature white blood cells called entity and the underproduction of healthy blood cells .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|blasts MDS oligodendrocytes basophil neutrophils|monocytes platelets eosinophils fibroblasts neutrophils|metamyelocytes|associated with evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , entity and granulocytes ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|cell|proliferative CD34 plexus neovascularization angiogenic|hepatocytes islets erythrocytes platelets oocytes|pituicytes|mechanism of action of lum-201 ghsr1a activation via lum-201 binding induces gh release , as demonstrated in vitro in rat entity ( lum-201 ec50 1 . 3 nm ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|cell|proliferative CD34 plexus neovascularization angiogenic|adipocytes hepatocytes islets SHR PBMCs|pituicytes|in addition , the treatment of entity with lum-201 augments the effect of ghrh on gh secretion , as the two compounds synergistically stimulated gh release from rat
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblasts counting neutrophils blasts eosinophils|tears AGEs lenses fibroblasts regimens|keratocytes|activated entity have been associated with increased collagen deposition and collagen disorganization which correlate with corneal haze and regression of the correction
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|fibroblasts counting neutrophils blasts eosinophils|layers BCC keratinocytes epithelium melanomas|keratocytes|the superficial entity initially undergo apoptosis , followed by proliferation and activation of the remaining entity .
OrderedDict([('OTHER', 4), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblasts counting neutrophils blasts eosinophils|fibroblasts keratinocytes epithelium endothelium ECs|keratocytes|treatment resulted in a reduction of pro-fibrotic gene expression from day 7-14 post-injury , indicating that target engagement was achieved in entity and myofibroblasts in the corneal stroma .
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|fibroblasts blasts proliferative Inflammatory neutrophils|fibroblasts adipocytes mesenchymal MSCs HSCs|fibrocytes|igf-1r , the receptor for igf-1 , is highly expressed in entity , cells that are derived from the bone marrow and that have the potential to differentiate into either myofibroblasts or fat
OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|fibroblasts blasts proliferative Inflammatory neutrophils|mediators subsets chemokines subpopulations locations|fibrocytes|inflammation and when chronically activated , drives the development of fibrosis via several pathways and several cell inflammatory cell types and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|Skin melanocytes Cells Melan Mamm|melanocytes|entity produce melanin , the pigment that determines skin color and protects the body from ultraviolet radiation .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|keratinocytes melanocytes fibroblasts melanin neutrophils|melanocytes|tanning is mediated by entity producing melanin , which is subsequently transferred to the keratinocytes .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes pigment keratinocytes epidermal melanin|melanocytes|vitiligo is an autoimmune condition in which the skin turns white due to the loss of entity , cells that produce the pigment melanin , which gives skin color .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes dermis epidermis stroma iris|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes keratinocytes pigmentation sunlight melanin|melanocytes|melanin is produced by entity and is the pigment that gives human skin , hair and eyes their color .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes keratinocytes melanin Langerhans epidermal|melanocytes|the skin cells that produce the melanins are called entity and comprise 5 to 10% of the total cellular population in the epidermis .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes scalp Caucasians man Langerhans|melanocytes|melanoma is a malignant tumor of entity , a potentially dangerous form of skin cancer .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|epithelium keratinocytes melanocytes glands layers|melanocytes|cutaneous melanomamelanoma tumors originate in the pigment-producing entity in the basal layer of the epidermis .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes keratinocytes melanomas melanin endothelium|melanocytes|· melanoma : melanoma is a cancer that begins in specific skin cells called entity , and exposure to ultraviolet rays is a major risk factor for most melanomas .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes fibroblasts keratinocytes dermis adipocytes|melanocytes|the epidermis is comprised of specialized cells such as keratinocytes and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|pigmented epidermal pigment proliferating melanocytes|melanocytes|melanoma begins in entity cells that make a pigment called melanin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes dermis epidermis stroma keratinocytes|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation of the skin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes melanomas nevi melanin keratinocytes|melanocytes|melanoma is a disease in which pigmented cells in the skin , called entity , turn into cancer cells .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes photoreceptors tumours melanomas nevi|melanocytes|melanoma occurs when entity ( pigment cells ) become malignant .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|keratinocytes fibroblasts epithelium melanocytes epithelia|melanocytes|normal entity do not express mcam , but expression is turned on and continues to increase as the cells become more malignant .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanomas tumours neoplasms locations foci|melanocytes|malignant melanoma - predominantly a skin cancer , malignant melanoma can also occur in entity found in the bowel and the eye .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|scalp melanocytes cervix epidermis iris|melanocytes|melanoma is a cancer of the entity , the cells that produce pigment in the skin .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|melanocytes keratinocytes fibroblasts melanomas endothelium|melanocytes|melanoma melanoma is a cancer that begins in specific skin cells called entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|periphery epithelium stroma vicinity fundus|melanocytes|melanoma is primarily a skin tumor , although it may also occur less frequently in the entity of the eye .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neuroblastoma tyrosinase pigmentation psoriasis AND|cervix scalp penis retina extremities|melanocytes|melanoma is a malignant tumor of the entity .
OrderedDict([('OTHER', 4), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|Formation algae parasites fungi seeking|pathogens parasites pathogen bacterium fungus|endospores|proteins and cross-linking of unprotonated proteins thereby denaturing the proteins to corrupt and penetrate the bacterial walls to kill the entity and other microorganisms .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 3)])|cell|neuroblastoma fibroblasts glia proliferative Neuro|oligodendrocytes glia neuroblastoma astrocytes Schwann|neuroblasts|a neuroblastoma tumor develops from immature nerve cells called entity and arises predominantly in the adrenal glands and abdomen .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|neuroblastoma fibroblasts glia proliferative Neuro|vaccines chemicals kits hypotheses cigarettes|neuroblasts|the license also covers methods for the production and screening of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|lacking contain chloroplasts called comprising|astrocytes hepatocytes mitochondria cardiomyocytes erythrocytes|protoplasts|electroporation is a method for increasing dna uptake by entity through prior exposure to a high voltage , which results in the temporary formation of small pores in the cell membrane .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|tyrosinase pigmentation melanin seeking melanocytes|melanocytes photoreceptors pigment keratinocytes Cells|melanophores|entity are pigment-bearing cells .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|tyrosinase pigmentation melanin seeking melanocytes|pigments melanocytes protons cones melanin|melanophores|for most types of lower animals , entity are the primary chromatophores responsible for skin color control .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|tyrosinase pigmentation melanin seeking melanocytes|melanocytes photoreceptors spheroids melanin keratinocytes|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|tyrosinase pigmentation melanin seeking melanocytes|melanocytes keratinocytes Cells Skin fibroblasts|melanophores|entity are amphibian cells that are responsible for skin color .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|tyrosinase pigmentation melanin seeking melanocytes|melanocytes photoreceptors spheroids melanin keratinocytes|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|tyrosinase pigmentation melanin seeking melanocytes|photoreceptors Will leaves Cells melanocytes|melanophores|entity undergo a color change in response to light or stimulation by chemicals .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|blasts astrocytes EPCs neutrophils CD133|eg ie hemolysis anemia thrombocytopenia|spherocytes|the laboratory evaluation of waiha begins with a peripheral blood analysis revealing evidence of extravascular hemolysis ( entity , low haptoglobin , elevated bilirubin and elevated ldh ) .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2)])|cell|blasts MDS neutrophils CD34 platelets|defects anemia transfusions blasts varices|sideroblasts|treatment of anemia failing an erythropoiesis stimulating agent in adult patients with very low- to intermediate-risk mds who have ring entity and require rbc transfusions .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 2)])|cell|blasts MDS neutrophils CD34 platelets|defects blasts RBCs platelets deletions|sideroblasts|patients to evaluate the efficacy and safety of luspatercept in patients with anemia due to lower-risk mds with ring entity who require regular rbc transfusions .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|blasts MDS neutrophils CD34 platelets|defects varices haemorrhage GVHD anemia|sideroblasts|the medalist trial , a global phase 3 study in patients with very low , low , or intermediate risk , mds with ring entity who require red blood cell transfusions , is currently enrolling .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|blasts MDS neutrophils CD34 platelets|stained sign blue bright labelled|sideroblasts|when at least 15% of the cells in an mds patients bone marrow are ring entity , this patient is considered rs positive .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|cell|blasts MDS neutrophils CD34 platelets|defects hemolysis blasts fused thrombocytopenia|sideroblasts|new class of therapy , for the treatment of adult patients with very low- to intermediate-risk mds-associated anemia who have ring entity and require red blood cell ( rbc ) transfusions .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|blasts MDS neutrophils CD34 platelets|GVHD defects transfusions anemia thrombocytopenia|sideroblasts|the phase 3 mds medalist trial targets patients with very low , low or intermediate risk mds with ring entity who require rbc transfusions .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|blasts MDS neutrophils CD34 platelets|erythrocytes sider platelets chromosomes shapes|sideroblasts|patients with mf that has transformed into aml , known as blast-phase mf , and in patients with refractory anemia with ringed entity , or rars , a subpopulation of mds .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|blasts MDS neutrophils CD34 platelets|deletions translocation defects editing splicing|sideroblasts|the majority of patients with mds that develop cytopenias lack ring entity or a single , defining splicing factor mutation and are termed non-rs .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|blasts MDS neutrophils CD34 platelets|erythrocytes RBCs platelets fingers shapes|sideroblasts|clinical safety and efficacy data on imetelstat from patients with a form of mds known as refractory anemia with ringed entity ( mds-rars ) enrolled as part of the mayo clinic pilot study .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|blasts MDS neutrophils CD34 platelets|sign defects bodies fibres dystrophy|sideroblasts|of contents subgroup of patients with mds that show the presence of iron deposits around the mitochondria , known as ring entity .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|cell|blasts MDS neutrophils CD34 platelets|anemia GVHD blasts episodes AND|sideroblasts|all patients presented with ring entity were rbc transfusion dependent and were either refractory or intolerant to prior erythropoiesis-stimulating agent ( esa ) therapy , or were esa naïve
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 3)])|cell|blasts MDS neutrophils CD34 platelets|RBCs platelets saturation hematocrit blasts|sideroblasts|and safety of luspatercept versus placebo in patients with anemia due to very low , low , or intermediate-risk mds with ring entity ( ≥ 15% ) who require red blood cell transfusions .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|blasts MDS neutrophils CD34 platelets|rings designs tablets sizes defects|sideroblasts|these ring entity are associated with ineffective erythropoiesis and anemia .
OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|blasts MDS neutrophils CD34 platelets|rings bonds alleles roots implants|sideroblasts|in the overall trial population , the rate of ≥8-week rbc ti did not differ based on the presence of ringed entity , indicating activity of imetelstat across different subtypes of mds .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2), ('DRUG', 1)])|cell|AND Disease vulgaris fertilization VI|platelets Hb ferritin CRP neutrophils|retic|g / dl . this was thought to be not clinically possible for a hgb at this level in conjunction with markedly elevated entity and low rbc counts .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|AND Disease vulgaris fertilization VI|eryth reticul leuk leuc thrombocyt|retic|mg / kg , *** ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|AND Disease vulgaris fertilization VI|eryth reticul leuk thrombocyt leuc|retic|mg / kg ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|AND Disease vulgaris fertilization VI|banding MTT aspiration FISH BMT|retic|the entity procedure , which is now implemented , measures the number of entityulocytes ( immature red blood cells produced in the bone marrow ) and
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND Disease vulgaris fertilization VI|eryth leuk reticul polymorphonuclear cerv|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p < 0 . 005 , *
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND Disease vulgaris fertilization VI|eryth leuk reticul polymorphonuclear nucle|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p 2 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND Disease vulgaris fertilization VI|reticul eryth microl leuc Gran|retic|in may 1996 , the company received fda 510 ( k ) clearances for two additional commonly performed microscope procedures : entityulocyte count ( entity ) and anti-nuclear antibodies ( anas ) .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|clones clone clonal representing blasts|tumours infarcts deletions vessels clones|subclones|progressive disease to elucidate whether these alterations were newly acquired following ibrutinib exposure or represent selective expansions of pre-existing small entity .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|nuclei lysates subsets pools subpopulations|subclones|evidence against the existence of mammalian tpe comes from a comparison of mrna levels for a telomeric neo gene in entity of sv40-transformed human fibroblasts with varying telomere lengths .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|construction creation collection derivation lysates|subclones|such non-limiting examples include : entity of unmodified cell lines , purified or fractionated subsets of materials provided by atcc , proteins expressed by dna / rna supplied by atcc ,
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|construction stocks lysates mixture creation|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by university , monoclonal
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|construction lysates stocks mixtures collection|subclones|some examples include : entity of unmodified or modified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|names items references words sentences|subclones|the term " moab 7e11 " includes all entity claimed in such patent .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|mixtures mixture subsets subpopulations collection|subclones|some examples include : entity of cell lines ; purified or fractionated subsets of the original materials or progeny ; dna or rna ; genetic material ; secreted or
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|construction lysates stocks clones mixtures|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by genencor or
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|insertions gains deletions substitutions exons|subclones|with information concerning the enzymes being used for ongoing subcloning to determine -9- 11 the absolute orientation and position of entity and deletions with respect to the original clone .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|unmodified cloned fresh mutated progeny|subclones|( i ) licensed products means materials and all progeny , entity , and unmodified derivatives of the cell clones .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|reads libraries genomes files primers|subclones|concentrate samples and load curagen  s dna sequencing gels , allowing the integrated system to generate base called sequences directly from dna entity .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|construction clones lysates mixtures derivation|subclones|some examples include : entity of unmodified cell lines , purified or fractionated subsets of the material , proteins expressed by dna / rna supplied by m . i . t . , or monoclonal
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|batches copies parts capsules preparations|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|analogues ingredients composites parts supplements|subclones|biological materials means the materials identified in appendix a together with any progeny , entity , or derivatives thereof provided by the foundation or created by licensee .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|clones CTL ones otherwise CSCs|subclones|in the face of immune pressure , entity susceptible to t cell killing are eliminated , leaving behind resistant tumor clones that are mhc deficient , and hence no longer
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|batches copies parts capsules preparations|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clones clone clonal representing blasts|parts copies files kits messages|subclones|materials shall mean the tangible material specifically described in exhibit a and physically transferred to licensee and any unmodified copies , progeny and entity made therefrom .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|allogeneic CTL Transplantation CD3 AND|allo ex imatinib pep ep|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( “licensed products” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|allogeneic CTL Transplantation CD3 AND|allo ex imatinib pep ep|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|allogeneic CTL Transplantation CD3 AND|allo ex imatinib pep ep|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#8220 ; licensed products&#8221 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|allogeneic CTL Transplantation CD3 AND|allo ex iso imatinib ep|allostim|the license granted covered two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|allogeneic CTL Transplantation CD3 AND|allo imatinib ex trastuzumab iso|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( “licensed products” ) .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|peel extraction alfa mL chlorhexidine|log benzo Cs sigma Su|carticel|the improvement in gross margin is primarily the result of an increase in entity [ r ] aucc sales and a reduction in labor and manufacturing expenses and decreased material expenses .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|cell|peel extraction alfa mL chlorhexidine|naltrexone buprenorphine MDMA methamphetamine cocaine|carticel|through june 30 , 1997 , gtr had received approximately $5 . 1 million in revenues from u . s . sales of entity ( tm ) acc since its market introduction in march 1995 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|decades durability AAA EVAR BMS|carticel|efficacy data demonstrating durability of repair is now out to 20 years for entity .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|cell|peel extraction alfa mL chlorhexidine|trastuzumab Su HbA bevacizumab paclitaxel|carticel|the following table summarizes the early results of the commercialization of entity ( tm ) acc in the u . s . :
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|author van FDA log he|carticel|if gtr were prohibited from marketing entity ( tm ) aucc in the u . s . , its results of operations would be materially adversely affected .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|swab syringe sham ink specimen|carticel|the company recognizes maci ( or entity ) kit revenue upon delivery of the biopsy kit at which time the customer ( the doctor ) is in control of the
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|http www van publication Su|carticel|in august 1997 , the fda approved gtr  s bla for entity ( tm ) aucc .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|pharmacy retail gross cigarette government|carticel|for the first half of 2015 , total entity and epicel net product revenues increased approximately 17% over pro-forma net product revenues for the same period in 2014 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|your HB BC NIR WB|carticel|the blue cross blue shield association has determined that its technology assessment committee does not believe that entity chondrocytes meets all of its published criteria for new treatments .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|capsules tablets gels ointment formulations|carticel|the cambridge facility has been used for u . s . manufacturing and distribution of entity , worldwide manufacturing and distribution of epicel and production of maci for clinical testing .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|ve ou se AND da|carticel|orthopaedics gabi*  sepra  synvisc®  provisc® ( alcon )  entity  hylaform® ( inamed ) focused on treating disease and restoring health through local effects on biology
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|pharmacy retail market gross tax|carticel|total entity and epicel net product revenues in the second quarter increased approximately 31% over pro-forma second-quarter net product revenues in 2014 .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|peel extraction alfa mL chlorhexidine|GSK trastuzumab FDA Poly Su|carticel|the commercial success of entity ( tm ) aucc will also depend materially on the ability of gtr to increase the approval rate for reimbursement of the product
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|peel extraction alfa mL chlorhexidine|cochlear orthopedic orthopaedic penile silicone|carticel|total revenues for the quarter ended june 30 , 2015 were $13 . 6 million and included $9 . 1 million in net sales of entity implants and surgical kits and $4 . 3 million in net sales of epicel .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|peel extraction alfa mL chlorhexidine|cannabis medicines cigarettes contraceptives pharmacies|carticel|the increase is primarily due to higher demand for entity , offset , in part , by a decline in sales of epicel due to a decrease in patients requesting this service .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|peel extraction alfa mL chlorhexidine|your dermat Derm keratocon colp|carticel|genzyme believes that entity chondrocytes does in fact meet all of these criteria and are discussing the evaluation with the blue cross blue shield
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|cell|peel extraction alfa mL chlorhexidine|trastuzumab paclitaxel carboplatin bevacizumab gefitinib|carticel|( 5% ) 16 ( 76% ) 1 ( 5% ) 4 ( 19% ) gtr has compiled safety data on 460 patients who have undergone treatment with entity ( tm ) acc .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|arthroscopy THA allograft autograft Surgery|carticel|entity is indicated for the repair of symptomatic cartilage defects of the femoral condyle ( medial , lateral or trochlea ) caused by acute
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|peel extraction alfa mL chlorhexidine|arthroscopy operations TKA arthroplasty return|carticel|market opportunity for entity in the u . s . annually , there are approximately 1 million arthroscopic procedures and more than 250 , 000 cartilage surgical procedures .
OrderedDict([('OTHER', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|cell|peel extraction alfa mL chlorhexidine|Su HbA van naltrexone QT|carticel|gtr is conducting additional research relating to entity ( tm ) aucc pursuant to a sponsored research agreement with the university of gotenburg in sweden and certain physicians , including the two
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|alfa GSK vulgaris Versus Beta|TM rituximab PBS ATG GSK|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t-cell product designed to accelerate immune recovery after hsct and to reduce relapse of leukemia following
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|alfa GSK vulgaris Versus Beta|CMV CYP3A4 VEGF RSV JAK2|rivogenlecleucel|rimiducid will be administered to inactivate entity ( rivo-cel ) in the event of gvhd not responsive to standard of care treatment updated 8 nov 2018 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|alfa GSK vulgaris Versus Beta|cel EPO ASC TAC MSC|rivogenlecleucel| rivo-cel ( entity , formerly known as bpx-501 ) is a product candidate intended to improve hsct outcomes in the treatment of hematologic malignancies , including
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|alfa GSK vulgaris Versus Beta|TM PBS GSK rituximab EPO|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t cell product designed to reduce the rate of relapse of leukemia following a stem cell
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|mit fever vulgaris psoriasis Bay|premature cytokine pathogen unintended undesirable|kymriah|– conserving the clinically validated cd19 car cell manufacturing process minimizes confounding risks penn process , not novartis process ; avoids entity release
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|approved manufactured licensed sponsored funded|kymriah|the fda has also approved two non-aav gene therapy products , entity by novartis international ag , for pediatric and young adult patients with a form of acute lymphoblastic leukemia and yescarta by
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|vaccines approval licensed don FDA|kymriah|two such companies , novartis international ag ( entity® ) and kite pharma inc . / gilead sciences , inc . ( yescarta® ) , have now commercialized autologous car+ t cells against cd19 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|mit fever vulgaris psoriasis Bay|he she cannabis buprenorphine FDA|kymriah|the company did not recognize royalty revenue in the comparative periods in the prior year given that entity was first approved for commercial sale in the second half of 2017 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|mit fever vulgaris psoriasis Bay|yes uveitis com urticaria respond|kymriah|only 20% of entity or yescarta patients treated with tocilizumab had resolution of signs and symptoms 6 days after onset of crs and ~50%
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|yes neoadjuvant ir RECIST corrected|kymriah|nomenclature ‘zuma-19 , may be the basis for the registration of lenzilumab , given the similar trial design to yescartas and novartiss entity® ( “entity” or “entity®” ) registration trials .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|yes ad responders sad ex|kymriah|both entity and yescarta carry “black box” warnings in their labels for nt and crs and are subject to a rems program ,
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|aug da oper ex ad|kymriah|maintaining clear leadership in share of voice entity polivy xpovio yescarta share of voice aug sep oct monjuvi compared to >50% monjuvi monjuvi 50% 30% 0% hcp engagement
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|mit fever vulgaris psoriasis Bay|TKI formulation mAb FDA ADC|kymriah|the fda approved entity ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute lymphoblastic leukemia ( all ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|cell|mit fever vulgaris psoriasis Bay|rituximab MMF infliximab bortezomib bevacizumab|kymriah|because of the risk of cytokine release syndrome and neurological events , entity is being approved with a rems .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|license market patent approved library|kymriah|september 2018 , we entered into a license and collaboration agreement with novartis to manufacture and supply their car-t cell therapy entity® in china .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|compar another taxa ad ab|kymriah|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to yescarta or entity source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|mit fever vulgaris psoriasis Bay|pepper rice ginseng migraine rape|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , namely , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|namely ie Mexico India eg|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|publication marketing granted adoption purchase|kymriah|in august 2017 , novartis received fda approval for entity and paid the company $2 . 5 million as a result of the achievement of a related milestone .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|mit fever vulgaris psoriasis Bay|HSCT SCT Vaccine Chemotherapy vaccination|kymriah|entity is a genetically-modified autologous t-cell immunotherapy .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|mit fever vulgaris psoriasis Bay|monkey bean ginseng vulgaris nut|kymriah|there are currently two car-t therapies approved in the u . s . and eu , novartis entity ( tisagenlecleucel ) and gilead / kites yescarta ( axicabtagene ciloleucel ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cell|mit fever vulgaris psoriasis Bay|ed etc war say says|kymriah|commenting on the results , joseph jimenez , ceo of novartis , said : “novartis became the first company to commercialize a car-t therapy , entity , in q3 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|mit fever vulgaris psoriasis Bay|CAR Vaccine Therapy CD19 rituximab|kymriah|• entity ( tisagenlecleucel ) is a cd19-directed genetically modified autologous chimeric antigen receptor t-cell ( car-t ) therapy delivered as an intravenous infusion .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|cell|mit fever vulgaris psoriasis Bay|rituximab bortezomib thalidomide docetaxel imatinib|kymriah|yescarta has been approved for the treatment of relapsed or refractory large b-cell lymphoma and entity for the treatment of relapsed or refractory b-cell precursor acute lymphoblastic leukemia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|cell|AND psoriasis vulgaris comparing iii|bortezomib imatinib thalidomide everolimus paclitaxel|yescarta|in 2017 , the fda approved the first two car-t cell therapies , kymriah and entity , after these products demonstrated strong efficacy in select relapsed or refractory b cell malignancies .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND psoriasis vulgaris comparing iii|FDA approval mAbs CD20 pipeline|yescarta|one of these therapies , entity® obtained accelerated approval for treatment of refractory non-transplant-eligible dlbcl patients in october 2017 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND psoriasis vulgaris comparing iii|Asia ago Europe ones FDA|yescarta|finally , two car-t cell therapies were just approved for the treatment of all – kymriah™ ( novartis ) and entity™ ( gilead ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|AND psoriasis vulgaris comparing iii|vaccines MSCs adjuvants vectors ginseng|yescarta|novartis kymriah™ and gileads entity™ , two gene-modified cell-based therapies , are approved in both the united states and europe .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND psoriasis vulgaris comparing iii|chemicals medicines equipment goods wine|yescarta|further , if contaminants are discovered in our supply of entity or in the manufacturing facilities , such manufacturing facilities may need to be closed for an extended period of time to
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|cell|AND psoriasis vulgaris comparing iii|rituximab bortezomib trastuzumab everolimus imatinib|yescarta|in october 2017 , kite obtained fda approval to commercialize entity for the treatment of adults with relapsed / refractory diffuse large b-cell lymphoma .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|cell|AND psoriasis vulgaris comparing iii|bortezomib bevacizumab everolimus gemcitabine capecitabine|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|AND psoriasis vulgaris comparing iii|FDA another historical everolimus sham|yescarta|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to entity or kymriah source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|cell|AND psoriasis vulgaris comparing iii|bortezomib tacrolimus rituximab everolimus bevacizumab|yescarta|the objective of the phase 2 trial is to determine the effect of mavrilimumab on the safety of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|AND psoriasis vulgaris comparing iii|psoriasis BMD scoliosis angiogenesis BD|yescarta|kite has published data on entity in all as well .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND psoriasis vulgaris comparing iii|Medicine Common Food Public goods|yescarta|arcalyst® is a registered trademark of regeneron pharmaceuticals , inc . and entity® is a registered trademark of gilead sciences , inc . , or its related companies . ​5 table of contentspart 
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND psoriasis vulgaris comparing iii|market marketing business trade travel|yescarta|the royalties stem from sales and milestones related to the entity® product .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|AND psoriasis vulgaris comparing iii|ICS bevacizumab sildenafil FDA CAM|yescarta|additionally , in october 2017 , kite received approval from the fda for entity ( axicabtagene ciloleucel ) , formerly known as kte-c19 , for treatment of patients with r / r nhl .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND psoriasis vulgaris comparing iii|approval versions approved formulations FDA|yescarta|both kymriah® and entity® were approved with a rems .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|AND psoriasis vulgaris comparing iii|ones mAbs another approved rituximab|yescarta|two car-t therapies have been approved to treat large b-cell lymphoma , kymriah® and entity® , and others are being tested in clinical trials .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND psoriasis vulgaris comparing iii|patent pharmaceutical market SAR approval|yescarta|pipeline , building on current marketed products and late-stage clinical candidates for patients with hematological malignancies at kite and gilead , including entity® , tecartus® and magrolimab .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('BIO', 1)])|cell|AND psoriasis vulgaris comparing iii|bortezomib bevacizumab everolimus gemcitabine capecitabine|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND psoriasis vulgaris comparing iii|AST ICS OC ACT AK|yescarta|the initial results of axicabtagene ciloleucel ( entity ) , the prognosis of high-grade chemo refractory nhl , is dismal with a medium survival time of a few weeks .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('BIO', 1)])|cell|AND psoriasis vulgaris comparing iii|Chemotherapy rituximab bortezomib Surgery cyclophosphamide|yescarta|entity is a therapy for patients who have not responded to or who have relapsed after at least two other kinds
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|AND psoriasis vulgaris comparing iii|relapsed PFS remission progressed recurred|yescarta|this was notable given the patient had relapsed following treatment with entity® .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|alfa AND vulgaris Beta Culture|GSK TM France Canada BAT|tabelecleucel|recent highlights and anticipated upcoming milestones tab-cel® ( entity ) • two phase 3 clinical studies are ongoing ( match and allele ) to evaluate tab-cel® for patients with ebv+ ptld
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|cell|alfa AND vulgaris Beta Culture|rituximab HSCT BAT everolimus bortezomib|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda- and ema-approved therapy for
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('BIO', 1), ('DIS', 1)])|cell|alfa AND vulgaris Beta Culture|rituximab HSCT BAT bortezomib everolimus|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda and ema approved therapy
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|alfa AND vulgaris Beta Culture|investigators scientists FDA expertise stakeholders|tabelecleucel|with entity poised to potentially become the first approved off-the-shelf t-cell therapy and a robust pipeline of high potential candidates , our ambition
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|vertebral orthopedic ophthalmic facial optic|tendon|and adcon-t / n to be marketed in the 19 european union countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|tendon Achilles ligament plaque tendons|tendon|warnings and precautions risk of tendinitis , entity rupture , peripheral neuropathy and central nervous system effects is increased with use of fluoroquinolones .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|tendon ligament bony dural dura|tendon|and / or product development for various treatments for or involving fracture repair , spine fusion surgery , cartilage defect repair and ligament and entity repair .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|tendon meniscal ligament ACL suture|tendon|graftjacket® maxforce extreme is a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of entity and ligament repairs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|facial orthopedic ophthalmic visceral vertebral|tendon|now being sold in all major countries in the eu , as well as australia and new zealand for use in entity and peripheral nerve surgeries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|tendon ligament bony osseous ligaments|tendon|therapeutic devices utilizing its nonthermal ultrasound technology ( " orthosound " ) for use in medical applications that relate to bone , cartilage , ligament or entity diagnostics and healing .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|teeth ligament pulp tooth ligaments|tendon|extent the gingiva functions as part of the apparatus holding the tooth to the jaw ) , ligament ( including the periodontal ligament ) , entity and / or cartilage .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|neurologic allergic seizure hematologic coagulation|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|seed nutrition gum scalp vegetable|tendon|bone & entity pill it consists of extracts of a variety of chinese medicinal herbs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|neurologic allergic seizure hematologic coagulation|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|tendon muscular musculoskeletal mucosal joints|tendon|the medicinal product is to be taken orally for the purpose of curing bone and entity disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|influenza antimicrobial ocular prescription diarrhea|tendon|warnings regarding the risk of entity related adverse events were already included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|tendon tendons ligament meniscal ligaments|tendon|graftjacket® is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|tendon meniscal ACL mucosal hernia|tendon|by augmenting the strength of the entity repair and incorporating biologically , graftjacket® regenerative tissue matrix increases surgeons confidence in the surgical outcome .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|tendon tendons ligament meniscal ligaments|tendon|graftjacket® matrix is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|mediastin oesophag cellul divertic laryng|tendon|fluoroquinolones are 26 known for several undesirable effects such as entityitis , achilles entity rupture , c . difficile colitis , and hepatotoxicity and central nervous system side effects .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|vertebral orthopedic ophthalmic facial optic|tendon|adcon-l and adcon-t / n to be marketed in the 19 european countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|prescription antimicrobial ocular dosing influenza|tendon|currently , warnings regarding the risk of entity related adverse events are included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|ligament ligaments tendon rotator Bank|tendon|ligament and entity repair ligaments are the soft tissues that connect bone to bone .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|echocardiography VI Ultrasound ultrasonography coagulation|ocular mucosal corneal chromosomal tooth|tendon|further , in july 2008 , the fda requested manufacturers of fluoroquinolones to include a black box warning for entity damage .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|neovascularization peel macular retina plaque|macular mac ocular choroidal retinopathy|macula|optina for diabetic entity edema on october 7 , 2013 , we received positive results from the interim analysis of optina trial for diabetic macular edema .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|neovascularization peel macular retina plaque|scientific ophthalm academic intellectual ophthalmic|macula|company presented preclinical data at the association for research and vision in opthalmology conference in may 2012 , and at the entity society meeting in june 2012 .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|neovascularization peel macular retina plaque|epithelium peritoneum intestine cornea epidermis|macula|the leakage of fluid , solutes , proteins and immune cells cause the entity to swell and thicken .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|neovascularization peel macular retina plaque|choroid photoreceptors epithelium RPE ganglion|macula|described as a partial or total loss of visual field resulting from certain progressive disease or degeneration of the retina , entity or nerve fiber bundle .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|neovascularization peel macular retina plaque|choroid RPE photoreceptors retina vitreous|macula|in patients with dme , leakage from these abnormal blood vessels occurs in the central portion of the retina , called the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|neovascularization peel macular retina plaque|retina pancreas cornea legs thymus|macula|introduction to amd amd is a progressive and irreversible disorder of the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|neovascularization peel macular retina plaque|retina choroid photoreceptors RPE cornea|macula|the entity is the central portion of the retina in the eye and is responsible for both high acuity vision and color
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|neovascularization peel macular retina plaque|colour distance visible acquired outer|macula|according to the entity vision research foundation , as many as 15 million people in the united states suffer from some form of amd , with more
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|neovascularization peel macular retina plaque|retina cornea photoreceptors iris globe|macula|these vessels can leak fluid and blood , which may lead to swelling and damage of the entity causing vision loss .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|neovascularization peel macular retina plaque|V1 VF periphery ON retina|macula|implies , usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) because of damage to the retina .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|neovascularization peel macular retina plaque|wet retinitis degeneration cup sickle|macula|for age-related entityr degeneration , or amd , which is a disorder of the central portion of the retina , known as the entity , that may result in blindness .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|neovascularization peel macular retina plaque|retina cornea globe RPE vitreous|macula|or neovascularization , causes vision loss due to blood and protein - 94 - table of contents leakage below the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|neovascularization peel macular retina plaque|ed next ASC FA FI|macula|the principal investigator of study 003 presented a case report from the first patient to complete the protocol at the entity society meeting on february 19 , 2014 .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|neovascularization peel macular retina plaque|retina cornea RPE epithelium photoreceptors|macula|in the dry form , there is a breakdown of retinal pigment epithelial cells in the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|neovascularization peel macular retina plaque|choroid RPE retina vitreous cornea|macula|the wet form is caused by growth of abnormal blood vessels ( cnv ) under the central part of the retina or entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5)])|tissue|neovascularization peel macular retina plaque|choroid retina iris RPE CNV|macula|an eye disease characterized by the growth of abnormal blood vessels under the central part of the retina , called the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|neovascularization peel macular retina plaque|Peri Mac Vit Gi Bruc|macula|entityr edema is the build-up of fluid that can cause abnormal swelling of the macula , the portion of the retina responsible for central vision and color perception .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|neovascularization peel macular retina plaque|choroid retina periphery photoreceptors RPE|macula|the central portion of the retina is the entity , which is the region responsible for seeing color and the acute central vision necessary for activities such as reading , face
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|neovascularization peel macular retina plaque|V1 retina periphery cornea V2|macula|that usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|neovascularization peel macular retina plaque|retina choroid vitreous photoreceptors periphery|macula|this process , known as angiogenesis or neovascularization , results in fragile blood vessels that leak fluid and blood into the entity , the center portion of the retina .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cervix plexus neovascularization sheath adenocarcinoma|fibres epithelium dermis tendon tendons|perineurium|the lamellar structure of the entity and a deficiency in collagen packing in the endoneurium was observed more frequently and to a larger extent in fibromyalgia
OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|lidocaine botulinum bupivacaine neuromuscular blockers|dermis stroma cytoplasm nerves epidermis|endoneurium|the lamellar structure of the perineurium and a deficiency in collagen packing in the entity was observed more frequently and to a larger extent in fibromyalgia patients than in controls .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium stroma fibroblasts glands nerves|urothelium| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium fibroblasts stroma nerves endothelium|urothelium|months post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|urothelial superficial muscular mucosal submucosal|urothelium|bladder carcinoma is a specific form of bladder cancer resulting from the development and progression of cancerous tumors within the entity layer .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|ureter pelvis urethra urothelial ovary|urothelium|eligible patients included those with transitional cell carcinoma of the entity , including renal pelvis , ureters , urinary bladder , and urethra .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|next delivered intermittent injected vaginal|urothelium|not effectively permeating the entity  rtgel delivered treatment to the bladder as expected with dwell time of up to 10 hours
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium barrier cytoskeleton cilia stroma|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium fibroblasts stroma endothelium nerves|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium epithelia stroma lining medulla|urothelium|upper tract urothelial carcinoma ( utuc ) utuc refers to malignant changes of the entity ( the epithelial lining ) of the upper urinary tract of the calyces , renal pelvis and ureter .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium fibroblasts glands stroma endothelium|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium epidermis dermis stroma esophagus|urothelium|beneath the entity , there is a layer called the lamina propria .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|cervix cornea gut esophagus intestine|urothelium|apollo trial did not meet the primary endpoint , believed to be the result of botox not effectively permeating the entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium barrier cytoskeleton cilia stroma|urothelium|one theory of pbss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|urethra epithelium cervix vagina reservoir|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag , layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium barrier cytoskeleton cilia stroma|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium microenvironment stroma endothelium barrier|urothelium|implantation of stray " floating " tumor cells in areas in which the entity has been disrupted may be followed by the growth of the implanted cells to form a new tumor .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|epithelium barrier cilia cytoskeleton microcirculation|urothelium|one theory of bpss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|urothelial tubular squamous transitional luminal|urothelium|the innermost lining is comprised of cells called urothelial or transitional cells , and this inner layer is called the entity or transitional epithelium .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|urethra epithelium cervix vagina capsule|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|cervix adenocarcinoma epithelium dysplasia proliferative|integrity innervation contraction anatomy microcirculation|urothelium|be well positioned , as it will address both the acute pain the patient experiences and the dysfunctional aspect of the entity of the bladder wall .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium stroma crypt rectum lumen|epithelium|overview of ibd ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the entity and the submucosa of the colon .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium plexus retina zone bundle|epithelium|key portions of the eye that were evaluated for levels of drug remaining were the sclera-choroid-retinal pigmented entity , or scr , the neural retina and the vitreous .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium plexus zone layers epithelia|epithelium|in occult lesions , all of the blood vessels are below the retinal pigment entity , or rpe , and the areas on angiograms have a stippled appearance .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium epithelia integrity innervation parts|epithelium|this includes injuries to the hematopoietic and immune systems , the entity of the digestive tract and hair follicles .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|fibroblasts epidermis fibroblast epithelium keratinocytes|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|fibroblasts epidermis fibroblast keratinocytes epithelium|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity , which should lessen the occurrence of ras .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium epithelia plexus photoreceptors photoreceptor|epithelium|by the much greater amount of the fluorescent protein expressed ) with aav8 as compared to aav2 in the retinal pigment entity ( rpe ) and to the photoreceptor ( pr ) layer .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium gut intestine microcirculation cytoplasm|epithelium|of calcium and phosphate ions , which are hypothesized to exert their beneficial effects by diffusing into intracellular spaces in the entity and permeating the mucosal lesion in mucositis .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|graft grafts endothelium epithelium autograft|epithelium|these events are commonly observed following removal of the corneal entity and in the treatment group of our trials , occurred at a higher incidence than observed in control patients .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|architecture morphometry integrity maturation densities|epithelium|pathologic analysis showed marked effects on breast duct entity in ducts treated with either drug compared with untreated ducts .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium endothelium barrier lumen architecture|epithelium|blood causes a prolonged period of low blood flow to the intestines that can lead to damage to the intestinal entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium lumen crypt villous tree|epithelium|the expression of il-15 in the intestinal entity is necessary for villous atrophy in animal models of celiac disease and circumstantial evidence suggests this to be the case
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium endothelium stroma graft cornea|epithelium|the procedure involves the removal of " bowman  s layer , " an intermediate layer between the entity ( outer corneal layer ) and the stroma ( middle corneal layer ) .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium compartment sheath envelope niche|epithelium|the hair matrix entity is one of the fastest growing cell populations in the human body .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|mucin IgA mucus barrier mediators|epithelium|the gi tract is highly sensitive due to the continuous need for crypt stem cells and production of mucosal entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium plexus epithelia photoreceptors layers|epithelium|loss of the functional oca2 protein results in a lack of pigment in the retinal pigment entity and the underlying choroid layers .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium plexus pigment photoreceptors epithelia|epithelium|for lca2 , retinal function was restored by reconstituting gene function in the retinal pigment entity ( rpe ) .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|cavity milieu circulation cavities compartment|epithelium|the nasal administration is intended to determine if physiologic measurement of cftr function can be obtained in the nasal entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|epithelium lumen milieu cavity barrier|epithelium|our vaginal products adhere to the vaginal entity until discharged upon normal cell turnover , a physiological process that can take 72 hours , or longer , and provide sustained and
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma epithelium dysplasia squamous neovascularization|cavity epithelium bulb lumen tip|epithelium|however , the nasal entity is the most accessible site for measuring cftr function in humans and provides a human model of epithelial cell uptake
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|embryo mesoderm embryogenesis endometrium embryos|glia epithelium neuron mesenchymal mesoderm|ectoderm|and the capability to differentiate into cells representing the three germ layers - endoderm ( gut epithelium ) , mesoderm ( striated muscle ) and entity ( neural epithelium ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|tissue|embryo follicle endometrium epithelium epithelia|dendritic autologous somatic progenitor islet|endoderm|the third patent , granted in the united states , covers the method for deriving entity cells using stem cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|embryo follicle endometrium epithelium epithelia|mesoderm embryo myogenic somatic pluripotent|endoderm|territory patent no . general subject matter expiration us 7 , 763 , 466 method to produce entity cells may 2025 us 7 , 955 , 849 method of enriching population of mesoderm cells may 2023 us
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|tissue|embryo follicle endometrium epithelium epithelia|NK Kupffer dendritic mast mesenchymal|endoderm|in particular , entity cells make cells of internal organs such as the lung , pancreas , and liver as well as other internal cell types .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|embryo follicle endometrium epithelium epithelia|your dead dendritic progenitor effector|endoderm|by way of example , we are currently a party to an interference proceeding that involves patent filings for making entity cells from hescs .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|embryo follicle endometrium epithelium epithelia|mesoderm som trophoblast neuro haemat|endoderm|that the derivation of any of the entityal lineage cells from embryonic stem cells would necessarily pass through the definitive entity stage .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|embryo follicle endometrium epithelium epithelia|approval publication conclusions proof investigators|endoderm|if we are not successful in the viacyte appeal , viacyte would retain its patent claims directed to definitive entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3)])|tissue|embryo follicle endometrium epithelium epithelia|pancreas islets epithelium islet intestine|endoderm|definitive entity is an early pre-cursor of numerous cell types including liver and β-cells of the pancreas that could potentially treat diabetes ,
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|embryo follicle endometrium epithelium epithelia|NK Kupffer Tumor Stem Beta|endoderm|entity cells develop into the internal organs such as the heart , liver , pancreas and intestines , among other cell types .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|tissue|embryo follicle endometrium epithelium epithelia|dendritic mesenchymal mononuclear somatic stromal|endoderm|australia patent 2010200610 – the claims in this patent relate to cell cultures comprising entity cells , one of the three major lineages of cells that make up the human body .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|tissue|embryo follicle endometrium epithelium epithelia|dorsal primitive differentiating inner ventral|endoderm|stem cells and pluripotency stem cell primative and thus unspecialized self-renewing can differentiate into cells with specific functions ectoderm mesoderm entity skin hair brain nerves etc .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|tissue|embryo follicle endometrium epithelium epithelia|mesoderm glia osteoblasts adipocytes neuron|endoderm|mesentity cells are precursor cells that differentiate into mesoderm and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|tissue|embryo follicle endometrium epithelium epithelia|progenitor spindle blast precursor dendritic|endoderm|these rulings related to interference proceedings involving patent filings relating to definitive entity cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|angiogenesis CD34 AND neovascularization embryo|tooth enamel hair neuron embryo|mesoderm|emt is essential for numerous developmental processes including entity formation and neural tube formation .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|angiogenesis CD34 AND neovascularization embryo|Muscle Stem Tumor satellite mesenchymal|mesoderm|entity cells develop into muscle , bone and blood , among other cell types .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|angiogenesis CD34 AND neovascularization embryo|next pharmaceutical Drosophila eukaryotic parasite|mesoderm|developing a drug-targeting platform based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2), ('DRUG', 1)])|tissue|angiogenesis CD34 AND neovascularization embryo|hematopoiesis erythropoiesis embryogenesis MDS CML|mesoderm|the libraries and screens will focus on genes important to entity and early hematopoietic development .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|mesoderm mesenchymal epidermal epidermis germline|mesoderm|produce such cells , and applications of such cells for es cell-derived immature pluripotent precursors of all the cells of the entity and endoderm lineages .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|called tuber Wnt seed cab|mesoderm|table of contents raptors entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|next pharmaceutical translational latest Drug|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|angiogenesis CD34 AND neovascularization embryo|epidermis stroma endothelium epithelium mesoderm|mesoderm|in the early embryo , the middle layer of cells ( known as the entity ) and certain portions of the outer cell layers give rise to groups of cells that differentiate into bone marrow stroma ,
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|formulation awaiting scaffold throughout Fab|mesoderm|promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|translational pharmaceutical next therapeutics accelerated|mesoderm|- 38 - table of contents our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|angiogenesis CD34 AND neovascularization embryo|pharmaceutical next Drosophila latest parasite|mesoderm|are developing drug-targeting platforms based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|mesoderm epidermis epithelium oocytes mesenchymal|mesoderm|mesendoderm cells are precursor cells that differentiate into entity and endoderm .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|formulation awaiting throughout ex warrants|mesoderm|and drug delivery platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|angiogenesis CD34 AND neovascularization embryo|mesenchymal mesoderm glial epidermal fibroblast|mesoderm|the seven new cell lines have markers of diverse entity and neural crest cell types and are designated w11 , z2 , sk31 , sm35 , t36 , en51 , and en55 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|tissue|angiogenesis CD34 AND neovascularization embryo|glioblastoma multidrug glioma scaffold microtubule|mesoderm|is a promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated protein ( rap ) and entity development protein ( mesd ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|own latest next translational innovative|mesoderm|· our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|next pharmaceutical translational latest Drug|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|next latest pharmaceutical own translational|mesoderm|• our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|next own translational latest pharmaceutical|mesoderm| our entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|angiogenesis CD34 AND neovascularization embryo|skeleton limbs extremities embryo jaw|mesoderm|mesenchymal stem cells ( mscs ) : embryonic-like cell capable of differentiating into multiple tissues of the entity , including cartilage , bone , tendon , ligament , muscle , stroma and fat .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI adenocarcinoma C3 IHC AND|lamina substantia stratum zona otitis|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial ( ht-29 ) cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina fascia pars muscular stratum|lamina|beneath the urothelium , there is a layer called the entity propria .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina gut muscular substantia biliary|lamina|the adaptive response is mediated by gluten-reactive cd4+ t cells in the entity propria that recognize gluten-derived peptides when presented by the hla class ii molecules dq2 or dq8 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina substantia gut pars muscular|lamina|gliadin fragments in celiac disease , they are able to pass thru the leaky paracellular pathway from the lumen to the entity propria , where the immune cells reside and are then activated .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina substantia pars zona submuc|lamina|targeted localization of amt-101 to the gi tissue entity propria is expected to translate into clinically meaningful reductions in inflammation and disease activity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina muscular submuc submucosal mucosal|lamina|gi tissue or entering into systemic circulation : when designing our product candidates , we can target the therapeutic payload to the entity propria of the local gi tissue .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina muscular fascia substantia submuc|lamina|in healthy bowel wall , bacteria cannot pass from the lumen to the entity propria because tight junctions are maintained between the epithelial cells ( intact barrier function of the bowel wall ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|FDA authority him publication investigators|lamina|on february 25 , 2015 , the company entered into the license agreement with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina muscular substantia gut submuc|lamina|at any given time , over 70% of an individuals immune system resides in the entity propria , which is the target-rich tissue of the intestinal tract .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|dura pedicle cage graft autograft|lamina|in a decompressive laminectomy , the surgeon removes bone , known as the entity , from the back part of the symptomatic vertebrae over the spinal canal to create more space for , and relieve pressure
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina my mucous substantia muscular|lamina|cell-secreted gp96-ig-peptide complexes induce entity propria and intraepithelial cd8+ cytotoxic t lymphocytes in the intestinal mucosa .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|India Brazil California Belgium Mexico|lamina|entity is a private corporation over which dr . raouf guirguis has sole control .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|financial trade pharmaceutical pharmacy private|lamina|&#160 ; on february 25 , 2015 , the company entered into a license agreement with entity equities corporation ( &#8220 ; entity&#8221 ; ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina substantia stratum zona ciliary|lamina|these data were collected in tests in human entity cribrosa cells grown from human optic nerve heads and from human intestinal epithelial cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI adenocarcinoma C3 IHC AND|disk specimen herniation portion slip|lamina|of all or part of a damaged disc , and laminectomy , which is the removal of all or part of a entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina substantia gut muscular pars|lamina|in the gut antigens such as gluten are processed by resident dendritic cells in the entity propria which then migrate to the local mesenteric 31 lymph nodes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina gut substantia corpus propria|lamina|disease activity index , colonic leukocytic infiltration , entity propria neutrophils and colonic tnf expression were used as endpoints .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina substantia stratum zona ciliary|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|VI adenocarcinoma C3 IHC AND|lamina muscular substantia pars fascia|lamina|ta and cis are limited to the urothelial layer , and t1 is limited to the layer below , which is the entity propria .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI adenocarcinoma C3 IHC AND|crypt cholangi bronchi laryngeal Mycoplasma|lamina|by inhibiting factor 5a , we were able to reduce tnf-a induced apoptosis by 80% in entity cribrosa cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|graft myocardium grafts limbs intestine|myocardium|finally , the cells could promote regeneration of viable new tissue , improving the functional capacity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium circulation arteries hearts legs|myocardium|thus such a molecule should have desirable properties in experiments aimed at inducing collateral circulation in the entity of patients with coronary stenosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium ventricle microcirculation mitochondria myocytes|myocardium|may also provide information on cardiac mitochondrial membrane potential , enabling global and regional assessment of the electro-physiologic integrity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|lungs abdomen thorax myocardium esophagus|myocardium|characterized by thoracic pain and a feeling of suffocation , most often due to anoxia ( lack of oxygen supply ) to the entity precipitated by physical exertion or excitement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|lungs kidneys legs livers arteries|myocardium|the primary objectives of this trial are to evaluate the safety and efficacy of injecting 150 million mpcs into the native entity of lvad recipients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|electrode polymer electrodes fibroblasts neuron|myocardium|cm1 has been shown to couple electrically and mechanically with the host entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium vulnerability infarct cardiomyocytes endothelium|myocardium|the death of myocardial cells first occurs in the area of entity that is most distal to the arterial blood supply , the endocardium .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium septum cavity walls chamber|myocardium|potassium channels that control normal functioning of the middle layer of heart wall composed of cardiac muscle , or the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium hearts graft myocytes atria|myocardium|the hesc-cm treated heart ( right ) shows a large graft of human heart muscle ( green ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium myocytes myocyte septum cavity|myocardium|appear to target these channels which mediate atrial arrhythmia without disrupting potassium channels that control normal functioning of the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium hearts myocytes cardiomyocytes graft|myocardium|the heart of an nhp by hesc-cm transplantation the saline-treated heart ( left ) shows infarct scar tissue ( blue ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium hearts brains zones zone|myocardium|responsive relationship , with higher doses of bone marrow mononuclear cells resulting in reduced fibrosis and increased microvascular change in infarcted entity 60 days after treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium clinic zone periphery compartment|myocardium|the targeted 24 table of contents cardiomyocytes are expected to produce sustained therapeutic protein levels in the entity where it is needed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium zones brains arteries vessels|myocardium|when injected into ischemic entity , mlcs are very potent inducers of large caliber arteriogenesis compared to 104 table of contents index to financial statements
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium infarct retina brains pancreas|myocardium|bfpet has been designed to effectively differentiate among those cells of the entity that are ischemic , infarcted and those that are healthy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium vessels arteries grafts veins|myocardium|physicians to screen for coronary artery disease , to assess flow rates and flow reserve , and to distinguish viable from nonviable entity for bypass and transplant candidates .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium vessels hearts recipients territories|myocardium|if blood flow can be restored to at-risk entity , more heart muscle can be saved from irreversible damage or death .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|apex myocardium border septum infarct|myocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the entity and ultimately to the epicardium .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|bloodstream cornea microcirculation lungs capillary|myocardium|this results in the solution entering the entity via post capillary venules .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myocardium myocardial cardiomyopathy angina pectoris|myocardium scar ventricle endothelium hearts|myocardium|we believe that ik-5001 will work as a temporary structural support while the damaged entity heals by replacing the dead tissue that would normally support the wall of the heart .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma mesothelioma peritoneum Primary NOS|your grant another you USD|mesothelium|the company will license entity mab from the nih and in return the agreement , requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma mesothelioma peritoneum Primary NOS|peritoneum stroma epithelium lungs pleural|mesothelium|mesothelioma mesothelioma is a rare form of cancer in which malignant cells develop in the entity , a protective lining that covers most of the bodys internal organs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|tissue|adenocarcinoma mesothelioma peritoneum Primary NOS|chimeric monoclonal dendritic licensed liposomal|mesothelium|of march 22 , 1999 , the company and nih entered into an exclusive worldwide licensing agreement to develop and commercialize a entity antigen therapy ( mesothelin mab ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma mesothelioma peritoneum Primary NOS|your grant another USD you|mesothelium|the company will license entity mab from the nih and in return , the agreement requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma mesothelioma peritoneum Primary NOS|peritoneum pleural lungs stroma mediastinum|mesothelium|malignant pleural mesothelioma is an aggressive form of cancer that occurs in the entity , the thin layer of tissue that covers the lungs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma mesothelioma peritoneum Primary NOS|lungs mediastinum peritoneum abdomen thorax|mesothelium|differentiating mesothelioma from adenocarcinoma mesothelioma is a cancer that develops in the entity - a protective sac that covers most of the bodys internal organs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma mesothelioma peritoneum Primary NOS|parenchyma walls periphery bulk parts|mesothelium|when ovarian cancer spreads to the entity of the organs within the peritoneal cavity , it can result in encasement of these organs with significant pain and eventual
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma mesothelioma peritoneum Primary NOS|stroma bulk peritoneum epithelium lungs|mesothelium|about malignant mesothelioma malignant mesothelioma is a cancer that originates in the entity – the tissue that surrounds different organs in the body .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|fertilization VI mineralization P2Y proteomics|dentin dentine enamel pulp teeth|dentine|the lactic acid erodes the mineral in enamel and entity , weakening the tooth and ultimately resulting in decay .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|enamel endodontic investigational autologous ideal|enamel|ongoing dental projects include : o an entity matrix protein-based product for endodontic therapy ( treatment of dental pulp ) - a phase i trial is underway .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|enamel tooth pulp teeth tubules|enamel|fluorinex has developed a unique device that delivers fluoride ions directly to the tooth entity via a sophisticated electro-chemical technique .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|autologous investigational injectable enamel Oral|enamel|o an entity matrix protein-based product to reduce pain and discomfort following scaling and root planing of periodontal pockets - a phase ii
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|Zealand Africa Netherlands America market|enamel|in nail entity , sally hansen® , the number one brand , increased its market share to 27 . 4% .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|colored coat filter black rubber|enamel|toilet core walls shall receive 2 coats latex entity paint .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|painted wood colored wooden cotton|enamel|d . exposed columns and ironwork at open ceiling areas shall be cleaned , primed painted with semi-gloss entity paint to cover .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|Den Oral Pro Dental White|enamel|entity care is the first toothpaste to combine the cleaning and whitening properties of baking soda with fluoride and patented liquid calcium to fill tooth surfaces and restore enamel luster .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|enamel dentin calcified salivary dentine|enamel|the active ingredient is the entity matrix protein amelogenin and the product has been launched in north america , europe and japan for treatment of patients who
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|teeth enamel pulp roots apex|enamel|derives its energy from carbohydrate metabolism as it converts dietary sugar to lactic acid which , in turn , erodes the tooth entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|mouth Oral tooth periodontal Dental|enamel|- more - early in the quarter , the company launched arm & hammer entity care toothpaste , its most important oral care initiative in several years .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|phosphatase extraction mineralization fertilization enamel|outdoor hot floor wet dry|enamel|wash and polish all mirrors , powder shelves , bright work and entity surfaces , including flushometers , piping , toilet set hinges , and all metal .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|tags cover marks shade tips|enamel|will continue to market multiple nat robbins color cosmetics items including lipliner pencils , lipsticks , eyeliner pencils , eye shadow , mascara , nail entity and assorted accessories .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|phosphatase extraction mineralization fertilization enamel|industrial alcoholic outdoor ice apple|enamel|simply wow™ was compared to orange clean , fantastik and formula 409 for the ability to remove cooked-on grease from an entity stovetop .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|cover dressing colour pigmentation covering|enamel|number of its principal product categories in the u . s . mass-market distribution channel , including the lip , eye , face makeup and nail entity categories .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|phosphatase extraction mineralization fertilization enamel|enamel teeth bodies pulp bones|enamel|hap is naturally found in bone and tooth entity and is rapidly integrated into the human body .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|phosphatase extraction mineralization fertilization enamel|disposal ulcers preparations dressing aging|enamel|remover and nail care products in certain countries outside the u . s . in 2003 , the company launched colorstay always on nail entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|substitute dressing cream belt blocker|enamel|on net sales of a hair-off mitten that is a depilatory-product accessory , and nutra nail 60 , a fast- acting nail entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|tooth enamel pulp resin dentin|enamel|as a person ages the adult teeth often become darker due to changes in the mineral structure of the tooth , as the entity becomes less porous and phosphate-deficient .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|floor cut exterior shelf ground|enamel|floors , hand brush corners and hand brush toilet edges with approved germicidal detergent solution . 2 . wash completely all partitions , tile walls and entity surfaces .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|phosphatase extraction mineralization fertilization enamel|enamel pulp plaque dentin dentine|enamel|tooth decay is characterized by the dissolution of entity and dentin , eventually resulting in the destruction of the entire tooth .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Calcium calcification implants titanium phosphatase|junctions ligament apex walls barrier|cementum|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root entity , gingiva and / or periodontal ligament .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Calcium calcification implants titanium phosphatase|dentin canals dentine epithelium lamina|cementum|by coating the surface of the exposed dental root with emdogaingel during periodontal surgery , new root entity , periodontal ligament fibers , and surrounding bone tissue can be formed .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Calcium calcification implants titanium phosphatase|apex epithelium margin ligament floor|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jawbone and cushions the
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Calcium calcification implants titanium phosphatase|apex epithelium ligament margin dentin|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jaw bone and cushions
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Calcium calcification implants titanium phosphatase|dentin dentine enamel teeth pulp|cementum|the extent , the gingiva functions as 6 7 part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|Calcium calcification implants titanium phosphatase|teeth nerves pulp ligaments vessels|cementum|the periodontal setting , these agents do not directly stimulate the repair of other important tissues such as periodontal ligaments or entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Calcium calcification implants titanium phosphatase|dentin dentine enamel teeth pulp|cementum|only to the extent , the gingiva functions as part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Calcium calcification implants titanium phosphatase|ligament tendon pulp capsule tooth|cementum|are utilized even though these methods do not have the same capability as emdogain of regenerating the tissues - bone , entity and ligament - that make up the tooth-supporting structures .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|probing plaque psoriasis Ability diseased|mouth teeth tooth lips tongue|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provide a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|probing plaque psoriasis Ability diseased|teeth mouth tooth lips tongue|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provides a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|probing plaque psoriasis Ability diseased|tendons bones graft nerves teeth|periodontium|these patents relate to the biodegradable in situ forming implants and the biodegradable system for regenerating the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|probing plaque psoriasis Ability diseased|teeth mouth tongue TMJ PDL|periodontium|dr . caton has conducted many studies evaluating various treatment modalities for periodontitis and other diseases involving the entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium SMCs myocytes walls beds|endothelium|drug candidate indicates that consistent increases in gb3 levels were measured in cardiomyocytes ( as opposed to decreases measured in vascular entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|neovascularization AND CD31 eNOS endothelium|board list section membership journal|endothelium|research articles , serves as an editorial board member to several biomedical journals and is the founder of the biomedical journal entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium stroma dermis intima epithelium|endothelium|in the inflammatory component , white blood cells begin to roll along and then adhere to the entity , the thin layer of cells that lines the interior surface of blood vessels .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium epidermis epithelium nerves dermis|endothelium|that the company believes may be important in identifying unique sites on the lining of the blood vessels or the entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium microcirculation vasculature retina lumen|endothelium|atherosclerotic plaque to 732 nanometer light delivered through a catheter resulted in elimination of the lesions without damage to the entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium intima ECM aorta arteries|endothelium|atherosclerotic apoe ko mice corresponding to initial steps of atherosclerosis that comprise cell to cell adhesion of monocytes / macrophages to the entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium epithelium stroma monocyte erythrocyte|endothelium|the interaction between certain cell adhesion molecules on the surface of both the leukocyte and the entity facilitates these contacts .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 1)])|tissue|neovascularization AND CD31 eNOS endothelium|leukocytes endothelium platelets neutrophils monocytes|endothelium|into inflamed areas because sle ( x ) present on the surface of white blood cells binds to selectin molecules present on activated entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium platelets arteries bloodstream vessels|endothelium|nitric oxide produced by the entity also inhibits the clumping of platelets , which are cells in the blood that promote clotting , and the adhesion of platelets
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|neovascularization AND CD31 eNOS endothelium|intima ECM endothelium SMC SMCs|endothelium|initially , this new tissue consists of healthy cells from the lining of the arterial wall ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|neovascularization AND CD31 eNOS endothelium|sprouting outgrowth circulation maturation remnants|endothelium|large caliber arteriogenesis compared to only small vessel angiogenesis obtained with hematopoietic stem cells which only give rise to the entity of capillaries .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|tissue|neovascularization AND CD31 eNOS endothelium|thrombus endothelium clot microcirculation vessels|endothelium|clot is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium thrombus microcirculation vessels vasculature|endothelium|cascade is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium epithelium retina SMCs walls|endothelium|these experiments used cells important in human disease and aging--retinal pigment epithelium , fibroblasts , and vascular entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium beds walls plaques SMCs|endothelium|white blood cells express carbohydrates on their surfaces that bind to e-selectin that is present on inflamed vascular entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium epithelium vasculature retina bloodstream|endothelium|specifically , we believe that by inhibiting selectin-mediated adhesion of white blood cells to the entity , rivipansel prevents propagation of voc and promotes early resolution .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium intima arteries retina dermis|endothelium|the entity , a single-cell lining of the arteries that acts as an interface between the blood and arterial wall , is impaired in
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|tissue|neovascularization AND CD31 eNOS endothelium|vasculature vessels endothelium platelets epithelium|endothelium|protein markers , unique to the surface of the entity in specific organs and those markers that distinguish tumor blood vessels from those vessels in healthy tissue , are thought to
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium plaque intima epithelium vasculature|endothelium|an overgrowth of the entity that forms capillaries and lines blood vessel interiors contributes to atherosclerosis .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 5), ('DIS', 3)])|tissue|neovascularization AND CD31 eNOS endothelium|endothelium platelets RBC leukocytes erythrocytes|endothelium|binding of all three types of selectins and inhibit the selectin-mediated recognition and binding of white blood cells to the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|peel Combining Formation Classification Fib|TMJ allograft meniscus ACL capsule|fibrocartilage|another type of cartilage ( entity ) serves a shock-absorbing function in the knee and in the spine between the vertebrae .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|tissue|peel Combining Formation Classification Fib|deposits degeneration chondrocytes synovitis epithelium|fibrocartilage|biopsies from 135 of 141 of these re-looks showed the development of meniscus-like entity , confirming the devices effectiveness as a surgical mesh .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|endometrium ligament peel dividing neovascularization|absent fibroblasts astrocytes cytoplasm glia|perichondrium|model was completed and bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|endometrium ligament peel dividing neovascularization|absent roots cytoplasm mitochondria neither|perichondrium|by dr . yu yamaguchi , bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|neovascularization narrowing proliferative calcification vessels|epithelium walls architecture lumen capillaries|mesangium|igan is a nonsystemic renal disease that is characterized by predominant iga deposition in the glomerular entity , causing mesangial proliferation and fibrosis .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|neovascularization narrowing proliferative calcification vessels|epithelium architecture capillaries walls lumen|mesangium|iga nephropathy igan is a common glomerulopathy diagnosed by the predominant histologic presence of galactose-deficient iga1 deposits in the glomerular entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|tissue|neovascularization narrowing proliferative calcification vessels|walls lumen cytoplasm periphery bulk|mesangium|these iga containing immune complexes deposit in the entity of glomeruli in the kidney and are proinflammatory .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|tissue|neovascularization narrowing proliferative calcification vessels|glomeruli kidneys glomerular nephron tubules|mesangium|chronic activation of inflammatory pathways also leads to long-term structural alterations in the entity , which results in reduced glomerular surface area and gfr .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|tissue|embryo plexus stromal neuroblastoma cervix|Stem Sertoli Schwann NK Endothelial|neuroectoderm|entity cells are committed to developing into cells of the skin and nervous systems .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|embryo plexus stromal neuroblastoma cervix|mesoderm mesenchymal granulosa endocardial stromal|neuroectoderm|with the differentiation signals resulting from the physical attributes of the cell culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('BIO', 3), ('OTHER', 3), ('DIS', 1)])|tissue|embryo plexus stromal neuroblastoma cervix|Stem Sertoli Langerhans Skin Schwann|neuroectoderm|entity cells are committed to developing into cells of the skin and cells of the nervous system .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|tissue|embryo plexus stromal neuroblastoma cervix|mesoderm myoblasts cardiomyocytes adipocytes myotubes|neuroectoderm|van rooijen m , xu x , zweigerdt r , mummery c , passier r . insulin redirects differentiation from cardiogenic mesoderm and endoderm to entity in differentiating human embryonic stem cells .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|embryo plexus stromal neuroblastoma cervix|mesoderm mesenchymal granulosa endocardial stromal|neuroectoderm|together with the differentiation signals resulting from the physical attributes of the culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tons cervix adenocarcinoma eosinophils squamous|clip sponge suction stick shower|tonsil|the company introduced during fiscal 1995 a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|tons cervix adenocarcinoma eosinophils squamous|hemostatic Surgical vaginal disposable sterile|tonsil|( b ) entity sponges - a round , fiber filled gauze constructed with a strong abdominal tape string sewn into the sponge to anchor
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|tons cervix adenocarcinoma eosinophils squamous|pancreas cervix lungs ovary esophagus|tonsil|tumor shrinkage was also seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tons cervix adenocarcinoma eosinophils squamous|colorectal trophoblast synovial bronchial chori|tonsil|tjx7 has been shown to completely inhibit the migration of primary human entity b cells .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tons cervix adenocarcinoma eosinophils squamous|clip cutting suction sponge shower|tonsil|the company has also introduced a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are used in a variety of surgical procedures .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|tons cervix adenocarcinoma eosinophils squamous|pancreas cervix lungs ovary esophagus|tonsil|tumor shrinkage also was seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|tons cervix adenocarcinoma eosinophils squamous|cutting piercing suction blunt disposable|tonsil|products used primarily in the operating room environment ; medical action introduces a line of specialty sponges , which include dissecting sponges , entity sponges , stick sponges and eye spears .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|bones BMD joints functionality teeth|cartilage|it has a dual method of action that could provide the unique benefit of protecting bones and preserving entity in patients with osteoarthritis and osteoporosis , all in one medication .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|corneal meniscal chondrocyte ACL tracheal|cartilage|in comparison with tissue stiffness , streaming potentials measured showed almost identical behavior for the normal and degraded entity explant .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|meniscal tendon anatomical bony ligament|cartilage|developed and commercialized chondrocelect , the first cell-based medicinal product to receive marketing authorization from the ema , which was indicated for entity repair in the knee .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|degeneration BMD walking VI Osteoarthritis|meniscal biomechanical ACL anatomical meniscus|cartilage|the secondary endpoints were entity repair at 12 months by assessment of changes of the knee joint entitys volume measured with 3d spgr quantitative mri ,
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|callus osteoclasts osteoblasts hydroxyapatite osteocalcin|cartilage|these compounds induce the formation of entity and regenerates new bone .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|degeneration BMD walking VI Osteoarthritis|stimulus sensor sound speech specimen|cartilage|the handle ; o software for the acquisition of electrical signals and for the analysis and interpretation of data to quantify entity quality ; and o a computer system .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|degeneration BMD walking VI Osteoarthritis|semen histological specimen oocyte histologic|cartilage|the simplicity of the technique for the assessment of entity quality was demonstrated .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|degeneration BMD walking VI Osteoarthritis|tendon ligament dentine tooth dentin|cartilage|in both of these prior positions dr . christgau worked in the area of bone and entity research .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|capsule joints capsules tendons ligament|cartilage|disease that affects almost 1% of the adult population worldwide and it ultimately results in irreversible damage of the joint entity and bone .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|chondrocytes apparatus capsule discs lining|cartilage|oa background oa is a joint disorder involving the degeneration of the articular entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|degeneration BMD walking VI Osteoarthritis|capsule compartment discs parts facet|cartilage|treatment of various injuries and degeneration of other tissue structures such as the intervertebral disc of the spine and articular entity of degenerated joints .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|lungs skull joints bones nerves|cartilage|sarcomas are cancers of the bone , entity , fat , muscle , blood vessels , or other connective or supportive tissue .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|degeneration BMD walking VI Osteoarthritis|nerves vessels Tissue arteries barrier|cartilage|entity on any of these surfaces can be damaged due to disease or injury , leading to pain and inflammation requiring knee
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|tissue|degeneration BMD walking VI Osteoarthritis|mineralization osteogenesis BMD ossification alignment|cartilage|it assists in regained mobility as it refurbishes entity in the bone end of joints , consisting of the same cellular structure , collagen type ii .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|degeneration BMD walking VI Osteoarthritis|ACL hernia cleft endovascular meniscal|cartilage|a fully functional clinical version of the arthro-bst ( tm ) was presented at the third meeting of the international entity repair society ( icrs ) in sweden in april 2000 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|degeneration BMD walking VI Osteoarthritis|tendon joints tendons ligaments nerves|cartilage|from a mouse with cia with no treatment showing severe inflammation in the joint with sever damage to bone and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|degeneration BMD walking VI Osteoarthritis|fibroblasts lining leucocytes chondrocytes spaces|cartilage|major teaching hospital and other institutions have demonstrated that the use of the company  s compounds inhibit the loss of synovial entity in the joint .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|chondrocytes discs bones layers meniscus|cartilage|this condition grows more severe over time and leads to progressive thinning of articular entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|nerves adipocytes fibroblasts endothelium tendons|cartilage|product development programs utilize adult bone marrow stem and progenitor cells for forming solid tissues such as bone , vascular tissue , entity , and blood and immune system cells .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|degeneration BMD walking VI Osteoarthritis|hair mucosal bony histological accelerated|cartilage|additional studies are being carried out to confirm the entity regrowth .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|embryo adenocarcinoma fibroblasts epithelium proliferative|maturation morphogenesis patterning plasticity epithelium|mesenchyme|the scientific publication demonstrates that 4d20 . 8 cells possess site-specific markers of craniofacial entity , in particular , markers of proximal mandibular entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|glioma astrocytes neuroblastoma Primary CD34|barrier astrocytes glia microglia parenchyma|ependyma|filters toxins 1 cerebrospinal fluid ( csf ) – brain barrier / glymphatic system : extracts toxins from the brain 2 ventricle brain entity ( glial cells ) astrocytes ( glial cells )
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|extremity Ability cervix surgeon psoriasis|breasts nipple cheeks lips ovaries|umbilicus|it usually involves the face , digits , arms , inguinal area , anogenital area , entity and nipples , and can also affect the hair .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|extremity Ability cervix surgeon psoriasis|ankle heel endpoint waist start|umbilicus|reductions observed in the circumference at the entity and treatment area volume were the same in both the placebo and lipo-202 treatment groups .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|extremity Ability cervix surgeon psoriasis|endpoint waist start weekend ankle|umbilicus|manual tape measure procedure , the 0 . 4 µg total weekly dose of lipo-202 produced significant reductions in abdominal circumference at the entity compared to placebo .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis dermis epithelium stroma epidermal|epidermis|most common form of skin cancer , is an uncontrolled growth of abnormal cells arising from the squamous cells in the entity , the skins outermost layer .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|hair epidermis scalp sun Skin|epidermis|skin in order to achieve enough heating at the required depth significantly increases the risk of damaging or burning the entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis dermis epithelium epidermal keratinocyte|epidermis|bcc develops in the basal , or lower , layer of the entity , and accounts for approximately 80% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis plaque dermis nail hair|epidermis|psoriasis , for example , which is characterized by inflammation and accelerated growth of the entity , can sometimes be triggered by a simple cut or abrasion to the skin .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|hair follicle barrier epidermis scalp|epidermis|removal is based upon the selective heating of hair follicles while cooling the surface of the skin to protect the entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|dermis epidermis superficial scalp dark|epidermis|scc usually develops in the entity , the upper layer of the skin , and accounts for approximately 16% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis epithelium tape epidermal papilla|epidermis|autologous skin regeneration construct of its kind , which can regrow full-thickness and functional polarized skin , including all layers ( dermis & entity ) , hair , and skin appendages .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis dermis epithelium fascia intima|epidermis|by precisely focusing ultrasound energy to cause permanent disruption , or ablation , of fat cells , or adipocytes , without damage to the entity , dermis or underlying tissues and organs .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis epithelium epidermal tape papilla|epidermis|to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , entity and dermis level .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|follicle follicles hair ovaries retina|epidermis|the cold sapphire tip protects the entity while allowing the laser light to efficiently destroy the target follicles .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis keratinocytes dermis keratinocyte melanocytes|epidermis|plaque psoriasis is a disease marked by hyperproliferation of the entity , resulting in inflamed and scaly skin plaques .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis epithelium epidermal tape dermis|epidermis|designed to penetrate below the skin  s surface to correct damage in all layers of the skin ( the stratum corneum , the entity and the dermis ) and accelerate cellular turnover .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|pathogen fetus hosts graft parasites|epidermis|topical interferon alpha-2b is intended to deliver interferon alpha-2b therapy to the viable entity , combating hpv infections where they would otherwise cause abnormal cellular proliferation .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis epidermal epithelium mucosal mucous|epidermis|the ability to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the entity and dermis level .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|hair flap scar epidermis dermis|epidermis|these changes can visibly affect the shape of the entity and resemble an orange peel-like dimpling of the skin . 1 in the normal subcutaneous fat layer directly under the skin , there
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|dermis epidermis epithelium epidermal follicle|epidermis|keratinocytes are the predominant cell type in the entity , the outermost layer of the skin .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|deeper superficial epidermal dermal inner|epidermis|our products will be naturally infused into hair follicles , dermis and entity layers of the scalp through the direct application and use of all-natural products .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|epidermis dermis epithelium endothelium epidermal|epidermis|vii collagen , or col7 , that forms anchoring fibrils that bind the dermis , or inner layer of the skin , to the entity , or outer layer of the skin .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|dermis epidermis dark bloodstream nail|epidermis|concentration of hydroquinone , which is designed to correct skin pigmentation problems by normalizing the production of new melanin in the entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|tissue|squamous adenocarcinoma stratum Ki67 epidermal|aureus epidermidis pneumoniae lactis pathogenic|epidermis|azitra inc . is developing azt-02 , a staphylococcus entity strain engineered to express lekti in preclinical development .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|appendix section Section item Table|anlage|thereof ; 4 . 1 . 3 all running expenses as defined in appendix 3 to section 27 , subsection 1 , of the second computation order ( entity 3 zu section 27 abs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|style es bar van word|anlage|the business address for each of the persons listed below other than christopher k . norton is messeturm , friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|der den am Form Table|anlage|l . der verkaufer verkauft und ubertragt hiermit samtliche vertrags-erfindungen und vertrags-schutzrechte , die in den in entity 1 und entity 2 beigefugten schutzrechtskaufvertragen definiert sind .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|der ein au den bis|anlage|des verschmelzungsplans ) wird die übernehmende gesellschaft die neue satzung , wie sie als entity 2 dem verschmelzungsplan beigefügt ist , beschließen .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|Version war bis von mit|anlage|zeitpunkt dieser lizenzerklärung im eigentum der sag stehen , darin insbesondere eingeschlossen die patente und patentanmeldungen gemäss entity 2 , die sich auf die substanz prostone
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|der war den bis von|anlage|verkauft und ubertragen werden daher insbesondere die in der entity 3 aufgefuhrten vermogensgegenstande und rechte ( insgesamt der , , kaufgegenstand " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|ein mit von bis der|anlage|schutzrechtsanmeldungen , die vom dkfz parallel dazu gemäß entity 2 vorgenommen worden sind .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|Pro style name Med id|anlage|the principal business address of each of gscp ii germany and gs ohg is messeturm friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|der zone du von am|anlage|belastungen des in entity 1 . 1 beschriebenen grundbesitzes in abteilung iii des grundbuchs werden vom käufer nicht übernommen .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|von mit bis der ein|anlage|schutzrechtsanmeldungen gemäß entity 2 zugrundeliegenden erfindungen zu zahlen ist , steht den erfindern von asta pharma ein anteil von 20% zu .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|der au ein dies si|anlage|​ die satzung der übernehmenden gesellschaft , als aus der gesellschaft hervorgehende gesellschaft , ist als entity 1 zu diesem verschmelzungsplan beigefügt .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|am au He he von|anlage|dr . thomas drosdeck beiten burkhardt rechtsanwaltsgesellschaft mbh bockenheimer entity 15 mozartplatz 60322 frankfurt am main germany 30 . 13 execution by counterpart .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|Disease PSA Surgery Biopsy Primary|der den Form ke dies|anlage|rechten und ansprüchen gegen sie an pcof 1 llc ( der zessionar ) im wege der sicherungsabtretung abgetreten haben , einschließlich der in entity 1 genannten forderungen .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|osteoblastic adenocarcinoma dysplasia histologically calcified|trabecular ash vertebral osteoclast graft|osteoid|the six patients had mean entity volume / bone volume decreases from 24 . 3 percent to 7 . 0 percent , representing a 71 percent improvement .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 2)])|tissue|osteoblastic adenocarcinoma dysplasia histologically calcified|trabecular osteoclast plaque graft ash|osteoid|at 48 weeks , all ten patients with evaluable paired bone biopsies demonstrated meaningful improvements from baseline in mean entity volume / bone volume .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|osteoblastic adenocarcinoma dysplasia histologically calcified|trabecular flap RNFL corneal graft|osteoid|the patients also demonstrated mean improvements of 32% and 26% in entity thickness and entity surface / bone surface parameters respectively .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|anatomy fascia septum floor barrier|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery and are not good candidates for a
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|tendons tendon fascia flexor sole|fascia|background dupuytrens disease is a slowly progressive fibroproliferative disease of the palmar entity in the hand .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|warning sign alert command informed|fascia|any changes or additions to the entity sign shall be subject to landlords prior written approval , in landlords sole discretion , and shall be made at tenant  s sole cost and expense .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma fascia phosphatase cervix propria|tendon dermis tendons nerves fascia|fascia|plantar fibromatosis is a non-malignant thickening of the feets deep connective tissue or entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|warning vital alert sign 1st|fascia|for all purposes under the lease , the entity sign shall be deemed to be tenant  s off-premises equipment . 7 . brokerage .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|floor blocks building zone clothing|fascia|tenant shall repair , paint , and / or replace the building entity surface to which its signs are attached upon vacation of the premises , or the removal or alteration of its signage ,
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|closing floor entrance roof cut|fascia|no alteration shall ( i ) affect the exterior walls , entity or fenestration of the building or the demising walls of the premises , ( ii ) affect any part of the project other than
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|adenocarcinoma fascia phosphatase cervix propria|dermis fascia pericardial myocardium diaphragm|fascia|are you going to start accepting dermis , entity and pericardium recoveries?
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma fascia phosphatase cervix propria|fascia ice pars vaginal da|fascia|the revenue increase was primarily due to an increase in the demand for our entity lata products to treat incontinence and urologic and gynecologic defects .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|adenocarcinoma fascia phosphatase cervix propria|bones nerves ligaments tendons dura|fascia|muscoloskeletal conditions  means conditions of the muscles , bones , joints ( including the intervertebral discs ) , ligaments , tendons , cartilage and entity of the body .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|anatomy septum fascia floor architecture|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|your wear install he driving|fascia|green  s dairy road a . all entity signs to be single faced cabinets , and shall be constructed of 100% aluminum with stencil cut aluminum backgrounds with white
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma fascia phosphatase cervix propria|epidermis dermis scalp superficial feet|fascia|cutaneous eosinophilias are inflammatory diseases that manifest in dermal and subcutaneous layers including the entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|name sign word letter text|fascia|signage no entity , sign , name plate , bill , notice , placard , advertisement or similar device shall be affixed to or displayed in or on any
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|fascia stratum pars lat tensor|fascia|meanwhile , the company is offering alternative tissues such as entity lata and bovine pericardium to the market .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|implants prostheses objects instruments teeth|fascia|kind and quality and having made good any material physical damage resulting from the removal of any tenant  s fixtures , fittings , entity or signs .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|flexor heel fascia plexus ring|fascia|the plantar entity is the foots shock absorber .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|adenocarcinoma fascia phosphatase cervix propria|nerves joints bones vessels tendons|fascia|a therapeutic protein and / or bioactive rna for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma fascia phosphatase cervix propria|event Life lost sickness Project|fascia|entity inventories are higher than normal by $720 due to reduced demand and the anticipation of the launch of a new
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|adenocarcinoma fascia phosphatase cervix propria|nerves joints bones vessels tendons|fascia|therapeutic protein and / or bioactive ribonucleic acid for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|phosphatase excluding Mycobacterium Calcium AND|ECM cytoskeleton myocardium stroma fibre|endomysium|- 5 - in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|phosphatase excluding Mycobacterium Calcium AND|ECM cytoskeleton stroma myocardium scaffold|endomysium|in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|tissue|epithelium glioma adenocarcinoma sheets neuroblastoma|nose odor smell latter gut|neuroepithelium|the entity is the tissue by which man detects the presence of odor .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|epithelium glioma adenocarcinoma sheets neuroblastoma|epithelium bulb nerves epithelia retina|neuroepithelium|smell ) can result from a number of causes , including mechanical obstruction of the nasal cavity and damage to the olfactory entity , the olfactory bulb , or the nerves between them .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|mole adenocarcinoma trophoblast neoplasia dysplasia|mole|the major histologic entities for this disease include complete molar pregnancy , partial molar pregnancy , invasive entity , and choriocarcinoma .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|square decade meter minute pixel|mole|mm  shall mean one-thousandth of a entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|mole adenocarcinoma trophoblast NEC neoplasia|mole|the term gestational trophoblastic neoplasia ( gtn ) is used when molar and non-molar pregnancies become malignant , and comprise the morphologic entities of invasive entity and choriocarcinoma .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|acne BCC CNV AK flare|mole|to 12-month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|margin margins ulceration sign ring|mole|cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|acne BCC CNV AK eruption|mole|to 12 month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|margin margins adenocarcinoma ulceration sign|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|neoplasm hemangioma meningioma nodule granuloma|mole|present in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|participant person woman tooth client|mole|we believe that their software , at present , cannot define whether a entity is a new one or not .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|mol liter mL microl microL|mole|referred to antibodies excluded from the licence 1all antibodies to alpha tumour necrosis factor having an association constant greater than 106l / entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|ne cul sy es int|mole|tks , tps , stks and related downstream signalling entitycules ( target identification ) and vali- dation of the role , if any , of those entity- cules in a given disease ( target valida- tion ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|neoplasm category entities variant configuration|mole|the abcd rule is defined as follows : a ● asymmetry , a benign entity that is not asymmetrical ; b ● border , a benign entity has smooth , even borders , unlike melanomas ; c ● color .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|biomarker smear neoplasm clone nodule|mole|one of the best early indicators of melanoma is a new or changing entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|box dal hat ru pa|mole|/ s / weisberg , polansky , kulberg , einhorn & entity , llp carle place , new york july 30 , 1996 exhibit 23 . 8 consent of independent certified public accountants we consent to the
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|mole evacuation abortion rupture section|mole|choriocarcinoma metastasizes hematogenously and can follow any type of pregnancy , but most commonly develops after complete hydatidiform entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|neoplasm hemangioma meningioma nodule granuloma|mole|itself in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|margin margins adenocarcinoma ulceration sign|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|AND triglycerides HER2 adenocarcinoma psoriasis|continuum cornea neoplasm stroma nodule|mole|it may begin in a entity as skin melanoma , but can also begin in other pigmented tissues , such as in the eye or in the intestines .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|dermis latter intima stroma former|dermis|the entity is comprised largely of connective tissue fibers made of collagen and elastin .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|nerves intestine epidermis cornea dermis|dermis|muscle cells , azx100 may inhibit the scarring that results from wound healing and may mitigate fibrotic disease states in the entity , blood vessels , lungs , liver and other organs .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|tendons tendon ligaments joints ligament|dermis|type 1 collagen is the primary fibril-forming collagen in bone , entity , tendons and ligaments and is the most abundant protein in the human body .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|forehead dermis scalp eyelids nose|dermis| hst-002 is a human-derived collagen and extracellular matrix dermal filler intended to be injected into the entity for the treatment of facial folds and wrinkles .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|dermal dermis composite epidermal polymer|dermis|our acellular entity scaffolds are utilized in wound care and plastic and reconstructive procedures .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|dermis epidermis cornea capillaries epithelium|dermis|temporarily permeable , allowing a drug to diffuse through the stratum corneum in the epientity , and then into and through the entity , where it can enter the bloodstream through the capillaries .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|dermis lungs fibroblasts trachea forearm|dermis|we believe that the fibroblasts created by our isolagen process and injected into the patient  s entity continue to multiply and lead to the production of collagen and elastin .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|rights engagement capital volunteers error|dermis|human entity initiatives training sales force product introduced in 2nd quarter to clinical sites product launched july 2007 markets currently a $50
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|epidermal hair TM SLN SC|dermis|with the dermavac , entity mos are rapidly harvested under local anesthetic from just under the skin to provide unique tissue structures with long-term viability
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|forehead scalp forearm thigh finger|dermis|( mos )  our proprietary device , the dermavac , is used to extract a small piece of tissue from the skins lower level , the entity of the patient .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|epidermal mucosal ultrastructural hydration barrier|dermis|penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , epientity and entity level .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|es ed stand art Key|dermis|at ciba-geigy , novartis , prosanos , adventrx participated / led development and launch of voltaren , apligraf , femara and exjade 4 5 epientity dermis subcut .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|finally additionally hence consequently furthermore|dermis|in undamaged skin , the epientity , or the surface layer of skin , and entity , the deeper layer , form a protective barrier against the external environment .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|grafts polymers preparations intraoperatively implants|dermis|in october 2001 , the company entered into a project with mentor for use of tutoplast ( r ) processed entity in urological and gynecological indications .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|dermis layers epidermis barrier sheath|dermis|due to the structure of the skin , its two main layers , the outer epientity and inner entity , effectively inhibit the transdermal delivery of most therapeutics .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|bloodstream dermis cornea vasculature microcirculation|dermis|small molecular weight sodium hyaluronate can penetrate into the entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|dermis epidermis elasticity pigmentation vasculature|dermis|skin means that part of the human anatomy consisting of the entity , the epientity , and the appendages of the skin , to wit , the nails , the hair and hair follicles , the sudoriferous and
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|dermis silicone graft rubber glue|dermis|currently rely on single source suppliers for the silicone and fabric used in our male prostheses and for the porcine entity and mesh used in many of our female products .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|vessels spaces gut cavity propria|dermis|small molecular weight sodium hyaluronate can penetrate into the 7 table of contents entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|tissue|vulgaris psoriasis VI adenocarcinoma squamous|electrode electrodes needle tip scalp|dermis|the faces handpiece uses a vacuum to fold the skin between two electrodes , ensuring tight contact and positioning the entity in direct alignment with the path of radio frequency energy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|endocardial myocardium septum thrombus adjacent|myocardium border infarct apex scar|endocardium|of myocardial cells first occurs in the area of myocardium that is most distal to the arterial blood supply , the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|endocardial myocardium septum thrombus adjacent|lumen endothelium border apex periphery|endocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the entity to the myocardium and ultimately to the epicardium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|plaque Secondary probing Primary pockets|pulp ligament teeth tooth periodontal|gingiva|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root cementum , entity and / or periodontal ligament .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|plaque Secondary probing Primary pockets|gum mouth lips excipients sugar|gingiva|exposure of the gel on the strips to the entity ( gums ) should be avoided since it can cause irritation to the tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|plaque Secondary probing Primary pockets|gum lips cheeks mouth tongue|gingiva|in heart rate ; ( ii ) focal hyperpigmentation ( darkening of the skin on certain parts of the body ) , including the face , gums ( entity ) and breasts ; and ( iii ) nausea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|plaque Secondary probing Primary pockets|mouth teeth tongue tooth lips|gingiva|in the case of the dental product , a 1mm biopsy is taken from the patient  s entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|plaque Secondary probing Primary pockets|legs scalp ears hands cheeks|gingiva|focal hyperpigmentation : reported by 1% of patients who received up to 8 doses per month , including involvement of the face , entity and breasts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|plaque Secondary probing Primary pockets|kidneys lungs esophagus pancreas gut|gingiva|lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , sinuses , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|plaque Secondary probing Primary pockets|kidneys bones lungs pancreas skeleton|gingiva|common lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|VI staging cervix Disease ligament|ligament tendon fascia suture meniscal|ligament|a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of tendon and entity repairs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|VI staging cervix Disease ligament|tendon meniscal allograft tendons composite|ligament|begun to earn royalties on a portion of the estimated 2005 $800 million to $1 billion u . s . tissue market , which includes entity , tendon and bone allografts .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|VI staging cervix Disease ligament|tendons tendon meniscal repairs ACL|ligament|first albany annual growth conference page 15 entity and tendon repairs , we mentioned , is still in preclinical work .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI staging cervix Disease ligament|ligament tendon fascia meniscal ligaments|ligament|group ; and  use our glucan technology to develop product candidates for intra-operative and injection applications in tendon , entity and bone surgeries and injuries .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI staging cervix Disease ligament|ligament ligaments capsule bundle notch|ligament|the impact of fortetropin® on reducing muscle atrophy in dogs after tibial-plateau-leveling osteotomy ( tplo ) surgery to repair the cranial cruciate entity ( ccl ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|VI staging cervix Disease ligament|burn ligament tendon neurologic crush|ligament|svf is a regenerative treatment for a number of conditions including osteoarthritis , tendon repair , entity injuries and other traumatic and degenerative diseases .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|VI staging cervix Disease ligament|ligament graft bypass tendon instability|ligament|announced receipt of the technical section complete letter for effectiveness for nocita to provide local post-operative analgesia for cranial cruciate entity surgery in dogs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|VI staging cervix Disease ligament|shoulder orthopedic penile metallic prosthetic|ligament|continues to develop a collagen based tissue patch , a collagen and calcium phosphate based bone cement , and a collagen based entity prosthesis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI staging cervix Disease ligament|ligament epithelium ligaments sulcus pockets|ligament|of periodontal pockets ( spaces between the gum and tooth ) resulting from loss of the tooth  s supporting structure ( bone and periodontal entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|VI staging cervix Disease ligament|fascia ligament scar tendon epidermal|ligament|for the technology include pressure ulcer ( bed sore ) prevention , chronic wounds , burns , dermatology , and product testing and superficial tendon and entity pathology .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI staging cervix Disease ligament|meniscus meniscal tear corneal cutaneous|ligament|college of veterinary medicine at kansas state university&#160 ; to study the impact of fortetropin on reducing muscle atrophy in dogs after entity tear repair surgery .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI staging cervix Disease ligament|tendon ligament ligaments tendons dura|ligament|stimulation of growth factors and the potential use of ultrasound technology in diagnostic and therapeutic applications relating to bone , cartilage , entity or tendon .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI staging cervix Disease ligament|ligament ligaments tendon capsule meniscus|ligament|for example , attempts to replicate mouse anterior cruciate entity , or acl , transection findings using different animal models of osteoarthritis , or oa , have proven to be challenging , as it is
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI staging cervix Disease ligament|meniscus ligaments ligament capsule meniscal|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity performed annually in the united states .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|VI staging cervix Disease ligament|ligaments tendons tendon ligament bones|ligament|studies with engineered cartilage and bone for reconstructive applications and have constructed an entire joint consisting of bone , cartilage and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|VI staging cervix Disease ligament|ligament deficient arthroplasty retaining arthroscopy|ligament|the agreement covers such products as , bone-tendon-bone ( btb ) implants used for acl ( anterior cruciate entity ) procedures .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|VI staging cervix Disease ligament|ligament meniscal osseous meniscus ligaments|ligament|to extend its worldwide license for chrysalin to include the rights for orthopedic " soft tissue " indications , including cartilage , tendon and entity repair .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|VI staging cervix Disease ligament|ligaments tendons nerves joints bones|ligament|of protein synthesis at a particular site in the body and can be used in soft tissue such as skin , entity , tendons and cartilage , as well as hard tissue such as bone .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI staging cervix Disease ligament|ligaments ligament spaces junctions nerves|ligament|the spacer is placed between the spinous processes through the interspinous entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|VI staging cervix Disease ligament|meniscus ligaments ligament capsule meniscal|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity , performed annually in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|AND maturation exclusion VI chemistry|myelin fibrous sheath outer axonal|myelin|we refer to the axon and its surrounding entity sheath as a nerve fiber .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND maturation exclusion VI chemistry|myelin tendon fibrous hair sheath|myelin|the disease is believed to be caused by the destruction of entity sheaths by the body  s own immune system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|AND maturation exclusion VI chemistry|axon axonal myelin retrograde proper|myelin|loss of entity insulation in surviving axons can cause nerve impulses to be delayed or lost entirely , resulting in impaired neurological function .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND maturation exclusion VI chemistry|myelin neurovascular intramedullary dural optic|myelin|we believe a therapy that could repair entity sheaths has the potential to restore neurological function to those affected by deentityating conditions .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|AND maturation exclusion VI chemistry|myelin axon glial fibrous sheath|myelin|the entity sheath that surrounds axons in the brain and spinal cord provides insulation that facilitates the transmission of nerve impulses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|AND maturation exclusion VI chemistry|myelin axon fibrous glial axonal|myelin|ms attacks the covering surrounding nerve cells , or entity sheaths , leading to loss of entity ( deentityation ) and nerve damage .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND maturation exclusion VI chemistry|myelin sheath outer axon lamina|myelin|the entity sheath is composed of multiple layers of tightly packed cell membrane and is vulnerable to damage in conditions like ms
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND maturation exclusion VI chemistry|boundary glial barrier outer fibrous|myelin|by neurons as well as remove compounds that are toxic to them ; and  form the insulating entity layer around the axons of neurons , enabling their normal function for signal transmission .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|AND maturation exclusion VI chemistry|myelin fibrous nervous glial sheath|myelin|multiple sclerosis , or ms , is an autoimmune disease in which immune cells attack and destroy the entity sheath , which insulates neurons in the brain and spinal cord .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND maturation exclusion VI chemistry|myelin axon sheath fibrous neurovascular|myelin|when the entity sheath is destroyed , nerve messages are sent more slowly and less efficiently .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|AND maturation exclusion VI chemistry|myelin axons nerves glia NGF|myelin|the loss of entity disrupts the conduction of nerve impulses , producing the symptoms of multiple sclerosis including vision loss , incontinence , short-term memory loss , fatigue ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|AND maturation exclusion VI chemistry|myelin axon axonal fibrous glial|myelin|reentityation reentityation is the process propagating oligodendrocyte precursor cells to form oligodendrocytes to create new entity sheaths on deentityated axons in the cns .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND maturation exclusion VI chemistry|Muscle Brain Skin BAT Fat|myelin|entity is the fatty tissue that surrounds and protects the nerve fibers of the central nervous system and facilitates the flow of nerve impulses to and from the brain .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|AND maturation exclusion VI chemistry|axonal axon neurovascular myelin neurite|myelin|clene also has state of matter claims for entity protection , remyelination , neuroprotection that will last until 2032 and manufacturing device and process patents that will last beyond 2030 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND maturation exclusion VI chemistry|SC CA1 RNFL barrier M1|myelin|in laboratory studies , dalfampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer , called entity , has been damaged .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|AND maturation exclusion VI chemistry|lymphoid mucosal perivascular synovial connective|myelin|the identified autoimmune mechanisms directed at entity tissue of the cns may play an important role in the pathogenesis of ms .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND maturation exclusion VI chemistry|hair epithelium nerves myocardium teeth|myelin|currently , there is no available therapy indicated to repair entity that has been destroyed in ms or other deentityating diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|AND maturation exclusion VI chemistry|hippocampal histological myelin axonal glomerular|myelin|to evaluate the effect of ehp-101 on entity damage in a cuprizone-induced deentityation murine model , brain coronal sections from animals after 6 weeks of cpz 0 . 2% diet and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|AND maturation exclusion VI chemistry|Fat Collagen Muscle Skin BAT|myelin|entity , a fatty tissue , surrounds and protects the nerve fibers of the cns and helps those nerve fibers to conduct electrical impulses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|tissue|AND maturation exclusion VI chemistry|CD34 autologous allogeneic EBV dendritic|myelin|to formulate tovaxin t cell vaccine , the patient  s own entity peptide-specific activated t cell lines are harvested and attenuated on the day of vaccine administration .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|malignancies Transplantation pancreas allograft harvesting|MSCs platelets exosomes CSCs CTCs|organoids|as a stem cell derived system , entity are a renewable model permitting repeat testing from a single patients biopsy .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|malignancies Transplantation pancreas allograft harvesting|registry enrollment enrolment registries registration|organoids|out of the hubrecht institute , knaw and university medical center utrecht in the netherlands to evaluate the nonsense-bearing cf patient entity in its biobank .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|tissue|malignancies Transplantation pancreas allograft harvesting|Cells EVs DCs MSCs Tumors|organoids|entity derived from nonsense mutation cf patients lack apparent swelling in this system due to their lack of functional cftr .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|malignancies Transplantation pancreas allograft harvesting|PBMCs sputum saliva leukocytes EVs|organoids|in a poster titled : “cftr protein detection in entity from healthy and cf patients with nonsense mutations support using organoid model to test elx-02 mediated cftr read-through restoration” , we
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|malignancies Transplantation pancreas allograft harvesting|donors recipients clones genotypes mutants|organoids|significant restoration of cftr protein expression as measured via a capillary-based immunoassay approach in multiple g542x or w1282x nonsense carrying entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|malignancies Transplantation pancreas allograft harvesting|biofilms Cells roots fibroblasts leaves|organoids|·g542x entity treated with elx-02 demonstrate proper cell surface cftr localization on the apical surface , which is consistent with increased cftr , mrna ,
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|tissue|malignancies Transplantation pancreas allograft harvesting|fibroblasts DCs PBMCs neutrophils EPCs|organoids|the ex vivo portion of the study will quantify the functional response of patient-derived entity to pti investigational agents dirocaftor , posenacaftor and nesolicaftor .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|malignancies Transplantation pancreas allograft harvesting|Sera Samples Cells PBMCs Specimens|organoids|entity from over 100 individuals bearing rare nonsense mutations in the cftr have been collected and are being tested for responsiveness to elx-02 in the laboratory .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|malignancies Transplantation pancreas allograft harvesting|xenografts datasets cohorts PCs subsets|organoids|the first dataset evaluated elx-02 in 31 patient-derived entity and demonstrated activity in the majority of them .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|malignancies Transplantation pancreas allograft harvesting|xenografts lungs spheroids tumours scaffolds|organoids|to change the classic model of drug discovery using 3d bioprinted human tissues and other 3d models ( sometimes known as “entity” or “organs on a chip” ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|malignancies Transplantation pancreas allograft harvesting|xenografts datasets cohorts xenograft clones|organoids|high content imaging to identify mcla-158 after screening hundreds of bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|malignancies Transplantation pancreas allograft harvesting|license counterpart prototype counterparts market|organoids|going concern the company has a history of operating losses as it has developed its human entity for drug toxicity and efficacy testing .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('BIO', 4), ('DIS', 1)])|tissue|malignancies Transplantation pancreas allograft harvesting|photoreceptors retina vasculature xenografts degeneration|organoids|we also plan to test the editor for editing efficiency in human retinal entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|malignancies Transplantation pancreas allograft harvesting|registry databases phantom files portal|organoids|the internal position was subject to change upon review of additional clinical and ex vivo data from the patient derived entity when such data were made available .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|malignancies Transplantation pancreas allograft harvesting|xenografts cohorts datasets clones pairs|organoids|content imaging to identify mcla-158 after screening more than 500 bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|malignancies Transplantation pancreas allograft harvesting|investigators Cells xenografts Studies Currently|organoids|entity are cell cultures based on cancer cells from patients that mimic the physiology of tumor growth and depend on the
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|malignancies Transplantation pancreas allograft harvesting|microenvironment too niche milieu checkpoint|organoids|of cancers . 1 they may include : smarca4 , arid1a , and smarcb4 swi / snf complex mutations sensitize to lsd1 immunomodulatory effects , turning cold tumor entity hot .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|tissue|malignancies Transplantation pancreas allograft harvesting|IBD PCa CRC myeloma NSCLC|organoids|the intent of the program is to use these positive results to enroll patients with responsive entity in a prospective trial with elx-02 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|malignancies Transplantation pancreas allograft harvesting|sputum questionnaires funding swabs datasets|organoids|hit-cf recently announced completion of the first phase of the program with the collection of entity from patients at 47 of the biggest cystic fibrosis centers in 16 countries throughout europe .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|malignancies Transplantation pancreas allograft harvesting|xenografts fibroblasts tumours clones supernatants|organoids|humanized anrp2-10 decreased viability , inhibited formation of mammospheres and anchorage-independent growth in cells or entity from tnbc patients .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|osteoblasts perioste osteoblastic GCT ossification|tendons defects teeth wounds nerves|periosteum|graftjacketò regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|osteoblasts perioste osteoblastic GCT ossification|tendons defects teeth wounds nerves|periosteum|graftjacket® regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|osteoblasts perioste osteoblastic GCT ossification|floor roof lining dura epithelium|periosteum|● the pericranium is the entity ( a membrane that lines the outer surface of all bones ) of the skull bones and provides nutrition to the bone
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|osteoblasts perioste osteoblastic GCT ossification|tendon suture meniscal bony fascia|periosteum|for maci is less invasive than for carticel , entailing a mini-arthrotomy or even arthroscopic delivery , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|osteoblasts perioste osteoblastic GCT ossification|graft dura flap latter autograft|periosteum|the entity is a membrane covering the shin bone .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|osteoblasts perioste osteoblastic GCT ossification|trabecular cancellous osteoblasts endos stromal|periosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of entity and endosteum bone mineral mass .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|osteoblasts perioste osteoblastic GCT ossification|graft allograft autograft dermis flap|periosteum|a small piece of entity , the membrane that covers bone , is taken from the patient  s lower leg and sutured over the defect to hold the cells in place .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|tissue|osteoblasts perioste osteoblastic GCT ossification|dressing irrigation debridement analgesia hemostasis|periosteum|at surgery , entity was lacking ; the wound was debrided , and the bone fragments realigned .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|osteoblasts perioste osteoblastic GCT ossification|dura skull perioste graft retina|periosteum|the periosteal patch is a thin collagen membrane that is cross linked and functions as a patch on the entity .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|osteoblasts perioste osteoblastic GCT ossification|suture scleral flap cutaneous hair|periosteum|the implant procedure for maci is less invasive than for carticel , entailing a mini-arthrotomy , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|osteoblasts perioste osteoblastic GCT ossification|microscope cornea dermis scalp vagina|periosteum|the cultured cells are then implanted under the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum abdomen gut intestine lungs|peritoneum|it is also used in surgery for treating a wide range of localized infections in the entity ( the lining of the abdominal cavity ) , as well as the eye , ear , nose and throat , and sinuses .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum abdomen pelvis rectum stroma|peritoneum|it is formed by small , round cancer cells surrounded by scar-like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum filter endothelium dialysate peritoneal|peritoneum|peritoneal dialysis removes waste products and excess fluids from the blood by use of the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum lungs mediastinum myocardium diaphragm|peritoneum|antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the pleura , pericardium and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|gut bloodstream intestine airways lungs|peritoneum|peritonitis is a bacterial infection of the entity which can result in serious adverse health consequences , including death .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|mouth bed legs forehead tongue|peritoneum|a machine is used to " cycle " solution to and from the patient  s entity during sleep .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|tip peritoneum endoscope epithelium intestine|peritoneum|upon immediate penetration of the entity , the membrane that forms the lining of the abdominal cavity , our kii® fios® first-entry creates a space for the tip
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum diaphragm lungs mediastinum peritoneal|peritoneum|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , pleura , entity ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneal pleural subcutaneous intraperitoneal retroperitoneal|peritoneum|peritoneal dialysis uses the entity space in the abdomen as a dialyzer .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|rectum peritoneum bowel ureter vagina|peritoneum|these studies established that local injection of up to one billion mak cells in the pleural cavity , bladder or entity is well-tolerated .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|reservoir filter latter pump syringe|peritoneum|the entity operates as the filtering membrane and , after a specified dwell time , the solution is drained and disposed .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|intestine gut pancreas bowel esophagus|peritoneum|fibrosis can affect any tissue and organ system , and is most common in the heart , liver , lung , entity , and kidney .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum abdomen pelvis rectum stroma|peritoneum|it is formed by small , round cancer cells surrounded by scar‑like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum filter endothelium microcirculation gut|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|lungs peritoneum pancreas intestine testis|peritoneum|aggressive human pancreatic cancer cell line , l3 . 6pl , that is known to metastasize from the pancreas to the liver and the entity in mice .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum ovaries ovary pelvis uterus|peritoneum|ovarian cancer by age 70 . ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|pancreas islets striatum islet duodenum|peritoneum|experiments were conducted using encapsulated pig islets transplanted into the entity of a diabetic rat model .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|pump filter dialysate reservoir cannula|peritoneum|introduces a sterile 77 85 dialysis solution from a solution bag through a tube into the peritoneal cavity and the entity operates as the filtering membrane .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum ovaries ovary pelvis rectum|peritoneum|ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma peritoneum peritoneal cervix endometriosis|peritoneum filter dialysate endothelium peritoneal|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area , as a filter .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|lungs vasculature endothelium skeleton airways|pleura|however , the distinction between mesothelioma and carcinomas that involve the entity , in particular peripheral pulmonary adenocarcinoma , can be challenging .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|Ten Ben Meta 125 Iso|pleura|entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and 104 table of contents entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|lungs peritoneum epithelium parenchyma airways|pleura|malignant mesothelioma is a rare cancer , primarily affecting the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|embryo infiltr invade indole come|pleura|microrna to help differentiate malignant entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|epithelium lining walls parenchyma peritoneum|pleura|mesothelioma overview malignant mesothelioma is a malignant tumor of mesothelial cells which make up the entity , or tissue lining , of many internal organs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|lungs kidneys intestine gut pancreas|pleura|and certain of annapurnas scientific founders teams demonstrated that this aav serotype also allows very efficient delivery to the heart , entity and liver , as well as additional organs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|Lung Skin Fat Chest BAL|pleura|entity refers to the thin layer of tissue that lines the chest cavity and covers the lungs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|lungs peritoneum epithelium parenchyma airways|pleura|malignant mesothelioma is a rare cancer , primarily affecting 8 the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|peritoneum lungs epithelium pleural parenchyma|pleura|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , entity , peritoneum ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|esophagus peritoneum pancreas mediastinum bones|pleura|mirview™ meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|esophagus peritoneum mediastinum pancreas bones|pleura|mirviewtm meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|kidneys lungs bones intestine gut|pleura|dissemination through the blood may also occur , affecting the lungs and entity , liver , and bones .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|peritoneum lungs endothelium epithelium myocardium|pleura|targets mesothelin , an antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the entity , pericardium and peritoneum .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|peritoneum esophagus mediastinum bones pancreas|pleura|and is able to accurately diagnose mesothelioma and distinguish it from lung adenocarcinoma and other malignancies involving the lung and entity with very high sensitivity and specificity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|visceral endothelium fascia bones nerves|pleura|visceral pain is defined as pain that originates within muscle , entity , connective tissue , nervous system or solid organs within the abdomen or peritoneum .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|esophagus pancreas peritoneum larynx mesothelioma|pleura|is increasingly important to determine with certainty whether a carcinoma is mesothelioma or a different carcinoma of the lung or entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|esophagus peritoneum pancreas mediastinum bones|pleura|squamous non-small cell lung cancer ; and · mirviewtm meso : for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|peritoneum cavity parenchyma lungs cavities|pleura|mesothelioma most commonly occurs in the entity surrounding the lung , but occasionally involving the peritoneum surrounding internal organs of the digestive tract , the lining of the heart
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|esophagus peritoneum pancreas mediastinum bones|pleura|mirview® meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|tissue|adenocarcinoma abscess pleural NSCLC mesothelioma|esophagus pancreas peritoneum rectum bones|pleura|squamous from non squamous non-small cell lung cancer ; and 3 . mirview® meso — for differentiating mesothelioma from carcinomas in the lung and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|Formation Iron endometrium larvae Plasmodium|trabecular cancellous tibial thereby surrounding|endosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of periosteum and entity bone mineral mass .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|Primary vulgaris Paulo Disease IIIa|lymphatic superficial beyond visceral peritoneum|subserosa|tumor penetrates muscularis propria and invades entity t4 : tumor directly invades other organs or structures or perforates visceral peritoneum nodal status ( n ) nx : regional lymph nodes cannot
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|plaque arteries neovascularization CD34 epicardial|intima flap dome sheath conduit|adventitia|delivery catheter that allows prt-201 to be administered locally in the outer layer of the artery , which is called the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma propria polyps endometrium epithelium|epithelium walls lumen lining airways|submucosa|it is associated with hyperplasia and hypertrophy of the mucus-producing glands found in the entity of large cartilaginous airways .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma propria polyps endometrium epithelium|loops epithelium contents metaplasia lumen|submucosa|development and manufacture of the regentys ecmh™ ( extracellular matrix hydrogel ) rectal solution , an extracellular matrix hydrogel derived from small intestinal entity ( sis ) of pigs .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|adenocarcinoma propria polyps endometrium epithelium|dermis epithelium epidermis glands peritoneum|submucosa|sites include the dermis , gut mucosa and entity , conjunctiva and pulmonary alveoli and airways .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma propria polyps endometrium epithelium|stroma lining epithelium lumen floor|submucosa|ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the epithelium and the entity of the colon .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|adenocarcinoma propria polyps endometrium epithelium|fibroblasts epithelium fibroblast stromal urothelial|submucosa|post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma propria polyps endometrium epithelium|submucosal propria superficial esophagus epithelium|submucosa|tx : primary tumor can not be assessed tis : carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|adenocarcinoma propria polyps endometrium epithelium|fibroblasts epithelium urothelial fibroblast stromal|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|adenocarcinoma propria polyps endometrium epithelium|fibroblasts epithelium urothelial fibroblast stromal|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|adenocarcinoma propria polyps endometrium epithelium|dome lumen floor outlet orifice|submucosa|this material is injected into the entity of the bladder at the junction of the ureter and bladder in order to reduce the size of the opening
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|adenocarcinoma propria polyps endometrium epithelium|fibroblasts epithelium fibroblast stromal urothelial|submucosa|months post-implantation the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|adenocarcinoma propria polyps endometrium epithelium|fascia superficial epithelium esophagus submucosal|submucosa|carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa t4 : tumor directly invades other organs or
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|adenocarcinoma propria polyps endometrium epithelium|fibroblasts epithelium urothelial fibroblast stromal|submucosa| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peel stratum sheath cervix septum|atrium diaphragm apex aorta septum|epicardium|extensive adhesions form between the surface of the heart ( entity ) and the inner surface of the sternum after virtually every open-heart surgical procedure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|peel stratum sheath cervix septum|cytoskeleton endothelium microenvironment ECM latter|epicardium|the entity plays a critical role in the differentiation , expansion , and maturation of cardiomyocytes during development , or during cardiac repair responses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|peel stratum sheath cervix septum|walls sides endothelium periphery floor|epicardium|heart toxicity ( epicardial hyperplasia with inflammation primarily on the entity of the atria ) was observed in the 0 . 75 and 1 . 5 mg / kg / day groups .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peel stratum sheath cervix septum|outside myocardium scar ventricles thorax|epicardium|to the inside of the heart ; and surgical cardiac ablation devices , which are used to ablate cardiac tissue from the entity ( outside the heart ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|peel stratum sheath cervix septum|periphery infarct myocardium lumen microcirculation|epicardium|occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the myocardium and ultimately to the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|peel stratum sheath cervix septum|ventricle myocardium esophagus aorta abdomen|epicardium|• mpc-150-im , injected directly into the entity , is being evaluated in a phase 2b trial in patients with nyha class iv / end-stage heart failure who have received a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|Primary AND Secondary Cholesterol Vascular|intimal neoin SMC atherosclerotic VSMC|intima|in a rat model of percutaneous transluminal balloon angioplasty , the researchers demonstrated that elafin administration prevented entity hyperplasia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|Primary AND Secondary Cholesterol Vascular|triple mix Plus powder prime|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , gentlelase , vbeam perfecta , picoway , co2re , co2re entity , profound and elōs plus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|Primary AND Secondary Cholesterol Vascular|intima shear intimal capillary resist|intima|the study did not show any statistically significant difference in carotid entity media thickness between subjects in the two treatment arms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|Primary AND Secondary Cholesterol Vascular|mix triple prime powder pack|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elos plus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|Primary AND Secondary Cholesterol Vascular|intima lumen endothelium epithelium intimal|intima|similarly , okuda et al53 reported a higher rate of age-dependent telomere attrition in both the entity and media of the distal versus proximal human abdominal aorta .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|Primary AND Secondary Cholesterol Vascular|capillary slice intimal shear intima|intima|the fda  s primary grounds for rejecting the claim relate to the clinical utility of evaluating skin cholesterol with carotid wall entity thickness ( cimt ) as the clinical endpoint .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|Primary AND Secondary Cholesterol Vascular|intima intimal adventi resist epicardial|intima|the study also showed that tesamorelin improved triglycerides , c-reactive protein and carotid entity medial thickness , a cardiovascular marker , without aggravating glucose .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|Primary AND Secondary Cholesterol Vascular|mix prime nut bar tax|intima|the company has a wide portfolio of trusted , leading products including ultrashape power , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elōs plus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|Primary AND Secondary Cholesterol Vascular|intima intimal IMT radial epicardial|intima|sterol levels ( university of wisconsin ) l determine relationship between skin sterol and cad as measured by carotid entity medial thickness
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|Primary AND Secondary Cholesterol Vascular|intimal neoin SMC fibrous VSMC|intima|in 2013 , the researchers demonstrated that elafin administration prevented entity hyperplasia in a rat model of percutaneous transluminal balloon angioplasty .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|Primary AND Secondary Cholesterol Vascular|lumen intima tip walls endothelium|intima|the saline / chemical irritates the entity ( lining ) of the vein , causing it to collapse .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|Primary AND Secondary Cholesterol Vascular|funding deployment positioning cooling investigational|intima|we are positioned to address this growth segment with our core entity device , which we anticipate releasing internationally in 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|Primary AND Secondary Cholesterol Vascular|endothelium intima ECM aorta lumen|intima|smooth muscle cell migration into the entity mediated by growth factors such as platelet-derived growth factor ( " pdgf " ) is thought to play an important role in the entityl
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|Primary AND Secondary Cholesterol Vascular|intima intimal thickened shear lowest|intima|this trial is called restore-it , or the randomized evaluation of short-term rifalazil treatment on carotid atherosclerosis and entity media thickness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|Primary AND Secondary Cholesterol Vascular|propria intima fascia tun lamina|intima|it is characterized by the thickening of the tunica entity of a blood vessel as a complication of a reconstruction procedure or endarterectomy , the surgical removal of plaque from an
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|integrate incorporate introduce insert embed|clone|blunt ends , however , have a slight affinity for one another , which makes it possible for researchers to entity these fragments into blunt-ended cloning vectors .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|clone map characterise analyse isolate|clone|the company is utilizing this technology to discover and entity the genes that code for human receptor subtypes that may be associated with specific disorders .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|clone niche cascade character microenvironment|clone|several cases , including cmml and aml , tumor microenvironmental pdcs have been shown to be neoplastic and part of the malignant entity , indicating a potential need for therapeutic targeting .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|variant isoform polymorphism transcript subtype|clone|in fact , the presence of the hmga2 entity has steadily declined over time to the point that it is no longer the most common entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|clone CD34 clones CML KIT|myeloma clone compartment precursor neoplasm|clone|multiple myeloma is a condition in which these plasma cells become malignant , with a single entity growing at an uncontrolled pace .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|manipulate divide locate isolate hit|clone|following leaps identification of the cell of interest , we entity the cell , thereby generating millions of cells that produce high concentrations of the biological molecule of interest .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|map description dissection characterisation overview|clone|heska has produced a molecular entity of the cellular receptor for the ige antibody .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|formulation prodrug substance derivative scaffold|clone|a entity with a “highly similar” profile to herceptin has been chosen for further process development .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|tissue|clone CD34 clones CML KIT|melanomas clone gliomas neoplasms neoplasm|clone|these data suggest that imetelstat inhibits the progenitor cells of the malignant entity believed to be responsible for the underlying disease in a relatively selective manner .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|clone map characterise isolate define|clone|it is utilizing this technology both to discover and entity the genes that code for human receptor subtypes associated with specific disorders and to design compounds that can potentially be
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|cDNA library clone collection transcriptome|clone|our omnibank mouse entity library and its backup are stored in liquid nitrogen freezers located at our facility in the woodlands , texas , and our
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|analyse discover isolate clone visualize|clone|in addition , we plan to utilize our high-throughput capabilities to rapidly entity and expression-test thousands of genes for drug development and agriculture .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|see another Direct Any My|clone|the company , on the following boards of directors of the companys partners and affiliates ( each , a p & a board ) : entity international pty .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|express clone introduce choose replace|clone|in addition , conventional genetic engineering techniques for protein production may face technical limitations arising from the need to first entity the gene of interest .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|clone express manipulate isolate analyse|clone|these companies are competing with one another to be the first to identify , entity and express the finite number of genes thought to be of commercial importance .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|clone CD34 clones CML KIT|disrupt manipulate probe locate map|clone|tools and approaches in bacterial molecular genetics , which allow it to create and use gene mutants to quickly and directly entity essential bacterial genes .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|isolate clone amplify prepare map|clone|pcr cloning is another method that can be used to entity a dna fragment when some information about its sequence is known .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|clone isolate map express discover|clone|in 1998 we began marketing our " high-throughput " gene cloning and expression technology , which allows us to entity and expression-test genes on an industrial scale .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|batch clone suspension lot passage|clone|a mab is a type of protein that is produced by a single entity of cells or cell line and made to bind to a specific substance in the body .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone CD34 clones CML KIT|clone manipulate isolate analyse characterise|clone|this strategy consists of four principal objectives , the first of which is to aggressively discover and entity g protein-coupled receptor genes .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|floor building ground bottom front|basement|situated in the building upon lot c and adjacent to said common area leading from the second floor to the entity ; all as set forth in said deed recorded in book 7370 , page 304 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|rear front west south north|basement|scope 1 . 1 location altarex will occupy the west wing on the first floor plus some space in the entity as shown on the attached plan .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|clinic Internet institution ambulance city|basement|some hospitals have constructed a dedicated o . r . in the entity to reduce the transportation distance .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|span radius vicinity interior neighborhood|basement|this termination option will not apply to any space in the entity of 320 bent street if the company has exercised its option to continue to lease such entity space .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|remote shorter specialized extreme unplanned|basement|but these entity o . r .  s are remote from the surgical center , creating staffing and logistical difficulties .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|AND adenocarcinoma squamous VI Disease|anatomical pleural epidural bony dead|basement|any vault or entity space not within the property line of the building , which tenant may be permitted to use or occupy , shall be
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND adenocarcinoma squamous VI Disease|basement junctional amniotic tight connective|basement|additional biological activities shown to reduce inflammation , stimulate the formation of collagen , and up-regulate the expression of laminin-5 , a subepithelial entity membrane protein .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|basement synovial amniotic outer cytoplasmic|basement|separating the two is the specialized type of extracellular matrix , known as the entity membrane .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|basement filtration mesangial glomerular capillary|basement|as is caused by a genetic defect in type iv collagen , a component of the glomerular entity membrane in the kidney , resulting in defects in its structure and function .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|nearest 2nd server another next|basement|) sublessor and sublessee each agree to log access to the server room on the 2nd floor and entity network room , and to provide these access logs to the other party if requested .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|packaging washing transportation collecting closing|basement|use of any mezzanine , entity or storage space shall be at no additional charge and the area of such space shall not be included in
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|ceiling floor transportation closing trail|basement|in particular , access to the building and courtyard , vehicle passage , building and entity or other open areas and spaces must not be blocked with objects of any kind .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|travel decision waiting virtual job|basement|if landlord leases the entity space to other tenants before service of a notice from the tenant exercising this additional right of first offer , the
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|basement mucous outer cytoplasmic luminal|basement|tumors must ordinarily degrade the entity membrane and extracellular matrix of surrounding tissues in order to grow and heparanase is an enzyme that facilitates this process .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|vertical virtual another anatomical wider|basement|no vault or entity space not within the property line of the building is leased hereunder , anything to the contrary indicated elsewhere in this lease notwithstanding .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|front ceiling orbit chamber advance|basement|f of dry bulb , 74 ( degrees ) f wet bulb of zero f . new equipment to be placed on the roof and in entity ( location to be determined as tenant requirements are finalized ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|basement mucous amniotic tympanic luminal|basement|by definition , carcinomas that originate on the epithelial side of the entity membrane are considered to be benign , as long as the cells forming them remain on the same side .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|AND adenocarcinoma squamous VI Disease|basement luminal stroma stromal mucosal|basement|however , many carcinomas acquire the ability to penetrate the entity membrane , and individual cancer cells or groups of cancer cells begin to invade the stroma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|tissue|AND adenocarcinoma squamous VI Disease|floor roof ceiling bottom outlet|basement|tenant shall not enter into or upon the roof or entity of the building or any storage , heating , ventilation , air-conditioning , mechanical or elevator machinery housing areas .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|glioma Malignant astrocytoma GCT Primary|glioblastoma astrocytoma meningioma anaplastic glioma|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|glioma Malignant astrocytoma GCT Primary|astrocytoma variant meningioma glioma anaplastic|oligodendroglioma|the patients in the resection injection trial predominantly had gbm ( 79 . 1% ) with other histologies including aa ( 11 . 6% ) , anaplastic entity ( 2 . 3% ) and other ( 7 . 0% ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioma Malignant astrocytoma GCT Primary|glioblastoma meningioma astrocytoma glioma neuroblastoma|oligodendroglioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , entity , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|glioma Malignant astrocytoma GCT Primary|glioblastoma astrocytoma meningioma anaplastic glioma|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|glioma Malignant astrocytoma GCT Primary|GBM glioblastoma glioma gliomas astrocytoma|oligodendroglioma|p / 19q loss is diagnostic for entity , and helps to determine sensitivity to response to chemotherapy , radiation and temozolomide treatment .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|glioma Malignant astrocytoma GCT Primary|astrocytoma meningioma glioblastoma glioma anaplastic|oligodendroglioma|the main glioma types are astrocytoma ( which includes glioblastoma ) , entity , ependymoma , and mixed glioma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|glioma Malignant astrocytoma GCT Primary|glioma astrocytoma gliomas glioblastoma meningioma|oligodendroglioma|three patients have completed the study to date , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|glioma Malignant astrocytoma GCT Primary|glioma astrocytoma gliomas glioblastoma meningioma|oligodendroglioma|patients had completed the study at the time of the abstract , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma glioma gliomas lymphomas glioblastoma|astrocytoma|bt-8 phase ii study of antineoplastons a10 and as2-1 in patients with anaplastic entity ; revised 4 / 14 / 97 ; revised 9 / 15 / 97 .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|glioblastoma glioma NSCLC neuroblastoma gliomas|astrocytoma|based on phase i and ii data , the company may conduct additional phase ii clinical trials in entity ( a type of primary brain cancer ) , ovarian and non-small cell lung cancers .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|glioma NSCLC CRC gliomas CKD|astrocytoma|we intend to commence a pivotal 396-patient phase iii randomized , multicenter clinical trial of tvi-brain-1 in newly diagnosed grade 4 entity patients .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma adenoma glioblastoma glioma neoplasm|astrocytoma|afinitor is also approved for subependymal giant cell entity ( sega ) and renal angiomyolipoma associated with tuberous sclerosis complex ( tsc ) .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma glioblastoma meningioma glioma anaplastic|astrocytoma|the main glioma types are entity ( which includes glioblastoma ) , oligodendroglioma , ependymoma , and mixed glioma .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma glioma glioblastoma adenoma meningioma|astrocytoma|afinitor is also approved for subependymal giant cell entity and renal angiomyolipoma associated with tuberous sclerosis complex .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|glioblastoma astrocytoma glioma gliomas meningioma|astrocytoma|glioblastoma multiforme , or gbm , also called grade iv entity , is the most common type of malignant primary brain tumor , comprising about 30% of all primary brain tumors in adults .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|mesothelioma glioma meningioma pheochromocytoma hyperthermia|astrocytoma|the patient died in december 2003 , and the case was originally reported by a clinical trial investigator as malignant entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|gliomas glioma astrocytoma glioblastoma meningiomas|astrocytoma|center at san antonio initiated a clinical trial of th-302 in combination with bevacizumab in patients with recurrent high grade entity including glioblastoma .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|diarrhea env parasites allergy simultaneously|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the u . s . food and drug administration .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|ALS psoriasis VAP migraine BCC|astrocytoma|hospital and select , dated august 15 , 2000 , to perform and conduct a clinical trial study of verotoxin for treatment of entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma glioma gliomas meningioma degeneration|astrocytoma|current treatments for glioblastoma and anaplastic entity involve surgical resection , radiation therapy , and chemotherapy .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|glioma gliomas mesothelioma astrocytoma melanomas|astrocytoma|initially primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma neoplasm adenoma granuloma glioma|astrocytoma|in november , the japanese health authority approved afinitor for the treatment of renal angiomyolipoma and subependymal giant cell entity ( sega ) associated with tsc .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma glioma glioblastoma neuroblastoma meningioma|astrocytoma|the time from the initial brain tumor diagnosis to enrollment on the study ranged from four months to 301 months ( this last timing for a patient diagnosed with childhood anaplastic entity ) .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|gliomas malignancies lymphomas astrocytoma glioblastoma|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the fda .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma glioma gliomas meningioma glioblastoma|astrocytoma|the protocol included the provision to enroll up to 24 patients with recurrent supratentorial anaplastic entity and glioblastoma multiforme ( " gbm " ) .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|glioma gliomas mesothelioma melanomas astrocytoma|astrocytoma|our initial focus is on patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma glioblastoma meningioma glioma neuroblastoma|astrocytoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , entity , oligodendroglioma , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma glioma anaplastic astrocytoma AND|astrocytoma glioma glioblastoma meningioma adenoma|astrocytoma|patients ( 69% ) entered the study with a diagnosis of glioblastoma multiforme , seven of which were secondary to transformation from anaplastic entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|sarcomas adenocarcinoma hyperplasia cervix leiomy|carcinosarcoma|additional cabozantinib data presentations included results from trials in endometrial cancer and uterine entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|adenocarcinoma cervix hyperplasia neoplasia neoplasm|carcinosarcoma|four patients ( three ovarian cancer patients and one uterine entity patient ) had a partial response , and 17 patients had stable disease .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|adenocarcinoma GIST GCT neoplasm SCC|carcinosarcoma|one patient , a 63 year old female with a poorly differentiated uterine entity , had a complete response .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|peritoneal colorectal retroperitoneal testicular anaplastic|carcinosarcoma|objective responses were seen in eight patients including ovarian , breast , entity , and peritoneal mesothelioma , seven of whom had prior therapy with paclitaxel or docetaxel .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|NSCLC MBC SCLC GBM PC|carcinosarcoma|the study has been expanded to include dkn-01 monotherapy and paclitaxel combination cohorts in patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|NSCLC MBC adenocarcinoma mesothelioma DCIS|carcinosarcoma|partial responses in patients with endometrial cancer , and dkn-01 plus paclitaxel has generated a partial response in a patient with entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|KIT BRAF HER2 PTEN JAK|carcinosarcoma|patients , including those with entity and wnt pathway alterations , have experienced partial responses and durable clinical benefit in both the monotherapy and combination arms of
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|participating surviving latter registry next|carcinosarcoma| gynecologic cancers study : updated follow-up data from the entity patients is expected in late 2020 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|serous cervix uterine intraepithelial squamous|carcinosarcoma|over 40% of uterine entity cancers and 10% to 20% of ovarian and stomach cancers harbor ccne1 amplification .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|NSCLC T2DM CRC T2D gliomas|carcinosarcoma|patient follow-up is continuing in this study , which has been expanded to include focused cohorts of patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|adenocarcinoma sarcomas cervix melanomas lymphomas|carcinosarcoma|the partial responses occurred in patients with ovarian cancer and uterine entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|interventional participating cooperative latter randomization|carcinosarcoma|enrollment has recently completed in the entity groups .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|adenoma adenocarcinoma hyperplasia carcinomas adenomas|carcinosarcoma|no mammary adenoma was diagnosed by the pathologists who provided the original study report ; the incidence of mammary entity did not change from the initial report .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|NSCLC gemcitabine Japan Europe mesothelioma|carcinosarcoma|odkn-01 plus paclitaxel in entity : fifteen patients with carcinosarcoma were enrolled in the dkn-01 plus paclitaxel arm , six of whom were evaluable for response as of the data-cut off
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|neuroblastoma cervix carcin GCT adenocarcinoma|psoriasis NSCLC T2DM SLE MTD|carcinosarcoma|in addition , based on the clinical activity observed in part 1 , we have added a cohort for patients with entity in part 2 of the study .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|GCT glioma terat neuroblastoma embryo|neoplasia degeneration scar dysplasia scarring|teratoma|were not only insufficient for regeneration or reconstruction of the damaged cns , but also accompanied by unacceptably high incidents of entity and / or neoplasm formation .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|GCT glioma terat neuroblastoma embryo|cytotoxicity aneuploidy angiogenesis dysplasia senescence|teratoma|there was no evidence of entity , or tumor growth , in these cells .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|GCT glioma terat neuroblastoma embryo|Following Through Upon From Under|teratoma|$ 47 , 535 project 2 : entity assessment of the generation of three germ layers scope of work the goal of this project is to assess the
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cancer|GCT glioma terat neuroblastoma embryo|granuloma scar abscess callus collateral|teratoma|pluripotent properties of wolfram syndrome-ipscs were also assessed by entity formation on intramuscular injection of undifferentiated wolfram syndrome-ipscs into scid mice .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|GCT glioma terat neuroblastoma embryo|xenografts tumours plaques remission autoimmunity|teratoma|in a humanized mouse model on left : human ipsc proliferate ( as visualized by luminescence of live cells ) and form entity in nsg mice ( n=3 ) with adoptive transferred human nk cells .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|GCT glioma terat neuroblastoma embryo|sphere scar blastocyst hair synapse|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been observed in clinical studies to date .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|GCT glioma terat neuroblastoma embryo|blastocyst capillary biofilm sphere scar|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been 264 table of contents observed in clinical studies to date .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cancer|GCT glioma terat neuroblastoma embryo|scar granuloma myelin abscess hematoma|teratoma|included in the safety package were studies that showed no evidence of entity formation 12 months after injection of clinical grade grnopc1 into the injured spinal cord of rats and mice .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|GCT glioma terat neuroblastoma embryo|neoplastic malign cancerous borderline harm|teratoma|know that one of the scientific tests to determine that the cells are hescs , is whether they can produce a entity or benign tumor .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|GCT adenocarcinoma cervix neuroblastoma NHL|night lost ou para pound|seminoma|dyspnoea 1 chest pain 1 entity 1 weight increased 1 hot flush 1 mood swings 1 erectile dysfunction 1 uri 1 hot flush 1 headache 1
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|sarcomas defects augmentation blocks prolapse|sarcoma|based on the outcome of picasso 3 in soft tissue entity and the resulting revision in the companys development plans for palifosfamide , enrollment in this study was suspended with 188 patients
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|CRC burn COPD ESRD AIDS|sarcoma|institute of health ( which we refer to as nih ) and physician collaborators , salarius believes that there are approximately 500 ewing entity patients diagnosed annually in the united states .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|influenza onc Vaccine vaccination your|sarcoma|contracts and agreements nci entity vaccine grant in july 2010 , the national cancer institute ( “nci” ) awarded the company a small business innovation research
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|osteosarcoma myeloma osteogenic dysplasia mesenchymal|sarcoma|endorex has received orphan drug designation for immther ( r ) by the fda for two types of bone cancer , ewings entity and osteogenic entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|error dysplasia neoplasm neoplasia specimen|sarcoma|but pathologists ( doctors who specialize in diagnosing cancers by how they look under the microscope ) , may not always agree on the exact type of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|Disease curse anemia encephalitis jelly|sarcoma|thalidomide , as well as to the orphan drug designations we already received for its use in brain cancer and kaposi  s entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|expert cooperative scientific consensus oncology|sarcoma|he holds the position of the french entity group , and acts as network director of the european reference network for rare adult cancers ( euracan ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|sarcomas pathologies defects tumours neoplasms|sarcoma|we also received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue entity , including angioentity , in 2016 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|neoplasms sarcomas malignancies neoplasm osteosarcoma|sarcoma|the most common types of entity in adults are undifferentiatedpleomorphic entity ( previously called malignant fibrous histiocytoma ) , lipoentity , and leiomyoentity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|masses tumours neoplasms sarcomas cysts|sarcoma|for example , leiomyoentitys are the most common abdominal entity , while lipoentitys and undifferentiated pleomorphic entity are most common in legs .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|scientific legal intellectual academic ethical|sarcoma|patel is a member of the board of directors for the entity foundation of america .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|tumorigenesis carcinogenesis predisposition latency senescence|sarcoma|ewing entity is driven by an easily diagnosed chromosomal translocation , i . e . , ews-fli sankar et al . clinical cancer research 20 . 17 oncogenes ( tumor growth )
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|glioblastoma adenocarcinoma myeloma osteosarcoma glioma|sarcoma|synovial entity is an ini1-deficient tumor of particular interest for treatment with an ezh2 inhibitor .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|scientific academic lay wider biomedical|sarcoma|“the entity community has been very supportive following the esmo presentation in which we showed a clear benefit for adp-a2m4 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|DLBCL ALL CLL myeloma NHL|sarcoma|and mcl and are also conducting a dose-escalation phase 1 trial of tk216 in patients with relapsed or refractory ewing entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|comprising called wherein whereby carrying|sarcoma|kaposis entity the novel mt-1000 class constructs are designed to specifically deliver doxorubicin , a chemotoxin , which can kill ks tumor cells
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|Ontario affiliated province oncology clinic|sarcoma|during the three months ended sept . 30 , 1998 , the company expanded the clinical trial for immther ( r ) in ewings entity to memorial sloan-kettering , a major cancer center .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|sarcomas neoplasms neoplasia gliomas malignancies|sarcoma|our preclinical data for synovial entity we have generated in vivo proof of concept data that demonstrates antitumor activity of fhd-609 in synovial sarcoma cdx models .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 2)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|dysplasia osteosarcoma hyperplasia ossification sarcomas|sarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyoentity , ewings entity and osteoentity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cancer|adenocarcinoma AND neuroblastoma cervix hematologic|SCC sarcomas tumours gliomas osteosarcoma|sarcoma|current treatment for ewing entity consists of an intensive chemotherapy regime , radiation and often disfiguring surgeries .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|nude inbred ICR xenograft syngeneic|osteosarcoma|+ mbil-15 nk cells ( graphical ) the graphical data above are an average of the mice studied in the entity mouse model shown above .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('BIO', 2), ('OTHER', 2)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|neuroblastoma myeloma ALL osteosarcoma retinoblastoma|osteosarcoma|rare pediatric disease designations for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|binary dichotom null publication interim|osteosarcoma|: 93 , 1995 junovan : phase iii entity results overall survival years proportion surviving 0 1 2 3 4 5 6 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 -
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|neuroblastoma osteosarcoma NSCLC retinoblastoma mesothelioma|osteosarcoma|overexpressed , including her2+ gastric , endometrial , ovarian , colorectal , lung , pancreatic , cervical , and bladder cancers , as well as her2+ pediatric indications including entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|toxicities neurotoxicity attrition bias hepatotoxicity|osteosarcoma|typically , treatment duration is limited to two years because of the risk of entity revealed in preclinical testing .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|osteosarcoma GCT MM MCC PC|osteosarcoma|her2 is overexpressed in certain solid-tumor cancers , including pediatric bone cancer ( or entity ) , breast cancer , esophageal , and gastric cancer .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|neuroblastoma malignancies sarcomas ALL retinoblastoma|osteosarcoma|according to the childrens oncology group , the survival of children with entity has remained at 60-65 percent since the mid-1980s .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|GCT ACC osteosarcoma MTC CMT|osteosarcoma|entity is a bone tumor that occurs predominantly in adolescents and young adults .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|nephrotoxicity hepatotoxicity hypoglycaemia hypercalcemia osteoporosis|osteosarcoma|because of the potential risk of entity , natpara is recommended only for patients who cannot be well-controlled on calcium and active forms of vitamin d alone .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|CRC IBD dementia ACS SLE|osteosarcoma|assuming similar prevalence as in the united states , we estimate approximately 1 , 500 patients diagnosed with entity per year in europe .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|comorbidities disabilities CKD T2DM dementia|osteosarcoma|any revenues generated will be limited by the number of patients with entity , our ability to obtain appropriate pricing and reimbursement for junovan , and the effects of competition .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|CRC NSCLC IBD psoriasis CLL|osteosarcoma|each year , approximately 1 , 000 new patients are diagnosed with entity in the united states .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|leukemias mammary sarcomas malignancies osteosarcoma|osteosarcoma|filed for a product license from the usda for at-014 , a novel her2 / neu-directed cancer immunotherapy for the treatment of canine entity and other cancers .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|Tuberculosis AIDS Asthma Influenza PML|osteosarcoma|entity is an orphan disease with fewer than 1 , 000 new cases diagnosed in the united states each year .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|NSCLC CRC osteosarcoma SCLC mesothelioma|osteosarcoma|cxcr4 antagonist to determine whether inhibition of cxcr4 leads to a decrease of lung metastases in a mouse model of entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|osteosarcoma glioblastoma mesothelioma glioma neuroblastoma|osteosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|hepatotoxicity colitis neurotoxicity diarrhea nephrotoxicity|osteosarcoma|it is unknown if tymlos will cause entity in humans .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|glioblastoma osteosarcoma glioma mesothelioma neuroblastoma|osteosarcoma|in subsequent testing in mouse xenograft models of neuroblastoma , ewing sarcoma , rhabdomyosarcoma and entity , clr 131 provided significant benefits on tumor growth rates and survival .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|NSCLC GBM CRC GIST SCLC|osteosarcoma|the standard treatment for entity is tumor resection with combination chemotherapy before and after surgery .
OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|AND osteosarcoma neuroblastoma adenocarcinoma squamous|orthotopic EMT xenograft TNBC adenocarcinoma|osteosarcoma|the presentation will discuss the work related to the anti-metastatic properties of ctce-9908 in an entity model and the potential mechanisms involved .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|GCT Primary Malignant arising chondro|sacral musculoskeletal bony neuroendocrine mesenchymal|chondrosarcoma|the most common locations for entity tumors are the bones of the extremities and the pelvis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|GCT Primary Malignant arising chondro|GCT osteosarcoma MTC ACC MM|chondrosarcoma|entity is a rare , life-threatening bone cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|GCT Primary Malignant arising chondro|osteosarcoma neuroblastoma retinoblastoma glioblastoma mesothelioma|chondrosarcoma|idh2 mutations have also been found in several solid tumor types such as melanoma , glioma and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|GCT Primary Malignant arising chondro|NSCLC mesothelioma SCLC adenocarcinoma glioblastoma|chondrosarcoma|we expect to announce additional data from the entity and malignant pleural mesothelioma treatment cohorts in the fourth quarter of 2020 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|GCT Primary Malignant arising chondro|cholangiocarcinoma adenocarcinoma glioblastoma meningioma mesothelioma|chondrosarcoma|idh1 mutation alterations are seen in aml , glioma , entity , and intrahepatic cholangiocarcinoma .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cancer|GCT Primary Malignant arising chondro|osteosarcoma neuroblastoma meningioma glioblastoma adenocarcinoma|chondrosarcoma|partial responses were seen , in one patient each , with entity , extra-skeletal myxoid entity , leiomyosarcoma and a desmoid tumor .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cancer|GCT Primary Malignant arising chondro|osteosarcoma osteogenic undifferentiated cutaneous osseous|chondrosarcoma|” in this phase 2 study , the single agent activity of krx-0401 is being evaluated in patients with entity , alveolar soft part sarcomas and extra-skeletal myxoid entitys .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|GCT Primary Malignant arising chondro|mesothelioma myeloma SCLC adenocarcinoma NSCLC|chondrosarcoma|at the 3 . 1 mg / m2 dose level , one patient with prostate cancer and one with entity had no dlt during 4 and 9 cycles of treatment , respectively .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|GCT Primary Malignant arising chondro|Tuberculosis ACC CRC Stroke SCC|chondrosarcoma|entity predominantly affects middle-aged and older adults , usually occurring in patients over 40 years old , with the incidence gradually increasing up
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|GCT Primary Malignant arising chondro|SCLC NSCLC mesothelioma adenocarcinoma MM|chondrosarcoma|both malignant pleural mesothelioma and entity are serious , life-threating medical conditions with very limited treatment options , for which inbrx-109 could fulfill an unmet medical need .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|GCT Primary Malignant arising chondro|NSCLC CRC PC SCLC PDAC|chondrosarcoma|the preclinical data support infinitys ongoing phase 2 double-blind , randomized , placebo-controlled trial of ipi-926 in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|GCT Primary Malignant arising chondro|mesothelioma NSCLC glioblastoma myeloma neuroblastoma|chondrosarcoma|and tolerability as a single agent in patients with advanced solid tumors with an idh1 mutation , including glioma , cholangiocarcinoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|GCT Primary Malignant arising chondro|NSCLC MM BC neuroblastoma CRC|chondrosarcoma|includes 2 patients with triple negative breast cancer , 1 renal cell carcinoma patient , 1 mesothelioma patient and 1 idh1 mutant entity patient .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|GCT Primary Malignant arising chondro|NSCLC CRC GBM PC PDAC|chondrosarcoma|in particular , there are no approved effective systemic therapy options for recurrent , unresectable and metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cancer|GCT Primary Malignant arising chondro|osteosarcoma Japan osteoporosis PC BC|chondrosarcoma|in the united states , entity accounts for approximately one-third of the 2 , 000 cases of primary bone cancer 5 table of contents diagnosed each year .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|GCT Primary Malignant arising chondro|NSCLC PC ESCC NPC CRC|chondrosarcoma|initiated a phase 2 clinical trial evaluating ipi-926 as a single agent in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|adenocarcinoma DCIS Primary serous cervix|papillary borderline serous infiltrating mucinous|cystadenocarcinoma|reactivity was higher in particular subsets of these cancers ; for example , over 80% of serous entity ovarian cancer tumors were reactive .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|adenocarcinoma DCIS Primary serous cervix|adenocarcinoma serous mucinous cholangiocarcinoma RCC|cystadenocarcinoma|the patients tumor types were as follows : colon , rectal , breast , pancreatic , esophageal , gastric , papillary entity , cholangiosarcoma , carcinoid , unknown primary .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|adenoma degeneration carcinomas hyperplasia dysplasia|carcinoma|hepatitis c viral infection ( " hcv " ) is a potentially deadly disease that , if not treated , may lead to cirrhosis and hepatocellular entity , or liver cancer .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma Carcinoma tumours neoplasm|carcinoma|dart study , a randomized , double-blind study of dalantercept plus axitinib , compared to placebo plus axitinib in patients with advanced renal cell entity ( rcc ) .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma Carcinoma cholangiocarcinoma cirrhosis|carcinoma|we are working to develop and potentially commercialize tivozanib in the u . s . as a treatment for rcc and hepatocellular entity , or hcc .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma Carcinoma adenoma malignancies|carcinoma|trials in colon cancer , gastric cancer , small cell lung cancer and hepatocellular entity are investigator-sponsored .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenoma adenomas Carcinoma adenocarcinoma|carcinoma|ended march 31 , 2002 , we disclosed plans to pursue phase 3 clinical studies with t67 for the treatment of hepatocellular entity , or primary liver cancer .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|adenocarcinoma NPC SCC carcinomas squamous|carcinoma|in addition , argx-110 is being evaluated in an open-label phase 1 clinical trial in patients with nasopharyngeal entity .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma Carcinoma neoplasm RCC|carcinoma|programs of archexin and will cease enrollment in the current phase iia clinical study of archexin in metastatic renal cell entity ( mrcc ) .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenoma adenomas foci neoplasms|carcinoma|by approximately 20 weeks of age , mice began to develop hepatocellular entity ( hcc ) .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|lysate trait harvest BC concentrate|carcinoma|net revenue from our two collaborations with genentech unless and until we obtain fda approval to commercialize our basal cell entity product candidate .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma malignancies Carcinoma tumours|carcinoma|approved in more than 80 countries and regions including the us , eu member states and japan for advanced renal cell entity following vascular endothelial growth factor-targeted therapy .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|glands duct ducts epithelium adenocarcinoma|carcinoma|; 32 : 1207–1218 vx15 ( pepinemab ) anti-sema4d antibody for cancer sema4d expression is concentrated at invasive margin of tumor mammary entity ( tubo .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma Carcinoma malignancies glioma|carcinoma|our focus on hepatocellular entity , or hcc , is based on the fact that liposomal nanoparticle formulations have a tendency to deliver their payload to the
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma Carcinoma adenoma hepatoma|carcinoma|t67 has shown activity in phase 1 and phase 2 trials for the treatment of hepatocellular entity , a refractory malignancy for which there are no approved systemic chemotherapeutic agents .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|adenocarcinoma carcinomas neoplasm glioblastoma Carcinoma|carcinoma|archexin received " orphan drug " designation from the fda for five cancer indications ( renal cell entity ( rcc ) , glioblastoma , ovarian cancer , stomach cancer and pancreatic cancer ) .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma malignancies adenocarcinomas tumours|carcinoma|we initiated a phase ii clinical trial in the third quarter of 2002 in patients with renal cell entity expressing the muc1 antigen .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma malignancies RCC TCC|carcinoma|when used in combination with the checkpoint inhibitor opdivo , nktr-214 showed important clinical responses in melanoma , renal cell entity and nsclc patients .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|Carcinoma dysplasia carcinomas adenocarcinoma hepatoma|carcinoma|with tekmira to develop sirna to silence the csn5 gene , which could represent a novel therapeutic target to treat hepatocellular entity ( hcc ) and other cancers .
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|adenocarcinoma carcinomas adenocarcinomas SCC neoplasm|carcinoma|lung cancer , including nsclc and small cell lung entity , or sclc , is the most common form of human cancer , and about 80% of diagnosed lung cancer cases are categorized
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|adenocarcinoma carcinomas urothelial serous squamous|carcinoma|bacillus calmette-guérin ( bcg ) -refractory entity in situ ( cis ) bladder cancer—cis of the urinary bladder is a rare form of bladder cancer , affecting about 7 of
OrderedDict([('DIS', 4), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cervix DCIS squamous hepatocellular adenocarcinoma|carcinomas adenocarcinoma Carcinoma malignancies neoplasm|carcinoma|renal cell entity doesn  t respond to chemotherapy and 15 to 20% of the patients respond to cytokine ( il2 or ifn-y ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|mesothelioma NSCLC SCLC neuroblastoma glioblastoma|cholangiocarcinoma|phase 1 / 2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer ( nsclc ) , ovarian cancer , malignant pleural / peritoneal mesothelioma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|cholangiocarcinoma gallbladder papillary adenocarcinoma pancreas|cholangiocarcinoma|biliary cancers , including entity , gallbladder and ampullary carcinoma , are cancers originating in the bile duct , a vessel that transports bile from the liver to
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|NSCLC MM T2DM CLL psoriasis|cholangiocarcinoma|[ *** ] after a specified period of time following regulatory approval of varlitinib for the treatment of entity in south korea and ( ii ) milestone payments of $
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|India Europe France Germany Japan|cholangiocarcinoma|additionally , we made a payment of $325 , 000 to hyundai in order to buy back the rights to commercialize varlitinib in entity ( cca ) and recorded as operating costs in february 2019 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|mesothelioma glioblastoma NSCLC glioma osteosarcoma|cholangiocarcinoma|that ros1 is rearranged in non-small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , gastric cancer patients and entity patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|NSCLC TKI gefitinib imatinib trastuzumab|cholangiocarcinoma|in november , the fda accepted the new drug application ( nda ) for pemigatinib in second-line entity for priority review .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|colitis pancreatitis cholangiocarcinoma mesothelioma glioma|cholangiocarcinoma|compared to phenoxodiol , triphendiol has substantially greater activity in laboratory testing against pancreatic cancer and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|NSCLC SCLC mesothelioma ESCC CRC|cholangiocarcinoma|dkn-01 is in clinical trials in esophageal cancer and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|NSCLC CRC GIST GBM PDAC|cholangiocarcinoma|the fda has also granted fast-track designation to ivosidenib for treatment of patients with previously treated , unresectable or metastatic entity with and idh1 mutation .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|gallbladder cholangiocarcinoma biliary colorectal extrahepatic|cholangiocarcinoma|had been granted orphan drug status by the fda for the treatment of pancreatic cancer and for the treatment of entity , or bile duct cancer .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|malignancies cholangiocarcinoma carcinomas tumours neoplasms|cholangiocarcinoma|biliary tract cancer consists of intra-hepatic and extra-hepatic entity ( cancer of the bile duct ) , cancer of the gall bladder and papilla of vater ( the final portion of the bile
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|CRC PC BC PLC CLD|cholangiocarcinoma|one type of liver cancer ( entity ) that is rare in most parts of the world has high incidence rates in thailand and other parts of asia
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|cholangiocarcinoma extrahepatic intrahepatic adenocarcinoma cholestasis|cholangiocarcinoma|the development of rly-4008 will focus on solid tumor patients with fgfr2 alterations , including intrahepatic entity ( icc ) patients harboring fgfr2 gene fusions .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|steatosis cholestasis shunting cirrhosis congestion|cholangiocarcinoma|“icca” means intrahepatic entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|urothelial NSCLC adenocarcinoma TCC colorectal|cholangiocarcinoma|in october 2017 , we initiated a phase 1b / 2 clinical trial to assess tecentriq with pegph20 in patients with entity and gall bladder cancer ( halo 110-101 / matrix ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DRUG', 1), ('DIS', 1)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|CNV AMD PAH GBM PCV|cholangiocarcinoma|opaganib received orphan drug designation from the u . s . fda for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|NSCLC SCLC CRC mesothelioma cholangiocarcinoma|cholangiocarcinoma|dkn-01 is currently being studied in clinical trials in esophageal cancer and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|demonstrating undergo achieving approved Any|cholangiocarcinoma|breast cancer gastric cancer , nsclc pancreas cancer , gastric cancer gall bladder cancer , entity robust pan-tumor testing of pegph20 17 1 pending continued enrollment rate .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|mesothelioma osteosarcoma NSCLC neuroblastoma retinoblastoma|cholangiocarcinoma|studies suggest that ros1 is rearranged in non small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , and entity patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cancer|cholangiocarcinoma adenocarcinoma unresectable AND cirrhosis|NSCLC PDAC MBC Asian mesothelioma|cholangiocarcinoma|the company commenced a second combination trial , examining the combination of prolindac and gemcitabine in entity patients , in the fourth quarter of 2011 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|neovascularization psoriasis BCC Malignant pigmented|perforation restenosis esophagitis ulceration ISR|keratoacanthoma|in the pooled safety population , cuscc and entity occurred in 7% and 1 . 9% of 351 patients , respectively .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|neovascularization psoriasis BCC Malignant pigmented|rash neuropathy neurotoxicity diarrhea neutropenia|keratoacanthoma|the two trsaes included a grade 2 infusion reaction and a grade 1 entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|neovascularization psoriasis BCC Malignant pigmented|BCC SCC adenocarcinoma melanomas dysplasia|keratoacanthoma|tafinlar results in an increased incidence of cutaneous squamous cell carcinoma ( cuscc ) , entity and melanoma .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cancer|neovascularization psoriasis BCC Malignant pigmented|SCC BCC adenocarcinoma melanomas dysplasia|keratoacanthoma|in the columbus trial , cutaneous squamous cell carcinoma , including entity , occurred in 2 . 6% and basal cell carcinoma occurred in 1 . 6% of patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|neovascularization psoriasis BCC Malignant pigmented|BCC SCC melanomas adenocarcinoma MM|keratoacanthoma|cutaneous squamous cell carcinoma , including entity , occurred in 7% of patients receiving the combination and 19% of patients receiving tafinlar as a single agent .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma ductal malignancies neuroendocrine acinar|adenocarcinoma|treatment of cervical cancer and other solid tumors , including head and neck cancer , squamous non-small-cell lung cancer , or nsclc , pancreatic entity and colorectal cancer .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma Carcinoma adenocarcinomas SCC Tumor|adenocarcinoma|entity of the pancreas , which accounts for approximately 95% of all cases of pancreatic cancer , has a median overall survival of
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|glioblastoma NSCLC oncology glioma CRC|adenocarcinoma|o ing-1 is a human engineered ( tm ) monoclonal antibody developed by us to specifically target tumor cells in entity patients .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma PC adenocarcinomas cholangiocarcinoma PLC|adenocarcinoma|it is estimated that around 65 , 000 patients were diagnosed with pancreatic cancer ( mainly entity ) in the united states and the top 5 eu countries .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma malignancies NET adenocarcinomas neoplasms|adenocarcinoma|of medicine , which investigated marker therapeutics , inc . s ( the “company” ) multitaa t cell therapy for the treatment of patients with pancreatic entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma malignancies neoplasms islets NET|adenocarcinoma|clinical trial led by baylor college of medicine ( bcm ) , evaluating the companys multitaa t cell therapy in patients with pancreatic entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma adenocarcinomas carcinomas PDAC Carcinoma|adenocarcinoma|am0010 development for the treatment of pancreatic ductal entity in our phase 1 / 1b clinical trial , we treated 22 pdac patients with am0010 monotherapy and 21 patients with am0010 in
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma adenocarcinomas carcinomas malignancies NSCLC|adenocarcinoma|trial evaluating keytruda as monotherapy and in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma adenocarcinomas adenoma osteosarcoma mesothelioma|adenocarcinoma|types of nsclc include squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|squamous NSCLC neuroendocrine anaplastic mucosal|adenocarcinoma|studies suggest that ros1 is rearranged in non small cell lung entity cancer patients , stomach cancer patients , glioblastoma patients and cholangiocarcinoma patients .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma adenocarcinomas carcinomas malignancies PDAC|adenocarcinoma|the u . s . food and drug administration ( fda ) approved abraxane in combination with gemcitabine as first-line treatment of patients with metastatic entity of the pancreas .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma adenocarcinomas carcinoid undifferentiated anaplastic|adenocarcinoma|about 85% of lung cancers are nsclc , which has different subtypes , including squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma SCC carcinomas BC ductal|adenocarcinoma|the study will target enrolling 35 patients with histologically or cytologically confirmed diagnosis of invasive entity originating in the breast .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma carcinomas hyperplasia malignancies PCa|adenocarcinoma|and multiple myeloma , and expects to commence clinical trials of maxamine for the treatment of additional cancers , such as prostate entity , in 1998 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma adenocarcinomas carcinomas malignancies neoplasms|adenocarcinoma|high msi is present in about 15% of gastrointestinal tumor cancers , including in approximately 22% of stomach entity and 16% of colorectal cancer .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|Carcinoma CIN Tuberculosis BPH SCC|adenocarcinoma|entity is a general term that refers to a cancer that starts in glandular tissues anywhere in the body .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|serovar serogroup virulent PV STI|adenocarcinoma|· inability to detect entitys — pap tests are unable to detect the presence of the more virulent entity ( clinical laboratory medicine , 20 : 140 ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma adenocarcinomas carcinomas malignancies PDAC|adenocarcinoma|abraxane® was approved for the treatment of metastatic entity of the pancreas in the united states in september 2013 and the european union in december 2013 . net sales of abraxane®
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma adenocarcinomas PDAC carcinomas PC|adenocarcinoma|our phase 1 clinical trial , which was a safety and tolerability study in patients with previously treated metastatic pancreatic ductal entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|adenocarcinoma NSCLC squamous colorectal cervix|adenocarcinoma carcinogenesis carcinomas maturation NSCLC|adenocarcinoma|the first target of the collaboration is early stage lung entity .
OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cancer|GCT blast neuroblastoma blasts CML|profession professionals Sciences graduates addiction|blastoma|neuroentity - market insights , epidemiology and market forecast - 2027 the market of neuro entity in 7mm was found to be usd 733 . 58 million in 2016 , and is expected to increase at from 2016 -
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|extrahepatic extracranial locoregional nodal bony|melanoma|five patients experienced entity relapses shortly after inclusion in the trial and despite initiation of standard treatment had progressing metastases at start of their
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|randomised multicenter investigational pivotal multicentre|melanoma|that our cash reserves are sufficient to fund two years of anticipated operating activities , including our recently announced phase ii entity combination trial .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|glioblastoma colorectal glioma neuroblastoma osteosarcoma|melanoma|in preclinical studies conducted by the company  s scientists , tlc ell-12 has been shown to be active in tumor models of entity , lung cancer , leukemia and multiple drug resistant cell lines .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|melanomas CRC NSCLC osteosarcoma malignancies|melanoma|provectus has completed phase 2 trials of pv-10 as a therapy for metastatic entity , and of ph-10 as a topical treatment for atopic dermatitis and psoriasis .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|ct mock historical MM sham|melanoma|• data from the nsclc and entity cohorts of the encore 601 trial will each be featured during oral presentations at the american association of cancer research
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|spasticity AIDS diarrhea BV rabies|melanoma|bms / p  s most advanced program involves a vaccine called gmk that incorporates qs-21 with a ganglioside preparation called gm2 to treat entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|CRC osteosarcoma NSCLC melanomas RCC|melanoma|what im trying to say here is we have completely changed the outcome and treatment of patients with metastatic entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|NSCLC CRC CKD SCLC BC|melanoma|we introduced canvaxin that was manufactured using this new process into our two phase 3 clinical trials for advanced-stage entity in 2003 .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|carcinomas malignancies CRC cholangiocarcinoma NSCLC|melanoma|triphendiol has recently been granted orphan drug status by the fda for pancreatic and bile duct cancers , and late stage entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|cirrhosis hepatitis sorafenib hepatoma hepatocellular|melanoma|the company has received orphan drug designations from the fda for its entity and hepatocellular carcinoma indications .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|CRC melanomas malignancies RCC NSCLC|melanoma|accordingly , a comparable distribution of patients with liver metastases is important in clinical trials of metastatic entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|CRC NSCLC RCC melanomas osteosarcoma|melanoma|it was approved to treat metastatic entity by the fda in 2015 .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|NSCLC malignancies CRC HNSCC STS|melanoma|the first oncolytic immunotherapy , imlygic , also known as t-vec , which was approved by the fda for the treatment of advanced entity in 2015 .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|RCC NSCLC mesothelioma adenocarcinoma CRC|melanoma|have completed enrollment in part i of a phase 3 trial for renal cell carcinoma and a phase 3 trial for metastatic entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|mesothelioma glioma gliomas CRC BC|melanoma|the improvement in two and three year survival remained statistically significant in the subpopulation of advanced malignant entity patients with liver metastases .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|MDS CRC neuroblastoma PCa NSCLC|melanoma|the pivotal phase iii study in high-risk entity patients completed enrollment in 1999 .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|glioblastoma neuroblastoma adenocarcinoma glioma osteosarcoma|melanoma|product has potential utility in adjuvant therapy and for the treatment of advanced cancers that express the gd2 ganglioside , including entity , small cell lung cancer and sarcoma .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|NSCLC CRC PC RCC PCa|melanoma|we  re recruiting patients with metastatic entity for a phase i safety study in israel .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|gliomas mesothelioma glioma hyperthermia neoplasms|melanoma|and metastatic breast cancer ; and intron a injection , marketed for numerous anticancer indications worldwide , including as adjuvant therapy for malignant entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|cancer|neuroblastoma psoriasis neovascularization adenocarcinoma vulgaris|monotherapy pivotal vaccination investigational randomised|melanoma|the most common adverse events associated with our entity trials have consisted of flu-like symptoms such as fever , chills and nausea .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|osteosarcoma meningioma neuroblastoma glioblastoma synovial|leiomyosarcoma|or cbr , rates was achieved in the three most prevalent types of sarcoma , namely bone sarcoma ( cbr rate of 30% ) , entity ( 33% ) and liposarcoma ( 30% ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|neuroblastoma meningioma mesothelioma glioblastoma lymphomas|leiomyosarcoma|these include patients with osteosarcoma , ewing sarcoma family tumours , malignant fibrous histiocytoma , synovial sarcoma , fibrosarcoma and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|recruitment latter registry epidemiological landmark|leiomyosarcoma|the entity study was initiated and screening of patients began in early 2006 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|NSCLC responder evaluable MBC CLL|leiomyosarcoma|we also enrolled a first entity patient in the phase 2 basket arm evaluating ide196 as monotherapy , expanding the tissue-agnostic approach to additional solid tumors harboring
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|NSCLC BC CRC MM adenocarcinoma|leiomyosarcoma|out of 2 heavily pre-treated stage iv entity patients and 1 heavily pre-treated triple negative breast cancer patient experienced stable disease as best response .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|glial astrocytic glioblastoma neuroendocrine neuroblastoma|leiomyosarcoma|developed a fully-human antibody , designated imc-3g3 , that effectively blocks the function of pdgfra and inhibits the growth of glioblastoma and entity tumors in animal models .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|lymphomas mesothelioma gliomas melanomas leukemias|leiomyosarcoma|elevated cd47 has been reported in solid tumors , including breast , colon , ovarian , brain , liver and prostate cancers and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|mesothelioma CLL GBM osteosarcoma neuroblastoma|leiomyosarcoma|doxorubicin has historically been the standard of care for the treatment of entity and other sts .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|osteosarcoma meningioma glioblastoma neuroblastoma synovial|leiomyosarcoma|this multicenter clinical trial is to assess the efficacy of ap23573 in four groups of sarcomas : bone sarcoma , entity , liposarcoma , and other soft tissue sarcomas .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|diffuse glioblastoma astrocytoma sporadic GBM|leiomyosarcoma|●results by year end are expected from ongoing clinical trials evaluating ptc596 in entity and diffuse intrinsic pontine glioma ( dipg ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|colorectal NSCLC squamous nasopharyngeal oropharyngeal|leiomyosarcoma|on these findings , as well as pre-clinical data , the phase 2 dose employed in the arq 501 monotherapy trials in entity and head and neck cancer is 450 mg / m2 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|monotherapy CLL responders DLBCL myeloma|leiomyosarcoma|ptc596 is also being evaluated in entity , or lms , in patients who have relapsed or are refractory to current treatments .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|osteosarcoma neuroblastoma meningioma glioblastoma retinoblastoma|leiomyosarcoma|the most common types of sarcoma in adults are undifferentiatedpleomorphic sarcoma ( previously called malignant fibrous histiocytoma ) , liposarcoma , and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|osteosarcoma sarcomas meningioma neuroblastoma glioblastoma|leiomyosarcoma|clinical-benefit responses were demonstrated in 39% of bone sarcoma patients , 50% of entity , 21% of liposarcoma , and 24% of other soft-tissue sarcomas .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|osteosarcoma sarcomas meningioma glioblastoma neuroblastoma|leiomyosarcoma|the 246 patients with entity or liposarcoma comprise 57% of the total trial population .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|pivotal definitive registry latter multicenter|leiomyosarcoma|interim data from the entity study show a 17 . 5 percent objective response rate among patients to monotherapy treatment with arq 501 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|meningioma osteosarcoma synovial adenocarcinoma sarcomas|leiomyosarcoma|-- the cbr rates were not statistically different among the four sub-groups ( i . e . , bone , 30% ; entity , 33% ; liposarcoma , 30% ; and other , 23% ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|osteosarcoma neuroblastoma sarcomas glioblastoma retinoblastoma|leiomyosarcoma|axl is a tyrosine kinase receptor that is highly expressed and activated in numerous human sarcomas , including aggressive subtypes of entity , ewings sarcoma and liposarcoma .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|osteosarcoma sarcomas adenocarcinoma gliomas carcinomas|leiomyosarcoma|entity and liposarcoma are the two most common types of sts and accounted for 57% of the patients enrolled in the
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|stromal cervix osteosarcoma neuroblastoma sarcomas|osteosarcoma glioblastoma STS neuroblastoma sarcomas|leiomyosarcoma|trabectedin ( yondelis® ) was approved in 2015 for patients with entity or liposarcoma that have had prior treatment with an anthracycline such as doxorubicin .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 2)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|neuroblastoma malignancies oncology ALL osteosarcoma|rhabdomyosarcoma|indications for our impact therapeutic vaccines and have developed cell lines for ovarian cancer , triple negative breast cancer and pediatric entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|lymphomas glioblastoma neuroblastoma CML astrocytoma|rhabdomyosarcoma|vincristine is used to treat hodgkin  s disease , leukemia , entity , neuroblastoma , and wilms  tumor .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|neuroblastoma glioblastoma retinoblastoma ALL glioma|rhabdomyosarcoma|rare pediatric disease designations and odds were granted for the treatment of , neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|glioblastoma glioma neuroblastoma osteosarcoma mesothelioma|rhabdomyosarcoma|in 2018 , the fda granted orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 2)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|neuroblastoma retinoblastoma osteosarcoma glioblastoma ALL|rhabdomyosarcoma|granted orphan drug designation to clr 131 , the companys lead phospholipid drug conjugate™ ( pdc ) product candidate , for the treatment of entity , a rare pediatric cancer .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|osteosarcoma glioblastoma neuroblastoma glioma mesothelioma|rhabdomyosarcoma|since then the drug has been used to treat various types of cancer , including wilms tumor , entity , ewing  s sarcoma , trophoblastic neoplasm , and testicular cancer .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|glioblastoma glioma meningioma neuroblastoma osteosarcoma|rhabdomyosarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|glioblastoma neuroblastoma glioma mesothelioma osteosarcoma|rhabdomyosarcoma|pv-10 is also undergoing preclinical study for pediatric solid tumor cancers ( including neuroblastoma , ewing sarcoma , entity , and osteosarcoma ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|glioblastoma meningioma glioma neuroblastoma osteosarcoma|rhabdomyosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|feline osteosarcoma canine mammary murine|rhabdomyosarcoma|description / conclusion the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|conjunction front NSCLC collaboration tandem|rhabdomyosarcoma|the nci has initiated a phase i / ii clinical trial in entity of ganitumab with the kinase inhibitor dasatinib based on promising preclinical animal model data with this combination .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|glioblastoma neuroblastoma mesothelioma glioma CML|rhabdomyosarcoma|multiple myeloma as well as orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|osteosarcoma hemangioma sarcomas neuroblastoma RMS|rhabdomyosarcoma|“entity is the most common type of tissue sarcoma in children .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|osteosarcoma mammary feline murine embryo|rhabdomyosarcoma|the poster covers preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|osteosarcoma mammary feline glioblastoma embryo|rhabdomyosarcoma|the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|osteosarcoma DMD neuroblastoma sarcomas GCT|rhabdomyosarcoma|entity is a skeletal muscle neoplasm occurring primarily in the first decade of life , while osteosarcoma , a bone neoplasm , occurs primarily
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|osteosarcoma glioblastoma mesothelioma meningioma glioma|rhabdomyosarcoma|is to investigate the gene expression patterns stimulated by sca using two malignant tumor cell lines , saos-2 ( osteosarcoma ) and rd ( entity ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|neuroblastoma rhabdomy osteosarcoma stromal anaplastic|NSCLC CRC glioma colitis glioblastoma|rhabdomyosarcoma|the nci has conducted pk / pd and dose escalation studies in preclinical models of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|autoimmune_disease|psoriasis proliferative neuropathy lupus occlusive|Disease AND Diseases arthritis sclerosis|polyradiculoneuropathy|oral 2008 2015 / iii chronic inflammatory demyelinating entity 2012 2016 / iii hsc835 tbd stem cell regeneration stem cell transplantation
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|autoimmune_disease|psoriasis proliferative neuropathy lupus occlusive|polyneuropathy neuropathy demyelinating PNS encephalomyelitis|polyradiculoneuropathy|a phase ii / iii study of gilenya in patients with chronic inflammatory demyelinating entity was initiated in 2012 .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|autoimmune_disease|psoriasis proliferative neuropathy lupus occlusive|polyneuropathy syndromes encephalomyelitis neuropathy fever|polyradiculoneuropathy|development work for a u . s . pediatric indication to treat primary immunodeficiencies and a phase 3 indication in chronic inflammatory demyelinating entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|osteoporosis infertility abortion anemia prolapse|hypertension|addition , matria provides home healthcare services for the management of other complicated obstetrical and gynecological conditions , such as pregnancy induced entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|sedation hypotension desaturation discomfort tilt|hypertension|however , the letter indicated that such a boxed warning could be reconsidered if suitable data demonstrating a lack of severe entity in a fully supine position were provided .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|allergies eczema migraine allergy psoriasis|hypertension|aventis claims its therapeutic innovations rank among the leading treatments for lung and breast cancer , thrombosis , seasonal allergies , diabetes and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|parenchyma congestion vasoconstriction infiltrates vasculature|hypertension|pulmonary entity in interstitial lung diseases market there are no therapies currently approved for ph-ild .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|cardiology oncology physiology echocardiography pharmacology|hypertension|dr . oparil has an extensive bibliography in clinical cardiology and entity , including over 350 journal articles , books and book chapters .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|T2DM psoriasis glaucoma BPH migraine|hypertension|the subpoena requests documents relating to benicar® , benicar hct® , and azor® , prescription medications approved for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|angina CHF COPD syncope hypercholesterolemia|hypertension|the king board made note of mylans proprietary product nebivolol , a beta blocker for the treatment of entity , the nda for which was accepted for filing in june by the fda .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|oedema embolism thromboembolism emphysema hypoplasia|hypertension|he was responsible for the clinical trials and subsequent approval of inhaled nitric oxide for the treatment of persistent pulmonary entity of the newborn .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|thromboembolism calcification leak Hypertension pressures|hypertension|release announcing united states food and drug administration approval of intravenous dosing of remodulin for the treatment of pulmonary arterial entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|hypertensive glaucoma hypotension Hypertension tamponade|hypertension|rhopressa® , and our product candidate , roclatantm , are designed to lower intraocular pressure ( iop ) in patients with open-angle glaucoma or ocular entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|rash diarrhea fever urticaria alopecia|hypertension|most common non-hematologic adverse reactions : ( ≥20% ) were entity , rash , abdominal pain , fatigue , headache , dry skin , constipation , arthralgia , nausea , and pyrexia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|dyslipidemia hypercholesterolemia hyperlipidemia hyperglycemia MetS|hypertension|have been found to be an independent predictor of a number of cardiovascular risk factors including obesity , abnormal lipid levels , entity , type 2 diabetes , and systemic inflammation .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 2), ('BIO', 1)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|CHF hypercholesterolemia osteoporosis angina hypotension|hypertension|about plendil plendil ( felodipine ) is a calcium antagonist for the treatment of entity and angina .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|psoriasis acne T2DM NSCLC COPD|hypertension|lotrel ( +11% us ) , the leading us fixed combination treatment for entity , sustained double-digit sales growth well ahead of market ( +6% ytd ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|tremor insomnia RLS anaemia hypercholesterolemia|hypertension|therapy for depression , is approved in the united states as inversine for the management of moderately severe to severe essential entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|pheochromocytoma insomnia hyperthyroidism hypercholesterolemia migraine|hypertension|phentolamine has been approved by the fda for the treatment of entity and for use in the diagnosis of certain tumors of the adrenal gland , and has been used " off-label " by urologists ,
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|analgesia Pain analgesic headache morphine|hypertension|partner product / candidate application status teva clonidine tds entity marketed par fentanyl tds pain marketed p&g crest whitestrips ( 5 products )
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|embolism infiltrates thromboembolism emphysema congestion|hypertension|pulmonary entity may be present in as many as 74% of patients depending on how the pulmonary entity ( “ph” ) is defined .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 2)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|anemia T2DM anaemia angina hemophilia|hypertension|we cannot be certain that darusentan for the treatment of resistant entity will be approved in the united states or in countries outside of the united states or whether marketing approvals will
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|uncontrolled mellitus Uncontrolled pectoris hyperlipidemia|acne constipation diarrhea pruritus IBS|hypertension|except for inversine for the management of entity , neither the fda nor any foreign regulatory authority has approved any of our product candidates for marketing .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|Europe Japan Canada Asia France|vasculitis|dr . jaynes research includes investigator-initiated international trials and the introduction of newer therapies in entity and sle with collaborators on five continents .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|arthritis vasculitis dermatitis ulcer psoriasis|vasculitis|ifx-1 is currently being developed for various inflammatory indications , including hidradenitis suppurativa , anca-associated entity and pyoderma gangraenosum .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|vasculitis arthritis uveitis glomerulonephritis purpura|vasculitis|rituxan we are currently planning for phase iii clinical trials in systemic lupus eruthematosus , lupus nephritis and anca-associated entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|vasculitis arthritis purpura entities autoantibodies|vasculitis|ccx168 for anca-associated entity understanding anca-associated entity ancas are autoantibodies that attack certain type of white blood cells called neutrophils .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|arthritis dermatitis pneumonia vasculitis colitis|vasculitis|ifx-1 is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and covid-19 induced pneumonia .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|Inflammation Hypertension Diabetes Osteoarthritis Obesity|vasculitis|entity is an inflammatory process of blood vessels , histopathologically characterized by vessel wall destruction and occlusion of the vascular lumen .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|scleroderma psoriasis fibromyalgia gout migraine|vasculitis|test could be used by clinicians in the management of several autoimmune diseases , including but not limited to rheumatoid arthritis , entity and irritable bowel disease .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|SLE inactive quiescent refractory lupus|vasculitis|in 2012 , we plan to initiate phase 3 trials of benlysta in entity and active lupus nephritis .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|neurodegeneration malignancies carcinogenesis tumorigenesis colitis|vasculitis|of those cells to do damage in response to c5a activation , which is known to be the driver of anca-associated entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|purpura amyloidosis vulgaris urticaria arthritis|vasculitis|all iga protease-mediated diseases , including iga nephropathy , linear iga bullous dermatitis , iga pemphigus , and henoch-schonlein purpura ( also known as iga entity ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|tolerable worse absent insignificant intense|vasculitis|the method of claim 1 , wherein the adverse effect is entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|psoriasis migraine alopecia arthritis pruritus|vasculitis| completed enrollment of the companys pivotal phase iii advocate trial of avacopan for the treatment of anca-associated entity ; top line data expected in the fourth quarter of 2019 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|deposition deposits thrombi aggregation breakdown|vasculitis|toxicological findings included changes in hematologic and chemistry parameters and fibrinoid entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|scleroderma psoriasis SLE autoimmunity vasculitis|vasculitis|actually , my first experience outside of ms was treating a condition called entity and thats another autoimmune disease .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|vasculitis glomerulonephritis nephropathy arthritis nephritis|vasculitis|rituxan is also being evaluated in lupus nephritis and anca-associated entity in collaboration with biogen idec .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|exacerbation attack rash cough latter|vasculitis|in egpa , patients usually develop asthma initially , before the entity extends to inflammation in the walls of small blood vessels that supply tissues in the lungs , sinuses , skin , nerves and
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|dermatitis rash purpura vasculitis syndromes|vasculitis|as basal cell cancer in the area of laviv® injections and the risk of immune-mediated hypersensitivity reactions such as leukocytoclastic entity ) , which must be completed by 2016 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|vasculitis glomerulonephritis nephropathy uveitis lupus|vasculitis|anca-associated entity is a rare autoimmune disease that largely affects the small blood vessels of the kidneys , lungs , sinuses , and a variety
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|arthritis dermatitis alopecia psoriasis vasculitis|vasculitis|vilobelimab is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and severe covid‑19 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|psoriasis vulgaris uncontrolled vasculitis mellitus|arthritis vasculitis uveitis neuropathy myelopathy|vasculitis|evaluated in phase iii clinical trials for anti-tnf ( tumor necrosis factor ) refractory rheumatoid arthritis , primary progressive multiple sclerosis , and anca-associated entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma vasculitis arteri astrocytoma granulomas|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-large blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma astrocytoma granulomas arteri vasculitis|arteritis|abbvie initiated a phase 3 clinical trial to evaluate the efficacy and safety of upadacitinib in subjects with giant cell entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma arteri vasculitis astrocytoma granulomas|arteritis|targeting gm-csfrα ) ·kiniksa recently announced positive data from the global phase 2 clinical trial of mavrilimumab in giant cell entity ( gca ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|arteri granuloma arterio angio pan|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the medium-to-large arteries that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma vasculitis myocarditis granulomas arteri|arteritis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma arteri vasculitis astrocytoma aneurysms|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , or gca , an inflammatory disease of the blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma astrocytoma granulomas arteri aneurysms|arteritis|current treatment landscape for giant cell entity glucocorticoids , a type of corticosteroid , are the mainstay for the treatment of gca because they normalize inflammatory markers and resolve
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma granulomas myocarditis vasculitis astrocytoma|arteritis|testing gevokizumab in a variety of small clinical studies , including polymyositis / dermatomyositis and schnitzler syndrome ; a third study in giant cell entity , is expected to open shortly .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma vasculitis myocarditis granulomas arteri|arteritis|in 2013 , servier began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|restenosis acceptance mucositis retinopathy angiogenesis|arteritis|developed to address the accelerated inflammation of grafted blood vessels common in chronic organ transplant rejection and known as transplant entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma granulomas astrocytoma aneurysms arteri|arteritis|an ongoing phase iii study , announced in november 2015 , is currently investigating sirukumab in giant cell entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|arteri granuloma angio arterio haem|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the blood vessels that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma granulomas vasculitis encephalitis myocarditis|arteritis|the focus of these compounds appears to be in chronic autoimmune disorders such as rheumatoid arthritis , ankylosing spondylitis , giant cell entity and related disorders .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|vasculitis granuloma arteri hyperplasia aneurysms|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-to-large arteries .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma granulomas vasculitis arteri astrocytoma|arteritis|· kiniksa plans to advance to a phase 2 clinical trial of mavrilimumab for the treatment of giant cell entity in the second half of 2018 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|angina pectoris psoriasis vasculitis mellitus|granuloma arteri eosinophilia vasculitis granulomas|arteritis|in november 2015 gsk announced the start of a phase iii study of sirukumab for patients with giant cell entity ( gca ) , and plans to start a study in asthma were disclosed at gsk  s r&d day .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|AEs hypoglycemia agitation toxicities hypoglycaemia|phlebitis|intermune requested this self-imposed clinical hold in part due to the observance of entity at the infusion site judged to be unexpectedly greater in incidence and severity than anticipated .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|ulceration neovascularization vasculitis neuropathy neither|phlebitis|levels were generally well tolerated with one subject at the 5 mg / kg dose level experiencing moderate localized blood vessel inflammation , or entity , that was attributed to the study drug .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|itching irritation discomfort erythema neuropathy|phlebitis|the product may also cause entity ( vein irritation ) in approximately one-third of treated patients .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|embolism thrombus embolization emboli veins|phlebitis|for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery - thrombus deep entity , etc .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|embolism thrombus embolization emboli hematoma|phlebitis|hepatitis ) propylgallate for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery-thrombus deep entity , etc .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|hematoma tearing itching extravasation irritation|phlebitis|blood collection by venipuncture is associated with mild discomfort , and the possibility of localized bruising , entity , or extravasation .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|vasoconstriction vasospasm hypotension arrhythmias ischaemia|phlebitis|other events such as entity , mechanical block of the capillaries or arterioles , activation of platelets , or subsequent generation of microthrombi are also possible .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|bacteremia pneumothorax thromboembolism pneumonia VTE|phlebitis|peripheral venous catheters have been associated with a 7% to 9% incidence of entity and a 0 . 2% to 0 . 4% incidence of bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|itching irritation vasoconstriction pruritus discomfort|phlebitis|sdp-016 is designed to reduce the vein irritation and entity associated with the iv-delivered drug .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|cure QOL hope QoL remission|phlebitis|in terms of entity , which is another thing that the fda mentioned in their complete response , that is something that we feel has been
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|AEs toxicities rash erythema neutropenia|phlebitis|patients who received dyloject ( tm ) also had a lower incidence and severity of entity at the site of intravenous administration compared to those given voltarol ( r ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|bacteremia pneumonia osteomyelitis fever neutropenia|phlebitis|peripheral venous catheters have been associated with entity and bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|recurrences amputation relapses failures SSI|phlebitis|we believe that some clinicians elect to use a central line or a different chemotherapeutic regimen as a means to avoid entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|nephrotoxicity neurotoxicity pruritus erosion solubility|phlebitis|we believe the current formulations of these drugs have limitations , such as entity , erythema and hypersensitivity reactions , that present opportunities for improvement .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|pruritus vomiting itching diarrhea irritation|phlebitis|the most common adverse reactions in clinical trials associated with cinryze were rash , headache , nausea , erythema , entity and local reactions at the injection site .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|ulceration ulcer scar superficial mucosal|phlebitis|local none pain pain and swelling with inflammation or entity ulceration plastic surgery indicated fever of unknown origin
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|hydrocephalus meningitis vasospasm embolism haemorrhage|phlebitis|cerebral infarction and thrombosis , brain damages like apoplectic sequela , cerebral trauma , brain surgery sequela , also used for thromboangitis obliterans and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|anemia neuropathy thrombocytopenia neurotoxicity diarrhea|phlebitis|clinically significant toxicities observed to date include neutropenia , thrombocytopenia and mild to moderate entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|headache nausea erythema thrombocytopenia itching|phlebitis|the main side effect at the maximum dose tested was moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|neuropathy psoriasis Peripheral ulcer Symptomatic|headache nausea neuropathy neurotoxicity GI|phlebitis|the main side effect at the maximum dose tested has been moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|psoriasis ulcer neuropathy claudication vasculitis|embolism ischaemia DVT embolization veins|thrombophlebitis|eight of the patients had pulmonary embolism and / or deep vein thrombosis with three additional patients reporting an event of superficial entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|cardiovascular_disease|psoriasis ulcer neuropathy claudication vasculitis|lipase ALT postprandial ULN triglycerides|thrombophlebitis| 1 % elevated lipase   1 % entity ( associated with infusion sites )  1 %  a for the
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|psoriasis ulcer neuropathy claudication vasculitis|superficial hematoma veins embolism ulcer|thrombophlebitis|events included : deep venous thrombosis , pulmonary embolism , superficial entity , and retinal vein thrombosis with vision loss .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|psoriasis ulcer neuropathy claudication vasculitis|SSI ulcers hematoma wounds DVT|thrombophlebitis|no venous thromboembolism events or occurrences of superficial entity were observed or reported .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|psoriasis ulcer neuropathy claudication vasculitis|thromboembolism thromb dissection vasospasm thrombus|thrombophlebitis|thalidomide in combination with other agents may have an increased incidence of thromboembolic events such as pulmonary embolism , deep vein entity , entity , or thrombosis .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|psoriasis ulcer neuropathy claudication vasculitis|next latter worst opposite missing|thrombophlebitis|both saes have subsequently resolved , with the entity sae verbally reported to the company as resolved following the safety data cut-off date .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|psoriasis ulcer neuropathy claudication vasculitis|Toxicity Pain itching pruritus GI|thrombophlebitis|entity ( vein irritation ) was significantly less with dyloject than with ketorolac or placebo .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|embolism thromboembolism DVT thrombus pneumothorax|thromboembolism|pulmonary embolism : a pulmonary embolism , or entity , occurs when a blood clot , generally a venous thrombus , becomes dislodged from its site of formation and embolizes to the
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|arrhythmias arrhythmia thromboembolism pneumonia coagulopathy|thromboembolism|poaf is independently associated with an increased risk of morbidity and mortality caused by stroke , heart failure , ventricular arrhythmias , entity and bleeding from anticoagulation .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism congestion insufficiency ulcers return|thromboembolism|james d . extended-duration prohylaxis against venous entity after total hip or knee replacement : a meta-analysis of the randomized trials .  the lancet .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|angiogenesis tumorigenesis carcinogenesis coagulation fibrinolysis|thromboembolism|inhibition of intracellular signaling involved in tumor growth and metastases and 2 ) inhibition of early coagulation processes associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism insufficiency calcification reflux congestion|thromboembolism|risk factors for arterial vascular disease and / or venous entity ( vte ) should be managed appropriately .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|VTE thromboembolism DVT coagulopathy thrombocytopenia|thromboembolism|heparin is also used to prevent the occurrence of entity and to prevent clotting during dialysis and other surgical procedures , particularly vascular surgery .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism ulcer ulceration insufficiency embolism|thromboembolism|and states that esas increase the risk of death and major adverse cardiovascular events , such as myocardial infarction , stroke , venous entity and thrombosis of vascular access .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism spasm embolism ulceration hypotension|thromboembolism|a risk associated with hormonal contraceptives is a rare but serious adverse event called venous entity , or vte , which involves the formation of a blood clot in a vein .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism ulceration ulcers embolism congestion|thromboembolism|fdas approval of annovera™ , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism embolism thrombi thrombus insufficiency|thromboembolism|xa in phase 3 development for extended duration prophylaxis , or preventive treatment , of a form of thrombosis known as venous entity , or vte , in acute medically ill patients .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 1)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|infarcts embolism haemorrhage ischaemia vasospasm|thromboembolism|similarly , cerebral entity and cerebral vasculitis would be unexpected ( by virtue of greater specificity ) if the labeling only listed cerebral vascular accidents .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|dyslipidemia hypercholesterolemia CVD hyperlipidemia MetS|thromboembolism|pipeline we aim to broaden our cv portfolio into the areas of entity , dyslipidaemia , type 2 diabetes / metabolic syndrome , atrial fibrillation and vascular disease prevention .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism insufficiency embolism thrombectomy ulcers|thromboembolism|are in danger of forming life-threatening blood clots as a result of atrial fibrillation , prosthetic heart valve replacement or venous entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism ulceration insufficiency ulcers ulcer|thromboembolism|the committees concluded that users of evra have an increased risk of venous entity , or vte compared to users of second generation contraceptives , such as those containing lng .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|GVHD OSA AE psoriasis CIN|thromboembolism|patients and physicians are advised to be observant for the signs and symptoms of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism insufficiency ulceration embolism congestion|thromboembolism|of the ag200-15 patch , levonorgestrel ( lng ) , is considered as one of the safest progestins , with the lowest risk for venous entity ( vte ) when combined with ee .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism ulceration ulcers embolism congestion|thromboembolism|the approval of annovera , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism VTE embolism DVT strokes|thromboembolism|in the ats heart valve is intended to lower the likelihood of blood clot formation and the resulting incidence of entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|pneumonia influenza endocarditis myocarditis meningitis|thromboembolism|response clinical tests are commercially available for the aid in early detection of heart attack , congestive heart failure , entity , sepsis , influenza a and b and rsv .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arrhythmia Pregnancy uncontrolled embolism thromboembolic|thromboembolism ulcers malformations ulcer insufficiency|thromboembolism|there were approximately 510 , 000 patients being treated for venous entity in the united states in 2005 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism thromboembolism aspergillosis oedema aspiration|embolism|pulmonary entity is the most common preventable cause of hospital death and a leading cause of increased length of hospital stay .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism thromboembolism haemorrhage oedema emboli|embolism|to sell abbokinase for the treatment of acute massive pulmonary entity , we are required to continue an ongoing 200-patient immunogenicity clinical trial that commenced in 2003 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('BIO', 1)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|thrombi hemorrhages platelets thrombus effusions|embolism|will look natural to blood as it passes through the valve , thus inhibiting platelet aggregation that may later lead to entity or blood clots .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism thromboembolism emboli haemorrhage hemorrhages|embolism|urokinase is an fda-approved thrombolytic , or clot-dissolving agent , indicated for the treatment of acute massive pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism oedema exacerbation thromboembolism emboli|embolism|the primary efficacy endpoint is the occurrence of venographically-confirmed dvt , pulmonary entity , or death during the treatment phase , when measured at day 30 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism emboli oedema thromboembolism embolization|embolism|allegedly sustained as a result of their product use ; the most common alleged injuries are deep vein thrombosis and pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism emboli oedema thromboembolism emphysema|embolism|used berlex hrt products together with other hrt products and suffered injuries , including breast cancer , ovarian cancer , stroke and pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism infarct leak burn overload|embolism|one patient in the mst-188 group died due to cardiopulmonary arrest , which was considered secondary to a fat entity based on autopsy .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|oedema embolism emboli abscess encephalopathy|embolism|patients were dyspnea ( 7 percent ) , pneumonia ( 5 percent ) , hypoxia ( 4 percent ) , neoplasm progression ( 4 percent ) , pyrexia ( 2 percent ) and pulmonary entity ( 2 percent ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism thromboembolism haemorrhage oedema emboli|embolism|abbokinase is fda approved and marketed for the treatment of acute massive pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism oedema embol thromboembolism leak|embolism|the blood clots can travel to the lung and cause a pulmonary entity development all activities required to bring a new drug to the market .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism thromboembolism abscess embol exacerbation|embolism|in two cases , the patient developed a pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism emboli thromboembolism oedema haemorrhage|embolism|numerous companies either offer or are developing competing treatments for ischemic stroke , massive pulmonary entity and catheter occlusion , the three indications we are currently targeting .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism thromboembolism emboli exacerbation exacerbations|embolism|ivc filters have been shown in several studies to significantly reduce the risk of pulmonary entity and related mortality in certain high risk patient populations .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism thromboembolism emboli embolization embol|embolism|triage d-dimer test as an aid in the assessment and evaluation of patients suspected of having thromboembolic events , including pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism oedema emboli thromboembolism vasoconstriction|embolism|in some cases , a venous clot can cause lung injury ( pulmonary entity ) by migrating from the veins to the lungs .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism exacerbation rash event infiltrate|embolism|were a total of 48 serious adverse events , two of which were determined to be related to glybera , a pulmonary entity and fever .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism thromboembolism emboli embolization embol|embolism|patients at high risk for pulmonary entity are typically patients undergoing a significant surgical procedure , trauma patients or patients that have experienced a previous embolic event .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism abscess oedema aspergillosis thromboembolism|embolism|the most frequent ( >1% ) principal diagnoses were als , sepsis , respiratory failure , aspiration pneumonia , pneumonia , pulmonary entity , and urinary-tract infection ( table 2 ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|embolism thrombus arrhythmia Pregnancy dissection|embolism embol leak nodule infiltrate|embolism|in addition , one patient was reported to have a pulmonary entity ( grade 4 ) that was an incidental finding on ct scan .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|thromboembolism transfusions fibrinolysis haemorrhage hemolysis|thrombosis|pnh is a rare chronic blood disease characterized by severe anemia and risk of blood clotting or entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|DIC bacteremia malnutrition peritonitis AKI|thrombosis|crbsis and entity represent key complications among hemodialysis , intensive care , cancer and total parenteral nutrition , or tpn , patients with cvcs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|stenoses occlusions restenosis calcification malfunction|thrombosis|the angiojet system is marketed in the united states for treatment of dialysis access graft entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|thrombus thromboembolism thrombolysis dissection occlusions|thrombosis|potential applications of catheter delivered thrombolytics include apao ( acute peripheral arterial occlusion ) , dvt ( deep vein entity ) , and ischemic stroke .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1), ('BIO', 1)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|hemolysis haemorrhage vasoconstriction thromboembolism vasospasm|thrombosis|the most devastating consequence of chronic hemolysis is entity , which can occur in blood vessels throughout the body , damaging vital organs and causing premature death .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|thrombi occlusions thromboembolism thromb thrombus|thrombosis|cs-3030 is an oral direct factor xa inhibitor used to treat deep vein entity , or blood clots , and pulmonary embolism .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|thromboembolism vasospasm embolism occlusions dissection|thrombosis|in early 2003 , lovenox will be submitted in japan for the prevention of deep-vein entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|occlusions thrombi thrombus thromboembolism embolism|thrombosis|venous clots occur principally in the arms or legs ( deep vein entity ) , and may cause local inflammation , chronic pain and other complications .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|osteoporosis anemia fever hypotension shivering|thrombosis|candidates include kaitong , a lipid emulsion of alprostadil for the treatment of peripheral vascular diseases , cardiocerebral microcirculation disorder and post-surgery entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|angina CABG cardiology CHF IHD|thrombosis|rnapc2 was originally developed as a cardiovascular therapy for entity and other indications .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|plaque spasm another narrowing RCA|thrombosis|angina is caused by partial blockage of a coronary artery from entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|thromboembolism calcification insufficiency occlusions ulcers|thrombosis|positioned angiomax as a replacement for heparin , which is a widely used , inexpensive , generic drug used in patients with arterial entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|pharmaceutical market warfarin labour French|thrombosis|we are initially targeting three segments of the entity market in which safe and rapid removal of blood clots is essential for patient care , including ischemic stroke , pulmonary embolism
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|Stroke DVT Complications Lesions AIS|thrombosis|entity can be treated surgically or through drug therapy with anticoagulant and thrombolytic drugs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|thromboembolism dissection vasospasm embolism occlusions|thrombosis|patients withdrew due to adverse events ( one due to a recurrence of crohns disease and one due to deep vein entity ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|VAP VTE NEC CVD SSI|thrombosis|may 2015 , we entered into an exclusive license agreement with bayer to develop and commercialize ionis-fxirx for the prevention of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|neurodegeneration migraine psoriasis allergies autoimmunity|thrombosis|the therapeutic areas pursued by celera included oncology , autoimmunity , respiratory diseases and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|thromboembolism ulcers malformations embolism insufficiency|thrombosis|each year in the u . s . , over 270 , 000 patients are diagnosed with venous entity and approximately 50 , 000 patients die from pulmonary embolisms .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|thromboembolism vasospasm spasm dissection embolization|thrombosis|that trial was discontinued due to the hypotension and because defibrotide can also be administered orally to prevent deep vein entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|arrhythmia Stroke uncontrolled embolism Pregnancy|thromboembolism occlusions thrombus thrombi catheterization|thrombosis|as an anticoagulant , or blood thinner , to prevent clotting of blood in the vein , commonly referred to as deep vein entity , and acute coronary syndromes .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|cognition neurodegeneration neuroinflammation neurogenesis angiogenesis|arteriosclerosis|served as vice president of research at the winters institute , a non-profit biomedical research institution , at which dr . waitz studied entity in primates .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|vasculitis scleroderma dysplasia emphysema aneurysms|arteriosclerosis|the skin , copd in the lung , fibrotic disease in the liver and kidney , crohn  s disease in the intestine , chf and entity in the arteries .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|vasospasm ischaemia infarct aneurysms embolism|arteriosclerosis|pharmaceutical research conducted to date indicates that aso 989 has the potential to treat ischemia of extremities , cerebral thrombosis , cerebral entity and coronary heart disease .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|vasospasm spasm steal syndromes insufficiency|arteriosclerosis|designed to treat the symptoms of coronary entity , angina pectoris and hyperlipemia .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|hyperlipidemia dyslipidemia hypercholesterolemia proteinuria hyperglycemia|arteriosclerosis|the product can be used in treatment of anoxemic cardiovascular and cerebrovascular disease , as well as hypertension and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|glaucoma arrhythmias myocardial arrhythmia osteoporosis|arteriosclerosis|this product is used to treat ischemic heart and cerebrovascular diseases , entity and cerebral thrombosis bezoar antipyrotic tablet .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|vasospasm spasm vasoconstriction ischaemia restenosis|arteriosclerosis|moreover , damage to the blood vessels may cause blockage due to entity and lead to the tearing of the vessels .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|stones hypercholesterolemia reflux cholangitis pancreatitis|arteriosclerosis|claims fabacs , including aramchol , as well as methods for preventing or dissolving cholesterol gallstones in bile and reducing or preventing entity using fabacs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('BIO', 1)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|osteoporosis neurodegeneration arthritis migraine autoimmunity|arteriosclerosis|of variations in a gene which control blood levels of a protein and predict increased disposition or susceptibility to osteoporosis , entity , cancer and immune disorders .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|angiogenesis hemostasis arrhythmia arrhythmias vasculitis|arteriosclerosis|he is also a member of the american heart association council on stroke , and council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|comorbidities pathologies degeneration contraindications reasons|arteriosclerosis|million patients require bypass surgery each year because of age related entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|angiogenesis hemostasis coagulation angina cerebrovascular|arteriosclerosis|on april 20 , 2012 , alnylam presented aln-pcs data at the american heart associations entity , thrombosis , and vascular biology ( atvb ) 2012 scientific sessions held in chicago , il .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|vasospasm palsy ischaemia embolism infarct|arteriosclerosis|used for coronary heart disease , angina , cerebral entity , ischemic cerebrovascular disease .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|CRC NSCLC TNBC gliomas PCa|arteriosclerosis|in vivo validation of this model , enabling a route to screen for compounds against this target specifically to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|academic scientific fitness mission rehabilitation|arteriosclerosis|since 1973 , he has served as director of the entity center at the massachusetts institute of technology ( " mit " ) , of which he was the founder .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|hemostasis angiogenesis microcirculation fibrinolysis coagulation|arteriosclerosis|with non hdl -c ( ³130 mg / dl ) in type 2 diabetes mellitus” was given at the american heart association , council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|CVD IHD menopause osteoporosis MetS|arteriosclerosis|balancing female hormones may lower the risk of entity by utilizing the bodys natural protection against heart diseases before menopause .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|SAH migraine alcoholism vasospasm ethanol|arteriosclerosis|and chronic peripheral vascular-metabolic disorders , brain occlusion , occlusion of retina central vein , acute and chronic cerebral vascular-metabolic disorders caused by entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|dyslipidemia hyperlipidemia osteoporosis hypercholesterolemia nephropathy|arteriosclerosis|excess dietary fat is the primary cause of obesity , heart disease , high blood pressure , diabetes , entity and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|Peripheral neovascularization neuropathy plaque proliferative|angiogenesis migraine glaucoma restenosis aging|arteriosclerosis|angiogenic therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer , blindness and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|periodontitis psoriasis acne leishmaniasis arthritis|atherosclerosis|patent applications also cover estrogen-related compounds with anti-fungal activity and the treatment of localized entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|hypercholesterolemia dyslipidemia hyperlipidemia aging stasis|atherosclerosis|chd usually results from entity , a hardening and narrowing of the arteries caused by a buildup of fatty plaque composed of cholesterol and other lipids ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|hypercholesterolemia T2DM dyslipidemia CAD SCD|atherosclerosis|current treatments : most patients with entity have high levels of a particular type of cholesterol particle known as ldl-c . the current standard of care is treatment
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|NEC colitis AKI NASH pancreatitis|atherosclerosis|several studies have demonstrated that lxr agonists will promote rct in vivo in mice and prevent the development of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|PAD CAD SLE T2DM SCD|atherosclerosis|test cleared by the fda to aid in assessing risk for both coronary heart disease and ischemic stroke associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|hypercholesterolemia aspirin hyperlipidemia statins aging|atherosclerosis|preclinical studies conducted by pharmacyclics and our collaborators have demonstrated that texaphyrins also accumulate in vascular plaque caused by entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|arrhythmias autoimmunity pathophysiology carcinogenesis exacerbations|atherosclerosis|chlamydia pneumoniae ( " c . pneumoniae " ) infections may play a role in entity in heart diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|CHF arrhythmias angina cardiomyopathy COPD|atherosclerosis|oxidative stress ( the physiological condition of inadequate oxygen supply ) may worsen entity and make heart muscle more susceptible to damage .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|neurodegenerative neurodegeneration aging autoimmunity migraine|atherosclerosis|mitochondrial-derived peptides ( mdps ) into mbts offers the potential to address a broad range of diseases including type 2 diabetes , cancer , entity and neurodegenerative disorders .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|psoriasis SLE IBD endometriosis colitis|atherosclerosis|inhibitors of certain classes of pdes , in particular pde4 , may be novel compounds for the treatment of inflammation related to entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|Hypertension Stroke Diabetes Smoking Obesity|atherosclerosis|entity is the major cause of cardiovascular disease , peripheral artery disease and cerebral artery disease , and can cause heart attack , loss
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|photodynamic antiplatelet endovascular Laser topical|atherosclerosis|entity therapy antrin for photoangioplasty of atherosclerosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|anemia alcoholism eczema AIDS meningitis|atherosclerosis|including hemorrhage , severe trauma , ischemic heart disease , diabetes , acute myocardial infarction , acute transient cerebral ischemic attack , sickle cell disease and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|aging academic cardiology Alzheimer AIDS|atherosclerosis|spent 11 years at bristol-myers squibb ( nyse : bmy ) , from 1986 to 1997 , in various capacities , including executive director , heart failure and entity clinical research .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|Diabetes Hypertension Disease Osteoarthritis vasculitis|atherosclerosis|entity is a disease that is commonly referred to as a hardening of the arteries and is characterized by the deposition
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|plaque lumen luminal infarct atherosclerotic|atherosclerosis|ldl and hdl particle in coronary entity size were also important predictors of disease progression .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|psoriasis periodontitis gout uveitis fibromyalgia|atherosclerosis|thc has been found to reduce inflammation in chronic inflammatory diseases , such as entity and rheumatoid arthritis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|CAD CVD PAD dyslipidemia MetS|atherosclerosis|elevated plasma cholesterol and triglycerides are independent risk factors for entity , the buildup of cholesterol rich lesions and plaques in the arteries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|NSCLC psoriasis CRC CML CLL|atherosclerosis|in february 2005 , we initiated phase i trials on rus 3108 , our drug candidate for the treatment of entity , in ireland .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|Cholesterol mellitus plaque Coronary pectoris|T2DM SSc CKD SLE CAD|atherosclerosis|the medical literature that increased vascular oxidative stress is a primary mechanism of impaired blood vessel elasticity in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|Stroke TIA attack accident pectoris|called mimicking accompanying refractory simulating|stroke|ep-4104 ( dantrolene ) for exertional heat entity exertional heat stroke , or ehs , is a rare , emergency and serious medical condition that is potentially life-threatening .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|Stroke TIA attack accident pectoris|decision alert alarm manual error|stroke|the triage meter , triage micro product line and triage entity panel are not included .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|Stroke TIA attack accident pectoris|preconditioning cardiomyopathy retinopathy colitis IRI|stroke|kingdom to determine the safety , efficacy and pharmacokinetics of ldp-01 for the reduction of reperfusion tissue damage associated with ischemic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|Stroke TIA attack accident pectoris|orthopedic burn neurologic musculoskeletal joints|stroke|the majority of people with ms and sci experience some form of spasticity , as do many people following entity or brain injuries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|Stroke TIA attack accident pectoris|strokes Stroke attack cardiomyopathy attacks|stroke|and drug administration , or fda , to initiate a third clinical study administering multistem to patients for the treatment of ischemic entity , a leading cause of death and disability .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|Stroke TIA attack accident pectoris|IBD psoriasis T1D obese Asian|stroke|pfizer is expected to conduct additional safety and tolerability studies in entity patients later this year .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|Stroke TIA attack accident pectoris|attack colitis Stroke attacks strokes|stroke|the last subjects follow-up assessment in the company  s non-gcp phase ii trial evaluating nsi-566 , for the treatment of chronic ischemic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|Stroke TIA attack accident pectoris|Stroke Diabetes COPD Dementia Depression|stroke|entity is currently the third leading cause of death , and the leading cause of disability , in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|Stroke TIA attack accident pectoris|strokes colitis cerebrovascular cardiomyopathy attack|stroke|there is a tremendous need for new ways to treat ischemic entity patients ,  said anne legrand , senior vice president and general manager , ultrasound , for philips medical systems .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|Stroke TIA attack accident pectoris|rehabilitation neuroprotection neuroscience aging SCI|stroke|$30 , 000 that is part of the $342 , 000 small business innovation research grant from the national institute of neurological disease and entity , and $10 , 000 in licensing revenue .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|Stroke TIA attack accident pectoris|Europe Japan Germany France Mexico|stroke|if the company  s anticipated phase i / iia study in entity is supportive , the company will consider pursuing an ind filing for myocardial infarction in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|Stroke TIA attack accident pectoris|investigational medicinal approved Alzheimer GSK|stroke|currently , the company  s parkinson  s disease , aids dementia and entity product candidates are all in or have just recently completed phase i clinical trials .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|Stroke TIA attack accident pectoris|troponin toxicology INR biomarker chemistry|stroke|shortness of breath panel , triage d-dimer test and triage tox drug screen and others currently under development , including the triage entity panel .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cardiovascular_disease|Stroke TIA attack accident pectoris|axonal neuron axon neurologic sensorimotor|stroke|recent advances in entity recovery by stem cell therapy highlight the regenerative potential of stem cell therapies for neurodegenerative conditions and further support the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1), ('DRUG', 1)])|cardiovascular_disease|Stroke TIA attack accident pectoris|CVD eg osteoporosis dyslipidemia arrhythmias|stroke|individuals that are clinically obese have elevated rates of cardiovascular disease , entity , certain types of cancer and diabetes .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|Stroke TIA attack accident pectoris|traumatic acquired electrical idiopathic aging|stroke|of researching , developing and providing medical technologies to restore the vision of patients with neurological visual loss predominantly resulting from entity or traumatic brain injury .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|Stroke TIA attack accident pectoris|TIA CAD CHF syncope hospitalization|stroke|factor assessment to identify moderate and high-risk individuals who may actually be at an increased risk for heart attack or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|Stroke TIA attack accident pectoris|glioma herniation penetration abscess swelling|stroke|our initial targeted medical conditions are brain entity and wound healing .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|Stroke TIA attack accident pectoris|event episode spot accident thrombus|stroke|study in the u . s . to evaluate the safety and efficacy of the starflex® closure technology to prevent a recurrent embolic entity and / or tia in patients with a pfo .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|Stroke TIA attack accident pectoris|migraine encephalitis dementia idiopathic encephalopathy|stroke|these underlying neurologic conditions include but are not limited to als , ms , alzheimers disease , parkinsons disease , entity and traumatic brain injury .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|graft prosthesis ring prosthetic endovascular|aneurysm|procedures in which these catheters are used include angioplasty , embolization , abdominal aortic entity ( aaa ) stent-grafts and vena cava filter placements .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|CABG orthopedic colorectal orthopaedic cataract|aneurysm|studies in which hetacool will be used to replace all of the patient  s circulating blood volume at near-freezing temperatures in entity surgery .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|graft valvular anatomical ring autograft|aneurysm|usually aortic entity reconstruction surgery involves much more blood loss than post cardiopulmonary bypass surgery .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|clip metallic titanium silicone endovascular|aneurysm|needs of neurosurgeons with a range of implantable and single-use products , including cerebral spinal fluid shunts , external drainage products and entity clips .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|dissection prosthesis etiology insufficiency anatomy|aneurysm|in patients with a known aortic entity or patients who are at greater risk for aortic entitys , reserve baxdela for use only when there are no alternative
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|evaluable MM mesothelioma glioblastoma BCC|aneurysm|as of december 18 , 2001 , a total of 39 entity cases have been treated in the trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|dissection calcification rupture aneurysms erosion|aneurysm|fluoroquinolones have been associated with an increased risk of aortic entity and dissection , especially in elderly patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|AAA AVM ACC IH AIS|aneurysm|however , transcatheter devices currently used to repair an entity are often too large to be considered a truly minimally invasive procedure .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|cistern mur aneurysmal cover Mass|aneurysm|outcomes and transform the management of entityal subarachnoid hemorrhage , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|aneurysms AVM SAH malformation AAA|aneurysm|patients who require an external ventricular drain ( evd ) , and undergo either neurosurgical clipping or endovascular coiling for repair of their entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|aneurysms dissection aorta dilatation calcification|aneurysm|in the united states each year , abdominal aortic entity -- a weakening of the walls of one of the body  s main arteries , sometimes to the point of rupture --
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|annulus autograft aperture envelope allograft|aneurysm|the les utilizes a material which is delivered as a liquid that fills and conforms to the shape of an entity or avm .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|prosthetic bypass endovascular prosthesis graft|aneurysm|company is considering for study are peripheral avms , uterine fibroid tumors , liver tumors and persistent endoleaks related to abdominal aortic entity graft treatments .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|AAA tear ACL aorta tendon|aneurysm|after the ruptured entity is repaired , these patients remain at risk for multiple complications that are managed over the course of the patients treatment
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|aneurysms dissection AAA pathologies leak|aneurysm|endologix  s first product , the powerlink system , is a catheter-based alternative treatment for abdominal aortic entity , or aaa .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|cistern mur aneurysmal Mass cover|aneurysm|transform the management of entityal subarachnoid hemorrhage , or asah , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|AVM hematoma glioma infarct malformation|aneurysm|in a surgical procedure to treat a brain entity , a clip is placed across the base , or neck , of the entity for the purpose of excluding the entity from further blood flow .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|aneurysms pathologies dissection stenoses leak|aneurysm|it is a direct side effect of an aortic clamping procedure during a surgical operation to treat abdominal aortic entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|graphene titanium smart wire alloy|aneurysm|titanium entity clip was developed in collaboration with biotek engineering , inc . ( " biotek " ) under an exclusive worldwide royalty bearing license to the patents
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|dissection uncontrolled ligation coil Disease|hernia AAA defects AVM ulcer|aneurysm|be treated through a combination of pharmacological therapy and non-invasive monitoring or undergo a major surgical procedure to repair the entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|neovascularization proliferative psoriasis plaque vasculitis|peritonitis meningitis leprosy mastitis osteomyelitis|angiomatosis|he discovered two previously uncharacterized , uncultivated bacterial pathogens , agents of bacillary entity and whipple  s disease .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|neovascularization proliferative psoriasis plaque vasculitis|dysplasia malformations cleft malformation migraine|angiomatosis|sws , also known as encephalofacial entity , is a neurocutaneous disorder that occurs as a sporadic congenital condition .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1), ('DRUG', 1)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|hypercholesterolemia ataxia syndromes anaemia calcifications|angioedema|members of the medical and regulatory teams that successfully developed the orphan drug , cinryze , which is used to treat hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('BIO', 1)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine fever dyspepsia anemia neuropathy|angioedema|firazyr for hereditary entity ( “hae” ) in the us prior to shires acquisition , in april 2008 jerini received a not approvable letter for firazyr for
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|syndromes predisposition coagulopathy defects anomalies|angioedema|our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary entity , or hae .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine urticaria vasculitis attacks gout|angioedema|submitted a therapeutic biologic application ( bla ) to the fda for ruconest® seeking approval for the treatment of acute attacks of entity in patients with hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine urticaria fever episodic vertigo|angioedema|clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary entity ( “hae” ) attacks .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|amyloidosis ataxia encephalopathy migraine polyneuropathy|angioedema|disease description • hereditary entity ( hae ) is a rare , autosomal dominant genetic disorder 1 • hae is characterized by recurrent , unpredictable , debilitating and potentially life
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine thromboembolic gout thrombotic VTE|angioedema|identified several proprietary , small molecule kallikrein inhibitors in an effort to produce an orally administered therapy for the prevention of entity attacks .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|polyposis syndromes psoriasis polyps colitis|angioedema|therapeutic compounds for the treatment of chronic inflammatory diseases , with initial development to be focused on the treatment of hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine amyloidosis osteomyelitis colitis urticaria|angioedema|the most advanced indication for dx-88 is in the treatment of hereditary entity ( hae ) , a potentially life-threatening inflammatory condition .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine urticaria anaphylaxis vasculitis angina|angioedema|the study is designed to examine the use of c1-inh in both treating acute attacks of entity and in preventing the onset of such attacks .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|cataract amyloidosis AMD glaucoma blindness|angioedema|includes product candidates designed to treat wet age-related macular degeneration ( wamd ) and rare diseases alpha-1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine pancreatitis FAP ataxia amyloidosis|angioedema|company completes the randomization of 68 evaluable subjects in its phase iii clinical trial for the acute treatment of hereditary entity on or before december 31 , 2006 ( the “options” ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|manufacturing marketing vaccination approval eradication|angioedema|dyax retains exclusive rights to dx-88 in all other indications , including its hereditary entity program , currently in its second phase 3 trial , as well as for the manufacturing of dx-88 .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine angio hemorrhagic urticaria vertigo|angioedema|two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily , oral treatments for the prevention of hereditary entity ( hae ) attacks .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine urticaria vertigo fever RAS|angioedema|( berotralstat ) for prophylaxis to prevent attacks of hereditary entity in adults and pediatric patients 12 years and older .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|emphysema coagulopathy amyloidosis hypercholesterolemia anemia|angioedema|gene therapy programs to address unmet needs in wet amd and rare diseases alpha 1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|coagulopathy vasculitis DIC thrombocytopenia hypotension|angioedema|of c1-inh activity , activated c1 and plasmin generate certain inflammatory mediators which are thought to be causal factors of the entity observed in patients with hae .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|syndromes malignancies amyloidosis ataxia neoplasia|angioedema|and senior medical director , where she worked on a variety of rare genetic diseases including lysosomal storage diseases and hereditary entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|ascites pruritus itch proteinuria nausea|angioedema|published studies by others have shown c1-inh treatment to resolve entity in 30 minutes to two hours , compared to 24-72 hours when untreated .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|urticaria vulgaris allergic psoriasis Known|migraine gout panic angina stone|angioedema|we market and sell cinryze in the united states for routine prophylaxis against entity attacks in adolescent and adult patients with hae .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|headache dizziness diarrhea rash constipation|hypotension|the most frequently observed adverse events in both the placebo and treatment groups were nausea , vomiting and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|anemia thrombocytopenia neutropenia neuropathy diarrhea|hypotension|the most common were neutropenia , thrombocytopenia , and entity ( 19% each ) .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|arrhythmias hypotension bradycardia shocks consequences|hypotension|we believe that this characteristic would offer a safety advantage over current vasodilators , which can cause dangerous entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|hypotension intolerance sweating tachycardia hyperalgesia|hypotension|of symptoms associated with idiopathic and diabetic gastroparesis , and our norepinephrine and serotonin reuptake inhibitor ( " nsri " ) td-9855 in neurogenic orthostatic entity ( " noh " ) .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|nausea headache hematuria exacerbation deterioration|hypotension|in the 50 mcg dex-in treatment group and one in the 35 mcg dex-in treatment group ) discontinued due to symptomatic entity and one subject ( 35 mcg dex-in ) due to fever .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|hypotension tachycardia syncope dizziness bradycardia|hypotension|no patients with blood pressure decrease , entity nor with bradycardia required medication to treat these events .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|hypotension dizziness headaches syncope intolerance|hypotension|like other opioids ( e . g . , heroin , methadone , oxycodone , morphine ) , bunavail may produce orthostatic entity ( dizzy spells ) in ambulatory individuals .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('BIO', 1)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|bevacizumab rituximab bortezomib docetaxel gemcitabine|hypotension|profile , in particular its ability to provide clinical benefit without adding to the systemic effects of other therapies such as entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|hypotension intolerance tachycardia rigidity sweating|hypotension|our preclinical studies indicate that ( s ) -doxazosin exhibits potential for a reduction in orthostatic entity and is potentially more potent than the parent drug .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|burning vomiting itching rash swelling|hypotension|these reactions consisted of erythema , pruritus , and entity and occurred within hours of administration of chemotherapy .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|itching pruritus erythema fever rash|hypotension|reactions are characterized by transient entity and an allergic type response , which appear to cease upon stopping drug administration .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|pruritus AEs toxicities arrhythmias neutropenia|hypotension|vazculep is indicated for the treatment of clinically important entity occurring in the setting of anesthesia .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|hypoglycaemia hyperglycemia hypotension falls proteinuria|hypotension|benefit from aliskiren and there was a higher incidence of adverse events related to non-fatal stroke , renal complications , hyperkalaemia and entity in this high-risk population .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|exacerbations hypoglycemia hypoxemia episodes hypoglycaemia|hypotension|however , such patients may be subject to protracted severe entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|dosing hospitalization infusions interruption titration|hypotension|in the acute care setting , this should allow the physician to alter the dose and avoid prolonged entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|nausea diarrhea headache neutropenia vomiting|hypotension|in humans , and it was shown to be well tolerated , with the most common adverse events reported being gi toxicities , entity and fatigue .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|dizziness vomiting insomnia diarrhea nausea|hypotension|the most frequently reported aes included somnolence , dizziness , nausea , headache , and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|infusions olanzapine propofol paclitaxel irinotecan|hypotension|the data suggest that the limiting side effect of entity is related to peak plasma drug level , which means that slower infusions could allow delivery of more drug .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|dizziness vomiting nausea pruritus itching|hypotension|dosing , seven of the 40 olinciguat-treated subjects reported headache , seven reported tachycardia , three 78 table of contents ​ ​ reported entity and three reported nausea .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|uncontrolled hypotension arrhythmia arrhythmias bradycardia|cure dizziness dyspepsia dysphagia relevance|hypotension|no other adverse events of symptomatic entity were seen in the 95 patients treated .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cardiovascular_disease|Known AND dysplasia IIa psoriasis|PCs ECs PC PFC FC|angiodysplasia|the gi blood vessels respond to vascular dysfunction and reduced flow by generation of abnormal thin-walled , leaky capillaries ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|psoriasis plaque telangiect neovascularization pigmentation|AIS scoliosis myopia SCD glaucoma|telangiectasis|treatment options for entity are limited to corrective surgery or mixed light pulse therapy , known as photoderm , which directs a series of light pulse
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cardiovascular_disease|psoriasis plaque telangiect neovascularization pigmentation|varices arterioles capillaries ulcers veins|telangiectasis|rosacea progresses to a severe stage , dilated blood vessels that become distended under the surface of the skin , known as entity , appear .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|psoriasis plaque telangiect neovascularization pigmentation|itching scarring burning pruritus pigmentation|telangiectasis|however , local side effects are common , in particular skin thinning , entity , bruising , hypopigmentation , acne , striae and secondary infection .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|GVHD MDS COPD hematology psoriasis|endocarditis|as you saw from our press release yesterday , we have continued to make progress in our phase 3 trail in entity and bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|endocarditis keratitis peritonitis meningitis keratoplasty|endocarditis|exebacase to potentially re-sensitize mrsa to penicillin derivatives and first generation cephalosporins , both in vitro and in the rabbit infective entity model .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|bacteremia colitis SBP abscess perforation|endocarditis|the primary efficacy endpoint is clinical response at day 14 in patients with mrsa bacteremia , including right-sided entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|bacteremia meningitis MRSA pneumonia osteomyelitis|endocarditis|in addition to background standard of care soc antibiotics compared to soc antibiotics alone for the treatment of staph aureus bacteremia , including entity in adult patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|meningitis endocarditis bacteremia peritonitis osteomyelitis|endocarditis|these infections may lead to complications associated with staphylococcal bacteremia , including infectious arthritis , pneumonia , septic shock , entity and abscesses .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|bacteremia sided abscess perforated SBP|endocarditis| data from this study , if positive , could support an expansion of the current label to include right-sided entity and / or complicated bacteremia due to s . aureus .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|NSCLC SCLC tumours malignancies aneurysms|endocarditis|key points from the meeting with the fda are highlighted below :  further enrollment of patients with left-sided entity is not required .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|endocarditis meningitis keratitis arthritis peritonitis|endocarditis|especially cardiac devices which contribute substantially to the growing prevalence of staph aureus bacteremia , and secondary infections such as infective entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|MRSA bacteremia meningitis pathogens etiology|endocarditis|for the expanded label for cubicin® ( daptomycin for injection ) in the treatment of staphylococcus aureus bacteremia with known or suspected entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|bloodstream superficial ocular pleural mucosal|endocarditis|that patients acquire while being treated or cared for in a hospital or out-patient setting and include , among others , pneumonia , entity and bloodstream infections , or bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|endocarditis meningitis keratitis IE arthritis|endocarditis|of further concern , the incidence of infective entity is increasing , with over 47 , 000 cases in 2011 , due to the growth of the at-risk populations , such as adults with
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|meningitis osteomyelitis pneumonia bacteremia burns|endocarditis|gentamicin is an antibiotic used to treat entity , septicemia and bacterial , bone , respiratory tract , soft tissue , urinary tract and other infections .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|meningitis endocarditis pneumonia keratitis overgrowth|endocarditis|taken either drug has any invasive procedure for which antibiotic prophylactic treatment is recommended to prevent the development of bacterial entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|approved easy outside urgent Internet|endocarditis|to get just what  hopefully get what youre looking for or do you feel like youre at loggerheads on an entity indication?
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|endocarditis AND dissection arrhythmia valvular|endocarditis bacteremia thromboembolism cytomegalovirus influenza|endocarditis|the silzone® coating was intended to reduce the risk of entity , a bacterial infection affecting heart tissue , which is associated with replacement heart valves .
#Masked F1-score:0.91|CLS F1-score:0.98|Masked Confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 930), ('OTHER', 285), ('DIS', 78), ('BIO', 2)])), ('OTHER', OrderedDict([('DRUG', 0), ('OTHER', 0), ('DIS', 0), ('BIO', 0)])), ('DIS', OrderedDict([('DRUG', 62), ('OTHER', 192), ('DIS', 1450), ('BIO', 31)])), ('BIO', OrderedDict([('DRUG', 68), ('OTHER', 437), ('DIS', 256), ('BIO', 759)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('OTHER', 0), ('DIS', 1.0), ('BIO', 1.0)]), 'recall': OrderedDict([('DRUG', 0.72), ('OTHER', 0), ('DIS', 0.84), ('BIO', 0.5)]), 'f1_score': OrderedDict([('DRUG', 0.84), ('OTHER', 0), ('DIS', 0.91), ('BIO', 0.67)]), 'max_f1': 0.91}|CLS confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 926), ('DIS', 274), ('OTHER', 90), ('BIO', 5)])), ('DIS', OrderedDict([('DRUG', 32), ('DIS', 1677), ('OTHER', 11), ('BIO', 15)])), ('OTHER', OrderedDict([('DRUG', 0), ('DIS', 0), ('OTHER', 0), ('BIO', 0)])), ('BIO', OrderedDict([('DRUG', 99), ('DIS', 728), ('OTHER', 76), ('BIO', 617)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('DIS', 1.0), ('OTHER', 0), ('BIO', 1.0)]), 'recall': OrderedDict([('DRUG', 0.72), ('DIS', 0.97), ('OTHER', 0), ('BIO', 0.41)]), 'f1_score': OrderedDict([('DRUG', 0.84), ('DIS', 0.98), ('OTHER', 0), ('BIO', 0.58)]), 'max_f1': 0.98}
